{
  "nodes": {
    "75": {
      "name": "SLC7A5",
      "text": ""
    },
    "1801": {
      "name": "apoptosis",
      "text": ""
    },
    "1856": {
      "name": "colorectal cancer(CRC)",
      "text": ""
    },
    "418": {
      "name": "SLC46A1",
      "text": ""
    },
    "1795": {
      "name": "proliferation",
      "text": ""
    },
    "1872": {
      "name": "breast cancer(BC)",
      "text": ""
    },
    "136": {
      "name": "SLC16A1",
      "text": ""
    },
    "1796": {
      "name": "ferroptosis",
      "text": ""
    },
    "1993": {
      "name": "Laryngeal Cancer",
      "text": ""
    },
    "371": {
      "name": "SLC38A5",
      "text": ""
    },
    "1802": {
      "name": "oxidative phosphorylation",
      "text": ""
    },
    "2583": {
      "name": "ischemic proliferative retinopathies",
      "text": ""
    },
    "81": {
      "name": "SLC7A11",
      "text": ""
    },
    "2747": {
      "name": "liposarcoma",
      "text": ""
    },
    "232": {
      "name": "SLC25A11",
      "text": ""
    },
    "1794": {
      "name": "chemotherapy resistance",
      "text": ""
    },
    "2119": {
      "name": "hepatocellular carcinoma (HCC)",
      "text": ""
    },
    "225": {
      "name": "SLC25A4",
      "text": ""
    },
    "25": {
      "name": "SLC3A2",
      "text": ""
    },
    "1917": {
      "name": "Gastric cancer (GC)",
      "text": ""
    },
    "9": {
      "name": "SLC2A1",
      "text": ""
    },
    "1800": {
      "name": "migration",
      "text": ""
    },
    "1868": {
      "name": "lung cancer",
      "text": ""
    },
    "1809": {
      "name": "Bone Cancer",
      "text": ""
    },
    "106": {
      "name": "SLC10A3",
      "text": ""
    },
    "1806": {
      "name": "Brain Tumor",
      "text": ""
    },
    "180": {
      "name": "SLCO1B3",
      "text": ""
    },
    "2056": {
      "name": "Cervical cancer",
      "text": ""
    },
    "2154": {
      "name": "preeclampsia (PE)",
      "text": ""
    },
    "367": {
      "name": "SLC38A1",
      "text": ""
    },
    "1797": {
      "name": "oxidative stress",
      "text": ""
    },
    "127": {
      "name": "SLC13A3",
      "text": ""
    },
    "1831": {
      "name": "Neuroendocrine Tumor",
      "text": ""
    },
    "2209": {
      "name": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "313": {
      "name": "SLC31A1",
      "text": ""
    },
    "1836": {
      "name": "pancreatic cancer(PC)",
      "text": ""
    },
    "1853": {
      "name": "ovarian cancer",
      "text": ""
    },
    "2264": {
      "name": "laryngeal carcinoma",
      "text": ""
    },
    "2193": {
      "name": "pancreatic ductal adenocarcinoma (PDAC)",
      "text": ""
    },
    "185": {
      "name": "SLC22A2",
      "text": ""
    },
    "1839": {
      "name": "bladder cancer",
      "text": ""
    },
    "1813": {
      "name": "Sarcoma",
      "text": ""
    },
    "45": {
      "name": "SLC5A8",
      "text": ""
    },
    "265": {
      "name": "SLC25A44",
      "text": ""
    },
    "380": {
      "name": "SLC39A3",
      "text": ""
    },
    "1798": {
      "name": "stemness",
      "text": ""
    },
    "138": {
      "name": "SLC16A3",
      "text": ""
    },
    "1799": {
      "name": "glycolysis",
      "text": ""
    },
    "5": {
      "name": "SLC1A5",
      "text": ""
    },
    "2228": {
      "name": "acute myeloid leukemia (AML)",
      "text": ""
    },
    "1811": {
      "name": "Osteosarcoma(OS)",
      "text": ""
    },
    "91": {
      "name": "SLC9A2",
      "text": ""
    },
    "393": {
      "name": "SLC40A1",
      "text": ""
    },
    "2296": {
      "name": "ferroptosis-relative osteoarthritis",
      "text": ""
    },
    "2287": {
      "name": "septic myocardial injury",
      "text": ""
    },
    "1864": {
      "name": "prostate cancer",
      "text": ""
    },
    "250": {
      "name": "SLC25A29",
      "text": ""
    },
    "372": {
      "name": "SLC38A7",
      "text": ""
    },
    "131": {
      "name": "SLC15A1",
      "text": ""
    },
    "191": {
      "name": "SLC22A8",
      "text": ""
    },
    "2346": {
      "name": "treatments with cytostatics such as methotrexate and cisplatin",
      "text": ""
    },
    "184": {
      "name": "SLC22A1",
      "text": ""
    },
    "294": {
      "name": "SLC28A1",
      "text": ""
    },
    "52": {
      "name": "SLC6A2",
      "text": ""
    },
    "1924": {
      "name": "Head and Neck Cancer",
      "text": ""
    },
    "1815": {
      "name": "leukemia",
      "text": ""
    },
    "322": {
      "name": "SLC34A2",
      "text": ""
    },
    "2099": {
      "name": "Multicancer",
      "text": ""
    },
    "2741": {
      "name": "embryonal carcinoma",
      "text": ""
    },
    "129": {
      "name": "SLC13A5",
      "text": ""
    },
    "10": {
      "name": "SLC2A2",
      "text": ""
    },
    "59": {
      "name": "SLC6A9",
      "text": ""
    },
    "383": {
      "name": "SLC39A6",
      "text": ""
    },
    "400": {
      "name": "SLC42A2",
      "text": ""
    },
    "2202": {
      "name": "human esophageal cancers",
      "text": ""
    },
    "58": {
      "name": "SLC6A8",
      "text": ""
    },
    "1850": {
      "name": "liver cancer",
      "text": ""
    },
    "2429": {
      "name": "diabetes vascular complications",
      "text": ""
    },
    "385": {
      "name": "SLC39A8",
      "text": ""
    },
    "1931": {
      "name": "Nasopharyngeal Cancer (NPC)",
      "text": ""
    },
    "2393": {
      "name": "clear cell renal cell carcinoma (CCRCC)",
      "text": ""
    },
    "92": {
      "name": "SLC9A3",
      "text": ""
    },
    "2379": {
      "name": "pancreatic tumor growth",
      "text": ""
    },
    "2290": {
      "name": "oral squamous cell carcinoma (OSCC)",
      "text": ""
    },
    "63": {
      "name": "SLC6A14",
      "text": ""
    },
    "2159": {
      "name": "age-related macular degeneration (AMD)",
      "text": ""
    },
    "98": {
      "name": "SLC9A9",
      "text": ""
    },
    "179": {
      "name": "SLCO1B1",
      "text": ""
    },
    "298": {
      "name": "SLC29A1",
      "text": ""
    },
    "38": {
      "name": "SLC5A1",
      "text": ""
    },
    "2751": {
      "name": "acute myeloid leukemia",
      "text": ""
    },
    "2365": {
      "name": "Neuroblastoma (NBM)",
      "text": ""
    },
    "90": {
      "name": "SLC9A1",
      "text": ""
    },
    "2105": {
      "name": "cancer tissues",
      "text": ""
    },
    "2557": {
      "name": "malignt cancers",
      "text": ""
    },
    "407": {
      "name": "SLC44A1",
      "text": ""
    },
    "159": {
      "name": "SLC17A9",
      "text": ""
    },
    "2001": {
      "name": "Bone cancer",
      "text": ""
    },
    "1819": {
      "name": "skin cancer",
      "text": ""
    },
    "272": {
      "name": "SLC25A51",
      "text": ""
    },
    "2146": {
      "name": "liver hepatocellular carcinoma (LIHC)",
      "text": ""
    },
    "85": {
      "name": "SLC8A1",
      "text": ""
    },
    "2344": {
      "name": "ureteral obstruction",
      "text": ""
    },
    "32": {
      "name": "SLC4A7",
      "text": ""
    },
    "2178": {
      "name": "Ras mutant pancreatic ductal adenocarcinom",
      "text": ""
    },
    "354": {
      "name": "SLC35G5",
      "text": ""
    },
    "30": {
      "name": "SLC4A4",
      "text": ""
    },
    "224": {
      "name": "SLC25A3",
      "text": ""
    },
    "1938": {
      "name": "Kidney Cancer",
      "text": ""
    },
    "2404": {
      "name": "triple-negative breast cancer(TNBC)",
      "text": ""
    },
    "2196": {
      "name": "glioma",
      "text": ""
    },
    "4": {
      "name": "SLC1A4",
      "text": ""
    },
    "2715": {
      "name": "lung adenocarcinoma",
      "text": ""
    },
    "2255": {
      "name": "multiple myeloma (MM)",
      "text": ""
    },
    "222": {
      "name": "SLC25A1",
      "text": ""
    },
    "94": {
      "name": "SLC9A5",
      "text": ""
    },
    "2025": {
      "name": "Anal Cancer",
      "text": ""
    },
    "1929": {
      "name": "Nasopharyngeal Carcinoma(NPC)",
      "text": ""
    },
    "381": {
      "name": "SLC39A4",
      "text": ""
    },
    "139": {
      "name": "SLC16A4",
      "text": ""
    },
    "2282": {
      "name": "Esophageal squamous cell carcinoma (ESCC)",
      "text": ""
    },
    "40": {
      "name": "SLC5A3",
      "text": ""
    },
    "2137": {
      "name": "hearts suffered ischemia/reperfusion (I/R)",
      "text": ""
    },
    "1845": {
      "name": "Endometrial Cancer (EC)",
      "text": ""
    },
    "2087": {
      "name": "Glioblastoma (GBM)",
      "text": ""
    },
    "405": {
      "name": "SLC43A3",
      "text": ""
    },
    "260": {
      "name": "SLC25A39",
      "text": ""
    },
    "1843": {
      "name": "Prostate Cancer",
      "text": ""
    },
    "416": {
      "name": "SLC45A4",
      "text": ""
    },
    "1893": {
      "name": "Thyroid Cancer",
      "text": ""
    },
    "12": {
      "name": "SLC2A4",
      "text": ""
    },
    "2412": {
      "name": "endometrial carcinoma (EC)",
      "text": ""
    },
    "190": {
      "name": "SLC22A7",
      "text": ""
    },
    "188": {
      "name": "SLC22A5",
      "text": ""
    },
    "3": {
      "name": "SLC1A3",
      "text": ""
    },
    "2770": {
      "name": "intrahepatic cholangiocarcinoma",
      "text": ""
    },
    "1821": {
      "name": "Germ Cell Tumor",
      "text": ""
    },
    "227": {
      "name": "SLC25A6",
      "text": ""
    },
    "112": {
      "name": "SLC11A1",
      "text": ""
    },
    "2477": {
      "name": "Kidney renal clear cell carcinoma (KIRC)",
      "text": ""
    },
    "288": {
      "name": "SLC27A2",
      "text": ""
    },
    "1897": {
      "name": "Heart Tumor",
      "text": ""
    },
    "2269": {
      "name": "Nonsmall cell lung cancer (NSCLC)",
      "text": ""
    },
    "2133": {
      "name": "autism spectrum disorders",
      "text": ""
    },
    "166": {
      "name": "SLC19A2",
      "text": ""
    },
    "226": {
      "name": "SLC25A5",
      "text": ""
    },
    "21": {
      "name": "SLC2A13",
      "text": ""
    },
    "2532": {
      "name": "Pulmory arterial hypertension (PAH)",
      "text": ""
    },
    "238": {
      "name": "SLC25A17",
      "text": ""
    },
    "2353": {
      "name": "inflammatory bowel disease",
      "text": ""
    },
    "2677": {
      "name": "Retinoblastoma",
      "text": ""
    },
    "2450": {
      "name": "Head and Neck tumors",
      "text": ""
    },
    "1900": {
      "name": "lymphoma",
      "text": ""
    },
    "2766": {
      "name": "Glioblastoma multiforme",
      "text": ""
    },
    "290": {
      "name": "SLC27A4",
      "text": ""
    },
    "299": {
      "name": "SLC29A2",
      "text": ""
    },
    "1805": {
      "name": "autophagy",
      "text": ""
    },
    "391": {
      "name": "SLC39A14",
      "text": ""
    },
    "2613": {
      "name": "Esophageal Cancer",
      "text": ""
    },
    "300": {
      "name": "SLC29A3",
      "text": ""
    },
    "116": {
      "name": "SLC12A2",
      "text": ""
    },
    "117": {
      "name": "SLC12A3",
      "text": ""
    },
    "2050": {
      "name": "Wilms Tumor",
      "text": ""
    },
    "1823": {
      "name": "Melanoma",
      "text": ""
    },
    "1804": {
      "name": "disulfidoptosis",
      "text": ""
    },
    "1940": {
      "name": "Cholangiocarcinoma",
      "text": ""
    },
    "143": {
      "name": "SLC16A8",
      "text": ""
    },
    "435": {
      "name": "SLC51B",
      "text": ""
    },
    "28": {
      "name": "SLC4A2",
      "text": ""
    },
    "39": {
      "name": "SLC5A2",
      "text": ""
    },
    "13": {
      "name": "SLC2A5",
      "text": ""
    },
    "233": {
      "name": "SLC25A12",
      "text": ""
    },
    "2360": {
      "name": "acute and chronic renal failure",
      "text": ""
    },
    "1834": {
      "name": "SLC7A12",
      "text": ""
    },
    "1920": {
      "name": "Cervical Cancer",
      "text": ""
    },
    "142": {
      "name": "SLC16A7",
      "text": ""
    },
    "2539": {
      "name": "Hepatic ischemia-reperfusion (I/R)",
      "text": ""
    },
    "2351": {
      "name": "celiac disease",
      "text": ""
    },
    "432": {
      "name": "SLC50A1",
      "text": ""
    },
    "199": {
      "name": "SLC22A16",
      "text": ""
    },
    "1803": {
      "name": "radioresistance",
      "text": ""
    },
    "2366": {
      "name": "SLC22A",
      "text": ""
    },
    "1817": {
      "name": "Myeloproliferative Neoplasms",
      "text": ""
    },
    "53": {
      "name": "SLC6A3",
      "text": ""
    },
    "1": {
      "name": "SLC1A1",
      "text": ""
    },
    "425": {
      "name": "SLC48A1",
      "text": ""
    },
    "2188": {
      "name": "colon adenocarcinoma (COAD)",
      "text": ""
    },
    "2440": {
      "name": "Venous thromboembolism (VTE)",
      "text": ""
    },
    "119": {
      "name": "SLC12A5",
      "text": ""
    },
    "97": {
      "name": "SLC9A8",
      "text": ""
    },
    "2470": {
      "name": "bladder urothelial carcinoma",
      "text": ""
    },
    "291": {
      "name": "SLC27A5",
      "text": ""
    },
    "2": {
      "name": "SLC1A2",
      "text": ""
    },
    "2717": {
      "name": "lung squamous cell carcinoma",
      "text": ""
    },
    "1828": {
      "name": "Testicular Cancer",
      "text": ""
    },
    "2668": {
      "name": "Vaginal Cancer",
      "text": ""
    },
    "146": {
      "name": "SLC16A11",
      "text": ""
    },
    "243": {
      "name": "SLC25A22",
      "text": ""
    },
    "403": {
      "name": "SLC43A1",
      "text": ""
    },
    "269": {
      "name": "SLC25A48",
      "text": ""
    },
    "2708": {
      "name": "glioblastoma",
      "text": ""
    },
    "100": {
      "name": "SLC9B2",
      "text": ""
    },
    "123": {
      "name": "SLC12A9",
      "text": ""
    },
    "2468": {
      "name": "uveal melanoma (UVM)",
      "text": ""
    },
    "2758": {
      "name": "papillary thyroid carcinoma",
      "text": ""
    },
    "27": {
      "name": "SLC4A1",
      "text": ""
    },
    "2097": {
      "name": "penile cancer",
      "text": ""
    },
    "1862": {
      "name": "Myelodysplastic Syndrome",
      "text": ""
    },
    "2756": {
      "name": "oral squamous cell carcinoma",
      "text": ""
    },
    "396": {
      "name": "SLC41A2",
      "text": ""
    },
    "79": {
      "name": "SLC7A9",
      "text": ""
    },
    "369": {
      "name": "SLC38A3",
      "text": ""
    },
    "326": {
      "name": "SLC35A2",
      "text": ""
    },
    "2234": {
      "name": "breast invasive carcinoma (BRCA)",
      "text": ""
    },
    "335": {
      "name": "SLC35C2",
      "text": ""
    },
    "395": {
      "name": "SLC41A1",
      "text": ""
    },
    "2763": {
      "name": "Invasive Lobular Carcinoma",
      "text": ""
    },
    "292": {
      "name": "SLC27A6",
      "text": ""
    },
    "120": {
      "name": "SLC12A6",
      "text": ""
    },
    "368": {
      "name": "SLC38A2",
      "text": ""
    },
    "2627": {
      "name": "Oral squamous cell carcinoma",
      "text": ""
    },
    "121": {
      "name": "SLC12A7",
      "text": ""
    },
    "11": {
      "name": "SLC2A3",
      "text": ""
    },
    "2739": {
      "name": "oral squamous cell carcinoma",
      "text": ""
    }
  },
  "relations": {
    "75-1801": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "apoptosis",
      "text": "Further study on the function of SLC7A5 gene in SKM-1 cell line showed that downregulation of SLC7A5 inhibited SKM-1 cells proliferation, increased apoptosis and caused cell cycle arrest in the G0/G1 stage.\nYAP/TAZ protects cells from KRAS inhibitor-induced apoptosis by downregulating the expression of proapoptotic genes such as BMF, BCL2L11, and PUMA\nSLC7A5 knockdown in LUSC cells reduces colony formation and induces apoptosis.\nSlc7a5 deletion in chondrocytes led to general disorganization of chondrocytes in the vertebral growth plate, along with an increase in apoptosis and a decrease in cell proliferation.\nThese findings indicate that SLC7A5 mediates the effect of Dex on cell viability, thus providing a novel molecular target for the prevention and treatment of Dex-induced cell cycle arrest and apoptosis in placental cells.\nCirc-SLC7A5 depletion impaired cell growth, migration, invasiveness, and promoted apoptosis.\nTransfection of microRNA-194 mimics increased apoptosis of H9c2 cells, which was rescued by overexpression of pcDNA3/Slc7a5.\nMoreover, laboratory experiments confirm that SLC7A5 promotes the proliferation of NSCLC cells, and the knockout of SLC7A5 significantly increases tumor cell apoptosis.\nWe identified how miR-626 causes apoptosis and macula degeneration in RPE cells by targeting SLC7A5 through the mTOR signaling pathway.\nThe impaired amino acids uptake leads to inhibition of mTOR signaling which in turn causes inhibited proliferation and enhanced autophagy and apoptosis in BeWo cells.\nWe show here that a potent and LAT1 selective inhibitor (JPH203) decreased leukemic cell viability and proliferation, and induced transient autophagy followed by apoptosis.\nNext, loss-of-function experiments demonstrated that LINC00857 knockdown suppressed CRC cell viability, proliferation and migration, as"
    },
    "1801-1856": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "colorectal cancer(CRC)",
      "text": "Morin inhibited the viability, migration, and invasion of 5-FU/CRC cells and promoted apoptosis.\nCEMIP downregulation inhibited CRC cell growth, migration, invasion, and stemness while promoting apoptosis.\nIn vitro, FZYL inhibited SW620 cell proliferation and induced apoptosis via the IGF2/IGF1R/PI3K/AKT pathway.\nAstaxanthin promotes apoptosis by suppressing growth signaling pathways in HT-29 colorectal cancer cells.\nThis upregulation suppressed CRC cell migration and invasion, induced G2/M cell cycle arrest, and promoted apoptosis.\nIt also induced apoptosis and inhibited β-catenin and PI3K/Akt signaling, while upregulating cholesterol efflux genes.\nAmong SCFAs, sodium butyrate (NaB) is known to inhibit TS expression, reduce CRC cell viability, and promote apoptosis.\nPD15, a steroidal saponin, induces apoptosis of HCT116 colorectal cancer cells via suppressing the Akt/GSK3β pathway.\nCathayanon E induces apoptosis and enhances oxaliplatin sensitivity in colorectal cancer through suppression of MCL1.\nA 1H-1,5-benzodiazepine derivative induces apoptosis in colorectal cancer cells by inhibiting JAK/STAT signaling pathway.\nFuzheng YiLiu decoction promote colorectal cancer apoptosis and reduce its proliferation via IGF2/IGF1R/PI3K/AKT pathway.\nWe demonstrated that thymol significantly inhibited the proliferation, viability, and induced apoptosis of HCT116 and CT26 cells.\nUpregulating DST inhibited CRC and DDP-resistant cell viability, proliferation, invasion, and migration while promoting apoptosis.\nThe cell extracts of lactobacilli strains combined with 5-FU reduced HT-29 cell viability effectively and increased cell apoptosis."
    },
    "418-1795": {
      "type": "slc_pathway",
      "key1": "SLC46A1",
      "key2": "proliferation",
      "text": "Although SLC19A1 mRNA and protein expression were unaltered, remarkably, mitogen induced-T cell proliferation was significantly reduced at suboptimal folic acid and supraoptimal folinic acid concentrations.\nl-LV displayed an 8-fold and 3.5-fold higher substrate affinity than d-LV for the reduced folate carrier (RFC/SLC19A1) and proton coupled folate transporter (PCFT/SLC46A1), respectively.\nIn MCF10A and Hs578T cells, FA treatment decreased pathways associated with apoptosis, cell death and senescence, but increased those associated with cell proliferation.\nThese findings suggest that physiological concentrations of FA can induce cell type-specific changes in gene regulation in a manner that is consistent with proliferative phenotype.\nFD caused cell cycle arrest at G0/G1 phase and increased the rate of apoptosis, which was associated with disrupted expression of folate transport and methyl transfer genes.\nHere we use HT-22 hippocampal neuron cells as model to investigate the effect of folate deprivation (FD) on cell proliferation and apoptosis, and to elucidate the underlying mechanism.\nTitle: Folate deprivation induces cell cycle arrest at G0/G1 phase and apoptosis in hippocampal neuron cells through down-regulation of IGF-1 signaling pathway.\nFOLR1 and SLC46A1 were (P<0.01) down-regulated, while SLC19A1 was up-regulated (P<0.01) in FD group.\nThe folate transporters SLC19A1, SLC46A1 and FOLR1 were differentially expressed between cell lines tested.\nThe patient demonstrated a combined immunodeficiency with an impaired T cell proliferation response, pan-hypogammaglobulinemia, and an imbalanced pro-inflammatory cytokine profile.\nT cell proliferation, methotrexate resistance, NK cell cytotoxicity, Treg cells and cytokine production by T cells were examined by flow cytometric assays.\nUsing proliferation assays, we investigated their potential to protect cancer cells from cytot"
    },
    "1795-1872": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "breast cancer(BC)",
      "text": "These factors activate oncogenic pathways (NF‑κB and PI3K/AKT/mTOR pathways), which promote DNA damage, cell proliferation and immunosuppression.\nBy inhibiting FAK activation and upregulating PIK3IP1, Ifebemtinib and paclitaxel blocked the PI3K/Akt pathway, effectively suppressing TNBC proliferation and metastasis.\nFunctional assays including colony formation, Transwell, and apoptosis detection demonstrated that FDX1 upregulation inhibited proliferation, migration, invasion, and promoted apoptosis.\nMechanistically, in CUBs we observed that LicA downregulated PI3K-AKT-SREBP1-dependent lipogenesis, NF-kB-dependent inflammation, and de novo nucleotide biosynthesis, stalling proliferation.\nIn vivo, the combination inhibited TNBC cell proliferation and spontaneous lung metastasis.\nKnockdown of UGP2 in vitro can inhibit the proliferation, migration and invasion abilities of breast cancer cells.\nSublethal SKD (25 nM) impaired migration in MDA-MB-231 cells and reduced proliferation and motility in SUM149 cells.\nAs for its biofunctions, overexpression of ASCL2 promoted proliferation, migration and invasion of MCF-7 and MDA-MB-231 cells.\nIn vitro, the combination of Ifebemtinib and paclitaxel synergistically suppressed proliferation and colony-formation of TNBC cells.\nIncreased proliferation of BC cells in response to tamoxifen (TAM) and its metabolites (TAM+M) has been shown to rely on the cell's BK status.\nOur investigation revealed that TRIM25 effectively promoted cell proliferation, cell cycle progression, and paclitaxel chemoresistance of BC cells.\nWe demonstrated that LicA significantly reduced proliferation in seven human breast cell lines and suppressed ER+ and ER- xenograft tumors in mice.\nMethotrexate (MTX) is one of the most prevalent drugs used in the treatment of autoimmune disorders as it"
    },
    "136-1796": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "ferroptosis",
      "text": "Finally, through inhibiting SLC7A11 expression, silencing SLC16A1-AS1 induced ferroptosis via increasing miR-143-3p.\nThe present results suggest that silencing lncRNA SLC16A1-AS1 can induce ferroptosis through miR-143-3p/SLC7A11 signaling in renal cancer.\nIn addition, through the construction of stable SLC16A1 knockdown and overexpression models in HNSCC cells along with and experiments, the study comprehensively illuminated the pivotal role of SLC16A1 in promoting the proliferation, migration, and invasiveness of HNSCC cells, as well as enhancing their resistance to ferroptosis.\nOur research findings indicate that SLC16A1 acts as an oncogene in HNSCC, and that abnormally high expression of SLC16A1 significantly accelerates the development and progression of HNSCC by conferring resistance to ferroptosis.\nexperimental results demonstrated that when SLC16A1 was knocked down, the proliferation, migration, and invasion capabilities of HNSCC cell lines were significantly reduced and the extent of RAS-selective lethal 3-induced lipid peroxidation increased compared with control cells.\nKnockdown SLC16A1-AS1 inhibited cell viability, proliferation, and migration of renal cancer cells.\nexperiments further corroborated the pivotal role of SLC16A1 in promoting HNSCC tumor growth.\nFurthermore, it was demonstrated that SLC16A1-AS1 served as a sponge of miR-143-3p, and knockdown SLC16A1-AS1 significantly increased the enrichment of miR-143-3p.\nConversely, HNSCC cell lines overexpressing SLC16A1 exhibited enhanced proliferation, migration, and invasion capabilities, accompanied by lower levels of lipid peroxidation.\nMoreover, knockdown SLC16A1-AS1 could aggravate this effect.\nAnd then, SLC7A11 was identified as the target protein of miR-143-3p, and overexpression miR-143-3p remarkably inhibited the expression of SLC7A"
    },
    "1796-1993": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Laryngeal Cancer",
      "text": ""
    },
    "371-1802": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1802-2583": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "ischemic proliferative retinopathies",
      "text": ""
    },
    "81-1796": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "ferroptosis",
      "text": "GLEXG and quercetin alleviate GTW-induced SGD by inhibiting ferroptosis via HIF-1α/SLC7A11.\nMechanistically, ACSL1 elevated ROS, activated p53, downregulated SLC7A11/GPX4, and triggered ferroptosis.\nHOXA13 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating SLC7A11 and SLC3A2.\nOur findings indicate that RBMS2 inhibits CRC progression by promoting ferroptosis and regulating SLC7A11 mRNA stability.\nBECN1 activator peptide Tat-beclin 1 promotes ferroptosis via the BECN1-SLC7A11 axis to inhibit NSCLC progression.\nPteris wallichiana bioactives induce ferroptosis via the SLC7A11-GSH-GPX4 axis to directly suppress colorectal cancer.\nIn summary, ALA inhibits ferroptosis in macrophages by activating the Nrf2/SLC7A11/GPX4 pathway and attenuates HS-induced ALI.\nSesamin promotes the survival of skin flaps in rats by inhibiting ferroptosis through the Nrf2/SLC7A11/GPX4 signaling pathway.\nFindings demonstrate that HnRNPU promotes proliferation and inhibits ferroptosis by regulating the mRNA stability of SLC7A11 and SLC3A2.\nTat-beclin 1 promotes ferroptosis and tumor suppression in NSCLC by activating BECN1 and inhibiting SLC7A11-mediated system Xc⁻ activity.\nExpression of COX2 was downregulated, whereas key ferroptosis suppressors, SLC7A11, GPX4, and FTH1, were upregulated following hUC-MSC treatment.\nIGF2BP2 plays a critical role in NSCLC by stabilizing SLC7A11 mRNA via m6A modification, promoting cell proliferation and suppressing ferroptosis."
    },
    "1796-2747": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "liposarcoma",
      "text": ""
    },
    "232-1794": {
      "type": "slc_pathway",
      "key1": "SLC25A11",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2119": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": ""
    },
    "225-1795": {
      "type": "slc_pathway",
      "key1": "SLC25A4",
      "key2": "proliferation",
      "text": "SLC25A4 attenuated cell proliferation, cell invasion, and exerted its biological function by inhibiting the STAT3 signaling pathway.\n-overexpressing OS cells exhibited suppressed proliferation, migration, invasion and enhanced apoptosis.\nResults showed that PBD-2 could interact with pro-apoptotic solute carrier family 25 member 4 (SLC25A4), also known as adenine nucleotide translocase 1, and thereby inhibited SIV-induced cell apoptosis.\nThis remodeling impairs mitochondrial lipid transport and results in neutral lipid accumulation, thereby suppressing HCC proliferation.\nThen CCK-8 assay showed significantly decreased cell proliferation, and the inhibition of migration was verified by scratch wound healing assay and transwell assay.\nPorcine β-defensin 2 (PBD-2) is a host defense peptide and our previous study has shown that PBD-2 inhibits proliferation of enveloped pseudorabies virus both in vitro and in transgenic (TG) mice.\nUsing cell cycle analysis and Annexin V/PI straining assay, G1 phase cell cycle arrest was found to be a reason for the suppression of cell proliferation and migration upon REST silencing, while apoptosis was not affected by REST silencing.\nELF-MF exposure altered the expression levels of several PBMC proteins without affecting cell proliferation, cell viability, or cell cycle progression.\nElevated NAD activates sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK), leading to remodeling of lipid metabolism.\nThe proportion of Ki67 cells and the concentration of nitric oxide (NO) were high in SRGN high expression cells, suggesting that SRGN may be involved in the proliferation of HUVECs.\nThis study proposes a stratified therapeutic approach: targeting the SLC25A4-NAD-SIRT1-AMPK axis may benefit HCC patients with preserved SLC25A4 expression.\nIn conclusion, ELF-MF exposure induces metabolic reprogramming in human PBMCs, characterized by the upregulation of mitochon"
    },
    "1795-1856": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "colorectal cancer(CRC)",
      "text": "These mutations activate pathways that drive cell proliferation, impair differentiation, and suppress apoptosis.\nINHBB was upregulated in CRC, and the alleviation of INHBB suppressed the proliferation and migration of CRC cells.\nBaicalein inhibits proliferation, suppresses metastasis, induces apoptosis, and modulates key pathways like PI3K/Akt, MAPK, and TLR4/NF-κB.\nFurthermore, cell phenotype assays demonstrated that enhances proliferation and migration, suppresses apoptosis, and engages in the signaling pathway.\nIn CRC cells, lentivirus-mediated 5-HT7 overexpression enhanced proliferation, migration, and invasion, whereas RNA interference-mediated knockdown suppressed these processes.\nMechanistically, reactive oxygen species (ROS) accumulation drives senescence and autophagy inhibition, which inactivates the PI3K/AKT/mTOR pathway, thereby inhibiting CRC cell proliferation, invasion, and migration.\nKnockdown of PIN1 in MSS CRC cells significantly reduced cell proliferation (assessed by CCK-8 assay), impaired migratory capacity (assessed via wound-healing assay), and increased the apoptotic rate (detected by flow cytometry).\nOur study revealed that CACNA2D3, which is expressed at low levels in CRC, inhibits CRC cell proliferation and promotes apoptosis by up-regulating intracellular Ca and ROS levels and activating the mitochondrial apoptotic pathway.\nPINK1 acts as a tumor suppressor in colorectal cancer by inhibiting proliferation and migration, promoting apoptosis, and remodeling the epigenetic landscape through altering histone modifications and enhancing chromatin accessibility.\nIn conclusion, Frondanol inhibits CRC cell proliferation and induces apoptosis through the mitochondrial pathway in vitro, suggesting that it is a potential nutraceutical for the prevention of human colorectal cancer or a valuable source of anticancer compounds.\nWe identified 226 differentially expressed genes from TCGA-CRC cohort, among which the upregulated genes were mainly involved in pathways of cancer progression, proliferation, migration,"
    },
    "25-1796": {
      "type": "slc_pathway",
      "key1": "SLC3A2",
      "key2": "ferroptosis",
      "text": "SLC3A2 and SLC7A11 are two subunits of the system x, which is one key inhibitory regulator of ferroptosis.\nHOXA13 drives PCa progression by transcriptionally activating SLC7A11 and SLC3A2, which suppress ferroptosis and enhance proliferation and metastasis.\nMechanistically, ERα transcriptionally upregulated the expression of SLC7A11 and SLC3A2, two subunits of the system x, which is one key inhibitory regulator of ferroptosis.\nOverexpression of the exogenous SLC7A11 and SLC3A2 was able to mitigate ferroptosis induced by ERα inhibition.\nKnockdown of SLC3A2 promoted ferroptosis, inflammation, and fibrosis, while BMSCs reversed these effects, likely through the inhibition of the MAPK signaling pathway.\nFurthermore, HOXA11-AS was found to enhance SLC3A2 expression, a key regulator of ferroptosis, by interacting with the transcriptional repressor POU2F2.\nIFN-γ activated STAT1 phosphorylation and downregulated system Xc components solute carrier family 3 member 2 (SLC3A2), glutathione, and GPX4 thereby triggering ferroptosis in SGEC.\nTaken together, knockdown of hsa_circ_0050900 inhibited SLC3A2 expression via sponging hsa-miR-605-3p to promote ICC cell ferroptosis, and finally suppressed proliferation and migration.\nMechanically, SLC3A2 deficiency facilitated ferroptosis through upregulating the expression of mTOR and P70S6K, whereas inhibited p-mTOR and p-P70S6K expression in laryngeal carcinoma cells.\nMoreover, Mo and/or Cd exposure could downregulate the expression levels of xCT (SLC7A11 and SLC3A2), GPX4 and FTH-1 and upregulate the expression levels of PTGS2 and NCOA4, which led to iron over"
    },
    "1796-1917": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Gastric cancer (GC)",
      "text": "Sorafenib, a tyrosine kinase inhibitor, has an important antitumor effect as a ferroptosis inducer in multiple cancers, including gastric cancer (GC).\nXN4 promotes ferroptosis of gastric cancer (GC) cells.\nNOX4 expression in gastric cancer (GC), its prognostic significance, and underlying mechanisms, focusing on promoting ferroptosis through increased ROS production.\nYiqi Huayu Decoction (YQHY) induced ferroptosis in gastric cancer (GC) by using network pharmacology and experimental validation.\nSince the discovery of ferroptosis, which plays an important role in gastric cancer (GC), its activation has been crucial for developing tumor therapeutic strategies.\nMETTL14 promoted ferroptosis and inhibited GC cell malignancy through SIRT5.\nCOL12A1 specifically enhanced GC cell progression and stemness via suppressing ferroptosis.\nDownregulation of TPM4 inhibits GC cell growth and induces ferroptosis by suppressing SCD1 expression.\nAC enhanced ferroptosis and repressed immune escape by downregulating the Wnt/β-catenin signaling in GC.\nUBE2C-mediated ubiquitination of ACSL4 inhibits ferroptosis and promotes gastric cancer progression.\nSIRT1/APE1 promotes the viability of gastric cancer cells by inhibiting p53 to suppress ferroptosis.\nDioscin induces ferroptosis to suppress the metastasis of gastric cancer through the SLC7A11/GPX4 axis.\nHD-SB was shown to induce ferroptosis in GC cells by suppressing the PI3K/AKT/HIF-1α pathway.\nOphiopogonin B induces gastric cancer cell death by blocking the GPX4/xCT-dependent ferroptosis pathway.\nThrough targeting the MYB/AKR1B10/ACC axis, exo-miR-1911-5p inhibits ferroptosis to enhances cisplatin resistance.\nBrucine Inhibits Gastric Cancer via Activation of Ferroptosis Through Regulating"
    },
    "9-1800": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "migration",
      "text": "Loss of tumor-suppressive miR-1291 enhanced RCC cell proliferation, migration and invasion through targeting SLC2A1/GLUT1.\nDownregulation of SLC2A1 could not only inhibit cell proliferation, migration and cell cycle, but also promote cell apoptosis.\nKnockdown of SLC2A1 resulted in reduced cell viability, decreased migration, and increased apoptosis in Caco-2 and SW480 cells.\nIn vitro functional experiments have shown that knocking down SFXN1 inhibits the proliferation and migration of LUAD cells, promotes cell apoptosis, and may inhibit tumor activity by regulating the expression of glycolytic related genes SLC2A1, HK2, GPI, ALDOA, GAPDH, ENO1, PKM, and LDHA.\nknockdown of these genes in LUAD cells by transfection with small interfering RNAs significantly inhibited LUAD cell proliferation and migration, and promoted anoikis.\nIn PC9 cells, SLC2A1 overexpression significantly promoted cell proliferation, invasion and migration, and SLC2A1 knockdown significanty increased cell death and inhibited cell invasion and proliferation.\nIn vitro cell experiments have shown that interfering with DARS2 expression can inhibit the proliferation and migration of LUAD cells, promote cell apoptosis, and inhibit the glycolytic activity of tumor cells by inhibiting the expression of glycolytic related genes SLC2A1, GPI, ALDOA, and PGAM1.\nTogether, silencing PVT1 downregulated SLC2A1 expression via targeting miR-378c, and then repressed lung ADC cells growth, migration, and invasion.\nCC-DG inhibited the proliferation, migration, invasion of SGC7901/MFC gastric cells, and in turn, suppressed tumorigenesis by regulating glucose metabolism through regulation of LDHA and SLC2A1 genes.\nTargeted inhibition of glycolysis via SLC2A1 siRNA attenuated metabolic stress, evidenced by reduced extracellular acidification rate (Seahorse) and tricarboxylic"
    },
    "1800-1868": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "lung cancer",
      "text": ""
    },
    "1796-1809": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Bone Cancer",
      "text": "Inhibition of spinal ferroptosis-like cell death alleviates hyperalgesia and spontaneous pain in a mouse model of bone cancer pain.\nPVT1 promotes OS metastasis by activating the STAT3/GPX4 pathway to inhibit ferroptosis.\nMicroRNA-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4.\nLncRNA-PVT1 Inhibits Ferroptosis through Activating STAT3/GPX4 Axis to Promote Osteosarcoma Progression.\nSLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.\nLncSNHG14 promotes nutlin3a resistance by inhibiting ferroptosis via the miR-206 /SLC7A11 axis in osteosarcoma cells.\nRab27b-mediated CAFs derived exosomal miR-22-3p suppresses ferroptosis and promotes cisplatin resistance in osteosarcoma.\nExperiments in vivo validated that CAFs derived exosomal miR-22-3p downregulated ferroptosis and promoted resistance to cisplatin.\nRBM15-mediated the m6A modification of MAT2A promotes osteosarcoma cell proliferation, metastasis and suppresses ferroptosis.\nMechanistically, the increased radiosensitization of OS cells by the combined use of the two inhibitors was mediated by increased ferroptosis.\nExosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1.\nMETTL5-mediated m6A modification of UBE3C promotes osteosarcoma progression by suppressing ferroptosis via inducing AHNAK ubiquitination.\nIn vivo, SHK effectively suppressed OS growth with favourable biosafety, confirming the molecular mechanism underlying SHK-induced ferroptosis in OS.\nMechanistically, ACBP-mediated FAO increased ATP and NADPH production, reduced reactive"
    },
    "106-1796": {
      "type": "slc_pathway",
      "key1": "SLC10A3",
      "key2": "ferroptosis",
      "text": "In vivo experiments also demonstrated that silencing SLC10A3 effectively induces ferroptosis in GBM and inhibits GBM progression.\nFunctional analysis showed that SLC10A3 regulates GBM growth and progression through ferroptosis and that silencing SLC10A3 enhances sensitivity to the ferroptosis inducer Erastin.\nMechanistically, SLC10A3 modulates STAT3 transcription and phosphorylation, impacting GBM ferroptosis via the STAT3-GPX4 pathway, and the STAT3 phosphorylation inhibitor Stattic effectively reverses this process.\nSLC10A3 correlated with immune infiltration in LGG and moderately correlated with the gene signature of pyroptosis, lysosome-dependent cell death, necroptosis, apoptosis, ferroptosis, alkaliptosis, and autophagy-dependent cell death.\nFerroptosis is closely related to disease progression and treatment response in human brain gliomas;\nFunctional analysis showed that SLC10A3 might participate in the transport of multiple substances, neurogenic signaling, immune response, and programmed cell death in LGG.\nIdentifying new ferroptosis regulatory factors holds promise for addressing the aberrant regulation of ferroptosis in glioblastoma (GBM) and overcoming its treatment resistance."
    },
    "1796-1806": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Brain Tumor",
      "text": "Ferroptosis, a regulated form of cell death induced by lipid peroxidation, has been identified as a natural tumor suppression mechanism in various cancers.\nFerroptosis is a type of regulated cell death that plays an essential role in various brain diseases, including cranial trauma, neuronal diseases, and brain tumors.\nIn GBM, ferroptosis stimulation inhibits tumor growth, improves patient survival, and increases the efficacy of radiation and chemotherapy.\nFerroptosis, a recently discovered regulated cell death, can be induced for killing glioma cells.\nFerroptosis, a newly discovered mechanism of regulated cell death, has been identified as a tumor suppressor in solid tumors and represents an alternative to apoptosis resistance.\nZBTB20 promotes ferroptosis through inhibiting TMEM109 expression in glioblastoma cells.\nKIF4A inhibits ferroptosis in GBM cells through the CHMP4B/GPX4 axis and promotes TMZ resistance.\nPseudolaric acid B triggers ferroptosis in glioma cells via activation of Nox4 and inhibition of xCT.\nKDM2B promotes chemoresistance in glioma cells by inhibiting ferroptosis via the LINC01018/miR-182-5p axis.\nFatostatin induces ferroptosis through inhibition of the AKT/mTORC1/GPX4 signaling pathway in glioblastoma.\nDown-regulated BNC1 promotes glioma by inhibiting ferroptosis via TCF21/PI3K signaling pathway.\nLINC01564 Promotes the TMZ Resistance of Glioma Cells by Upregulating NFE2L2 Expression to Inhibit Ferroptosis.\nThe ubiquitin hydrolase OTUB1 promotes glioma cell stemness via suppressing ferroptosis through stabilizing SLC7A11 protein.\nLongikaurin A induces ferroptosis and inhibits glioblastoma progression through DNA methylation - Mediated GPX4 suppression.\nIn conclusion, the findings indicated that promotes ferroptosis in GBM cells through transcriptionally repressing the expression of."
    },
    "180-1794": {
      "type": "slc_pathway",
      "key1": "SLCO1B3",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2056": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Cervical cancer",
      "text": ""
    },
    "81-1801": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "apoptosis",
      "text": "Restoring the expression of SLC7A11/GPX4 can enhance cell viability, alleviate neuronal apoptosis, and reduce Fe overload.\nGas (25µM) increased cell viability, decreased LDH, Fe, MDA and ACSL4 levels, up-regulated SLC7A11 and GPX4 and ameliorated OGD/R-induced apoptosis (P < 0.01).\nMoreover, Icariside II suppressed SKOV3 cell proliferation, inhibited cells migration and invasion, and promoted apoptosis by downregulating SLC7A11 expression.\nPDT promotes apoptosis and ferroptosis of cholangiocarcinoma cells by activating the P53/SLC7A11/GPX4 signaling pathway and inhibits the growth of cholangiocarcinoma.\nVB promoted the proliferation and inhibited apoptosis, inflammation and ferroptosis in OGD/R-treated SK-N-SH cells by regulating METTL14/CHAC1/NRF2/SLC7A11/GPX4 pathway.\nOverexpression of miR-490-3p downregulated the expression of SLC7A11, inhibiting the proliferation, invasion, and metastasis of HCC cells while promoting apoptosis and erastin-induced ferroptosis.\nCordycepin suppressed HG-induced apoptosis, inflammation, and ferroptosis in podocytes in vitro, and ameliorated renal injury and inflammation in STZ-induced diabetic mice by activating the SLC7A11/GPX4 pathway.\nIn summary, CBR-470-1 prevented I/R-mediated cardiac injury possibly through inhibiting cardiomyocyte apoptosis, ferroptosis and pyroptosis via Nrf2-mediated inhibition of p53 and Nlrp3 and activation of the SLC7A11/GPX4 pathway.\nMoreover, AKR1C1 upregulation repressed cell apoptosis and ferroptosis induced by ICH through downregulating the expression of pro-apoptotic factors, inhibiting iron accumulation and lipid peroxidation,"
    },
    "1801-2154": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "preeclampsia (PE)",
      "text": "Overexpression of hsa-miR-335-5p in trophoblast cells resulted in inhibited proliferation, decreased invasion, and increased apoptosis, particularly under hypoxic conditions.\nWhen the PHLDA2 was overexpressed in JEG-3 cells, the proliferative proteins were significantly reduced, while the expression levels of apoptosis-related proteins p27 and cleaved-caspase3 were significantly increased.\nCollectively, this study reveals for the first time that IRN mitigates PE-associated pathological phenotypes by activating the PI3K/AKT/mTOR pathway, thereby ameliorating mitochondrial dysfunction and inhibiting oxidative stress and apoptosis in trophoblast cells.\nExpression of the delactylation-mimetic K469R/K473R mutant significantly attenuated hypoxia-induced mitochondrial fragmentation, preserved mitochondrial membrane potential, reduced cytochrome c release and caspase-3 activation, and maintained trophoblast invasive capacity.\nMoreover, IRN inhibited the expression of apoptosis-related markers, underscoring its potent anti-apoptotic effects.\nFunctional studies revealed that Hsp60 lactylation promotes mitochondrial fission by modulating Drp1 phosphorylation, increases mitochondrial ROS production, and sensitizes trophoblasts to apoptosis.\nReduced CD34 levels were found to exacerbate endothelial oxidative stress and induce inflammation-related endothelial pyroptosis in the placenta.\nMost importantly MLT treatment significantly upregulated CD34 expression and downregulated proinflammatory cytokine levels in PE animal and cell models, thereby inhibiting pyroptosis.\nPreeclampsia is characterized by placental hypoxia and metabolic reprogramming toward glycolysis, leading to increased lactate production and protein lactylation.\nUsing placental tissue microarrays and HTR-8/SVneo trophoblast cells, we found that Hsp60 undergoes aberrant lactylation in preeclamptic placentas, particularly under hypoxic conditions.\nThese findings identify Hsp60 lactylation as a novel mechanism linking metabolic adaptation to mitochon"
    },
    "367-1797": {
      "type": "slc_pathway",
      "key1": "SLC38A1",
      "key2": "oxidative stress",
      "text": "RIPK1 inhibition in Mecp2-deficient microglia reduced oxidative stress, cytokines production and induction of SLC7A11, SLC38A1, and GLS, which mediate the release of glutamate.\nSLC38A1 was identified as a significantly downregulated marker for aging skeletal muscle.\nMoreover, increased expression of GLS and SLC38A1 was observed exclusively at the 2.5 concentration group, suggesting a shift in glutamate synthesis mechanisms depending on PQ exposure levels.\nGlutamate emerged as a pivotal metabolite, with its upregulation being accompanied by a significant increase in SLC7A11 expression increasing with PQ concentration, indicating an enhanced cellular response to oxidative stress via glutathione synthesis.\nand upregulated the ferroptosis-associated genes, including Ptgs2 (prostaglandin-endoperoxide synthase 2), GLS2 (glutaminase 2), solute carrier family 1 member 5 (SLC1A5), and solute carrier family 38 member 1 (SLC38A1) in HT22 cells, indicating the inductive role of FA in the ferroptosis of HT22 cells.\nIn contrast, SLC38A1 overexpression markedly reduced the accumulation of ROS, mtROS, iron concentration, and lipid peroxidation associated with D-gal treatment in these cells.\nIn both D-gal treated and sh-SLC38A1 C2C12 cells, increased ROS levels, elevated mtROS, higher intracellular iron concentrations, and intensified lipid peroxidation were observed.\nOverexpression of SLC38A1 mitigated cellular aging in D-gal treated C2C12 cells.\nIn conclusion, through screening analyses and validation experiments, we identified SLC38A1 as a ferroptosis-related regulator for skeletal muscle aging.\nOur work underscores the role of Gln transporters and the NUPR1-mediated stress response in PCa cell survival, oxidative stress, mitochondrial functions, and radioresistance.\nAnalysis of the hippocampus performed 6 months after the exposure"
    },
    "1797-2119": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": ""
    },
    "127-1796": {
      "type": "slc_pathway",
      "key1": "SLC13A3",
      "key2": "ferroptosis",
      "text": "Furthermore, silencing of SLC13A3 depletes GSH and induces autophagic ferroptosis in β-catenin-activated liver cancer cells.\nMechanistically, tumor cells uptake itaconate via SLC13A3 from tumor-associated macrophages (TAMs), thereby activating the NRF2-SLC7A11 pathway and escaping from immune-mediated ferroptosis.\nThus, we identify the interplay between tumors and TAMs via the SLC13A3-itaconate-NRF2-SLC7A11 axis as a previously unknown immune ferroptosis resistant mechanism in the TME and SLC13A3 as a promising immunometabolic target for treating SLC13A3 cancer.\nHere, we discover SLC13A3 is an itaconate transporter in tumor cells and endows tumor ferroptosis resistance, diminishing tumor immunity and ICB efficacy.\nDeletion of ACOD1 (an essential enzyme for itaconate synthesis) in macrophages, genetic ablation of SLC13A3 in tumors, or treatment with SLC13A3i sensitize tumors to ferroptosis, curb tumor progression, and bolster ICB effectiveness.\nImmune checkpoint blockade (ICB) triggers tumor ferroptosis.\nTumors might evade ferroptosis in the tumor microenvironment (TME)."
    },
    "1796-1831": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Neuroendocrine Tumor",
      "text": "MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors.\nGW4869 mediated PD-L1 based exosomal inhibition revitalized T cells and enhanced the ferroptosis.\nMoreover, upregulated interferon-γ efficiently inhibits system x activity and sensitizes cancer cells to Ferroptosis.\nBy suppressing the expression of target gene DKK1, miR-130b-3p activated the Nrf2/HO-1 pathway, whereby repressing ferroptosis.\nThen we proved that CAMKK2 negatively regulated ferroptosis through the activation of NRF2 and the suppression of lipid peroxidation.\nWe found that inhibition of DCPS by shRNA or RG3039 induced gene transcript alteration and ferroptosis through reducing the mRNA turnover of GLRX.\nIn conclusion, ELK4 enhances proliferation, invasion, and migration while inhibiting ferroptosis in SKCM cells by upregulating CHMP6 transcription.\nWe also show that Arg2 suppresses ferroptosis by activating the Akt/GPX4 signaling pathway, negatively regulating sorafenib-induced cell death in melanoma cells.\nIn vivo experiments confirmed that vemurafenib treatment enhanced PSMB9 expression, increased iron ion accumulation, and suppressed tumor growth via ferroptosis induction.\nThus, T cell-promoted tumour ferroptosis is an anti-tumour mechanism, and targeting this pathway in combination with checkpoint blockade is a potential therapeutic approach.\nAt the same time, the expression of ATF3 protein increased and the expression of NRF2 protein decreased, suggesting that metformin may induce ferroptosis through the ATF3/NRF2 axis.\nFerroptosis, driven by iron-dependent lipid peroxidation (LPO), enhances immunogenicity through damage-associated molecular pattern (DAMP) release and depletion of immunosuppressive cells.\nMeanwhile lipid peroxidation is a hallmark of ferroptosis, and we confirm that MEN1 promotes ferroptosis by inhib"
    },
    "81-1795": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "proliferation",
      "text": "EOGT knockdown promotes ferroptosis and inhibits hepatocellular carcinoma proliferation by regulating SLC7A11 via HEY1.\nHnRNPU promotes proliferation and inhibits ferroptosis by regulating the mRNA stability of SLC7A11 and SLC3A2.\nKnockdown of EOGT inhibited HCC cell proliferation and enhanced sensitivity to ferroptosis by downregulating SLC7A11, a process mediated by HEY1.\nIGF2BP2 plays a critical role in NSCLC by stabilizing SLC7A11 mRNA via m6A modification, promoting cell proliferation and suppressing ferroptosis.\nIncreased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway.\nIcariside II suppressed SKOV3 cell proliferation, inhibited cells migration and invasion, and promoted apoptosis by downregulating SLC7A11 expression.\nVB promoted the proliferation and inhibited apoptosis, inflammation and ferroptosis in OGD/R-treated SK-N-SH cells by regulating METTL14/CHAC1/NRF2/SLC7A11/GPX4 pathway.\nConsistent with its inhibitory role in ferroptosis, FERRIN promotes in vitro cancer cell proliferation and in vivo xenograft tumor growth through its modulation of SLC7A11.\nTIMP1 knockdown enhanced ferroptosis sensitivity, suppressed CRC cell proliferation and migration, and reduced expression of ferroptosis regulators GPX4 and SLC7A11.\nKnockdown of circRNA_0030042 promoted the proliferation, repressed the iron ion level, ROS level, increased SLC7A11 and GPX4 protein expressions in HO-induced AC16 cells via miR-568/PRG4 pathway.\nCD2AP silencing inhibited HCC cell proliferation and enhanced disulfidptosis susceptibility in SLC7A11-high cells, likely via NADPH depletion and actin network disruption."
    },
    "1795-2209": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "313-1802": {
      "type": "slc_pathway",
      "key1": "SLC31A1",
      "key2": "oxidative phosphorylation",
      "text": "Targeted deletion of CTR1 in neuroblastoma cells produced copper deficiency that was associated with a metabolic shift favoring glycolysis over oxidative phosphorylation."
    },
    "1802-1836": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "pancreatic cancer(PC)",
      "text": "Our study revealed that glycolytically suppressed cells upregulated mitochondrial function and relied on oxidative phosphorylation (OXPHOS) to obtain the ATP necessary for their survival.\nWithin the cluster 2 group, 28 oxidative phosphorylation genes exhibited reduced expression, CDKN2A gene mutations were upregulated, and there was significant downregulation of Tregs infiltration and related immune gene expression.\nMoreover, a functional analysis revealed that BA-induced downregulation of protein clusters that participate in mitochondrial complex 1 activity and oxidative phosphorylation, which was related to decreased expressions of RNA polymerase mitochondrial (POLRMT) and translational activator of cytochrome c oxidase (TACO1), suggesting that the influence on mitochondrial function explains the effect of BA on PDAC cell growth and migration.\nAt the molecular level, ISG15 loss results in decreased mitochondrial ISGylation concomitant with increased accumulation of dysfunctional mitochondria, reduced oxidative phosphorylation (OXPHOS) and impaired mitophagy.\nMechanistically, both HSP60 knockdown and oxidative phosphorylation (OXPHOS) inhibition by metformin decreased Erk1/2 phosphorylation and induced apoptosis and cell cycle arrest, whereas Erk1/2 reactivation with EGF promoted cell proliferation.\nThe fatty acid cargo of tumour EVPs-particularly palmitic acid-induced secretion of tumour necrosis factor (TNF) by Kupffer cells, generating a pro-inflammatory microenvironment, suppressing fatty acid metabolism and oxidative phosphorylation, and promoting fatty liver formation.\nIn conclusion, our results suggest that chidamide promotes Mcl-1 degradation through the ubiquitin-proteasome pathway, suppressing the maintenance of mitochondrial aerobic respiration by Mcl-1, and resulting in inhibition of pancreatic cancer cell proliferation.\nMcl-1 is frequently upregulated in human cancers, which has been demonstrated to participate in oxidative phosphorylation, in addition to its anti-apoptotic actions as a Bcl-2 family member."
    },
    "75-1795": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "proliferation",
      "text": "Vitro experiment showed that SLC7A5 was upregulated in LUAD and knockdown of SLC7A5 obviously suppressed tumor cell proliferation.\nALYREF silencing decreased SLC7A5 expression and subsequently inactivated mTORC1 pathway, resulting in decreased tumor proliferation.\nConversely, inhibiting the expression of miR-126 markedly increased the expression of SLC7A5 and alleviated cell proliferation inhibition.\nJPH203, a specific inhibitor of SLC7A5, effectively reversed the above phenomena, inhibited mTORC1 signaling activation, and reduced the proliferation of fibroblasts.\nFurther study on the function of SLC7A5 gene in SKM-1 cell line showed that downregulation of SLC7A5 inhibited SKM-1 cells proliferation, increased apoptosis and caused cell cycle arrest in the G0/G1 stage.\nYAP/TAZ reverses KRAS inhibitor-induced proliferation retardation by activating the SLC7A5/mTORC1 axis.\nknockdown of MRPL35 suppressed NSCLC cell proliferation, invasion, and glutamine metabolism in vitro and impeded tumor growth in vivo by upregulating SLC7A5, providing a promising therapeutic target for NSCLC.\nRNA-seq analysis demonstrated increased translation and reduced proliferation in Slc7a5 KD bone marrow B cells.\nSlc7a5 deletion in chondrocytes led to general disorganization of chondrocytes in the vertebral growth plate, along with an increase in apoptosis and a decrease in cell proliferation.\nBlocking the MAPK-c-MYC-SLC7A5 signaling axis cooperates with asparagine restriction to effectively suppress melanoma cell proliferation.\nour study demonstrated that FTO promoted gastric cancer proliferation through the circFAM192A/SLC7A5 axis in the mA-dependent manner.\nDex significantly inhibited (P<0.05) cell proliferation in cytotrophoblasts and down-regulated amino acid transporter SLC7A5 in syncytiotrophoblasts."
    },
    "1795-1853": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "ovarian cancer",
      "text": "Meanwhile, TIM-3 and PD-1 co-blockades effectively enhanced the function and proliferation of CD8TILs and TIDCs from ID8-bearing mice.\nHowever, in multiple cell types, the activities of CDK4 and CDK6 (CDK4/6) compensate for CDK2 inhibition and sustain tumor cell proliferation, enabling CDK2 reactivation.\nIn vivo, knockdown of FAM172A suppressed tumor progression and enhanced the efficacy of cisplatin.\nargyi exerts potent anti-OvC activity by suppressing proliferation and migration, and by inducing apoptosis via JUN/MAPK10 signaling.\nBoth metabolites significantly inhibited cell proliferation and clonogenicity.\nEA markedly inhibited OvC cell proliferation (IC₅₀ = 6.212 and 9.569 μg/ml) and migration, while inducing apoptosis and autophagy.\nWhen knocking down the LINC00857 expression level, the invasion, migration, proliferation, and sphere-forming capabilities of cells were all notably reduced.\nFirst, small RNA sequencing and proteomic analysis of NK92 cells and NK92 cell-derived exosomes revealed that the exosomes retained the anti-tumor activity of parental NK cells, inhibiting tumor progression by modulating apoptosis, proliferation, and metastasis.\nIn vitro, FAM172A promoted malignant behavior and conferred resistance to cisplatin.\nScu markedly diminished cell viability, proliferation, and colony formation in both SKOV3 and HO-8910 cells.\nWe found that cyclin E1-driven ovarian cancers often coexpressed the tumor suppressor p16, which inhibited CDK4/6 signaling.\nSingle-cell time-lapse imaging showed that high abundance of p16 conferred increased sensitivity to CDK2 inhibitors, whereas depletion of p16 rendered cells more resistant to CDK2 inhibition through CDK4/6-dependent compensation.\nConcordantly, acquired resistance to CDK2 inhibitors correlated with reduced p16 and increased cyclin D1 protein abundance."
    },
    "75-1794": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-1856": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "colorectal cancer(CRC)",
      "text": ""
    },
    "1800-2264": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "laryngeal carcinoma",
      "text": "Our findings support that GDF-10 can inhibit the proliferation, migration, and invasion, and promote apoptosis of laryngeal carcinoma AMC-HN-8 cells.\nIt showed that ceramide C2 reduced human laryngeal carcinoma cells' migration capability and proliferation for 24 hours.\nNext, we found that oridonin significantly inhibited the migration and invasion of human laryngeal carcinoma Hep-2 and TU212 cell lines by wound healing assay and transwell assay.\nOverexpression of miR-375 inhibited the viability and migration and promoted apoptosis of LSCC cells.\nAfter TMA7 downregulation, the autophagy level was increased, and the proliferation, migration, and invasion of LSCC cells were inhibited.\nLoss-of-function assays revealed that HOXA11-AS knockdown inhibited the viability, migration, and invasion, but promoted the apoptosis of CDDP-resistant LSCC cells.\nIn addition, we found that overexpression of ZNF671 could inhibit the viability, proliferation, migration and invasion of LSCC cells, while promoting cell apoptosis.\nIn vitro experiments showed that the ability of cell proliferation, migration, invasion and glycolysis were significantly decreased and the ability of apoptosis was enhanced after down-regulation of DCUN1D5.\nCompared with the control group, silencing circ-MTCL1 could inhibit cell proliferation, overexpression of circ-ABCB10 promoted cell migration, and downregulation of circ-ABCB10 significantly inhibited cell movement ( < 0.001).\ncirc_CORO1C silencing constrained cell proliferation and promoted apoptosis via reducing cell proliferation, inducing cell cycle arrest, inhibiting epithelial-mesenchymal transition, and promoting apoptosis, as well as restraining cell migration and invasion.\nMyosin X augments the expression of Cortactin, MMP2 and MMP9, which could upregulate the cell migration and the matrix degradation, and consequently reduce the expression of E-cadherin and β-catenin, thereby"
    },
    "1795-2193": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "pancreatic ductal adenocarcinoma (PDAC)",
      "text": "C5aR1 knockdown and CCX168, the specific C5aR1 inhibitor, impaired proliferation and the activation of the PI3K/mTOR pathway, and enhanced gemcitabine sensitivity by increasing apoptosis.\nA correlation between radiosensitivity and enhanced proliferation and decreased hypoxia was observed.\nEMP1 knockout reduced proliferation, metastasis, and drug resistance, whereas overexpression enhanced malignant features.\nTXNRD1 was identified as a potential oncogene that promotes cell migration and proliferation, while inhibiting cell apoptosis.\nOur findings suggest that lipid raft inhibition can modulate proliferation, distinct cell death pathways, and treatment response in PDAC.\nKnockdown of CCNB2 significantly inhibited PDAC cell proliferation, invasion, and migration, while reducing the expression of glycolytic-related proteins HK II, GLUT1, and PKM2, potentially via the PI3K/AKT signaling pathway.\nHigh-throughput integration of multiomics datasets coupled with metabolic tracing showed that the ECM enhances the generation of guanylates in PDAC cells, the accumulation of which alleviates oxaliplatin-induced DNA damage, and boosts PDAC cell proliferation.\nSilencing HERVH markedly suppresses PDAC proliferation and tumor growth.\nOCIAD2 promotes tumor proliferation, migration, invasion, and resistance to gemcitabine in PDAC.\nThe results indicated that both drugs inhibited the proliferation, migration, & colony formation\nIn co‑culture experiments, senescent fibroblasts enhanced Panc‑1 cell invasion, migration and proliferation.\nRestoring CHPT1 suppressed proliferation, migration, and epithelial-mesenchymal transition while enhancing GEM sensitivity.\nAdditionally, fostamatinib inhibited PDAC cell proliferation even in the absence of viral infection, while ruxolitinib did not.\nPLIN5 inhibited PSC proliferation and migration, reduced extracellular matrix protein secretion, and restored lipid droplets formation.\nGlycolytic inhibitors significantly suppressed PDAC cell proliferation both in vitro an"
    },
    "185-1800": {
      "type": "slc_pathway",
      "key1": "SLC22A2",
      "key2": "migration",
      "text": "and (4) increased SLC22A1/OCT1, SLC22A2/OCT2, and SLC31A1/CTR1 platinum influx transporter expression.\nIn vitro experiments further substantiated that perfluorooctanoic acid exposure promoted the malignant phenotypes of OC cells and the changes of SLC22A2, SPOCK3, and APOD expressions.\nMoreover, using Boyden chambers and western blot techniques, we also showed that miR-21 overexpression increased migratory, invasive, proliferative, and anti-apoptotic signaling pathways whereas opposite results were observed using an anti-miR-21-based silencing strategy.\nThe effects of PFAS on the phenotype of OC cells were analyzed by quantitative real-time PCR, CCK8, migration, and invasion detection."
    },
    "1800-1853": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "ovarian cancer",
      "text": "UA was capable of effectively inhibiting the proliferation, migration, and colony formation of ovarian cancer cells.\nUA can inhibit ovarian cancer cell proliferation, migration, colony formation, and may inhibit tumor cell autophagy by promoting tumor cell ERS, and ultimately promote ovarian cancer cell apoptosis.\nTIMM8B enhanced oxidative phosphorylation, glycolysis, proliferation, migration, and invasion and inhibited apoptosis in ovarian cancer cells.\nMLLT6 knockdown inhibited ovarian cancer cell proliferation, migration, invasion, and significantly enhanced Paclitaxel sensitivity by reducing IC50 values.\nATP6V1B1 promotes the proliferation, migration, and invasion of ovarian cancer cells in vitro, while ATP6V1B1 knockout inhibits tumor growth in vivo.\nTβ4-17 peptide combined with DDP significantly inhibited the proliferation and migration of drug resistance cells in ovarian cancer, promoted apoptosis, and increased the chemo-sensitivity of ovarian cancer cells to DDP.\nGA significantly suppresses the proliferation of ovarian cancer cells both in vitro and in vivo, reduces their migration and invasion capability, and enhances macrophage cytotoxicity in the murine ID8 xenograft tumor microenvironment (TME).\nEA decreased the ability of ovarian cancer cells for migration, increased the rate of apoptosis by inhibiting BIRC5 and activating CASP3, triggered cell cycle arrest in the G2/M phase, and caused a decrease in mitochondrial membrane potential and genotoxic effects.\nthe combination of and paclitaxel synergistically inhibited the growth, migration, and invasion of ovarian cancer cells and induced apoptosis, providing supporting evidence that the combination of HDAC6 inhibitors and paclitaxel may be a promising treatment strategy for ovarian cancer.\nLow hsa_circ_0000129 and TPM3 expression repressed viability, migration, and proliferation of ovarian cancer cells.\nBCKDK is overexpressed in epithelial ovarian cancer (EOC), which promotes proliferation and migration via MEK-ERK.\nFBXO45 is a key E3 ubiquitin ligase in ov"
    },
    "25-1795": {
      "type": "slc_pathway",
      "key1": "SLC3A2",
      "key2": "proliferation",
      "text": "Overexpression of hsa-miR-605-3p regulated SLC3A2 to promote ICC cell ferroptosis and inhibit proliferation and migration.\nTaken together, knockdown of hsa_circ_0050900 inhibited SLC3A2 expression via sponging hsa-miR-605-3p to promote ICC cell ferroptosis, and finally suppressed proliferation and migration.\nOur results suggest that circBTBD7-420aa may inhibit the abnormal proliferation and migration of human coronary artery smooth muscle cells by promoting SLC3A2 degradation through the ubiquitin-proteasome pathway.\nCell experiments confirmed that melanocyte proliferation decreased, whereas apoptosis increased, after SLC3A2 knockdown.\nHOXA13 drives PCa progression by transcriptionally activating SLC7A11 and SLC3A2, which suppress ferroptosis and enhance proliferation and metastasis.\nIn vitro experiments showed that knocking down of SLC3A2 was associated with reduced migration, invasion, and proliferation, but increased apoptosis of OSCC cells.\nMechanistic study showed that HCMV-miR-US33-5p bound to the 3'-untranslated region of EPAS1 to suppress its expression, leading to suppression of SLC3A2 expression, which ultimately promoted cell apoptosis and inhibited cell proliferation.\nReduced expression of SLC3A2 inhibited OS cell proliferation through G2/M phase arrest.\nIn vitro, CLDND1 knockdown reduced viability and proliferation, accompanied by morphological degeneration and decreased SRC, GPX4, SLC3A2, COL1, and KI67\nThis was confirmed by the findings that silencing EPAS1 significantly reduced the SLC3A2 expression and inhibited proliferation and key factors of integrin signal pathway.\nThese findings highlight that macrophage-derived l-glutamine promoted CRC cell proliferation and adhesion by regulating FOXA2 activity through SLC3A2-mediated metabolic sensing.\nIn addition, MYCN directly increased polyamine synthesis and promoted neuroblastoma cell proliferation by"
    },
    "1795-1839": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "bladder cancer",
      "text": "COL6A1 downregulation inhibited bladder cancer cell proliferation, invasion, and migration and induced cell apoptosis.\nCircFAM64A(3) promoted bladder cancer proliferation and inhibited CD8 + T cell via sponging to miR-149-5p and activated IL-6/JAK/STAT pathway.\nHPP induced bladder cancer cell autophagy by regulating macrophages in the co-culture system, resulting in the inhibition of cancer cell proliferation.\nE2F8 knockdown suppressed bladder cancer cell proliferation, accompanied by the performance of G1 phase arrest and the upregulated Cyclin D1 protein expression.\nHigh expression of miR-204-5p promotes proliferation, migration and invasion and reduces apoptosis of bladder cancer cells by negatively regulating RAB22A expression.\nRescue experiments showed that knockdown reversed the inhibitory effect of knockdown on cell proliferation, upregulated PCNA, MCM2, and Cyclin D1 (all <0.05), and promoted bladder cancer cell proliferation (<0.001).\nYTHDF2 was upregulated in bladder cancer cell lines, and its knockdown suppressed cell viability (<0.001), downregulated PCNA, MCM2, and CyclinD1 (all <0.05), reduced colony numbers 3-fold (<0.01), and inhibited proliferation.\nOverall, this study suggests that bladder tumors can increase PD-L1 expression to promote PD-L1-mediated intrinsic tumor growth pathways, and metformin effectively downregulates PD-L1 expression, suppresses bladder cancer cell proliferation, and prolongs survival in an orthotopic bladder cancer mouse model.\nIn vitro, SQ-diEG inhibited proliferation and induced apoptosis in bladder cancer cell lines.\nIncreased CELF2 expression suppressed the proliferation and migration of bladder cancer cells.\nBrazilin significantly inhibited bladder cancer cell proliferation and induced apoptosis and DNA damage in vitro.\nIn bladder cancer cells, miR-204-5p overexpression significantly promoted cell proliferation, migration and invasion and reduced cell apopt"
    },
    "136-1794": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1796-1813": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Sarcoma",
      "text": "MicroRNA-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4.\nAURKA inhibition induces Ewing's sarcoma apoptosis and ferroptosis through NPM1/YAP1 axis.\nAURKB inhibition induces rhabdomyosarcoma apoptosis and ferroptosis through NPM1/SP1/ACSL5 axis.\nLncRNA-PVT1 Inhibits Ferroptosis through Activating STAT3/GPX4 Axis to Promote Osteosarcoma Progression.\nSarcoma protein kinase inhibition alleviates liver fibrosis by promoting hepatic stellate cells ferroptosis.\nSLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.\nLncSNHG14 promotes nutlin3a resistance by inhibiting ferroptosis via the miR-206 /SLC7A11 axis in osteosarcoma cells.\nCarbonic Anhydrase Inhibitors Induce Ferroptosis through Inhibition of AKT/FTH1 Signaling in Ewing Sarcoma Tumor Cells.\nRab27b-mediated CAFs derived exosomal miR-22-3p suppresses ferroptosis and promotes cisplatin resistance in osteosarcoma.\nRBM15-mediated the m6A modification of MAT2A promotes osteosarcoma cell proliferation, metastasis and suppresses ferroptosis.\nExosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1.\nMETTL5-mediated m6A modification of UBE3C promotes osteosarcoma progression by suppressing ferroptosis via inducing AHNAK ubiquitization.\nSLC38A5 promotes osteosarcoma cell proliferation, migration, and invasion via the glutamine-mediated PI3K/AKT/mTOR signaling pathway and inhibits ferr"
    },
    "225-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A4",
      "key2": "oxidative phosphorylation",
      "text": "At the same time, more ATP was produced by coupling with mitochondrial small G protein ARF-like 2 (ARL2) GTPase, which triggered the phosphorylation of ANT1 (SLC25A4) to affect the opening degree of mitochondrial permeability transition pore (mPTP), and significantly promoted the aerobic oxidation and oxidative phosphorylation of glucose.\nThe mitochondrial ADP/ATP carrier (SLC25A4), also called the adenine nucleotide translocase, imports ADP into the mitochondrial matrix and exports ATP, which are key steps in oxidative phosphorylation.\nOur results show that SLC25A46 interacts with a large number of proteins and protein complexes involved in the mitochondria architecture, energy production, and flux and also in inter-organellar contacts.\nA total of 79 co-immunoprecipitated proteins were common in two or more tissues, mainly participating in mitochondrial activities such as oxidative phosphorylation (OXPHOS) and ATP production, active transport of ions or molecules, and the metabolism.\nOur proteomic approach confirmed known mitochondrial interactors of SLC25A46 including MICOS complex subunits and also OPA1 and VDACs, while we identified novel interactors including the ADP/ATP translocases SLC25A4 and SLC25A5, subunits of the OXPHOS complexes and FF-ATP synthase, and components of the mitochondria-ER contact sites.\nIn aerobic eukaryotic cells, the high energy metabolite ATP is generated mainly within the mitochondria following the process of oxidative phosphorylation.\nMitochondrial DNA (mtDNA) maintenance is critical for oxidative phosphorylation (OXPHOS) since some subunits of the respiratory chain complexes are mitochondrially encoded.\nThe mitochondrial ATP is exported to the cytoplasm using a specialized transport protein, the ADP/ATP carrier, to provide energy to the cell.\nTherefore, acetylation of ANT1 could have dramatic physiological effects on ADP-ATP exchange.\nInsertion of these derived binding affinities as parameters into a complete mathematical description of ANT1 kinetics predicte"
    },
    "1802-2193": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "pancreatic ductal adenocarcinoma (PDAC)",
      "text": "Pancreatic ductal adenocarcinoma (PDAC) requires mitochondrial oxidative phosphorylation (OXPHOS) to fuel its growth, however, broadly inhibiting this pathway might also disrupt essential mitochondrial functions in normal tissues.\nenhanced oxidative phosphorylation decreased the AMP/ATP ratio and suppressed AMPK activity, resulting in the activation of the HSF1-heat shock protein pathway, which is required for environmental stress tolerance.\nBA-induced downregulation of protein clusters that participate in mitochondrial complex 1 activity and oxidative phosphorylation, which was related to decreased expressions of RNA polymerase mitochondrial (POLRMT) and translational activator of cytochrome c oxidase (TACO1), suggesting that the influence on mitochondrial function explains the effect of BA on PDAC cell growth and migration.\nNR5A2 suppresses MYC, leading to the activation of the mitochondrial biogenesis factor PPARGC1A and a shift in metabolism towards oxidative phosphorylation, which is a crucial feature of stemness in PDAC.\nLipid-laden CAFs then enhance tumor progression by providing lipids for mitochondrial oxidative phosphorylation via ABCA8a transporter.\nISL2 regulates the expression of metabolic genes, and its depletion increases oxidative phosphorylation (OXPHOS).\nElevated CIB1 expression combined with upregulated glycolysis, oxidative phosphorylation (Oxphos), hypoxia pathway activation, and cell cycle promoted PDAC tumor growth and increased tumor cellular com-ponents.\nThese findings suggest that the suppression of oxidative phosphorylation contributes to GEM resistance by reducing ROS production.\nIncreased levels of tryptophan metabolites contribute to NAD synthesis and oxidative phosphorylation, leading to a stem cell-like phenotype.\nglucose-starvation causes PDAC cells to enhance mitochondrial oxidative phosphorylation.\nCLPX knockdown disrupts mitochondrial homeostasis, and reduces oxidative phosphorylation, thus leading to mitochondrial dysfunction and impaired PDAC cell proliferation.\nmetabolic reprogramming, including shifts between glycolysis an"
    },
    "45-1801": {
      "type": "slc_pathway",
      "key1": "SLC5A8",
      "key2": "apoptosis",
      "text": "Besides, decreased proliferation activity and increased apoptosis were also observed in CC cells overexpressing SLC5A8 plasmid.\nThe changes in gene expression in SLC5A8/butyrate-induced apoptosis include upregulation of pro-apoptotic genes and downregulation of anti-apoptotic genes.\nMoreover, the impaired proliferation activity and increased apoptosis proportion of CC cells induced by SLC5A8 over-expression could be counteracted by the Wnt signaling pathway activator LiCl.\nHowever, when transfected with SLC5A8 or treated with inhibitors of DNA methylation, these cells underwent apoptosis in the presence of 3-bromopyruvate.\nReexpression of SLC5A8 in colon cancer cells leads to apoptosis but only in the presence of butyrate.\nEctopic expression of the transporter in MCF7 cells led to apoptosis, and the mechanism involved the inhibition of HDAC1/HDAC3.\nButyrate treatment-induced apoptosis of wild-type T cells but not Fas-deficient (Fas(lpr)) or FasL-deficient (Fas(gld)) T cells, revealing a potential role of Fas-mediated apoptosis of T cells as a mechanism of butyrate function.\nOur data thus suggest that butyrate delivers a double-hit: induction of T cell apoptosis to eliminate the source of inflammation and suppression of IFN-γ-mediated inflammation in colonic epithelial cells, to suppress colonic inflammation.\nPossible cell death pathways included expression of caspase 8 and activated caspase 3, autophagy, Slc5a8-mediated inactivation of survivin (Birc5), and pStat3-mediated lysosomal lysis, the latter of which is the principal death route in involuting wild type cells.\nAcetate was shown to induce apoptosis in CRC cells.\nMoreover, an apoptosis assay, demonstrated that the TTFM extracts significantly increased the proportion of apoptotic cells.\nThese studies show that SLC5A8 mediates the tumor-suppressive effects"
    },
    "1801-1917": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Gastric cancer (GC)",
      "text": "AO/EB staining confirmed reduced viability with increased apoptosis at high dose.\nWe hypothesised that apoptosis pathways in TP53_WT GC may be suppressed post-transcriptionally by activated MDM2.\nNaB decreased cell viability, impaired cellular aggregation, and induced apoptosis and mitochondrial dysfunction.\nBesides, JMJD3 overexpression promoted proliferation and reduced apoptosis by upregulating Notch in GC cells under hypoxia conditions.\nHSPB1 overexpression enhanced proliferation, invasion, and migration while suppressing apoptosis by downregulating PANoptosis markers.\nEFNB2 knockdown inhibited cellular proliferation and viability, increased apoptosis, and induced cell cycle arrest at the G/G phase in GC cells.\nThis study confirms that HF promotes apoptosis and inhibits metastasis and invasion in GC cells, primarily by modulating the TNF signaling pathway.\nCollectively, these data indicate that submicromolar DZN promotes proliferation and suppresses apoptosis of GC cells by perturbing neuronal signaling networks.\nIn the CDDP-treated GC cells, DNMT1 overexpression significantly reversed the siRNA-OCT4-induced cell apoptosis, γ-H2AX upregulation, and proliferation decrease.\nCh-AuNPs-NB inhibited the PI3K/AKT/mTOR pathway, induced apoptosis, and arrested the cell cycle in AGS cells, highlighting its potential as a targeted GC therapy.\nIn addition, morin treatment significantly suppressed the growth of GC in vivo by upregulating BAD and the subsequent activation of its downstream apoptosis pathway.\nIn conclusion, C-PC effectively inhibits the growth and proliferation of MKN45 gastric cancer cells while promoting apoptosis by downregulating Bcl-2 gene expression.\nTherefore, 18β-GA can promote cell apoptosis by inhibiting the TCTP/AKT/P53 signaling pathway, arrest the cell cycle and inhibit the proliferation and metastasis of GC."
    },
    "1801-1836": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "pancreatic cancer(PC)",
      "text": "CRO-67 also significantly decreased cell proliferation and enhanced apoptosis by inhibiting cell cycle progression through G2/M phase in PDAC cells and patient-derived CAFs in vitro.\nExperiments conducted both in vitro and in vivo revealed that the increased expression of BCL11A suppressed tumor growth and triggered apoptosis through endoplasmic reticulum (ER) stress.\nSORBS1 knockdown promoted tumor proliferation and reduced PPH-induced apoptosis.\nIt also inhibited the proliferation and migration of pancreatic cancer cells and promoted apoptosis.\nIn vitro experiments demonstrated that SFN suppressed PANC-1 cell proliferation and metastasis, induced G2/M arrest, and promoted apoptosis.\nCompared to paclitaxel, which is effective against cancer cells but inactive on PCSCs, compound 1 induced marked apoptosis in PCSCs, demonstrating its selectivity as a PCSC-targeted inhibitor.\nCompound significantly reduced lactate production and induced apoptosis in pancreatic Mia PaCa-2 cells and demonstrated robust antitumor effects following oral administration at 100 mg/kg, with no apparent toxicity observed.\nDextromethorphan, particularly in combination with gemcitabine, appears to enhance apoptosis and suppress EMT-associated marker expression in PANC-1 cells, supporting its potential as an adjuvant agent in pancreatic cancer therapy.\nFurthermore, in vivo targeted genetic inhibition of eEF2K suppressed tumor growth in two different PDAC mouse models, reduced tumor-associated macrophages (TAMs), and induced marked apoptosis in tumor tissues without any signs of toxicity.\npracinostat activates the p53 signaling pathway by targeting the miR-381-3p/MDM2 axis, thereby inhibiting the proliferation of pancreatic cancer cells.\nThe increase in 7-AAD cells confirmed diminished cell viability, and annexin V-FITC assays showed apoptosis as the dominant death pathway.\nCRO-67 treatment in these explants significantly reduced tumor cell and αSMA CAF frequency, decreased cell proliferation and increased cell death."
    },
    "265-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A44",
      "key2": "oxidative phosphorylation",
      "text": "Blocking BCAA entry into mitochondria by knockdown of SLC25A44 inhibited M2 macrophage polarization.\nBCAA supplementation promoted M2 macrophage polarization both in vitro and in vivo and increased oxidative phosphorylation in M2 macrophages.\nThe high-risk group had a lower activation of oxidative phosphorylation and a more abundant immune infiltration phenotype than the low-risk group.\nAccording to co-expression network studies, SLC25A11, SLC25A29, and SLC25A44 were involved in the energy metabolism of PC and prevented tumor growth, invasion, and metastasis.\nMoreover, the recruitment of numerous immune cells was positively correlated with SLC25A11 and SLC25A44 but negatively correlated with SLC25A29.\nFurthermore, M2 macrophages polarization was suppressed by knockdown of Branched-chain amino-acid transaminase 2 (BCAT2) and branched chain keto acid dehydrogenase E1 subunit alpha (BCKDHA), both of which are key enzymes involved in BCAA oxidation.\nMetabolomic analysis identified increased BCAA metabolism as one of the most significantly rewired pathways upon alternative activation.\nOverall, our findings suggest that BCAA catabolism plays an important role in polarization toward M2 macrophages."
    },
    "380-1795": {
      "type": "slc_pathway",
      "key1": "SLC39A3",
      "key2": "proliferation",
      "text": "Results: The analytic results suggested that SLC39A1, SLC39A3, SLC39A4, SLC39A5, SLC39A6, SLC39A7, SLC39A9, SLC39A10, SLC39A11 and SLC39A13 were significantly up-regulated in BC tissues compared with normal breast tissues.\nMoreover, SLC39A7 was associated with proliferation and cloning of BC.\nHigh expression of SLC39A2, SLC39A3, SLC39A4, SLC39A5, SLC39A7, SLC39A12 and SLC39A13 was significantly associated with worse OS in patients with BC.\nThe SLC39A7 played a key role in growth and survival of BC cells."
    },
    "1795-1836": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "pancreatic cancer(PC)",
      "text": "Overexpression of KLF10 suppressed pancreatic cancer cell proliferation and induced apoptosis through the TGF-β signaling pathway.\nThe extracts derived from moringa seeds inhibit cancer proliferation and promote cancer cell apoptosis through multiple signaling pathways.\nTHBS1 knockdown suppressed cell proliferation, migration, and invasion while enhanced cell apoptosis through the JAK2/STAT3 signaling pathway.\nIt also inhibited proliferation and induced apoptosis via pathways involving reactive oxygen species, mitochondrial damage, and caspase activation.\nmiR-1305 overexpression prominently inhibited PC cell proliferation and metastasis promoted cell apoptosis in vitro, and alleviated PC formation in vivo.\nThe upregulation of TRIM46 rescued ONECUT3 knockdown-induced suppression of cell proliferation, migration and invasion abilities, and tumor growth in PC.\nOur results indicated that PUS7 could promote cell proliferation, mobility and glycolysis, and inhibit apoptosis by interacting ANLN to activate the MYC pathway in PC.\nExperiments related to cell viability demonstrated that MLN0905 inhibited cell proliferation, induced cell cycle arrest, and promoted apoptosis in gemcitabine-resistant PC cell lines.\ntRF-Pro-CGG acts as a tumor suppressor in pancreatic cancer by inhibiting cell proliferation, migration, invasion, and promoting apoptosis, likely through targeting CSF1 and regulating the PI3K-AKT signaling pathway.\nMechanistically, miR-145-5p overexpression increased the sensitivity of PC drug-resistant cells to gemcitabine through the inhibition of CDCA3, thereby inhibiting the proliferation and migration of PC drug-resistant cells.\nFurther investigation revealed that the interaction between SCEL and Jagged-1 promotes the activation of the Notch signaling pathway, effectively inhibiting the senescence of PC cells while enhancing their proliferation, invasion, and metastatic capabilities.\nMechanistically, TAX interacted with MDM2, a critical regulator of proliferation, and decreased its stability by inducing ubiquitin-mediated degradation, which facilitates the nuclear translocation of"
    },
    "81-1798": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "stemness",
      "text": "MiR-375 can trigger the ferroptosis through targeting SLC7A11, which is essential for miR-375-mediated inhibition on GC cell stemness.\nTogether, our results reveal that enhanced stemness increases the susceptibility to ferroptosis, and the DUBA-SLC7A11-c-Myc axis is pivotal for differentiated cancer stem cells (CSCs) resistant to ferroptosis, providing a promised targets to eradicate CSCs through ferroptosis.\nOur results demonstrate that the overexpression of SLC7A11-AS1 in gemcitabine-resistant PDAC cells can scavenge ROS by blocking SCF-mediated ubiquitination and degradation of NRF2, leading to a low level of intracellular ROS, which is required for the maintenance of cancer stemness.\nAdditionally, DUBA promotes stemness by deubiquitinating SLC7A11.\nMoreover, circRPPH1 promoted the stemness of gastric cancer cells dependent on the miR-375/SLC7A11.\nOverexpression of SLC7A11-AS1 enhanced the activin A-induced Smad2/3 phosphorylation and promoted cancer stemness properties in PDAC cells.\nAdditionally, the inhibitory effects of Tanshinone IIA on GC cell stemness were reversed by ferroptosis inhibitor (Fer-1) or overexpression of SLC7A11, which is a critical ferroptosis inhibitor.\nIn addition, bioinformatic analysis and luciferase assays were used to identify E2F1 as a critical upstream transcription factor of SLC7A11 (the gene encoding for xCT) that facilitated CRC progression and cell stemness.\nThese results suggest that the miR-375/SLC7A11 regulatory axis could serve as a potential target to provoke the ferroptosis and thus attenuate the stemness of GC cells.\nMechanistically, SLC7A11 was identified as a direct target of miR-375 and miR-375 attenuated the stemness of GC cells mainly through triggering SLC7A11-dependent ferroptosis."
    },
    "1798-1872": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "breast cancer(BC)",
      "text": "Moreover, inhibition of PI3K/AKT signaling suppressed the C1ql4-induced stemness and EMT.\nDownregulation of MED16 markedly reduced the sensitivity of ER+ BC cells to tamoxifen and increased the stemness and autophagy of ER+ BC cells.\nTRG16 could suppress the activation of the NF-κB pathway in BC cells, which is a positive pathway in BC progression and contributes to the maintenance of cancer cell stemness.\nThis upregulation correlated with poor patient prognosis, cancer stemness, and metabolic reprogramming, which was driven by genetic alterations such as gene amplification and reduced promoter methylation.\nMechanistically, TIM3 increases β-catenin/interleukin-1β (IL-1β) signaling, leading to stemness and immune-evasion by inducing immunosuppressive γδ T cells and reducing CD8 T cells during micrometastasis.\nBy inhibiting anti-immune effects and promoting non-immune mechanisms such as tumor cell stemness, epithelial-mesenchymal transformation (EMT) and angiogenesis, MDSCs effectively promote tumor growth and metastasis.\nIn this sense, the macrophage migration inhibitory factor (MIF), a pleiotropic pro-inflammatory cytokine and an upstream regulator of the immune response, enhances breast tumorigenesis through escalating cancer cell proliferation, survival, angiogenesis, invasion, metastasis, and stemness, which then brings tumorigenic effects by activating key oncogenic signaling pathways and inducing immunosuppression.\nMoreover, miR-155 induced stemness and DCA resistance by inhibiting the direct target gene tetraspanin-5 (TSPAN5).\nFurthermore, miR-143-5p reduces cell proliferation, cell cycle entry, and stemness, while promoting apoptosis moderately.\nRestoration of Let-7a also suppressed the resistin-induced expression of genes associated with growth, survival, and stemness.\nAdditionally, the expression of genes associated with stemness and metastasis was also decreased and the expression of genes associated with differentiation were increased.\nMechanistic studies showed that ZSCAN1 directly bin"
    },
    "75-1800": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "migration",
      "text": "Knockdown of SLC7A5 obviously decreased the viability, migration, and invasion of oxaliplatin-resistant GC cells in vitro and tumor growth in vivo.\nand functional experiments confirmed that the ZNF24-SLC7A5 signaling axis promoted the proliferation, invasion and migration of KRAS mutant lung adenocarcinoma.\nSLC7A5 was associated with adverse prognosis in bladder cancer patients, activating the Wnt pathway and promoting bladder cancer cell cycle progression, proliferation, migration, and invasion.\nCirc-SLC7A5 depletion impaired cell growth, migration, invasiveness, and promoted apoptosis.\nKnocking down SLC7A5 significantly inhibited human and mouse TNBC cell proliferation, migration, and invasion.\nFinally, the proliferation and migration abilities of HNSCC cells significantly decreased after the expression of IGF2BP2 and SLC7A5 reduced.\nBy depleting CRKL in gastric cancer SGC-7901 cells, the SLC7A5 expression was impaired, and the invasion and migration of SGC-7901 cells were suppressed.\nOur results also showed that the knockdown of MIF, SOD2 and SLC7A5 by RNAi significantly decreased the proliferation and migration abilities of HEC-1A cells (p < 0.05).\nSLC7A5 deficiency abrogated proliferation, migration and mTORC1 pathway activity.\nLAT1 (SLC7A5) plays a crucial role in mediating the uptake of amino acids into breast cancer cells, influencing proliferation, invasion, migration, drug resistance, and prognosis through the mTOR signaling pathway.\nFurthermore, the depletion of LAT1 reduced PMA-induced cell migration in a wound-healing assay.\nThis correlated with increase in glutaminase 1 (GLS1) expression, whose inhibition reduced cell migration.\nProliferation assay and wound healing assay validated the effects of SLC7A5 on proliferation and migration of LUAD cells.\nCell survival, migration, and invasion experiments found that hsa_circ_0032462 and S"
    },
    "1800-1856": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "colorectal cancer(CRC)",
      "text": "Loss of UHRF1 upregulated ECRG4, inhibited EMT, and reduced cell migration and invasion.\nINHBB was upregulated in CRC, and the alleviation of INHBB suppressed the proliferation and migration of CRC cells.\nMAZ promotes CRC cell migration, invasion, and EMT by transcriptionally activating UHRF1, which downregulates ECRG4 through DNA methylation.\nIn CRC cells, lentivirus-mediated 5-HT7 overexpression enhanced proliferation, migration, and invasion, whereas RNA interference-mediated knockdown suppressed these processes.\nMechanistically, reactive oxygen species (ROS) accumulation drives senescence and autophagy inhibition, which inactivates the PI3K/AKT/mTOR pathway, thereby inhibiting CRC cell proliferation, invasion, and migration.\nMechanistically, androsin promotes apoptosis the PI3K/Akt/mTOR/caspase3/PARP pathway in the high-concentration range, and inhibits invasion and migration the NOX2/ROS/FAK/PI3K/Akt/NF-κB/MMP7 pathway in the low-concentration range.\nPINK1 acts as a tumor suppressor in colorectal cancer by inhibiting proliferation and migration, promoting apoptosis, and remodeling the epigenetic landscape through altering histone modifications and enhancing chromatin accessibility.\nWe identified 226 differentially expressed genes from TCGA-CRC cohort, among which the upregulated genes were mainly involved in pathways of cancer progression, proliferation, migration, and invasion, while downregulated genes were significantly enriched in pathways of tyrosine metabolism and immunity.\noverexpression of this gene enhanced cell proliferation, inhibited apoptosis, and promoted invasion and migration.\nIn vitro, NR suppressed CRC cell proliferation, migration, invasion, and fatty acid metabolism but promoted apoptosis.\nImportantly, PRDX1 deletion in macrophages reversed the immunosuppressive phenotype and reciprocally enhanced the phagocytosis, inhibited CRC cell growth and migration."
    },
    "138-1798": {
      "type": "slc_pathway",
      "key1": "SLC16A3",
      "key2": "stemness",
      "text": "Thus, the differential expression of TMPRSS11B adds to metabolic heterogeneity in PDAC and its absence supports the reverse Warburg metabolism in PDAC cells by the enhancement of BSG-supported lactate uptake through SLC16A1 and subsequent phenotype alterations towards greater stemness.\nMoreover, knock-down and overexpression of TMPRSS11B differentially impacted proliferation and chemoresistance under reverse Warburg conditions in Panc1 or BxPc3 and T3M4 cells, respectively, as well as their stemness properties indicated by altered colony formation rates and expression of the stem cell markers Nanog, Sox2, KLF4 and Oct4.\nThose regions exhibiting low or no TMPRSS11B expression but concomitant high expression of SLC16A1 and BSG revealed greater amounts of KLF4."
    },
    "9-1799": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "glycolysis",
      "text": "The expression of glycolysis-related gene SLC2A1 (also known as GLUT1) was found to be upregulated, while notably WNT5A was downregulated.\nThen, miR-30d inhibited aerobic glycolysis through regulating SLC2A1 and HK1 expression by directly targeting the transcription factor RUNX1, which bound to the promoters of the SLC2A1 and HK1 genes.\nTherefore, the present study demonstrated that exosomes derived from patients with sepsis may inhibit glycolysis and promote the apoptosis of human myocardial cells through exosomal hsa‑miR‑1262 via its target SLC2A1.\nThe silencing of SLC2A1 promoted apoptosis and suppressed glycolysis in AC16 cells, whereas SLC2A1 overexpression resulted in the opposite effects.\nSLC2A1-AS1 promoted cell growth in vitro and in vivo, migration and invasion, and suppressed apoptosis, leading to EMT progression and increased glycolysis in ESCC cells.\nMiR-378a-3p inhibited cell proliferation and invasion as well as induced apoptosis, resulting in reduced glycolysis, which was partly reversed by SLC2A1-AS1 or Glut1 overexpression in ESCC cells.\nMechanistic investigations revealed that elevated SM enhances SLC2A1-dependent glucose uptake and glycolysis, leading to increased lactate production and subsequent CASP3 lactylation on lysine residue 14, which inhibits CASP3 activation and apoptosis.\nMechanically, SLC2A1 promoted the formation of CD90 and EpCAM CSCs via activating glycolysis.\nAn upregulation of HK1, PFKP and SLC2A1 was observed, while components of the respiratory chain were downregulated, confirming a metabolic shift towards aerobic glycolysis.\nIn conclusion, Dex has been demonstrated to attenuate renal IRI by inhibiting SLC2A1-mediated glycolysis, which was regulated by SLC2A1 expression, internalization,"
    },
    "1799-1868": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "lung cancer",
      "text": ""
    },
    "5-1799": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "glycolysis",
      "text": "We also found CDDO-Me could inhibit N-linked glycosylation of SLC1A5, which promotes protease-mediated degradation.\nIn summary, the ATF4/SLC1A5 axis plays a significant role in the progression of colorectal cancer by regulating glutamine metabolism and glycolysis.\nOur results demonstrate a novel adaptive mechanism of glycolytic inhibition in which Trx-1 increases GSH levels by regulating SLC1A5 to rescue cytotoxicity induced by 2DG in CRC cells.\nWe also found that the SLC1A5 expression was upregulated in CRC tissues, and inhibition of SLC1A5 significantly enhanced the inhibitory effect of 2DG on the growth of CRC cells in vitro and in vivo.\nThis includes the upregulation of glutamine transporter SLC1A5 and glutamine uptake, with concomitant build-up of essential amino acids, and mTORC1 activation, to ameliorate the effects of LDHA inhibition.\npromoter enrichment is increased by anti-ATF4 antibody immunoprecipitation in -overexpressing colorectal cells, indicating that ATF4 targets SLC1A5 to promote glutamine and glucose metabolism in these cells.\nIn addition, Trx-1 promoted SLC1A5 expression by increasing the promoter activity of the SLC1A5 gene by binding to SP1.\nOverexpression of SLC1A5 reduced the cytotoxicity of 2DG in combination with PX-12 treatment in CRC cells.\nInhibition of glycolysis in combination with inhibition of Trx-1 or SLC1A5 may be a promising strategy for the treatment of CRC.\nThe role of activating transcription factor 4 (ATF4) in solute carrier family 1 member 5 (SLC1A5)-mediated glutaminolysis and glycolysis remains to be elucidated.\nMoreover, we confirmed that SLC1A5 depletion reduced the ratio of glutathione/oxidized glutathione.\nWe also verified CDDO-Me downregulated glutamine transporter"
    },
    "1799-1856": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "colorectal cancer(CRC)",
      "text": "MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels.\nIn the E705 CRC cell line, it induced cell apoptosis and caused the downregulation of glycolysis, inhibiting cell proliferation.\nIn conclusion, excess iron promotes glycolysis and colon tumor growth at least partly through the inhibition of the PDH complex function.\nAndrographolide enhanced radiosensitivity by downregulating glycolysis via inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 cells.\nIn conclusion, PTBP1 knockdown enhanced the sensitivity of drug-resistant colon cancer cells to vincristine and oxaliplatin through repression of glycolysis.\nN-acetyl-L-cysteine, an ROS inhibitor, prevented p,p'-DDT-induced promotion of aerobic glycolysis, ERK1/2 activation, upregulation, and nucleus translocation of PKM2.\nThese findings indicate that shRNA-mediated silencing of PKM2 gene promotes apoptosis and inhibits aerobic glycolysis, proliferation, migration, and invasion in CRC cells.\nMETTL14 was downregulated in CRC tissues and cells, which overexpression inhibited proliferation and glycolysis, as well as promoted apoptosis and ferroptosis in CRC cells.\nIn colon cancer cells, Abhd5 deficiency induces epithelial-mesenchymal transition by suppressing the AMPKα-p53 pathway, which is attributable to increased aerobic glycolysis.\nMoreover, miR-103a-3p knockdown inhibited the growth, proliferation, and glycolysis of CRC cells and promoted the Hippo-YAP1 signalling pathway in nude mice in a xenograft model.\nAdditionally, METTL14 restrains aerobic glycolysis in p53-WT CRC, by repressing SLC2A3 and PGAM1 expression via selectively promoting m A-YTHDF2-dependent pri-miR-6769b/pri-miR-499a processing."
    },
    "367-1795": {
      "type": "slc_pathway",
      "key1": "SLC38A1",
      "key2": "proliferation",
      "text": "Subsequently, increased uptake of amino acids by the transporters (SLC38A1 and SLC7A5) activates mammalian target of rapamycin complex 1 (mTORC1), a master regulator of cell growth, and stimulates cell proliferation.\nSLC38A1 silencing prominently attenuated the OTUD5-induced increase in HCC cell proliferation.\nInhibition of SLC38A1 reduced tumour growth and suppressed proliferation and migration of SW480 cells.\nSLC38A1 knockdown suppressed HCC cell proliferation, migration, invasion, and EMT and inhibited ferroptosis in vitro.\nMoreover, the knockdown of SLC38A1 and HIF1A by RNAi resulted in a significant decrease in the proliferation of HEC1A cells (p < 0.05).\nTCF12 targeted SLC38A1 to promote HCC cell proliferation, migration and invasion and restrained ferroptosis, providing a novel sight for HCC pathogenesis.\nThese results suggest that theanine accelerates cellular proliferation and subsequent neuronal specification through a mechanism relevant to upregulation of Slc38a1 gene in undifferentiated neural progenitor cells.\nThe twofold aim of this study was to provide insight into whether a variance in the expression of SLC38A1 exists between human colorectal cancer and healthy human tissues and to determine how silencing or overexpressing the SLC38A1 gene could affect the proliferation, viability and migration of colorectal cancer cells.\nUpregulation of transcript expression is found for one of the GLN transporter isoforms, Slc38a1, besides the promotion of both proliferation and neuronal commitment along with acceleration of the phosphorylation of mechanistic target of rapamycin (mTOR) and relevant downstream proteins, in murine NPCs cultured with theanine.\nIn neural progenitor cells with sustained exposure to L-theanine, upregulation of the L-GLN transporter isoform Slc38a1 expression and promotion of both proliferation and neuronal commitment are seen along with marked acceleration of the phosphorylation of mammalian target of rapamycin ("
    },
    "1795-2228": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "acute myeloid leukemia (AML)",
      "text": ""
    },
    "81-1794": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-1811": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Osteosarcoma(OS)",
      "text": ""
    },
    "91-1795": {
      "type": "slc_pathway",
      "key1": "SLC9A2",
      "key2": "proliferation",
      "text": "ETS1 could promote the proliferation, invasion, and aerobic glycolysis ability of OS cells, as well as tumor growth in vivo by inhibiting the expression of SLC9A2.\nThus, SLC9A2 can function as a key inhibitory factor in the aerobic glycolysis to inhibit proliferation and invasion of OS.\nImportantly, SLC9A2 overexpression in SW480 cells led to a notable inhibition of cell proliferation, migration, and invasion.\nCCK-8, transwell, western blotting and Seahorse XFe24 Cell Metabolic Analyzer assays demonstrated that overexpression of SLC9A2 could constrain OS cell proliferation, invasion, and aerobic glycolysis.\nWe addressed the role of NHE8 [solute carrier 9A8 (SLC9A8)] and its interplay with NHE2 (SLC9A2) in luminal proton extrusion during acute and chronic enterocyte acidosis and studied the differential effects of NHE8 and NHE2 on enterocyte proliferation.\nDual-luciferase reporter gene assay and chromatin immunoprecipitation (ChIP) assays indicated ETS proto-oncogene 1 (ETS1) was a transcription suppressor of SLC9A2, and overexpression of ETS1 could promote methylation levels in specific regions of the SLC9A2 promoter.\nIn addition, SLC9A2, suppressing by ETS1, restrains growth and invasion of OS via inhibition of aerobic glycolysis.\nAlterations in NHE2 and NHE8 expression/activity affected proliferation, with C2Bbe/shNHE2 cells having lower and C2Bbe/shNHE8 having higher proliferative capacity, accompanied by amplified ERK1/2 signaling pathway and increased EGFR expression in the latter cell line.\nCombined use of a knockout mouse model, intestinal organoid technology, and specific inhibitors revealed previously unrecognized actions of NHE2 and NHE8 in enterocyte proliferation and differentiation."
    },
    "1795-1811": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Osteosarcoma(OS)",
      "text": "Functional assays confirmed TNK2's role in cell proliferation, viability, and migration, and showed that TNK2 knockdown mitigated cycloheximide-induced proliferation inhibition, linking TNK2 to paraptosis regulation.\nOE FEZF1-AS1 promoted HOS cell proliferation and invasion, upregulated 125 genes, suppressed 48 genes, and impacted 1156 alternative splicing events (ASEs), including pathways like C-type lectin receptor signaling and Yersinia pestis infection.\nThe results showed that TIMM23-induced M2 polarization upregulated TIMM23-PARGP1 expression in OS cells, thereby enhancing their proliferation, migration, and invasion while inhibiting apoptosis and reducing the effectiveness of chemotherapeutic agents.\nIn the K7M2 osteosarcoma model (initial tumor volume 80 mm), HPB@MET increased the tumor inhibition rate from 55% with HPB to 76.5%, with median survival extended to 57 days, indicating that HPB@MET synergistically suppresses tumor cell proliferation via POD activity and mitochondrial dysfunction, effectively suppressing osteosarcoma progression.\nThe present study revealed that ALKBH1 served as a tumor suppressor by promoting apoptosis, inhibiting proliferation, and suppressing metastasis in OS.\nImmunohistochemistry of xenograft tumors from Riluzole-treated mice revealed increased and cleaved caspase-3 levels, indicating elevated apoptosis, while reduced NUMA expression suggested diminished tumor proliferation.\nAdditionally, KA inhibited M2 macrophage-mediated enhancement of malignant behaviors in OS cells.\nMechanistically, ITGA2 promoted tumor invasion and bone metabolism imbalance by regulating osteoclastogenic signaling, while its targeted inhibition synergistically suppresses tumor growth and restores bone homeostasis, highlighting ITGA2 as a pivotal therapeutic target for osteosarcoma.\nMAT2A inhibition or methionine restriction reduced H3K27me3 levels, induced DNA damage, and suppressed OS cell growth."
    },
    "393-1802": {
      "type": "slc_pathway",
      "key1": "SLC40A1",
      "key2": "oxidative phosphorylation",
      "text": "As a co-activator of N-methyl-D-aspartate receptor (NMDAR), sarcosine also exerted its pro-ferroptosis effect via regulating ferrous export through the NMDAR/MXD3/SLC40A1 axis.\nMetabolic flux analysis showed limited conversion of sarcosine to other metabolites in LUAD cells, while untargeted metabolomic profiling and seahorse assays indicated a metabolic shift from glycolysis to oxidative phosphorylation.\nSarcosine enhanced pyruvate dehydrogenase activity to generate more ROS by interacting with PDK4, reducing PDHA1 phosphorylation.\nAccordingly, the main pathways disturbed include metabolic pathways, proteasome, oxidative phosphorylation, cancer, etc.\nBy gene ontology analyses, these differentially expressed genes were significantly enriched in several major biological processes including oxidation reduction, translation, iron ion transport, cell redox, homeostasis, etc.\nFinally, at least four of these genes, frh3 (ferrintin H3), mgst1 (microsomal glutathione S-transferase-like), cmbl (carboxymethylenebutenolidase homolog) and slc40a1 (solute carrier family 40 [iron-regulated transporter], member 1) could be confirmed in individual medaka fish similarly treated by arsenic;"
    },
    "1802-1853": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "ovarian cancer",
      "text": "TIMM8B enhanced oxidative phosphorylation, glycolysis, proliferation, migration, and invasion and inhibited apoptosis in ovarian cancer cells.\naerobic glycolysis was suppressed and oxidative phosphorylation was increased in ovarian cancer cells after PTTG suppression.\noxidative phosphorylation is suppressed and glycolysis is increased with long exposure to LPA in ovarian cancer cells compared with non-transformed epithelial cells.\nSpheroid architecture strongly enhances miR-221/222 expression and promotes oxidative phosphorylation in an ovarian cancer cell line through a mechanism that includes restriction of miR-9 expression.\nStudies in breast and ovarian cancer HRD models depict a metabolic shift that includes enhanced expression of the oxidative phosphorylation (OXPHOS) pathway and its key components and a decline in the glycolytic Warburg phenotype.\nCryptotanshinone (CT), a lipid-soluble bioactive anticancer molecule of Salvia miltiorrhiza, inhibits both glycolysis and oxidative phosphorylation (OXPHOS) in ovarian cancer cells leading to growth suppression and apoptosis induction.\nCisplatin-resistant ovarian cancer cells are dependent on mitochondrial OXPHOS for energy supply, and intracellular PGC1α-mediated mitochondrial biogenesis levels are increased in this cell line, indicating the important role of mitochondrial oxidative phosphorylation in cisplatin resistance.\ninhibiting oxidative phosphorylation overcomes cisplatin resistance in ovarian cancer.\nChemoresistant ovarian cancer cells showed increased oxidative phosphorylation (OXPHOS) compared to chemosensitive cells.\noverexpression of SIRT6 enhances glycolysis and oxidative phosphorylation in ovarian cancer cells.\nTRPM7 silencing enhanced AMPK activation to shift glycolysis to oxidative phosphorylation by promoting HIF-1α ubiquitination degradation in ovarian cancer.\nthe combination of both increased mitochondrial content and enhanced respiratory complex I (CI) boosted intrinsic oxidative phosphorylation (OXPHOS) power output."
    },
    "9-1801": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "apoptosis",
      "text": "Downregulation of SLC2A1 could not only inhibit cell proliferation, migration and cell cycle, but also promote cell apoptosis.\nKnockdown of SLC2A1 resulted in reduced cell viability, decreased migration, and increased apoptosis in Caco-2 and SW480 cells.\nTherefore, the present study demonstrated that exosomes derived from patients with sepsis may inhibit glycolysis and promote the apoptosis of human myocardial cells through exosomal hsa‑miR‑1262 via its target SLC2A1.\nOur results showed that simvastatin increased the expression of miR-140-5p in a dose dependent manner via activating transcription factor NRF1, reduced cell proliferation and induced apoptosis, and we also found that SLC2A1 was a new target of miR-140-5p.\nIn vitro functional experiments have shown that knocking down SFXN1 inhibits the proliferation and migration of LUAD cells, promotes cell apoptosis, and may inhibit tumor activity by regulating the expression of glycolytic related genes SLC2A1, HK2, GPI, ALDOA, GAPDH, ENO1, PKM, and LDHA.\nThe silencing of SLC2A1 promoted apoptosis and suppressed glycolysis in AC16 cells, whereas SLC2A1 overexpression resulted in the opposite effects.\nSLC2A1-AS1 promoted cell growth in vitro and in vivo, migration and invasion, and suppressed apoptosis, leading to EMT progression and increased glycolysis in ESCC cells.\nMiR-378a-3p inhibited cell proliferation and invasion as well as induced apoptosis, resulting in reduced glycolysis, which was partly reversed by SLC2A1-AS1 or Glut1 overexpression in ESCC cells.\nMechanistic investigations revealed that elevated SM enhances SLC2A1-dependent glucose uptake and glycolysis, leading to increased lactate production and subsequent CASP3 lactylation on lysine residue 14, which inhibits CASP3 activation and apoptosis."
    },
    "1801-2296": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "ferroptosis-relative osteoarthritis",
      "text": "HIF-1α, MALAT1, and apoptosis levels were increased after SLC2A1 knockout in chondrocyte cells (p = 0.0017).\nOur findings indicated that CAT inhibited HIF-1a expression and reduced ferroptosis-relative osteoarthritis progression by activating SLC2A1.\nMoreover, CAT reduced ferroptosis-dependent osteoarthritis in vivo and in vitro.\nHowever, the protective effect of CAT against ferroptosis-dependent osteoarthritis could be eliminated by silencing SLC2A1.\nFerroptosis is an iron-dependent cell death that has been found to aggravate the progression of osteoarthritis (OA) and gut microbiota- OA axis refers to the bidirectional information network between the gut microbiota and OA, which may provide a new way to protect the OA."
    },
    "9-1796": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "ferroptosis",
      "text": "SLC2A1 knockdown caused obvious activation of cell ferroptosis, reduced GPX4 and xCT expressions, and increased intracellular levels of ROS and Fe.\nHigh SLC2A1 expression is correlated with poor prognosis of patients with LUAD, and inhibiting SLC2A1 can induce ferroptosis and autophagy of LUAD cells, suggesting the potential of SLC2A1 as a target for LUAD diagnosis and treatment.\nWe discovered that during the induction of environmental factors, the transcription and methylation levels of SLC2A1 were greatly increased, autophagy and ferroptosis were inhibited, and the immune system was defective, resulting in a poor prognosis for patients.\nOur findings indicated that CAT inhibited HIF-1a expression and reduced ferroptosis-relative osteoarthritis progression by activating SLC2A1.\nValidation experiments revealed that SLC2A1 functions by regulating ferroptosis.\nSTAT3, MAPK14, HSPA5, MTOR and SLC2A1 may influence CKD onset by regulating ferroptosis.\nDownregulation of SLC2A1 expression promoted ferroptosis and suppressed tumor cell growth in breast cancer cells ( < 0.01), while overexpression of TXNIP or ATF3 had the same effect ( < 0.01).\nHowever, the protective effect of CAT against ferroptosis-dependent osteoarthritis could be eliminated by silencing SLC2A1.\nSLC2A1 knockdown also resulted in increased cell autophagy shown by increased LC3B expression, which could be reversed by treatement with 3-MA.\nMechanistically, SLC2A1-mediated glucose uptake promotes glycolysis and, thus, facilitates pyruvate oxidation, fuels the tricyclic acid cycle, and stimulates fatty acid synthesis, which finally facilitates lipid peroxidation-dependent ferroptotic death.\nAdditionally, FA inhibited ferroptosis and apoptosis by suppressing the HIF-1 signaling pathway, up-regulating the expression of GPX4 and Bcl2, and down-regulating the expression of HIF-1"
    },
    "1796-2287": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "septic myocardial injury",
      "text": "GPX4- and FSP1-mediated ferroptosis are involved in myocardial injury in mice with CLP-induced sepsis, and inhibition of ferroptosis can attenuate septic myocardial injury, in which Lcn2 may play a role.\n(1) HIF1A/BNIP3 activation aggravated septic myocardial injury and ferroptosis;\nIn this study, we investigated the regulatory role of HIPK2 regarding the level of ferroptosis in septic myocardial injury.\nMatrine regulates PI3K/AKT pathway activity to inhibit apoptosis and ferroptosis and thereby alleviates sepsis-induced myocardial injury.\nThis study investigates the interaction between the HIF1A/BNIP3 signaling pathway and the ferroptosis axis, SLC7A11/GPX4, in septic myocardial injury.\nNaHS was demonstrated to attenuate sepsis‑induced myocardial cell and tissue injury by significantly inhibiting the phosphorylation of BECN1 and significantly increasing expression levels of the ferroptosis regulatory proteins solute carrier family 7 member 11 and glutathione peroxidase 4.\nOur findings reveal the potential of targeting the FTO/BACH1 axis and ferroptosis inhibitors as therapeutic strategies for sepsis-induced cardiac injuries.\nNaHS decreased ferroptosis of H9c2 cells induced by LPS and decreased injury of myocardial cells by improving iron metabolism disorder and oxidative stress levels.\nFunctionally, METTL3 silencing repressed the ferroptosis phenotype induced by LPS.\nCompared with the control H9c2 cells, the LPS-treated H9c2 cells exhibited decreased cell viability and increased cytotoxicity, ferroptosis, and inflammatory responses.\nThe overexpression of FTO-suppressed ferroptosis alleviated heart inflammation and dysfunction and improved survival rates in vivo.\nMoreover, matrine increased PI3K/AKT pathway-related molecule expression and thus modulated ferroptosis and apoptosis."
    },
    "81-1799": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "glycolysis",
      "text": "Among them, we show that LUC7L2 represses OXPHOS and promotes glycolysis by multiple mechanisms, including (1) splicing of the glycolytic enzyme PFKM to suppress glycogen synthesis, (2) splicing of the cystine/glutamate antiporter SLC7A11 (xCT) to suppress glutamate oxidation, and (3) secondary repression of mitochondrial respiratory supercomplex formation.\nCirc_0072088 elicited oncogenic role in malignant cell progression and glycolysis of PDAC cells through circ_0072088/miR-545-3p/SLC7A11 pathway.\nBlocking circ_0072088 suppressed cell proliferation, migration, invasion, and glycolysis in PDAC cells.\nSND1 bound with and promoted the expression of SLC7A11, an aerobic glycolysis regulator.\nFurther research indicated that ISL promoted DC efferocytosis by regulating SLC7A11-mediated glycolysis.\nAltogether, SNHG1 contributes to sorafenib resistance of liver cancer cells by promoting SND1-m6A-SLC7A11-mediated aerobic glycolysis.\nMoreover, SLC7A11 downregulation could be mediated by both circ_0072008 siRNA and miR-545-3p mimic, and participating in suppressive role in cell progression and glycolysis of SW1990 and PANC-1 cells.\nSLC7A11-deficient dendritic cells were dependent on aerobic glycolysis using glucose derived from glycogen stores for increased efferocytosis;\nFurthermore, either silencing SLC7A11 or blocking aerobic glycolysis with 2-deoxy-d-glucose (2-DG) was able to reverse the promotion of Snhg1 overexpression on malignancy, sorafenib resistance, and aerobic glycolysis of HepG2 cells.\nTranscriptomic analyses across cancers demonstrate strong correlations between GSH, SLC7A11, PKM2, glycolysis, and ferroptosis pathways."
    },
    "1799-1864": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "prostate cancer",
      "text": "LIAS promotes cuproptosis and inhibits cancer cell proliferation in PC by activating the p53 signaling pathway to suppress glycolytic activity.\nJuglone promotes antitumor activity against prostate cancer via suppressing glycolysis and oxidative phosphorylation.\nNPAS2 is upregulated in prostate cancer and promotes cell survival by promoting glycolysis and inhibiting oxidative phosphorylation in PCa cells.\nFibroblast growth factor pathway promotes glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in prostate cancer.\nFV-429 induced glycolysis inhibition and apoptosis in human prostate cancer cells by downregulating the AR-AKT-HK2 signaling network.\nOur findings reveal that COUP-TFII represses MPC1 expression in prostate cancer cells to facilitate a metabolism switch to increase glycolysis and promote cancer progression.\nRSL3 could decrease the ATP and pyruvate content as well as the protein levels of HKII, PFKP, PKM2, which indicated that RSL3 induced glycolysis dysfunction in prostate cancer cells.\nWe further demonstrate that COUP-TFII, which is upregulated in the prostate cancer patient, regulates MPC1 and glycolysis to promote tumor growth and metastasis.\nDocetaxel treatment led to a significant inhibition of cell proliferation in prostate cancer cells through PFKP-mediated glycolysis.\nhsa_circ_0006620 downregulation inhibited prostate cancerby regulation of the miR-502-3p/HK2 axis mediated by aerobic glycolysis.\nOur results demonstrate a novel PKCε function that promotes cell growth in prostate cancer cells by increasing aerobic glycolysis through crosstalk between PKCε and Smad2/3.\nThe LIFR is upregulated by nuclear EGFR, which acts as a transcriptional regulator, directly binds to the LIFR promoter, and drives NE differentiation and glycolysis of prostate cancer.\nmiR-137 repressed glycolysis in prostate cancer through knockdown of NOX4."
    },
    "250-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A29",
      "key2": "oxidative phosphorylation",
      "text": "Functional groups displaying highly significant (P < 0.0001) increased expression included mitochondrion, oxidative phosphorylation and fatty acid metabolism while functional groups with decreased expression were mainly associated with structural genes and included the sarcoplasm, laminin complex and cytoskeleton.\nSixteen genes showed increased expression, including the mitochondrial genes ACADVL, MRPS21 and SLC25A29 encoded by the nuclear genome.\nThe high-risk group had a lower activation of oxidative phosphorylation and a more abundant immune infiltration phenotype than the low-risk group.\nAccording to co-expression network studies, SLC25A11, SLC25A29, and SLC25A44 were involved in the energy metabolism of PC and prevented tumor growth, invasion, and metastasis.\nExercise training in Thoroughbred racehorses results in coordinate changes in the gene expression of functional groups of genes related to metabolism, oxidative phosphorylation and muscle structure.\nThe most abundant mRNA transcripts in the muscle transcriptome were those involved in muscle contraction, aerobic respiration and mitochondrial function."
    },
    "372-1795": {
      "type": "slc_pathway",
      "key1": "SLC38A7",
      "key2": "proliferation",
      "text": "In addition, SLC38A7 knockdown induced a decrease in proliferation with G1 arrest in lung adenocarcinoma cell lines.\nSLC38A7 silencing suppressed cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in cancer cells.\nOur results suggest that SLC38A7, stabilized by METTL3 and IGF2BP2-mediated mA methylation, enhances cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in GC, highlighting its role as a potential therapeutic target for GC.\nIt is widely known that most cancer cells display an increased reliance on glutaminolysis to sustain proliferation and survival.\nOur findings demonstrate that SNAT7 plays a pivotal role in promoting tumour malignancy and is significantly associated with poor prognosis in lung adenocarcinoma.\nSLC38A7 overexpression had the opposite biological effects.\nGlutamine metabolism plays a crucial role in cancer cell proliferation and modulates the tumour microenvironment.\nSurprisingly, a combination of glutamine deprivation with archazolid did not lead to synergistic induction of cell death or reduction in proliferation.\nSolute carrier (SLC) 38 family, responsible for trans-membrane transport of neutral amino acids, plays a role in the proliferation, invasion, and metastasis of cancer cells, but its role in gastric cancer (GC) progression remains unclear.\nFurthermore, we found that the export of lysosomal glutamine derived from exogenous sources plays no role in the phenotype as knock-down of SLC38A7, the lysosomal glutamine exporter, could not increase V-ATPase inhibition-induced cell death or reduce proliferation."
    },
    "1795-1868": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "lung cancer",
      "text": "These findings demonstrate that BPF-induced MARK2 upregulation activates EMT signaling, promoting malignant phenotypes, including proliferation, migration, and ferroptosis suppression, in lung cancer cells.\nIt enhanced lung cancer cell proliferation, migration, and invasion while inhibiting apoptosis in cellular and animal models.\nIn vitro experiments using GBP2 knockdown in NCI-H1299 and A549 lung cancer cell lines showed reduced cell proliferation, increased apoptosis, and inhibited cell migration, alongside cell cycle arrest at the G2 phase.\nMechanistically, ADAR1 may promote proliferation, invasion, migration, and tumorigenesis in lung cancer cells via the ERK/c-FOS/MMP-9 axis.\nIGFL2-AS1 promoted lung cancer proliferation, metastasis, drug resistance, and stemness by upregulating HSPA1A expression both in vitro and in vivo.\nThe sulfated fraction showed significant cytotoxicity against human lung cancer (A549) cells by suppressing proliferation and inducing apoptosis through nuclear fragmentation.\nFunctional studies in PYCR1-knockout (PYCR1-KO) lung cancer cells generated via CRISPR-Cas9 showed reduced cell proliferation, migration, colony formation and tumor spheroid growth both in vitro and in vivo.\nIbrutinib effectively inhibited the proliferation and migration of lung cancer cells, and in a lung cancer bone metastasis model, this drug inhibited tumor growth, alleviated pain, and protected the tibial bone.\nThe proliferation of lung cancer cells was significantly inhibited by abietic acid.\nOur findings indicate that TBPH enhances lung cancer cell proliferation, as determined by CCK-8 and EdU assays.\nSilencing PTGFRN significantly inhibited non-small cell lung cancer cell proliferation, tumor formation, and metastatic capacity.\nIncreasing ECM stiffness can contribute to lung cancer progression and is sensed by integrins to promote proliferation and invasion.\nHigh CIP2A expression in lung cancer correlates with poor prognosis, increased tumor proliferation, and resistance to targeted therapies or chemotherapy."
    },
    "131-1801": {
      "type": "slc_pathway",
      "key1": "SLC15A1",
      "key2": "apoptosis",
      "text": "In conclusion, JBP485 alleviated indomethacin-induced intestinal injury through restoring the redox balance, suppressing inflammation, reducing apoptosis, which was further enhanced by Res via upregulation of Pept1 and improvement of bioavailability of JBP485, at least in part.\nMoreover, Met-Met increased tight junction protein and decreased apoptosis-related proteins expression in the jejunum and ileum.\nSpermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport.\nUnlike single decitabine treatment, the combined decitabine/PBA treatment caused > 95% inhibition of cell proliferation, prevented cell cycle progression especially in the S and G2-phase and induced programmed cell death.\nJBP485 treatment ameliorated indomethacin-induced enteropathy characterized by severe histopathological changes and a large number of TUNEL-positive cells in rat intestinal epithelium, elevated levels of MDA, MPO, TNF-α, IL-6, IL-1β and increased expression of COX-2, and reduced levels of SOD, GSH, CAT, HDL-c, PGE2, expression of COX-1 and Bcl-2/Bax ratio in rat intestinal tissues.\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport (p&lt;\nIL-6 and TNF-α expression and apoptosis were increased, and mitochondrial damage was severe, as indicated by increased mtDNA in the MDP group compared with controls.\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets (p&lt;0.05).\nFurthermore, Res increased the plasma concentration of JBP485 in both indomethacin-treated and healthy rats, as well as the intracellular accumulation of JB"
    },
    "1801-2119": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": "The miR-338-3p overexpression in hepatocellular carcinoma (HCC) cells was responsive to lenvatinib-induced apoptosis and cell progression inhibition.\nTaken together, knocking down SKA1 inhibited HCC progression by promoting the apoptosis signaling pathway.\nCAV1 downregulation induced apoptosis, inhibited metastasis and restored TKI sensitivity in both inherent and acquired TKI-resistant HCC cells.\nIn vitro studies confirmed that NB effectively activated the P38MAPK pathway, inhibited proliferation of HepG2 cells, and induced early apoptosis.\nand miR-7's inhibitory effect on CAV1 and FGFR4 suppressed the STAT3/P70S6K pathway, promoted autophagy and triggered apoptosis in lenvatinib-resistant cells.\nIn vitro studies indicated that (GalNAc)-CPT was effectively taken up by hepatocellular carcinoma (HCC) cells, significantly reducing cell viability and inducing apoptosis.\nWhen 20% YXC-mediated serum was added to MHCC97H cells, the increased apoptosis was significantly rescued by the addition of p53 inhibitor (PFT-α) or PI3K activator (740Y-P).\nThis effect was evidenced by their ability to significantly induce apoptosis, inhibit metastasis, reverse drug resistance, and interfere with CSC-associated signaling pathways.\nNevertheless, the adverse effects of TAA could be suppressed by natural plants, which not only eliminated ROS but also activated the PI3K-Akt cell survival pathway in the liver and prevented apoptosis approaches.\nIn vitro experiments showed that the efficiency of TOP2A knockdown mediated by siRNA was over 70% (P < 0.05), and it significantly inhibited the proliferation, invasion and migration of HCC cells (P < 0.05), promoted cell apoptosis (P < 0.05).\nFurther mechanism studies have shown that compound 7a could inhibit migration, induce mitochondrion-mediated apoptosis, thereby suppressing cell proliferation in HepG2 cells through regulation of Bcl"
    },
    "191-1797": {
      "type": "slc_pathway",
      "key1": "SLC22A8",
      "key2": "oxidative stress",
      "text": "The principal mechanisms are as follows: inhibition of XOD activity in the serum to reduce uric acid production, regulation of renal reabsorption and secretion of uric acid to increase uric acid excretion, and alleviation of oxidative stress reaction to decrease systemic damage and, eventually, treatment of HUA.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nIn vitro/vivo studies on OTA and CIT effects showed they elevate oxidative stress parameters.\nHere, we show that the multispecific organic anion transporters of drugs, OAT1 (SLC22A6 or NKT) and OAT3 (SLC22A8), play a role in organ sensing.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUbiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nAbstract: Several SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant molecules such as uric acid, ergothioneine, carnitine, and carnitine"
    },
    "1797-2346": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "treatments with cytostatics such as methotrexate and cisplatin",
      "text": ""
    },
    "184-1794": {
      "type": "slc_pathway",
      "key1": "SLC22A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-1831": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Neuroendocrine Tumor",
      "text": ""
    },
    "294-1799": {
      "type": "slc_pathway",
      "key1": "SLC28A1",
      "key2": "glycolysis",
      "text": "The key biochemical feature of malignant tumor is the conversion of energy metabolism from oxidative phosphorylation to glycolysis, which provides sufficient capacity and raw materials for tumor cell rapid growth."
    },
    "1799-1853": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "ovarian cancer",
      "text": "Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.\nTIMM8B promotes oxidative phosphorylation and glycolysis by inhibiting the mtROS/ASK1/JNK signaling pathway in ovarian cancer.\nResveratrol inhibits the proliferation and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK/mTOR signaling pathway.\ncardamonin-induced autophagy is associated with inhibition on glycolysis by down-regulating the activity of mTORC1 in ovarian cancer cells.\nPSⅦ inhibits glycolysis-induced cell proliferation and apoptosis through the RORC/ACK1 pathway, supporting its potential development as a candidate chemotherapeutic agent for ovarian cancer.\nRV can counteract IL-6-promoted ovarian cancer progression by rescuing glycolysis-mediated inhibition of autophagy and support the view that targeting Warburg metabolism can be an effective strategy to limit the risk for cancer metastasis.\nCT inhibited cellular glycolysis-induced cell growth and proliferation through repression of STAT3/SIRT3/HIF-1α signaling pathway, indicating that CT may be developed as a chemotherapeutic agent to treat ovarian cancer.\nthe interaction between IL-33 and TRIM28, which plays an antioxidant role, regulates glycolysis in BMDMs by promoting the PI3K/Akt pathway in ST2-independent manner, thereby reducing M2 polarization of macrophages is a way to inhibit ovarian cancer growth.\nInhibition of LINC00629 was required for increased glycolysis activity and cell proliferation in ovarian cancer.\nOvarian cancer patient-derived ascitic fluid-induced aerobic glycolysis in both NFs and Ovarian CAFs and it was inhibited by Ki16425.\naerobic glycolysis was suppressed and oxidative phosphorylation was increased in ovarian cancer cells after PTTG suppression.\nPSⅦ inhibites glycolysis and promotes cell apoptosis in ovarian cancer cells."
    },
    "1801-1811": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Osteosarcoma(OS)",
      "text": "AIL inhibited the proliferation of human OS cells and induced apoptosis through the ERS pathway.\nAdditionally, PLEKHF1 overexpression inhibited OS cell viability, colony formation, migration, invasion, and epithelial-mesenchymal transition (EMT), while promoting apoptosis.\nWP1066 suppressed STAT3 activation and induced apoptosis.\nHigh expression of NPR3 significantly inhibited proliferation and promoted apoptosis in UBE4A-overexpressing cells.\nOur results indicate that the system significantly induced apoptosis and inhibited migration in osteosarcoma cells.\nGS treatment led to a significant decrease in OS cell proliferation, induced cell cycle arrest at the G2/M phase, and promoted apoptosis.\nIn this study, we found that overexpression of SNHG11 in human osteosarcoma U2OS cells significantly inhibited cell proliferation and promoted apoptosis.\nAdditionally, ZIC2depletion inhibited proliferation, invasion and migration and induced apoptosis of OS cells, but ZIC2 overexpression had the opposite effects.\nAIL exhibited a dose-and time-dependent inhibitory effect on U-2OS cell growth, significantly reducing cell proliferation and migration rates while promoting apoptosis.\nFunctional assays revealed that the combination treatment markedly suppressed OS cell proliferation and migration, induced apoptosis, and exhibited low toxicity toward normal cells.\nNotably, silencing LINC01517 inhibited in vitro cell proliferation, activated NLRP3/caspase-1/GSDMD-mediated pyroptosis, promoted ferroptosis, and enhanced necroptosis in osteosarcoma cells.\nMechanistic studies suggest that compound 8e-induced 143B cell apoptotic is mediated by EEF1A2 inhibition of the AKT signaling pathway and EEF1A2 serves as a potential candidate for targeted OS therapy.\nThese derivatives efficiently induced apoptosis in osteosarcoma (OS) through a mitochondria-dependent pathway.\nOverexpression of UBE4A reversed the decrease in cell viability and induction of apoptosis caused by IGFBP3 knockdown."
    },
    "52-1798": {
      "type": "slc_pathway",
      "key1": "SLC6A2",
      "key2": "stemness",
      "text": "On the other hand, genes related to cell stemness were downregulated in patients with activation of the beta- adrenergic pathway."
    },
    "1798-1924": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Head and Neck Cancer",
      "text": "GMNL-346 selectively inhibited proliferation by disrupting the cell cycle and suppressing cancer stemness proteins, while sparing normal gingival epithelial cells.\nWhole-genome sequencing identified a heat-stable antimicrobial peptide that replicated GMNL-346's ability to suppress OSCC cell proliferation and cancer stemness protein expression.\nCompared to the parental cells, the rapidly acquired drug-tolerant persister (DTP) cells showed enhanced expression of those genes associated with stemness and epithelial-mesenchymal transition.\nKnockdown of HDAC2/6/9 and BRD4 markedly reduced the formation of DTP cells.\nThis study investigated heat-killed Lacticaseibacillus paracasei GMNL-346 as a potential therapeutic agent for OSCC, targeting tumor progression and gut microbiota dysbiosis.\nparacasei GMNL-346 may represent a promising and safe therapeutic candidate for OSCC, potentially acting through direct tumor suppression and microbiota modulation, which supports further exploration of its role in microbiome-based cancer therapy.\nIn OSCC xenograft mouse models, the treatment enhanced survival rates and reversed tumor-induced gut microbiota dysbiosis, increasing beneficial metabolites such as propionic and isobutyric acids, which are associated with reduced OSCC progression."
    },
    "138-1799": {
      "type": "slc_pathway",
      "key1": "SLC16A3",
      "key2": "glycolysis",
      "text": "Mechanistically, sorafenib itself upregulates SLC16A3 protein expression by enhancing glycolysis, increasing lactate secretion which fosters an immunosuppressive TIME.\nOur findings suggest that nodakenetin inhibits the viability, promotes apoptosis, and represses glycolysis in breast cancer cells through decreasing SLC16A3 expression, proving the anti-cancer potential of nodakenetin in breast cancer.\nThe upregulated genes in SLC16A3-positive epithelial cells were enriched in the glycolysis process pathway and monocarboxylic acid metabolic process pathway.\nThe study reveals that LINC00035 promotes OC progression by regulating glycolysis and cell apoptosis through CEBPB-mediated transcriptional promotion of SLC16A3.\nMonocarboxylate transporter 4 (MCT4), encoded by SLC16A3 gene, is responsible for exporting lactic acid into the extracellular microenvironment, and an acidic microenvironment promotes cytokine production and remodels chronic inflammation, providing a link from glycolysis to inflammatory bowel disease (IBD).\nSLC16A3 upregulation reversed the effects of nodakenetin on the viability, apoptosis, and glycolysis in breast cancer cells.\nStatistically significant associations between SLC16A3 and m6A modification (ALKBH5) gene (p<0.001), key genes in aerobic glycolysis, M2 macrophage infiltration (p=0.0058), and immune checkpoint regulation were observed.\nMutant TP53-related (mTP53) pathways and genes including PKM, SLC16A3, HK2, PFKP, PHGDH, and CTSC were obtained from enrichment analysis and interestingly, top pathways were associated with metabolism including glycolysis and mTORC1 pathway.\nWe found that HIF1α-responsive genes, including many essential for glycolysis (SLC2A1, PDK1, LDHA, SLC16A3), were underexpressed in IDH(mt) gliomas and/or derived BTSCs."
    },
    "1795-1815": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "leukemia",
      "text": "These dysregulated signals promote enhanced self-renewal, uncontrolled proliferation, impaired differentiation, and blocked apoptosis, collectively arresting leukemic cells at various stages of development.\nIts primary functions include inhibiting cell proliferation, invasion, and metastasis, as well as promoting apoptosis.\nFunctional validation employing AML cell lines MV-4-11 and MOLM13 demonstrated that RPPH1 overexpression enhanced cell proliferation and suppressed apoptosis, whereas its knockdown resulted in opposite effects.\nLeukemia is a clonally hematologic malignancy whose pathogenesis is driven primarily by the aberrant activation of key signaling pathways.\nRecent studies have demonstrated a close association between PDCD4 and leukemia development, indicating that PDCD4 regulates this process mainly by participating in abnormally activated signaling pathways.\nProgrammed cell death 4 (PDCD4) is a tumor suppressor characterized by its MA3 domain-mediated binding to eIF4A, which suppresses protein synthesis.\nMechanistically, RPPH1 enhanced NF-κB p65 phosphorylation and upregulated IL-17 A expression, thereby activating downstream oncogenic targets, including PLAC8, LRP12, and CRABP2.\nGenomically agnostic approaches combine hypomethylating agents and venetoclax (HMA-Ven) with novel agents directed at oncogenic pathways critical for leukemic cell survival, proliferation, metabolism, or differentiation.\nThis review examines the expression and regulation of PDCD4 in leukemia, with a focus on its role as a molecular hub that connects the JAK/STAT, PI3K/AKT, and MAPK signaling pathways into a comprehensive network of leukemia pathways.\nThe present findings suggest that RPPH1 regulates AML progression via the NF-κB/Th17A signaling axis, providing new insights into its role in disease pathogenesis and immune microenvironment remodeling."
    },
    "75-1796": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "ferroptosis",
      "text": "SLC7A5 overexpression weakened the protective effect of YTHDF1 knockdown, resulting in decreased cell viability, deterioration of mitochondrial function, and increased ferroptosis.\nThis subpopulation suppresses ferroptosis in malignant cells through the transcriptional upregulation of SLC7A5 mediated by high TP63 expression, thereby promoting tumor growth and resistance to immunotherapy.\nOur research elucidates the TME in HNSCC before and after immunotherapy, revealing a novel mechanism by which TP63 SLC7A5 HNSCC inhibits ferroptosis and enhances tumor resistance via TP63-induced SLC7A5 upregulation.\nPLB ameliorates DHT-induced mitochondrial dysfunction and ferroptosis in KGN cells by inhibiting YTHDF1 expression, and its action is dependent on the mechanism by which YTHDF1 regulates SLC7A5 translation through m6A modification.\nFurthermore, the application of sublethal doses of ferroptosis-inducers such as erastin and sorafenib, low cystine growth conditions, or genetic knockdown of SLC7A11 and GPX4 all similarly protect cells from Golgi stress and lead to modulation of ACSL4, SLC7A5, SLC7A11 or GPX4 levels.\nSLC7A5, SLC7A11, and CHAC1 may affect the development of psoriasis by regulating ferroptosis.\nInterestingly, SSPH I elevated the expression levels of SLC7A5, which is the negative regulator of ferroptosis.\nThe experimental results demonstrated that the overexpression of TP63 upregulated the expression of SLC7A5 and suppressed the concentrations of Fe and ROS in HNSCC cells.\nBy integrating bulk transcriptome data, we developed a clinical scoring model based on TP63 and SLC7A5, which are closely associated with tumor stage, revealing the significant prognostic efficacy of the TP63 SLC7A5 HNSCC-mediated ferroptosis mechanism in HNSCC patients."
    },
    "1796-1924": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Head and Neck Cancer",
      "text": ""
    },
    "322-1800": {
      "type": "slc_pathway",
      "key1": "SLC34A2",
      "key2": "migration",
      "text": "In contrast, the repression of SLC34A2 mitigated the miR-650 silencing-induced inhibition of migration and invasion in LCCs and LCSCs.\nGW2974 (EGFR inhibitor) increased SLC34A2 knockdown-inhibited cell proliferation, migration/invasion, as well as enhanced SLC34A2 knockdown-increased the TMZ sensitivity of glioma cells.\nOverexpression of SLC34A2 inhibited the proliferation, migration, and invasion of OS cells.\nThe following studies proved that SLC34A2 knockdown exhibited suppressive effects on cell proliferation and migration/invasion.\nOur result also revealed a dramatic inhibitory effects of SLC34A2 on cell growth, migration and invasion of several NSCLC cell lines.\nOur previous researches have reported that overexpression of SLC34A2 significantly inhibited proliferation, migration and invasion of LUAD cells.\nOur data suggested MEG3 was involved in stem cell-like state of LCCs and curbed migration and invasion through miR-650/SLC34A2 axis in NSCLC.\nMoreover, restoring SLC34A2 expression effectively reversed the miR-410-mediated promotion of cell growth, invasion and migration in NSCLC cells.\nFunctional assays revealed that MOGAT2 knockdown in H1299 cells promoted proliferation and migration, induced G2 cell cycle arrest, and decreased apoptosis.\nSLC34A2 knockdown also inhibited epithelial-mesenchymal transition (EMT) phenotype, as evidenced by the increased E-cadherin expression, and the decreased N-cadherin and fibronectin expressions.\nFurthermore, a series of in vivo and in vitro gain- or loss-of-functional assays elucidated the role of SLC34A2 in boosting cell proliferation, cell cycle progression, migration, invasion, and adhesion of PTC cells.\nUpregulation of MEG3 suppressed migration and invasion in LCCs and LCSCs.\nFurthermore, miR-650 mimic attenuated the MEG3 upregulation-mediated inhibition of migration and invasion."
    },
    "1800-2099": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Multicancer",
      "text": "Recently, USP4 has been found to exert versatile influences on cells proliferation, migration and invasion, also apoptosis of various tumors.\nBy programming and precisely assembling multiple functions in one system, the Mb-H platform with spatial-temporal controlled release of cytokine transforming growth factor beta (TGF-β) and various functionalized Mb-H platforms with intelligent adjustment of cell-matrix interactions are engineered to coordinate the 3D invasive migration of cancer cell spheroids.\nUSP4, one of the DUBs members which participates in deubiquitination, an inverse process of ubiquitination, can regulate various classical cancer-related signaling pathways, and thereby plays a vital role in some pathological and physiological processes including tumor initiation and progression.\nIn the research of cancer cell invasion and metastasis, recreation of physiologically relevant and faithful three-dimensional (3D) tumor models that recapitulate spatial architecture, spatiotemporal control of cell communication and signaling pathways, and integration of extracellular cues remains an open challenge.\nThis review will give a comprehensive introduction of USP4 about its regulatory mechanisms, related signaling pathways, pathophysiological functions and the roles in various cancers which may help us better understand its biological functions and improve future studies to construct suitable USP4-targeted cancer therapy system.\nTherefore, a versatile therapeutic target which is involved in various cancer-related signaling pathways and different cancers may be more effective for cancer targeted therapy.\nThis programmable and adaptable 3D cancer cell invasion micro platform takes a new step toward mimicking the dynamically changing (localized) tumor microenvironment and exhibits wide potential applications in cancer research, bio-fabrication, cell signaling, and drug screening."
    },
    "1795-2119": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": ""
    },
    "1795-2741": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "embryonal carcinoma",
      "text": ""
    },
    "129-1794": {
      "type": "slc_pathway",
      "key1": "SLC13A5",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "10-1802": {
      "type": "slc_pathway",
      "key1": "SLC2A2",
      "key2": "oxidative phosphorylation",
      "text": "Metformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nMetformin caused mitochondrial dysfunction and metformin's effects on 2D-cultures were phenocopied by treatment with rotenone and antimycin-A, including upregulation of GDF15 expression, previously linked to metformin dependent weight loss.\nWe conclude that metformin affects glucose uptake, glycolysis and GDF-15 secretion, likely downstream of the observed mitochondrial dysfunction."
    },
    "1802-1917": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Gastric cancer (GC)",
      "text": "Here, we show that gastric cancer (GC) cells with high metastatic potential strongly promote the metabolic switch from oxidative phosphorylation to aerobic glycolysis in fibroblasts.\nThe upregulated expression of NDUFA4 then greatly promoted the proliferation and decreased the apoptosis of gastric cancer cells through activation of the oxidative phosphorylation pathway.\nThe ingenuity pathway analysis (IPA) results indicated that the sirtuin signaling pathway was the most activated pathway in GC tissues whereas oxidative phosphorylation was the most inhibited.\nProteomic analyses revealed that LQWDD protected the integrity of the oxidative phosphorylation pathway during gastric carcinogenesis, which was significantly suppressed in human gastric intraepithelial neoplasia and MNNG-induced gastric carcinoma.\nWe showed that inhibition of autophagy in gastric cancer cells promotes epithelial-mesenchymal transition (EMT) and metastasis, alters metabolic phenotype from mitochondrial oxidative phosphorylation to aerobic glycolysis and converts cell phenotype toward malignant, which maybe further contribute to chemoresistance and poor prognosis of gastric cancer.\nSLC38A7 silencing suppressed cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in cancer cells.\nRescue experiments showed that overexpression of ULK1 reversed the suppression of GC stemness and OXPHOS levels induced by DAZAP1 silencing.\nFunctional enrichment analysis suggested that DAZAP1 enhanced tumor stemness by promoting oxidative phosphorylation (OXPHOS), which was validated through Seahorse assays and measurements of mitochondrial potential.\nMechanistically, NIT2 interacted with bromodomain-containing protein 1 (BRD1) to inhibit HBO1-mediated acetylation of histone H3 at lysine-14 (H3K14ac) and RELA-targeted oxidative phosphorylation (OXPHOS) gene expression.\nThe three systems are known to promote alterations in the gastric epithelium through intracellular signaling pathways, such as oxidative phosph"
    },
    "59-1794": {
      "type": "slc_pathway",
      "key1": "SLC6A9",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-1806": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Brain Tumor",
      "text": ""
    },
    "1799-1815": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "leukemia",
      "text": "We demonstrate that hexokinase 2-mediated glycolysis in leukemic cells leads to lactate accumulation, which enhances histone H3 lysine 18 lactylation and upregulates plasminogen activator inhibitor-1 expression, impairing fibrinolysis.\nHere, we identify lactate-driven histone lactylation as a mechanism promoting thrombosis in acute myeloid leukemia.\nLactate released by acute myeloid leukemia cells is internalized by vascular endothelial cells via monocarboxylate transporter 1, amplifying plasminogen activator inhibitor-1 expression and thrombotic risk.\nInhibition of hexokinase 2-mediated lactate production or monocarboxylate transporter 1-mediated lactate uptake attenuates thrombosis.\nOur findings reveal a critical link between tumor metabolism, epigenetic modifications, and coagulation dysfunction in acute myeloid leukemia.\nAcute myeloid leukemia is an aggressive hematological malignancy frequently complicated by coagulation disorders, including thrombosis and hemorrhage, which contribute to poor outcomes."
    },
    "1796-2193": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "pancreatic ductal adenocarcinoma (PDAC)",
      "text": "Ferroptosis activators induce MGST1 upregulation in human pancreatic ductal adenocarcinoma (PDAC) cell lines in an NFE2L2-dependent manner.\nOSGIN1 expression is upregulated by pharmacological ferroptosis inducers in an NFE2 like BZIP transcription factor 2 (NFE2L2)-dependent manner, rather than through the TP53 pathway, in human pancreatic ductal adenocarcinoma (PDAC) cells.\nE1A binding protein P300 (EP300) acetyltransferase promotes ferroptosis in human pancreatic ductal adenocarcinoma (PDAC) cells via the acetylation of heat shock protein family A (Hsp70) member 5 (HSPA5), also known as GRP78 or BIP) on the site of K353.\nFerroptosis may be the silver bullet treatment for multiple cancers, including immunotherapy- and chemotherapy-insensitive cancers such as pancreatic ductal adenocarcinoma (PDAC).\nSolute carrier family 25 member A22 (SLC25A22) is a glutamate transporter in the inner mitochondrial membrane that is known to suppress ferroptosis in pancreatic ductal adenocarcinoma (PDAC).\nCurrent therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC) have limited efficacy in increasing patient survival rates, largely due to ferroptosis resistance and immunosuppression.\nGenetic or pharmacological inhibition of EP300-mediated HSPA5 acetylation on K353 increases PDAC cell resistance to ferroptosis.\nSTAT3 is a positive regulator of ferroptosis in human pancreatic ductal adenocarcinoma (PDAC) cell lines.\nCiprofloxacin enhances the protein stability of GPX4, a crucial regulator that suppresses ferroptosis by inhibiting lipid peroxidation.\nBoth in vivo and in vitro experiments have demonstrated that PDAC cells develop resistance to ATO through the suppression of drug-induced ferroptosis."
    },
    "383-1795": {
      "type": "slc_pathway",
      "key1": "SLC39A6",
      "key2": "proliferation",
      "text": "Experimentally, the suppression of SLC39A6 expression promoted ESCC cell apoptosis but abrogated proliferation and invasion, and induced an EMT phenotype that included enhanced expression of E-cadherin, loss of vimentin, and morphological changes in ESCC cells in vitro.\nResults of this investigation demonstrate that inhibition of IRE1 signaling enzyme function affects the expression of NRIP1, EBBP, ESRRA, E2IG5, PGRMC2, and SLC39A6 genes in U87 glioma cells in gene specific manner and these changes possibly contribute to the suppression of the cell proliferation.\nKnockdown of SLC39A6 expression suppressed proliferation and invasion in ESCC cells.\nKnockdown of SLC39A6 reduced proliferation of ESCC cells in culture and metastasis of xenograft tumors in mice.\nFurthermore, knockdown of SLC39A6 inhibited the proliferation, migration and invasion of liver cancer cells and .\nSLC39A6 was overexpressed in tissues from GA patients and in GA cell lines, and SLC39A6 knockdown in GA cell lines inhibited their proliferation, migration and invasion.\nRNA analyses show significant correlations between CelTIL responses, high proliferation genes (e.g., CCNE1, MKI67), and low expression of luminal genes (e.g., NAT1, SLC39A6).\nCollectively, the results of the present study suggested that SLC39A6 may be a promising prognostic biomarker for liver cancer and is associated with the proliferation, migration and invasion of liver cancer.\nConsistent with our proposed model, activated ZIP6 levels correlated with mitotic cells, which could be efficiently inhibited through use of our anti-ZIP6 monoclonal antibody.\nPTCH1, a receptor of Hedgehog (Hh) pathway, is reported to suppress cell proliferation.\nCells that overexpressed SLC39A6 had significant increases in intracellular levels of zinc and were more invasive in assays, activating phosphatidylinositol 3-kinase signaling to AKT serine/thr"
    },
    "400-1796": {
      "type": "slc_pathway",
      "key1": "SLC42A2",
      "key2": "ferroptosis",
      "text": ""
    },
    "1796-2202": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "human esophageal cancers",
      "text": "siRNA-mediated knockdown of GPX4 and SLC7A11 reduced ESCC sensitivity to ponicidin-induced ferroptosis.\nSilencing of ALDH5A1 can reduce DDP resistance in ESCC through promoting ferroptosis signaling pathways.\nTaken together, our findings suggest that IQGAP1 promotes chemoresistance by blocking ferroptosis through targeting YAP.\nHMGA1 is upregulated in ESCC and works as a key driver for cisplatin (DDP) resistance in ESCC by repressing ferroptosis.\nThis in turn not only inhibits the proliferation and migration of ESCC cells but also upregulates the ferroptosis pathway.\nMETTL3 enhances esophageal squamous cell carcinoma progression by suppressing ferroptosis through the PBX3/CA9 cascade.\nIn summary, circPDE3B promotes ESCC progression by suppressing ferroptosis through recruiting HNRNPK/SLC7A11 and miR-516b-5p/CBS axes.\nML385 promotes ferroptosis and radiotherapy sensitivity by inhibiting the NRF2-SLC7A11 pathway in esophageal squamous cell carcinoma.\nlncRNA BBOX1-AS1 silencing inhibits esophageal squamous cell cancer progression by promoting ferroptosis via miR-513a-3p/SLC7A11 axis.\nThrough integrated analyses of scRNA-seq and TCGA datasets, we found that AKR1C3 was likely to enhance radioresistance by inhibition of ferroptosis.\nFunctional studies revealed that FBXO10 ablation suppressed ESCC cell proliferation, migration, and invasion via ACSL4-dependent ferroptosis activation.\nAKR1C3 enhances radioresistance in esophageal adenocarcinoma via inhibiting ferroptosis through suppressing TRIM21-mediated ubiquitination of HSPA5.\nRNA-seq and enrichment analysis suggested the blocked tumor progression was affected by ferroptosis, together with the NFκB signaling pathway activation in ESCC.\nIn summary, our findings indicate that gl"
    },
    "58-1796": {
      "type": "slc_pathway",
      "key1": "SLC6A8",
      "key2": "ferroptosis",
      "text": "SLC6A8-mediated creatine uptake suppresses ERK2-FSP1 signaling and induces ferroptosis in colorectal cancer.\nInhibiting the creatine transporter SLC6A8 reduces creatine uptake and activates ERK2.\nActivated ERK2 then binds, phosphorylates ferroptosis suppressor protein 1 (FSP1) at Thr109, and stabilizes it to inhibit ferroptosis.\nHere, using untargeted metabolomics, we demonstrate that creatine potently induces ferroptosis in colorectal cancer (CRC).\nMechanistically, creatine binds extracellular signal-regulated kinase 2 (ERK2), impairing its activation by mitogen-activated protein kinase kinase 1 (MEK1).\nOur study identifies ERK2 as a creatine sensor regulating FSP1 stability and ferroptosis resistance, highlighting the therapeutic potential of creatine supplementation in combination cancer immunotherapy."
    },
    "1796-1850": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "liver cancer",
      "text": ""
    },
    "1796-1868": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "lung cancer",
      "text": ""
    },
    "1795-1864": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "prostate cancer",
      "text": "Gilteritinib suppresses prostate cancer cell proliferation and migration and induces ER stress-mediated non-autophagic cytoplasmic vacuolization cell death.\nTripartite Motif-Containing Protein 65 Promotes Proliferation and Inhibits Ferroptosis in Prostate Cancer via Enhancing NKD Inhibitor of WNT Signaling Pathway 2 Ubiquitination.\nFagonia cretica inhibits proliferation of colorectal and prostate cancer cells through DNMT1 downregulation, oxidative stress induction, and ER-beta activation: An in Vitro and in silico study.\ndown-regulation of ACSM1 expression in LNCaP prostate cancer cells significantly inhibits cell proliferation and migration, while overexpression enhances these processes in normal cells.\nLINC01179 impaired prostate cancer cell proliferation and migration ability by suppressing TLL1 expression to deactivate TGF-β signaling activity.\noverexpression of KCNMA1 promoted the infiltration of M1 macrophages by inhibiting the RAS/RAF/MEK/ERK signaling pathway, thereby inhibiting the proliferation, migration, and invasion of prostate cancer cells.\nWe developed a nanocarrier system based on engineered OMVs (OMV-PD-1) to deliver the natural anticancer compound Curcumol, aiming to regulate epigenetic modifications and enhance tumor immune responses, thereby effectively inhibiting the proliferation and metastasis of prostate cancer cells.\nROBO1 promoted the proliferation, migration and invasion of prostate cancer cells.\nKDM3B suppresses castration-resistance prostate cancer cell proliferation by promoting PTEN expression.\nCircRHOBTB3 suppresses MAOA by promoting cytoplasmic retention of NONO to inhibit prostate cancer proliferation and metastasis.\nThe anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.\ndihydrocapsaicin can induce proliferation suppression in human prostate cancer cells by hindering"
    },
    "294-1800": {
      "type": "slc_pathway",
      "key1": "SLC28A1",
      "key2": "migration",
      "text": "SNPs in the genes ADAMTS9 (rs7631391), DOCK2 (rs77594147), SLC28A1 (rs28649017), ARHGAP5 (rs7151991), and CIITA (rs45601437) were most highly differentiated in the Asian comparison.\nWe found SNPs within or proximal to the genes CIITA (rs6498115), SMC6 (rs1834619), and KLHL29 (rs2288697) were most differentiated in the Amerindian-specific branch, while SNPs in the genes ADAMTS9 (rs7631391), DOCK2 (rs77594147), SLC28A1 (rs28649017), ARHGAP5 (rs7151991), and CIITA (rs45601437) were most highly differentiated in the Asian comparison.\nThese analyses have identified candidate genes for selection within Amerindian ancestry, and by comparison of the two analyses, those for which the differentiation may have arisen during the migration from Asia to the Americas."
    },
    "1800-1836": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "pancreatic cancer(PC)",
      "text": "In this study, downregulation of BUB1 enhanced the sensitivity of PC cells to Erastin, and inhibited cell proliferation and migration.\nThus, irradiation increases exosomal miR-3160-5p expression and inhibits cell migration and invasion via a decrease in RGMB expression.\nTHBS1 knockdown suppressed cell proliferation, migration, and invasion while enhanced cell apoptosis through the JAK2/STAT3 signaling pathway.\nwe showed that cell viability and migration was largely reduced in Nogo-B knockout or knockdown cells, while enhanced by Nogo-B overexpression.\nStable increase of miR-330 expression after transfection in PC cells reduces viability, mitochondrial membrane potential, invasion, and migration.\nFunctional assays demonstrated that miR-510 overexpression enhanced, while its inhibition reduced, PC cell viability, migration, invasion, and EMT.\nThe upregulation of TRIM46 rescued ONECUT3 knockdown-induced suppression of cell proliferation, migration and invasion abilities, and tumor growth in PC.\nCell functional experiments verified that miR-130b suppressed cell proliferation, migration, promoted apoptosis, and inhibited the PI3K/Akt pathway by targeting MET in PC cells.\nThe TPCH protein induced senescence and apoptosis in telomerase-positive cancer cells through the p21 signaling pathway and inhibited the migration of telomerase-positive cancer cells.\nFurthermore, in PANC-1 cells, miR-141-5p overexpression suppressed TGF-induced epithelial-mesenchymal transition (EMT), cell migration, and cell invasion through direct binding to the 3'UTR of TGFBR1 and TGFBR2.\nSubsequently, we demonstrated that UCA1 enhanced the migration capability, increased MMP, enhanced mitochondrial fusion, and inhibited mitochondrial autophagy in pancreatic cancer cells via the MAPK/ERK pathway.\ntRF-Pro-CGG acts as a tumor suppressor in pancreatic cancer by inhibiting cell proliferation, migration, invasion, and promoting apoptosis, likely through targeting CSF1 and regulating"
    },
    "1794-1868": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "lung cancer",
      "text": ""
    },
    "138-1802": {
      "type": "slc_pathway",
      "key1": "SLC16A3",
      "key2": "oxidative phosphorylation",
      "text": "TNFα alone reduced the expression of monocarboxylate transporters slc16a1 and slc16a3, suggesting effects of TNFα on butyrate uptake into colonocytes.\nMaintenance of the proteasome requires oxidative phosphorylation (ATP) and mitigation of oxidative damage, in an increasingly dysfunctional relationship with aging.\nDuplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nWe measured ATP levels, cell viability, mitochondrial membrane potential (MMP), reactive oxygen species (ROS), mitochondrial oxidative phosphorylation, and glycolytic activity in colonocytes following exposure to either butyrate or TNFα, or both.\nAdditional gene purging included mitochondrial BCAA aminotransferase (BCAT2), pointing to reduced oxidation of BCAA and increased hepatic conversion to triglycerides and glucose.\nEndurance in mammalian muscle depends in part on oxidation of BCAA\nWe found that both butyrate and TNFα lowered cellular ATP levels towards a quiescent cell energy phenotype, characterized by decreased oxygen consumption and extracellular acidification.\nThe relative expression levels of pyruvate dehydrogenase kinase 4 () were increased via co-treatment of butyrate and TNFα, suggesting the synergistic inhibition of glycolysis."
    },
    "1802-2429": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "diabetes vascular complications",
      "text": ""
    },
    "371-1801": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "apoptosis",
      "text": "Both conditions also lower reproductive hormone levels, increase oxidative stress, and promote germ cell apoptosis.\nSeven differentially expressed genes (Slc38a5, Adgrg2, Gpc1, Arx, Egr2, Ebp, Il2rb) were identified in CoQ10-treated rats with either condition.\nChanges in alternative splicing of the Slc38a5 and Uspl1 genes were detectable in prephenotypic-stage embryos and neonates but became more pronounced with the severity of the phenotype."
    },
    "1801-2583": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "ischemic proliferative retinopathies",
      "text": "TRIM65 knockdown inhibited high glucose-induced HREC cell apoptosis and angiogenesis and decreased the expression of VEGFA and HIF-3α, both of which are potential targets of miR-29a-3p.\nIn vivo studies revealed that intravitreal injection of miR-29a-3p inhibited neoangiogenesis in mice with Oxygen-Induced Retinopathy (OIR).\nNLY01 significantly suppressed global induction of retinal inflammatory cytokines, promoted reparative angiogenesis, and suppressed pathologic retinal neovascularization.\nIn age-related macular degeneration, curcumin acts by reducing ROS and inhibiting apoptosis inducing proteins and cellular inflammatory genes and upregulating HO-1, thioredoxin and NQO1.\nHere we show that Cx43 plays a critical role in astrocyte apoptosis and the resulting preretinal neovascularization in a mouse model of oxygen-induced retinopathy.\nThis may lead to reduced vessel stability, the onset of EC apoptosis, and subsequent retinal ischemia leading to angiogenesis and eventually, severe vision loss due to late proliferative diabetic retinopathy (PDR).\nIn conclusion, this study demonstrated that the knockdown of TRIM65 inhibits neoangiogenesis in proliferative diabetic retinopathy by regulating miR-29a-3p.\nThese results indicate that PEDF may play its neuroprotection role through inhibiting ER stress and oxidative stress in ischemic retinopathy, which is a novel molecular mechanism of PEDF protecting photoreceptors from ischemic damage, thereby suggesting that PEDF is an effective therapeutic agent for the treatment of neuron damage in ischemic retinal diseases.\nThese ncRNAs are key regulators of neurodegeneration, apoptosis, inflammation, and oxidative stress in DR.\nHigh glucose-induced angiogenesis is the main component in Proliferative Diabetic Retinopathy (PDR) development.\nIn PDR, ischemia and hypoxia have been identified as key stim"
    },
    "385-1794": {
      "type": "slc_pathway",
      "key1": "SLC39A8",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-1872": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "breast cancer(BC)",
      "text": ""
    },
    "81-1802": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "oxidative phosphorylation",
      "text": "tropicalis, which was attributed to augmented mitochondrial oxidative phosphorylation (OXPHOS) caused by reduced SLC7A11 expression.\nKetotic cows exhibited lower ferroportin (FPN), solute carrier family 7 member 11 (SLC7A11), glutathione peroxidase 4 (GPX4), mitochondrial oxidative phosphorylation complexes I-V (CO I-V), peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α), mitofusin-2 (MFN2), nuclear respiratory factor 1 (NRF-1), and mitochondrial transcription factor A (Tfam) protein expression levels, along with lower ATP content compared with control cows.\nConversely, hnRNPK overexpression was correlated with enhanced ferroptosis pathway and improved ECM organization, but was also associated with reduced oxidative phosphorylation and protein synthesis.\nAmong them, we show that LUC7L2 represses OXPHOS and promotes glycolysis by multiple mechanisms, including (1) splicing of the glycolytic enzyme PFKM to suppress glycogen synthesis, (2) splicing of the cystine/glutamate antiporter SLC7A11 (xCT) to suppress glutamate oxidation, and (3) secondary repression of mitochondrial respiratory supercomplex formation.\nThe expression of EPAS1 and SLC7A11 was significantly correlated with oxidative phosphorylation and immune cell infiltration levels.\nWe further explore the effects of GLUD1 inhibition in endocrine therapy-resistant ILC cells using the small-molecule inhibitor R162, which reduces ER protein levels, increases reactive oxygen species, and inhibits oxidative phosphorylation.\nDHA and Sora significantly inhibited the cell energy metabolism by decreasing the ATP synthesis rate of oxidative phosphorylation and glycolysis rate, and induced ferroptosis by increasing the level of lipid reactive oxygen species (L-ROS), labile iron pool (LIP) as well as malondialdehyde (MDA) and decreasing the level of glutathione (GSH) in"
    },
    "1802-1856": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "colorectal cancer(CRC)",
      "text": "BCAP31 promotes colorectal cancer metastasis via oxidative phosphorylation-dependent macrophage immunosuppression.\nOverexpression of LINC01852 induces a metabolic switch from aerobic glycolysis to oxidative phosphorylation, which attenuates the chemoresistance of CRC cells by inhibiting PKM2-mediated glycolysis.\nTICs exhibited strong stemness potential, genomic instability, and early activation of epithelial-mesenchymal transition (EMT) and interferon signaling, accompanied by suppression of oxidative phosphorylation.\nA recent study shows that loss of Erbin increases the release of acyl-carnitine (Acar) through abolishing interaction with prothrombotic protein endothelial cell-specific adhesion molecule (ESAM), promotes mitochondrial oxidative phosphorylation in B cells, and ultimately suppresses lung metastasis of CRC.\nWnt/β-catenin inhibition increased mitochondrial oxidative phosphorylation (OXPHOS) and CRC cell differentiation.\nColorectal cancer (CRC) cells often exhibit altered energy metabolism, characterized by increased glycolysis and reduced oxidative phosphorylation.\nSam68 significantly promoted cell proliferation and caused a decrease of / ratio, resulting in the metabolism of glucose switched from oxidative phosphorylation to glycolysis in CRC cells.\nOur in vitro findings demonstrated that LAA suppressed CRC cell proliferation, induced mitochondrial oxidative stress (reactive oxygen species (ROS)), inhibited oxidative phosphorylation (OXPHOS), and induced apoptosis.\nSpecifically, blockade of ACO2 caused a reduction in TCA cycle intermediates and suppression of mitochondrial oxidative phosphorylation, resulting in an increase in glycolysis and elevated citrate flux for fatty acid and lipid synthesis.\nImportantly, NOP2/Sun RNA methyltransferase 3 (NSUN3) protein was identified as the target specific binding to , which inhibits oxidative phosphorylation of mitochondrial energy metabolism and enhances glycolytic activity by binding to NSUN3.\nPLD6 depletion also disrupts mitochondrial metabolic reprogram"
    },
    "136-1800": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "migration",
      "text": "SLC16A1-AS1 suppressed miR-1269 maturation and promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis, while miR-1269 displayed the opposite trend.\nexperimental results demonstrated that when SLC16A1 was knocked down, the proliferation, migration, and invasion capabilities of HNSCC cell lines were significantly reduced and the extent of RAS-selective lethal 3-induced lipid peroxidation increased compared with control cells.\nKnockdown SLC16A1-AS1 inhibited cell viability, proliferation, and migration of renal cancer cells.\nUpregulation of SLC16A1-AS1 suppressed BC cell viability, colony formation, invasion, and migration and growth sponging miR-552-5p to release WIF1.\nSLC16A1-mediated lactylation was analyzed by immunofluorescence, lactate production analysis, colony formation, transwell, and wound healing assays to investigate its role in promoting the proliferation and migration of PDAC cells.\nIn addition, through the construction of stable SLC16A1 knockdown and overexpression models in HNSCC cells along with and experiments, the study comprehensively illuminated the pivotal role of SLC16A1 in promoting the proliferation, migration, and invasiveness of HNSCC cells, as well as enhancing their resistance to ferroptosis.\nAdditionally, low SLC16A1 expression inhibited the proliferation, migration, and invasion of glioma cells.\nPFN2 overexpression or circ-SLC16A1 inhibition restored proliferation and migration of NSCLC cells after silencing of circ-SLC16A1.\nConversely, HNSCC cell lines overexpressing SLC16A1 exhibited enhanced proliferation, migration, and invasion capabilities, accompanied by lower levels of lipid peroxidation.\nFurthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways.\nIn vitro experiments showed that overexpression of SLC16A1-AS1 promoted cell proliferation and invasion but suppressed cell apoptosis"
    },
    "1800-1872": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "breast cancer(BC)",
      "text": "FDX1 upregulation inhibited proliferation, migration, invasion, and promoted apoptosis.\nIBT-T-Lipo demonstrated potent anticancer efficacy, reducing IC values by 4.24- and 8.06-fold in MCF-7 and MDA-MB-231 cells, respectively, while enhancing apoptosis, elevating the Bax/Bcl-2 ratio, and suppressing migration.\nThrough bioinformatics analysis of The Cancer Genome Atlas (TCGA) database and experimental validation by qRT-PCR, we found that FDX1 is downregulated in BC tissues and cells.\nMechanistically, the m6A methyltransferase METTL3 was highly expressed in BC and suppressed FDX1 expression via m6A methylation, as confirmed by MeRIP-qPCR and RNA stability analysis.\nThis METTL3-mediated m6A modification of FDX1 accelerated BC malignant progression.\nOur study elucidates that the METTL3-FDX1 axis plays an instrumental role in BC progression, revealing a novel epigenetic regulatory mechanism.\nCollectively, these results establish TPGS-liposomes as an efficient delivery platform that augments IBT's therapeutic potential in BC through both active and passive targeting."
    },
    "1794-1931": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Nasopharyngeal Cancer (NPC)",
      "text": ""
    },
    "5-1795": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "proliferation",
      "text": "Knockdown SLC1A5 in gastric cancer cells suppressed cell proliferation, caused G0/G1 arrest and inhibited cell invasion as well as migration partly by inactivated mTOR/p-70S6K1 signaling pathway.\nMoreover, ABHD11-AS1 enhanced the abilities of cell proliferation, migration, and invasion, inhibited apoptosis in vitro, promoted tumorigenesis in vivo via sponging miR-199a-5p and then induced SLC1A5 activation.\nKnockdown of circSEPT9 or SLC1A5 inhibited glutamine uptake and cell proliferation, but induced cell apoptosis in BC cells.\nMoreover, inhibition of SLC1A5 significantly enhanced the inhibitory efficacy of cetuximab on CRC proliferation both in vitro and in vivo.\nKnockdown of SLC1A5 decreased proliferation, colony formation, and migration, but increased apoptosis and increased sensitivity to chemotherapy drugs.\nSLC1A5var knockdown reduced cancer cell proliferation, colony formation, and migration, whereas SLC1A5var overexpression increased cell proliferation and migration.\nImportantly, inhibiting SLC1A5 blocked cell proliferation by downregulating mTORC1 in long-term arsenite-treated cells.\nStudies have also shown that downregulation of SLC1A5 can inhibit wound healing, invasion, and proliferation of HCC cells.\nFurthermore, the effects of downregulated circ-LDLRAD3 on cell proliferation, apoptosis and mobility were all reversed by knocking down miR-137 and overexpressing SLC1A5.\nIn addition, SLC1A5 knockdown could significantly inhibit glioma cell proliferation and invasion, and reduce the sensitivity of ferroptosis via the GPX4-dependent pathway.\nRemarkably, silencing SLC1A5 expression partially counteracted the promotion of CRC cell proliferation by LINC01134 overexpression and alleviated its inhibition of apoptosis.\nThe uptake of macrophage-derived glutamine by satellite cells through the glutamine transporter SLC1A5 activates mTOR an"
    },
    "1795-2393": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "clear cell renal cell carcinoma (CCRCC)",
      "text": ""
    },
    "92-1795": {
      "type": "slc_pathway",
      "key1": "SLC9A3",
      "key2": "proliferation",
      "text": "Loss of SLC9A3‑AS1 reduced NPC cell proliferation, colony formation, migration, and invasion but induced cell apoptosis .\nThe proliferation potential, migration, and invasion behaviors were weakened by si-SLC9A3-AS1 and reversed by the miR-486 inhibitor.\nNHE3-/- colonoids showed increased cell proliferation and reduced ECM adhesion.\nInhibition of NHE3, unconfounded by chronic inflammatory or microbial pressure, may represent a permissible mechanism beneficial to the host by modulating cellular plasticity and promoting epithelial wound healing.\nOverall, is a novel potential biomarker involved in CRC progression and promotes the proliferation and migration of tumor cells by positively regulating the function of Hsp70.\nColonic organoids from NHE3+/+ and NHE3-/- mice and SK-CO-15 cells with shRNA-mediated NHE3 knockdown (NHE3KD) were used to assess the intrinsic role of NHE3 in cellular proliferation, migration, wound healing, adhesion to the extracellular matrix (ECM), activation status of focal adhesion kinase (pFAKY397), and in gene transcription.\nFinally, the effects of SLC9A3‑AS1 silencing on NPC cells were reversed by inhibiting miR‑486‑5p or overexpressing E2F6.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.\nCombined use of a knockout mouse model, intestinal organoid technology, and specific inhibitors revealed previously unrecognized actions of NHE2 and NHE8 in enterocyte proliferation and differentiation.\nReciprocally, ovarian fibroblasts educated by ITGA6high exosomes exhibited cancer-associated fibroblasts (CAFs) phenotypes and enhanced tumor cell proliferation, thereby initiating the early stage of pre-metastatic niche formation.\nAnimal experiments further revealed that the depletion of SLC9A3‑AS1 hindered NPC tumour growth ."
    },
    "5-1802": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "oxidative phosphorylation",
      "text": "These results suggest that activated ISR-induced increased expression of SLC1A5var may regulate mitochondrial oxidative phosphorylation and glycolytic metabolic characteristics to enhance glucose depletion-induced cell death.\nMechanistically, upregulation of glutamine transporter solute carrier family 1 member 5 (SLC1A5) transcription compensates for the increased glutamine requirement upon OXPHOS inhibition.\nThe activity of C1 in glutamine metabolism and transport is significantly enhanced, while its oxidative phosphorylation activity is reduced.\nWe show that genetic inhibition of MYC or SLC1A5 acts to phenocopy the impairment of OXPHOS observed with STAT3 inhibition, thereby establishing this axis as a regulatory mechanism linking STAT3 to energy metabolism.\nOxygen consumption rates also decreased upon BPTES treatment, indicating a glutamine dependency for oxidative phosphorylation.\nMechanistically, iMQT_020 reduces glutamine anaplerosis and oxidative phosphorylation, resulting in a broad disruption of cancer metabolism.\nMoreover, the knockdown of SLC1A5var reduces the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) while increasing the maximal OCR and ECAR under glucose depletion.\nInhibition of SLC1A5 reduces intracellular levels of glutamine, glutathione, and multiple tricarboxylic acid (TCA) cycle metabolites, leading to reduced TCA cycle activity and inhibition of OXPHOS.\nDYRK1A directly phosphorylates SMAD3 Thr132, thereby suppressing the negative impact of TGF-β signaling on transcription of SLC1A5, leading to intrinsic resistance of liver cancer cells to OXPHOS inhibition.\nSTAT3 regulates AML-specific expression of MYC, which in turn controls transcription of the neutral amino acid transporter gene SLC1A5.\nOur findings establish that TRAP-1 contributes to enhanced glutamine utilization through the HIF2α-SLC1A5-GLS axis.\nWe show that STAT3 inhibition selectively leads to cell death in AML stem"
    },
    "1802-2379": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "pancreatic tumor growth",
      "text": "Our study revealed that glycolytically suppressed cells upregulated mitochondrial function and relied on oxidative phosphorylation (OXPHOS) to obtain the ATP necessary for their survival.\nAdditionally, enhanced oxidative phosphorylation decreased the AMP/ATP ratio and suppressed AMPK activity, resulting in the activation of the HSF1-heat shock protein pathway, which is required for environmental stress tolerance.\nMoreover, a functional analysis revealed that BA-induced downregulation of protein clusters that participate in mitochondrial complex 1 activity and oxidative phosphorylation, which was related to decreased expressions of RNA polymerase mitochondrial (POLRMT) and translational activator of cytochrome c oxidase (TACO1), suggesting that the influence on mitochondrial function explains the effect of BA on PDAC cell growth and migration.\nGenetic or pharmacologic inhibition of autophagy leads to increased reactive oxygen species, elevated DNA damage, and a metabolic defect leading to decreased mitochondrial oxidative phosphorylation.\nMitochondrial analysis showed that SLC5A3 inhibition disrupted the mitochondrial dynamics, leading to increased reactive oxygen species production, mitochondrial fission, and impaired oxidative phosphorylation.\nAt the molecular level, ISG15 loss results in decreased mitochondrial ISGylation concomitant with increased accumulation of dysfunctional mitochondria, reduced oxidative phosphorylation (OXPHOS) and impaired mitophagy.\nAdditionally, NR5A2 suppresses MYC, leading to the activation of the mitochondrial biogenesis factor PPARGC1A and a shift in metabolism towards oxidative phosphorylation, which is a crucial feature of stemness in PDAC.\nMechanistically, both HSP60 knockdown and oxidative phosphorylation (OXPHOS) inhibition by metformin decreased Erk1/2 phosphorylation and induced apoptosis and cell cycle arrest, whereas Erk1/2 reactivation with EGF promoted cell proliferation.\nThe fatty acid cargo of tumour EVPs-particularly palmitic acid-induced secretion of tumour necrosis factor (TNF) by Kupffer cells, generating a pro-inflammatory microen"
    },
    "136-1801": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "apoptosis",
      "text": "Remarkably, PDIA6 and SLC16A1 were observed to inhibit the proliferation of pancreatic β cells and promote apoptosis in vitro, while downregulation of PDIA6 and SLC16A1 expression led to enhanced insulin secretion.\nThese findings indicated that HS-induced autophagy regulates lactate secretion by inhibiting apoptosis and increasing mRNA transcript and protein levels of SLC2A3, LDHA, and SLC16A1, which suggests that HS-induced autophagy may enhance lactate secretion by SCs.\nFunctionally, SLC16A1-AS1 overexpression could inhibit the viability and proliferation of lung cancer cell, block the cell cycle and promote cell apoptosis in vitro which may result from reduced phosphorylation of rat sarcoma (RAS)/ proto-oncogene serine/threonine-protein kinase (RAF)/ mitogen-activated protein kinase kinase (MEK)/ extracellular regulated protein kinases (ERK) pathway caused by elevated expression of SLC16A1-AS1.\nIn vitro experiments showed that overexpression of SLC16A1-AS1 promoted cell proliferation and invasion but suppressed cell apoptosis.\nOverexpression of SLC16A1-AS1 inhibited HCC cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) process as well as promoted cell apoptosis.\nSLC16A1-AS1 suppressed miR-1269 maturation and promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis, while miR-1269 displayed the opposite trend.\nAlso, silencing of circ-SLC16A1 promoted apoptosis of NSCLC cells.\nMechanistically, lactate retention due to Slc16a1 deletion initiates adipocyte apoptosis and cytokine release.\nIt also resulted in significantly less lactate secretion and increased apoptosis but showed no effect on B-cell lymphoma-2 expression in heat-treated immature SCs."
    },
    "1801-1872": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "breast cancer(BC)",
      "text": "In parallel, Kv1.3 plays a pivotal role in mitochondrial-mediated apoptosis, and its inhibition can induce cancer cell death.\nATE1 stabilized MYC protein via ERK-mediated phosphorylation at Ser62, promoting cell cycle progression and suppressing apoptosis.\nTransfection with si-NEAT1 and miR-133b mimics inhibited viability, promoted apoptosis and enhanced MRP and BCRP expressions in SKBR3-PR cells.\nTreatment with LDH@si-NEAT1 effectively inhibited migration and invasion, promoted apoptosis, and reduced MRP, BCRP and PD-L1 expressions in the tumor cells.\nFunctional assays demonstrated that overexpression of TFAP2A-AS1 suppressed proliferation, clonal formation, migration, and invasion, while promoting apoptosis in TNBC cells.\nMechanistically, STX11 promoted the M1 polarization of macrophages, and macrophages overexpressing STX11 can inhibit BC proliferation and migration by regulating the PI3K-AKT pathway.\nSTX11 is associated with a favorable prognosis in patients with BC and facilitates M1 polarization, and macrophages overexpressing STX11 can inhibit BC malignancy by regulating the PI3K-AKT pathway, suggesting its role as a potential immunotherapeutic candidate.\nBoth fractions induced G0/G1 cell cycle arrest and promoted apoptosis through multiple pathways, upregulating pro-apoptotic genes (TP53, AIFM1, CASP3, BAX) and downregulating anti-apoptotic markers (BCL2, miR-155).\nUA exerts its anticancer effects by modulating multiple signaling pathways, such as PI3K/AKT, NF‑κB, and Wnt/β‑catenin, thereby effectively inhibiting tumor cell proliferation, inducing apoptosis, reversing chemoresistance, and suppressing cancer stem cell characteristics.\nIn vitro assays validated that L-mimosine inhibits breast cancer cell proliferation by inducing DNA damage an"
    },
    "1795-2379": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "pancreatic tumor growth",
      "text": "In vitro, we confirmed that SNH inhibited the proliferation and invasion, promoted mitochondrial damage and induce apoptosis of PANC-1 cells.\nThe experiments showed that STOML2 overexpression promoted proliferation, invasion, migration and autophagy, while inhibiting apoptosis in Huh7 cells.\nIn conclusion, SSD synergistically enhanced the antitumor effects of GEM by inhibiting pancreatic cancer cell proliferation, and inducing apoptosis and autophagy.\nCellular experiments demonstrated that nano-curcumin liposomes significantly inhibited proliferation and invasive capacity of gastric adenocarcinoma cells while promoting cellular oxidative stress.\nPJP inhibits tumor growth, and its combination with gemcitabine exhibits enhanced inhibitory effects, partially alleviating immune suppression.\nFinally, downregulation of SLC27A5 altered tumor metabolism and cellular homeostasis, induced oxidative stress, and disrupted intracellular environmental stability, thereby suppressing the growth of gastric adenocarcinoma.\nIn vivo, SNH promoted tumor apoptosis and inhibited pancreatic cancer development in mice.\nPJP combats pancreatic cancer and enhances gemcitabine efficacy by remodeling the immunosuppressive tumor microenvironment.\nOur findings suggest that lipid raft inhibition can modulate proliferation, distinct cell death pathways, and treatment response in PDAC.\nAdditionally, PJP's treatment inhibited SW1990 cell proliferation indenpence of reducing IL-8 and downregulating NETs-related protein expression in the co-culture system.\nSimultaneously, the downregulation of BCL2 compromised the anti-apoptotic capacity of colorectal cancer cells, leading to increased oxidative stress and metabolic dysregulation that further hindered tumor proliferation and invasiveness.\nSilencing HERVH markedly suppresses PDAC proliferation and tumor growth.\nOCIAD2 promotes tumor proliferation, migration, invasion, and resistance to gemcitabine in PDAC.\nThe results indicated that both drugs inhibited the proliferation, migration, & colony formation.\nIn co‑culture experiments, senescent fibroblasts enhanced Panc‑1"
    },
    "1801-2290": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "oral squamous cell carcinoma (OSCC)",
      "text": ""
    },
    "63-1798": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "stemness",
      "text": "Inhibition of SLC6A14 reduces stemness, impairs tumor growth, and sensitizes tumors to chemotherapy.\nHigh SLC6A14 expression correlates with cancer stemness signatures and earlier onset in patient cohorts.\nMechanistically, DEHP exposure promotes tumor initiation by enhancing cancer stemness through mitochondrial fusion and glutamine-driven oxidative phosphorylation.\nDEHP upregulates the glutamine transporter SLC6A14 to enhance glutamine uptake, while suppressing mitochondrial fission factor (MFF), which exacerbates mitochondrial fusion.\nCollectively, the findings uncover a novel environmental-metabolic axis linking plasticizer exposure to EOBC and establish SLC6A14 as a promising metabolic vulnerability.\nThese results provide a strong preclinical rationale for targeting SLC6A14 in young breast cancer patients and offer new insights into mitigating the oncogenic impact of environmental pollutants."
    },
    "1798-1836": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "pancreatic cancer(PC)",
      "text": "Silencing USP22 can inhibit the Wnt/β-catenin pathway to reduce cell stemness and enhance the sensitivity of PC cells to cisplatin.\nWe revealed that circ_0030167 mainly regulates miR-338-5p, enhances Wif1 expression, and inhibits the Wnt8/β-catenin pathway, thereby inhibiting the stemness of PC cells and tumor progression.\nOur work suggested that Amatuximab inhibits the adhesion of cancer cells to peritoneum and suppresses the stemness and viability of those, that lead to enhance the sensitivity for gemcitabine.\nMCPIP1 knockdown enhanced tumor cell stemness, proliferation, migration, and hybrid epithelial-mesenchymal transition (hybrid EMT) in PC cell lines, whereas overexpression suppressed these phenotypes.\nIn addition, we found that knockdown of B3GNT5 in PC cells inhibited cell migration, invasion, and angiogenesis, as well as stemness of cancer stem cells and enhanced chemotherapy sensitivity to gemcitabine.\nThe overexpression of miR-135b promoted proliferation, migration, and invasion of PCSC, inhibited cell apoptosis and increased the expression of stemness-related factors (Sox-2, Oct-4, Nanog, Aldh1, and Slug).\nDownregulation of USP22 raised the sensitivity of PC cells to cisplatin, reduced the levels of stem cell markers, reduced the tumor sphere formation and migration, and promoted apoptosis.\nTaken together, the silencing of miR-135b promotes the JADE-1 expression, which inactivates the AKT/mTOR pathway and ultimately results in inhibition of self-renewal and tumor growth of PCSCs.\nMoreover, Akt inhibitor IV effectively decreased nestin expression via SRY-box containing protein 2 (Sox2) downregulation and overcame the enhanced sphere formation induced by nestin upregulation.\nHigh glucose condition in the tumor microenvironment promotes immune suppression by upregulating glycolysis in PC cells, which can be rescued via knockdown Bmi1 expression or after 2-deoxy-D-glucose treatment."
    },
    "1796-2159": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "age-related macular degeneration (AMD)",
      "text": "Dysregulation of iron homeostasis plays a crucial role in retinal diseases, contributing to oxidative stress, inflammation, and ferroptosis, key processes that drive the degeneration of the retinal pigment epithelium (RPE) and photoreceptors in age-related macular degeneration (AMD).\nTreatment with TF appeared to restore aspects of iron homeostasis and reduce oxidative stress, mitochondrial damage, inflammation, complement activation, and ferroptosis in this model.\nWe found that both GSDME elimination and MitoTEMPO treatment repressed atRAL-induced photoreceptor ferroptosis and retinal atrophy by inactivating the mitoROS-induced oxidative stress.\nMoreover, deleting the gene in photoreceptor cells prevented atRAL-induced ferroptosis by inhibiting mitochondrial reactive oxygen species (mitoROS) production, iron overload, and lipid peroxidation.\nHere, we show that superoxide activates ferroptosis in retinal pigment epithelium (RPE) cells via the Haber-Weiss reaction, thereby contributing to dry AMD.\nIn this study, we revealed that GSDME activation by atRAL triggered photoreceptor ferroptosis and retinal atrophy via mitochondrial damage and oxidative stress.\nWe validated blue light-induced ferroptosis in the RPE layer as a driver of the dry AMD phenotype in Sod2 mice.\nKnocking out GSDME significantly attenuated light-induced photoreceptor ferroptosis and retinal degeneration in mice.\nConsequently, SOD mimetics efficiently protected RPE against phototoxicity by reducing superoxide-activated ferroptosis.\nThe finding reveals that excessive superoxide contributes to phospholipid peroxidation, providing a promising approach for preventing dry AMD by elevating MnSOD to inhibit RPE cell ferroptosis.\nPrior studies have shown that light-induced atRAL accumulation promotes ferroptosis and activates gasdermin E (GSDME) in retinal photoreceptors of mice, a model for STGD1 and dry AMD that exhibits visual cycle disorders.\nFerroptosis, an iron-dependent cell death mechanism, is associated with mitochondrial"
    },
    "98-1798": {
      "type": "slc_pathway",
      "key1": "SLC9A9",
      "key2": "stemness",
      "text": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD."
    },
    "1798-1856": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "colorectal cancer(CRC)",
      "text": "CEMIP downregulation inhibited CRC cell growth, migration, invasion, and stemness while promoting apoptosis.\nRNA sequencing and network pharmacology also highlighted that PZH inhibited CRC stemness and PD-L1 to enhance T cell-mediated antitumor effects.\nFASN promotes CRC progression by enhancing CSC stemness and suppressing ferroptosis through SREBP2 inhibition, highlighting its potential as a therapeutic target.\nWnt5a was predominantly stromal-derived and suppressed CRC organoid growth by activating TGF-β/Smad2 signaling, which upregulated the Wnt inhibitor NOTUM and downregulated the stemness marker OLFM4.\nTICs exhibited strong stemness potential, genomic instability, and early activation of epithelial-mesenchymal transition (EMT) and interferon signaling, accompanied by suppression of oxidative phosphorylation.\nCritically, we observed constitutive activation of the AHCY/H3K4me3 axis in MSI tissues and cells, while baicalein treatment effectively suppressed AHCY activity and attenuated H3K4me3-mediated cancer stemness in MSI PDX models.\nfragilis colonized colon tumors and mediated its effect via its surface protein SusD/RagB binding to the Notch1 receptor in CRC cells, leading to activation of the Notch1 signaling pathway and the induction of epithelial-to-mesenchymal transition (EMT)/stemness to suppress chemotherapy-induced apoptosis.\nThese cellular changes are caused by the disruption of homeostasis signaling whereby: overactivation of WNT/β-catenin promotes stemness, dysregulation of Notch inhibits differentiation, suppression of BMP promotes hyperproliferation, and imbalance of FGF/WNT/BMP/NOTCH enhances cellular plasticity and invasion.\nCRC cells showed increased stemness and decreased 5-FU sensitivity in correlation with MT levels.\nFunctional studies revealed that LACTB overexpression promoted cell differentiation while suppressing cell stemness.\nIn a mouse subcutaneous tumor model of CRC,"
    },
    "179-1794": {
      "type": "slc_pathway",
      "key1": "SLCO1B1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "322-1795": {
      "type": "slc_pathway",
      "key1": "SLC34A2",
      "key2": "proliferation",
      "text": "Moreover, SLC34A2 induced autophagy to promote ESCC cell proliferation, whereas inhibition of autophagy suppressed the proliferation of ESCC cells.\nGW2974 (EGFR inhibitor) increased SLC34A2 knockdown-inhibited cell proliferation, migration/invasion, as well as enhanced SLC34A2 knockdown-increased the TMZ sensitivity of glioma cells.\nIn cellular assays in vitro, knockdown of SLC34A2 dramatically inhibited the proliferation and colony formation, induced the apoptosis and arrests the cell cycle progression of HCT-116 CRC cells.\nFurther studies showed that SLC34A2 interacted with an autophagy-related protein STX17 to promote autophagy and proliferation of ESCC cells by inhibiting the ubiquitination and degradation of STX17.\nSimultaneously, downregulation of SLC34A2 decreased the transcriptional activity and protein expression level of c-Myc in BC cells, whereas restoration of c-Myc expression could compromise the anti-proliferation effect of SLC34A2 depletion.\nOverexpression of SLC34A2 inhibited the proliferation, migration, and invasion of OS cells.\nOverexpression of SLC34A2 promoted ESCC cell proliferation, while silencing SLC34A2 had the opposite effect.\nThe following studies proved that SLC34A2 knockdown exhibited suppressive effects on cell proliferation and migration/invasion.\nOur previous researches have reported that overexpression of SLC34A2 significantly inhibited proliferation, migration and invasion of LUAD cells.\nOur present study illustrated that SLC34A2 has an important role in promoting proliferation and tumorigenicity of BC, and may represent a novel therapeutic target for this disease.\nSolute carrier family 34 member 2 (SLC34A2), a family member of sodium-driven phosphate cotransporters, has been reported to facilitate cell proliferation and tumor growth."
    },
    "1794-1850": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "liver cancer",
      "text": ""
    },
    "298-1801": {
      "type": "slc_pathway",
      "key1": "SLC29A1",
      "key2": "apoptosis",
      "text": "ENT1 inhibition attenuates apoptosis by activation of cAMP/pCREB/Bcl2 pathway after MCAO in rats.\nThe BM stroma secretes a soluble factor that significantly protects leukemia cells from cytarabine-induced apoptosis and blocks ENT1 activity.\nApoptosis of hENT1 silenced SKM-1 cells induced by DAC was decreased, and the susceptibility of these cells to demethylation treatment was also decreased.\nMoreover, NBTI significantly increased the level of CREB phosphorylation and extracellular adenosine concentration, and decreased the neuronal apoptosis 24 h after MCAO.\nIn an orthotopic pancreatic cancer mouse model, both low and high dose verapamil was shown to substantially reduce L3.6plGres-SP cell tumor growth and metastasis, enhance tumor apoptosis, and reduce microvascular density.\nFunctional analyses in iCC cell lines revealed that hENT-1 silencing inhibited cell proliferation and induced apoptosis in HUH-28 cells expressing hENT-1 on the cell membrane, but not in SNU-1079 cells expressing the transporter only in the cytoplasm.\nWestern blot analysis revealed decreased levels of cleaved caspase-3 and cleaved poly(ADP-ribose) polymerase in T24-GR and T24-CD cells following gemcitabine exposure, whereas these markers were upregulated in parental T24 and T24-CDKO cells.\nENT1 inhibition prevented neuronal apoptosis and improves neurological deficits through cAMP/PKA/CREB/Bcl-2 signaling pathway after MCAO in rats.\nIn vitro, the BM stromal cells secreted a soluble factor that mediated significant chemoprotection to leukemia cells from cytarabine induced apoptosis.\nBy suppressing apoptosis and altering drug metabolism pathways, highlighting CDCP1 as a potential therapeutic target for overcoming gemcitabine resistance in UC.\nCRISPR/Cas9-mediated knockout of CYR61 increased expression of"
    },
    "38-1800": {
      "type": "slc_pathway",
      "key1": "SLC5A1",
      "key2": "migration",
      "text": "Here, we explore the role of glucose (SLC5A1) and inositol transporters (SLC5A3) in GBM cell migration.\nWhile GBM cell migration was significantly increased by extracellular inositol and glucose, it was strongly impaired by SLC transporter inhibition.\nWe provide several lines of evidence for the involvement of SLC5A1 and SLC5A3 in GBM cell migration, thereby complementing the migration-associated transportome.\nThis flavonoid dose-dependently reduced cancer cell proliferation, migration, and invasion.\nOverexpressing SLC5A1 significantly reduced the inhibitory effects of Hesperidin, highlighting its crucial role in this context.\nWe also employed wound-healing assays to examine the effect of SLC inhibition on GBM cell migration and examined the chemotactic potential of inositol.\nOur findings were significantly restored following SLC5A1 overexpression in colon cancer cells, highlighting its pivotal role in Hesperidin-induced responses.\nExpression levels of endometrial GRP, IGFBP1, and LGALS15, whose products stimulate trophectoderm cell migration and attachment, were increased by PGE2, PGI2, and IFNT.\nInvasive cell migration has been linked to the aberrant expression of transmembrane solute-linked carriers (SLC).\nWe employed clone formation, EdU incorporation, Transwell, and wound healing assays to clarify Hesperidin efficacy on cancer cell proliferation, invasion, and migration.\nInterestingly, in GBM cells migrating via blebbing, SLC5A1 and SLC5A3 were predominantly detected in nascent and mature blebs, respectively.\nIn single GBM cells, both transporters were primarily localized at the leading edge of the lamellipodium.\nIn the GBM cell monolayers, both SLCs were exclusively detected in the migrating cells at the monolayer edge.\nHesperidin exerts its anticancer effects on colon cancer by inhibiting SLC5A1 expression and consequently downregulating EGFR phosphorylation."
    },
    "92-1800": {
      "type": "slc_pathway",
      "key1": "SLC9A3",
      "key2": "migration",
      "text": "Loss of SLC9A3‑AS1 reduced NPC cell proliferation, colony formation, migration, and invasion but induced cell apoptosis .\nKnockdown of SLC9A3-AS1 notably further inhibited viability, migration as well as invasion in Huh7 cells.\nThe proliferation potential, migration, and invasion behaviors were weakened by si-SLC9A3-AS1 and reversed by the miR-486 inhibitor.\nInhibition of NHE3, unconfounded by chronic inflammatory or microbial pressure, may represent a permissible mechanism beneficial to the host by modulating cellular plasticity and promoting epithelial wound healing.\nNHE3-/- colonoids showed increased cell proliferation and reduced ECM adhesion.\nNHE3-/- colonoids and NHE3KD cells showed increased spontaneous motility, enhanced migration in serum gradient, and in 2 models of wound healing.\nInhibition of FAK autophosphorylation eliminated the effect of NHE3 deficiency on cell migration.\nFinally, the effects of SLC9A3‑AS1 silencing on NPC cells were reversed by inhibiting miR‑486‑5p or overexpressing E2F6.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.\nEctopic expression of the E620K mutant increased cell migration, invasion and colony formation in vitro, as well as OM in animals bearing GC xenograft tumors.\nAnimal experiments further revealed that the depletion of SLC9A3‑AS1 hindered NPC tumour growth .\nIn summary, SLC9A3‑AS1 exerted carcinogenic effects on NPC cells by adjusting the miR‑486‑5p/E2F6 axis.\nThus, we aimed to investigate the role of NHE3 in colonic epithelial cell proliferation and migration during wound healing.\nThis was associated with FAK and Src activation and modulation of genes associated with cell-cell interactions, cell-ECM interactions, and the formation of focal adhesions."
    },
    "1794-2751": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "acute myeloid leukemia",
      "text": ""
    },
    "5-1798": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "stemness",
      "text": "Transcription factor YY1 binds to SLC1A5 promoter region to induce SLC1A5 expression, and the inhibition effect of YY1 knockdown on GBM cell growth, invasion, stemness, and glutamine metabolism can be reversed by SLC1A5 overexpression.\nSilibinin inhibits GBM cell proliferation, invasion, stemness, and glutamine metabolism, while promotes apoptosis.\nIn addition, Silibinin reduces GBM tumor growth by regulating YY1/SLC1A5 pathway.\nSilibinin plays an anti-tumor role in GBM process, which may be achieved via inhibiting YY1/SLC1A5 pathway.\nSLC1A5 overexpression abolishes the anti-tumor effect of Silibinin in GBM cells.\nIGF2BP3 presented a negative correlation with the ferroptosis molecule NFE2L2, and a positive correlation with the ferroptosis molecule SLC1A5 as well as the immune checkpoint HAVCR2.\nThe data showed that IGF2BP3 may enhance the proliferation, colony formation and invasion capacities of HCC cells, and IGF2BP3 is mainly positively correlated with the expression level of stemness marker SOX2.\nFurthermore, we also provide evidence for the increased abundance of pSTAT3 and the stemness marker ALDH1A1 upon EV-induced resistance."
    },
    "1798-2365": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Neuroblastoma (NBM)",
      "text": ""
    },
    "1801-1868": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "lung cancer",
      "text": "Compound Qu in SYQ can effectively inhibit the PI3K/AKT pathway, regulate the expression levels of BCL2 and CASP3 proteins, and induce apoptosis.\nQu can inhibit the PI3K/AKT pathway, downregulate BCL2 expression, and activate the cleavage of the apoptotic protein caspase-3, ultimately triggering apoptosis in H1299 cells.\nFunctional assays demonstrated that silencing L1CAM reduced cell proliferation, migration, and invasion, increased apoptosis, and inhibited activation of the PI3K/AKT/mTOR pathway.\nWe identified paeoniflorin as a novel therapeutic agent that suppresses NSCLC growth and promotes apoptosis.\nHGXJ formula exhibited significant in vivo and in vitro antitumor activity by promoting apoptosis and inhibiting proliferation.\nPaeoniflorin inhibited the FGF2-mediated PI3K-AKT-mTOR signaling axis, modulated key autophagy biomarkers and triggered autophagy-regulated apoptosis.\nMechanistic studies confirmed apoptosis induction, inhibition of clonogenic survival, and telomerase suppression.\nFlow Cytometry analysis showed that BIQO-9 induces G₂ phase cell cycle arrest and promotes apoptosis in A549 cells.\nNotably, BIQO-9 could significantly enhance the efficacy of Gefitinib in inducing cell apoptosis and G phase arrest.\nCRM1 was observed to induce apoptosis, as indicated by DNA fragmentation, an increase in Sub-G1 cell population, as well as elevated caspase-3 cleavage and Bax expression.\nIn vitro studies demonstrated enhanced cytotoxicity, elevated ROS production, mitochondrial membrane depolarization, and apoptosis in LC cells, while sparing maintaining normal fibroblasts.\nThe results revealed that chamuangone (10 mg L) inhibited cancer cell proliferation by inducing G0/G1 phase arrest and apoptosis in 4T1-luciferase (4T1-luc) and Michigan Cancer Foundation-7"
    },
    "367-1798": {
      "type": "slc_pathway",
      "key1": "SLC38A1",
      "key2": "stemness",
      "text": ""
    },
    "1798-2119": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": ""
    },
    "90-1795": {
      "type": "slc_pathway",
      "key1": "SLC9A1",
      "key2": "proliferation",
      "text": "The increase in NBCn1 density was similar in magnitude to that observed for Na(+)/H(+)-exchanger NHE1 (SLC9A1), a transporter previously implicated in cell migration, proliferation and malignancy.\nProliferation was increased in Panc-1 cells and decreased in BxPC-3 cells, upon TGFβ-1 treatment, and this, as well as EMT , was unaffected by NHE1- or NBCn1 inhibition.\nWhile increased sensitivity to acidosis for cell survival in 2-dimensions was not observed, clonogenic proliferation and 3-dimensional spheroid growth in particular were greatly reduced.\nFunctional assays demonstrated that knockdown of either gene not only suppressed proliferation, colony formation, migration, and induced apoptosis in breast cancer cells, but also led to reduced expression of the sodium-calcium exchanger NCX1.\nExtrusion of the acid load from the cancer cells raises intracellular pH, while it decreases extracellular pH creating an inverted pH gradient across the plasma membrane compared to normal cells and promoting cancer cell metabolism, proliferation, migration, and invasion.\nAccordingly, knockdown of either NHE1 or NBCn1 reduced proliferation, prolonged cell cycle progression in a manner involving S phase prolongation and delayed G2/M transition, and altered the expression pattern and phosphorylation of cell cycle regulatory proteins.\nNHE1-ko significantly reduced tumor cell proliferation both in normoxia and hypoxia while CA9-ko dramatically reduced growth in hypoxic conditions.\nZoniporide reduced the maximal proliferation capacity, cell number, thymidine incorporation, and ki67 (marker of proliferation) fluorescence in haOC cells.\nNHE1 and NBCn1 are not required for EMT or EMT-associated proliferation changes, but are essential for the potentiation of invasiveness induced by Merlin knockdown.\nCombined use of a knockout mouse model, intestinal organoid technology, and specific inhibitors revealed previously unrecognized actions of NHE2 and NHE8 in enterocyte proliferation and differentiation."
    },
    "75-1798": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "stemness",
      "text": "Mechanistically, elevated extracellular acidosis impairs methionine uptake and metabolism via downregulation of SLC7A5, therefore altering H3K27me3 deposition at the promoters of key T cell stemness genes.\nIn all, CAFs-derived exosomal METTL3 promoted the proliferation, invasion, stemness and glutaminolysis in NSCLC cells by inducing SLC7A5 m6A modification.\nOur analysis revealed HCSC important hubs as candidate regulators for targeting hepatic cancer stemness such as, miR-148a, miR-214, E2F family, MYC and SLC7A5.\nThe inhibition of LAT1 by a small molecule inhibitor, JPH203, or by RNA interference led to a significant reduction in tumorsphere formation and the downregulation of several cancer stemness genes in NSCLC cells through decreased AKT serine/threonine kinase (AKT)/mammalian target of rapamycin (mTOR) activation.\nAmong them, L-type amino acid transporter 1 (LAT1) upregulation was unique in concert with increased expression of the EMT regulator SNAIL and the cancer stemness marker doublecortin-like kinase 1.\nThe treatment of the cell-permeable leucine derivative promoted AKT/mTOR phosphorylation and reversed the inhibitory effect of JPH203 in the reduction of CSC activity in pemetrexed-resistant lung cancer cells.\nNonetheless, system L inhibition did not alter expression of stemness genes in NTERA2 cells.\nWe found that CAFs promoted the proliferation, invasion, stemness and glutaminolysis in NSCLC cells.\nMoreover, SLC7A5 overexpression abolished the inhibitory effects of exosomal METTL3-decreased CAFs on NSCLC cells.\nMechanistically, exosomal METTL3-induced m6A modification in SLC7A5 mRNA and stabilized its expression in NSCLC cells.\nThe PD-L1/LAT1 subpopulation of NSCLC cells displayed great CSC activity with increase"
    },
    "1798-2105": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "cancer tissues",
      "text": ""
    },
    "63-1794": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2557": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "malignt cancers",
      "text": ""
    },
    "138-1800": {
      "type": "slc_pathway",
      "key1": "SLC16A3",
      "key2": "migration",
      "text": "Mechanistically, SLC16A3 emerged as a critical regulator promoting STAD cell proliferation, invasion, and migration while modulating the metabolic landscape.\nRescue experiments found SLC16A3 overexpression resisting to LINC00035 knockdown on SKOV3 and A2780 cell viability, migration, invasion, apoptosis, glucose uptake, lactate release, and ATP production.\nOverexpression of MCT4 and/or CD147 increased, and their knockdown decreased, migration, invasion and the degradation of fluorescently labeled gelatin.\nMoreover, MCT4 overexpression enhances cell migration and invasiveness via reorganization of the actin cytoskeleton.\nThe study reveals that LINC00035 promotes OC progression by regulating glycolysis and cell apoptosis through CEBPB-mediated transcriptional promotion of SLC16A3.\nIn fibroblasts, lactate promotes cell migration, IL-6 production and increases glycolysis.\nMore importantly, we confirmed that silencing of LCIIAR expression significantly inhibits the proliferation, and migration abilities of these tumour cells.\nTo further characterize the biological role of hsa_circ_0008621 expression in CRC, in vitro hsa_circ_0008621 inhibition was performed and the effects on cellular growth, migration, invasion, apoptosis, and glycolysis were explored.\nMCT4 was positively correlated with gene families responsible for invasion, migration, and immune modification, proving it to be one of the most important MCTs for therapeutic intervention.\nThe findings highlight SLC16A3 as a promising candidate for therapeutic intervention aimed at modulating lactic acid metabolism in the TME, thereby advancing personalized treatment strategies in gastric cancer management.\nWe investigated how lactate regulates fibroblast and macrophage movement, IL-6 secretion and metabolism via specific lactate transporters.\nMechanistically, this involves MCT4-CD147-dependent stimulation of ECM degradation and specifically of MMP-mediated collagen-I degradation.\nWhile silencing miR-491-5p promoted viability and migration, and significantly suppressed the expression of α-SMA, calponin, SM22"
    },
    "1800-2429": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "diabetes vascular complications",
      "text": "Impaired angiogenesis in endothelial cells is a hallmark of diabetes vascular complications.\nKnockdown of RasGRP1 significantly attenuated VEGF-induced migration and tube formation activities of HUVECs and activation of AKT pathway.\nThe expression of VEGF, RasGRP1, and AKT phosphorylation was downregulated in HUVECs exposed to high glucose compared with normal glucose, whereas metformin upregulated the RasGRP1-dependent VEGF signaling and ameliorates the impaired angiogenesis caused by high glucose.\nThis leads to enhanced proliferation and migration capabilities of vascular endothelial and smooth muscle cells, two types of cells that are responsible in forming blood vessels, through cell-cell communication.\nAPS promoted the migration and angiogenesis of endothelial cells in co-cultured of HUVECs and macrophages under high glucose.\nRasGRP1 is involved in the VEGF-induced angiogenesis and the pro-angiogenesis effects of metformin under hyperglycemia.\nHyperglycemia induces systemic abnormalities, including impaired angiogenesis, causing diabetic patients to be highly susceptible in suffering hindlimb ischemia (HLI).\nConversely, homing of progenitor cells contributes to the diabetes vascular complications.\nThe CXCL12 is an extensively active chemokine that serves as a recruiter for migration and trafficking of leukocytes and hematopoietic progenitor cells.\nOur results demonstrated that APS ameliorated vascular endothelial dysfunction in diabetes by stimulating macrophage polarization to M2 via enhancing the Nrf2/HO-1 pathway.\nFurthermore, endothelial cells proliferation and apoptosis were ameliorated after APS treatment.\nSkeletal muscle cells secrete multiple angiogenic factors, hence, recently are reported to be critical for angiogenesis; however, hyperglycemia disrupted the paracrine function in skeletal muscle cells, leading to the impaired angiogenesis potential observed in diabetic patients.\nAs one of the most severe manifestations of diabetes, vascular complications are"
    },
    "225-1796": {
      "type": "slc_pathway",
      "key1": "SLC25A4",
      "key2": "ferroptosis",
      "text": "Forced overexpression of SLC25A4 in two LUAD cell lines inhibited their growth, viability, and migration.\nThe majority of these genes are associated with mitochondrial protein transport, ferroptosis, calcium signaling, metabolism, OXPHOS function, TCA cycle, apoptosis, and MARylation."
    },
    "1796-1856": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "colorectal cancer(CRC)",
      "text": "PRAP1 promotes CRC cell proliferation and inhibits ferroptosis by Nrf2 pathway.\nThis subsequently activated EGFR signaling and ultimately suppressed ferroptosis in CRC cells.\nALKBH5 was downregulated in CRC and ALKBH5 overexpression promoted ROS release and ferroptosis.\nTan IIA induces ferroptosis in CRC by suppressing SLC7A11 expression through the PI3K/AKT/mTOR pathway.\nCHI3L1 promotes radiation resistance by suppressing ferroptosis in CRC cells through the p53/SLC7A11 axis.\nCAPG inhibits apoptosis and ferroptosis, while promoting CRC cell proliferation by repressing the P53 pathway.\nFurthermore, we found that SRSF9 inhibition increased erastin-induced ferroptosis by downregulating GPX4 level.\nSolanine treatment upregulated ALOX12B levels and silencing ALOX12B could suppress solanine-induced ferroptosis.\nSLC7A11 inhibition through polyubiquitination by HECTD3 increased ferroptosis, thereby inhibiting CRC tumor growth.\nNotably, the COMB promoted lipid peroxidation and downregulated xCT levels, suggesting the induction of ferroptosis.\nAnd they upregulated the levels of ferroptosis makers and downregulated the expression of anti-ferroptosis proteins.\nTo investigate the molecular mechanism of TA-III as a novel ferroptosis inducer in suppressing CRC through lipophagy.\nOur findings indicate that RBMS2 inhibits CRC progression by promoting ferroptosis and regulating SLC7A11 mRNA stability.\nInactivation of the PI3K/AKT pathway by the inhibitor partially reversed the anti-ferroptosis effect of CPT1A overexpression.\nMARCH8 promoted CRC cell ferroptosis via inhibiting PI3K/AKT pathway by enhancing the ubiquitination and degradation of CEMIP.\nThus, HECTD3 could suppress SLC7A11 levels to attenuate the SLC7A11-mediated cyst"
    },
    "407-1795": {
      "type": "slc_pathway",
      "key1": "SLC44A1",
      "key2": "proliferation",
      "text": "LINC00704 promotes EOC cell aggressiveness in vitro by regulating the miR-323a-3p/SLC44A1 axis.\nCCK-8 and EdU assays showed that LINC00704 knockdown inhibited EOC cell proliferation.\nenforced expression of the MCPIP1 gene in BE(2)-C cells caused a significant decrease in neuroblastoma proliferation and viability.\nLINC00704 upregulated SLC44A1 expression by competitively binding to miR-323a-3p.\nSLC44A1 overexpression could reverse LINC00704 silencing-mediated effects on the malignant behaviors of EOC cells.\nFlow cytometry analysis demonstrated that LINC00704 silencing induced EOC cell cycle arrest and apoptosis.\nTranswell assays indicated the inhibitory effects of LINC00704 silencing on EOC cell migration and invasion.\nThe choline transporter, CTL1, encoded by the SLC44A1 gene, was significantly repressed at the specific mRNA and protein levels and most importantly this translated into a decreased choline transport in MCPIP1-overexpressing cells."
    },
    "1795-1924": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Head and Neck Cancer",
      "text": "GOT1 knockdown inhibited proliferation and promoted apoptosis via ROS overproduction from mitochondrial dysfunction, thereby increasing cisplatin sensitivity.\nBGN knockdown inhibited cell proliferation and induced cell cycle arrest, which was rescued by recombinant BGN.\nWe also found that SHMT1 could inhibit the proliferation, migration, and invasion of laryngeal squamous cell carcinoma cells while promoting cell apoptosis by constructing SHMT1-overexpressing cell lines.\nExperimentally, RAD51 knockdown suppressed malignant behaviours and enhanced ROS production and chemosensitivity in HSC-3 cells.\nRAD51 drives OSCC progression by enhancing malignant phenotypes, suppressing immune infiltration, promoting aberrant DNA repair, elevating oxidative stress and promoting therapy resistance.\nCIA1 treatment reduced BGN expression, suppressed cell proliferation, and modulated macrophage polarization.\nGINS2 knockdown suppressed proliferation, colony formation, migration, and invasion, and inhibited tumor growth.\nKnockdown of AURKA suppresses cell proliferation, migration, and invasion, while inducing apoptosis and reactive oxygen species generation in oral squamous cell carcinoma.\nTumor-derived BGN activated the AKT signaling pathway, promoting tumor growth.\nAdditionally, high BGN expression facilitated M2 macrophage polarization and immune evasion through TLR4 signaling.\nGINS2 acts as a key oncogenic driver in OSCC, promoting tumor progression and facilitating immune evasion.\nGINS2 overexpression increased tumor-associated neutrophils (TANs), and Ly6G neutrophil depletion attenuated GINS2-driven tumor enhancement.\nAbstract: Reprogramming of amino acid metabolism (AAM) has been established as conducive to tumor cell proliferation and modulation of cellular oxidation-reduction dynamics.\nAurora kinase A is a key regulator of cell cycle progression and mitotic spindle assembly, which plays a critical role in the development and progression of OSCC.\nThis highlights the functional significance of AURKA in tumor progression and supports its potential as a novel therapeutic target."
    },
    "159-1802": {
      "type": "slc_pathway",
      "key1": "SLC17A9",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "45-1795": {
      "type": "slc_pathway",
      "key1": "SLC5A8",
      "key2": "proliferation",
      "text": "Besides, decreased proliferation activity and increased apoptosis were also observed in CC cells overexpressing SLC5A8 plasmid.\nConsistent with this, in cells expressing functional SLC5A8, 2,4,6-THBA induced CDK inhibitory proteins p21 and p27 and inhibited cell proliferation.\nMoreover, the impaired proliferation activity and increased apoptosis proportion of CC cells induced by SLC5A8 over-expression could be counteracted by the Wnt signaling pathway activator LiCl.\nOverexpression of SLC5A8 in the HeLa cell line decreased its proliferation by arresting cancer cells in the G1 phase and inhibiting cellular migration.\nFurthermore, we observed that pyruvate increased the SLC5A8 effect, inducing S-phase arrest and inhibiting the entry into mitosis.\nectopic expression of SLC5A8 in SLC5A8-deficient colon cancer cell lines leads to suppression of the colony-forming ability of these cells.\nThese variants significantly increased the proliferation, migration, and invasion abilities of CRC cells.\nSLC5A8 decreased tumor growth in xenograft transplants, significantly reducing the volume and tumor weight at 35 days of analysis.\nDecreased SLC5A8 expression caused by missense variants appeared to significant impair the tumor-suppressive function of the transporter.\nActivin A, a member of the transforming growth factor-β (TGF-β) superfamily, has been shown to inhibit the proliferation of a variety of tumor (and normal) human cell types.\nSLC5A8 can suppress colorectal cancer (CRC), and its tumor-suppressive function is mainly associated with butyrate, propionate, and pyruvate, which inhibit histone deacetylase.\nIn this study, we investigated the ability of one metabolite, 2,4,6-trihydroxybenzoic acid (2,4,6-THBA) to inhibit Cyclin Dependent Kinase (CDK) activity and cancer cell proliferation.\nSLC5A8 alleviates the progression of CC by regulating the Wnt signaling pathway."
    },
    "371-1796": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "ferroptosis",
      "text": "SLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.\nSLC38A5 promotes osteosarcoma cell proliferation, migration, and invasion via the glutamine-mediated PI3K/AKT/mTOR signaling pathway and inhibits ferroptosis.\nMechanistically, SLC38A5 mediates the activation of the PI3K/AKT/mTOR signaling pathway by transporting glutamine, which subsequently enhances the SREBP1/SCD-1 signaling pathway, thereby suppressing ferroptosis in osteosarcoma cells.\nNiclosamide, an FDA-approved anti-helminthic, blocks the functions of SLC7A11 and SLC38A5, thus inducing ferroptosis and suppressing macropinocytosis, with the resultant effective reversal of tumor-promoting actions of oncogenic changes in p53 and KRAS.\nTherefore, suppression of SLC38A5 triggers ferroptosis via two pathways that regulate lipid ROS levels.\nWe also found that the inhibition of SLC38A5 triggered the ferroptosis signaling pathway via RNA sequencing.\nOur studies show that the predominant effect of p53 deletion is to induce SLC7A11 with the resultant potentiation of antioxidant machinery and protection of cancer cells from ferroptosis, whereas KRAS activation induces not only SLC7A11 but also SLC38A5, thus offering protection from ferroptosis as well as improving amino acid nutrition in cancer cells via accelerated macropinocytosis.\nAlso, silencing SLC38A5 induced mitochondrial dysfunction and reduced glutamine uptake and glutathione (GSH) levels, and downregulated the expressions of GSH-related genes NRF2 and GPX4.\nThe blockade of glutamine uptake negatively modulated the mTOR-SREBP1-SCD1 signaling pathway."
    },
    "1796-2001": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Bone cancer",
      "text": "Inhibition of spinal ferroptosis-like cell death alleviates hyperalgesia and spontaneous pain in a mouse model of bone cancer pain.\nPVT1 promotes OS metastasis by activating the STAT3/GPX4 pathway to inhibit ferroptosis.\nMicroRNA-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4.\nLncRNA-PVT1 Inhibits Ferroptosis through Activating STAT3/GPX4 Axis to Promote Osteosarcoma Progression.\nSLC38A5 suppresses ferroptosis through glutamine-mediated activation of the PI3K/AKT/mTOR signaling in osteosarcoma.\nLncSNHG14 promotes nutlin3a resistance by inhibiting ferroptosis via the miR-206 /SLC7A11 axis in osteosarcoma cells.\nRab27b-mediated CAFs derived exosomal miR-22-3p suppresses ferroptosis and promotes cisplatin resistance in osteosarcoma.\nExperiments in vivo validated that CAFs derived exosomal miR-22-3p downregulated ferroptosis and promoted resistance to cisplatin.\nRBM15-mediated the m6A modification of MAT2A promotes osteosarcoma cell proliferation, metastasis and suppresses ferroptosis.\nMechanistically, the increased radiosensitization of OS cells by the combined use of the two inhibitors was mediated by increased ferroptosis.\nExosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1.\nMETTL5-mediated m6A modification of UBE3C promotes osteosarcoma progression by suppressing ferroptosis via inducing AHNAK ubiquitination.\nIn vivo, SHK effectively suppressed OS growth with favourable biosafety, confirming the molecular mechanism underlying SHK-induced ferroptosis in OS.\nMechanistically, ACBP-mediated FAO increased ATP and NADPH production, reduced reactive"
    },
    "10-1798": {
      "type": "slc_pathway",
      "key1": "SLC2A2",
      "key2": "stemness",
      "text": "Analysis of GEO datasets (GSE132606, GSE25417, GSE67848) and TCGA HCC data revealed that while SLC2A2 expression decreases with HCC progression, stemness-associated genes, including SOX2 and POU5F1, are upregulated.\nIn HepG2 cells, SLC2A2 knockdown increased stemness and IGF1R pathway markers, indicating a shift toward less differentiated states.\nThese findings suggest that SLC2A2 supports liver differentiation by regulating glucose metabolism and suppressing pathways associated with stemness and malignancy.\nWe further show that inhibition of RAC1 activation attenuated pluripotency marker expression and self-renewal ability, while depletion of RAC1b dramatically enhanced stemness features and clonogenic potential.\nEctopic expression in PANC-1 cells of dominant negative or constitutively active mutants of RAC1 activation blocked or enhanced, respectively, the cytokine-induced activation of a ductal-to-endocrine transdifferentiation transcriptional program (deTDtP) as revealed by induction of the NEUROG3, INS, SLC2A2, and MAFA genes.\nThese results indicated that VA may increase the stemness of intestinal stem cell in vitro.\nZebrafish embryos injected with SLC2A2-targeting morpholino exhibited reduced expression of the liver differentiation marker fabp10a without significantly altering the hepatoblast marker hhex.\nThe high-risk group exhibited higher proliferation and invasion capacity, MSI, and degree of stemness.\nThe risk score was significantly associated with immune cell infiltration, immune checkpoint expression, angiogenesis, and tumor stemness.\nBeyond its metabolic role, SLC2A2 contributes to cell differentiation and metabolic adaptation during embryogenesis and tissue regeneration.\nMoreover, the SLC2A family gene expression is significantly correlated with the pan-cancer stromal and immune scores, and the RNA and DNA stemness scores.\nTargeting SLC2A2 may serve as a promising therapeutic strategy for liver-related diseases, particularly HCC, by addressing its dual role in differentiation and tumor progression."
    },
    "1794-2105": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "cancer tissues",
      "text": ""
    },
    "81-1800": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "migration",
      "text": "Moreover, Icariside II suppressed SKOV3 cell proliferation, inhibited cells migration and invasion, and promoted apoptosis by downregulating SLC7A11 expression.\nAlthough SLC7A11 can increase the migration ability of tumor cells, BAY-876 effectively suppressed the viability of prostate cancer cells, particularly those with high SLC7A11 expression.\nFunctional assays revealed that TIMP1 knockdown enhanced ferroptosis sensitivity, suppressed CRC cell proliferation and migration, and reduced expression of ferroptosis regulators GPX4 and SLC7A11.\nJPX silence suppressed viability, migration, invasion and ECM production, yet facilitated ferroptosis of keloid fibroblasts, while these effects could be reversed by Fer-1 or SLC7A11 overexpression.\nAt the same time, our results show that the combination of SAL and 5-FU not only inhibits the proliferation, migration, and invasion of CRC cell lines and , but also promotes ferroptosis of CRC cell lines by downregulating the expression of GPX4 and SLC7A11.\nThe findings indicate that Fut8 upregulation increases P53 expression and reduces SLC7A11 and GPX4 levels, leading to altered intracellular concentrations of GSH and Fe, impaired mitochondrial function, and reduced migration capacity, all of which promote atherosclerosis.\nIn vitro experiments demonstrated that overexpression of SLC7A11 inhibited migration, invasion, and Caspase-1 expression levels in TNF-α-induced RA-FLSs.\nInterference with circ-CDK8 expression reduced SLC7A11 expression by sponging miR-615-5p, suppressed OSCC cell migration and invasion, and promoted ferroptosis by increasing ROS, MDA, and iron levels and decreasing GSH and GPX4 levels in OSCC cells.\nKRT15 overexpression promoted cell proliferation, migration, invasion, colony number, epithelial-mesenchymal transition (EMT, reflected by E-Cadherin, N-Cadherin, and Vimentin expressions), and S-stage cell"
    },
    "1800-1819": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "skin cancer",
      "text": "The results demonstrated that treatment with CAP induced ferroptosis, resulting in a significant reduction in the viability, migration, and invasive capacities of A431 squamous cell carcinoma, a type of skin cancer.\nZNF197-AS1 upregulates GABARAPL1 by sponging miR-425, inhibiting UM cell proliferation, migration, and invasion.\nPharmacological inhibition of CASP8 protein in a CASP8-wild type OSCC cell line showed enhanced levels of cellular migration and viability.\nFollowing VSIG-3/IGSF11 silencing in A2058 cells, viability, proliferation, and migration rates were decreased, while apoptosis was increased.\nIn conclusion, ELK4 enhances proliferation, invasion, and migration while inhibiting ferroptosis in SKCM cells by upregulating CHMP6 transcription.\nCENPA silencing induced changes in R-loop distribution, upregulated Hippo signaling activity, and inhibited tumor cell proliferation and migration.\nTGP inhibited cell viability and migration and induced mitochondrial dysfunction and apoptosis by promoting the degradation of α5-nAChR in melanoma cells.\nFunctionally, BiRDS was observed to inhibit the proliferation, migration, and invasion of UM cells while promoting apoptosis through the miR-30a-5p/E2F7 axis.\nUSP41 knockdown inhibited cell proliferation, migration, and invasion while promoting cell apoptosis and inhibiting phosphorylated PI3K, AKT, and mTOR in the PI3K/AKT signaling pathway.\nCrucially, PTK6 knockdown suppressed tumor progression through increased apoptosis, reduced cell viability, impaired migration, and decreased tumor volume, mediated by Hippo pathway activation.\nIndeed, in the presence of hAFSC-EVs, a reduction of the G2/M phase was observed on melanoma cell lines, an activation of the apoptotic pathway occurred and the migration and invasion ability reduced.\nThe findings demonstrated that silencing PURPL significantly repressed melanoma cell viability, colony formation, migration, and invasiveness, indicating its potential role in"
    },
    "272-1795": {
      "type": "slc_pathway",
      "key1": "SLC25A51",
      "key2": "proliferation",
      "text": "Here, we report that SLC25A51 is upregulated in multiple cancers, which promotes cancer cells proliferation.\nNotably, BACH1 deficiency promoted taurocholic acid (TCA)-induced proliferation of human umbilical vein endothelial cells (HUVECs), whereas this phenotype could be reversed by shRNA-mediated knockdown of SLC25A51.\nFurther studies confirmed that administration of the specific BACH1 inhibitor HPPE effectively alleviated TCA-induced suppression of HUVECs proliferation.\nIn the HepG2 animal model, overexpression of SLC25A19 significantly promotes tumor growth, while knockdown inhibits tumor growth.\nTogether, the data indicate that AML cells upregulate SLC25A51 to decouple mitochondrial NAD/NADH for a proliferative advantage by supporting oxidative reactions from a variety of fuels.\nOur findings reveal a novel lncRNA-microRNA-metabolic axis wherein LINC02802 facilitates NSCLC progression by reprogramming mitochondrial metabolism via miR-1976-mediated upregulation of SLC25A51.\nWe found that lowering SLC25A51 levels led to increased apoptosis and prolonged survival in orthotopic xenograft models.\nElevated SLC25A51 enhances mitochondrial NAD import, leading to an increased NAD/NADH ratio and promoting oxidative TCA cycle flux.\nMechanistically, LINC02802 acts as a competing endogenous RNA (ceRNA) for miR-1976, thereby relieving the suppression of solute carrier family 25 member 51(SLC25A51).\nInterestingly, either silencing LINC02802 with antisense oligonucleotides (ASOs) or treating cells with fludarabine phosphate, an SLC25A51 inhibitor, successfully reversed cisplatin resistance in lung cancer cells.\nNotably, we find fludarabine phosphate, an FDA-approved drug, is able to bind with and inhibit SLC25A51 functions, causing mitochondrial NAD decrease and proteins hyperacetylation, which could further synergize with aspirin"
    },
    "1794-2146": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "liver hepatocellular carcinoma (LIHC)",
      "text": ""
    },
    "1799-1850": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "liver cancer",
      "text": ""
    },
    "75-1802": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "oxidative phosphorylation",
      "text": "Targeting the BCAA transporter SLC7A5 with JPH203 inhibited oxidative phosphorylation and elicited strong antileukemia effects, specifically in mouse and patient AML samples while sparing healthy bone marrow cells.\nExperiments where TGF-β function was activated with extracellular TGF-β1 or inhibited through TGF-β receptor I silencing showed that TGF-β induces a switch from oxidative metabolism, coincident with a decrease in OCR and the upregulation of glutamine transporter Solute Carrier Family 7 Member 5 (SLC7A5) and GLS1.\nA diminished metabolic reprogramming, including a decrease in oxidative phosphorylation that regulates Hif-1α expression and subsequent control of glycolysis enzymes, was involved in the downregulation of Th17 differentiation by LAT1 inhibition.\nMechanistically, valine restriction reduced translation rates of mRNAs that encode subunits of mitochondrial complex I, leading to defective assembly of complex I and impaired oxidative phosphorylation.\nFinally, a genome-wide CRISPR-Cas9 loss-of-function screen in differential valine conditions identified several genes, including SLC7A5 and BCL2, whose genetic ablation or pharmacological inhibition synergized with valine restriction to reduce T-ALL growth.\nFurthermore, CD46 activation simultaneously drove expression of LAMTOR5, which mediated assembly of the AA-sensing Ragulator-Rag-mTORC1 complex and increased glycolysis and oxidative phosphorylation (OXPHOS), required for cytokine production.\nCytokine activation of NK cell glycolysis and oxidative phosphorylation (OXPHOS) are essential for robust NK cell responses.\nNK cell receptor ligation and IL2 collaborate to induce mTORC1/cMyc signalling leading to high rates of glycolysis and oxidative phosphorylation (OXPHOS) and prolonged NK cell survival.\nHere we found that in activated human T cells, autocrine stimulation of the complement receptor CD46, and specifically its intracellular domain CYT-1,"
    },
    "85-1801": {
      "type": "slc_pathway",
      "key1": "SLC8A1",
      "key2": "apoptosis",
      "text": "Down-regulation of the SLC8A1 gene, most likely mediated by its regulator miR-223, can lead to decreased calcium in penile carcinoma and consequently to suppressed apoptosis and increased tumor cell proliferation.\nThe results of experiments revealed that SLC8A1 promotes proliferation and inhibits the apoptosis and concentration of calcium ions in HTR-8/SVneo cells.\nExogenous overexpression of ZNF503-AS1 or SLC8A1 attenuated bladder cancer cell proliferation, invasion and migration, but promoted their apoptosis, accompanied by decreased Ca-ATPase activities and increased intracellular Ca concentrations.\nOverexpression of circRNA_SLC8A1 reduced cell viability, cell invasion, wound healing, and the expression of Vimentin, N-cadherin, Col I, and Col III, while enhancing apoptosis and E-cadherin expression in HSFs.\nZNF503-AS1 can recruit transcription factor GATA6 to up-regulate SLC8A1 expression, thereby increasing the intracellular Ca concentration and repressing the proliferation, invasion and migration, and enhancing the apoptosis of bladder cancer cells.\nConsistently, apoptosis of PTC cells was enhanced by SLC8A1-AS1 overexpression.\nSilencing lncRNA 93358 inhibits the apoptosis of myocardial cells in rats with myocardial infarction by inducing the expression of SLC8A1.\nWe discovered a correlation between gene expression and the 3D chromatin architecture of SLC8A1, which encodes a sodium-calcium antiporter whose modulation is known to induce apoptosis by comparison between HCC cell lines and HMECs.\nWe investigated whether dysregulation of SLC8A1 expression is associated with apoptosis and cell proliferation in penile carcinoma via modulation of the calcium concentration.\nWe demonstrated that SLC8A1 selective pharmacological inhibition, through CB-DMB, significantly reduced cancer proliferation and induced Ca-dependent cell death in GC cells, both alone and synergically with cisplatin treatment."
    },
    "1797-2344": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "ureteral obstruction",
      "text": "Intermedin is upregulated and attenuates renal fibrosis by inhibition of oxidative stress in rats with unilateral ureteral obstruction.\nSorafenib and edaravone protect against renal fibrosis induced by unilateral ureteral obstruction via inhibition of oxidative stress, inflammation, and RIPK-3/MLKL pathway.\nWe investigated the role of the Sirt1 activator, SRT1720, in unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis and aimed to determine whether this role depends on the inhibition of oxidative stress and the TGF-β1/CTGF pathway.\nOur results showed a progressive increase in oxidative stress and concomitant decrease in antioxidants over a period of 4 weeks ureteral obstruction.\nUnilateral ureteral obstruction (UUO) induces renal injury and troxerutin attenuates the inflammatory parameters and decreases oxidative stress.\nOral intake of hydrogen-rich water (HW) can reduce oxidative stress and suppress interstitial fibrosis in unilateral ureteral obstruction-induced renal injury in rats.\nAcetate treatment significantly ameliorated fibrosis induced by unilateral ureteral obstruction, and the oxidative stress marker phosphorylated histone H2AX (γH2AX) was also reduced.\nUnilateral ureteral obstruction evokes renal tubular apoptosis via the enhanced oxidative stress and endoplasmic reticulum stress in the rat.\nReactive oxygen species modulator 1 regulates oxidative stress and induces renal and pulmonary fibrosis in a unilateral ureteral obstruction rat model and in HK‑2 cells.\nThe induction of excessive autophagy by increased levels of oxidative stress is one of the main mechanisms underlying unilateral ureteral obstruction (UUO)-induced vascular endothelial cell dysfunction.\nSIN beneficially modulated the pro-fibrogenic protein expression in TGFβ-treated kidney cells and attenuated the renal fibrotic pathogenesis incurred by unilateral ureteral obstruction"
    },
    "1800-2105": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "cancer tissues",
      "text": ""
    },
    "32-1794": {
      "type": "slc_pathway",
      "key1": "SLC4A7",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2178": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Ras mutant pancreatic ductal adenocarcinom",
      "text": ""
    },
    "10-1799": {
      "type": "slc_pathway",
      "key1": "SLC2A2",
      "key2": "glycolysis",
      "text": "Moreover, SIRT6 could inhibit the Warburg effect by regulating glycolysis-related genes of SLC2A2, SLC2A4 and PKM2.\nTucum-do-cerrado consumption (Tuc) increased hepatic Slc2a2, Prkaa1α, Prkaa2α and intestinal Slc5a1 mRNA levels, also decreased hepatic G6Pase activity, muscle Slc2a4 and Prkaa2α in relation to CT group.\nThe association of tucum-do-cerrado with iron-enriched diet increased hepatic Prkaa1 and Pck1 compared to the CT and + Fe groups, intestinal Slc2a2 mRNA levels compared to the +Fe group, while decreased hepatic G6Pase activity in relation to the CT, +Fe and Tuc + Fe groups and muscle Slc2a4 and Prkaa2α compared to CT group.\nMetformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nThese results suggest that tucum-do-cerrado consumption might induce Prkaa1α and Prkaa2α expression, which may inhibit gluconeogenic rate limiting enzyme, G6Pase, and upregulates GLUT2 hepatic glucose uptake.\nIron supplementation increased muscle lipid and protein oxidation, hepatic glucokinase (GK) and phosphofrutokinase 1 (PFK1) activities and decreased hepatic glucose-6-phosphatase (G6Pase), intestinal Scl2a2 and muscle Slc2a4 and Prkaa2α mRNA levels compared to CT group.\nTo satisfy the improved energy demands, glycolysis flux is increased in cancers compared with healthy tissues."
    },
    "1799-1839": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "bladder cancer",
      "text": "Puerarin suppressed cell viability, migration, invasion, and glycolysis, and induced apoptosis in bladder cancer.\nMoreover, suppression of PI3K/AKT and HIF-1α attenuated Vitamin K2-increased glucose consumption and lactate generation, indicating that Vitamin K2 promotes PI3K/AKT and HIF-1α-mediated glycolysis in bladder cancer cells.\nHere, our study was the first to show that Vitamin K2 significantly promoted the glycolysis in bladder cancer cells by upregulating glucose consumption and lactate production, whereas inhibited TCA cycle by reducing the amounts of Acetyl-CoA.\nPFKs were critical genes in charge of glycolysis and were upregulated in bladder cancer.\nOverexpression of ALYREF promoted bladder cancer cell proliferation by PKM2-mediated glycolysis.\nIn summary, exerts strong inhibitory influences on bladder cancer cell proliferation and glycolysis via its destabilization of PDHK1.\nMechanistically, we illustrated that CASC8 reduced the glycolysis of bladder cancer cells via interacting with the fibroblast growth factor receptor 1 (FGFR1).\nPuerarin impedes cell viability, migration, invasion, and glycolysis, and promoted apoptosis in bladder cancer by regulating circ_0020394/miR-328-3p/NRBP1 axis.\nSFN downregulates the unique glucose transport aberrant-independent aerobic glycolysis existed in bladder cancer via blocking the AKT1/HK2 axis and PDH expression.\nInvestigation of the underlying mechanism by which hampers glycolysis in bladder cancer cells revealed that it interacted with PDHK1 to inhibit its protein stabilization.\nThis suppresses the enzymatic activity of HK1, leading to an effective reduction of glycolysis, which triggers cell death via apoptosis in cells derived from human bladder cancer.\nMoreover, the PTEN/PI3K/AKT/mTOR pathway, hyper-activated in bladder cancer, acts as central regulator of aerobic glycolysis, hence contributing to cancer metabolic switch and tumor cell"
    },
    "1795-1819": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "skin cancer",
      "text": "Therefore, this proof-of-concept study reveals PTAU as the first example of a nucleoside analog with potential multifunctional applications, including photodynamic action, bioimaging, and the inhibition of skin cancer cell proliferation.\nMelanoma, the most lethal form of skin cancer, is commonly associated with mutations in the BRAF gene, particularly BRAFV600E, which drives tumor proliferation via the ERK1/2 signaling cascade.\nThis study suggests that Erianin is a novel compound capable of inducing cell apoptosis while suppressing the activation of the VEGF/PI3K/AKT signalling pathway in A375 cells, thereby inhibiting cell proliferation.\nMacrophage migration inhibitory factor (MIF) is an upstream immunoregulatory cytokine that promotes transformed cell proliferation and survival, and generates a tumor-permissive immune landscape of immunosuppressive myeloid and T cells.\nOur findings demonstrated that SASH1 inhibits proliferation, migration, invasion, epithelial-mesenchymal transition, and promotes melanin synthesis through TGF-β1 signaling, while THBS1 counteracts the increase in TGF-β1 levels induced by SASH1 knockdown.\nIntriguingly, TTD melanoma cells exhibited reduced proliferation and an increased signature of the melanocyte lineage factor MITF, along with a strong basal upregulation of REDD2, an inhibitor of the mTOR/S6K/4EBP1-dependent messenger RNA (mRNA) translation machinery.\nIts downregulation suppresses the protective effect of the autophagy-initiating ULK1 and AMBRA1, regulators of normal cell survival and proliferation, and upregulates the sequestosome 1 (SQSTM1/p62), an autophagic cargo adapter which mediates selective degradation of ubiquitinated proteins.\nWe provide strong evidence that ZNF224 overexpression in melanoma cell lines positively modulated p21(CIP1/WAF1) gene transcription in a p53-dependent manner and enhanced AKT-triggered p21(CIP1/WAF1) oncogenic effects through its protein cyt"
    },
    "354-1794": {
      "type": "slc_pathway",
      "key1": "SLC35G5",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-1924": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Head and Neck Cancer",
      "text": ""
    },
    "30-1794": {
      "type": "slc_pathway",
      "key1": "SLC4A4",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-1836": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "pancreatic cancer(PC)",
      "text": ""
    },
    "224-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A3",
      "key2": "oxidative phosphorylation",
      "text": "Variants in the SLC25A3 gene, which codes for the mitochondrial phosphate transporter (PiC), lead to a failure of inorganic phosphate (Pi) transport across the mitochondrial membrane, which is required in the final step of oxidative phosphorylation.\nPiC delivers phosphate, a key substrate of oxidative phosphorylation, across the inner mitochondrial membrane.\nwe show that CYTB-187AA is mainly localized in the mitochondrial matrix and promotes the pluripotent state in primed-to-naive transition by interacting with solute carrier family 25 member 3 (SLC25A3) to modulate ATP production.\nThe mitochondrial phosphate carrier (PiC) is a mitochondrial solute carrier protein, which is encoded by SLC25A3 in humans.\nWe demonstrate that this CuCOX peak is enhanced under metabolic conditions favoring oxidative phosphorylation, such as high Cu supplementation or galactose-containing media, and correlates with increased mitochondrial respiration.\nFunctional RNA interference (RNAi) experiments targeting key Cu transporters revealed that CuCOX formation is independent of the high-affinity Cu importer CTR1, but instead relies on alternative transporters including DMT1, LAT1, and the mitochondrial carrier SLC25A3.\nThis transport activity is also relevant for allowing effective mitochondrial calcium handling.\nThe significance of PiC has been supported by the recent discovery of a fatal human condition associated with PiC mutations.\nFurthermore, PiC has also been described to affect cell survival mechanisms via interactions with cyclophilin D and the viral mitochondrial-localized inhibitor of apoptosis (vMIA).\nCopper (Cu) is an essential trace element required for mitochondrial respiration via its incorporation into cytochrome c oxidase (CuCOX), the terminal enzyme of the electron transport chain.\nThe mitochondrial genome transcribes 13 mRNAs coding for well-known proteins essential for oxidative phosphorylation."
    },
    "1802-1938": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Kidney Cancer",
      "text": "We similarly apply UnitedMet to determine that advanced kidney cancers upregulate oxidative phosphorylation relative to early-stage disease, that oxidative metabolism in kidney cancer is associated with inferior outcomes to anti-angiogenic therapy and that kidney cancer metastases demonstrate elevated oxidative phosphorylation.\nWe similarly apply UnitedMet to determine that advanced kidney cancers upregulate oxidative phosphorylation relative to early-stage disease, that oxidative metabolism in kidney cancer is associated with inferior outcomes to combination therapy, and that kidney cancer metastases themselves demonstrate elevated oxidative phosphorylation relative to primary tumors.\nMetabolic alterations underlying clear cell renal cell carcinoma (ccRCC) progression include aerobic glycolysis, increased pentose phosphate pathway activity and reduced oxidative phosphorylation.\nBesides, we observed that overexpression of PTPRG activated oxidative phosphorylation and inhibited apoptosis.\nHigh-CSPI tumors exhibited enhanced tumor stemness phenotypes, metabolic reprogramming (ROS/oxidative phosphorylation), and suppressed immune activity.\nOverexpression of MRPL12 enhances oxidative phosphorylation (OXPHOS) and suppresses aerobic glycolysis, while MRPL12 knockdown produces the opposite effects.\nOur findings indicate that the severe compromise of oxidative phosphorylation and rapid glycolytic flux in UOK 262 are an essential feature of this TCA cycle enzyme-deficient form of kidney cancer.\nWe found that treatment with the drugs etomoxir and buformin significantly reduced mitochondrial oxidative phosphorylation and induced cell death under glucose-deprivation conditions in starvation-resistant RCC cells.\nThe specific PPARα inhibitor GW6471, as well as a siRNA specific to PPARα, attenuates the enhanced fatty acid oxidation and oxidative phosphorylation associated with glycolysis inhibition, and PPARα antagonism also blocks the enhanced glycolysis that has been observed in RCC cells;\nRNA sequencing (RNAseq) and untargeted metabolomics analyses of samples from TRACK kidneys demonstrate that HIF1α activates the transcription of genes that cause increased glucose uptake, glycolysis, and lactate production"
    },
    "45-1798": {
      "type": "slc_pathway",
      "key1": "SLC5A8",
      "key2": "stemness",
      "text": ""
    },
    "1802-2404": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "triple-negative breast cancer(TNBC)",
      "text": "MDA-MB-231, a TNBC cell line with reduced sensitivity to doxorubicin, reduced ΔφM, and enhanced mitophagy to maintain ROS production through oxidative phosphorylation (OXPHOS)-based metabolism.\nThese findings and scRNA-seq analysis of CSC subpopulations indicate that MUC1-C regulates self-renewal and redox balance by integrating activation of glycolysis with suppression of oxidative phosphorylation.\nMoreover, we identified that CPT inhibits mitochondrial oxidative phosphorylation and mitochondrial fusion via autophagy and transcriptional activation of the apoptosis signal-regulating kinase 1 (ASK1) pathway.\nIts mechanism of action involves mitochondrial impairment and the inhibition of oxidative phosphorylation (OXPHOS), achieved through direct binding to C1QBP, thereby promoting its ubiquitin-dependent degradation.\nWe developed and characterised the efficacy of novel AMPK activator (SU212) that selectively induces oxidative phosphorylation and decreases glycolysis in TNBC cells, while not affecting these pathways in normal cells.\nUsing coherent anti-Stokes Raman scattering and two-photon excited fluorescence microscopy, we show that CDCP1 depletes lipids from cytoplasmic lipid droplets (LDs) through reduced acyl-CoA production and increased lipid utilization in the mitochondria through FAO, fueling oxidative phosphorylation.\nWe observed that the MYC-suppressed persistent triple-negative breast cancer (TNBC) cells are metabolically flexible and can upregulate mitochondrial oxidative phosphorylation (OXPHOS) genes and respiratory function (\"OXPHOS-high\" cell state) in response to DNA-damaging anthracyclines such as doxorubicin, but not to taxanes.\nRNA sequencing and Ingenuity Pathway Software Analysis (IPA) of the transcriptomic data revealed several upregulated and downregulated gene expressions along with novel core canonical pathways including Sirtuin signaling, Oxidative Phosphorylation and Mitochondrial dysfunction events involved in EM"
    },
    "322-1802": {
      "type": "slc_pathway",
      "key1": "SLC34A2",
      "key2": "oxidative phosphorylation",
      "text": "Moreover, we uncovered the regulatory networks of PHF5A-TOMM22-oxidative phosphorylation, TLR3-CTSO inflammation-related pathway, SECISBP2L-targeted RNA (ADGRF5, TGFBR2, CD302, AC096921.2, AHCYL2, RPS6KA2, SLC34A2, and SFTPB) angiogenesis, and SECISBP2L-AKAP13 signaling (DNA repair, MTORC1 signaling, and MYC targets).\nThese biomarkers were enriched in oxidative phosphorylation and mitogen-activated protein kinase signaling pathways, which are relevant to DM.\nFour genes [ATP binding cassette subfamily C member 8 (), retinol binding protein 4 (), Ras protein-specific guanine nucleotide-releasing factor 1 (), and solute carrier family 34 member 2 ()] were identified as ubiquitin-pyroptosis-related biomarkers in T2DM, based on consistent expression trends and significant differences in GSE76894 and GSE41762."
    },
    "1802-2099": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Multicancer",
      "text": "ERR1- and PGC1α-associated mitochondrial alterations correlate with pan-cancer disparity in African Americans"
    },
    "1799-1917": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Gastric cancer (GC)",
      "text": "Previously, we reported that Pumilio 1 (PUM1), a RBP, could regulate glycolysis metabolism and promote the progression of gastric cancer (GC).\nOur previous studies have found that TOP1MT is a crucial gene that inhibits glycolysis and cell metastasis of gastric cancer (GC) cells, but the mechanism of its regulation of glycolysis remains unclear.\nGlycolysis is activated in various cancers, including gastric cancer (GC).\nHowever, the role of ISL1 in stimulating glycolysis to promote tumorigenesis in gastric cancer (GC) is unclear.\nHere, it is revealed that N4-acetylcytidine (ac4C), a newly identified mRNA modification, enhances hypoxia tolerance in gastric cancer (GC) cells by promoting glycolysis addiction.\nHere, we show that gastric cancer (GC) cells with high metastatic potential strongly promote the metabolic switch from oxidative phosphorylation to aerobic glycolysis in fibroblasts.\nBesides, we demonstrate that the inhibition of miR-5683 promotes glycolysis by upregulating the PDK4 expression, thus leading to GC progression.\nWhen upregulated, we also determined that miR-7 was able to inhibit the proliferation, colony formation, and glycolysis of GC cells owing to its regulation of LDH-A.\nUnder the glucose deprivation condition, knockdown of PGM1 significantly suppressed cell viability, proliferation and glycolysis, whereas lipid metabolism was enhanced.\nIn conclusion, we demonstrated for the first time that knockdown of MDFI inhibited the increase in GC cell proliferation and glycolysis by regulating the Wnt/β-catenin pathway.\nMechanistically, enhances the glycolysis pathway and facilitates PD-L1 lactylation through the PI3K/AKT/HIF1α signaling pathway, thereby suppressing anti-tumor immunity in CD8 T cells.\nIn our previous study, we demonstrated that fructose-1,6-bisphosphatase-2 (FBP2), an enzyme that suppresses cell glycolysis and growth, is downregulated in GC due to promot"
    },
    "393-1796": {
      "type": "slc_pathway",
      "key1": "SLC40A1",
      "key2": "ferroptosis",
      "text": "Mechanistically, CAP downregulated transferrin (Trf) and upregulated solute carrier family 40 member 1 (SLC40A1), which helped maintain iron levels in the cells and prevent ferroptosis.\nThe PI3K/AKT signaling pathway mediates TBMS1-induced ferroptosis, which was accompanied by altered expression of NRF2, SLC40A1, and GPX4, ultimately suppressing cell proliferation and collagen synthesis.\nThe natural IGF1R inhibitor PPP induced ferroptosis through blockage of PI3K/AKT/NRF2 signaling pathway and subsequent inhibition of downstream gene expression of SLC7A11 and SLC40A1 in hepatocellular carcinoma.\nMechanistically, iCoDMSNs upregulate heme oxygenase 1 (HMOX1), which increases transferrin receptors and reduces solute carrier family 40 member 1 (SLC40A1), resulting in Fe accumulation and ferroptosis initiation.\nValidation of transcriptome data showed that 1,25(OH)D inhibits ferroptosis in zebrafish larvae and ZFL caused by excessive FAC via promoting the expression of slc40a1 and hmox1a genes and increasing SLC40A1 protein levels.\nMechanistically, JIB04 suppressed nuclear-factor-E2-related factor 2 (Nrf2) and reduced chromatin accessibility at distal regulatory regions of its downstream target solute carrier family 40 member 1 (Slc40a1), impairing iron efflux and promoting ferroptosis in tumor cells.\nNRF2 attenuated PQ-induced ferroptosis in A549 cells, mainly through the upregulation of SLC40A1 to encourage the movement of iron to the extracellular side to alleviate iron overload, and the upregulation of SLC7A11 to promote the expression of GPX4 to inhibit lipid peroxidation.\nSubsequently, the contributions of abnormal GSK-3β expression to NaIO3-induced mice and HLE-B3 cell model were further evaluated, inhibition of"
    },
    "1796-2196": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "glioma",
      "text": ""
    },
    "4-1801": {
      "type": "slc_pathway",
      "key1": "SLC1A4",
      "key2": "apoptosis",
      "text": "More importantly, the knockdown of SLC1A4 or simple supplementation of serine suppressed CTX-induced apoptosis of GCs.\nFurthermore, the functional analysis revealed that silenced SLC1A4 inhibited cell proliferation, migration, cell cycle, and promoted cell apoptosis in HCC.\nIn addition, we observed that miR-27b-3p was highly expressed in hUSC-Exo and markedly suppressed CTX-induced GC apoptosis by specifically inhibiting the expression of SLC1A4, a serine transporter, in ovarian GCs, which, in turn, elevated the concentration of the intracellular serine by inhibiting the outflux of cellular serine.\nFinally, we demonstrated that CTX-induced apoptosis of ovarian GCs was essential for POF by reducing the intracellular serine concentration via elevating the expression of SLC1A4, whereas hUSCs protected against CTX-induced POF via miR-27b-3p/SLC1A4/serine axis-mediated activation of the PI3K/AKT/mTOR signaling pathway.\nhUSCs remarkably inhibited CTX-induced apoptosis and promoted the proliferation of GCs, respectively.\nThis metabolic disruption causes mitochondrial damage, impaired energy production, and increased apoptosis in GC cells.\nGSEA and REACTOME analyses identified altered signaling in cells exposed to amino acid deprivation, such as pathways related to stress responses, the cell cycle and apoptosis.\nPlacentitis was associated with the upregulation of matrix metalloproteinase (MMP1, MMP2, and MMP9) and apoptosis-related genes such as caspases (CASP3, CASP4, and CASP7) in CA.\nFunctional enrichment highlighted DEG involvement in cell death/apoptosis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways like apoptosis, tumor necrosis factor (TNF), and NF-κB signaling.\nKey PCD types included apoptosis, immunogenic cell death, necrosis, necroptosis, and ferroptosis."
    },
    "5-1796": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "ferroptosis",
      "text": "Thus, inhibiting SLC1A5 or GLS1 activity could alleviate the antagonistic effect of YAP1 on the ferroptosis of RSL3-induced CRPC cells.\nDownregulation of SLC1A5 could inhibit TAM-induced hepatocyte ferroptosis, thereby alleviating HSCs activation and the increased expression of ECM proteins.\nCollectively, data in the present study indicated that targeting the miR-338-3p/SLC1A5 axis could block high glucose-induced ferroptosis in RPE cells.\nInhibitors against apoptosis, autophagy, or ferroptosis rescued the cell viability repressed by SLC1A5 knockdown.\nCRISPR/dCas9-mediated SLC1A5 induction conferred cisplatin resistance and reduced apoptosis, autophagy, and ferroptosis.\nOur study suggests that TAM induces hepatocyte ferroptosis through SLC1A5, leading to HSC activation and liver fibrosis.\nFurthermore, the mechanism of how APOC1 inhibits ferroptosis in prostate cancer through PI3K/AKT/SREBP2/SLC1A5 was detected.\nNotably, the overexpression of SLC1A5 could activate the mTORC1 signaling pathway and may increase the cellular sensitivity to ferroptosis.\nCollectively, our findings indicated that SLC1A5 may act as a suppressor gene against ferroptosis and can be a potential target for ionizing radiation mediated effects.\nIn addition, SLC1A5 knockdown could significantly inhibit glioma cell proliferation and invasion, and reduce the sensitivity of ferroptosis via the GPX4-dependent pathway.\nCollectively, the results demonstrated that curcumin exhibited antitumorigenic activity in BC by promoting SLC1A5-mediated ferroptosis, which suggests its use as a potential therapeutic agent for the treatment of BC.\nNotably, the anti-ferroptosis function of APOC1 was mediated through SREBP2-dependent transcriptional regulation, with Cut&Tag (Cleavage Under Targets and Tagmentation) confirming SREBP-2's direct binding to"
    },
    "1796-2715": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "lung adenocarcinoma",
      "text": "SNX30 inhibits lung adenocarcinoma cell proliferation and induces ferroptosis by regulating SETDB1 expression.\nLncRNA SLC7A11AR promotes lung adenocarcinoma progression by inhibiting ferroptosis via promoting SLC7A11 expression.\nTFAP2A Promotes Cell Progression and Suppresses Ferroptosis in Lung Adenocarcinoma via Activating Transcription of CST1.\nIGF2BP3 suppresses ferroptosis in lung adenocarcinoma by m6A-dependent regulation of TFAP2A to transcriptionally activate SLC7A11/GPX4.\nNeutrophil extracellular traps promote growth of lung adenocarcinoma by mediating the stability of m6A-mediated SLC2A3 mRNA-induced ferroptosis resistance and CD8(+) T cell inhibition.\nRNF216 inhibits ferroptosis in lung adenocarcinoma by promoting p53 ubiquitination.\nThe role of PCBP1 in carbon ion-induced ferroptosis and inhibition of lung adenocarcinoma proliferation.\nHigh expression of SLC2A1 inhibits ferroptosis and promotes proliferation and invasion of lung adenocarcinoma cells.\nThe application of ferroptosis inducer FIN56 to decrease antioxidant levels in lung adenocarcinoma (LUAD) is a promising tumor eradication technique.\nFerrostatin-1 significantly reversed the effects of the SNX30-plasmid on cell ferroptosis in lung adenocarcinoma, as confirmed by the reduced ROS levels, inhibited intracellular total iron and Fe levels, decreased Ptgs2 and Chac1 expression, and increased Cys, GSH, and GPX4 release.\nCircRNA circ_0015278 induces ferroptosis in lung adenocarcinoma through the miR-1228/P53 axis.\nSTAT1 increases the sensitivity of lung adenocarcinoma to carbon ion irradiation via HO-1-mediated ferroptosis.\nDihydroisotanshinone I regulates ferroptosis via PI3K"
    },
    "313-1794": {
      "type": "slc_pathway",
      "key1": "SLC31A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1801-2159": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "age-related macular degeneration (AMD)",
      "text": "Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss, primarily driven by oxidative stress-induced degeneration of retinal pigment epithelium (RPE).\nErythropoietin (EPO), a hematopoietic cytokine with neuroprotective properties, has been shown to reduce apoptosis and retinal degeneration.\nIn this study, we examined the cytoprotective role of a non-erythropoietic EPO variant, EPO-R76E, in suppressing oxidative stress and mitochondrial dysfunction related to oxidative stress in RPE cells.\nOur study positions EPO-R76E as a promising therapeutic candidate for halting RPE degeneration in AMD."
    },
    "1800-2255": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "multiple myeloma (MM)",
      "text": ""
    },
    "9-1802": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "oxidative phosphorylation",
      "text": "We assessed the functional relevance of these SLCs in efferocytic phagocytes and observed a robust induction of an aerobic glycolysis program, initiated by SLC2A1-mediated glucose uptake, with concurrent suppression of the oxidative phosphorylation program.\nCEBPD promoted glucose uptake and lactate production by upregulating SLC2A1 and HK2, leading to mitochondrial fission, increased extracellular acidification rate and decreased oxygen consumption rate to fuel cell growth.\nMetformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nOxygen consumption rates also decreased upon BPTES treatment, indicating a glutamine dependency for oxidative phosphorylation.\nOn the contrary, metabolic shifts from oxidative phosphorylation to glucose metabolism promote cardiomyocyte (CM) proliferation after heart injury.\nWe report that genetic or pharmacological inhibition of GLUT1 with BAY-876 impairs the growth of a subset of TNBC cells displaying high glycolytic and lower oxidative phosphorylation (OXPHOS) rates.\nExposure of mesothelial cells to TGF-β1 increased production of lactate (P < .05), increased HIF1A mRNA (P < .05), and protein, and increased concentrations of mRNAs encoded by glycolysis-associated genes (LDHA, PDK1, SLC2A1;\nRecognizing the elevated expression of glucose transporter 1 (GLUT1, encoded by SLC2A1) and associated metabolic dependencies in TNBC, we investigated the vulnerability of TNBC cell lines and patient-derived samples to GLUT1 inhibition.\nThis coincided with an upregulation of glucose importers SLC2A1/3, hexokinases and HIF1 and 2."
    },
    "1800-2001": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Bone cancer",
      "text": "TIMM23-induced M2 polarization upregulated TIMM23-PARGP1 expression in OS cells, thereby enhancing their proliferation, migration, and invasion while inhibiting apoptosis and reducing the effectiveness of chemotherapeutic agents.\nHsa-miR-877-3p was upregulated by PD treatment, and functional experiments demonstrated that the miR-877-3p-mimic enhanced PD's suppressive effects on NSCLC cell proliferation, colony formation, migration, and invasion, while the miR-877-3p-inhibitor abrogated these effects.\nKnocking down GPX8 expression inhibited the promoting effects of KLF16 overexpression on OS cell proliferation, invasion, and migration, whereas overexpressing GPX8 reversed the inhibitory effects of KLF16 knockdown on OS cell proliferation, invasion, and migration.\nIbrutinib effectively inhibited the proliferation and migration of lung cancer cells, and in a lung cancer bone metastasis model, this drug inhibited tumor growth, alleviated pain, and protected the tibial bone.\nOur recent data demonstrated that NNMT upregulation in osteosarcoma (OS) and Merkel cell carcinoma (MCC) led to a significant increase in cell proliferation and migration ability, together with a reduction in sensitivity to chemotherapeutic treatment.\nKnocking down GPX8 expression significantly inhibited OS cell proliferation, migration, and invasion;\nCCK-8, wound healing, and transwell assays demonstrated that ibrutinib significantly suppressed the proliferation and migration of lung cancer cell lines.\nIbrutinib, a selective inhibitor of EGFR-mutated non-small cell lung cancer, has been shown to inhibit the proliferation and migration of lung cancer cells.\nTIMM23 promotes M2 polarization through mitophagy modulation.\nFlow cytometry demonstrated that TIMM23 promotes M2 polarization, while confocal and transmission electron microscopy confirmed its role in regulating mitophagy in M2 macrophages.\nIn conclusion, TIMM23 enhances OS chemoresistance and tumor progression by promoting M2 macrophage polarization via mitophagy an"
    },
    "222-1795": {
      "type": "slc_pathway",
      "key1": "SLC25A1",
      "key2": "proliferation",
      "text": "Furthermore, Slc25a1 inhibition under HFD conditions activated the SIRT1/PGC1α pathway, promoting mitochondrial proliferation and enhancing oxidative phosphorylation for energy production.\nMechanistically, SLC25A1 loss results in a proliferation defect and activates two distinct senescence pathways, oncogene-induced senescence (OIS) and mitochondrial dysfunction-induced senescence (MiDAS), both involving the p53 tumor suppressor and driven by two discernible signals: the accumulation of 2HG, inducing OIS, and mitochondrial dysfunction, triggering MiDAS.\nOverexpression of SLC25A1 attenuated both the decreased proliferation and enhanced apoptosis caused by DMC-GF (p < 0.01).\nSurprisingly, inactivation of both Slc25a1 alleles results in alterations in the development of multiple organs, and in a severe proliferation defect by activating two senescence programs, oncogene-induced senescence (OIS) and mitochondrial dysfunction-induced senescence (MiDAS), which converge upon the induction of the p53 tumor suppressor.\nCellular experiments showed that SLC25A1 knockdown significantly reduced the proliferation of lung adenocarcinoma cells.\nOverexpression of miR-331-3p or inhibition of SLC25A1 resulted in significantly suppressed proliferation, migration and invasion of PTC cells.\nInhibiting these senescence programs or blocking p53 activity reverses the growth defect caused by SLC25A1 dysfunction and restores proliferation.\nReplenishing the pool of NAD or promoting the clearance of 2HG rescues the proliferation defect of cells with dysfunctional SLC25A1 in a cooperative fashion.\nKnockdown or pharmacological inhibition of SLC25A1 significantly suppressed AML cell proliferation by inducing apoptosis, without affecting cell cycle progression or differentiation.\nThe Slc25a1 regulates mitochondrial citrate transport and has been shown to affect cell proliferation and migration in cancer.\nSolute carrier family 25 member 1 (SLC25A"
    },
    "1795-2196": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "glioma",
      "text": "Formononetin dose-dependently reduced cell viability, proliferation, migration, and colony formation, while inducing apoptosis.\nNeutrophils accumulate around the surgical cavity and release NETs to promote the proliferation and migration of postoperative residual GBM cells.\nIt downregulated survivin, cyclin D1, MMP-9, and, unregulated Bad.\nMoreover, other cancer hallmarks, such as wound healing rate closure and migration, were markedly inhibited by postbiotics.\nInjection of a hydrogel loaded with copper selenide nanozyme and doxorubicin into the surgical cavity successfully inhibit the formation of NETs and improve the therapeutic efficacy against GBM.\nGlioblastoma multiforme (GBM) remains a formidable challenge due to its aggressive proliferation, heterogeneity, and invasiveness.\nMTT and trypan blue exclusion assays revealed a significant reduction in cell proliferation, and flow cytometry analysis corroborated this data, demonstrating a cell cycle arrest in treated cells.\nOn the other hand, primary astrocytes viability and the blood-brain barrier (BBB) integrity were not impaired, suggesting a selective effect of postbiotics on proliferating-undifferentiated cells.\nHerein, we focus on the important roles of neutrophil extracellular traps (NETs) in the progression of GBM in mice and patients.\nTo investigate the anti-glioblastoma potential of the natural isoflavone formononetin, focusing on its impact on cell survival, proliferation, migration, mediated through a potential mechanism involving oxidative stress modulation.\nCytotoxicity (MTT), proliferation (trypan blue), migration (wound healing), clonogenicity (colony formation), and apoptosis (Hoechst staining) were assessed.\nFormononetin exerts potent anti-glioblastoma effects by inducing apoptosis and inhibiting key cancer hallmarks, mediated through a unique mechanism involving the paradoxical activation of the cellular antioxidant system, ultimately disrupting redox balance."
    },
    "94-1798": {
      "type": "slc_pathway",
      "key1": "SLC9A5",
      "key2": "stemness",
      "text": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD."
    },
    "90-1800": {
      "type": "slc_pathway",
      "key1": "SLC9A1",
      "key2": "migration",
      "text": "The increase in NBCn1 density was similar in magnitude to that observed for Na(+)/H(+)-exchanger NHE1 (SLC9A1), a transporter previously implicated in cell migration, proliferation and malignancy.\nFunctional assays demonstrated that knockdown of either gene not only suppressed proliferation, colony formation, migration, and induced apoptosis in breast cancer cells, but also led to reduced expression of the sodium-calcium exchanger NCX1.\nExtrusion of the acid load from the cancer cells raises intracellular pH, while it decreases extracellular pH creating an inverted pH gradient across the plasma membrane compared to normal cells and promoting cancer cell metabolism, proliferation, migration, and invasion.\nThe results demonstrate that in RGM1 cells, migratory velocity is increased by NHE1 activation, while NHE2 activity inhibit this process.\nThrough multi-omics analysis of GEO and TCGA cohorts, we identified two sodium homeostasis-related genes, TRPM4 and SLC9A1, as consistently upregulated oncogenes in breast cancer, with significant diagnostic and prognostic relevance.\nand disrupted NHE1 expression can reduce triple-negative breast cancer growth.\nA differential activation of NHE1 and NHE2 may therefore, play a role in the initiation and completion of the epithelial restitution process.\nCellular assays-with some discrepancies-link NHE1 activity to proliferation, migration, and invasion;\nThe role of the basolaterally expressed NHE1 (Slc9a1) and the presumably apically expressed NHE2 (Slc9a2) in epithelial restitution was investigated in the nontransformed rat gastric surface cell line RGM1.\nWhen pH 7.1 was maintained during the restitution period, migratory speed was reduced to ∼10% of the speed at pH 7,4, and the residual restitution was further inhibited by NHE1 inhibition.\nGrowth factors accelerated wound healing in a partly NHE1-dependent fashion."
    },
    "4-1798": {
      "type": "slc_pathway",
      "key1": "SLC1A4",
      "key2": "stemness",
      "text": "As a result, silencing SLC1A4 inhibited the proliferation, migration, and stemness of hepatic cancer cells, which was successfully reversed by the introduction of exogenous AKT.\nSLC1A4 Promotes Malignant Transformation of Hepatocellular Carcinoma by Activating the AKT Signaling.\nIn conclusion, SLC1A4 promotes the malignant transformation of HCC through activating signal transduction mediated by AKT.\nMechanically, silencing SLC1A4 inhibited the phosphorylation activation of AKT by suppressing the ubiquitin modification of AKT at lysine 63 and amino acid influx represented by D-serine, decreasing the protein level of -catenin in the cell nucleus and suppressing the transcriptional activity of c-Myc and EpCAM promoters.\nHere, we report that ac4C and its catalytic enzyme NAT10 drive leukaemogenesis and sustain self-renewal of leukaemic stem cells/leukaemia-initiating cells through reprogramming serine metabolism.\nMechanistically, NAT10 facilitates exogenous serine uptake and de novo biosynthesis through ac4C-mediated translation enhancement of the serine transporter SLC1A4 and the transcription regulators HOXA9 and MENIN that activate transcription of serine synthesis pathway genes.\nMoreover, epithelial-mesenchymal transition (EMT) in vitro and metastasis potential in vivo of hepatic cancer cells was suppressed by the downregulated SLC1A4 level."
    },
    "1798-2025": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Anal Cancer",
      "text": "The iCAF_PLAU population enhances the stemness and aggressiveness of cancer cells through the ligand-receptor pairs WNT5A_FZD3_LRP6 and NRG1_ERBB3.\nARMM cancer cells exhibited marked intratumoral heterogeneity, and elevated angiogenesis, hypoxia, stemness, and epithelial-mesenchymal transition characteristics.\nWe also identified the cancer stem cell subpopulation c5_Mel_CD55_VEPH1 in ARMM.\nMoreover, we identified a unique population of PLAU + fibroblast cells (iCAF_PLAU) in ARMM that likely have differentiated from myofibroblasts under hypoxic conditions.\nOur data suggest a potential role of iCAF_PLAU in mediating cell-cell interactions within the TME of ARMM, highlighting potential therapeutic targets for this aggressive malignancy."
    },
    "5-1794": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2404": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "triple-negative breast cancer(TNBC)",
      "text": ""
    },
    "1796-1929": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Nasopharyngeal Carcinoma(NPC)",
      "text": "EMC2 suppresses ferroptosis and promotes tumor progression, and the EMC2-TFRC axis is a novel ferroptosis regulatory pathway.\nThese findings indicated that isoquercitrin might enhance oxidative stress and ferroptosis in NPC via AMPK/NF-κB p65 inhibition.\nEMC2 knockdown promoted ferroptosis, inhibiting cell viability, migration, and invasion, and enhancing the efficacy of cisplatin in NPC cells.\nHOXA9 restrained ferroptosis via promoting UBR5 expression, and UBR5 suppressed ferroptosis through promotion of SIRT6 ubiquitination and degradation.\nOur findings suggest that the AGT-HIF-1α-HILPDA pathway promotes radioresistance in NPC by enhancing lipid droplet accumulation, thereby suppressing ferroptosis.\nRescued experiments indicated that FGFR2 overexpression inhibited DDP-induced ferroptosis, and CAFs protected against DDP-induced ferroptosis via FGF5/FGFR2 axis in NPC cells.\nMechanistically, NAT10 promotes proteins of solute carrier family 7 member 11 (SLC7A11) expression through ac4C acetylation, inhibiting sorafenib-induced ferroptosis in NPC cells.\nTaken together, our data suggest that BBR induced ferroptosis of NPC cells via suppressing the system Xc/GSH/GPX4 axis, provides new insights into the mechanism of BBR anti-NPC metastasis.\nCrucially, ferroptosis inhibitors (Fer-1/Lip-1), but not apoptosis, necroptosis, or autophagy inhibitors, rescued solasodine-induced cell death, confirming ferroptosis as the dominant mechanism.\nCD38 inhibits ferroptosis in nasopharyngeal carcinoma cells by stabilizing SLC7A11 proteins to activate the SLC7A11/GSH/GPX4 ferroptosis signaling axis, thereby promoting radiotherapy resistance.\nIn conclusion, luteolin reduces the binding of SOX4 to the GDF15 promoter by suppressing SOX"
    },
    "372-1796": {
      "type": "slc_pathway",
      "key1": "SLC38A7",
      "key2": "ferroptosis",
      "text": ""
    },
    "1796-1872": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "breast cancer(BC)",
      "text": "Silencing USP24 enhances ferroptosis-mediated tumor suppression in TNBC cells.\nGATA3 promotes ferroptosis resistance by repressing integrin β1 signaling.\nMETTL3-modified lncRNA DSCAM-AS1 promotes breast cancer progression through inhibiting ferroptosis.\nUSP35 promotes the growth of ER positive breast cancer by inhibiting ferroptosis via BRD4-SLC7A11 axis.\nTan IIA promoted ferroptosis and inhibited tumor growth and metastasis via suppressing KDM1A/PIAS4/SLC7A11 axis.\nZC3H13-mediated m6A modification reduces DOX resistance in TNBC by promoting ferroptosis via KCNQ1OT1/TRABD axis.\ninhibition of ASCL1 increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis.\nCAPE activates AMPK and Foxo3 signaling to induce growth inhibition and ferroptosis in triple-negative breast cancer.\nKnockdown of cDTL significantly inhibited breast cancer cell growth both in vitro and in vivo through promoting ferroptosis.\nPSMD14/E2F1 Axis-Mediated CENPF Promotes the Metastasis of Triple-Negative Breast Cancer Through Inhibiting Ferroptosis.\nPSMD14 could suppress arachidonic acid metabolism-induced ferroptosis in TNBC cells through the E2F1/CENPF axis.\nSIM induced ferroptosis in TNBC cells through reduced glutathione (GSH) levels, increased iron levels, ROS and lipid peroxidation.\nADAR1 promotes breast cancer progression via inhibiting ferroptosis.\nSRPX2 knockdown inhibited TNBC cell viability, invasion, and Stemness of tumor while promoting TNBC cell apoptosis and ferroptosis.\nThe PSMD14/E2F1 axis-mediated CENPF could promote the metastasis of TNBC by inhibiting arachidonic acid metabolism-"
    },
    "232-1800": {
      "type": "slc_pathway",
      "key1": "SLC25A11",
      "key2": "migration",
      "text": "Loss of OGC promoted cell proliferation and migration through Slug-mediated EMT.\nOGC silencing aggravated EMT, while overexpression attenuated TGF-β2-induced EMT, cell proliferation, and migration.\nOGC knockdown significantly enhanced RPE EMT, as evidenced by upregulated expression of α-SMA, fibronectin, collagen type I, and Slug, while E-cadherin was downregulated.\nOGC depletion stimulated EMT via pSmad2/3 upregulation, dependent on the PI3K/AKT signaling pathway activation.\nIn vivo studies further demonstrate that subretinal fibrosis was significantly augmented in OGC mice via TGF-β2-dependent PI3K signaling.\nmodulating OGC expression in RPE affects EMT and mitochondrial function, making OGC a potential therapeutic target for subretinal fibrosis in nAMD.\nEpithelial-to-mesenchymal transition (EMT) in RPE cells is a key early step in subretinal fibrosis."
    },
    "1800-2119": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": ""
    },
    "381-1796": {
      "type": "slc_pathway",
      "key1": "SLC39A4",
      "key2": "ferroptosis",
      "text": ""
    },
    "1796-1836": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "pancreatic cancer(PC)",
      "text": "Inhibition of KLF5 facilitated the cytotoxic effect of oxaliplatin via promoting ferroptosis.\nInterestingly, KRAS-mutant cells upregulate expression of ferroptosis suppressor protein 1 (FSP1).\nFurthermore, overexpression of CMTM7 induced ferroptosis in PC by inhibiting the Wnt/β-catenin pathway.\nIts knockdown induces ferroptosis in PC and suppresses tumor progression via CMTM7-mediated Wnt/β-catenin pathway.\nTargeting SMYD2 inhibits PC progression by promoting ferritinophagy-dependent ferroptosis through the c-Myc/NCOA4 axis.\nGenetic or pharmacological inhibition of EP300-mediated HSPA5 acetylation on K353 increases PDAC cell resistance to ferroptosis.\nBoth the ferroptosis inhibitor and inducer exhibit antitumor effects through killing cancer cells or directly affecting tumor growth.\nNrf2 subsequently translocates into the nucleus and activates the glutathione peroxidase 4 (GPX4) pathway, thereby suppressing ferroptosis.\nBoth in vivo and in vitro experiments have demonstrated that PDAC cells develop resistance to ATO through the suppression of drug-induced ferroptosis.\nDuring ferroptosis induction, PRMT6 mediated p62 ADMA to promote its phase separation, sequestering Keap1 to activate Nrf2 signaling and inhibit ferroptosis.\nFurther mechanistic studies revealed that LINC02086 inhibits ferroptosis and promotes PC progression by acting as a sponge for miR-342-3p to upregulate CA9 expression.\nFurthermore, we show that inhibition of LONP1 activates the Nrf2/Keap1 signal pathway and up-regulates the expression of GPX4, a key peroxidase in regulating ferroptosis.\nThis study revealed that Methyltransferase like 3 (METTL3), as a key oncogenic factor, is frequently upregulated and inhibits ferroptosis by stabilizing SLC7A11 mRNA in"
    },
    "139-1799": {
      "type": "slc_pathway",
      "key1": "SLC16A4",
      "key2": "glycolysis",
      "text": "Both ALDOB-knockdown and SLC16A4-knockdown CRC cell lines showed increased basal motichondrial OxPhos and decreased basal glycolysis.\nFinally, APs/CRCs with enhanced glycolysis had increased SLC16A4 expression.\nMoreover, the increase of mitochondrial ATP-linked respiration and the decrease of glycolytic capacity were showed in SLC16A4-knockdown cells.\nKnockdown or pharmacologic inhibition of CA9 in PDAC cells significantly reduced pHi in cells under hypoxic conditions, decreased gemcitabine-induced glycolysis, and increased their sensitivity to gemcitabine.\nUnder hypoxic conditions, PDAC cells had increased levels of HIF1A and HIF2A, upregulated expression of CA9, and activated glycolysis.\nIn response to hypoxia, PDAC cells that express activated KRAS increase expression of CA9, via stabilization of HIF1A and HIF2A, to regulate pH and glycolysis.\nKnockdown of KRAS in PDAC cells, or incubation with trametinib, reduced the posttranscriptional stabilization of HIF1A and HIF2A, upregulation of CA9, pHi, and glycolysis in response to hypoxia.\nIdentified genes were knocked down in WiDr and colo205 CRC cell lines, and their expression was analyzed in APs/CRCs with enhanced glycolysis.\nTwo metabolic genes ALDOB and SLC16A4 were up-regulated in APs.\nOCR/ECAR ratio was decreased in APs over 1 cm, APs with a villous component and CRCs, indicating their glycolytic tendencies.\nIn larger studies, subgroups of glioblastomas may emerge according to oncogene-related effects on glycolysis, such as control of pH via effects on carbonic anhydrases, with prognostic and treatment implications.\nFinally, the ALDOB and SLC16A4 may contribute to the glycol"
    },
    "371-1800": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "migration",
      "text": "Upregulation of SLC38A5 promotes proliferation, migration, and invasion of osteosarcoma cells, while the PI3K inhibitor BKM120 can counteract these effects.\nSLC38A5 promotes osteosarcoma cell proliferation, migration, and invasion via the glutamine-mediated PI3K/AKT/mTOR signaling pathway and inhibits ferroptosis.\nFurthermore, the deletion of SLC38A5 decreased the proliferation and migration of gemcitabine-resistant PDAC cells.\nSLC38A5 inhibition could attenuate the pro-tumoral abilities of CAFs in terms of proliferation, migration, and invasion.\nMoreover, SLC38A5 deficiency could hinder CRC cell proliferation, migration, invasion, glycolysis, and improved L-OHP sensitivity in vitro.\nA series of in vitro functional experiments, including CCK-8, colony formation, wound healing, and transwell invasion assays, were conducted to evaluate the effects of SLC38A5 on the proliferation, migration, and invasion of osteosarcoma cells.\nImportantly, some cell migration-related genes, including AOC3, CCR6, SSTR5, and SCL7A11, were significantly downregulated.\nBET inhibitor treatment in HCC cell lines reduces cell migration through the downregulation of SMARCA4.\nAdditionally, silencing of SLC38A5 inhibits tumor growth in vivo.\nThe absence of subretinal neovascularization in DKO mice is associated with inhibited migration of ECs into the photoreceptor cell layer.\nFurthermore, knockdown of SMARCA4 gene expression by siRNA treatment significantly reduced cell migration and the expression of migration-related genes.\nSLC38A5 transcriptionally mediated by ETV4 expedites CRC cell growth, metastasis, glycolysis, L-OHP resistance, which provides a promising therapeutic target for CRC treatment.\nSimilarly, we observed that knockdown of SLC38A5 restored gemcitabine sensitivity by hindering tumor growth and metastasis in the orthotopic mouse model.\nMice with a loss of LRP5 display underdeveloped intraretinal"
    },
    "1801-2282": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Esophageal squamous cell carcinoma (ESCC)",
      "text": "Bru promoted Bad-mediated mitochondrial apoptosis and inhibited the ESCC cell metastasis by targeting Akt1.\nknockdown reduced proliferation and migration while enhancing apoptosis (p < 0.01).\nWWOX exerts inhibitory effects on the proliferation and migration of ESCC and promotes apoptosis by suppressing the Hippo signaling pathway.\nRNF185 knockout suppressed cell proliferation, induced apoptosis, and caused mitochondrial damage and mtDNA release, activating the cGAS-STING-IRF3 pathway.\nTriptonide treatment downregulated FOXK1 and AKT2 expression, inhibited proliferation, induced apoptosis, and sensitized ESCC cells to cisplatin in a synergistic manner.\nBru was found to trigger mitochondria-mediated cell apoptosis (approximately 5.9- and 3.3-fold increases in the level of apoptosis at high concentrations (80 nM) in the KYSE30 and KYSE450 cells) and inhibit metastasis (49% wound closure decreases at high concentrations (80 nM) in both cells, compared to that in the DMSO group) in ESCC cells.\nPIGU knockdown inhibited ESCC cell proliferation and promoted apoptosis.\nThe FOXK1/AKT2 axis promoted cell proliferation and suppressed cisplatin-induced apoptosis.\nmiRNA-191-5p overexpression promoted cell survival and reduced cell apoptosis after irradiation.\nEmodin inhibited ESCC cell proliferation, facilitated intrinsic apoptosis, and induced G2/M phase arrest.\nEmodin induces intrinsic apoptosis in ESCC cells by simultaneously inhibiting both glycolysis and OXPHOS.\nupon overexpression of WWOX, ESCC cell proliferation and migration decreased, while apoptosis increased.\nthe apoptosis induced by GRPEL2 loss can be largely reversed by treatment with SP600125, a JNK inhibitor.\nLINC00261 overexpression markedly suppressed cell proliferation, invasion, and met"
    },
    "298-1802": {
      "type": "slc_pathway",
      "key1": "SLC29A1",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1802-2119": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": ""
    },
    "381-1794": {
      "type": "slc_pathway",
      "key1": "SLC39A4",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2282": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Esophageal squamous cell carcinoma (ESCC)",
      "text": ""
    },
    "40-1800": {
      "type": "slc_pathway",
      "key1": "SLC5A3",
      "key2": "migration",
      "text": "Lentiviral SLC5A3 overexpression construct transduction upregulated the cellular myo-inositol level and promoted Akt-mTOR activation, enhancing cervical cancer cell proliferation and migration.\nIn addition, suppressing the expression of the signature gene, SLC5A3, in a SKCM cell line through the utilization of small interfering RNAs (siRNAs) could inhibit the proliferation and migration of cells, as evidenced by the implementation of colony formation assay, CCK8, and cell transfection techniques.\nConversely, ectopic overexpression of SLC5A3 further enhanced proliferation and migration in primary NSCLC cells.\nWhile GBM cell migration was significantly increased by extracellular inositol and glucose, it was strongly impaired by SLC transporter inhibition.\nWe provide several lines of evidence for the involvement of SLC5A1 and SLC5A3 in GBM cell migration, thereby complementing the migration-associated transportome.\nIn primary NSCLC cells and immortalized lines, SLC5A3 depletion, using small hairpin RNA (shRNA) and CRSIRP/Cas9 methods, robustly impeded cell proliferation and migration, simultaneously provoking cell cycle arrest and apoptosis.\nTogether, elevated SLC5A3 promotes NSCLC cell growth possibly by maintaining myo-inositol contents and promoting Akt-mTOR activation.\nWe also employed wound-healing assays to examine the effect of SLC inhibition on GBM cell migration and examined the chemotactic potential of inositol.\nInvasive cell migration has been linked to the aberrant expression of transmembrane solute-linked carriers (SLC).\nIn single GBM cells, both transporters were primarily localized at the leading edge of the lamellipodium.\nIn the GBM cell monolayers, both SLCs were exclusively detected in the migrating cells at the monolayer edge.\nInterestingly, in GBM cells migrating via blebbing, SLC5A1 and SLC5A3 were predominantly detected in nascent and mature blebs, respectively."
    },
    "1796-2137": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "hearts suffered ischemia/reperfusion (I/R)",
      "text": "This study aims to explore whether targeting MALT1 can reduce I/R-induced ferroptosis via enhancing the Nrf2/SLC7A11 pathway.\nInhibition of USP7 activated p53 via suppressing deubiquitination, which led to down-regulation of TfR1, accompanied by the decreased ferroptosis and myocardial I/R injury.\nAbstract: The dysregulation of nuclear factor erythroid 2-related factor 2 (Nrf2) and/or solute carrier family 7 member 11 (SLC7A11) is believed to contribute to ferroptosis in the hearts suffered ischemia/reperfusion (I/R), but the mechanisms behind the dysregulation of them are not fully elucidated.\nThe SD rat hearts were subjected to 1h-ischemia plus 3h-reperfusion to establish the I/R injury model, which showed myocardial injuries (increase in infarct size and creatine kinase release) and up-regulation of MALT1 while downregulation of Nrf2 and SLC7A11 concomitant with the increased ferroptosis, reflecting by an increase in glutathione peroxidase 4 (GPX4) level while decreases in the levels of acyl-CoA synthetase long chain family member 4 (ACSL4), total iron, Fe and lipid peroxidation (LPO);\nKnockdown of TfR1 inhibited H/R-induced ferroptosis without p53 deubiquitination.\nConsistent with the results in vivo, inhibition or knockdown of USP7 reduced the H/R injury (decrease of LDH release and necrosis) and enhanced the ubiquitination of p53 along with the decreased levels of p53 and TfR1 as well as the attenuated ferroptosis (manifesting as the decreased iron content and lipid peroxidation while the increased GPX activity)."
    },
    "1802-2365": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Neuroblastoma (NBM)",
      "text": ""
    },
    "9-1798": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "stemness",
      "text": "We provided evidence suggesting that SLC2A1 could influence the migration, invasion, and stemness of ESCA cells, and it was associated with sensitivity to Foretinib.\nFinally, our results revealed that SLC2A1 had the highest correlation with B cells in single-cell data analysis, and we validated its correlation with B cells and its expression with FA-related genes, tumor invasiveness, stemness, and drug sensitivity.\nWe found that stem cell-like GBM tumor subpopulations possessed higher basal levels of glycolytic activity and increased expression of several glycolysis-related enzymes including, GLUT1/SLC2A1, PFKP, ALDOA, GAPDH, ENO1, PKM2, and LDH, compared to their non-stem-like counterparts.\nAlso, we found that hypoxia strongly expressed anti-senescence related genes such as HDAC1 (histone deacetylase 1), DNMT1 (DNA (cytosine-5)-methyltransferase 1), Bcl-2 (inhibitor of apoptosis), TERT (telomerase reverse transcriptase), LDHA (lactate dehydrogenase A), SLC2A1 (glucose transporter), and DKC1 (telomere holoenzyme complex) and differentiation potential of cAD-MSCs into chondrocytes, than seen under the normoxic culture conditions.\nCombinatorial treatment of stem cell-like GBM tumor subpopulations with autophagy and glycolysis inhibitors blocked the induction of senescence while drastically impairing their stemness capacity which drove cells towards apoptotic cell death.\nWhile treatment with glycolysis inhibitors induced senescence in stem cell-like GBM tumor subpopulations, as evidenced by increased β-galactosidase staining and upregulation of the cell cycle regulators p21/CDKN1A and p16/CDKN2A, these cells maintained their aggressive stemness features and failed to undergo apoptotic cell death.\nSimilarly, blocking autophagy in stem cell-like GBM tumor subpopulations induced senescence-associated growth arrest without hampering stemness capacity or indu"
    },
    "1798-1850": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "liver cancer",
      "text": ""
    },
    "1796-1845": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Endometrial Cancer (EC)",
      "text": "Fancd2 increases drug resistance in EC cells by inhibiting the cellular ferroptosis pathway.\nTBX2 suppressed Cisplatin-induced ferroptosis through up-regulating FSP1 expression level in EC cells.\nInterestingly, silence FSP1 could reverse TBX2-mediated ferroptosis inhibition and tumor-promoting effect.\nAs a result, AF inhibited the viability and proliferation of KLE cells but promoted apoptosis and ferroptosis.\nSOX4 inhibits ferroptosis and promotes proliferation of endometrial cancer cells via the p53/SLC7A11 signaling.\nLncRNA FAM83H-AS1 inhibits ferroptosis of endometrial cancer by promoting DNMT1-mediated CDO1 promoter hypermethylation.\nKnockdown of FOXM1 downregulated ferroptosis-resistant gene expression and increased MDA and ROS levels in DDP-resistant EC cells.\nGPX4 suppresses ferroptosis to promote malignant progression of endometrial carcinoma via transcriptional activation by ELK1.\nNORAD promoted m6A modification to down-regulate GPX4 by interacting with FTO, and promoted ferroptosis to inhibit tumor growth in vivo.\nGFC may attenuate estrogen-induced endometrial hyperplasia in mice through triggering ferroptosis via inhibiting p62-Keap1-NRF2 pathway.\nThese findings collectively suggested that SOX4 inhibited ferroptosis and promoted proliferation of EC cells via the p53/SLC7A11 signaling.\nThis ACAA1/PI3K/AKT/Nrf2 axis suppresses ferroptosis by regulating redox homeostasis and lipid peroxidation, thereby promoting EC progression.\nHNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2.\nTaken together, our findings revealed that EZH2 act as a suppressor in the induced cell ferroptosis through a PRC2-independent methyltransferase mechanism."
    },
    "30-1800": {
      "type": "slc_pathway",
      "key1": "SLC4A4",
      "key2": "migration",
      "text": "Upregulation of SLC4A4 promoted apoptosis in the LUAD cell line and significantly inhibited the migration and invasive ability of cancer cells (P<0.01).\nSLC4A4 knockdown inhibited cell proliferation, migration and invasion, while facilitated apoptosis, which was also confirmed in vivo.\nTherefore, hsa_circRNA_001587 inhibits PC cell migration, invasion, angiogenesis and tumorigenesis by impairing miR-223-mediated SLC4A4 inhibition.\nOverexpression of miR-223 downregulates the expression of SLC4A4 and promotes PC cell growth.\nOur functional analysis revealed that SLC4A4 knockdown retards tumor growth and lowers invasion and migration potential.\nIn MDA-MB-231 breast cancer cells expressing high levels of SLC4A4 compared to LS174 cells, SLC4A4 knockdown had a strong impact on cell proliferation, migration, and invasion.\nOverexpressing miR-224-5p increased the proliferative, migratory and invasive abilities of CRC cells and inhibit CRC cell apoptosis, while overexpressing SLC4A4 caused the opposite result.\nMoreover, SLC4A4 promoted PCa progression through the AKT-mediated signalling pathway.\nSLC4A4 knockdown suppressed PCa development in vitro and in vivo.\nNDBT inhibition (S0859) and shRNA knockdown suppressed migration (40% reduction) and invasion (70% reduction) in vitro.\nImportantly, SLC9A2 overexpression in SW480 cells led to a notable inhibition of cell proliferation, migration, and invasion.\nDelivery of circ_0086375 by nanoparticles suppresses the tumorigenicity of pancreatic cancer by miR-646/SLC4A4 axis, suggesting a new potential target for future pancreatic cancer treatment.\nTumour xenograft metastasis in vivo was significantly reduced by NDBT knockdown.\nFirstly, we reported the SLC4A4/GSK-3β/β-catenin signaling axis, which reg"
    },
    "1800-1864": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "prostate cancer",
      "text": "Gilteritinib suppresses prostate cancer cell proliferation and migration and induces ER stress-mediated non-autophagic cytoplasmic vacuolization cell death.\nBAY-876 effectively suppressed the viability of prostate cancer cells, particularly those with high SLC7A11 expression.\ndown-regulation of ACSM1 expression in LNCaP prostate cancer cells significantly inhibits cell proliferation and migration, while overexpression enhances these processes in normal cells.\nLINC01179 impaired prostate cancer cell proliferation and migration ability by suppressing TLL1 expression to deactivate TGF-β signaling activity.\noverexpression of KCNMA1 promoted the infiltration of M1 macrophages by inhibiting the RAS/RAF/MEK/ERK signaling pathway, thereby inhibiting the proliferation, migration, and invasion of prostate cancer cells.\nXZF exerts its therapeutic potential through multiple mechanisms, including direct antiproliferative effects on cancer cells, enhancement of T-cell responses, modulation of immune checkpoint pathways, and macrophage-mediated suppression of prostate cancer cell survival and migration.\nROBO1 promoted the proliferation, migration and invasion of prostate cancer cells.\nLan C promotes apoptosis and inhibits the migration and invasion of prostate cancer cells.\nResveratrol, when combined with flutamide, can reduce malignant cell migration, colony formation, and proliferation and promote apoptosis in prostate cancer cell lines.\nBufadienolides extracts and its major components, bufalin and resibufogenin, significantly inhibited prostate cancer cell proliferation and migration, induced apoptosis, and promoted ROS production.\nTMSB10 silencing suppresses cell proliferation, migration, and invasion, while overexpression enhances these oncogenic processes.\npyripyropene O inhibited the survival, proliferation and migration of prostate cancer cells, and also showed that pyripyropene O blocked the prostate cancer cell cycle at the G2/M phase and induced apoptosis.\nASPN functions as a HER3 ligand to induce cellular migration, and inhibition with anti-HER2 or anti"
    },
    "25-1801": {
      "type": "slc_pathway",
      "key1": "SLC3A2",
      "key2": "apoptosis",
      "text": "HCMV-miR-US33-5p suppressed proliferation, key factors of integrin signal pathway, and EPAS1/SLC3A2 expression, but promoted HA-VSMC apoptosis.\nUpregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin.\nNUP210 and SLC3A2 were significantly upregulated in clinical CRPC tissues, and their knockdown resulted in significant suppression of cellular growth of LNCaP95 through apoptosis and growth arrest.\nNotably, flow cytometry further showed that SLC3A2 inhibition also enhanced the apoptosis of rat cardiomyocytes.\nCell experiments confirmed that melanocyte proliferation decreased, whereas apoptosis increased, after SLC3A2 knockdown.\nIn vitro experiments showed that knocking down of SLC3A2 was associated with reduced migration, invasion, and proliferation, but increased apoptosis of OSCC cells.\nMechanistic study showed that HCMV-miR-US33-5p bound to the 3'-untranslated region of EPAS1 to suppress its expression, leading to suppression of SLC3A2 expression, which ultimately promoted cell apoptosis and inhibited cell proliferation.\nTNFSF9 regulated by SP1 aggravated CIRI via boosting ferroptosis, apoptosis, and release of inflammatory mediators of BMECs under OGD/R situation by suppressing SLC3A2 expression in vitro and in vivo.\nEx vivo and in vitro, loss of CD98hc suppressed proliferation and induced apoptosis in VSMCs.\nCD98 depletion decreased cell proliferation, clonogenic survival, and migration and induced apoptosis in HCC cells.\nSLC3A2 exerted a harmful effect on OSCC patients by increasing migration, invasion and proliferation, and decreasing apoptosis.\nCD98hc KO cells showed reduced endoreplication capacity and lower sensitivity towards PRZ induced apoptosis than wild type cells."
    },
    "1801-1839": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "bladder cancer",
      "text": "Dasatinib induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells.\nCOL6A1 downregulation inhibited bladder cancer cell proliferation, invasion, and migration and induced cell apoptosis.\nHigh expression of miR-204-5p promotes proliferation, migration and invasion and reduces apoptosis of bladder cancer cells by negatively regulating RAB22A expression.\nThese results confirmed that dasatinib is a potent chemotherapeutic drug which induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells.\nCompound 27 inhibited bladder cancer progression by upregulating DUSP5 expression and negatively regulating the p38 MAPK pathway, modulating the immune response and promoting apoptosis.\nIn vitro, SQ-diEG inhibited proliferation and induced apoptosis in bladder cancer cell lines.\nBrazilin significantly inhibited bladder cancer cell proliferation and induced apoptosis and DNA damage in vitro.\nRo-31-8220 treatment suppressed bladder cancer cell migration and invasion and also induced cell apoptosis in a dose-dependent manner.\nIn bladder cancer cells, miR-204-5p overexpression significantly promoted cell proliferation, migration and invasion and reduced cell apoptosis.\nIn this study, we demonstrated that lncRNA UCA1 inhibits epirubicin-induced cell apoptosis by supporting abnormal lipid metabolism in bladder cancer cells.\nE2F8 downregulation facilitated cisplatin-induced apoptosis of bladder cancer cells.\nIn conclusion, this study demonstrates that BKPyV promotes bladder cancer cell growth and impairs cisplatin-induced apoptosis, with miR-B1 targeting ATF3 as a key mechanism.\nThis study presents new copper(II) complexes that can significantly induce bladder cancer cells death by enhanced CDT through bimodal apoptosis and ferroptosis, providing a promising approach for cancer therapy.\nNotably, the dysregulation of genes and metabolites associated with reactive oxygen species (ROS)-related pathways may serve as a central mechanism by"
    },
    "92-1797": {
      "type": "slc_pathway",
      "key1": "SLC9A3",
      "key2": "oxidative stress",
      "text": ""
    },
    "1797-2087": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Glioblastoma (GBM)",
      "text": ""
    },
    "405-1794": {
      "type": "slc_pathway",
      "key1": "SLC43A3",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2196": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "glioma",
      "text": ""
    },
    "63-1795": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "proliferation",
      "text": "Reducing SLC6A14 increased cell proliferation and suppressed apoptosis.\nA pharmacological blocker of SLC6A14, α-methyltryptophan, induced amino acid starvation in pancreatic cancer cells and reduced the growth and proliferation of these cells, both in vitro and in vivo.\nLastly, lysine can promote cell proliferation and the synthesis of β-casein through SLC6A14 in BMECs.\nUpregulated SLC6A14 expression promoted glutamine catabolism and enhanced BC cell proliferation, migration, and invasion.\nThe above results indicate that lysine promotes cell proliferation and the synthesis of β-casein through the SLC6A14-ERK-CDK1-mTOR signaling pathway in BMECs.\nFunctionally, we confirmed that SLC6A14 was highly expressed in PC and its knockdown suppressed the proliferation, migration, invasion and EMT signal via regulating Wnt/β-catenin signaling pathway.\nThe salient features of this study are that SLC6A14 is markedly up-regulated in pancreatic cancer and that pharmacological blockade of this transporter interferes with amino acid nutrition and reduces growth and proliferation of pancreatic cancer cells.\nFurther knockdown SLC6A14 with siRNA or treatment with α-MT in CRC cell lines reduced cell proliferation and migration in vitro and inhibited xenograft tumor growth in vivo.\nWhile SLC6A14 genetic deficiency does not have a major impact on cell proliferation, combined depletion of AMPK and SLC6A14 leads to an increase in apoptosis upon methionine starvation, suggesting that combined targeting of SLC6A14 and AMPK can be exploited as a therapeutic approach to starve tumor cells.\nBlockade of SLC6A14 with α-MT inhibited the activation of mTOR signaling.\nInhibition of heat shock proteins, known to be upregulated in cancer, directs SLC6A14 to degradation.\nIn PDAC cell line, knockdown inhibited cells proliferation, migration and promoted cells apoptosis.\nAdditionally, FOXA1 knockout inhibited cell proliferation and further increase"
    },
    "1795-2557": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "malignt cancers",
      "text": ""
    },
    "371-1794": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-1864": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "prostate cancer",
      "text": ""
    },
    "58-1802": {
      "type": "slc_pathway",
      "key1": "SLC6A8",
      "key2": "oxidative phosphorylation",
      "text": "By combining drug profiling with transcriptomics and through a whole-genome CRISPR/Cas9 screen, we demonstrate that HSPD1-targeted anti-cancer effects are dependent on oxidative phosphorylation and validated molecular determinants of KHS101 sensitivity, in particular, the creatine-transporter SLC6A8 and the subunit of the cytochrome c oxidase complex COX5B.\nHSPD1 knockdown or its chemical disruption by the small molecule KHS101 induces a drastic breakdown of oxidative phosphorylation, and suppresses cell proliferation both in vitro and in vivo.\nStimulation of macrophages with Mtb lysate or lipopolysaccharide (LPS) induced a relative increase in glycolysis versus oxidative phosphorylation.\nThis process further enhances oxidative phosphorylation and glycolysis of leukemia cells, thereby boosting ATP production to foster proliferation and infiltration.\nOur investigation revealed impaired mitochondrial oxidative phosphorylation, reduced spare respiratory capacity, elevated oxidative stress, and significant alterations in amino acid transporter activity.\nCreatine transporter deficiency (CTD) caused by mutations in SLC6A8 encoding the creatine transporter (CRT), leads to cerebral creatine deficiency syndromes\nDespite the diminished role of creatine and phosphocreatine in oxidative phosphorylation in CTD, we found no elevation of lactate or lowered pH, indicating that the brain energy supply still largely relied on oxidative metabolism.\nWe observed severe intracellular creatine deficiency (> 90% reduction), leading to impaired energy metabolism (low ATP and high ADP/ATP)."
    },
    "1802-1815": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "leukemia",
      "text": "Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation.\nTargeting JMJD1C-mediated metabolism via pharmacologic inhibition of glycolysis and oxidative phosphorylation led to ATP depletion, induced necrosis/apoptosis and decreased tumor growth in vivo in leukemias co-expressing JMJD1C and HOXA9.\nAs acute myeloid leukemia (AML) cells and stem cells have an increased reliance on oxidative phosphorylation, we sought to evaluate polymerase γ inhibitors in AML.\ninhibition of autophagy induces an accumulation of lipid droplets (LD) due to a decrease in fatty acid β-oxidation, that leads to a reduction of oxidative phosphorylation (OxPHOS) in acute myeloid leukemia (AML), but not in normal cells.\ncombined inhibition of the MEK/ERK pathway and mitochondrial oxidative phosphorylation effectively inhibited the growth of human and mouse leukemia cells in vitro.\nOxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia.\nT-cell acute lymphoblastic leukemia (T-ALL) cells are characterized by increased oxidative phosphorylation and robust ATP production.\nAcute myeloid leukemia (AML) cells are highly dependent on oxidative phosphorylation and the mitochondrial dynamics regulated by fusion-related genes MFN1, MFN2, and OPA1 and fission-related genes DNM1L and MFF.\nwe identified a downregulated expression of oxidative phosphorylation (OXPHOS) at relapse in AML with inv(16), and explored the in vitro effects of metformin as a potential drug to enhance chemosensitivity in this setting.\nWe also review the role of oxidative phosphorylation (OxPhos) in maintaining leukemia stem cells (LSCs), how recurrent genomic alterations in AML alter downstream metabolism, and focus on how the BCL-2 pathway and the mitochondria are inextricably linke"
    },
    "1800-1806": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Brain Tumor",
      "text": "Shikonin inhibited cell proliferation, migration, invasion, and EMT and upregulated miR-361-5p expression in GBM cells.\nFurthermore, CENPF promoted cell viability, invasion, and migration, and inhibited apoptosis and CD8 T cell immunity in GBM.\nFunctional studies reveal that SIN1 upregulation enhances glioma cell proliferation and migration while suppressing apoptosis.\nIn addition, CN-3 could upregulate the expression of miR-4465 in cells, thereby inhibiting migration and invasion of glioma cells.\nFunctional analyses following EXO1 knockdown revealed significant suppression of GBM cell viability, proliferation, migration, invasion, and induced DNA fragmentation.\nLic-A induced mitochondrial dysfunction by regulating Bcl-2 family and induced reactive oxygen species (ROS), while ROS inhibition enhanced the migration and invasion of glioma cells.\nGene silencing of SUV39H1 in SJ-GBM2 and CHLA-200 cells induced a significant decrease in cell viability and cell migration, followed by reduced expression of vimentin, β-catenin, and TCF4 protein levels.\nFunctionally, LK-A impaired EMT-induced cell migration, invasion, and glioma stem cell-like traits, evidenced by decreased gliosphere formation and downregulation of stemness markers such as Sox2 and Oct4.\nThe lipid core with docosahexaenoic acid (DHA)-conjugated Temozolomide (TMZ) enhances FABP7-mediated uptake, promotes lysosomal escape via lipid peroxidation, and reduces tumor migration and drug resistance.\nFurther investigation reveals that the PI3K/AKT agonist treatment partially inhibits p53 expression, alleviates Ru2-PDT-induced apoptosis, and reverses its inhibitory effects on PDFS cell migration and invasion.\nBDNF-AS overexpression markedly attenuated the malignant characteristics of glioma cells, as evidenced by decreased viability, proliferation, migration, invasion, and angiogenesis, along with increased apoptosis."
    },
    "1795-1917": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Gastric cancer (GC)",
      "text": "TPP1 knockdown inhibited GC cell metastasis but not proliferation, while TPP1 overexpression enhanced metastasis.\nMoreover, combination treatment with Pen-H and 5-fluorouracil (5-Fu) resulted in enhanced inhibition of cell proliferation and tumor growth compared to monotherapy.\nStomach cancer, or gastric cancer (GC), is a major global health problem characterized by the malignant proliferation of cells in the gastrointestinal lining.\nThe levels of proliferation, migration, and invasion in both cell lines significantly decrease with increasing concentrations of Esculin, while the apoptosis rate significantly increases.\nFunctional studies in GC cells showed that IGF2BP3 knockdown suppressed proliferation, migration, invasion, and G1/S cell cycle transition, while its overexpression promoted oncogenic phenotypes.\nThese mechanisms not only promote uncontrolled proliferation but also reinforce therapeutic resistance by dynamically modifying the tumor microenvironment (TME).\nKnockdown of JMJD6 suppressed GC cell proliferation, migration and invasion in a TP53 mutation-independent manner, and reduced PD-L1 (Programmed cell death ligand 1) expression via BRD4 (Bromodomain-containing protein 4) and IRF1 (Interferon regulatory factor 1) down-regulation.\nSREBP-1 depletion significantly inhibits the proliferation, migration, and invasion of GC cells.\nCo-culturing of CAFs with GC cells promoted the proliferation, invasion and migration of GC cells.\nBC plays an important role in inducing apoptosis, inhibiting cell proliferation, and suppressing metastasis in GC cells.\nOur previous studies found that Menin was highly expressed in gastric cancer (GC) and could promote GC progression.\nIn vitro and in vivo functional assays demonstrate that EPDR1 promotes the proliferation, migration, and invasion of GC cells.\nFunctional experiments demonstrated that DAZAP1 promotes tumor proliferation, cell cycle progression, and chemotherapy resistance in vitro and in vivo.\nMZF1-AS1 enhances RAB13 expression by promoting its mRNA stability,"
    },
    "9-1794": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2290": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "oral squamous cell carcinoma (OSCC)",
      "text": ""
    },
    "1799-2146": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "liver hepatocellular carcinoma (LIHC)",
      "text": "Aerobic glycolysis is a hallmark of cancers including liver hepatocellular carcinoma (LIHC).\nIncreased glycolytic flux is a hallmark of cancer\nTherefore, inhibiting the aerobic glycolysis pathway holds promise as a therapeutic strategy for treating liver tumors.\nClinical trials have shown that inhibitors of rate-limiting enzymes in the glycolysis pathway can enhance the effectiveness of sorafenib, a targeted drug for hepatocellular carcinoma, by reducing drug resistance.\nThe glycolytic metabolism in VECs co-cultured with HCC cells is highly active, and the increased glycolysis in these endothelial cells accelerates the malignant transformation of HCC cells.\nLactate, the final product of aerobic glycolysis, contributes to an acidic environment within the tumor, promoting the formation of an immunosuppressive microenvironment and accelerating tumor progression by impeding anti-tumor immunity.\nAs a solid tumor with high glycolytic activity, hepatocellular carcinoma (HCC) produces excess lactic acid and increases extracellular acidity, thus forming a unique immunosuppressive microenvironment.\nMetabolic reprogramming, specifically enhanced glycolysis, is a prominent feature of cancer progression.\nThis abnormal metabolic pattern, known as the 'Warburg' effect or aerobic glycolysis, promotes cancer progression.\nIn conclusion, GJB2 promotes HCC progression by activating glycolysis through cytoplasmic translocation and generating a suppressive tumor microenvironment.\nUCHL5 downregulates its degree of ubiquitination by binding to β-catenin, which activates the Wnt/β-catenin pathway and accelerates HCC cell glycolysis.\nCell experiments verified that the activation of the glycolysis pathway by overexpression of STIL promoted stemness in HCC.\nYAP1 knockdown inhibited GLUT1-mediated aerobic glycolysis, whereas YAP1 overexpression promoted GLUT1-mediated aerobic glycolysis in HCC cells.\nIn this study, we confirmed that inhibition of YAP1 expression lowers GLUT1-mediated aerobic glycolysis in HCC cells and enh"
    },
    "260-1796": {
      "type": "slc_pathway",
      "key1": "SLC25A39",
      "key2": "ferroptosis",
      "text": "Consequently, genetic inhibition of the NFE2L2-GSH-SLC25A39 pathway enhances cuproptosis-mediated tumor suppression in cell culture and in mouse tumor models.\nExogenous addition of glycine significantly increased the levels of the anti-oxidant GSH and the expression of anti-oxidant-related genes (glutathione peroxidase 4 [GPX4], catalase [CAT], superoxide dismutase 1 [SOD1], superoxide dismutase 2 [SOD2], and mitochondrial solute carrier family 25, member 39 [SLC25A39]), decreased the lipid peroxidation caused by reactive oxygen species (ROS) and reduced the level of malondialdehyde (MDA) by enhancing the functions of mitochondria, peroxisomes and lipid droplets (LDs) and the levels of lipid metabolism-related factors (peroxisome proliferator activated receptor coactivator 1 alpha [PGC-1α], peroxisome proliferator-activated receptor γ [PPARγ], sterol regulatory element binding factor 1 [SREBF1], autocrine motility factor receptor [AMFR], and ATP).\nIt is found that mitochondrial inhibition either increases or decreases ferroptosis susceptibility in cellular models, depending on contextual factors that dictate whether mitochondria act as a net GSH producer or consumer, respectively.\nGCLM and GCLC are rate-limiting enzymes in GSH synthesis, and increased GSH is transported into mitochondria via the solute carrier family 25 member 39 (SLC25A39) transporter.\nThese findings not only reveal distinct mechanisms of GSH in inhibiting cuproptosis and ferroptosis, but also suggest a potential combination strategy to suppress PDAC tumor growth.\nThese effects further reduced ferroptosis and maintained the normal structure and function of the cell membrane.\nMechanistically, GSH inhibits cuproptosis by chelating copper, contrasting its role in blocking ferroptosis by inhibiting lipid peroxidation.\nBut mitochondria also consume GSH via the SLC25A39 transporter.\nIt is demonstrated that mitochondrial function an"
    },
    "1796-1843": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Prostate Cancer",
      "text": "Understanding the interplay between immunogenic cell death (ICD), ferroptosis, and prostate cancer (PCa) is critical for elucidating the underlying mechanisms of PCa pathogenesis.\nCrucially, downregulated MCM5 attenuated its physical interaction with NRF2, leading to uncontrolled activation of the NRF2/HMOX1 pathway, GPX4 suppression, and accumulation of ferroptosis hallmarks.\nThrough integrated in vitro, in vivo, and bioinformatics analyses, this study demonstrated that MEL functioned as a novel ferroptosis inducer in PCa by disrupting androgen receptor (AR) liquid-liquid phase separation (LLPS).\nThese findings defined an AR/MCM5/NRF2 axis regulating ferroptosis susceptibility, establishing MEL as the first-reported ferroptosis inducer that expands the mechanistic foundation and therapeutic potential of MEL-based PCa treatment strategies.\nWe found that MEL effectively inhibited PCa proliferation, migration, and invasion in vitro while suppressing tumor growth safely in mice models.\nMechanistically, MEL impaired AR LLPS dynamics, reducing AR-driven transcription of minichromosome maintenance protein 5 (MCM5).\nMCM5 was a clinically relevant biomarker associated with aggressive PCa and poor survival.\nA three-gene IFRG-based prognostic model was developed, which effectively stratified PCa patients into high- and low-risk groups with significantly different survival outcomes.\nThe three-gene IFRG-based prognostic model may serve as a promising prognostic biomarker for PCa, providing predictive value and novel insights into the complex interactions between IFRGs and PCa progression."
    },
    "1801-2193": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "pancreatic ductal adenocarcinoma (PDAC)",
      "text": ""
    },
    "131-1796": {
      "type": "slc_pathway",
      "key1": "SLC15A1",
      "key2": "ferroptosis",
      "text": "Notably, AHNAK2 impedes ferroptosis, promoting LUAD progression in vitro.\nFurthermore, we present AHNAK2 as a novel regulator of ferroptosis, which requires further investigation to understand its mechanism.\nFerritinophagy, a newly recognized autophagy process linked to ferroptosis, has been associated with LUAD development.\nWe further investigated the impact of the ferritinophagy-related gene AHNAK2 on LUAD cell proliferation, invasion, migration, and ferroptosis in vitro.\nOur prediction model, comprising seven genes (AHNAK2, ARNTL2, CD27, LTB, SLC15A1, SLC2A1, and SYT1), has shown potential in predicting the prognosis of individuals diagnosed with LUAD.\nRecent studies have shown a dysregulation of genes related to ferritinophagy in LUAD, indicating its potential as a therapeutic target.\nOur research suggests that ferritinophagy-associated genes are promising prognostic markers for LUAD and lay the groundwork for further exploration of ferritinophagy's role in LUAD."
    },
    "1796-2056": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Cervical cancer",
      "text": "We identified that 5-ALA-PDT inhibited cell viability and induced ferroptosis in cervical cancer.\nThe ferroptosis induced by CENPF inhibition in cervical cancer cell lines is likely mediated through the Nrf2/HO-1 pathway.\nIn conclusion, these data inspired that METTL5-mediated mA modification of SLC7A11 promoted cervical cancer by inhibiting ferroptosis, providing a novel insight for cervical cancer.\nThis study confirmed that USP34 could upregulate PIN1 expression and SUMOylation, thereby inhibiting ferroptosis by suppressing the cGAS-STING pathway and in turn promoting the progression of cervical cancer.\nTherefore, our findings revealed that inhibiting ANXA6 can promote tumor cell ferroptosis by activating the cGAS-STING pathway, thereby provide potential strategies that enhancing the efficacy of anti-tumor immunotherapy in cervical cancer.\nThe decreased levels of p62 protein facilitated the degradation of Nrf2 by regulating the p62-Keap1-Nrf2 axis, thereby diminishing the antioxidant capacity of cervical cancer cells, ultimately leading to the induction of apoptosis and ferroptosis.\nMechanistically, CNIH4 elevated solute carrier family 7 member 11 (SLC7A11)-mediated cystine import, and subsequently increased intracellular glutathione synthesis and glutathione peroxidase 4 activity, thereby inhibiting ferroptosis of human cervical cancer cells.\nFurther use of siRNA to interfere with ACSL4 expression in cervical cancer cells revealed that the inhibitory effect of OA on cell viability and proliferative capacity was counteracted, while a decrease in ROS levels and GPX4 was detected, suggesting that OA activated ferroptosis in Hela cells by promoting ACSL4 expression, thereby reducing the survival rate of Hela cells.\nDHODH inhibition inhibited the proliferation and promoted the ferroptosis in cervical cancer cells.\nPIN1 can increase the proliferation and invasion of cervical cancer cells by significantly inhibiting ferroptosis.\nCervical cancer is a prevalent form of cancer in women, and the"
    },
    "129-1797": {
      "type": "slc_pathway",
      "key1": "SLC13A5",
      "key2": "oxidative stress",
      "text": "These DEGs were mainly correlated with fat metabolism, oxidative stress and some inflammatory pathways."
    },
    "32-1795": {
      "type": "slc_pathway",
      "key1": "SLC4A7",
      "key2": "proliferation",
      "text": "SLC4A7 inhibited tumor progression, including metastasis, invasion and proliferation.\nOverexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells.\nIn addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment.\n(2022) show that bicarbonate uptake by SLC4A7 fuels de novo nucleotide synthesis and cell proliferation and is regulated by mTORC1.\nIn vitro and in vivo experiments showed that dysregulation of SLC4A7 had minor influence on the proliferation of HNSCC but impacted HNSCC's migration and invasion.\nDisrupting NBCn1 expression delays ErbB2-induced breast cancer development, inhibits cancer cell proliferation, and decelerates tumor growth.\nWe propose that axial pHi gradients enhance VSMC migration whereas global acidification inhibits VSMC proliferation and media hypertrophy after carotid artery ligation.\nDisruption of NBCn1 expression inhibited cell proliferation-evaluated by staining for the proliferative marker Ki67-particularly in central tumor areas with predicted increase in acid loading from glycolytic metabolism.\nExtrusion of the acid load from the cancer cells raises intracellular pH, while it decreases extracellular pH creating an inverted pH gradient across the plasma membrane compared to normal cells and promoting cancer cell metabolism, proliferation, migration, and invasion.\nMoreover, the inhibitory role of SLC4A7 in regulating tumor stemness was verified.\nThese results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.\nProliferation was increased in Panc-1 cells and decreased in BxPC-3 cells, upon TGFβ-1 treatment, and this, as well as EMT , was unaffected by NHE1- or NBC"
    },
    "1795-2178": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Ras mutant pancreatic ductal adenocarcinom",
      "text": ""
    },
    "25-1798": {
      "type": "slc_pathway",
      "key1": "SLC3A2",
      "key2": "stemness",
      "text": "Silencing ATF4 or CCT3 inhibited the selection and growth of TRCs whereas reduction of SLC3A2 or hsa-miR-199a-5p promoted TRCs growth.\nFurther studies showed that CCT3 promoted cell proliferation and stemness in vitro, while its suppression inhibited TRCs-induced tumor formation.\nBesides, these genes were critical regulators modulating drug resistance, tumor microenvironment infiltration, and cancer stemness.\nBy integrating networks for membrane proteins, the WNT pathway and cancer-related genes, we identified key molecules in the selection of TRCs, such as ATF4, SLC3A2, CCT3, and hsa-miR-199a-5p.\nIn this mini-review, we discuss the physiological functions of CD98hc, its role in regulating tumor stemness, metastases, and therapy resistance, and the clinical significance of CD98hc as a tumor marker and therapeutic target.\nWe also contemplated CCT3 as a stemness-related gene.\nOur results suggest that the microbiome is heavily associated with castration resistance and stemness in prostate cancer.\nAdditionally, we observed positive correlations between these DRGs and tumor stemness (DNAss DNA stemness score and RNAss RNA stemness score) as well as RNA modifications, particularly m6A modification, in several cancer types.\nHere we evaluated the transcriptome alteration during TRCs generation in 3D culture and revealed that a variety of molecules related with integrin/membrane and stemness were continuously altered by mechanical environment.\nThis multifaceted role makes CD98hc one of the critical regulators of tumor growth, therapy resistance, and metastases.\nIn this way, CD98hc connects the signaling pathways sustaining cell proliferation and migration, biosynthesis and antioxidant defense, energy production, and stem cell properties.\nThey regulated membrane genes and the downstream mechanotransduction pathways such as Hippo/WNT/TGF-β/PI3K-AKT pathways, thus further affecting the expression of downstream cancer-related genes.\nAbstract: Tumor-repopulating cells (TRCs) are cancer stem cell (CSC)-like cells with highly tumorig"
    },
    "1798-2209": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "416-1797": {
      "type": "slc_pathway",
      "key1": "SLC45A4",
      "key2": "oxidative stress",
      "text": ""
    },
    "1797-2193": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "pancreatic ductal adenocarcinoma (PDAC)",
      "text": "Oxidative stress induced by reactive oxygen species (ROS) is promising treatment approach for pancreatic ductal adenocarcinoma (PDAC), which is typically insensitive to conventional chemotherapy.\nLimited nutrient availability in pancreatic ductal adenocarcinoma (PDAC), due to its dense extracellular matrix, presents a significant metabolic challenge that tumor cells must overcome to survive oxidative stress-induced cell death.\nAlcohol-induced C/EBP β-driven VIRMA decreases oxidative stress and promotes pancreatic ductal adenocarcinoma growth and metastasis via the m6A/YTHDF2/SLC43A2 pathway.\nMonocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby Promoting Resistance against Inhibitors of Glutamine Metabolism.\nLikewise, the glutamine uptake inhibitor V9302 and glutaminase-1 inhibitor CB839 induced oxidative stress in PDAC cells, along with cell death and cell cycle arrest that were again compensated by MCT1 upregulation and forced lactate uptake.\nDIRAS3-mediated KRAS inhibition induces ROS-mediated apoptosis in PDAC and LGSOC cells with KRAS mutations, but not in cells with wild-type KRAS, by downregulating NFE2L2/Nrf2 transcription, reducing antioxidants, and inducing oxidative stress.\nDIRAS3 also induces cytoprotective macroautophagy/autophagy that may protect mutant KRAS cancer cells from oxidative stress, by inhibiting mutant KRAS, activating the STK11/LKB1-PRKAA/AMPK pathway, increasing lysosomal CDKN1B/p27 localization, and inducing autophagic gene expression.\nMechanistically, this co-treatment causes energy and oxidative stress promoting apoptosis but does not exert inhibition of FAO.\nUsing a metabolomics approach, we discovere"
    },
    "383-1800": {
      "type": "slc_pathway",
      "key1": "SLC39A6",
      "key2": "migration",
      "text": "Furthermore, knockdown of SLC39A6 inhibited the proliferation, migration and invasion of liver cancer cells and .\nIn addition, SLC39A6 negatively correlated with miR-192 in HCC samples and promoted HCC cell migration and invasion.\nSLC39A6 was overexpressed in tissues from GA patients and in GA cell lines, and SLC39A6 knockdown in GA cell lines inhibited their proliferation, migration and invasion.\nInterestingly, our previous study showed PTCH1 silencing promoted cell proliferation but inhibited cell migration and invasion of NSCLC cells.\nCollectively, the results of the present study suggested that SLC39A6 may be a promising prognostic biomarker for liver cancer and is associated with the proliferation, migration and invasion of liver cancer.\nCells that overexpressed SLC39A6 had increased expression of mRNAs and proteins associated with metastasis, such as matrix metalloproteinase (MMP) 1, MMP3, MYC, and snail family transcriptional repressor 2 (SNAI2 or SLUG).\nSuppression of migration and invasion caused by miR-192 overexpression was alleviated by exogenous Snail expression.\nMoreover, miR-192 decreased SLC39A6 expression, subsequently downregulating SNAIL and upregulating E-cadherin expression.\nIn conclusion, we newly determined that miR-192 targeted the SLC39A6/SNAIL pathway to reduce tumor metastasis in HCC cells.\nCells that overexpressed SLC39A6 had significant increases in intracellular levels of zinc and were more invasive in assays, activating phosphatidylinositol 3-kinase signaling to AKT serine/threonine kinase 1 and mitogen-activated protein kinase 1.\nIn addition, we also observed that the proliferation and migration of A549 cells was obviously prevented by miR-3935 overexpression.\nKnockdown of SLC39A6 reduced proliferation of ESCC cells in culture and metastasis of xenograft tumors in mice."
    },
    "1800-1893": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Thyroid Cancer",
      "text": ""
    },
    "12-1797": {
      "type": "slc_pathway",
      "key1": "SLC2A4",
      "key2": "oxidative stress",
      "text": "RT-PCR validation of the pathways confirmed a significant decrease in SLC2A4 mRNA levels and a significant increase in PDK4, TXNIP, ANGPTL4 mRNA levels, suggesting that insulin sensitivity of the biceps femoris muscle may be reduced in cortisol offspring.\nAdditionally, TNFα treatments decreased insulin receptor substrate 1 (Irs1), insulin receptor substrate 2 (Irs2), solute carrier family 2, facilitated glucose transporter member 4 (Slc2a4), and phosphoinositide 3 kinase regulatory subunit 1 (Pik3r1) mRNA expression.\nHowever, silencing of Arf reduced mRNAs of Adipoq and Slc2a4 and enhanced release of Il6.\nHO release and dihydroethidium (DHE) staining was increased, while superoxide dismutase (SOD) activity was reduced in long-term cultured adipocytes, which is suggestive of enhanced oxidative stress in this group.\nMoreover, qRT-PCR revealed increased mRNAs of Nox4 (a subunit of NADPH oxidase complex), Ccl2 (a proinflammatory chemokine) and Il6 [a marker of senescence-associated secretory phenotype (SASP)] along with decreased levels of Pparγ, Adipoq and Slc2a4 (genes related to glucose metabolism).\nCBS gene KD in ASC52telo cells led to increased cellular inflammation (IL6, CXCL8, TNF) and oxidative stress markers (increased intracellular reactive oxygen species and decreased reduced glutathione levels) in parallel to decreased HS production and rejuvenation (LC3 and SIRT1)-related gene expression.\nIn this context, shCBS-ASC52telo cells displayed enhanced adipogenic (FABP4, ADIPOQ, SLC2A4, CEBPA, PPARG)-, lipogenic (FASN, DGAT1)- and adipocyte (LEP, LBP)-related gene expression markers, decreased expression of proinflammatory cytokines, and increased int"
    },
    "1797-2255": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "multiple myeloma (MM)",
      "text": "Multiple myeloma (MM) is a hematological cancer with underlying causes associated with increased oxidative stress.\nMultiple myeloma (MM) patients are often accompanied by heightened levels of oxidative stress, even following bone marrow transplantation.\nTreatment of multiple myeloma (MM) aims at inducing cell apoptosis by surpassing the limited capacity of MM cells to cope with oxidative stress.\nMultiple myeloma (MM) is the second most prevalent hematologic malignancy characterized by a high synthesis rate of disulfide bond-rich proteins and chronic oxidative stress.\nFormononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model.\nHere we report a mechanism underlying the ability of proteasome inhibitors bortezomib (BTZ) and carfilzomib (CFZ) to directly induce oxidative and ER stresses in multiple myeloma (MM) cells via transcriptional repression of a gene encoding mitochondrial thioredoxin reductase (TXNRD2).\nSuppression of MM cell survival by bortezomib is similarly driven by bortezomib-induced oxidative stress, being abrogated by added cholesterol.\nIt is generally accepted that intracellular oxidative stress induced by proteasome inhibitors is a byproduct of endoplasmic reticulum (ER) stress.\nDepletion of TXNRD2 to the levels detected in BTZ- or CFZ-treated cells causes oxidative stress, ER stress and death similar to those induced by proteasome inhibitors.\nUsing human myeloma cell lines and clinical samples, we demonstrate that TAZ promotes myeloma cells' sensitivity to oxidative stress and anticancer-induced cytotoxicity by inducing miR-224 to repress the NRF2 antioxidant program in MM.\nIn addition, oxidative stress decreased mitochondrial membrane potential (MMP), reduced gene expression levels of oxidative phosphorylation (OXPHOS), and increased in the density of mitochondrial crumpling, leading to mitochondrial structural abnormalities and dysfunction.\nThe proteasome inhibitor bortezomib induces testicular"
    },
    "294-1801": {
      "type": "slc_pathway",
      "key1": "SLC28A1",
      "key2": "apoptosis",
      "text": "IFN-β upregulated expression of the drug transporters SLC28A1 in BxPC-3 (252%) and SLC28A3 in BxPC-3 (127%) and CFPAC-1 (223%) (all p < 0.001).\nBoth ex vivo and in vivo data demonstrate a significant reduction in the number of proliferating cells, whereas apoptosis was increased.\nThis was driven by cell cycle modulation and associated with an upregulation of genes involving intracellular uptake of gemcitabine."
    },
    "5-1801": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "apoptosis",
      "text": "Moreover, ABHD11-AS1 enhanced the abilities of cell proliferation, migration, and invasion, inhibited apoptosis in vitro, promoted tumorigenesis in vivo via sponging miR-199a-5p and then induced SLC1A5 activation.\nKnockdown of circSEPT9 or SLC1A5 inhibited glutamine uptake and cell proliferation, but induced cell apoptosis in BC cells.\nKnockdown of SLC1A5 decreased proliferation, colony formation, and migration, but increased apoptosis and increased sensitivity to chemotherapy drugs.\nThe knockdown of the SLC1A5 high-affinity transporter for glutamine induces apoptosis and inhibits tumor formation in a mouse AML xenotransplantation model.\nInactivation of SLC1A5 genetically or pharmacologically decreased Gln consumption, inhibited cell growth, induced autophagy and apoptosis in a subgroup of NSCLC cell lines that overexpress SLC1A5.\nInhibitors against apoptosis, autophagy, or ferroptosis rescued the cell viability repressed by SLC1A5 knockdown.\nCRISPR/dCas9-mediated SLC1A5 induction conferred cisplatin resistance and reduced apoptosis, autophagy, and ferroptosis.\nFurthermore, the effects of downregulated circ-LDLRAD3 on cell proliferation, apoptosis and mobility were all reversed by knocking down miR-137 and overexpressing SLC1A5.\nRemarkably, silencing SLC1A5 expression partially counteracted the promotion of CRC cell proliferation by LINC01134 overexpression and alleviated its inhibition of apoptosis.\nDeprivation of Gln or blockade of Gln transporter solute carrier family 1 member 5 (SLC1A5) inhibits bone resorption by enhancing apoptosis of monocytes.\nIn vitro findings showed that SLC1A5 knockdown reduced THCA cell activity and accelerated apoptosis, and the results were consistent with the effect of SLC1A5 inhibitor GPNA"
    },
    "1801-2412": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "endometrial carcinoma (EC)",
      "text": "SIM2 depletion inhibited EC cell viability, induced cell cycle arrest, and promoted apoptosis.\nIt augmented cisplatin- induced proliferation inhibition and enhanced apoptosis, correlating with caspase-3 activation and ROS upregulation.\nOnce activated in vitro, endometrial cancer (EC) cell growth appears to be inhibited through increased apoptosis, but the mechanism remains unclear.\nTherefore, OA may exhibit significant anti-EC effects by regulating the ERβ/PI3K/AKT pathway to promote apoptosis and inhibit epithelial-mesenchymal transition (EMT).\nMG132 enhances the therapeutic efficacy of cisplatin in human EC cells by suppressing the ubiquitin- proteasome pathway, reducing cell viability, enhancing apoptosis, and shifting the inflammatory response.\nFurther functional analysis revealed that the functions of KAT2B in UCEC cell proliferation, DNA damage and apoptosis were mediated by MCM4, and Celastrol enhanced RBPJ acetylation and reduced MCM4 expression.\nNef could block the cell cycle and induce the activation of the mitochondrial apoptotic pathway involving the Ca-mediated ERS pathway and the PI3K/AKT pathway, thereby inducing apoptosis in EC cells, confirming the potential role of Nef in the prevention and treatment of EC.\nOverexpression of SIRT1 enhanced FOXO3 deacetylation and activity, promoting BNIP3 transcription and PINK1/Parkin-mediated mitophagy, which in turn promoted cell proliferation, migration, invasion, and inhibited apoptosis in vitro, as well as increased tumor growth and hormone resistance in vivo.\nThe expression of MYO3B was an influential factor in EC recurrence, and the expression of MYO3B was significantly up-regulated in EC tissues and cells, but down-regulated in KLE cells, and MYO3B knockdown inhibited the proliferation, migration, and invasion ability of EC cells and promoted apoptosis, suggesting that MYO3B plays a tumor-promoting role in EC."
    },
    "10-1801": {
      "type": "slc_pathway",
      "key1": "SLC2A2",
      "key2": "apoptosis",
      "text": "Abrogation of glut2 led to defective brain organogenesis, reduced glucose uptake and increased programmed cell death in the brain.\nIn conclusion, we describe EDEM2 as a likely/potential novel diabetes gene, in which inhibition in vitro reduces the expression of β-cell genes involved in the glucose-stimulated insulin secretion (GSIS) pathway, leading to an overall suppression of insulin secretion but not apoptosis.\nModerate hypoxia also induced apoptosis in MIN6 cells.\nAblating Isl-1 in postnatal β-cells reduced glucose tolerance without significantly reducing β-cell mass or increasing β-cell apoptosis.\ncell apoptosis examination showed that high concentration of oligosaccharide increased cell death, while at low concentration protected cells from streptozotocin-induced apoptosis.\nEsculentin-2CHa(1-30) peptides markedly reduced high fat diet-induced increase in beta cell proliferation and apoptosis.\nFurther analysis revealed an increase in BiP and the PDI family member PDIA4, but without any concomitant apoptosis and cell death.\n[D-Ser]palmitoyl-paddlefish glucagon stimulated proliferation of BRIN-BD11 cells and protected against cytokine-mediated apoptosis as effectively as GLP-1.\nPFKFB4 was overexpressed in LR cells, and its knockdown significantly enhances the antiproliferative and pro-apoptotic effects of lenvatinib on resistant cells.\nOverall, the current study suggests that miR-143 is ubiquitously expressed among tissues and is likely to be involved in the regulation of cell proliferation and apoptosis.\nAlthough no developmental phenotype was detected during embryogenesis, mutant mice displayed reduced insulin-expressing β-cells at P14 and P21 without any changes in the rate of cell death and proliferation.\nEnrichment analysis of Gene Ontology (GO) biological processes showed that the regulation of insulin secretion, glucose homeostasis, apoptosis, nitric oxide biosynthesis, and cell signaling are significantly enriched for hypoglycemia.\nWe then measured the level of four selected circular RNAs in the islets"
    },
    "81-1797": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "oxidative stress",
      "text": "Mechanistically, AA activated the Nrf2/Keap1 pathway, upregulating antioxidant proteins GPX4 and SLC7A11, thereby inhibiting oxidative stress and ferroptosis.\nVNS protects against myocardial injury from hepatic ischemia-reperfusion, likely by inhibiting oxidative stress and ferroptosis through activation of the SLC7A11/GPX4 axis.\nOXA suppressed oxidative stress, upregulated OX1R and HO-1 protein expression, elevated ferroptosis-related markers (SLC7A11 and GPX4), and promoted the nuclear translocation of Nrf2.\nATF3 was found to be highly expressed in VaD rat hippocampus, while its silencing improved cognitive dysfunction and resulted in repressed ferroptosis in the hippocampus, reduced iron content and COX2, and upregulated SLC7A11/GPX4, thus alleviating inflammatory reaction and oxidative stress in VaD rat hippocampus.\nTunicamycin insult prompted cardiac remodeling (interstitial fibrosis), deranged echocardiographic (higher LVESD, dropped ejection fraction and fractional shortening), cardiomyocyte mechanical and intracellular Ca features alongside mitochondrial injury (collapsed mitochondrial membrane potential and ultrastructural change), oxidative stress, compromised Akt-GSK3β signaling, ER stress (upregulated GRP78 and Gadd153), carbonyl formation, apoptosis and ferroptosis (decreased GPX4, SLC7A11).\nSimultaneously, the Fe²⁺ levels increased and SLC7A11 and GPX4 protein expressions decreased, causing oxidative stress.\nIn vitro, BAP1 promoted ferroptosis by increasing oxidative stress and iron accumulation while inhibiting SLC7A11 expression.\nAt the gene level, TCDD exposure induced the expression of ferroptosis-related genes (tf, tfr, tfr1b, and fpn), inflammatory factor-related genes (NF-kB, ptgs2a, and ptgs2b), and lipid degeneration and autophagy"
    },
    "1797-1836": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "pancreatic cancer(PC)",
      "text": "Corosolic acid enhances oxidative stress-induced apoptosis and senescence in pancreatic cancer cells by inhibiting the JAK2/STAT3 pathway.\nSTAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.\nCRA increased OS-induced cell apoptosis and senescence in HAPC and SW1990 cells.\nQuercetin may exert antitumor activity during the prevention of pancreatic cancer progression by regulating oxidative and inflammatory networks, which can promote immune escape of cancer cells by inducing immunosuppressive cytokines.\nThe resulting mitochondrial oxidative stress induces immunogenic cancer cell pyroptosis and upregulates PD-L1 expression.\nSuppression of wtIDH1 impairs redox balance, results in increased ROS levels, and enhances chemotherapy induced apoptosis in pancreatic cancer vis ROS damage.\nAltogether, hypoxia-mediated oxidative stress induces autophagy in PC, leading to the MUC4 degradation to enhance survival, possibly by offering required metabolites to stressed cells.\nBy disrupting multiple metabolic pathways, GSTP1 depletion creates potential therapeutic vulnerabilities that could be targeted through metabolic and oxidative stress-inducing therapies to enhance treatment efficacy.\nOur findings demonstrate that melatonin potentiates gemcitabine's cancer-suppressing effects via modulation of the Kelch-like-ECH associated protein-1 (Keap1)/p62 pathway, resulting in reduced fibrosis, oxidative stress, and inflammatory markers.\nType 2 diabetes mellitus (T2DM) and insulin resistance (IR) are also managed by reducing gluconeogenesis via AMPK pathway activation, promoting autophagy, protecting pancreatic β-cells from oxidative stress and enhancing glucose-stimulated insulin secretion.\nFurthermore, oxidative stress induced by erastin and vitamin C could enhance the expression of HMOX1 via the AMP-activated protein kinase (AMPK)/nuclear factor erythroid 2-related factor 2 (NRF2) pathway to increase the labile iron level, which is named the noncl"
    },
    "9-1795": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "proliferation",
      "text": "The inhibition of miR-378b or the enhancement of SLC2A1 reversed ZNF609 depletion-regulated glioma cell proliferation.\nLoss of tumor-suppressive miR-1291 enhanced RCC cell proliferation, migration and invasion through targeting SLC2A1/GLUT1.\nDownregulation of SLC2A1 could not only inhibit cell proliferation, migration and cell cycle, but also promote cell apoptosis.\nKnocking down SFXN1 inhibits the proliferation and migration of LUAD cells, promotes cell apoptosis, and may inhibit tumor activity by regulating the expression of glycolytic related genes SLC2A1, HK2, GPI, ALDOA, GAPDH, ENO1, PKM, and LDHA.\nKnockdown of these genes in LUAD cells by transfection with small interfering RNAs significantly inhibited LUAD cell proliferation and migration, and promoted anoikis.\nMiR-378a-3p inhibited cell proliferation and invasion as well as induced apoptosis, resulting in reduced glycolysis, which was partly reversed by SLC2A1-AS1 or Glut1 overexpression in ESCC cells.\nIn PC9 cells, SLC2A1 overexpression significantly promoted cell proliferation, invasion and migration, and SLC2A1 knockdown significanty increased cell death and inhibited cell invasion and proliferation.\nInterfering with DARS2 expression can inhibit the proliferation and migration of LUAD cells, promote cell apoptosis, and inhibit the glycolytic activity of tumor cells by inhibiting the expression of glycolytic related genes SLC2A1, GPI, ALDOA, and PGAM1.\nCC-DG inhibited the proliferation, migration, invasion of SGC7901/MFC gastric cells, and in turn, suppressed tumorigenesis by regulating glucose metabolism through regulation of LDHA and SLC2A1 genes.\nIn vitro Cell Counting Kit-8, colony formation, transwell assays as well as in vivo tumorigenesis and metastasis assays showed that SLC2A1-AS"
    },
    "1795-2282": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Esophageal squamous cell carcinoma (ESCC)",
      "text": ""
    },
    "190-1796": {
      "type": "slc_pathway",
      "key1": "SLC22A7",
      "key2": "ferroptosis",
      "text": ""
    },
    "383-1797": {
      "type": "slc_pathway",
      "key1": "SLC39A6",
      "key2": "oxidative stress",
      "text": "Looking through the provided source text, I can only find one title that mentions SLC39A6's family (Slc39/ZiP) but does not contain any abstracts or text that explicitly describes promotion or suppression relationships between SLC39A6 and oxidative stress.\nSince the source material consists only of a title without accompanying abstract text that contains explicit mechanistic relationships between SLC39A6 and oxidative stress, I cannot extract verbatim phrases or sentences demonstrating promotion/suppression relationships between these two entities."
    },
    "138-1794": {
      "type": "slc_pathway",
      "key1": "SLC16A3",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2087": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Glioblastoma (GBM)",
      "text": ""
    },
    "232-1798": {
      "type": "slc_pathway",
      "key1": "SLC25A11",
      "key2": "stemness",
      "text": "Additionally, siRNA-mediated SLC25A11 knockdown and KN612-mediated MAS inhibition decreased the oxygen consumption rate, ATP levels, mitochondrial activity, and cell viability in GBM TSs and decreased the stemness and invasion ability of GBM cells."
    },
    "1799-1845": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Endometrial Cancer (EC)",
      "text": "Endometrial cancer (EC) cells exhibit abnormal glucose metabolism, characterized by increased aerobic glycolysis and decreased oxidative phosphorylation.\nAlthough increasing evidence demonstrates an association between EMT induction and enhanced aerobic glycolysis in human cancer, the mechanisms linking these two conditions in endometrial cancer (EC) cells remain poorly defined.\nCollectively, this study suggests that the ARNTL-mediated INO80-DHX15 axis induces glycolysis and immunosuppression during EC progression.\nMoreover, agents specifically targeting the glycolysis and/or OXPHOS pathways can inhibit tumor cell growth and promote chemosensitization.\nDLEU2 acted as an upstream activator for HK2-induced EMT and glycolysis in EC cells through two distinct mechanisms: (i) DLEU2 induced HK2 expression by competitively binding with miR-455, and (ii) DLEU2 also interacted with EZH2 to silence a direct inhibitor of HK2, miR-181a.\nMechanistically, lose-and-gain function assay, DNA sequencing, and CO-IP revealed HG increased ERRα expression to promote the transcription of HK2 and HMGCS1, which were the key rate-limiting enzyme of glycolysis-cholesterol synthesis and their metabolites suppressed the autophagy-lysosomal pathway in an ERRα-dependent manner.\nThus, inhibiting TMPO-AS1 and GLUT1 may prove beneficial in overcoming glycolysis-induced paclitaxel resistance in patients with EC.\nIn addition, LDHB knockdown inhibited the proliferation, invasion, and glycolysis and promoted apoptosis of RL95-2 and Ishikawa cells.\nFunctional studies demonstrated metabolic reprogramming of MSH2-deficient EC, including reduced oxidative phosphorylation and increased susceptibility to glycolysis suppression.\nFunctional studies revealed metabolic reprogramming of MSH2-deficient EC cells , including reduced oxidative phosphorylation and increased susceptibility to glycolysis suppression.\nKIFC1 promoted aerobic glycolysis in endometrial cancer cells by regulating the HMGA1/c"
    },
    "188-1802": {
      "type": "slc_pathway",
      "key1": "SLC22A5",
      "key2": "oxidative phosphorylation",
      "text": "Rats of the O+N group had a higher percentage of oxidative type I fibers and higher mRNA levels of genes encoding regulators of muscle fiber composition (Ppard, Ppargc1a, Ppargc1b), angiogenic factors (Vegfa, Vegfb), and genes involved in fatty acid utilization (Cpt1b, Slc25a20, Slc22a4, Slc22a5, Slc27a1) and oxidative phosphorylation (Cox4i1, Cox6a2) and a higher activity of the mitochondrial oxidative enzyme succinate dehydrogenase in muscle than rats of the O and L groups (P < 0.05).\nThese niacin-induced changes in muscle metabolic phenotype are indicative of an increased capacity of muscle for oxidative utilization of fatty acids and are likely mediated by the upregulation of Ppard, Ppargc1a, and Ppargc1b, which are key regulators of muscle fiber composition, mitochondrial biogenesis, angiogenesis, and genes involved in fatty acid catabolism and oxidative phosphorylation.\nfasting downregulated numerous metabolic pathways in human adipose tissue, including triglyceride and fatty acid synthesis, glycolysis and glycogen synthesis, TCA cycle, oxidative phosphorylation, mitochondrial translation, and insulin signaling"
    },
    "3-1802": {
      "type": "slc_pathway",
      "key1": "SLC1A3",
      "key2": "oxidative phosphorylation",
      "text": "Key pathways predicted to be modulated in astrocytes from EC-KO mice include oxidative phosphorylation and FOXO signaling, mitochondrial dysfunction and ephrin B signaling.\nGene set enrichment analysis revealed that 11 pathways were positively correlated to ITP, such as type I diabetes mellitus, intestinal immune network for IgA production, and oxidative phosphorylation.\nThe messenger RNA expression levels of the indicated genes, including HLA-DRB5, IGHV3-66, IFI27, FAM212A, PLD5, tumor necrosis factor (TNF)-α, interferon-γ, interleukin (IL)-1β, and IL-4, were significantly increased in patients with ITP compared with healthy humans, while MMP8, SLC1A3, CRISP3, THBS1, FMN1, and IL-10 were decreased."
    },
    "225-1797": {
      "type": "slc_pathway",
      "key1": "SLC25A4",
      "key2": "oxidative stress",
      "text": "Loci and pathway data in muscle suggest HS induced oxidative stress and that the stress response was moderated by ZH.\nIn addition, sh myoblasts displayed greater endoplasmic reticulum (e.g., increased CAPN activity and HSPA) and mitochondrial (e.g., mPTP formation, reduced mitochondrial membrane potential, elevated mitochondrial 4-HNE) stress.\nThe activation of HIF-1α in inflammatory macrophages may also drive proinflammatory cytokine production and complement activation and oxidative stress in infected lungs.\nHere, we show that the hypoxia-inducible factor (HIF-1α) transcriptional pathway is activated, perhaps due to a lack of oxygen or an accumulation of mitochondrial reactive oxygen species (ROS) in the lungs of adult Syrian hamsters infected with SARS-CoV-2.\nErythroid and B-cell development may be particularly vulnerable to Ant2 depletion-mediated mitochondrial dysfunction and oxidative stress.\nsh and myoblasts also displayed altered mitochondria-associated signaling (e.g., PPARGC1A, DNM1L, OPA1) and protein content (e.g., SLC25A4, VDAC1, CYCS).\nOmega-3 supplementation also increased the capacity for mitochondrial reactive oxygen species emission without altering the content of oxidative products, suggesting the absence of oxidative damage.\nTogether, these data demonstrate an essential role for autophagy in protecting myoblasts from mitochondrial oxidative stress and apoptotic signaling during differentiation, as well as in the regulation of mitochondrial network remodelling and myogenesis.\nSenescence, oxidative stress, and mitochondrial dysfunction are known contributory factors.\nProteomic analysis further revealed specific deficits in the mitochondrial ATP synthase (Atp5a1) within complex V and in the ATP/ADP translocase (Slc25a4).\nIn adipose, 4 loci (MISP3, APOL6, SLC25A4, and S100A12) were DE due to ZH on day 3, and 2 (RRAD, AL"
    },
    "1797-1856": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "colorectal cancer(CRC)",
      "text": "This disruption induced oxidative stress, ultimately resulting in cell death and reduced cell viability.\nWe can conclude that LH revealed the anticancer effect against the DMH induced CRC via suppression of inflammation and oxidative stress.\nthese results showed that the downregulation of miR-222-3p reduced oxidative stress, caspase-3 activity, IL-1β and TNF-α in DSS-induced NCM460 cells.\nData showed that l-carnitine and acetyl-l-carnitine reduced cell viability ( < 0.001), modulated cellular bioenergetics, and induced oxidative stress ( < 0.001).\nIn conclusion, WMP alleviated the AOM/DSS-induced CAC through inhibition of inflammation and oxidative stress by regulating AHCY-mediated hedgehog signaling in mice.\nIn summary, inhibiting miR-222-3p in IECs attenuates oxidative stress by targeting BRG1 to activate the Nrf2/HO-1 signaling, thereby reducing colonic inflammation and tumorigenesis.\nMoreover, HO-induced oxidative stress rescued FoxM1 expression in the presence of DDW treatment, and overexpression of FoxM1 was demonstrated to abolish the DDW-mediated tumor suppressive effects.\nThrough a series of in vitro and in vivo Nrf2 knockout mouse experiments, we found that AG and its components activate the Nrf2 pathway and decrease the oxidative stress in macrophages (mΦ) and colon epithelial cells in vitro.\nPPI and pH8 treatment (alkalization) of CMT93 mouse colon cancer cells inhibited cell growth and invasion, increased oxidative stress and apoptosis, and decreased mitochondrial volume and protein levels of cyclin D1 and phosphorylated extracellular signal-regulated kinase (pERK) 1/2.\nSpecifically, the suppression of cGAS through siRNA-mediated knockdown or doxycycline-inducible knockout reversed this metabolic switch, resulting in increased OXPHOS activity, elevated production of OXPHOS byproduct reactive oxygen species (ROS), and consequently caused oxidative stress."
    },
    "1796-2770": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "intrahepatic cholangiocarcinoma",
      "text": ""
    },
    "1794-2741": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "embryonal carcinoma",
      "text": ""
    },
    "1801-2001": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Bone cancer",
      "text": "We demonstrated that inhibiting miR-105-5p decreased viability and induced apoptosis.\nAIL inhibited the proliferation of human OS cells and induced apoptosis through the ERS pathway.\nPA induced apoptosis in osteosarcoma cells through a decrease in mitochondrial membrane potential.\nIn vitro, PSD dose-dependently induced apoptosis and inhibited the viability of HOS and K7M2 cells.\nHEA significantly decreased osteosarcoma cell viability and induced apoptosis in a dose- and time-dependent manner.\nIn in vitro studies, shRNA-mediated RNF135 knockdown in human OS cells inhibited proliferation and induced apoptosis.\nWe found that downregulation of USP22 could inhibit Sao-2 cell proliferation, migration, invasion, and induce apoptosis.\nMCAM was upregulated in OS, and MCAM overexpression promoted OS cell growth, invasion and migration and inhibited apoptosis.\nGO-Y030 dose-dependently reduced viability and induced sub-G1 arrest and apoptosis in human osteosarcoma U2OS and 143B cells.\nOn the other hand, activation of VEGFR2 decreased mitochondria-dependent apoptosis rate through VEGFR2-VARP-PI3K-AKT signalling.\nCDKN2C-OE combined with IR inhibited cell viability and proliferation, promoting apoptosis in vitro and inhibiting tumor growth in vivo.\nAdditionally, downregulation of ZNF560 resulted in decreased cell viability, fewer colonies, and induced apoptosis of osteosarcoma cells.\nOur findings revealed a wavelength- and time-dependent decrease in cell viability, accompanied by increased apoptosis and oxidative stress.\nSilencing of BCAR4 inhibited osteosarcoma cell proliferation and migration while promoting cellular apoptosis, primarily mediated by miR-1260a.\nUpregulation of COL12A1 promoted cell growth, accelerated cell cycle progression, and enhanced migration and invasion while inhibiting apoptosis.\nITGB3-KD had a radiosensitizing effect on oste"
    },
    "1797-1868": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "lung cancer",
      "text": ""
    },
    "367-1801": {
      "type": "slc_pathway",
      "key1": "SLC38A1",
      "key2": "apoptosis",
      "text": "Knockdown of SLC38A1 inhibited cell viability and cell cycle progression, induced apoptosis, and suppressed tumor growth in vivo.\nMoreover, METTL3 silencing inhibited cell viability, cell cycle progression, intracellular glutamine content, and induced apoptosis, but these effects were reversed by SLC38A1 overexpression.\nCircRUNX1 promoted CRC cell growth, metastasis and glutamine metabolism and repressed apoptosis by elevating SLC38A1 through sponging miR-485-5p, which might provide a novel target for CRC treatment.\nCircRUNX1 deficiency restrained CRC cell colony formation, migration, invasion and glutaminolysis and induced apoptosis in vitro as well as blocked tumour growth in vivo.\nWe suggest that hsFLT1 exerts an inhibitory influence on placental vascularization by reducing Vegf signaling, which leads to apoptosis in fetal vessels, impairing placental differentiation, and the nutrient exchange function of the labyrinth.\nWe describe how Slc38a2 senses amino acid availability and passes this onto intracellular signaling pathways and how it regulates protein synthesis, cellular proliferation and apoptosis through the mechanistic (mammalian) target of rapamycin (mTOR) and general control nonderepressible 2 (GCN2) pathways.\nMoreover, miR-485-5p overexpression repressed the malignant behaviours of CRC cells, with SLC38A1 elevation overturned the impacts.\nActivation of PPARs may in turn affect nutrient transport, PG synthesis, angiogenesis, apoptosis, or cell proliferation in this tissue.\nThe effects of circRUNX1 knockdown on CRC cell colony formation, migration, invasion, apoptosis and glutaminolysis were reversed by miR-485-5p inhibition.\nSuppression of endogenous SNAT1 leads to cell growth inhibition, cell cycle arrest, and apoptosis of 4T1 cells and lowered the phosphorylation level of Akt."
    },
    "1796-1821": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Germ Cell Tumor",
      "text": "Ferroptosis, driven by iron-dependent lipid peroxidation (LPO), enhances immunogenicity through damage-associated molecular pattern (DAMP) release and depletion of immunosuppressive cells.\nTargeting ferroptosis emerges as a promising strategy to enhance immunotherapy efficacy, prompting our investigation of antiplatelet agents that simultaneously promote ferroptosis and mitigate thromboembolic risks.\nIn melanoma, dysregulation of these pathways contributes to tumor progression and immunosuppression, yet their targeted activation reshapes the tumor microenvironment (TME) to synergize with ICIs.\nVorapaxar enhances immunotherapy-induced tumor ferroptosis and antitumor immunity across diverse melanoma models, including B16F10 tumor-bearing mice, Braf/Pten-driven spontaneous melanoma mice, and peripheral blood mononuclear cell (PBMC)-humanized mice.\nMechanistically, vorapaxar binds forkhead box O1 (FOXO1), inhibits its phosphorylation at Ser256, and facilitates nuclear translocation to upregulate heme oxygenase 1 (HMOX1), promoting mitochondrial iron overload and mitochondria-associated ferroptosis.\nstudies demonstrated that exogenous iron ions in PFE-PEG NPs induced ferroptosis through glutathione (GSH) depletion and glutathione peroxidase 4 (GPX4) inactivation, whereas EA-triggered caspase-mediated apoptosis and concurrently suppressed melanin synthesis via its intrinsic pharmacological activity.\nMechanistic analysis further revealed that the PFE-PEG NPs suppressed melanoma glycolysis, thereby disrupting metabolic homeostasis in the tumor microenvironment.\nexperiments demonstrated the potent inhibition of melanoma growth and metastasis by PFE-PEG NPs.\nThis work establishes a multimodal therapeutic strategy that coactivates ferroptosis and apoptosis while disrupting tumor metabolic dependencies, thereby achieving synergistic antitumor efficacy against melanoma.\nMechanistically, iEV-150 suppressed NF2 expression, disrupted the N"
    },
    "227-1797": {
      "type": "slc_pathway",
      "key1": "SLC25A6",
      "key2": "oxidative stress",
      "text": "Transcript levels of NFE2L2 (NRF2) and NF-κB1 were elevated, coinciding with reduced expression of the mitochondrial transporter gene SLC25A6, suggesting a compensatory response to oxidative stress.\nFurthermore, carvacrol has been shown to reduce VDAC1 protein expression, improve mitochondrial function and energy metabolism by regulating MMP, mPTP opening, ROS levels, and ATP production, and increase SLC25A6 protein expression.\napoptosis was reduced, enzymatic activity of cytochrome C oxidase (COX) and superoxide dismutase and expression of uncoupling protein 2, voltage-dependent anion channel 1, and Bcl 2 were upregulated and SLC25A6, MDA levels were downregulated.\nIt also decreased oxidative stress levels, inhibited excessive tube formation capacity, and promoted cytoskeletal remodeling.\nThe results of this study demonstrate that carvacrol exerts a protective effect on human microvascular endothelial cells by improving mitochondrial function and alleviating oxidative stress through the inhibition of VDAC1.\nIn the mechanism of inflammatory injury, SLC25A6 may act as a downstream effector of VDAC1.\nA significant 10-fold reduction in hemoglobin subunit alpha (HbA1) RNA was observed in disease groups compared to controls, indicating compromised oxygen transport and cellular stress."
    },
    "1802-2296": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "ferroptosis-relative osteoarthritis",
      "text": ""
    },
    "112-1801": {
      "type": "slc_pathway",
      "key1": "SLC11A1",
      "key2": "apoptosis",
      "text": "Furthermore, higher concentrations of IL-33 were associated with a decrease in myocyte enhancer factor 2C (MEF2C) expression, a transcription factor that regulates synaptic function, and an increase in apoptosis, NOD2, and SLC11A1 in clade B infection.\nMoreover, the impact of SLC11A1 on apoptosis and intracellular ROS level confirmed the potential association between SLC11A1 and COAD cell apoptosis.\nSLC11A1 induced CCL2 and PD-L1 expression, thereby activating the JAK/STAT3 pathway.\nIn vitro experiments confirmed that modulation of a key LDCD regulator, SLC11A1, affected the proliferation and invasiveness of COAD cells.\nSLC11A1 deficiency constrained KIRC cell malignant phenotypes and immune response via regulating CCL2 and PD-L1-mediated JAK/STAT3 pathway, providing a promising therapeutic target for KIRC treatment.\nEffects of KIRC cells on macrophage polarization and the proliferation and apoptosis of CD8 T cells were analyzed using flow cytometry assays.\nThe GSVA suggested that DNA repair, oxidative phosphorylation, peroxisome, IL-6-JAK-STAT3 signaling, and apoptosis were crucial in the development of IDD.\nThis led to neuroinflammation which dysregulates synaptic function and apoptosis.\nFine mapping supports SIVA1 as a candidate gene controlling SAL1-mediated resistance and indicates that the proposed cell-death mechanism associated with extracellular trap production, ETosis, likely functions through the CD27/Siva-1-mediated apoptotic pathway.\nThe causative agent, , produces mycolactone, a macrolide toxin, which causes apoptosis of mammalian cells.\nbovis (P<0.01), produced more nitric oxide (P<0.05) and were slightly more prone to undergo apoptosis than susceptible cells.\nbovis field strain induced more apoptosis than BCG, although the difference was not significant."
    },
    "1801-2477": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Kidney renal clear cell carcinoma (KIRC)",
      "text": "NF-κB pathway dysregulation, a common driver of therapy resistance in cancer, promotes survival by suppressing apoptosis.\nFurthermore, PLCL1 decreased lipid accumulation through UCP1-mediated lipid browning and facilitated tumor apoptosis by activating p38 phosphorylation.\nWe have demonstrated for the first time that CEP55 directly regulated RACGAP1 expression, and downregulation of RACGAP1 blocked ccRCC mitotic division at the G1 phase and induced apoptosis.\nThis study aims to fill this gap by demonstrating through a series of experiments that moscatilin can effectively inhibit the proliferation and migration of ccRCC and induce its apoptosis process.\nIn vitro, experiments demonstrated that ARPC1B knockdown suppressed ccRCC cell proliferation and induced apoptosis through the BAX-Bcl-2/c-caspase3/c-PARP axis, which was further validated by in vivo studies.\nFunctionally, miR-205-5p inhibition or CUL4B overexpression could recover the inhibition mediated by circ_0003520 knockdown on ccRCC cell proliferation, migration, invasion, and angiogenesis, as well as the enhancement of cell apoptosis.\nFurthermore, co-culture experiments were performed and we found that sunitinib-resistant RCC cells-derived exosomes (R-exos) promoted cell proliferation and upregulated proliferation-related genes cyclin D1 (CCND1) and proliferating cell nuclear antigen (PCNA) expression, and inhibited apoptosis and the expression of Bax and Caspase-3 of sunitinib-resistant RCC (RCC/R) cells by delivering lncRNA small nuclear RNA host gene 16 (SNHG16).\nKnockdown of RDM1 arrested the cell cycle, promoted cell apoptosis, and apparently suppressed ccRCC cell growth in vitro and in vivo.\nSilencing of KRM2 in RCC cells also significantly inhibited cell proliferation and migration and facilitated apoptosis and ferroptosis.\nAnd decreasing ABCG1 expression decreased the prolif"
    },
    "288-1797": {
      "type": "slc_pathway",
      "key1": "SLC27A2",
      "key2": "oxidative stress",
      "text": "This is associated with a number of adverse effects, including lipid deposition in cardiomyocytes, elevated levels of inflammation and oxidative stress, impaired cardiac function, decreased cardiomyocyte viability, and increased apoptosis.\nAn excessively high-fat diet has been demonstrated to result in an increased expression of solute carrier family 27 member 2 (Slc27a2/FATP2) on cardiomyocyte membranes.\nThe reduction of Slc27a2 expression downstream of this receptor has been demonstrated to enhance lipid metabolism and mitigate lipid overdeposition in cardiomyocytes, thereby conferring cardioprotection.\nThe administration of semaglutide was observed to partially reverse the cardiac dysfunction induced by an excessive high-fat diet, to protect cardiomyocytes, and to significantly reduce the expression of Slc27a2.\nMeanwhile, RT-qPCR and Western Blotting demonstrated that the mechanism of the antioxidant effect of EEP reversed the mRNA expression of EHHADH, HMGCR and SLC27A2 and the protein expression of FABP and HMGCR in AMPK and PPAR signaling pathways.\nThis study was designed to evaluate the antioxidative effect of ethanolic (EEP) on hyperthyroidism-induced oxidative stress mice using an integrated strategy combining transcriptomics with network pharmacology analysis.\nThe results showed that EEP significantly changed the thyroid-stimulating hormones and oxidative stress markers.\nHowever, the effects of EP on oxidative stress induced by hyperthyroidism have not yet been studied."
    },
    "1797-2209": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "1801-1897": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Heart Tumor",
      "text": "Gain-of-function analysis indicated that overexpression of miR-217 inhibited the proliferation and promoted the apoptosis of the primary CM cells.\nWhen CM cells were treated with si-AEG-1, si-AEG-1 attenuated IGF-1-induced CM cell growth and enhanced cell apoptosis.\ninducing apoptosis (miR-634 and miR-122), suppressing production of interleukins (miR-217), and reducing cell proliferation (miR-218).\nMoreover, downregulation of IL-6 by small interference RNA (siRNA) mimicked the tumor-suppressive effects of miR-217 in CM.\nThe proteolytic activation of caspase9 and caspase3, crucial mediators of the mitochondrial apoptotic pathway, are also observed within 6 min of exposure to this drug.\nHowever, recent studies have now demonstrated that chelerythrine can induce the loss of mitochondrial membrane potential (ΔΨm), a membrane permeability transition (MPT), and the subsequent activation of the mitochondrial apoptotic pathway, even in the cells deficient in Bax and Bak.\nFunctionally, we found the knockdown of AEG-1-inhibited G1/S transition and tumor formation of CM cells.\nThe extrinsic Fas/FasL-dependent apoptosis pathways in cardiac myxomas were proved by both RNA and protein levels.\nIn our current study, we show that chelerythrine induces the rapid apoptotic death of H9c2 cardiomyocyte-derived cells within 8 min of treatment.\nFurthermore, rescue experiments pointed out that restoration of IL-6 expression abrogated the anti-proliferative and pro-apoptotic effect induced by miR-217 overexpression in CM cells.\nIn cardiac myxoma, apoptosis documented by TUNEL (70.9% ± 17.6%) and the caspase-3 (66.5% ± 32.5%) final common pathway is characterized by the extrinsic Fas/ FasL dependent pathway (positive stained 70.9% ± 19.2%;"
    },
    "1796-2209": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "5-1800": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "migration",
      "text": "Knockdown SLC1A5 in gastric cancer cells suppressed cell proliferation, caused G0/G1 arrest and inhibited cell invasion as well as migration partly by inactivated mTOR/p-70S6K1 signaling pathway.\nMoreover, ABHD11-AS1 enhanced the abilities of cell proliferation, migration, and invasion, inhibited apoptosis in vitro, promoted tumorigenesis in vivo via sponging miR-199a-5p and then induced SLC1A5 activation.\nKnockdown of SLC1A5 decreased proliferation, colony formation, and migration, but increased apoptosis and increased sensitivity to chemotherapy drugs.\nSLC1A5var knockdown reduced cancer cell proliferation, colony formation, and migration, whereas SLC1A5var overexpression increased cell proliferation and migration.\nOverexpression of β-catenin in SLC1A5-knockdown HCC cell lines could augment Vimentin and N-cadherin expression, suppress E-cadherin expression, and increase the migration and drug resistance.\nCirc_0062558 promoted TNBC progression by enhancing proliferation, survival, migration, invasion, and glutamine metabolism via miR-876-3p/SLC1A5 axis, which was helpful for understanding the carcinogenic roles of circ_0062558.\nFinally, the overexpression of SLC1A5 markedly promoted proliferation, migration, and invasion of pancreatic cancer cells.\nThe inhibitory effects of miR-622 enrichment on EC cell proliferation, migration, EMT and glutamine metabolism were recovered by SLC1A5 overexpression.\nUpon further investigation, we found that SLC1A5 is a suppressor of ferroptosis in glioma, and SLC1A5 knockdown inhibited the proliferation and migration of glioma cells.\nFurthermore, loss-of-function assays using small interfering RNAs or an SLC1A5 inhibitor (V9302) in human ccRCC cell lines (A498 and Caki1) showed that inhibition of SLC1A5 significantly suppressed tumor growth, invasion, and migration."
    },
    "1800-2269": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Nonsmall cell lung cancer (NSCLC)",
      "text": ""
    },
    "1795-2133": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "autism spectrum disorders",
      "text": ""
    },
    "405-1795": {
      "type": "slc_pathway",
      "key1": "SLC43A3",
      "key2": "proliferation",
      "text": "Furthermore, the orphan protein SLC43A3, a core member of the 7-SLC classification system, was identified as a key facilitator of tumour cell proliferation and migration, suggesting its potential as a novel target for cancer therapy.\nThey play a crucial role in regulating the metabolism and functions of malignant cells and immune cells within the tumour microenvironment, making them a promising target in cancer therapy.\nOur findings unveiled specific SLC expression patterns and their correlation with the immune-suppressive microenvironment and metabolic status.\nThe 7-SLC classification system was validated in distinguishing subgroups within the microenvironment, specifically identifying subsets involving malignant cells and tumour-associated macrophages.\nCurrently, reshaping its tumour microenvironment has emerged as an appealing strategy to enhance therapeutic efficacy.\nWe established a classification system comprising 7-SLCs to predict the prognosis of glioma patients and their potential responses to immunotherapy and chemotherapy.\nAs the largest group of transmembrane transport proteins, solute carrier proteins (SLCs) are responsible for the transmembrane transport of various metabolites and ions."
    },
    "166-1795": {
      "type": "slc_pathway",
      "key1": "SLC19A2",
      "key2": "proliferation",
      "text": "Mutations in the SLC19A2 (c.1409insT) promote apoptosis and inhibit cell proliferation, thereby upregulating the mRNA and protein levels of ERS-associated factors glucose-regulated protein 78, protein kinase R-like endoplasmic reticulum kinase, C/EBP homologous protein, and activating transcription factor 4.\nFlow cytometry and cell counting kit-8 were used to analyse the effects of SLC19A2 (c.1409insT) mutation on cell apoptosis and proliferation, respectively.\nWhile thiamine is generally not limiting for cell proliferation, a DNA-barcode competition assay identifies leukemia cell lines that grow suboptimally under low thiamine and are characterized by low expression of solute carrier family 19 member 2 (SLC19A2), a thiamine transporter.\nSLC19A2 is necessary for optimal growth and ASNase resistance, when standard medium thiamine is lowered ~100-fold to human plasma concentrations."
    },
    "226-1797": {
      "type": "slc_pathway",
      "key1": "SLC25A5",
      "key2": "oxidative stress",
      "text": "Lower VT (LHe, -269 °C) positively affected the mRNA expression levels of apoptotic genes (BAD, BID, BTK, TP53, and TP53I3) and mitochondrial genes (COX6B1, DERA, FIS1, NDUFA1, NDUFA4, PRDX2, SLC25A5, TFB1M, and UQCRB), and reduced oxidative stress from freezing.\nEventually, the presence of multiple rare sequence variants in the Solute Carrier Family 25 Member 5 (SLC25A5) gene is suggestive of the role of this gene as a key factor linking mitochondria metabolism, ADP/ATP ratio and oxidative stress thus affecting extracellular matrix homeostasis and activation of pro-osteogenic factors.\nErythroid and B-cell development may be particularly vulnerable to Ant2 depletion-mediated mitochondrial dysfunction and oxidative stress.\nAnt2 depletion caused anemia in a cell-autonomous manner by maturation arrest of erythroid precursors with increased reactive oxygen species and premature deaths.\nMoreover, data reveal that changes in mitochondrial metabolic pathways are sustained by a genetic background and emphasize that a persistent chronic oxidative stress can further influence extracellular matrix homeostasis and cell signalling through the TGFβ-BMP axis.\nFurthermore, several signalling pathways essential for normal cellular function (actin cytoskeleton signalling, HGF signalling, NRF2-mediated oxidative stress, integrin signalling, calcium signalling) were also significantly regulated."
    },
    "1797-1850": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "liver cancer",
      "text": "Oxidative stress can be considered as a bona fide tumor promoter, contributing to the initiation and progression of liver cancer.\nOxidative Stress Promotes Liver Cancer Metastasis via RNF25-Mediated E-Cadherin Protein Degradation.\nTQ supplementation appears to suppress the development of DEN-initiated liver cancer by reducing oxidative stress, activating the intrinsic mitotic apoptosis pathway, and retaining the antioxidant enzymes.\nThis unique mechanism underscores αKG's potential as a liver cancer therapy by harnessing oxidative stress and disrupting metabolic signaling.\nMechanistically, HZSJF upregulated Keap1 and suppressed Nrf2/HO-1 signaling, thereby enhancing oxidative stress.\nHZSJF promotes ferroptosis and suppresses HCC progression by targeting the Keap1/Nrf2 axis.\nIn vivo experiments also showed that CG dose-dependent regulated oxidative stress and TRX1 expression, and promoted the expression of apoptotic proteins to inhibit HCC growth.\nprimary BAs induced oxidative stress, whereas the secondary BA lithocholic acid inhibited T cell function through endoplasmic reticulum stress, which was countered by ursodeoxycholic acid.\nFurther targeted proteomic and metabolomic studies demonstrated a decrease in GNMT transmethylation, increased flux through the polyamine pathway, and increased oxidative stress production contributing to NASH pathogenesis.\nTherefore, these findings suggest that TQ has a promising hepatoprotective property, as indicated by its potential to effectively suppress TAA-induced liver fibrosis in rats by inhibiting oxidative stress and inflammation via TGF-β/Smad signaling.\nThese findings suggest that cataranthine may exert its anticancer effects by reducing oxidative stress and promoting apoptosis, while decrease in miR34 and miR29 as well as increase in Nrf2 and Bcl2 may act as resistance mechanisms in cancer cells."
    },
    "1802-1839": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "bladder cancer",
      "text": "These findings from our study indicate that the down-regulation of GADD45B promotes the shift of cell mitochondrial oxidative phosphorylation towards glycolysis, thereby facilitating the progression of bladder cancer.\nExamination of qPCR array data demonstrated a noteworthy inhibition of mitochondrial oxidative phosphorylation in bladder cancer tissue, as evidenced by the down-regulation of a majority of genes associated with mitochondrial energy metabolism.\nThis enhanced a significant increase (p ≤ 0.001) in PDK1 to significantly downregulate PDH (p ≤ 0.001) in order to block oxidative phosphorylation in favor of glycolysis.\nAn increase in glucose uptake, decrease in normal cellular glycogen storage, and overproduction of lactate are consequences of decreased oxidative phosphorylation and inability to reuse glucose into the pentose phosphate and de novo fatty acid synthesis pathways.\nUsing a bladder cancer model of nongenetic plasticity, we discovered that rapid transition to drug resistance entails upregulation of mitochondrial gene expression and a corresponding metabolic shift towards the tricarboxylic acid cycle and oxidative phosphorylation.\nGO and KEGG pathway enrichment analyses indicated that upregulated genes were significantly enriched in the cell cycle and the negative regulation of the apoptotic process, while the downregulated genes were mainly involved in cell proliferation, cell adhesion molecules and oxidative phosphorylation pathways (P<0.05).\nOur results demonstrate that depletion of ARRB1 decreased glycolytic rate and induced metabolic reprogramming towards oxidative phosphorylation.\nSFN strongly downregulates ATP production by inhibiting glycolysis and mitochondrial oxidative phosphorylation (OXPHOS).\nOur findings reveal a distinct metabolic phenotype in AA BLCA characterized by elevated mitochondrial oxidative phosphorylation (OXPHOS), particularly through the activation of complex I.\nProteomic analyses revealed that several metabolic pathways, including the oxidative phosphorylation pathway and glycolysis, were significantly downregulated in salirasib-treated BC cells.\nThe ALA-mediated PpIX synthesis in UC cells was suppressed by beta-alanine, an"
    },
    "1796-2751": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "acute myeloid leukemia",
      "text": ""
    },
    "1802-1872": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "breast cancer(BC)",
      "text": "Our study reveals that aneuploid HMECs exhibit an increased reliance on pyrimidine biosynthesis and mitochondrial oxidative phosphorylation genes and demonstrate heightened fitness advantages upon loss of tumor suppressor genes.\nPRDX6 reduced ROS levels, upregulated mitochondrial transcription factor A (TFAM) expression, and promoted mitochondrial complex subunit expression and OXPHOS.\nCollectively, our findings demonstrate that LINC00667 inhibits breast cancer progression by promoting TRIM33-mediated ubiquitination and subsequent degradation of POTEE, thereby regulating mitochondrial OXPHOS activity.\nOxidative phosphorylation (OXPHOS) is a metabolic vulnerability of TNBC, but the molecular mechanism responsible for the enhanced OXPHOS remains unclear.\nPEG-Dendron-EPI@TPP-LND significantly suppressed tumor growth and prevented compensatory glycolytic activation without inducing observable systemic toxicity.\nFunctional characterization revealed that overexpression of LINC00667 suppresses malignant progression, while its knockdown promotes oncogenic phenotypes in BC.\nWe found that LINC00667 reduces POTEE expression and inhibits mitochondrial oxidative phosphorylation (OXPHOS).\nSpatially resolved multiomics analyses reveal that copper zonation drives a tumor metabolic preference for oxidative phosphorylation (OXPHOS) over glycolysis and promotes tumor metastatic and immune-desert phenotypes.\nOXPHOS inhibition via TPP-LND was synergized with chemotherapy via the EPI prodrug to effectively suppress tumor growth and mitigate systemic toxicity of TPP-LND and EPI.\nThis work demonstrated a new regulatory pathway of TNBC to promote the expression of mitochondrial genes by upregulating the nuclear gene LRPPRC, resulting in increased OXPHOS.\nPRDX6 maintains intracellular homeostasis by reducing ROS and promotes mitochondrial biogenesis and OXPHOS through TFAM-dependent and -independent pathways, driving BRCA progression.\nGAA inhibited OXPHOS metabolism by directly binding LRPPRC, causing LRPPRC degra"
    },
    "313-1797": {
      "type": "slc_pathway",
      "key1": "SLC31A1",
      "key2": "oxidative stress",
      "text": "Moreover, Cu supplementation intensified cisplatin-induced cell death, mitochondrial dysfunction, and oxidative stress in HK-2 cells, indicating the involvement of cuproptosis in cisplatin-induced AKI, whereas these changes were partially counteracted by SLC31A1 knockdown.\nThe expressions of the four markers were significantly positively correlated with the abnormal activation phenotypes of oxidative stress, the ROS and glucometabolic pathways, and suppressive immune infiltration.\nCluster and pseudotime analyses showed that macrophages with high SLC31A1 expression are often in advanced stages of cell growth, accompanied by notable changes in oxidative stress.\nThese data confirmed that PTBP1 plays a pivotal role in promoting the oxidative response and cuproptosis in Alzheimer's disease models via the SLC31A1 pathway.\nELF3 transcriptionally activated SLC31A1 to trigger cuproptosis that drove cisplatin-induced AKI through mitochondrial dysfunction, indicating that SLC31A1 might be a promising therapeutic target to mitigate AKI during cisplatin chemotherapy.\nICT consequently inhibited the FDX1-mediated cuproptosis pathway, reducing dihydrolipoamide S-acetyltransferase (DLAT) oligomerization, modulating cuproptosis sensitivity proteins, restoring copper homeostasis by increasing ATPase copper transporting beta (ATP7B) and decreasing solute carrier family 31 member 1 (SLC31A1), and suppressing the lipoylation pathway.\nE74 like ETS transcription factor 3 (ELF3) could directly bind to SLC31A1 promoter and promote its transcription.\nAccording to cross-sectional research, up to 50% of patients with micronutrient imbalances have been linked to oxidative stress, mitochondrial dysfunction, reduced ATP production, and the prognosis of various diseases.\nDOX administration induced significant cardiac dysfunction, oxidative stress, and upregulation of cuproptosis markers.\nThe enrichment score of the oxidative stress, ROS, metabolism, and inflammatory pathways was calculated, and we found that these pathways were significantly activated in IA"
    },
    "1797-1839": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "bladder cancer",
      "text": "Our results show that increased prolidase seems to be associated with increased NO levels and oxidative stress along with decreased antioxidant levels in bladder cancer.\nThe results suggested that these compounds could inhibit cell proliferation by p38-MAPK and/or c-Jun medicated caspase-3 activation and reduce the oxidative stress status in bladder cancer.\nTherefore, the co-treatment of EXCC/cisplatin reduces the proliferation of bladder cancer cells via oxidative stress-mediated mechanisms with normal cell safety.\nWe conclude that BZ can be activated by 5-LOX to produce ROS and oxidative stress, which may be associated with bladder cancer caused by BZ.\nAlso, the serum levels of ROMO1, TAC, TOS, and Oxidative Stress Index (OSI) were increased in patients with bladder cancer compared with healthy subjects.\nSelenocompounds are suggested to decrease oxidative stress caused by some chemicals, and selenium supplementation was shown to reduce the risk of bladder cancer.\nIt can be concluded that the overexpression of the ROMO1 gene is associated with advanced grades of bladder cancer as well as an increase in oxidative stress conditions.\nMoreover, genetic depletion of TIMM44 also arrested bladder cancer xenograft growth in nude mice, leading to oxidative stress, ATP reduction and Akt-S6K1 inhibition in xenograft tissues.\nOxidative stress and reactivation of long interspersed element-1 (LINE-1) are coincidently observed in bladder cancer (BlCa), but the mechanistic connection between these two oncogenic phenomena is unknown.\nAlthough, increased oxidative stress and hypomethylation of long interspersed nuclear element-1 (LINE-1) associate with bladder cancer (BCa) development, the relationship between these alterations is unknown.\nMoreover, PON2 overexpression in T24 cells led to a significant increase in tumor cell proliferation and resistance to oxidative stress.\nIncreased oxidative stress is a result of either increased ROS/RNS production or a decrease of antioxidant defense mechanisms.\nEnvironmental chemicals have been associated with the regulation of oxidative stress markers, which have the potential for the development of bladder cancer."
    },
    "21-1802": {
      "type": "slc_pathway",
      "key1": "SLC2A13",
      "key2": "oxidative phosphorylation",
      "text": "Oxygen consumption rates also decreased upon BPTES treatment, indicating a glutamine dependency for oxidative phosphorylation.\nThe current study suggests that BCR-ABL-positive cancer cells make use of enhanced glutamine metabolism to maintain TCA cell cycle activity in glycolytic cells.\nLactate and pyruvate levels were increased in BCR-ABL-expressing cells even under normoxia, coinciding with enhanced glutaminolysis which occurred in an HIF1/2-dependent manner.\nExpression of the glutamine importer SLC1A5 was increased in BCR-ABL+ cells, coinciding with an increased susceptibility to the glutaminase inhibitor BPTES."
    },
    "383-1801": {
      "type": "slc_pathway",
      "key1": "SLC39A6",
      "key2": "apoptosis",
      "text": "Experimentally, the suppression of SLC39A6 expression promoted ESCC cell apoptosis but abrogated proliferation and invasion, and induced an EMT phenotype that included enhanced expression of E-cadherin, loss of vimentin, and morphological changes in ESCC cells in vitro.\nAnd the zip6 deficiency increases caspase-related cell apoptosis in both zebrafish cells and human T cells.\nAmong them, FADD, FIBP, FIBP, GNE, IGF1R, MKL1, PIGP, and SLC39A6 were identified in the Reactome pathway database as involved in signal transduction, transcription, protein metabolism, immune system, cell cycle, and apoptosis.\nThe biological effects of SLC39A6 (LIV-1) and GrpE-like 1 (GRPEL1) on mitotic exit and apoptosis were evaluated both in vitro and in vivo using flow cytometry, western blotting, xenografts and time-lapse imaging.\nAnd the effects of SLC39A6 silencing by siRNA on cell proliferation, apoptosis, and invasiveness, as well as the proteins involved in epithelial-to-mesenchymal transition (EMT) of esophageal cancer cells, were studied.\nLIV-1-GRPEL1 axis depletion works to reduce the mitotic arrest by inducing PP2A-B55α phosphates activity, while inhibit apoptosis by banding AIF and preventing the latter's release into the nucleus.\nThese data demonstrate that LIV-1-GRPEL1 axis dually regulates mitotic exit as well as apoptosis by interacting with PP2A B55α and AIF.\nOverexpression of LIV-1 led to direct apoptosis.\nMost Zn-dependent genes that were expressed differently between early and late passages were correlated with changes in the expression of anti-apoptotic genes."
    },
    "32-1800": {
      "type": "slc_pathway",
      "key1": "SLC4A7",
      "key2": "migration",
      "text": "Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells.\nIn addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment.\nIn vitro and in vivo experiments showed that dysregulation of SLC4A7 had minor influence on the proliferation of HNSCC but impacted HNSCC's migration and invasion.\nRNA-seq, KEGG pathway enrichment analysis and Western blot further revealed that downregulation of SLC4A7 in HNSCC cells inhibited the PI3K/AKT pathway.\nOur findings suggest that SLC4A7 promotes EMT and metastasis of HNSCC through the PI3K/AKT/mTOR signaling pathway, which may be a valuable predictive biomarker and potential therapeutic target in HNSCC.\nMeanwhile, SLC4A7 could promote epithelial-mesenchymal transition (EMT) in HNSCC.\nIn this study, we identified the Na -coupled bicarbonate transporter, SLC4A7, play essential roles in the metastasis of HNSCC.\nWe propose that axial pHi gradients enhance VSMC migration whereas global acidification inhibits VSMC proliferation and media hypertrophy after carotid artery ligation.\nwith [Formula: see text] present), NBCn1-mediated [Formula: see text] uptake raises VSMC pHi and promotes filopodia, VSMC migration, and hypertrophic inward remodelling.\nKnock-out or pharmacological inhibition of NBCn1 also reduces filopodia and lowers initial rates of VSMC migration after scratch-wound infliction.\nInterventions to reduce H(+)-buffer mobility (omission of [Formula: see text] or inhibition of carbonic anhydrases) re-establish axial pHi gradients, filopodia, and migration rates in explants from NBCn1"
    },
    "1800-2178": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Ras mutant pancreatic ductal adenocarcinom",
      "text": ""
    },
    "1796-1839": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "bladder cancer",
      "text": "After adding ferroptosis activator, the viability of bladder cancer cells decreased, and the content of Fe and MDA increased.\nMechanistically, inhibition of the mTOR pathway and SREBP activity was found to reduce FADS2 expression and promote ferroptosis in bladder cancer.\nFunctionally, gain/loss-of-functional experiments illustrated that WTAP promoted the viability of bladder cancer cells and inhibited the erastin-induced ferroptosis.\nThis study suggests that MYH11 activates the PI3 K/AKT pathway by up-regulating the expression of NUPR1, and promotes bladder cancer progression by inhibiting ferroptosis and promoting M2 polarization of macrophages.\nTaken together, p53 activated the lipoxygenase activity of ALOX15B via inhibiting SLC7A11 to induce ferroptosis in bladder cancer cells, which provided insight into the molecular mechanism of the occurrence and development of bladder cancer.\nMechanistically, multiple rounds of sevoflurane exposure modulated lipid oxidation and lipogenesis in bladder cancer cells via the inhibition of Akt/mTOR/SREBP1 signaling, and reactivation of this signaling abrogated the influence of sevoflurane on ferroptosis and bladder cancer progression.\nIn bladder cancer cells, the compound tert-butylhydro-quinone (TBHQ), an activator of NRF2, suppressed erianin-induced ferroptosis.\nThis multifunctional nanomedicine effectively induces ferroptosis and growth inhibition in bladder cancer cells and patient-derived organoids.\nWe found that extracellular fluid from bladder cancer tissue promoted the growth and miR-217 expression of T24 cells and inhibited ferroptosis.\nMultiple rounds of sevoflurane treatment inhibited growth and metastasis and promoted reactive oxidative species (ROS) generation and ferroptosis in bladder cancer cells.\nKnockout of the rate-limiting enzyme GFPT1 in HBP metabolism inhibits O-GlcNAcylation, induces ferroptosis, and mitigates chemoresistance of orthotopic bladder cancer in mice."
    },
    "1802-2412": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "endometrial carcinoma (EC)",
      "text": "Endometrial cancer (EC) cells exhibit abnormal glucose metabolism, characterized by increased aerobic glycolysis and decreased oxidative phosphorylation.\nSubsequently, it is discovered that Ishikawa exhibits glucose metabolic reprogramming characterized by increased glycolysis and decreased oxidative phosphorylation.\nFunctional studies demonstrated metabolic reprogramming of MSH2-deficient EC, including reduced oxidative phosphorylation and increased susceptibility to glycolysis suppression.\nMoreover, agents specifically targeting the glycolysis and/or OXPHOS pathways can inhibit tumor cell growth and promote chemosensitization.\nThe pathway associated with oxidative phosphorylation (OXPHOS) was upregulated and have similar expression patterns in high-grade EC tissues and matched paracancerous tissues.\nFurthermore, overexpression of aurora kinase A and activation of oxidative phosphorylation were found in TP53-inactivated endometrial carcinomas, suggesting that the PI3K/mTOR and autophagy pathways are potential drug targets.\nPathways implicated in metastases included loss of PTEN activation and PI3K, AKT and PKA activation, leading to calcium signaling, oxidative phosphorylation and estrogen receptor-induced transcription, leading to platelet activation, epithelial-to-mesenchymal transition and senescence.\nAn increased expression of this protein seems to be a general feature of several malignant tumors that are able to reprogram their metabolism and switch from oxidative phosphorylation to aerobic glycolysis.\nOf note, women with metabolic syndromes (MetS), including obesity, hyperglycemia, dyslipidemia, and hypertension, have an increased risk of developing endometrial carcinoma (EC), suggesting a close link between metabolism and EC.\nOur present works elucidate that metabolism reprogramming is associated with high-grade, early-stage EC, particularly OXPHOS is upregulated.\nCurrently, it is commonly accepted that glycolysis is the main energy provider in EC cells, while OXPHOS is reduced or impaired.\nKEGG and GO analyses revealed that the genes positively correlated with CEBPA were enriched primarily in immune regulation and oxidative phosphorylation."
    },
    "1795-2532": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Pulmory arterial hypertension (PAH)",
      "text": "Functionally, Smurf1 inhibition decreased pathological endothelial proliferation and enhanced BMPR2-mediated Smad1/5/9 activation.\nSilencing of PLOD2 inhibits PI3K/AKT signaling to limit PASMC glycolysis which allows PASMC proliferation and migration in CIH-induced pulmonary arterial hypertension (PAH).\nIrisin suppresses proliferation of PDGF-induced PASMCs by promoting ubiquitination status of Enolase 1 via E3 ligase of down regulated protein 4 in neural precursor cell development.\nJag2 was upregulated under hypoxic conditions, promoting PASMC proliferation and migration and inhibiting apoptosis through NADPH oxidase 2 (NOX2)/reactive oxygen species (ROS) signaling.\nBosentan and macitentan also bind to the ET receptor, which is upregulated on SMCs and downregulated on endothelial cells in PAH, resulting in vasoconstriction, cell proliferation, and vascular remodeling.\nOur results suggest that IL-35 alleviates PAH-induced inflammation, apoptosis, and smooth muscle cell proliferation, reduces PAP, and restores vascular remodeling, thereby mitigating both structural and functional damage in PAH.\nSilencing of PLOD2 significantly inhibited the increase of RV/(LV + S) and RVSP, alleviated pathological changes of lung in CIH-induced mice and restrained the proliferation, migration, glycolysis and activation of PI3K/AKT in CIH-induced PASMCs.\nThe administration of Gö 6983 or the overexpression of IRS-1 effectively inhibited the activation of the PKC/IRS-1/ERK signaling pathway, leading to reduced proliferation and migration of PASMCs compared to stimulation with PDGF-BB alone.\nRecent studies indicate Sonic hedgehog (SHH) signaling is involved in the proliferation of human pulmonary arterial smooth muscle cells (hPASMCs) but the role of the SHH"
    },
    "1798-1819": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "skin cancer",
      "text": "Here, we report that VEGF-C enhances skin cancer migration, invasion and stemness through Slug up-regulation.\nThe VEGF-C-induced migration, invasion and stemness of skin cancer cells are also abrogated by the anti-VEGFR3 peptide.\nWe have previously shown that the stemness factor, Forkhead box D3 (FOXD3), is upregulated following inhibition of B-RAF-MEK signaling in mutant B-RAF melanoma cells.\nFascin regulates tumorigenesis and cancer cell stemness in melanoma through inhibition of the Hippo pathway kinase MST2 and the activation of transcription factor TAZ.\nWith the important role in stemness and skin CSC proliferation, the Wnt/β-catenin signaling pathway and its elements have the potential to be targets for skin cancer therapy.\nIn human mutant BRAF melanoma cells, the stemness transcription factor FOXD3 is rapidly induced by inhibition of ERK1/2 signaling and mediates adaptive resistance to RAF inhibitors.\nWe next showed that exposure of BRAF-mutated melanoma cells to MAPK pathway inhibitors enhanced stemness features by upregulating the expression of YAP/TAZ and downstream genes but surprisingly not SCD1.\nThese findings indicated that IL-32γ suppressed skin carcinogenesis through the inhibition of both stemness and the inflammatory tumor microenvironment by the downregulation of TIMP-1 and ITGAV via inactivation of NF-κB signaling.\nMelatonin significantly and synergistically enhanced vemurafenib-mediated inhibitions of proliferation, colony formation, migration and invasion and promoted vemurafenib-induced apoptosis, cell cycle arresting and stemness weakening in melanoma cells.\nThese important findings suggest that CD44v6 drives YAP1/TEAD signaling to enhance the CSCC cell cancer phenotype and that SFN treatment reduces CD44v6 level/function which, in turn, reduces YAP1/TEAD signaling leading to reduced stemness, EMT and tumor growth.\nDownregulated RNF128 activates Wnt signaling to"
    },
    "272-1800": {
      "type": "slc_pathway",
      "key1": "SLC25A51",
      "key2": "migration",
      "text": "Our findings reveal a novel lncRNA-microRNA-metabolic axis wherein LINC02802 facilitates NSCLC progression by reprogramming mitochondrial metabolism via miR-1976-mediated upregulation of SLC25A51.\nElevated SLC25A51 enhances mitochondrial NAD import, leading to an increased NAD/NADH ratio and promoting oxidative TCA cycle flux.\nMechanistically, LINC02802 acts as a competing endogenous RNA (ceRNA) for miR-1976, thereby relieving the suppression of solute carrier family 25 member 51(SLC25A51).\nFunctionally, this shift supports tumor cell proliferation and migration.\nRescue experiments confirmed that the oncogenic effect of LINC02802 is dependent on the miR-1976/SLC25A51 axis.\nInterestingly, either silencing LINC02802 with antisense oligonucleotides (ASOs) or treating cells with fludarabine phosphate, an SLC25A51 inhibitor, successfully reversed cisplatin resistance in lung cancer cells.\nTargeting this axis may offer therapeutic potential for metabolic intervention in NSCLC."
    },
    "250-1794": {
      "type": "slc_pathway",
      "key1": "SLC25A29",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1795-1831": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Neuroendocrine Tumor",
      "text": "In NECs, GSEA consistently showed downregulation of immune-related pathways and upregulation of proliferation-associated pathways compared to non-neuroendocrine tumor areas.\nGrade 3 neuroendocrine tumors have a lower Ki-67 proliferation index and tumor mutational burden compared to NECs.\nGrading neuroendocrine tumors using Ki-67 proliferation index (PI) is essential for prognostic assessment and therapeutic decision-making.\nIn the current World Health Organization (WHO) classification, well-differentiated grade 3 neuroendocrine tumors (G3-NETs) are distinguished from poorly-differentiated neuroendocrine carcinomas (NECs) based on morphology despite using the same proliferation indices, which poses diagnostic challenges.\nThe 5th edition World Health Organization classification of endocrine and neuroendocrine tumors categorizes MTC into low-grade and high-grade based on tumor necrosis, mitotic figures, and Ki-67 proliferation index, highlighting that histological grading and RET gene mutations are independent prognostic predictors.\nIn vivo studies demonstrate that KA reduces tumor growth and proliferation while promoting apoptosis, highlighting its potential as a therapeutic agent for neuroendocrine prostate cancer.\nHNF4α knockdown/knock-in experiments in VMRC-LCD and SBC5 (HNF4α-negative) revealed that HNF4α promoted cell proliferation by inhibiting apoptosis.\nTelotristat ethyl significantly decreased proliferation and serotonin secretion in a dose-dependent manner in GOT1 cells.\nTranscriptome sequencing identified CALCA as a key molecule in the synergistic inhibition of pNETs proliferation by SULF and KMP.\nGastrointestinal neuroendocrine tumors (GI-NETs) lack effective targeted options beyond somatostatin analogs and mTOR inhibitors.\nBoth GI-NET models expressed SYK and exhibited reduced growth upon SYK blockade, with dose-dependent suppression of viability and increased cytotoxicity relative to vehicle.\nCells were exposed to a selective SYK inhibitor (BI-1002494), and prolif"
    },
    "238-1795": {
      "type": "slc_pathway",
      "key1": "SLC25A17",
      "key2": "proliferation",
      "text": "sgRNA-mediated knockdown of SLC25A17 and SLC27A6 suppressed cell proliferation and migration in enzalutamide-resistant cells.\nFunctional assays demonstrated that SLC25A17 knockdown suppressed proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion.\nSLC25A17 inhibits autophagy to promote triple-negative breast cancer tumorigenesis by ROS-mediated JAK2/STAT3 signaling pathway.\nFurthermore, the pro-apoptotic effect of SLC25A17 knockdown was reversed when treated with autophagy inhibitor 3-MA in TNBC cells, suggesting that SLC25A17 knockdown-induced autophagic cell death.\nOn the other hand, SLC25A17 knockdown promoted autophagy through triggering ROS accumulation, which was counteracted by N-acetyl-l-cysteine (NAC).\nUpregulated PEX3 promotes abnormal lipid metabolism in LUAD cells by interacting with solute carrier family 25 member 17 (SLC25A17) to upregulate its protein levels.\nInhibition of SLC25A17 and SLC27A6 resulted in downregulation of fatty acid synthase and acetyl-CoA carboxylase with parallel decrease in the levels of lactic acid in enzalutamide resistant cells.\nAdditionally, SLC25A17 overexpression exacerbates lipid accumulation in A549 cells by activating the janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway, while AG490, a JAK2 inhibitor, eliminates this effect.\nIn conclusion, our study demonstrates that USF2 overexpression enhances SLC25A17-mediated JAK2/STAT3 signaling by promoting PEX3 transcriptional activation, thereby exacerbating abnormal lipid metabolism in A549 cells and accelerating LUAD progression.\nIn a nude mice xenograft study, SLC25A17 knockdown markedly decreased breast tumor growth and metastasis."
    },
    "1794-2269": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Nonsmall cell lung cancer (NSCLC)",
      "text": ""
    },
    "393-1794": {
      "type": "slc_pathway",
      "key1": "SLC40A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1801-1924": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Head and Neck Cancer",
      "text": "PLSCR1 knockdown inhibited TSCC cell proliferation, migration, and invasion, and upregulated apoptosis.\nThe present study found that CVB-D inhibited the viability of NPC cells, as well as induced NPC cell apoptosis.\nIts upregulation promoted proliferation, inhibited apoptosis, and enhanced migration and invasion in HNSCC cells.\nThe Ti/Coating system significantly reduced cell viability and induced early apoptosis without increasing necrosis.\nKnockdown of SARS1 in HNSCC cell lines inhibited cell viability, migration, and colony formation while promoting apoptosis.\nTranscriptome sequencing and Western blot analysis revealed that Ceritinib suppresses PI3K/Akt signaling to promote apoptosis.\nDownregulation of hsa_circ_0005325 can inhibit the proliferation and invasion of SCC25 and CAL-27 cells and promote their apoptosis.\nCollectively, the cytotoxic effects induced by CFZ involve cell growth inhibition and apoptosis via the PI3K/AKT/mTOR and p21 signaling pathways.\nRNF185 knockout suppressed cell proliferation, induced apoptosis, and caused mitochondrial damage and mtDNA release, activating the cGAS-STING-IRF3 pathway.\nBoth curcumin and EF24 inhibit the viability, migration, and invasion, and induce apoptosis of OSCC cells and the IC of EF24 was much lower than that of curcumin.\nUnder detachment stress, Nrf2 activation enhances cell viability, inhibits apoptosis, and facilitates multicellular aggregate formation, thereby promoting survival.\nOur study revealed anticancer efficacy of silibinin in suppressing cell viability and proliferation, promoting DNA damage, apoptosis and cell cycle arrest in HNSCC.\nTriptonide treatment downregulated FOXK1 and AKT2 expression, inhibited proliferation, induced apoptosis, and sensitized ESCC cells to cisplatin in a synergistic manner.\nIn summary, GOT1 knockdown inhibited proliferation and promoted ap"
    },
    "188-1795": {
      "type": "slc_pathway",
      "key1": "SLC22A5",
      "key2": "proliferation",
      "text": "In functional assays, knockdown of SLC22A5 inhibited L: -carnitine intake, resulted in lipid droplet accumulation, and suppressed the proliferation of breast cancer cells.\nSince SLC22A5 is a critical regulator of carnitine homeostasis, lipid metabolism, and cell proliferation, SLC22A5 may serve as a potential therapeutic target for breast cancer in the future.\nOCTN2 silencing reduced the proliferation rate of the colon cells, whereas OCTN2 overexpression increased the proliferation rate.\nexpression is altered in many types of cancer, giving an advantage to some of them by supplying carnitine for β-oxidation, thus providing an alternative to glucose source of energy for growth and proliferation.\nThis up-regulation was correlated positively with tumor size and Ki-67 and negatively with the progesterone receptor (PR) status, providing evidence of the opposite effects of OCTN2 and PR on tumor development.\nFatty acid oxidation (FAO) is a major energy-generating process in the mitochondria and supports proliferation, growth, and survival of cancer cells.\n[F]FPIA uptake correlated positively with Ki-67 ( < 0.01), SLC22A5 ( < 0.001) and SLC25A20 ( = 0.001), and negatively with CPT1 ( < 0.01) and SLC22A2 ( < 0.01).\nEtomoxir reduced [F]FPIA uptake, which correlated with decreased Ki-67 ( < 0.05).\nA growing number of observations reveal that tumors can utilize a wide range of substrates to sustain cell survival and proliferation.\nProper regulation of carnitine levels is important in the context of development and increased risk of cancer cells proliferation.\nThe majority of carnitine comes from the diet and is transported to the cell by ubiquitously expressed organic cation transporter novel family member 2 (OCTN2)/solute carrier family 22 member 5 (SLC22A5).\nLongitudinal PET imaging showed gradual increase in [F]FPIA uptake in orthotopic glioma models with disease progression ("
    },
    "1795-2353": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "inflammatory bowel disease",
      "text": "Co-cultures confirmed IPA enhanced proliferation and suppressed apoptosis via TGF-β1/Smads inhibition.\nThe inhibitor of the PI3K/AKT pathway effectively suppressed AREG-induced activation and proliferation of HIFs and attenuated colitis-associated fibrosis in mice.\nBy activating Gαq, Gαs, and Gα12/13 signaling pathways, GPR39 modulates key inflammatory signaling cascades, including NF-κB and MAPK, thereby inhibiting the release of inflammatory mediators, mitigating tissue damage, promoting cell proliferation, and enhancing tissue repair.\nFurthermore, this regulatory effect extended to the enhancement of epithelial cell proliferation and autophagy, characterized by the elevated expression of Ki-67, microtubule-associated protein 1A/1B-light chain 3 II, and Beclin-1, along with the suppression of cleaved caspase-3 and sequestosome 1.\nIn azoxymethane (AOM)/DSS-induced CAC, DCS decreased tumor burden and reduced Ki-67+ cell proliferation without systemic toxicity.\nImmunohistochemistry revealed that lipidated IL-22 increased epithelial cell proliferation and reduced CD3 T-cell infiltration, indicating enhanced mucosal healing.\nIn the DSS-induced inflamed small intestinal organoid model, ESPs reduced organoid damage and promoted the proliferation and differentiation of intestinal stem cells.\nIn vitro activation of murine and human T cells in the presence of RTA-408 resulted in suppressed proliferation, reduced expression of IFN-γ, cytotoxic granules and IL-17, but enhanced frequency of Foxp3+ Treg cells.\nIn HCoEpiC cells, PAL promoted cell proliferation, inhibited apoptosis, improved cell barrier function by reducing the penetration of FITC-dextran across the cell barrier and increasing transepithelial electrical resistance.\nIn addition, long-term intake of HPSIDF inhibited the degradation of Lactobacillus intestinalis and promoted the proliferation of Oscillospira and the production of beneficial substances such as Ag"
    },
    "1800-2677": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Retinoblastoma",
      "text": "Berberine suppressed cell migration and invasion via inactivation of PI3K/Akt and p38.\nEPAS1 overexpression significantly inhibited the viability, migration, and invasion of retinoblastoma cells and induced their apoptosis (P<0.05).\nThese findings indicate that SOST silencing promotes the proliferation, invasion and migration, and decreases the apoptosis of human retinoblastoma cells by activating the Wnt/β-catenin signaling pathway.\nIt was observed that treatment with the RPL41 peptide alone decreased the viability, migration, and invasion of retinoblastoma Y79 and Weri-Rb1 cells, in addition to promoting cell apoptosis and cell cycle arrest.\nOverexpression of miR-613 suppressed retinoblastoma cell proliferation, migration, and invasion and induced cell cycle arrest in vitro.\nOverexpression of NKILA resulted in decreased, while XIST overexpression resulted in increased proliferation, migration and invasion rates of retinoblastoma cells.\nWe identified the cytokines extracellular matrix metalloproteinase inducer (EMMPRIN) and macrophage migration inhibitory factor (MIF), both with reported immunosuppressive activity, secreted at high levels in retinoblastoma primary cell cultures.\nLnc00152 overexpressing retinoblastoma cells exhibited a tendency to transform into mesenchymal cells, with significantly increased migration and invasion capacities, significantly decreased E-cadherin expression levels, and significantly increased N-cadherin, SOX9 and ZEB2 expression levels.\nLINC-PINT was confirmed to function as a tumor suppressor factor in many cancers, such as triple-negative breast cancer, non-small cell lung cancer, gastric cancer, glioma, melanoma, osteosarcoma, laryngeal squamous cell carcinoma, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, retinoblastoma, ovarian cancer, thyroid cancer, hepatocellular carcinoma, and pancreatic cancer by promoting apoptosis and senescence, inhibiting proliferation, migration, invasion, drug resistance, cell"
    },
    "12-1796": {
      "type": "slc_pathway",
      "key1": "SLC2A4",
      "key2": "ferroptosis",
      "text": "ADPN inhibited oxidation/peroxide imbalance-induced ferroptosis in placental tissues of GDM mice.\nAdditionally, eight common genes of Tibetan plateau key and ferroptosis-related differentially expressed mRNAs (DEmRNAs) (CBS, SLC2A4, STAT3, ALOX15B, ATF3, IDO1, NOX4, and SOCS1) were identified in CAG.\nADPN ameliorated placental injury in GDM by correcting fatty acid oxidation/peroxide imbalance-induced ferroptosis via restoration of CPT-1 activity.\nIn addition to apoptosis pathways, Cd toxicity through ROS generation, ferroptosis and pyroptosis were summarized.\nThe common genes of Tibetan plateau key and ferroptosis-related DEmRNAs can play a role in the JAK-STAT signaling pathway.\nADPN inhibited the expression of CPT-1 and GLUT4 in placental tissues of GDM mice."
    },
    "1796-2255": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "multiple myeloma (MM)",
      "text": "Multiple myeloma (MM) has been reported to be insensitive to erastin-induced ferroptosis.\nThe progression of multiple myeloma (MM), an incurable malignancy of plasma cells, is often associated with the suppression of ferroptosis, a type of cell death driven by iron-dependent lipid peroxidation.\nOverall, ginsenoside Rh4 inhibited the malignant progression of MM and induced ferroptosis by regulating SIRT2.\nMechanistically, the direct binding of NC to ABCB6 suppressed PI3K/AKT signaling pathway to promote ferroptosis.\nFurthermore, the ferroptosis inducer erastin triggered ferroptosis, inhibited cell viability, and upregulated TDRKH-AS1.\nIn conclusion, this study confirmed that DCG066 inhibits MM proliferation and induces ferroptosis via the Nrf2/HO-1 pathway.\nMoreover, ferroptosis inhibitor liproxstatin-1rescued DSF-induced ferroptosis by promoting glutathione peroxidase 4 upregulation.\nTargeting potential regulatory factors in the ferroptosis pathway may promote or inhibit the disease progression of these malignancies.\nUsing 740 Y-P, a PI3K activator, and Fer-1, a ferroptosis inhibitor, we discovered that T-5224 induces ferroptosis through the PI3K/AKT pathway.\nHCS induced MM cell ferroptosis through the NRF2/HO-1 pathway in vivo, inhibiting MM progression similarly to the positive control drug bortezomib.\nOur results further demonstrated that altKLF4 inhibited drug sensitivity and ferroptosis induced by the GPX4 inhibitor RSL3 in multiple myeloma cells through a direct interaction with GPX4.\nServing as an oncogene repressing ferroptosis, promoting proliferation as well as shortening survival in LUAD, SEs-mediated activation of MYEOV might distinguish as a promising therapeutic target.\nRecent studies have found that in the blood system, tumor cells of lymphoma and multiple myeloma (MM) are more sensitive to ferroptosis and affect disease progression through a variety of mechanisms."
    },
    "32-1801": {
      "type": "slc_pathway",
      "key1": "SLC4A7",
      "key2": "apoptosis",
      "text": "The electroneutral sodium bicarbonate co-transporter SLC4A7 localizes in mitochondria and suppresses the ischaemia-induced activation of the mitochondrial pathway of apoptosis in coronary EC.\nIn Affymetrix primeview human GeneChip array, we found six upregulated genes (STAT1, ATF2, TNFRSF10B, TGFBR2, BAX, and SQSTM1) and two downregulated genes (SLC4A7 and CD274) related to apoptosis and proliferation of colorectal cancer cells after hsa_circ_0064559 knockdown.\nThe initial characterization of the participating mechanisms of SLC4A7-dependent apoptosis revealed an activation of the mitochondrial pathway of apoptosis, i.e.\nTUNEL staining uncovered the extensive apoptosis of retinal cells induced by slc4a7 knockdown.\nKnockdown of SLC4A7 in EC by transfecting appropriate siRNA similarly increased apoptosis of EC under simulated ischaemia.\nTreatment with S0859 significantly increased caspase-3 activity and elevated the number of apoptotic EC.\ncleavage of caspase-9 and binding of Bax to mitochondria.\nBy examining the expression of bicarbonate transporters (BT) in EC by reverse transcriptase polymerase chain reaction and western blotting, a marked expression of the electroneutral sodium bicarbonate co-transporter (SLC4A7) was defined.\nFinally, a mitochondrial localization of SLC4A7 was demonstrated.\nBicarbonate transport has been shown to participate in apoptosis under ischaemic stress.\nTo analyse the potential role of this transporter during apoptosis, a selective inhibitor (S0859, Sanofi-Aventis) was applied.\nHowever, the precise transporting mechanisms involved in ischaemic apoptosis are unknown and were thus the aim of the present study.\nIn contrast, no activation of the endoplasmic reticulum-dependent pathway (caspase-12 cleavage) or the extrinsic apoptotic pathway (caspase"
    },
    "1801-2178": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Ras mutant pancreatic ductal adenocarcinom",
      "text": ""
    },
    "136-1795": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "proliferation",
      "text": "In addition, SLC16A1-AS1 may downregulate miR-141 through methylation to promote cancer cell proliferation.\nRemarkably, PDIA6 and SLC16A1 were observed to inhibit the proliferation of pancreatic β cells and promote apoptosis in vitro, while downregulation of PDIA6 and SLC16A1 expression led to enhanced insulin secretion.\nIn vitro experiments showed that overexpression of SLC16A1-AS1 promoted cell proliferation and invasion but suppressed cell apoptosis.\nSLC16A1-AS1 suppressed miR-1269 maturation and promoted cell proliferation, migration, and invasion, and inhibited cell apoptosis, while miR-1269 displayed the opposite trend.\nexperimental results demonstrated that when SLC16A1 was knocked down, the proliferation, migration, and invasion capabilities of HNSCC cell lines were significantly reduced and the extent of RAS-selective lethal 3-induced lipid peroxidation increased compared with control cells.\nKnockdown SLC16A1-AS1 inhibited cell viability, proliferation, and migration of renal cancer cells.\nSLC16A1-AS1 was downregulated in OSCC and it may inhibit cell proliferation by suppressing maturation of miR-5088-5p.\nSLC16A1-AS1 may inhibit cell cycle progression and restrain TNBC cell proliferation by regulating the miR-182/PDCD4 axis.\nIn turn, the reciprocal SLC16A1-AS1/IL-6 signaling between HCC cells and M2 macrophages promoted the proliferation, invasion and glycolysis of HCC cells.\nCollectively, these findings show that miR-1287-5p/PFN2 signaling was associated with downregulation of circ-SLC16A1 and reduced invasion and proliferation of NSCLC cells.\nDownregulation of circ-SLC16A1 inhibited tumor growth by reducing proliferation, lung metastasis, and lymphatic metastasis of NSCLC cells, and arrested the cell cycle in the G1 phase."
    },
    "1795-2450": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Head and Neck tumors",
      "text": ""
    },
    "1801-1900": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "lymphoma",
      "text": ""
    },
    "1794-2766": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Glioblastoma multiforme",
      "text": ""
    },
    "290-1797": {
      "type": "slc_pathway",
      "key1": "SLC27A4",
      "key2": "oxidative stress",
      "text": "OSO remarkably upregulates levels of Fatp1 and Glut1 and decreases expression of Snat2 and Glut3.\nOSO decreased the level of IL-10 but increased expression of IL-1β in placenta and plasma.\nThe expression of Bax showed a linear increase, and Bcl-2 decreased as the oxidative degree increased.\nOn day 20 of gestation, OSO decreased placental and embryonic weights as the oxidative degree increased linearly and quadratically.\nThese results suggest that GLP-1 inhibits hepatic steatosis and inflammation through the inhibition of hepatic FFA influx and oxidative stress in a non-obese NASH model.\nAdditionally, it further decreased the hepatic SREBP-1c level and alleviated the MCD-mediated inhibition of the ACOX1 mRNA level.\nThe levels of hepatic sterol regulatory element-binding protein-1c (SREBP-1c) mRNA (lipogenesis-related gene) and acyl-coenzyme A oxidase 1 (ACOX1) mRNA (β-oxidation-related gene) had decreased at 4 wk and further decreased at 8 wk.\nFour weeks of MCD feeding induced hepatic steatosis and inflammation and increased the hepatic TG and FFA content.\nThe administration of exendin-4 significantly attenuated the MCD-induced increase in hepatic steatosis, hepatic TG and FFA content, and FATP4 expression as well as the MCD-induced augmentation of hepatic inflammation, macrophage recruitment, and MDA levels.\nand the level of malondialdehyde (MDA), an oxidative stress marker, were significantly augmented by a 4-wk MCD.\nThe expression of fatty acid transport protein 4 (FATP4), a hepatic FFA influx-related gene;\nOSO aggravates placental injury by modulating nutrient transporters and apoptosis-related genes, impedes placental growth and development, and ultimately leads to the decrease of fetal weight."
    },
    "1795-1850": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "liver cancer",
      "text": ""
    },
    "299-1794": {
      "type": "slc_pathway",
      "key1": "SLC29A2",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1796-2379": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "pancreatic tumor growth",
      "text": "Ferroptosis inhibits tumor progression in pancreatic cancer cells, while PITX2 is known to function as a pro-oncogenic factor in various tumor types, protecting them from ferroptosis and thereby promoting tumor progression.\nHowever, due to the dual role of ferroptosis in promoting and inhibiting pancreatic tumorigenesis, regulating the degree of ferroptosis is very important to obtain the best therapeutic effect of PDAC.\nBoth the ferroptosis inhibitor and inducer exhibit antitumor effects through killing cancer cells or directly affecting tumor growth.\nThe immunosuppressive cells activated by the ferroptotic tumor cells can promote the growth of residual tumor cells, hindering the application of ferroptosis stimulation in tumor treatment.\nIn summary, our investigation has shown that c-Fos acts as a transcriptional regulator of SLC7A11, which may enhance tumour growth in pancreatic cancer by inhibiting ferroptosis.\nActivated ferroptosis induced by the inhibition of GPX4 subsequently restricts tumor progression and reduces GEM resistance in PDAC.\nStudying genetically engineered mice, we found that the deletion of a system x subunit, , induced tumor-selective ferroptosis and inhibited PDAC growth.\nTargeting SMYD2 inhibits PC progression by promoting ferritinophagy-dependent ferroptosis through the c-Myc/NCOA4 axis.\nIts knockdown induces ferroptosis in PC and suppresses tumor progression via CMTM7-mediated Wnt/β-catenin pathway.\nMore interestingly, by targeting CMTM7-mediated Wnt/β-catenin signaling pathway, the knockdown of SOX10 was confirmed to induce ferroptosis in PC and suppress tumor progression in vivo.\nGlutamine deprivation inhibits pancreatic cancer growth and induces ferroptosis both and .\nTherefore, CIRBP acts as a tumor suppressor gene in pancreatic cancer and induces ferroptosis through the p53/GPX4 pathway to inhibit cell growth, which may be an important target for the diagnosis and treatment of pancreatic cancer.\nAlpha-Heredin suppresses PDAC progression by dual targeting of mitochondrial fission and ferr"
    },
    "38-1799": {
      "type": "slc_pathway",
      "key1": "SLC5A1",
      "key2": "glycolysis",
      "text": "Metformin increased expression of Slc2a1 (GLUT1), decreased expression of Slc2a2 (GLUT2) and Slc5a1 (SGLT1) whilst increasing GLUT-dependent glucose uptake and glycolytic rate as observed by live cell imaging of genetically encoded metabolite sensors and measurement of oxygen consumption and extracellular acidification rates.\nSGLT1 and SGLT2 are expressed in various tumors where they supply the tumor cells with glucose for euglycemic glycolysis.\nBoth glycolysis and glycogen formation require cellular glucose uptake which could be accomplished by the Na+ coupled glucose transporter-1 (SGLT1; SLC5A1).\nGlucose can be utilized not only for glycolysis but also for glycogen formation.\nWe conclude that metformin affects glucose uptake, glycolysis and GDF-15 secretion, likely downstream of the observed mitochondrial dysfunction.\nBulk RNA-sequencing analysis identified changes in hexose metabolism pathways, particularly glycolytic genes.\nLEFTY2 down-regulates Na+/H+ exchanger activity with subsequent inhibition of glycolytic flux and lactate production in endometrial cancer cells.\nA glycometabolism-related prognostic model consisting of four genes (PLOD2, CHSY3, SLC2A3 and SLC5A1) was developed and validated, effectively stratifying GC patients into high- and low-risk subgroups with distinct survival outcomes.\nAs a result, a 48-hour treatment with LEFTY2 significantly increased SGLT1 and GYS1 transcript levels as well as SGLT1 and GYS1 protein abundance in both Ishikawa and HEC1a cells.\nWe further show the treatment with LEFTY2 fosters cellular glucose uptake and glycogen formation and TGF-β can negate this effect in endometrial cancer cells.\nIn conclusion, LEFTY2 up-regulates expression and activity of the Na+ coupled glucose transporter SGLT1 and glycogen synthase GYS1 in a cell line specific manner.\nFunctional analyses revealed that PLOD2 promotes glycolysis and tumor"
    },
    "416-1795": {
      "type": "slc_pathway",
      "key1": "SLC45A4",
      "key2": "proliferation",
      "text": "Silencing of SLC45A4 significantly inhibited the proliferation, invasion, and metastasis of OCC by suppressing glucose uptake and glycolysis, and it also reduced the expression of HIF-α glycolysis signaling pathway in OC tissues.\nTumor cells promote malignant behaviors such as proliferation, invasion, and metastasis of cancer cells through glucose metabolic reprogramming, but the role of the H-dependent sugar cotransporter SLC45A4 in regulating metabolic reprogramming in ovarian cancer (OC) remains largely unknown.\nSilencing SLC45A4 inhibited proliferation in TP53 mutant PDA cells.\nKnockdown of SLC45A4 reduced glucose uptake and ATP production, which led to activation of autophagy via AMPK/ULK1 pathway.\nPVT1-214 knockdown suppressed cell growth, invasion and migration in vitro, whereas PVT1-214 overexpression promoted tumor proliferation in vivo.\nDeleting SLC45A4 in TP53 mutant HPAF-II cells inhibited the growth of xenografts in nude mice.\nIn vivo experiments using shRNA to knock down SLC45A4 in xenograft models in nude mice demonstrated a significant inhibition of tumor growth.\nThese findings suggest that SLC45A4 silencing can restrain the malignant progression of OC by inhibiting glucose uptake in OCC and affecting the reprogramming of glycolytic energy metabolism, indicating that SLC45A4 may serve as a potential therapeutic target for OC intervention.\nThe present study found that SLC45A4 prevents autophagy via AMPK/ULK1 axis in TP53 mutant PDA, which may be a promising biomarker and therapeutic target in TP53 mutant PDA.\nIn addition, PVT1-214 positively regulates SLC45A4 expression through its competitive endogenous RNA (ceRNA) activity against miR-671-5p.\nMoreover, high level of SLC45A4 expression was tightly associated with poor clinical outcomes in PDA patients.\nSLC45A4 was overexpressed in PDA for which"
    },
    "30-1802": {
      "type": "slc_pathway",
      "key1": "SLC4A4",
      "key2": "oxidative phosphorylation",
      "text": "Higher succinylation scores correlated with mitochondrial oxidative phosphorylation, while lower succinylation scores were linked to immune cell differentiation.\nA prognostic model consisting of 11 succinylation-related genes (ATP6V1C2, CAPS, DAPK1, P4HA1, PCED1A, RASL10B, AGT, EREG, HYAL1, SARAF, and SLC4A4) was developed."
    },
    "1801-2365": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Neuroblastoma (NBM)",
      "text": "We also demonstrated that similar to GPF treatment, miR-489 exhibited a significant anti-NBM capacity.\nOverall, our results indicated that GPF possessed an evident anti-NBM capacity dependent on AMPK/miR-489/XIAP pathway, providing an emerging strategy for clinical treatment of NBM.\nIn the present study, we demonstrated that 6'-O-galloylpaeoniflorin (GPF), a galloylated derivative of paeoniflorin isolated from the roots of , exerted significant inhibitory effects on proliferation and invasion of SH-SY5Y cells (an NBM cell line) and enhanced the sensitivity of SH-SY5Y cells to cisplatin in vitro.\nFurther studies showed that miR-489 directly targeted the X-linked inhibitor of apoptosis protein (XIAP).\nAccumulating evidence has proved that chemicals derived from natural products possess potent anti-NBM properties or can be used as adjuvants for chemotherapy."
    },
    "40-1805": {
      "type": "slc_pathway",
      "key1": "SLC5A3",
      "key2": "autophagy",
      "text": ""
    },
    "1805-1836": {
      "type": "pathway_disease",
      "key1": "autophagy",
      "key2": "pancreatic cancer(PC)",
      "text": ""
    },
    "179-1802": {
      "type": "slc_pathway",
      "key1": "SLCO1B1",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "391-1794": {
      "type": "slc_pathway",
      "key1": "SLC39A14",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1796-2613": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Esophageal Cancer",
      "text": "Treatment with QG significantly suppressed the viability, proliferation, and migration of PTX-resistant esophageal cancer cells and simultaneously induced ferroptosis.\nActivation of the PI3K pathway notably reversed the ferroptosis of PTX-resistant esophageal cancer cells that was induced by QG.\nCircBCAR3 promoted the proliferation, migration, invasion, and ferroptosis of esophageal cancer cells by miR-27a-3p.\nThe hypoxia-induced promotive effects on esophageal cancer cell migration and ferroptosis were rescued by circBCAR3 knockdown.\nSilencing of circBCAR3 repressed the proliferation, migration, invasion, and ferroptosis of esophageal cancer cells in vitro, as well as inhibited the growth and metastasis of esophageal xenograft in mice in vivo.\nCollectively, these findings demonstrate that GLUT1 preserves esophageal CSC-like characteristics by stabilizing EGFR to inhibit autophagy-dependent ferroptosis, highlighting targeting GLUT1 as a potential therapeutic strategy to eliminate CSCs and combat esophageal cancer progression.\nSilencing of ALDH5A1 can reduce DDP resistance in ESCC through promoting ferroptosis signaling pathways.\nDENR promotes cisplatin resistance in ESCC by inhibiting ferroptosis through an ATF4-dependent mechanism.\nREA induced ferroptosis and inhibited the migration of EC cells by activating the ROS-ASK1-p38 MAPK signaling pathway.\nTaken together, our findings suggest that IQGAP1 promotes chemoresistance by blocking ferroptosis through targeting YAP.\nHMGA1 is upregulated in ESCC and works as a key driver for cisplatin (DDP) resistance in ESCC by repressing ferroptosis.\nThis in turn not only inhibits the proliferation and migration of ESCC cells but also upregulates the ferroptosis pathway.\nIn summary, circPDE3B promotes ESCC progression by suppressing ferroptosis through recruiting HNRNPK/SLC7A11 and miR-516b-5p/CBS axes."
    },
    "300-1797": {
      "type": "slc_pathway",
      "key1": "SLC29A3",
      "key2": "oxidative stress",
      "text": ""
    },
    "1800-2296": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "ferroptosis-relative osteoarthritis",
      "text": ""
    },
    "1800-2087": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Glioblastoma (GBM)",
      "text": "Knockdown of RBM7 suppressed TR/U87 cell proliferation and migration, induced mitochondrial structural damage, and triggered ferroptosis.\nRBM7 promotes TMZ resistance by suppressing mitochondrial dysfunction and ferroptosis through destabilization of FBXL16.\nConversely, miR-101-mediated suppression of METTL3 disrupts EIF3J-AS1-FOXG1 binding, restoring MIF expression and promoting autophagy.\nTLR7 suppresses glioblastoma by inhibiting cell progression via the PI3K/AKT/mTOR signaling pathway and promoting an anti-tumoral immune microenvironment.\nThe Se(B-CD-CA-4-NPs) complex significantly reduced U-87MG cell viability, migration and invasion.\nIn the tumor microenvironment, TLR7 promoted M1 macrophage polarization, increasing M1 markers and pro-inflammatory cytokines while suppressing M2 markers.\nIn conclusion, the present study revealed that S100B may induce the invasion and migration of GBM cells through TGF‑β2‑induced EMT, providing novel insights and potential therapeutic targets for GBM.\nImportantly, in vivo studies confirmed that combined therapy with the SPHK1 inhibitor PF-543, the TLR4 antagonist TAK-242, and TMZ synergistically suppressed tumor growth and significantly enhanced the efficacy of TMZ.\nExtracellular soluble ENO1 robustly enhanced GBM cell proliferation, migration, and invasion in vitro.\nTLR7 overexpression significantly reduced GBM cell proliferation, colony formation, migration, and invasion.\nThe process of EMT can promote tumor cell migration and invasion, facilitating the spread of cancer cells within the brain.\nNeutrophils accumulate around the surgical cavity and release NETs to promote the proliferation and migration of postoperative residual GBM cells.\nATAD2 knockdown significantly reduced the proliferation, migration, and invasion capabilities of GBM cells, while its overexpression had the opposite effect.\nIn addition to inhibiting cell proliferation, 8a'"
    },
    "299-1795": {
      "type": "slc_pathway",
      "key1": "SLC29A2",
      "key2": "proliferation",
      "text": "Overexpression of FNDC3B or SLC29A2 in unamplified HCC cells promoted cell proliferation through activation of the signal transducer and activator of transcription 3 signaling pathway.\nKnockdown of these genes in amplified cells decreased cell proliferation, anchorage-independent growth, and tumor formation in xenograft models.\nImportantly, up-regulation of SLC29A2 in HCC tissues was significantly associated with advanced stages (P = 0.0031), vascular invasion (P = 0.0353), and poor patient survival (P = 0.0325).\nAberrant up-regulation of FNDC3B and SLC29A2 occurred in multiple HCC data sets.\nnutrient recovery and DNA methyltransferases inhibitor supplements partly rescued cell proliferation with decrease of DNA methylation and reactivation of several depressed genes, implying the possible intrinsic relationships among cell physiological state, mRNA expression, and DNA methylation.\nThe network-identified susceptibility genes represented biological processes mainly associated with purine nucleotide biosynthetic processes, lymphocyte proliferation, NF-KB activation, JAK-STAT signaling, and apoptotic signaling at oxidative stress.\nThese genes are associated with endothelial dysfunction, smooth muscle proliferation and migration, angiogenesis, and abnormal extracellular matrix (ECM) dynamics.\nIn an integrated transcriptome and DNA methylation analyses, 135 negatively correlated genes were determined, wherein the hub genes of gins2, cdca5, fbxo5, slc29a2, suv39h1b, and zgc:174160 were predominant responsive to the nutrient condition changes.\nThe down-regulated genes mainly annotated to the pathways of DNA replication and cell cycle that were consistent with cell physiological changes."
    },
    "1795-2613": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Esophageal Cancer",
      "text": "ID1 promotes the progression of esophageal cancer by inducing proliferation and immune suppression through regulation of the PTEN/YAP/Galectin-3 signaling pathway.\nOverexpression of ID1 significantly enhanced the proliferation of esophageal cancer cells and improved the phagocytic ability of macrophages, whereas after treatment with PTEN agonists and YAP inhibitors, the proliferation of esophageal cancer cells decreased markedly, and the phagocytic ability of macrophages was reduced.\ninhibited proliferation, migration, invasion, and colony formation of esophageal cancer cells.\nGNL3L was upregulated in ESCC specimens (p < 0.05) and knockdown reduced proliferation and migration while enhancing apoptosis (p < 0.01).\nFunctionally, PSAT1 knockdown markedly suppressed cell proliferation, migration, invasion, and xenograft tumor growth, while promoting ferroptosis in ESCC cells.\nRNF185 knockout suppressed cell proliferation, induced apoptosis, and caused mitochondrial damage and mtDNA release, activating the cGAS-STING-IRF3 pathway.\nTriptonide treatment downregulated FOXK1 and AKT2 expression, inhibited proliferation, induced apoptosis, and sensitized ESCC cells to cisplatin in a synergistic manner.\nIn vivo, PIGU knockdown inhibited ESCC cell proliferation and promoted apoptosis.\nThe FOXK1/AKT2 axis promoted cell proliferation and suppressed cisplatin-induced apoptosis.\nDepletion of KIN significantly inhibited proliferation and induced DNA damage accumulation in ESCC cells.\nFunctionally, EZR silencing significantly reduced EC cell proliferation, migration, and invasion, and increased apoptosis.\nJQ1 treatment at 1 and 2 μmol/L significantly inhibited ESCC cell proliferation, while JQ1 at 0.2 and 2 μmol/L promoted cell migration.\nIn cultured ESCC cells, LINC00261 overexpression markedly suppressed cell proliferation"
    },
    "1795-1821": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Germ Cell Tumor",
      "text": "Notch signaling may promote or inhibit cancer cell proliferation;\nTitle: Paeoniflorin inhibits glioblastoma proliferation and promotes autophagy through the AKT/mTOR pathway.\nFunctional studies reveal that SIN1 upregulation enhances glioma cell proliferation and migration while suppressing apoptosis.\nTitle: SCARA5 Induces Ferroptosis to Inhibit the Proliferation and Migration of Skin Melanoma Cells and Regulates the GPX4/ACSL4 Signaling Pathway.\nTitle: Neuroglobin-promoted autophagy inhibits the proliferation, migration and invasion of human glioblastoma cells through the EGFR/PI3K/AKT/mTOR signaling pathway.\nFunctional analyses following EXO1 knockdown revealed significant suppression of GBM cell viability, proliferation, migration, invasion, and induced DNA fragmentation.\nBoth CBD and CBD-HCE reduced cell proliferation and migration, increased apoptosis, and significantly downregulated HLA-G expression at both the mRNA and protein levels.\nMechanistically, FGL2 suppressed cell proliferation, migration, and invasion by regulating the nuclear factor kappa-light-chain-enhancer of activated B cells signaling pathway.\nTaken together, HIF-1α regulates the Wnt/β-catenin signaling pathway via its engagement with β-catenin, thereby promoting GBM proliferation and invasion, and inhibiting apoptosis.\nIn conclusion, 6-G impairs glioma cell proliferation, promotes apoptosis, induces G1 phase arrest, and inhibits migration and invasion, primarily through the suppression of the PI3K-AKT pathway.\nMoreover, RNA interference-mediated COL1A1 silencing reduced proliferation, increased apoptosis, and enhanced RT-induced DNA damage, underscoring its pivotal role in BRD4-mediated radioresistance.\nPLK1 inhibition effectively suppresses autophagy, cell proliferation, TMZ resistance, and tumorigenicity, while promoting apoptosis in GBM cells through the regulation of NPM1 serine 4"
    },
    "63-1799": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "glycolysis",
      "text": "Hypoxia-induced PYCR1 enhances glycolysis, leading to increased lactate production and elevated H3K18la levels, which upregulates SLC6A14 transcription and glutamine catabolism, thereby promoting BC growth and metastasis.\nUpregulated SLC6A14 expression promoted glutamine catabolism and enhanced BC cell proliferation, migration, and invasion.\nPYCR1 knockdown inhibited H3K18la levels, SLC6A14 expression, and BC cell aggressiveness\nHypoxia induced PYCR1 expression in BC cells, enhancing glycolysis and lactate production, which increased H3K18la levels.\nexperiments confirmed that the PYCR1/H3K18la/SLC6A14 axis is critical for hypoxia-driven BC growth and metastasis.\nThis study investigated how PYCR1 promotes BC progression through glycolysis, histone H3 Lysine 18 Lactylation (H3K18la), and Solute Carrier Family 6 Member 14 (SLC6A14)-driven glutamine catabolism."
    },
    "116-1798": {
      "type": "slc_pathway",
      "key1": "SLC12A2",
      "key2": "stemness",
      "text": "A loss-of-function study showed that knockdown of SLC12A2 expression restrained proliferation and stemness of CRC cells while a gain-of-function study showed the contrary results.\nMeanwhile, the high-risk group had a higher tumor stemness score ( < 0.05).\nAt the same time, we identified that SLC12A2 could promote tumor progression in CRC, which may serve as a potential therapeutic target."
    },
    "117-1795": {
      "type": "slc_pathway",
      "key1": "SLC12A3",
      "key2": "proliferation",
      "text": "Functional studies of SLC12A3 and ADH6 overexpression showed reduced cell proliferation, colony formation, and migratory capacity, suggesting their involvement in inhibiting tumor progression.\nAdministration of golvatinib, a selective Met inhibitor, or transfection of small interfering RNA for Met suppressed cell proliferation and downstream signaling only in the cell lines in which hyperphosphorylation of Met was observed.\nAdministration of golvatinib inhibited these phenotypes in MDCK cells.\nIn three-dimensional culture of Madin-Darby canine kidney (MDCK) cells as a cyst formation model of ADPKD, HGF activated Met, resulting in an increased total cyst number and total cyst volume.\nThe proportion of Ki67 cells and the concentration of nitric oxide (NO) were high in SRGN high expression cells, suggesting that SRGN may be involved in the proliferation of HUVECs.\nElectron microscopy revealed swelling and vacuolar degeneration of glomerular epithelial cells, diffuse proliferation of mesangial cells and matrix, accompanied by a small amount of low-density electron-dense deposition, and segmental fusion of epithelial cell foot processes in proband B.\nFunctional assays, including cell proliferation, colony formation, and wound healing, were performed to validate the hub genes.\nThis study emphasizes the critical roles of SLC12A3, ADH6, GSTM3, and CLCNKB in WT and their potential as both diagnostic biomarkers and therapeutic targets in WT management.\nAnalysis of gene expression data from publicly available GEO datasets revealed that SLC12A3, ADH6, GSTM3, and CLCNKB hub genes were significantly dysregulated in WT."
    },
    "1795-2050": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Wilms Tumor",
      "text": ""
    },
    "298-1794": {
      "type": "slc_pathway",
      "key1": "SLC29A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1798-1806": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Brain Tumor",
      "text": "Incorporating these highly stemness-equipped Ttsms enhances the response to anti-PD-1 therapy in immune-suppressed brain tumors.\nMalignant astrocytomas are aggressive primary brain tumors characterized by extensive hypoxia-induced, mitochondria-dependent changes such as altered respiration, increased chymotrypsin-like (CT-L) proteasome activity, decreased apoptosis, drug resistance, stemness, and increased invasiveness.\nOf note, presence of FGL2 transforms low grade to high grade brain tumors via promoting Treg, macrophages, and perhaps stemness.\nG9a inhibition decreased PD-L1 and increased MHC-I expressions by inactivating Notch pathway companying stemness decrease in GSCs.\nMutual regulation between NF-κB and FOSL1 contributes to glioma tumorigenesis and stemness through promoting G1/S transition and inhibiting apoptosis.\nTherefore, inhibition of GGCT function may be useful in suppressing stemness of glioblastoma stem cells accompanied by activation of the hedgehog pathway.\nA search for the underlying mechanism of NAT10-mediated enhancement of GBM stemness led to identification of polycomb repressive complex 2 (PRC2)-related genes as an epigenetic regulator.\nHere, we identify intercellular adhesion molecule 1 (ICAM1) as a key regulator of GSC stemness and tumorigenicity, promoting an immunosuppressive microenvironment via β-catenin/PD-L1 signaling.\nFunctionally, LK-A impaired EMT-induced cell migration, invasion, and glioma stem cell-like traits, evidenced by decreased gliosphere formation and downregulation of stemness markers such as Sox2 and Oct4.\nThe increased antiproliferative effect of combining the two compounds resulted from a stronger downregulation of STAT3-mediated downstream GBM stemness regulators through dual PRMT1 and CaMKIIγ function blockade.\nSimilarly, blocking autophagy in stem cell-like GBM tumor subpopulations induced senescence-associated growth arrest without hampering stemness capacity or indu"
    },
    "1799-1836": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "pancreatic cancer(PC)",
      "text": "Upregulation of SIRT6 significantly promoted the ferroptosis and inhibited the glycolysis in PC cells.\nCollectively, the present study indicated that SIRT6 promoted ferroptosis and inhibited glycolysis through inactivating the NF-κB signaling pathway in PC.\nOur results indicated that PUS7 could promote cell proliferation, mobility and glycolysis, and inhibit apoptosis by interacting ANLN to activate the MYC pathway in PC.\nMoreover, silencing of GSTM3 induced ROS accumulation and promoted glycolysis in PC, indicating its tumor suppressive effect, and vice versa when GSTM3 was upregulated.\nOverexpression of miR-202 in PC cells reduced cell proliferation and tumorigenesis by impairing glycolysis, while downregulation of miR-202 promoted the cells proliferative capacity.\nBesides, Trp deficiency caused by IDO1 overexpression suppressed the apoptosis of PC cells via promoting glycolysis, which reveals the presence of IDO1-glycolysis-apoptosis axis in PC.\nFurthermore, glycolysis inhibition-achieved through ENO1 knockdown, glucose deprivation, or treatment with 2-Deoxy-D-glucose (2-DG)-further enhanced the susceptibility of PC cells to gemcitabine.\nHigh glucose condition in the tumor microenvironment promotes immune suppression by upregulating glycolysis in PC cells, which can be rescued via knockdown Bmi1 expression or after 2-deoxy-D-glucose treatment.\nMechanistically, ROCK1 directly interacted with c-MYC, promoted its phosphorylation (Ser 62) and suppressed its degradation, thereby increasing the transcription of the key glycolysis regulatory factor PFKFB3, enhancing glycolytic activity and promoting PC growth.\nMechanistically, cold-induced BAT activation substantially decreases blood glucose and impedes the glycolysis-based metabolism in cancer cells.\nConclusively, targeting CDCA7 might be a promising therapeutic strategy to increase gemcitabine sensitivity by inhibiting glycolysis in PC cells."
    },
    "1798-2613": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Esophageal Cancer",
      "text": "Cancer stemness promoted viability in esophageal cancer, but it was suppressed in others.\nTumor-associated macrophages enhances the stemness of esophageal cancer cells, whereas aspirin attenuates the stemness by suppressing the expression of CCL2.\nBA enhances the chemical sensitivity of esophageal cancer cells to cisplatin by inhibiting cell proliferation, reducing cell stemness, and inducing pyroptosis.\nLINC-PINT was confirmed to function as a tumor suppressor factor in many cancers, such as triple-negative breast cancer, non-small cell lung cancer, gastric cancer, glioma, melanoma, osteosarcoma, laryngeal squamous cell carcinoma, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, retinoblastoma, ovarian cancer, thyroid cancer, hepatocellular carcinoma, and pancreatic cancer by promoting apoptosis and senescence, inhibiting proliferation, migration, invasion, drug resistance, cell stemness, EMT, radioresistance, and DNA damage repair.\nRGS1 targeted by miR-191-3p inhibited the stemness properties of esophageal cancer cells by suppressing CXCR4/PI3K/AKT signaling.\nKisspeptin 10 Inhibited the Proliferation, Migration, and Stemness of Esophageal Cancer Cells via Regulating the SIX1/Wnt/β-Catetin Signaling.\nFurthermore, we found that RGS1 knockdown activated the PI3K/AKT pathway by negatively regulating CXCR4 to promote the stemness of esophageal cancer cells.\nEPPK1 was downregulated in esophageal cancer tissues and cells, and EPPK1 depletion markedly repressed cell proliferation, invasion, migration, and stemness of esophageal cancer cells.\nOur findings revealed that RGS1 targeted by miR-191-3p inhibited the stemness of esophageal cancer cells by suppressing the CXCR4/PI3K/AKT pathway, which provide potential prognostic markers"
    },
    "138-1797": {
      "type": "slc_pathway",
      "key1": "SLC16A3",
      "key2": "oxidative stress",
      "text": "4-NQO/EtOH treatment also caused increases in markers of oxidative stress, including 4-HNE, MCT4/SLC16a3, and TOM20, as measured by immunohistochemistry.\nDuplications of the bidirectional α-ketoacid transporters SLC16A3, SLC16A7, the cystine transporters SLC7A9, SLC7A11, and N-glycan branching enzymes MGAT4B, MGAT4C in Neoaves suggests a shift to the transport of deaminated essential amino acid, and stronger mitigation of oxidative stress supported by the galectin lattice.\nIt was found for the first time that EMB promoted lactic acid accumulation and further induced redox dyshomeostasis and glycolysis disorder by simultaneously inhibiting SLC16A1/3.\nThe background working of the AMPK pathway through upregulation of AKT1, AMPK, SIRT1, PYGM, SLC2A4 and SERBP1 genes, and downregulation of PPARGICIA, IGF2, PPARA, SLC27A3, SLC16A3, TSC1/2, KCNJ2, KCNJ16, etc., evidence the repression of cellular transcriptional activity and energetic homeostasis modifications in response to heat stress.\nHigh inflammatory response was found to be responsible for oxidative-stress-mediated apoptosis of GCs and nodes towards the involvement of the NF-κB pathway and repression of the Nrf2 pathway.\nSubsequently, EMB was released and mediated the lactic acid accumulation and the GA-Fe nanoparticle synergistic Fenton reaction to promote ROS accumulation, thereby increasing the lethality of the nanoparticles on cervical cancer cells.\nAnalysis of the drug response profiles reveals that 77 drugs affect cell viability, with the top effective compounds targeting nucleic acid synthesis, oxidative stress, and the PI3K/mTOR pathway.\nSLC16A1/3 is the critical hub for regulating the internal and external environment, glycolysis, and redox homeostasis in cervical cancer cells."
    },
    "1794-1823": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Melanoma",
      "text": ""
    },
    "81-1804": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "disulfidoptosis",
      "text": ""
    },
    "1804-2677": {
      "type": "pathway_disease",
      "key1": "disulfidoptosis",
      "key2": "Retinoblastoma",
      "text": ""
    },
    "1799-1940": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Cholangiocarcinoma",
      "text": "In a chemically induced cholangiocarcinoma-afflicted rat model, the gemcitabine plus rad001 treatment suppressed tumor glycolysis as measured by F-fludeoxyglucose micro-positron emission tomography.\nETV4 promotes the progression of cholangiocarcinoma by regulating glycolysis via the TGF-β signaling.\nAldolase A Enhances Intrahepatic Cholangiocarcinoma Proliferation and Invasion through Promoting Glycolysis.\nTriptolide inhibits intrahepatic cholangiocarcinoma growth by suppressing glycolysis via the AKT/mTOR pathway.\nNNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis.\nTriiodothyronine promotes the proliferation and chemoresistance of cholangiocarcinoma cells via HIF-1α/Glut1-stimulated glycolysis.\nLong noncoding RNA FAM66C promotes tumor progression and glycolysis in intrahepatic cholangiocarcinoma by regulating hsa-miR-23b-3p/KCND2 axis.\nThese results demonstrate that chronic exposure to T3 can promote the proliferation and chemoresistance of cholangiocarcinoma cells through a pathway involving HIF-1α, Glut1, and glycolysis.\nBeyond gallstone prevention, melatonin demonstrates protective effects against GI malignancies, including hepatocellular carcinoma and cholangiocarcinoma, by regulating mitochondrial function, inhibiting glycolysis, and modulating apoptosis.\nUSP28 promotes tumor progression and glycolysis by stabilizing PKM2/Hif1-α in cholangiocarcinoma.\nMETTL3 promotes glycolysis and cholangiocarcinoma progression by mediating the m6A modification of AKR1B10.\nUSP21 deubiquitinates and stabilizes HSP90 and ENO1 to promote aerobic glycolysis and proliferation in cholangiocarcinoma."
    },
    "143-1799": {
      "type": "slc_pathway",
      "key1": "SLC16A8",
      "key2": "glycolysis",
      "text": "siRNA-mediated SLC16A8 knockdown effectively reversed hypoxia-induced changes, including reduced glucose consumption and lactate production.\nFurthermore, SLC16A8 silencing led to decreased expression of key metabolic enzymes PKM2 and LDHA, indicating its role in glycolytic regulation.\nUnder hypoxic conditions, HIF-1α induced SLC16A8 expression, leading to enhanced metabolic reprogramming and increased lactate production.\nOur findings reveal that SLC16A8 functions as a critical mediator of hypoxia-induced metabolic reprogramming in CRC progression.\nHypoxic conditions prompted examination of SLC16A8 expression, glycolysis, lactate efflux, and Warburg effect correlations in CRC cell lines.\nSLC16A8, a lactate efflux transporter, is upregulated in various cancers, but its effects on tumor microenvironments remain understudied.\nLactic acid was previously considered a waste product of glycolysis, and has now become a key metabolite for cancer development, maintenance and metastasis."
    },
    "45-1802": {
      "type": "slc_pathway",
      "key1": "SLC5A8",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1794-2450": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Head and Neck tumors",
      "text": ""
    },
    "1798-1868": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "lung cancer",
      "text": ""
    },
    "385-1796": {
      "type": "slc_pathway",
      "key1": "SLC39A8",
      "key2": "ferroptosis",
      "text": "inhibition of Slc39a14 and Slc39a8 significantly relieves VC by intercepting iron overload-induced ferroptosis in VSMCs, providing new insights into the VC treatment.\nCLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.\ncoumestrol was unable to upregulate the expression of ferroptosis pathway-related genes in CRC cell lines after SLC39A8 interference.\nCoumestrol was found to induce apoptosis in CRC cell lines by upregulating the expression of ferroptosis pathway-related genes SLC39A8, NCOA4, VDAC2, and NOX2.\ncircAMN1 regulated the expression of SLC39A8 to control erastin-induced ferroptosis and regulated the proliferation, invasion, and migration of trophoblast cells.\nwhether metalloproteins SLC39a14 and SLC39a8 are involved in ferroptosis induced by iron overload.\ncombined lead and cadmium exposure may exacerbate neurotoxicity by mediating microglia ferroptosis via STEAP3, SLC39A8.\na reduced ac4C level shortens the half-life of and mRNA, resulting in low levels of intracellular cystine and reduced GSH, failing to detoxify ROS, and leading to increased cellular oxPLs, which facilitate ferroptosis induction.\nzrt-/irt-like protein 8 (ZIP8), encoded by SLC39A8, was closely associated with ferroptosis of monocytes during sepsis.\nCLEC3B promoted CDDP chemosensitivity via inducing ferroptosis.\nthe heightened expression of ZIP8 may facilitate this progression.\ndownregulation of ZIP8 alleviated the lipopolysaccharide-induced lipid peroxidation, as well as restoring the reduction of GPX4, FTH1 and xCT.\nKEGG enrichment analysis suggested that ZIP8 plays"
    },
    "435-1798": {
      "type": "slc_pathway",
      "key1": "SLC51B",
      "key2": "stemness",
      "text": "A significant reduction in the stemness-related markers, CD24, CD44, CD20, FOXM1, and EpCAM, was found after the knockdown of CAD and other genes in HepG2 and Huh7 cells.\nFive genes, CAD, SLC51B, LGALS3, B3GAT3, and MT3, identified from 572 glycosylation-related genes, were used to construct a gene signature and predict HCC patient survival in the TCGA cohort.\nThe results demonstrated a significant positive correlation between patients in the high-risk group and both elevated gene expression and HCC dedifferentiation status.\nGlycosylation-related molecular subtypes are associated with HCC stemness and disease prognosis.\nThe ICGC-LIRI-JP cohort confirmed a similar relationship between glycosylation-related subtypes and stemness.\nThe relationship between gene expression profiles and stemness was confirmed using bulk and single-cell RNA-sequencing data.\nThe role of CAD and other genes in regulating the stemness of HCC was also validated by RT-qPCR, CCK-8, and colony formation assay.\nThis study explores the relationship between glycosylation and stemness in HCC.\nThese results provide new directions for further research on the relationship between glycosylation and stemness phenotypes.\nHowever, its function in regulating the acquisition and maintenance of the cancer stemness-like phenotype in HCC remains largely unknown.\nThere is also very little known about how CAD and other potential glycosylation regulators may influence stemness."
    },
    "63-1797": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "oxidative stress",
      "text": "Metabolic syndrome (MetS) is characterized by chronic inflammation, oxidative stress, and mitochondrial dysfunction.\nThirty-six male Slc6a14 mice were divided into four groups: low-fat diet (LFD), high-fat diet (HFD), HFD + 200 mg PSE/kg BW (PSE, p.o.), and HFD + 100 mg LUT/kg BW (LUT, p.o.) for 4 months.\nOutcome measures included glucose homeostasis, intestinal permeability, gut microbiome composition, and mRNA gene expression of mitochondrial homeostasis and inflammation/oxidative stress in the kidneys, colon, and ileum.\nRelative to the LFD group, the HFD group (1) upregulated mitochondrial fusion (MFN1, MFN2, OPA1), mitophagy (TLR4, PINK1, LC3B), and inflammation (NFκB, TNFα, IL6), and (2) downregulated mitochondrial fission (FIS1, DRP1), biosynthesis (PGC1α, NRF1, NRF2, TFAM), electron transport chain (complex I), and antioxidant enzyme (SOD1) in the kidneys, colon, and ileum.\nHFD resulted in glucose dysregulation with hyperglycemia and insulin resistance.\nPSE and LUT improved insulin tolerance and beta-cell function.\nPSE and LUT reversed such HFD-induced changes in the aforementioned gene expression levels.\nMetS is associated with increased intestinal permeability and dysbiosis.\nPSE and LUT mitigated HFD-increased serum lipopolysaccharide-binding protein concentration.\nPerturbations in the gut microbiome were associated with HFD, and PSE or LUT reversed some of these changes."
    },
    "1797-2557": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "malignt cancers",
      "text": ""
    },
    "313-1798": {
      "type": "slc_pathway",
      "key1": "SLC31A1",
      "key2": "stemness",
      "text": "ID1 depletion freed TCF12 to transactivate the cisplatin influx transporter SLC31A1, increasing intracellular cisplatin levels and cytotoxicity.\nFurther autophagy stimulation by serum-starvation and chemical modes triggered proteolysis of the stemness regulator ID1, driving the differentiation of chemo-resistant CSCs into chemo-sensitive non-CSCs.\nIn addition, CRGs were significantly correlated with RNA stemness score, DNA stemness score, microsatellite instability, and tumor mutational burden.\nThis study reveals a novel autophagy-ID1-TCF12-SLC31A1 axis where targeted autophagic degradation of ID1 enables rapid remodeling of CSCs to reverse chemo-resistance.\nPatient-derived tumor spheroids exhibited a functional association between autophagy, ID1, SLC31A1, and platinum sensitivity.\nOvarian CSCs exhibited increased basal autophagy compared to non-CSCs.\nThis study investigated the role of targeted autophagic protein degradation in regulating ovarian cancer stem cell (CSC) fate decisions and chemo-resistance."
    },
    "1798-1839": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "bladder cancer",
      "text": "Overall, this study reveals a novel mechanism for silibinin targeting bladder cancer metastasis, in which inactivation of β-catenin/ZEB1 signaling by silibinin leads to dual-block of EMT and stemness.\nThese findings indicate that KDM6A deficiency promotes cancer stemness and confers resistance to ALA-PDT in bladder cancer cells by suppressing ROS generation despite increased PpIX levels.\nAfter knockdown of HOXA-AS2 in bladder cancer 5637 and T24 cells, the migration, invasion and stemness of cancer cells were significantly inhibited, indicating the capability of HOXA-AS2 to promote the migration, invasion and stemness of bladder cancer cells.\nWe further found that depletion of ASAP1-IT1 in T24 cells by RNA interference reduced the stemness of bladder cancer, whereas forced overexpression of ASAP1-IT1 in J82 cells enhanced cancer cell stemness by sphere assay, ALDEFLUOR and flow cytometry assay on CD44+ population.\nSHOX2 promotes the migration, invasion and stemness of human bladder cancer cells possibly by regulating EMT via the TGF-β signaling pathway.\nMYBL2 CSCs derived CCL15, which bound to CCR1 and induced SPP1 upregulation in macrophages which reciprocally enhanced bladder cancer stemness and resistance to nICB through the SPP1-ITGα9β1 axis.\nThis study reveals that TET3 promotes tumor growth and progression in bladder cancer partly through modulation of the stemness pathway, highlighting its potential as a therapeutic target and prognostic marker.\nLncRNA XIST may act as an inhibitor of miR-200c to regulate the stemness properties and tumourigenicity of bladder cancer cells, and our findings might reveal a potential strategy of targeting XIST for bladder cancer therapy.\nTaken together, these results indicate that knockdown of cyclin D1b suppresses the malignant phenotypes of human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and epithelial-mesenchymal transition.\nDifferentiation and elimination therapies targeting EMT-"
    },
    "1795-1806": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Brain Tumor",
      "text": "glutamate increases PA proliferation without changing membrane depolarization.\nGlioma is a highly aggressive brain tumor marked by rapid proliferation, therapy resistance, and an immunosuppressive microenvironment.\nNotch signaling may promote or inhibit cancer cell proliferation;\nCCAR2 knockdown inhibited cell viability and proliferation and promoted apoptosis in glioma cells.\nSIN1 upregulation enhances glioma cell proliferation and migration while suppressing apoptosis.\nNeuroglobin-promoted autophagy inhibits the proliferation, migration and invasion of human glioblastoma cells through the EGFR/PI3K/AKT/mTOR signaling pathway.\nEXO1 knockdown revealed significant suppression of GBM cell viability, proliferation, migration, invasion, and induced DNA fragmentation.\nHIF-1α regulates the Wnt/β-catenin signaling pathway via its engagement with β-catenin, thereby promoting GBM proliferation and invasion, and inhibiting apoptosis.\nRNA interference-mediated COL1A1 silencing reduced proliferation, increased apoptosis, and enhanced RT-induced DNA damage, underscoring its pivotal role in BRD4-mediated radioresistance.\nCRIPSR-Cas9 mediated NUAK2 deletion in GBM cells results in suppression of proliferation, while overexpression leads to enhanced cell growth in both in vitro and in vivo models.\nPLK1 inhibition effectively suppresses autophagy, cell proliferation, TMZ resistance, and tumorigenicity, while promoting apoptosis in GBM cells through the regulation of NPM1 serine 4 phosphorylation.\nhypoxia-induced S100A10 expression facilitates proliferation and glycolysis and inhibits apoptosis by regulating the PI3K-AKT signaling pathway, which enhances TMZ resistance in GBM cells.\naptamer-functionalized exosomes exhibited enhanced specificity to glioma cells, leading to significant inhibition of cell proliferation through circNEFM-mediated pathways and effective reversal of chemoresistance."
    },
    "371-1797": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "oxidative stress",
      "text": "SLC38A5 transports glutamine, methionine, glycine and serine, and therefore activates mTOR signaling and induces epigenetic modifications.\nSLC7A11 transports cystine and increases the cellular levels of glutathione, which protects against oxidative stress and lipid peroxidation via glutathione peroxidase, a seleno (Se)-enzyme.\nNiclosamide decreased the glutathione levels, inhibited proliferation, suppressed GPX4 expression, increased lipid peroxidation, and induced ferroptosis in TNBC cells.\nOur previous work discovered niclosamide, an antiparasitic drug, as a potent inhibitor of SLC38A5.\nIn addition to the direct inhibition of SLC38A5 and SLC7A11, the pretreatment of TNBC cells with niclosamide reduced the expression of both transporters.\nHere, we found SLC7A11 to be inhibited by niclosamide with an value in the range of 0.1-0.2 μM.\nPharmacological inhibition of SLC38A5 with amiloride, significantly increased cell sensitivity to 5-FU and irinotecan, and improved mouse survival in metastasis models.\nConsequently, the loss of CDH17 increased sensitivity to 5-FU, irinotecan, oxidative stress and anoikis in CRC cells.\nCDH17 silencing also down-regulated various transporters associated with drug-resistance, including the glutamine-transporter SLC38A5.\nNotably, SLC38A5 silencing was necessary for CDH17-driven effects on drug resistance and survival.\nBoth conditions also lower reproductive hormone levels, increase oxidative stress, and promote germ cell apoptosis.\nSe-Met activated Nrf2 and induced the expression of Nrf2-target genes, including SLC7A11.\nWe found that SLC38A5 interacts with methionine and Se-Met with comparable affinity.\nSince SLC38A5 transports methionine, we examined its role in Se-Met uptake in TNBC cells."
    },
    "1797-2583": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "ischemic proliferative retinopathies",
      "text": "Although the initial trigger that leads to insufficient perfusion of the retina may be different, once a critical level of ischemia is achieved, all types of retinopathies seem to follow a common sequence-oxidative stress, followed by hypoxia-induced formation of morphologically abnormal vessels.\nOxidative stress and retinal ischemia are implicated in the development of proliferative diabetic retinopathy (PDR).\nHyperglycemia causes retinal damage through complex metabolic pathways leading to oxidative stress, inflammation, vascular damage, capillary ischemia, and retinal tissue hypoxia.\nWe discuss potential mechanisms through which sodium-glucose cotransporter 2 (SGLT2) inhibitors improve retinal hypoxia-through ketone bodies, which are energetically as efficient as glucose and yield more ATP per molecule of oxygen consumed than fat, with less oxidative stress.\nRetinal benefits would occur through improved fuel energetics, less hypoxia and through the anti-inflammatory/oxidative stress effects of ketone bodies.\nThese results indicate that PEDF may play its neuroprotection role through inhibiting ER stress and oxidative stress in ischemic retinopathy, which is a novel molecular mechanism of PEDF protecting photoreceptors from ischemic damage, thereby suggesting that PEDF is an effective therapeutic agent for the treatment of neuron damage in ischemic retinal diseases.\nHowever, PEDF significantly prevented ER stress and oxidative stress, as well as the damage of ultrastructure, resulting in diminution of photoreceptor apoptosis in OIR retinas.\nThe results revealed that ER stress and oxidative stress were notably activated under hypoxic conditions.\nRT-PCR and ELISA analyses indicated that cultured Müller cells produce bFGF, which is elevated under hypoxia or oxidative stress, as well as under stimulation with various growth factors and cytokines, including pro-inflammatory factors.\nRecent evidence indicates that DAMPs are associated with the sterile inflammation caused by aging, increased ocular pressure, high glucose, oxidative stress, ischemia, mechanical trauma, stress, or environmental conditions, in retinal diseases.\nAlterations contributing to oxidative and nitrosative stress, including elevated nitric oxide and superoxide production, changes in"
    },
    "28-1795": {
      "type": "slc_pathway",
      "key1": "SLC4A2",
      "key2": "proliferation",
      "text": "Notably, BPS exposure specifically induced SLC4A2 upregulation, while siRNA-mediated SLC4A2 knockdown significantly suppressed BPS-induced cell migration and reversed EMT phenotypes.\nThis study first demonstrates that BPS promotes CRC cell migration by activating the EMT signaling pathway via SLC4A2 upregulation.\nSLC4A2, being a key player in BPS-induced tumorigenesis, could function as a promising biomarker and therapeutic target for CRC.\nThese findings demonstrate that CD8(+) T cells are critically dependent on Ae2 for pHi homeostasis and tuning of cell proliferation and activation.\nMoreover, stimulated Ae2-deficient CD8(+) T cells show enhanced intracellular production of IL-2 and membrane expression of its receptor IL-2Rα, together with increased cell proliferation and activation.\nAcid uptake into CCD-112-CoN and NHDF-Ad cells was slower and comparable to levels in CRC cells, but increased alongside SLC4A2 expression under stimulation with transforming growth factor β1 (TGFβ1), a cytokine involved in cancer-stroma interplay.\nBPS exposure within the concentration range of 10⁻¹ ⁰ to 10⁻⁶ M did not significantly inhibit HCT8 cell viability but markedly enhanced migration and invasion capabilities, accompanied by EMT progression.\nThe impact of BPS on HCT8 cell proliferation, migratory ability, and EMT progression were systematically evaluated through Western blot, CCK-8 proliferation assays, scratch wound healing experiments, and Transwell assays for migration and invasion."
    },
    "40-1795": {
      "type": "slc_pathway",
      "key1": "SLC5A3",
      "key2": "proliferation",
      "text": "Lentiviral SLC5A3 overexpression construct transduction upregulated the cellular myo-inositol level and promoted Akt-mTOR activation, enhancing cervical cancer cell proliferation and migration.\nIn addition, suppressing the expression of the signature gene, SLC5A3, in a SKCM cell line through the utilization of small interfering RNAs (siRNAs) could inhibit the proliferation and migration of cells, as evidenced by the implementation of colony formation assay, CCK8, and cell transfection techniques.\nConversely, ectopic overexpression of SLC5A3 further enhanced proliferation and migration in primary NSCLC cells.\nAmong cellular responses towards this stress is the inhibition of proliferation through the activation of p38 MAPK and p53.\nKnockdown of TASK-1 by siRNA significantly enhanced apoptosis and reduced proliferation in A549 cells, but not in weakly TASK-1 expressing NCI-H358 cells.\nThe interference of significantly inhibited fat deposition during preadipocyte differentiation and promoted cell proliferation by increasing S-phase cell numbers.\nIn primary NSCLC cells and immortalized lines, SLC5A3 depletion, using small hairpin RNA (shRNA) and CRSIRP/Cas9 methods, robustly impeded cell proliferation and migration, simultaneously provoking cell cycle arrest and apoptosis.\nThe inhibition of ATP1A1 had the most prominent effect on the transcription of the rest of the transporters and was found to enhance the anti-proliferative effect of hyperosmotic conditions through an increased G2/M cell cycle block, ascribing to this pump a central role in the osmoregulatory response of nucleus pulposus cells.\nTransduction of sh-TonEBP AAV construct downregulated SLC5A3 expression and inhibited pCCa-1 cervical cancer xenograft growth.\nIn primary/established cervical cancer cells, shRNA/knockout (KO) exerted growth-inhibitory effects and promoted cell death/apoptosis.\nSLC5A3 KO also inhibited pCCa-1 cervical"
    },
    "1795-1823": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Melanoma",
      "text": ""
    },
    "1794-2365": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Neuroblastoma (NBM)",
      "text": ""
    },
    "1795-2290": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "oral squamous cell carcinoma (OSCC)",
      "text": ""
    },
    "190-1794": {
      "type": "slc_pathway",
      "key1": "SLC22A7",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2193": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "pancreatic ductal adenocarcinoma (PDAC)",
      "text": ""
    },
    "1800-1823": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Melanoma",
      "text": ""
    },
    "1797-2137": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "hearts suffered ischemia/reperfusion (I/R)",
      "text": "The most effective intervention for IHD is reperfusion, which ironically causes ischemia reperfusion (I/R) injury mainly due to oxidative stress-induced cardiomyocyte death.\nAllopurinol, a xanthine oxidase (XO) inhibitor, is reported to alleviate myocardial ischemia/reperfusion (I/R) injury by reducing the production of reactive oxygen species (ROS).\nIn a rat heart model of I/R, allopurinol alleviated I/R oxidative injury accompanied by decreased XO activity, XO-derived products (HO and uric acid), and VPO1 expression (mRNA and protein).\nAs an XO-derived product, HO can act as a substrate of vascular peroxidase 1 (VPO1) to induce the generation of hypochlorous acid (HOCl), a potent oxidant.\nIn a cardiac cell model of hypoxia/reoxygenation (H/R), allopurinol or XO siRNA reduced H/R injury concomitant with decreased XO activity, VPO1 expression as well as the XO and VPO1-derived products (HO, uric acid, and HOCl).\nFurthermore, recently identified mechanisms of mitochondrial regeneration can increase the capacity for oxidative phosphorylation, decrease oxidative stress and might help to beneficially impact myocardial remodeling, as well as invigorate the heart against subsequent ischemic insults.\nDue to its antioxidant properties, PNX may help reduce oxidative stress and cellular damage in organs.\nWe found that the approach of acupoint gel embedding could significantly reduce myocardial infarcted size, repair pathological changes, mitigate oxidative stress damage and inflammatory response, as well as inhibit apoptosis of cardiomyocytes."
    },
    "222-1798": {
      "type": "slc_pathway",
      "key1": "SLC25A1",
      "key2": "stemness",
      "text": "Our research shows that PTL inhibits the growth and stemness of LCSCs through SLC25A1-mediated mitochondrial function.\nMoreover, in different patient-derived tumors, resistance to cisplatin or to epidermal growth factor receptor (EGFR) inhibitor treatment is acquired through SLC25A1-mediated implementation of mitochondrial activity and induction of a stemness phenotype.\nHere we show that administration of PTL stimulated cell cycle arrest at the G1 phase, induced apoptosis, and decreased the stemness of LCSCs.\nIn addition, the inhibitory effect of PTL on mitochondrial function and self-renewal capacity of LCSCs was abolished by the knockdown of SLC25A1 or treatment with SLC25A1 inhibitor CTPI-2.\nWe demonstrate that SLC25A1 plays a key role in maintaining the mitochondrial pool of citrate and redox balance in CSCs, whereas its inhibition leads to reactive oxygen species build-up thereby inhibiting the self-renewal capability of CSCs.\nRNA sequencing (RNA-Seq) further shows that PTL decreased SLC25A1 expression at the mRNA level and that inhibition of SLC25A1 synergistically decreased the expression of IDH2 and several pivotal genes involved in mitochondrial respiratory chain complex, resulting in the production of ROS and mitochondrial dysfunction.\nWe show here that lung CSCs rely upon oxidative phosphorylation for energy production and survival through the activity of the mitochondrial citrate transporter, SLC25A1.\nFurther research indicates that PTL caused the production of ROS and the reduction of oxidative phosphorylation (OXPHOS) and mitochondrial membrane potential (MMP) levels of LCSCs."
    },
    "1798-2196": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "glioma",
      "text": ""
    },
    "5-1797": {
      "type": "slc_pathway",
      "key1": "SLC1A5",
      "key2": "oxidative stress",
      "text": "SLC1A5 knockdown also suppressed glutamine uptake, enhanced oxidative stress, and increased sensitivity to cisplatin.\nOur results suggest that chronic use of standard immunosuppressive regimens increases the risk of oxidative stress in the rat intestine, as manifested by increased expression of glutathione or the SLC1A5 transporter.\nUSP48 overexpression deubiquitinated SLC1A5 to elevate cell proliferation and suppress cell apoptosis, inflammation, ferroptosis and oxidative stress in HG-triggered ARPE-19 cells, thereby inhibiting the progression of diabetic retinopathy.\nTopotecan-induced hepatocytes death is dependent on ASCT2 down-regulation, which causes oxidative stress via inhibiting GSH production.\nTPT inhibits glutamine uptake via down-regulation of ASCT2 which causes oxidative stress and induces apoptosis through the mitochondrial pathway.\nstudies had shown that the knockdown of SLC1A5 resulted in a significant decrease in cell viability and promoted lipid peroxidation and oxidative damage introduced by irradiation (10 Gy).\nAg120 blocked glutamine uptake and metabolism, leading to reduced cell proliferation, elevated autophagy, and increased oxidative stress in CRC cells and , potentially the ERK and mTOR signaling pathways.\nCombination of ASCT2 inhibitor V9302 and proteasome inhibitor carfilzomib upregulates the intracellular levels of ROS and oxidative stress markers and triggers catastrophic UPR as shown by upregulated spliced Xbp1 mRNA, ATF3 and CHOP levels.\nER-localized HSP90B1 accelerates the clearance of radiotherapy-induced misfolded proteins and upregulates the PERK-EIF2α-ATF4 pathway, which further transcriptionally upregulates antioxidant factors, such as SLC1A5, GCLC, and CTNS, to inhibit radiotherapy-induced ROS accumulation, ultimately leading to radiotherapy resistance, and poor clinical outcomes.\nDisruptions in immune modulation, metabolism, and oxidative stress components were associated with"
    },
    "1797-2404": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "triple-negative breast cancer(TNBC)",
      "text": "We have also identified several pathways by which inhibition of growth suppression of chemoresistant cells occurs, including increased oxidative stress and mitophagy.\nEAD also induced oxidative stress and DNA damage, downregulated pathways linked to metabolism, cell cycle progression, pro-survival signalling, cell adhesion, motility and inflammatory response.\nTaken together, these results establish EKB as a promising therapeutic candidate that couples autophagy blockade with immune activation, and highlight oxidative stress as a significant contributing mechanism underlying its anticancer effects.\nApart from these, this synergistic mitochondrial copper depletion and oxidative stress elevation strategy significantly reverses the immunosuppressive microenvironment (promotes dendritic cell maturation and T cell vivification, regulates macrophage polarization and myeloid-derived suppressor cell infiltration), activates T cells in the spleen, and accelerates TNBC death with almost negligible systemic toxicity and is expected to provide perspective for the treatment of TNBC.\nConsequently, suppression of PHGDH by the use of the shRNA caused doxorubicin-induced oxidative stress and increased doxorubicin sensitivity.\nand 3) induced oxidative stress by suppressing the thioredoxin system, consequently inhibiting the activation of the redox sensitive transcription factor NF-κB.\nSK (SK), a secondary plant metabolite from Lithospermum erythrorhizon, is an inducer of oxidative stress and a DNA Topoisomerase inhibitor with promising anticancer properties.\nMitochondrial oxidative stress triggered a decrease in the native functional forms and an increase in the aggregated forms of LONP1 and CLPP, thereby disrupting mitochondrial proteostasis.\nTreatment with the ROS scavenger N-acetylcysteine (NAC) reduced nuclear stress, mitochondrial dysfunction, autophagy, and cell death, emphasizing the role of oxidative stress in SK-induced cell death.\nInterestingly, OLE increased the level of intracellular and mitochondrial reactive oxygen species (ROS) together with a decreased activity of ROS scavenging enzymes, confirming oxidative stress in both models.\nEXCC highly upregulated reactive oxygen species"
    },
    "1800-1850": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "liver cancer",
      "text": ""
    },
    "1795-2365": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Neuroblastoma (NBM)",
      "text": "In the present study, we demonstrated that 6'-O-galloylpaeoniflorin (GPF), a galloylated derivative of paeoniflorin isolated from the roots of , exerted significant inhibitory effects on proliferation and invasion of SH-SY5Y cells (an NBM cell line) and enhanced the sensitivity of SH-SY5Y cells to cisplatin in vitro.\nFurther studies showed that GPF treatment upregulated miR-489 in NBM cells via activating AMP-activated protein kinase (AMPK).\nFurther studies showed that miR-489 directly targeted the X-linked inhibitor of apoptosis protein (XIAP).\nOverall, our results indicated that GPF possessed an evident anti-NBM capacity dependent on AMPK/miR-489/XIAP pathway, providing an emerging strategy for clinical treatment of NBM.\nWe also demonstrated that similar to GPF treatment, miR-489 exhibited a significant anti-NBM capacity.\nAccumulating evidence has proved that chemicals derived from natural products possess potent anti-NBM properties or can be used as adjuvants for chemotherapy."
    },
    "1797-2146": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "liver hepatocellular carcinoma (LIHC)",
      "text": "Title: Hypoxia-activated oxidative stress mediates SHP2/PI3K signaling pathway to promote hepatocellular carcinoma growth and metastasis.\nFONE exerts selective cytotoxic effects against Hep-G2 cells, mediated by ROS-induced oxidative stress, DNA damage, and apoptosis induction.\nCompared with the control group, the HepG2 cells treated with H_2O_2 showed significantly decreased activities of SOD and GSH-Px and increased ROS and MDA levels.\nTitle: Frankincense oil nanoemulsion induces selective cytotoxicity and over ROS-mediated oxidative stress and apoptotic DNA damage in Hep-G2 hepatic cancer cells.\nOAG represents an innovative therapeutic approach to liver fibrosis and HCC, acting through autophagy-dependent pathways to inhibit inflammation and oxidative stress.\nIn conclusion, DMC initiated oxidative stress, which disrupted bioenergetic metabolism and activated the ATF4/ATF3/CHOP signaling pathway, ultimately leading to cell death in HCC cells.\nROS serve not only as critical biomarkers of cancer but also as potential therapeutic targets for HCC, given that their increased levels can either promote or inhibit disease progression.\nThese findings establish Erk1/2 activation as the central molecular mechanism orchestrating SSPH I-driven oxidative stress amplification, mitochondrial dysfunction and ferroptosis execution in HCC.\nBy conducting a comprehensive review of recent literature and experimental studies, we elucidate the molecular mechanisms through which excess copper induces oxidative stress, pyroptosis, and ferroptosis, thereby influencing tumorigenesis and progression.\nThis study was designed to evaluate alterations in NADPH oxidase 4 (NOX4) expression and oxidative stress during HCC progression in mice, induced with administration of diethylnitrosamine (DEN, 50 mg/kg) and phenobarbitone (PB, 500 mg/L via drinking water).\nCompared with the model group, different doses of Tan"
    },
    "90-1798": {
      "type": "slc_pathway",
      "key1": "SLC9A1",
      "key2": "stemness",
      "text": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD."
    },
    "136-1798": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "stemness",
      "text": "Thus, the differential expression of TMPRSS11B adds to metabolic heterogeneity in PDAC and its absence supports the reverse Warburg metabolism in PDAC cells by the enhancement of BSG-supported lactate uptake through SLC16A1 and subsequent phenotype alterations towards greater stemness.\nShRNA-mediated TMPRSS11B knock-down in Panc1 and BxPc3 cells enhanced lactate import through SLC16A1, as shown by GFP/iLACCO1 lactate uptake assay, whereas TMPRSS1B overexpression in T3M4 dampened SLC16A1-driven lactate uptake.\nMoreover, knock-down and overexpression of TMPRSS11B differentially impacted proliferation and chemoresistance under reverse Warburg conditions in Panc1 or BxPc3 and T3M4 cells, respectively, as well as their stemness properties indicated by altered colony formation rates and expression of the stem cell markers Nanog, Sox2, KLF4 and Oct4.\nThose regions exhibiting low or no TMPRSS11B expression but concomitant high expression of SLC16A1 and BSG revealed greater amounts of KLF4.\nIn contrast, other tumor areas exhibiting high expression of TMPRSS11B together with BSG and SLC16A1 were largely negative for KLF4 expression.\nSystematic bioinformatics analysis revealed that SLC16A1-AS1 was associated with histological tumor grades and overall survival status, as well as copy number variation, somatic mutation, tumor mutation burden, tumor stemness, tumor microenvironment and infiltrating immune cells.\nEmploying functional assays that are known to evaluate stemness, we demonstrate that elevated HMOX1 expression is associated with stemness in GBM and can be modulated through TGFβ.\nThese findings indicate that HMOX1 is a robust predictor of GBM CSC stemness and pathogenesis.\nFurthermore, circSIPA1L3 increased mRNA stability of the lactate export carrier SLC16A1 and the glucose intake enhancer RAB11A through either strengthening their interaction"
    },
    "1798-2450": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Head and Neck tumors",
      "text": ""
    },
    "1802-1868": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "lung cancer",
      "text": ""
    },
    "1801-2264": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "laryngeal carcinoma",
      "text": "Silencing circ-ABCB10 could significantly inhibit the growth and proliferation of laryngeal adenocarcinoma cells, while overexpression of circ-ABCB10 could significantly promote the growth of laryngeal adenocarcinoma cells, probably by inhibiting KLF6 to enhance the proliferation of laryngeal carcinoma and inhibit apoptosis.\nKnockdown of miR-21-5p reduced the EMT, while enhancing apoptosis of laryngeal carcinoma cell lines.\nThe results showed that chidamide had significant antitumour activity against laryngeal carcinoma cells and xenografts and could induce cell apoptosis, ferroptosis and pyroptosis.\nSuppressing Notch1 signaling activity in hypoxic cells could decrease proliferation and increase apoptosis.\nFarrerol suppressed the migration, invasion, and induced the apoptosis of LSCC cells via the mitochondria-mediated pathway.\nTranscriptome sequencing and Western blot analysis revealed that Ceritinib suppresses PI3K/Akt signaling to promote apoptosis.\nCurcumin treatment made LSCC cells viability reduce, cell cycle retardant, angiogenesis decrease, metastasis inhibition and apoptosis increase.\nNotably, FER1L overexpression significantly reduced the cell viability, proliferation, migration and invasion of LSCC cells, while promoting apoptosis.\nOverexpressed HAGLROS promoted the proliferation and angiogenesis yet inhibited apoptosis of LSCC cells by activating Erk1/2 and AKT or JNK signaling pathways.\nThe mitochondrial membrane potential was reduced, leading to the release of cytochrome C (Cyt C) and consequent activation of the intrinsic mitochondrial apoptosis pathway."
    },
    "381-1795": {
      "type": "slc_pathway",
      "key1": "SLC39A4",
      "key2": "proliferation",
      "text": "The in vitro experiments revealed that suppressing the expression of SLC39A4 in ICC cell lines resulted in reduced cell proliferation, colony formation, and cell migration.\nSLC39A4 has been identified to be a regulator of tumor cell metastasis and proliferation in vivo and in vitro, with an area under the curve of 0.874 for diagnosing CESC.\nThe effects of silencing solute carrier family 39 member 4 gene (SLC39A4) expression using siRNA were investigated using assays measuring cell proliferation, colony formation, and cell migration.\nZIP4 overexpression significantly reduced accumulation of gemcitabine in pancreatic cancer cells, increased growth of xenograft tumors in mice, and increased expression of the integrin subunits ITGA3 and ITGB1;\nPancreatic cancer cells with ITGA3 or ITGB1 knockdown had reduced proliferation and formed smaller tumors in mice, despite overexpression of ZIP4;\nOral zinc supplementation is shown to improve survival and weight gain of SBS mice and increase the proliferation of intestinal crypt cells in vitro.\nWe found ZIP4 to activate STAT3 to induce expression of ZEB1, which induced expression of ITGA3 and ITGB1 in KPC cells.\nCP had antiproliferative effects and reduced the expression of proliferative and stemness genes in jejunal organoids, effects that were largely independent of Zn chelation.\nIn studies of pancreatic cancer cell lines and mice, we found that ZIP4 increases expression of the transcription factor ZEB1, which activates expression of ITGA3 and ITGB1.\nThe assessment of the effect of SLC39A4 on cell growth and migration in CESC was conducted using MTT, colony formation, and Transwell assays.\nThe histopathological examination showed epidermal parakeratosis with mild hyperkeratosis, severe spongiform edema of the stratum cornicum, significant proliferation of acanthocytes, and vacuolation of keratinocytes.\nThese studies suggest that oral CQ (or other 8-hydroxyquinolines) coupled with zinc"
    },
    "129-1800": {
      "type": "slc_pathway",
      "key1": "SLC13A5",
      "key2": "migration",
      "text": "Extracellular sodium citrate significantly reduced cell viability partially due to reduction in intracellular Ca levels and decreased the migration of human PDAC cells.\nRecently, the uptake of extracellular citrate by the sodium-dependent citrate transporter (NaCT), encoded by , has been demonstrated to exert profound effects on cancer cell metabolism.\nThis approach holds promise for disrupting PDAC cell metabolism and inhibiting tumor progression.\nNotably, the combination treatment of gemcitabine and extracellular sodium citrate exhibited a synergistic anticancer effect in both two-dimensional (2D) and three-dimensional (3D) culture systems.\nFurthermore, we observed a decrease in the levels of the stem cell marker prominin I (CD133) following sodium citrate treatment.\nWe observed a positive correlation between glucose concentration and NaCT expression in PDAC cell lines."
    },
    "75-1797": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "oxidative stress",
      "text": "In vivo experiments showed that SLC7A5 promoted the activation of mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, enhanced serine synthesis and maintained oxidative stress balance in fibroblasts.\nMoreover, siRNA-mediated CTH knockdown induced oxidative stress in response to JPH203 leading to decreased cell viability in MDA-MB-231 cells.\n1,25(OH)D significantly upregulated LAT1 expression in placental trophoblasts, and also prevented the decrease of mTOR activity under CoCl-induced oxidative stress.\nJPH203, a specific inhibitor of SLC7A5, effectively reversed the above phenomena, inhibited mTORC1 signaling activation, and reduced the proliferation of fibroblasts.\nInhibition of Gln metabolism or knockdown of Gln transporters SLC1A5, SLC7A5, or SLC38A1 induces expression of NUPR1, a stress response transcriptional regulator, but simultaneously uncouples the NUPR1-driven metabolic stress-adaptation program.\nIn vitro: Mg deficiency reduced BeWo nutrient uptake (P < 0.01) and cell proliferation (P < 0.01), and increased oxidative stress (P < 0.01).\nl-Tryptophan at 0.4, 0.8, and 1.6 mM remarkably decreased the percentage of apoptosis and enhanced antioxidative capacity in HO-mediated BIEC.\nl-Tryptophan increased catalase and superoxide dismutase activities in HO-mediated BIEC, although not with a present mTOR inhibitor.\nSimilarly to the effect from NUPR1 knockdown, depletion of these Gln transporters led to reduced cell viability, accumulation of mitochondrial ROS, and increased PCa radiosensitivity.\nl-Tryptophan increased the protein expression of large neutral amino acid transporter 1 and alanine-serine-cysteine transporter 2 in HO-mediated BIEC with or without the presence of an mTOR inhibitor."
    },
    "1794-1813": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Sarcoma",
      "text": ""
    },
    "63-1802": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "oxidative phosphorylation",
      "text": "DEHP upregulates the glutamine transporter SLC6A14 to enhance glutamine uptake, while suppressing mitochondrial fission factor (MFF), which exacerbates mitochondrial fusion.\nMechanistically, DEHP exposure promotes tumor initiation by enhancing cancer stemness through mitochondrial fusion and glutamine-driven oxidative phosphorylation.\nInhibition of SLC6A14 reduces stemness, impairs tumor growth, and sensitizes tumors to chemotherapy.\nHigh SLC6A14 expression correlates with cancer stemness signatures and earlier onset in patient cohorts."
    },
    "39-1797": {
      "type": "slc_pathway",
      "key1": "SLC5A2",
      "key2": "oxidative stress",
      "text": "Dapagliflozin decreased oxidative stress, as evidenced by reduced levels of malondialdehyde (MDA), reactive oxygen species (ROS), increased superoxide dismutase (SOD) and Glutathione (GSH) activity.\nIncreased SGLT1 and SGLT2 protein levels were observed in the rat aortic arch, and Ang II- and eNOS inhibitor-treated thoracic aorta segments, and were associated with enhanced levels of oxidative stress and prevented by VAS-2780, losartan, Sota and Empa.\nAmong these, SGLT2Is inhibit fibrosis, hypertrophy, apoptosis, inflammation, and oxidative stress.\nIn addition, EMPA prevented increases in oxidative stress, sodium calcium exchanger expression and calcium/calmodulin-dependent protein kinase II activation to an equal degree in WT and SGLT2 KO animals.\nCompared with plaques from patients with diabetes, SGLT2i-treated patients with type 2 diabetes presented increased SIRT6 expression and collagen content and lowered inflammation and ion and oxidative stress, thus indicating a more stable plaque phenotype.\nUnexpectedly, mechanistic studies revealed that antagonism of AMPK aggravated oxidative stress and ferroptosis, reduced GPX4 (glutathione peroxidase 4) level, and partially abolished the anti-hypertrophic and anti-ferroptosis effects of SGLT2i in H9C2 cells.\nGene expression and protein levels of main biomarkers of cardiac fibrosis (galectin-3, sST2, serpin-4, procollagen type I amino-terminal peptide, procollagen type I carboxy-terminal propeptide, collagen, transforming growth factor [TGF]-β), inflammation (growth differentiation factor-15, interleukin-6, nuclear factor-κB [NF-κB]), oxidative stress (superoxide dismutase 1 [SOD1] and 2 [SOD2]), and cardiac metabolism (sodium-hydrogen exch"
    },
    "1795-2137": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "hearts suffered ischemia/reperfusion (I/R)",
      "text": "Downregulation of TRIM11 was determined to have significantly reduced I/R-induced proliferation suppression and apoptosis.\nBesides, I/R-activated c-Jun N-terminal kinase (JNK) signaling and cleaved caspase 3 and Bax expression were significantly inhibited by TRIM11 downregulation.\nIn addition, the overexpression of TRIM11 significantly promoted apoptosis in AC16 cells, and JNK1/2 inhibition and DUSP1 overexpression potently counteracted the induction of TRIM11 overexpression in AC16 cells.\nAfter TRIM11 downregulation in I/R cells, cell proliferation (0, 12, 24, and 48 h) and apoptosis at 48 h as well as the related molecular changes in oxidative stress-related pathways was detected.\nThese suggested that the downregulation of TRIM11 attenuates apoptosis in AC16 cells after I/R injury probably through the DUSP1-JNK1/2 pathways.\nThus, this study was designed to explore the effects of tripartite motif protein 11 (TRIM11) on cardiomyocytes I/R injury and its underlying mechanism.\nAs per our findings, it was determined that TRIM11 was highly expressed in the cardiomyocytes AC16 after I/R injury.\nCurrently, the prevention of ischemic diseases such as myocardial infarction associated with ischemia/reperfusion (I/R) injury remains to be a challenge."
    },
    "1800-1917": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Gastric cancer (GC)",
      "text": "PYCR1 upregulation has been reported in multiple malignancies including Hepatocellular Carcinoma (HCC), Lung Cancer (LC), Breast Cancer (BC), Bladder Cancer (BlC), and Gastric Cancer (GC), where it has been shown to promote cancer proliferation, migration, and therapy resistance, correlating significantly with advanced cancer stages and poor prognosis.\nKnockdown inhibited cell viability, migration, and invasion and promoted apoptosis.\nIn vivo, circMORC1 promoted proliferation, viability, and migration and inhibited apoptosis in AGS and SGC-7901 GC cell lines.\nTransfection with the mimic reduced cell viability, increased apoptosis, and inhibited migration, as shown by wound-healing assays.\nHSPB1 overexpression enhanced proliferation, invasion, and migration while suppressing apoptosis by downregulating PANoptosis markers.\nOverexpression of SNHG5 or knockdown of miR-92a-3p reduced GC cell proliferation and migration, and increased BTG2 expression while decreasing PI3K/AKT signaling activity.\nUpregulation of CAB39L inhibited GC cell proliferation, invasion, and migration, decreased the expression of PFKP and LDHA, and increased both apoptosis and AMPK activation.\nGPR176 was found to be upregulated in GC, and functional assays demonstrated that its knockdown suppressed proliferation and migration in the GC cell lines SGC-7901 and HGC-27.\nWe demonstrate that BAG2 upregulation inhibited apoptosis and increased proliferation, migration, and invasion of GC cells, whereas the opposite results were obtained in BAG2-deficient GC cells.\nRBPMS2 promoted the proliferation, invasion, and migration of GC cells while inhibiting pyroptosis by suppressing the NLR family pyrin domain containing 3 (NLRP3)/caspase - 1/gasdermin (DGSDMD) signaling pathway.\nThe high expression of GPX4 in GC inhibits EBV's immediate early lytic gene BZLF"
    },
    "13-1799": {
      "type": "slc_pathway",
      "key1": "SLC2A5",
      "key2": "glycolysis",
      "text": "Given that TKIs could inhibit SLC2A5 expression, repression of fructose utility after TKI treatment contributes to TKI-induced Ph+ALL cytotoxicity.\nMoreover, lung cancer cell migration and AKT activation were restrained by glycolysis inhibitor 2-deoxy-D-glucose (2-DG) or GLUT5-specific inhibitor 2,5-anhydro-D-mannitol (2,5-AM).\nSLC2A5, encoding the fructose transporter, GLUT5, was specifically upregulated in these cells.\nOur study unveils glycolysis/lactate/AKT pathway is responsible for lung cancer cell migration induced by GLUT5-mediated fructose metabolism, providing a potential therapeutic avenue for lung cancer metastasis.\nTo satisfy the improved energy demands, glycolysis flux is increased in cancers compared with healthy tissues.\nThe tyrosine kinase inhibitors (TKIs) imatinib and dasatinib repressed SLC2A5 expression and the cell uptake of fructose.\nOverexpression of SLC2A5 promoted migration of lung cancer cells both in vitro and in vivo, and shortened the overall survival of mice.\nMechanistically, in glucose-deprived but fructose-rich environments, GLUT5 could interact with ketohexokinase and inhibit its autophagy-dependent degradation, thus trapping fructose into glycolysis and tricarboxylic acid cycle for the malignant growth of CRC cells.\nEnhanced fructose metabolism mediated by GLUT5 directly contributes to cancer metastasis.\nGLUT5-mediated fructose utilization upregulated phosphorylated AKT, which was responsible for enhanced migration of lung cancer cells.\nGLUT5 permitted fructose to flux through glycolysis using hexokinase (HK) and not ketohexokinase (KHK).\nAdditionally, GLUT5-mediated fructose utilization boosted glycolysis with overproduction of lactate, resulting in upregulation of phosphorylated AKT.\nCompensating for this, fructose was flexibly"
    },
    "232-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A11",
      "key2": "oxidative phosphorylation",
      "text": "The concomitant down-regulation of all participating proteins (SLC25A11, SLC25A12, GOT2 and MDH2) of malate-aspartate shuttle might be responsible for the metabolic in-coordination between the cytosol and mitochondria resulting in the failure of energy metabolism.\nBioinformatics data mining and immunochemical validation of pivotal perturbed proteins revealed a global failure of the cellular energy metabolism in the infarcted tissues as seen by the parallel down-regulation of proteins related to glycolysis, pyruvate dehydrogenase complex, TCA cycle and oxidative phosphorylation.\nAccording to co-expression network studies, SLC25A11, SLC25A29, and SLC25A44 were involved in the energy metabolism of PC and prevented tumor growth, invasion, and metastasis.\nThe high-risk group had a lower activation of oxidative phosphorylation and a more abundant immune infiltration phenotype than the low-risk group.\nMitochondria do not produce GSH, and although the transport of GSH to mitochondria is not fully understood, two carrier proteins, the dicarboxylate carrier (DIC, SLC25A10) and the oxoglutarate carrier (OGC, SLC25A11) have been suggested to participate in GSH transport.\nInhibition of electron transport chain complexes and oxidative phosphorylation worsened RSL3-induced ferroptosis."
    },
    "233-1800": {
      "type": "slc_pathway",
      "key1": "SLC25A12",
      "key2": "migration",
      "text": "In addition, SLC25A12-silenced HCC cells show a strong reduction of cell migration.\nAGC1-knockdown in mouse lung carcinoma and melanoma cell lines leads to increased pulmonary metastasis following subcutaneous or intravenous injections, respectively.\nOn the other hand, conventional in vitro metastasis assays show no indication of increased metastasis capacity of AGC1-knockdown cells.\nLow AGC1 expression correlates with worse patient prognosis in many cancers.\nFurthermore, SLC25A12 knockdown by small interfering RNA, impairs HepG2 cell proliferation by inducing cell cycle arrest.\nAGC1 sustains HCC cell growth by supplying cytosolic aspartate for nucleotide biosynthesis.\nWe previously described that loss-of-aspartate glutamate carrier 1 (SLC25A12 or AGC1), an important component of the malate-aspartate shuttle, impairs cytosolic aspartate levels, NAD/NADH ratio, mitochondrial respiration, and tumor growth.\nThis study highlights that certain branches of metabolism impact tumor growth and tumor metastasis differently.\nIn addition, it also argues that commonly known metastasis indicators, including EMT genes, cell migration, or colony formation, do not always reflect metastatic capacity in vivo."
    },
    "1802-2105": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "cancer tissues",
      "text": "LINC00667 inhibits breast cancer progression by promoting TRIM33-mediated ubiquitination and subsequent degradation of POTEE, thereby regulating mitochondrial OXPHOS activity.\nMRPL13-SLC25A6 axis enhances mitochondrial function and promotes tumor progression in OC by inhibiting mPTP opening.\nOverexpression of LINC00667 suppresses malignant progression, while its knockdown promotes oncogenic phenotypes in BC.\nRestoring mitochondrial function using retinoic acid (RA) to boost mitochondrial biogenesis and a mitochondrial uncoupler to enhance respiration synergistically drives neuroblastoma differentiation and inhibits proliferation.\nLINC00667 reduces POTEE expression and inhibits mitochondrial oxidative phosphorylation (OXPHOS).\nChemoresistant ovarian cancer cells showed increased oxidative phosphorylation (OXPHOS) compared to chemosensitive cells.\nSilencing MARCH5 impaired mitochondrial oxidative phosphorylation (OXPHOS) and reduced ATP production, ultimately leading to mitochondrial dysfunction and apoptosis in MM cells.\nOverexpression of POTEE enhanced OXPHOS activity, which was counteracted by overexpression of LINC00667.\nSilencing of POTEE decreased the expression of OXPHOS complexes, an effect that could be rescued by knockdown of LINC00667.\nDietary RA and uncoupler treatment promoted tumor differentiation in an orthotopic neuroblastoma xenograft model, evidenced by neuropil production and Schwann cell recruitment.\nThese effects were abolished by electron transport chain (ETC) inhibitors or in ρ cells lacking mitochondrial DNA, emphasizing the necessity of mitochondrial function for differentiation.\nMitochondrial ribosomal protein L13 (MRPL13), involved in the translation of oxidative phosphorylation (OXPHOS) complex subunits, plays a critical role in regulating mitochondrial function.\nBoth in vitro and in vivo experiments confirmed that MRPL13 overexpression significantly promotes the malignant biological behavior of OC, while MRPL13 knockdown indu"
    },
    "185-1795": {
      "type": "slc_pathway",
      "key1": "SLC22A2",
      "key2": "proliferation",
      "text": "Moreover, inhibition of translational of both ODC1 and AGMAT mRNAs increased expression of ADC, SLC22A1, SLC22A2, and SLC22A3 mRNAs, as well as abundances of agmatine, putrescine, spermindine, and spermine in conceptus tissue.\nWe assessed proliferation (Ki-67) and the expression of lipid metabolism and transport proteins (CPT1, SLC22A2, SLC22A5, SLC25A20) by immunohistochemistry, along with etomoxir treatment to provide insights into [F]FPIA uptake.\nUsing five human HNSCC cell lines, we determined the concentrations of cisplatin, carboplatin, and oxaliplatin leading to 50% inhibition of cell proliferation (IC(50)).\nMean IC(50) among the five cell lines was 6.2 ± 1.9 μM for cisplatin and 11.6 ± 4.2 μM for oxaliplatin, whereas carboplatin showed significantly lower proliferation inhibition (IC(50) 107.5 ± 21.2 μM).\nEtomoxir reduced [F]FPIA uptake, which correlated with decreased Ki-67 ( < 0.05).\nSLC22A1 expression was significantly inverse correlated with expression of the proliferation marker MIB1/Ki-67 (rs = -0.464, P < 0.0001).\n[F]FPIA uptake correlated positively with Ki-67 ( < 0.01), SLC22A5 ( < 0.001) and SLC25A20 ( = 0.001), and negatively with CPT1 ( < 0.01) and SLC22A2 ( < 0.01).\nLongitudinal PET imaging showed gradual increase in [F]FPIA uptake in orthotopic glioma models with disease progression ( < 0.0001), and high tumor-to-brain contrast compared to [F]FDG ( < 0.0001).\nOur findings support the use of [F]FPIA P"
    },
    "1795-2360": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "acute and chronic renal failure",
      "text": "endocapillary hypercellularity and extracapillary proliferation) at the timing of biopsy increased over time, as did the rates of prescriptions of renin-angiotensin system blockers and corticosteroids (all P for trend <0.05).\nWhen stimulated, cells sorted by CD57/PD1 status upregulate markers of activation with proliferation.\nSurface CD28 protein is essential for T-cell proliferation and survival as well as cytokine production.\nMonoclonal gammopathy of undetermined significance (MGUS) is usually an asymptomatic pre-malignant condition caused by the proliferation of clonal plasma cells.\nA re-biopsy of the allograft 2 months later revealed resolution of the glomerular endocapillary proliferation and negative staining for NAPlr/plasmin activity, with worsening IFTA.\nAn allograft biopsy showed prominent glomerular endocapillary proliferation on light microscopy, granular C3 deposition on immunofluorescent microscopy, and subepithelial electron-dense deposits on electron microscopy, suggesting IRGN accompanied by moderate interstitial fibrosis and tubular atrophy (IFTA).\nA total of 63 patients (5.0%) developed ESRD.\nThe age-adjusted incidence of ESRD decreased significantly over time, i.e.\nThe effect of acute inflammatory histologic lesions on renal prognosis was drastically reduced over time.\nThese cells are replication incompetent alone but proliferated in the presence of unsorted PBMCs in a contact-independent manner.\nThe abrupt development of severe microscopic hematuria and renal dysfunction was observed approximately 2 weeks after the onset of a phlegmon in his right leg.\nAlthough the infection was completely cured with antibiotic therapy, renal dysfunction persisted.\nUntreated C3 glomerulopathy can lead to irreversible glomerular damage and end-stage renal failure, and a high index of suspicion is essential for timely diagnosis and management.\nGlomerular changes, including NAPlr/plasmin activity staining, almost disappeared after the cessation of infection, while interstitial"
    },
    "1834-1797": {
      "type": "slc_pathway",
      "key1": "SLC7A12",
      "key2": "oxidative stress",
      "text": ""
    },
    "1797-1831": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Neuroendocrine Tumor",
      "text": "However, the significant functions of mitochondrial genes related to oxidative stress (MTGs-OS) in pancreatic cancer (PC) and pancreatic neuroendocrine tumor (PNET) are yet to be investigated integrally.\nAdditionally, targeting the oxidative stress pathway may serve as a new strategy in clinical practice to enhance SKCM chemotherapy and sensitivity.\nMitochondrial dysfunction and oxidative stress-mediated inflammasome activation play critical roles in the pathogenesis of the non-alcoholic fatty liver disease (NAFLD).\nMoreover, NAG-1/GDF15 overexpression inhibited HFD- and FFA-induced oxidative stress and mitochondrial damage which in turn reduced double-strand DNA (dsDNA) release into the cytosol, while NAG-1/GDF15 siRNA showed opposite effects.\nIn conclusion, our results provide evidence that other than regulating lipid homeostasis, NAG-1/GDF15 protects against hepatic steatosis through a novel mechanism via suppressing oxidative stress, mitochondrial damage, dsDNA release, and AIM2 inflammasome activation.\nThe reduced ROS production and dsDNA release may be responsible for attenuated AIM2 activation by NAG-1/GDF15 upon fatty acid overload.\nThis study demonstrated that NTP exposure for 5 min results in the differential regulation of miRNAs related to the PI3K-AKT-ZEB1 axis and cell cycle dysregulation to facilitate melanoma suppression.\nWe conclude that the oxidative stress in the bloodstream decreases during the metastatic process and that nitrosative stress increases during the proliferation and growth of metastatic nodules in the tumor microenvironment.\nAn increase in blood plasma lipid peroxidation occurred at the earliest stage of the disease, with a progressive decrease in oxidative damage and an increase in antioxidant defense.\nVice versa, increased lipid peroxidation and 3-nitrotyrosine, and decreased antioxidant parameters were observed in the metastatic nodules throughout the disease.\nOxidative stress is known to be a major barrier for metastatic colonization, such that metastasizing cancer cells must rewire their metabolic pathways"
    },
    "1796-1920": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Cervical Cancer",
      "text": "We identified that 5-ALA-PDT inhibited cell viability and induced ferroptosis in cervical cancer.\nThe ferroptosis induced by CENPF inhibition in cervical cancer cell lines is likely mediated through the Nrf2/HO-1 pathway.\nIn conclusion, these data inspired that METTL5-mediated mA modification of SLC7A11 promoted cervical cancer by inhibiting ferroptosis, providing a novel insight for cervical cancer.\nThis study confirmed that USP34 could upregulate PIN1 expression and SUMOylation, thereby inhibiting ferroptosis by suppressing the cGAS-STING pathway and in turn promoting the progression of cervical cancer.\nTherefore, our findings revealed that inhibiting ANXA6 can promote tumor cell ferroptosis by activating the cGAS-STING pathway, thereby provide potential strategies that enhancing the efficacy of anti-tumor immunotherapy in cervical cancer.\nThe decreased levels of p62 protein facilitated the degradation of Nrf2 by regulating the p62-Keap1-Nrf2 axis, thereby diminishing the antioxidant capacity of cervical cancer cells, ultimately leading to the induction of apoptosis and ferroptosis.\nMechanistically, CNIH4 elevated solute carrier family 7 member 11 (SLC7A11)-mediated cystine import, and subsequently increased intracellular glutathione synthesis and glutathione peroxidase 4 activity, thereby inhibiting ferroptosis of human cervical cancer cells.\nFurther use of siRNA to interfere with ACSL4 expression in cervical cancer cells revealed that the inhibitory effect of OA on cell viability and proliferative capacity was counteracted, while a decrease in ROS levels and GPX4 was detected, suggesting that OA activated ferroptosis in Hela cells by promoting ACSL4 expression, thereby reducing the survival rate of Hela cells.\nDHODH inhibition inhibited the proliferation and promoted the ferroptosis in cervical cancer cells.\nPIN1 can increase the proliferation and invasion of cervical cancer cells by significantly inhibiting ferroptosis.\nCervical cancer is a prevalent form of cancer in women, and the"
    },
    "142-1798": {
      "type": "slc_pathway",
      "key1": "SLC16A7",
      "key2": "stemness",
      "text": ""
    },
    "45-1800": {
      "type": "slc_pathway",
      "key1": "SLC5A8",
      "key2": "migration",
      "text": "Overexpression of SLC5A8 in the HeLa cell line decreased its proliferation by arresting cancer cells in the G1 phase and inhibiting cellular migration.\nFurthermore, we observed that pyruvate increased the SLC5A8 effect, inducing S-phase arrest and inhibiting the entry into mitosis.\nThese variants significantly increased the proliferation, migration, and invasion abilities of CRC cells.\nSLC5A8 decreased tumor growth in xenograft transplants, significantly reducing the volume and tumor weight at 35 days of analysis.\nDecreased SLC5A8 expression caused by missense variants appeared to significant impair the tumor-suppressive function of the transporter.\nSLC5A8 can suppress colorectal cancer (CRC), and its tumor-suppressive function is mainly associated with butyrate, propionate, and pyruvate, which inhibit histone deacetylase.\nFinally, using colony-formation, wound-healing, and invasion assays, we investigated whether the decrease in SLC5A8 expression resulting from its variants could affect the tumor-suppressive function of the transporter.\nRPE cells from iron-overloaded mice exhibit several features of tumor cells: decreased senescence, enhanced migration, increased glucose uptake, and elevated levels of HDACs and DNMTs.\nVal193Ile and H2 significantly decreased SLC5A8 expression.\nThe expression of Slc5a8 was decreased in Hfe(-/-) RPE cells, but treatment with a DNA methylation inhibitor restored the transporter expression, indicating involvement of DNA methylation in the silencing of Slc5a8 in Hfe(-/-) cells."
    },
    "45-1794": {
      "type": "slc_pathway",
      "key1": "SLC5A8",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1797-2539": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Hepatic ischemia-reperfusion (I/R)",
      "text": "Hepatic ischemia-reperfusion (I/R) injury accompanied by oxidative stress is responsible for postoperative liver dysfunction and failure of liver surgery.\nThe present study aimed to reduce oxidative stress-induced hepatic damage resulting from ischemia and reperfusion due to aortic cross-clamping during surgery by means of resveratrol administration.\nMoreover, Pec treatment inhibited oxidative stress, inflammation and apoptosis and could activate the PI3K/AKT/Nrf2 pathway during I/R and H/R.\nIn conclusion, our results indicated that IL-22 inhibited I/R-induced oxidative stress injury, Ca overload, and mitochondrial apoptosis via STAT3 activation.\nVNS protects against myocardial injury from hepatic ischemia-reperfusion, likely by inhibiting oxidative stress and ferroptosis through activation of the SLC7A11/GPX4 axis.\nIn summary, our results show that Pec inhibits oxidative stress, inflammatory responses, and apoptosis, thereby attenuating I/R-induced liver injury and H/R-induced cell damage via activation of the PI3K/AKT/Nrf2 pathway.\nAdditionally, corynoline pretreatment significantly inhibited I/R-triggered oxidative stress and inflammatory responses, as indicated by enhanced mitochondrial function, reduced levels of ROS and MDA, reduced neutrophil infiltration and suppressed proinflammatory cytokine release.\nOverall, these findings revealed that PLK2 enhanced HO-1 expression and reduced oxidative stress damage in hepatic I/R injury, and this protective effect related to GSK3β activity.\nThis study demonstrates that OTUD1 alleviates oxidative stress, apoptosis, and inflammation induced by hepatic I/R injury.\nRemifentanil mitigates hepatic I/R-induced injury to D1-MSNs by upregulating FGF18, thereby reducing oxidative stress and inflammation while preserving neuronal structure and function.\nH I/R-induced injury resulted in impaired liver function and activated Keap1/Nrf2/HO-1/NQO1 and HMGB1/T"
    },
    "272-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A51",
      "key2": "oxidative phosphorylation",
      "text": "Mechanistically, glucose metabolism reprogramming from oxidative phosphorylation to glycolysis by activation of mitochondrial sirtuin 5 (SIRT5) was found to contribute to the promotion of growth and metastasis by SLC25A51 in HCC cells.\nThe nicotinamide adenine dinucleotide (NAD/NADH) pair is a cofactor in redox reactions and is particularly critical in mitochondria as it connects substrate oxidation by the tricarboxylic acid (TCA) cycle to adenosine triphosphate generation by the electron transport chain (ETC) and oxidative phosphorylation.\n-null cells have large decreases in TCA cycle flux, mitochondrial respiration, ETC complex I activity, and mitochondrial levels of NAD and NADH.\nSolute carrier family 25 member 20 (SLC25A51) is a newly identified mammalian mitochondrial NAD transporter.\nMCART1 is the long sought mitochondrial transporter for NAD in human cells.\nIsolated mitochondria from cells lacking or overexpressing have greatly decreased or increased NAD uptake in vitro, respectively."
    },
    "1796-2099": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Multicancer",
      "text": "Our experimental and computational strategy provides evidence that both factors regulate the expression of several coding and non-coding RNAs that in turn mediate for their cancer-promoting phenotypes, including but not limited to cell cycle, apoptosis, ferroptosis, and oxidative stress response.\nEctopic expression of the lineage survival transcription factors (LS-TFs) GATA4 and 6 promotes stomach oncogenesis."
    },
    "322-1797": {
      "type": "slc_pathway",
      "key1": "SLC34A2",
      "key2": "oxidative stress",
      "text": "SPAK (SPS1-related proline/alanine-rich kinase) and OSR1 (oxidative stress-responsive kinase 1), kinases controlled by WNK (with-no-K[Lys] kinase), are powerful regulators of cellular ion transport and blood pressure.\nSPAK and OSR1 both increased the maximal transport rate of the carrier.\nI(Pi) was observed in NaPi-IIb expressing oocytes but not in water injected oocytes, and was significantly increased by co-expression of SPAK, (T233E)SPAK, OSR1, (T185E)OSR1 or SPAK+OSR1, but not by co-expression of (T233A)SPAK, (D212A)SPAK, (T185A)OSR1, or (D164A)OSR1.\nSPAK and OSR1 are powerful stimulators of the intestinal Na+-coupled phosphate co-transporter NaPi-IIb."
    },
    "188-1797": {
      "type": "slc_pathway",
      "key1": "SLC22A5",
      "key2": "oxidative stress",
      "text": "We hypothesized that carnitine deficiency results in increased myocardial oxidative stress.\nThese findings suggest that increased oxidant stress may contribute to myocardial dysfunction and arrhythmogenesis in this disorder.\nImmunohistochemistry demonstrated accumulation of the reactive aldehyde 4-hydroxy-2-nonenal, indicative of increased lipid peroxidation, and sulfonylation of sarcoendoplasmic reticulum calcium ATPase 2 at cysteine 674.\nIntegration with IPF GWAS, eQTL, and mQTL data identified key genes and regulatory elements involved in IPF pathogenesis, highlighting the role of specific genes such as KCNMA1 and SLC22A5 in modulating IPF risk through epigenetic mechanisms.\nOxidative stress (OS) is crucial in idiopathic pulmonary fibrosis (IPF) pathogenesis, with its genes potentially acting as both causes and consequences of the disease.\nPrimary carnitine deficiency is an autosomal recessive disorder caused by mutations in the SLC22A5 gene which results in impaired carnitine transport, cytosolic fatty acid accumulation and impaired beta oxidation.\nMitochondrial dysfunction, oxidative stress and energy production have been implicated in the etiology of Parkinson's disease (PD)."
    },
    "1797-2351": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "celiac disease",
      "text": "Oxidative stress is considered to be one of the mechanisms responsible for gluten toxicity, but its role in celiac disease (CD) remains unclear.\nToxic gliadin peptide damages enterocytes in celiac disease by causing oxidative stress.\nOxidative stress is a factor involved in the pathogenesis of celiac disease (CD), possibly affecting the course of the disease and celiac-related complications.\nHigh levels of reactive oxygen species (ROS) and impaired antioxidant defense systems lead to oxidative stress (OxS) and tissue injury in different intestinal and extra intestinal conditions, including celiac disease (CD).\nThe gliadin administration induced oxidative stress, improved the activity of antioxidants enzymes, increased NOS2 and NFκB expressions and reduced pNFκB/NFκB ratio.\nAfter 24 h of challenge p31-43, but not palpha-2 or palpha-9, is still retained within LAMP1-positive perinuclear vesicles and leads to increased levels of reactive oxygen species (ROS) that inhibit TG2 ubiquitination and lead to increases of TG2 protein levels and activation.\nGliadin induces cellular oxidative stress, DNA damage and pro-apoptotic stimulation in Caco-2 cells and in the duodenal mucosa of celiac patients.\nGluten toxicity encompasses a wide spectrum of target organ functions and pathologies, including the activation of the immune response and triggering of oxidative stress.\nWe concluded that gliadin intake in combination with COX inhibition caused a basal inflammatory status and an oxidative stress condition in the small intestine of DQ8 mice, thus triggering the mucosal lesion and, subsequently, an antigen-specific immunity.\nEnteropathy onset was further characterized by high levels of oxidative stress markers, similar to CD.\nPro-inflammatory genes were upregulated in this group, with increased CD11b myeloid cell infiltration and oxidative stress parameters observed in aortic and heart tissue.\nThis study systematically assessed the regulatory roles of quercetin on intestinal oxidative damage, immune response, inflammatory damage, and intestinal microflora dysbiosis in celiac disease by utilizing the established celiac and models induced by gluten."
    },
    "432-1799": {
      "type": "slc_pathway",
      "key1": "SLC50A1",
      "key2": "glycolysis",
      "text": "Further in vitro and in vivo experiments confirmed that SLC50A1 can regulate cellular glycolysis and the cell cycle, thereby promoting the proliferation of HCC cells while reducing apoptosis.\nMoreover, our findings indicate that SLC50A1 enhances resistance of HCC cells to DOX and 2-DG.\nThe recognition and binding of the modified SLC50A1 by IGF2BP2 subsequently promote its stability and translational expression.\nFurthermore, we discovered that the m6A methyltransferase METTL3 mediates the methylation modification of SLC50A1.\nConsequently, our research identifies the METTL3/SLC50A1 axis as a novel therapeutic target in the context of HCC.\nThe relationship between SLC50A1, a member of the SLC family involved in glucose transmembrane transport, and HCC remains unclear.\nMetabolic reprogramming has been found to be closely associated with the occurrence and development of hepatocellular carcinoma (HCC)."
    },
    "1795-2099": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Multicancer",
      "text": "In vitro and in vivo studies show baicalein inhibits tumor growth, enhances apoptosis, and regulates cell proliferation, supporting its anticancer effects.\nMoreover, flow cytometric analysis displayed that knocking down of PL2L60 mRNA but not PIWIL2 mRNA effectively inhibited cancer cell proliferation and promoted apoptosis of cancer cells.\nTreatment with G4-stabilizing ligands decreased the fraction of the functional telomerase-encoding full-length isoform, whereas CRISPR/Cas9 deletion of VNTR6-1 increased this fraction and apoptosis while reducing cell proliferation.\nThese results suggested that various cancer could be suppressed by promoting autophagy.\nOur results demonstrate that VOCs directly perturb key targets (FN1, PECAM1, CDK1 etc.), hijacking PI3K-Akt signaling, ECM-receptor interactions, and cell cycle regulation to promote apoptosis evasion and unchecked proliferation.\nAdditionally, T-EVs reduced PD-L1 and Rab27a levels in cancer cells while enhancing the CD8 T-cell cytotoxicity and proliferation.\nWe found that overexpressed POU4F3 suppressed LUAD cell proliferation and , according to CCK-8, colony formation, and xenograft assays.\nThe function of four genes as hubs are confirmed by in vitro HMGB1 knockdown which led to inhibition of cell proliferation and metastasis in SW620 and SW480 cells.\nIn two cell lines, CRISPR/Cas9 deletion of VNTR6-1 increases the ratio of TERT-full-length (FL) to the alternative TERT-β isoform, promoting apoptosis and reducing cell proliferation.\nThe PL2L60 was downregulated in various types of cancer cells under the hypoxic condition independently of HIF‑1α, resulting in apoptosis of cancer cells.\nLUAD cell apoptosis was suppressed by POU4F3 overexpression based on Flow cytometry.\nMAPKs are key signaling molecules regulating cell proliferation, differentiation, stress response, and apoptosis."
    },
    "1800-2539": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Hepatic ischemia-reperfusion (I/R)",
      "text": ""
    },
    "199-1794": {
      "type": "slc_pathway",
      "key1": "SLC22A16",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2001": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Bone cancer",
      "text": ""
    },
    "1799-2001": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Bone cancer",
      "text": "Pharmacological inhibition of glycolysis counteracted the upregulation of ATF3 expression and increased stemness in OSCs by PDK1 overexpression.\nNotably, P4HA1 was upregulated in osteosarcoma tissues and promoted cell proliferation in a glycolysis-dependent manner, as evidenced by increased intracellular ATP levels, inhibited glucose absorption, and elevated lactate levels in P4HA1-overexpressing osteosarcoma cells.\nThus, our results demonstrate that VitC effectively increases the sensitivity of OS to low concentrations of ATO via inhibiting aerobic glycolysis to alleviate the toxic side effects of high doses of arsenic trioxide, suggesting that synthetic application of VitC and ATO is a promising approach for the clinical treatment of human OS.\nIn vitro experiments demonstrate that silencing PDK1 impairs glycolysis, reduces proliferation, and induces apoptosis in 143B osteosarcoma cells.\nOverexpression of circARHGAP12 promoted the Dox resistance half-maximal inhibitory concentration (IC50) and aerobic glycolysis (glucose uptake, lactate and ATP production) in OS cells (Saos-2/Dox, MG63/Dox).\nGS effectively counteracts OS progression by inhibiting glycolysis through MAPK pathway suppression.\nGenetic inhibition of PDK1 via RNA interference reduced OSC stemness, glycolysis, and heterotopic tumor formation.\nCPT1A promoted the proliferation, colony formation, invasion and glycolytic process of ENKTL-NT cells and suppresses apoptosis.\nAdditionally, ENO1 suppression resulted in shifting the primary ATP production pathway from glycolysis to oxidative phosphorylation.\nUSP22 could influence Sao-2 cell proliferation, apoptosis, migration, and invasion by regulating the glycolysis pathway, thereby promoting osteosarcoma progression.\nFurthermore, downregulation of USP22 significantly reduced aerobic glycolysis levels in Sao-2 cells and inhibited the expression of key enzymes and transporters"
    },
    "81-1803": {
      "type": "slc_pathway",
      "key1": "SLC7A11",
      "key2": "radioresistance",
      "text": ""
    },
    "1803-1931": {
      "type": "pathway_disease",
      "key1": "radioresistance",
      "key2": "Nasopharyngeal Cancer (NPC)",
      "text": ""
    },
    "136-1802": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "oxidative phosphorylation",
      "text": "Our results unveil a new gene regulatory program by which E2F1-induced lncRNA-SLC16A1-AS1 forms a complex with its transcription factor that promotes cancer metabolic reprogramming towards the acquisition of a hybrid oxidative phosphorylation/glycolysis cell phenotype favoring BC invasiveness.\nWe assessed the functional relevance of these SLCs in efferocytic phagocytes and observed a robust induction of an aerobic glycolysis program, initiated by SLC2A1-mediated glucose uptake, with concurrent suppression of the oxidative phosphorylation program.\nMoreover, SLC16A1-AS1 increases aerobic glycolysis and mitochondrial respiration and fuels ATP production by fatty acid β-oxidation.\nThe absence of MCT1 impaired CD8 T cell proliferation with a shift of ATP production to mitochondrial oxidative phosphorylation.\nSLC16A1 was upregulated after corpse uptake, increasing the release of lactate, a natural by-product of aerobic glycolysis.\nWhereas glycolysis within phagocytes contributed to actin polymerization and the continued uptake of corpses, lactate released via SLC16A1 promoted the establishment of an anti-inflammatory tissue environment.\nMechanistically, upon E2F1-mediated co-transactivation of the gene pair, SLC16A1-AS1 associates with E2F1 in a structure-dependent manner and forms an RNA-protein complex that enhances SLC16A1/MCT1 expression through binding to a composite SLC16A1-AS1:E2F1-responsive promoter element.\nThese metabolic changes are accompanied by alterations in the expression of the SLC16A1-AS1:E2F1-responsive gene PPARA, a key mediator of fatty acid β-oxidation.\nFunctional pathway analysis revealed TIC-specific activation of oxidative phosphorylation, PI3K-Akt signaling, and ribosome-related processes.\nTICs exhibited distinct transcriptomic signatures, including enrichment of non-coding RNAs (e.g., MIR4737 and SNORD19) and selective upregulation of metabolic transport"
    },
    "1802-2450": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Head and Neck tumors",
      "text": "In primary OaSC tumors, mitotic nuclear division and oxidative phosphorylation pathways are upregulated, while lipid biosynthesis and metabolism pathways are downregulated.\nMechanistic analyses showed that HYOU1 silencing promoted oxidative phosphorylation while inhibited aerobic glycolysis via downregulating LDHB at the posttranscriptional level.\nWe found that activation of PPARα through fenofibrate could inhibit oral cancer cell growth and switch the way of energy production from the Warburg effect to oxidative phosphorylation.\nLPLUNC1 or PHB1 overexpression decreased glycolysis and increased oxidative phosphorylation (OXPHOS)-related protein expression in NPC cells, promoting phosphorylated PHB1 nuclear translocation through 14-3-3σ.\nKnock-down of circPUM1 would result in lower intracellular oxygen concentration, downregulated oxidative phosphorylation, decrease of mitochondrial membrane potential, increase of ROS generation and shrinking of mitochondria, respectively.\nOur data highlight dual counter opposing impacts of atovaquone, serving as a hypoxic radiosensitiser though oxidative phosphorylation (OXPHOS) inhibition, but also in promoting stress induced ISR signaling, conferring resistance to radiation treatment.\nMechanistically, MRPL21 upregulated mitochondrial oxidative phosphorylation (OXPHOS) and increased PARylation level, inhibited autophagy through activating the downstream PI3K/AKT/mTOR signaling pathway, and ultimately led to tumor progression and cisplatin resistance in HNSCC.\nIn addition, tobacco exposed cells showed the Oxidative Phosphorylation (OXPHOS) phenotype with decreased expression of enzymes associated with glycolytic pathway and increased expression of a large number of mitochondrial proteins involved in electron transport chain as well as enzymes of the tricarboxylic acid (TCA) cycle.\nMechanisms underlying chronic damage include decreases in acinar differentiation markers, increases in acinar cell proliferation, immune and inflammatory dysregulation, and metabolic changes including increases in amino acids and reductions in glycolysis and oxidative phosphorylation"
    },
    "1800-1813": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Sarcoma",
      "text": "Silencing of BCAR4 inhibited osteosarcoma cell proliferation and migration while promoting cellular apoptosis, primarily mediated by miR-1260a.\nUpregulation of SLC38A5 promotes proliferation, migration, and invasion of osteosarcoma cells, while the PI3K inhibitor BKM120 can counteract these effects.\nITGB3-KD had a radiosensitizing effect on osteosarcoma in vitro by inhibiting cell viability, proliferation, migration, and invasion and promoting apoptosis.\nSLC38A5 promotes osteosarcoma cell proliferation, migration, and invasion via the glutamine-mediated PI3K/AKT/mTOR signaling pathway and inhibits ferroptosis.\nThis study revealed that NEK2 promotes osteosarcoma proliferation, invasion, migration, and chemoresistance while inhibiting apoptosis, likely through AKT/p-AKT signaling.\nAdditionally, NAMPT increased LOX-dependent cell migration and invasion in chondrosarcoma by suppressing miR-26b-5p generation through the c-Src and Akt signaling pathways.\nPAS treatment significantly reduced osteosarcoma cell viability in a cell selective manner, impaired MG-63 cell migration and increased ROS levels in a time-dependent manner.\nHMGCL inhibits the activation of the PI3K/AKT/mTOR signaling pathway mediated by β-HB, thereby reducing the proliferation, migration, and invasion of osteosarcoma cells while promoting autophagy.\nWe finally proved that HOXA5 silence weakened the inhibitory effect of sh- KDM5A on osteosarcoma proliferation and migration and promoted apoptosis via activating Wnt/β-catenin pathway in vivo and in vitro.\nThe results showed that the downregulation of TRIM17 significantly inhibited osteosarcoma cell clonability and survival potential, migration, and invasion, whereas its overexpression promoted these processes.\nAmong the six identified lncRNAs, AL031775.1 is notably downregulated in osteosarcoma patients and significantly promotes o"
    },
    "1796-1811": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Osteosarcoma(OS)",
      "text": "Furthermore, inhibition of MitoROS using Mito-TEMPO downregulated HIF-1α/HO-1 axis and mitigated the SHK-induced ferroptosis.\nMechanistically, the increased radiosensitization of OS cells by the combined use of the two inhibitors was mediated by increased ferroptosis.\nIn vivo, SHK effectively suppressed OS growth with favourable biosafety, confirming the molecular mechanism underlying SHK-induced ferroptosis in OS.\nKIAA1429 silencing reduced cell viability and increased the expression of ferroptosis-related markers in erastin-treated OS cells, and these effects were reversed by Fer-1.\nNotably, silencing LINC01517 inhibited in vitro cell proliferation, activated NLRP3/caspase-1/GSDMD-mediated pyroptosis, promoted ferroptosis, and enhanced necroptosis in osteosarcoma cells.\nNotably, the Keap1 inhibitor KI696 reversed Bru-induced ferroptosis.\nMAT2A knockdown reduced OS cell proliferation, migration, invasion and enhanced ferroptosis.\nSilence of HOTTIP promoted, while ectopic expression of HOTTIP suppressed, ferroptosis in OS cells and .\nKnockdown of KIAA1429 further enhanced SAS-induced ferroptosis and suppression of xenograft tumor growth.\nWe found that inhibition of miR-1343-3p reduced ferroptosis and promoted OS cell proliferation in vitro and in vivo.\nIn the present study, we found that SFN acted as a potent ferroptosis inducer in OS, which was demonstrated by various inhibitors of cell death.\nSynergetic inhibition of APE1 redox activity and ATM activation sensitized OS cells to IR by inducing ferroptosis, which provides a promising strategy for OS radiotherapy.\nM2-Exos-derived Apoc1 promoted ferroptosis resistance by inhibiting USP40 binding to ACSF2 and promoting ACSF2 ubiquitination and degradation, thus enhancing OS development.\nFurthermore, ANK1 overexpression inhibited the proliferation"
    },
    "227-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A6",
      "key2": "oxidative phosphorylation",
      "text": "In conclusion, our study elucidates the mechanism by which the MRPL13-SLC25A6 axis enhances mitochondrial function and promotes tumor progression in OC by inhibiting mPTP opening, suggesting that MRPL13 holds significant potential for prognostic evaluation and targeted therapy in OC.\nMoreover, MRPL13 knockdown impairs mitochondrial function in OC cells, leading to decreased OXPHOS and ATP levels, increased reactive oxygen species (ROS) generation, mitochondrial depolarization, aberrant opening of the mitochondrial permeability transition pore (mPTP), and mitochondrial structural damage.\nMRPL13 inhibits mPTP opening by accelerating the degradation of SLC25A6, thereby preventing cytochrome c release into the cytoplasm, inhibiting cell death, and enhancing mitochondrial function.\nMitochondrial ribosomal protein L13 (MRPL13), involved in the translation of oxidative phosphorylation (OXPHOS) complex subunits, plays a critical role in regulating mitochondrial function.\nMechanistically, MRPL13 specifically interacts with SLC25A6 and facilitates its degradation via lysine (K)48-linked ubiquitination.\nBoth in vitro and in vivo experiments confirmed that MRPL13 overexpression significantly promotes the malignant biological behavior of OC, while MRPL13 knockdown induces the opposite phenotype.\nThe mitochondrial ATP is exported to the cytoplasm using a specialized transport protein, the ADP/ATP carrier, to provide energy to the cell.\nIn aerobic eukaryotic cells, the high energy metabolite ATP is generated mainly within the mitochondria following the process of oxidative phosphorylation.\nAny deficiency or dysfunction of this membrane protein leads to serious consequences on cell metabolism and can cause various diseases such as muscular dystrophy."
    },
    "52-1797": {
      "type": "slc_pathway",
      "key1": "SLC6A2",
      "key2": "oxidative stress",
      "text": ""
    },
    "1794-1819": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "skin cancer",
      "text": ""
    },
    "405-1801": {
      "type": "slc_pathway",
      "key1": "SLC43A3",
      "key2": "apoptosis",
      "text": "In vitro cell apoptosis and viability analysis were employed to verify the specific tumor inhibition effects of AZD5153.\nAZD5153, a novel bivalent BET bromodomain inhibitor which could inhibit the transcription of MYC and E2F exhibited specific antitumor function for cells with high-risk score."
    },
    "1801-2196": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "glioma",
      "text": "CCAR2 knockdown inhibited cell viability and proliferation and promoted apoptosis in glioma cells.\nRECQL4-depleted glioma cells treated with TMZ and OLA exhibited reduced viability and increased levels of apoptosis markers.\nFunctional studies reveal that SIN1 upregulation enhances glioma cell proliferation and migration while suppressing apoptosis.\nWe investigated the DMC-induced apoptosis and autophagy via inhibition of the AKT/mTOR pathway in human glioma U87MG and T98G cell lines.\nIn conclusion, 6-G impairs glioma cell proliferation, promotes apoptosis, induces G1 phase arrest, and inhibits migration and invasion, primarily through the suppression of the PI3K-AKT pathway.\nTriptolide promoted glioma cell apoptosis by modulating BCL2L11, CASP3, MCL1, and TNF, while reprogramming the immune microenvironment by regulating IL6, IL-1β, IL10, and TGF-β1, thereby suppressing M2 macrophage polarization.\nEngineering overexpressing SYNGR1 could effectively inhibit the malignant biological behaviors, such as the proliferation, adhesion, and invasion, as well as promote the apoptosis of glioma cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling.\nThis study revealed for the first time that inhibition of TXN1 can destroy the apoptotic resistance mechanism of glioma by activating ASK1/P38 MAPK axis, resulting in G2/M phase arrest of glioma cells, inhibiting the proliferation of glioma cells, and promoting apoptosis of glioma cells in malignant gliomas.\nORMDL2 silencing inhibited glioma cell proliferation, lipid droplet formation, and promoted apoptosis in vitro.\nOverexpression of BTRC inhibits proliferation, migration and invasion, while promoting apoptosis in glioma cells.\nIts inhibition sensitizes glioma cells to TRAIL-induced apoptosis, identifying SETD"
    },
    "2366-1794": {
      "type": "slc_pathway",
      "key1": "SLC22A",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2099": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Multicancer",
      "text": ""
    },
    "1800-2282": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Esophageal squamous cell carcinoma (ESCC)",
      "text": ""
    },
    "25-1794": {
      "type": "slc_pathway",
      "key1": "SLC3A2",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "13-1794": {
      "type": "slc_pathway",
      "key1": "SLC2A5",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1796-1817": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Myeloproliferative Neoplasms",
      "text": "Taken together, this study demonstrated that ENO1 is a crucial biomarker for CML TKIs responses, and ENO1 blockade could augment TKIs sensitivity and promote the ferroptosis susceptibility in TKIs-resistant cells by ultimately inducing GPX4 autophagic degradation through AMPK/mTOR pathway and ENO1-TMEM164 interaction, which provide a potential novel target for the clinical treatment of CML.\nWe surmise that the combined inhibition of Trx1 and GCL promotes the induction of hydrogen peroxide and depletes GPX4 expression in CML cells, resulting in ferroptosis in cancerous cells.\nIn this study, we demonstrated that Disulfiram (DSF) induces ferroptosis to synergize with TKIs in inhibiting BCR-ABL+ cells, particularly targeting resistant cells and LSCs, using cell models, mouse models, and primary cells from patients.\nHesperadin can promote ferroptosis in K562 cells by regulating the SLC7A11/GPX4 axis.\nIn vitro experiments confirmed that the combination of a ferroptosis inducer called RSL3 effectively overcame drug resistance.\nBy conducting cellular experiments, we confirmed that CML-resistant cells are more sensitive to induction of ferroptosis and can enhance the sensitivity of imatinib treatment.\nMn-Zn Ferrite (Nano-Iron) enhances the therapeutic sensitivity of K562/ADR cells to adriamycin by inducing ferroptosis, demonstrating the therapeutic potential in reversing drug resistance.\nIn conclusion, we identified a subgroup of CML cells with tumor stem cell properties and demonstrated that ferroptosis inducer improved the efficacy of selinexor in overcoming drug resistance.\nFerroptosis scores were significantly lower in samples from patients with CML compared to normal samples, and these scores further decreased with disease progression and non-response to treatment.\nWe elucidated the mechanism by which DSF promotes GPX4 degradation to induce ferroptosis through immunofluorescence, co-immunoprecipitation (CO-IP), RNA sequencing, lipid peroxidation assays, and rescue experiments."
    },
    "367-1802": {
      "type": "slc_pathway",
      "key1": "SLC38A1",
      "key2": "oxidative phosphorylation",
      "text": "These results suggest that the controlled environment population may have enhanced glucose metabolic ability via activation of glycolysis/gluconeogenesis, the TCA cycle, and inositol phosphate metabolism, while the ex situ population may meet higher energy requirements via enhancement of the amino acid metabolism of the liver and muscle and oxidative phosphorylation."
    },
    "136-1799": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "glycolysis",
      "text": "It was found for the first time that EMB promoted lactic acid accumulation and further induced redox dyshomeostasis and glycolysis disorder by simultaneously inhibiting SLC16A1/3.\nSLC16A1 was upregulated after corpse uptake, increasing the release of lactate, a natural by-product of aerobic glycolysis.\nIn turn, the reciprocal SLC16A1-AS1/IL-6 signaling between HCC cells and M2 macrophages promoted the proliferation, invasion and glycolysis of HCC cells.\nWhereas glycolysis within phagocytes contributed to actin polymerization and the continued uptake of corpses, lactate released via SLC16A1 promoted the establishment of an anti-inflammatory tissue environment.\nOur results unveil a new gene regulatory program by which E2F1-induced lncRNA-SLC16A1-AS1 forms a complex with its transcription factor that promotes cancer metabolic reprogramming towards the acquisition of a hybrid oxidative phosphorylation/glycolysis cell phenotype favoring BC invasiveness.\nMoreover, SLC16A1-AS1 increases aerobic glycolysis and mitochondrial respiration and fuels ATP production by fatty acid β-oxidation.\nSLC16A1/3 is the critical hub for regulating the internal and external environment, glycolysis, and redox homeostasis in cervical cancer cells.\nGA-Fe@EMB can target cervical cancer marker SLC16A1/3 to regulate glycolysis and redox pathways, synergistically with photothermal therapy, which provides a new avenue for the synergistic treatment of malignant cervical cancer.\nWe further show both in vitro and in vivo that the sodium lactate-mediated inhibition of CD4+ T cell motility is due to an interference with glycolysis activated upon engagement of the chemokine receptor CXCR3 with the chemokine CXCL10.\nSLC16A1 functions to efflux lactic acid during aerobic glycolysis.\nIn HepG2 cells with the highest NaCT expression, extracellular citrate treatment upon hypoxia induced HIF1α degradation, which led to reduce"
    },
    "1799-1872": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "breast cancer(BC)",
      "text": "FOXM1 upregulates SQLE, which in turn mediates glycolysis to suppress anoikis in BC.\nThe glycolysis inhibitor 2-deoxy-D-glucose enhanced IR sensitivity in BC cells via circABCB10.\nHyperglycemia-downregulated tRF-Cys-GCA-029 enhances the malignancy and glycolysis of BC cells.\nTG2-induced activation of the MEK/ERK/LDH pathway and glycolysis were attenuated by MEK inhibitor U0126.\nMechanistically, PROM2 interacts with AKT to activate mTOR signaling, thereby promoting glycolysis and inhibiting ferroptosis.\nMiR-4458 overexpression suppressed cell glycolysis, proliferation, and metastasis and promoted apoptosis in BC cells through PGK1 upregulation.\nDownregulation of circ_0022587 inhibited cell viability, proliferation, invasion ability, tube angiogenesis and glycolysis, and promoted cell apoptosis.\nThe knockdown of ARL5B activated MDA5 signaling and thus led to the enhanced mitochondrial- mediated apoptosis and glycolysis inhibition in breast cancer cells.\nCircZFR silencing or miR-578 overexpression repressed BC cell viability, colony formation, migration, invasion, and glycolysis and enhanced cell apoptosis in vitro.\nTAMs promoted BC cells' proliferation, migration, invasion, and glycolysis through the transmission of exosomal IFI6 while inhibiting apoptosis and ROS accumulation.\nFollowing HOXC13 knockdown in BC cells, the viability, proliferation, glycolysis, migration, invasion and EMT were significantly decreased, and apoptosis was significantly increased.\nPARP14 was also notably associated with the glycolysis pathway, showing a positive correlation with genes that enhance glycolysis, and its suppression led to decreased glycolysis in T47D/TAMR cells.\nHT and LUT appeared to inhibit glycolysis and promote the hexosamine biosynthetic pathway in MDA-MB-231 cells, while MCF-7"
    },
    "1797-1917": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Gastric cancer (GC)",
      "text": "This study explored the promoting effect of oxidative stress-induced growth inhibitor family member 2(OSGIN2) on gastric cancer (GC) through public databases and in vitro experiments.\nAccumulating evidence suggests that some anti-tumor compounds and genes can induce massive production of reactive oxygen species (ROS) via inhibiting Nrf2 expression, which exacerbates oxidative stress and promotes Gastric cancer (GC) cell death, thereby enhancing the sensitivity of GC cells to chemotherapy-induced PCD.\nOxidative stress is linked to increased risk of gastric cancer (GC).\nOxidative stress, as a characteristic of cellular aerobic metabolism, plays a crucial regulatory role in the development and metastasis of gastric cancer (GC).\nOxidative stress (OS) plays a key role in gastric cancer (GC).\nSmoking is a risk factor for gastric cancer (GC) and causes oxidative stress.\nOxidative stress significantly influences the development and progression of gastric cancer (GC).\nGastric cancer (GC) is a significant global health issue, with oxidative stress playing a pivotal role in its pathogenesis.\nOxidative stress, immune response, and inflammation play an important role in the occurrence and progression of gastric cancer (GC).\npylori-induced oxidative stress in a host is stronger and GC-derived strains may have suppressive influences on the host's GSH-related defense systems.\nNotably, FTO knockdown resulted in increased oxidative stress, enhanced autophagy, and reduced tumorigenicity, which were reversed by CCL2 overexpression.\nFunctional assays revealed that CCL2 promotes GC cell proliferation and survival by suppressing autophagy and attenuating oxidative stress-induced apoptosis.\npylori-induced gastric tumor development accompanied by a decrease in gastric epithelial cell growth, oxidative stress, and expression of gastric epithelial stem cells markers.\nTumor growth and matrix metalloproteinase expression in tumor tissues were markedly inhibited, while oxidative stress was enhanced in nude mice after stable PSMA3-AS1 knockdown.\nMechanistically, ARHGAP15 inactivated RAC1 and then decreased intracellular accumulation of reactive"
    },
    "1800-1924": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Head and Neck Cancer",
      "text": "PLSCR1 knockdown inhibited TSCC cell proliferation, migration, and invasion, and upregulated apoptosis.\nMechanistic investigations revealed that 1A inhibits cancer cell migration and induces ROS-mediated apoptosis.\nIts upregulation promoted proliferation, inhibited apoptosis, and enhanced migration and invasion in HNSCC cells.\nKnockdown of SARS1 in HNSCC cell lines inhibited cell viability, migration, and colony formation while promoting apoptosis.\nThrough modulation of cytokine receptor activation on ATC cells, this process reduced ATC cell proliferation, invasion, and migration.\nGNL3L was upregulated in ESCC specimens (p < 0.05) and knockdown reduced proliferation and migration while enhancing apoptosis (p < 0.01).\nIn conclusion, WWOX exerts inhibitory effects on the proliferation and migration of ESCC and promotes apoptosis by suppressing the Hippo signaling pathway.\nBoth curcumin and EF24 inhibit the viability, migration, and invasion, and induce apoptosis of OSCC cells and the IC of EF24 was much lower than that of curcumin.\nSUZ12 knockdown inhibits the proliferation, migration, invasion and EMT in OTSCC cells by inhibiting DNMT1-mediated ZNF582 promoter methylation, thereby suppressing tumor growth in vivo.\nRescue assays further revealed that circCGNL1 inhibited NPC cell proliferation, migration, and invasion while increasing apoptosis by suppressing the activation of the AKT/mTOR signaling.\nNRG also induced HER3-dependent FAK phosphorylation, and FAK knockdown or inhibition with PF228 significantly reduced NRG-driven migration, highlighting the critical role of HER3-FAK signaling.\nThe results demonstrated that compounds , , and significantly inhibited cell proliferation and migration, induced apoptosis, and downregulated the expression of COX-2 and its downstream targets.\nBerberine induces ferroptosis and inhibits KB-1 oral cancer cell proliferation and migration by modulating the ferroptosis signaling"
    },
    "53-1795": {
      "type": "slc_pathway",
      "key1": "SLC6A3",
      "key2": "proliferation",
      "text": "We identify LRP5, SLC6A3, and SOX10 as potentially important genes related to cell proliferation and invasion in the pathogenesis of ameloblastomas, along with both parthenolide and vorinostat as inhibitory drugs that could be further investigated for the development of novel therapeutic approaches against ameloblastoma.\nAmong the nine prognostic genes, MMP1, identified as the most promising candidate, demonstrated the capacity to enhance tumor cell proliferation and invasion.\nThe objective of this study was the identification of key genes and inhibitory drugs related to the cell proliferation and invasion of ameloblastoma using bioinformatic analysis.\nGene ontology enrichment analysis identified four pathways related to cell proliferation and cell invasion.\nThe inhibitory drugs bioinformatically obtained for the above three genes were parthenolide and vorinostat.\nWhen considering neurogenesis genes, a downregulation of proliferating cell nuclear antigen (pcna) was noticed in zebrafish exposed to the mixture treatment, while for dopaminergic system-related genes (th and slc6a3) an upregulation was observed in MPs, Cu25 and Cu25 +MPs groups.\nCell proliferation, apoptosis, and invasion assays were conducted to investigate the functional role of the target gene.\nThe cell proliferation assay and wound-healing assay results showed that RSB does not affect PC12 cell proliferation and chemotaxis.\nhowever, only SLC6A3, SOX10, and LRP5 were negatively associated with overall survival (HR = 1.49 ( = 0.0072), HR = 1.55 ( = 0.0018), and HR = 1.38 ( = 0.025), respectively).\nCell proliferation and invasion are characteristic of many tumors, including ameloblastoma, and are important features to target in possible future"
    },
    "1801-1819": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "skin cancer",
      "text": "TTAU significantly reduced melanoma cell viability and induced apoptosis both in vitro and in vivo.\nThe compounds significantly reduced cell viability and promoted apoptosis in both cancer cell lines.\nNicotinamide Promotes Apoptosis in Malignant Melanoma via PARP1 Inhibition and Mitochondrial Pathway Activation.\nParthenolide inhibited cell viability and induced apoptosis and S-phase cell cycle arrest in BRAFi-resistant melanoma cells.\nAZD2811, a selective AURKB inhibitor, induces mitotic dysregulation and apoptosis in MCC cells, with greater efficacy in VP-MCC.\nErianin inhibits cell migration and induces apoptosis by inhibiting VEGF-α/PI3K/AKT signaling pathway in malignant melanoma.\nA significant decrease in cell viability is noted in the MB + ZnO NPs group, indicating increased cytotoxicity and apoptosis induction.\nFollowing VSIG-3/IGSF11 silencing in A2058 cells, viability, proliferation, and migration rates were decreased, while apoptosis was increased.\nThe E7107-exposed UM cell lines exhibited decreased cell viability and increased apoptosis, with the greatest effect on SF3B1-mutated UM cells.\nWe demonstrated that the overexpression of RIPK4 inhibits, while its downregulation enhances, CisPt- or DOX-induced apoptosis in melanoma cells.\nMeanwhile, the expression of the key oncogenic factors DDX5 was also reduced and apoptosis was promoted through the BAX/BCL-2/c-Caspase3 pathway.\nIn vitro findings revealed that (2-methylbutyryl) Shikonin significantly reduced the viability and promoted apoptosis in the B16F10 melanoma cells.\nThe study found that curcumin induced apoptosis in CTCL cells by activating mitochondrial signaling pathways and caspases leading to growth inhibition.\nSTING overexpression or cGAMP treatment significantly reduced cell viability, increased ROS levels, and enhanced apoptosis in irradiate"
    },
    "59-1795": {
      "type": "slc_pathway",
      "key1": "SLC6A9",
      "key2": "proliferation",
      "text": "Inhibiting glycine utilization via SLC6A9 knockdown or the treatment with betaine suppresses MM cell proliferation and enhances the effects of bortezomib on MM cells.\nKnockdown and overexpression experiments of in granulosa cells demonstrated that the number of EdU-positive cells significantly decreased in the knockdown group ( < 0.05), while the expression levels of ( < 0.05), / ( < 0.01), and ( < 0.05) were significantly upregulated, indicating that knockdown of markedly inhibited granulosa cell proliferation.\nIn contrast, overexpression of significantly promoted cell proliferation.\nMM cells utilize the channel protein solute carrier family 6 member 9 (SLC6A9) to absorb extrinsic glycine subsequently involved in the synthesis of glutathione (GSH) and purines.\nHere, we show that the glycine concentration in the BM microenvironment is elevated due to bone collagen degradation mediated by MM cell-secreted matrix metallopeptidase 13 (MMP13), while the elevated glycine level is linked to MM progression.\nTogether, we identify glycine as a key metabolic regulator of MM, unveil molecular mechanisms governing MM progression, and provide a promising therapeutic strategy for MM treatment.\nKEGG enrichment analysis showed that was significantly enriched in the glycine, serine and threonine metabolism and vitamin B6 metabolism pathways.\nNormal proliferation of ovarian granulosa cells is essential for follicular development."
    },
    "1-1800": {
      "type": "slc_pathway",
      "key1": "SLC1A1",
      "key2": "migration",
      "text": "R-2-HG hijacks SLC1A1 to promote mitochondrial Na/Ca exchange, which activates the mitochondrial respiratory chain and fuels vascular endothelial cell migration in tumor angiogenesis.\nmiR-96a-5p was identified as the putative target for CircRNA ZFR and its inhibition promoted HCC through modulating the expression of SLC1A1 gene.\nTogether, we identify a new role of SLC1A1 as a gatekeeper of R-2-HG-mediated crosstalk between IDH1-mutant tumor cells and vascular endothelial cells, and demonstrate the therapeutic potential of mIDH1 inhibitors in treating IDH1-mutant solid tumors via disrupting R-2-HG-promoted tumor angiogenesis.\nCircRNA ZFR overexpression promoted HCC cell proliferation, migration and invasion while its knockdown inhibited HCC progression.\nSLC1A1 deficiency in mice abolishes mIDH1-promoted tumor angiogenesis as well as the therapeutic benefit of mIDH1 inhibitor in solid tumors.\nMechanistically, SLC1A1, a Na-dependent glutamate transporter that is preferentially expressed in endothelial cells, facilitates the influx of R-2-HG from the tumor microenvironment into the endothelial cells as well as the intracellular trafficking of R-2-HG from cytoplasm to mitochondria.\nIn this study, we discover that R-2-HG produced by IDH1-mutant tumor cells is preferentially imported into vascular endothelial cells and remodels mitochondrial respiration to promote tumor angiogenesis, conferring a therapeutic vulnerability in IDH1-mutant solid tumors.\nCollectively, circRNA ZFR knockdown retarded HCC progression by sponging miR-96a-5p and modulating SLC1A1 expression, suggesting that the circZFR/miR-96a-5p/SLC1A1 axis may serve as potential therapeutic targets for HCC."
    },
    "166-1802": {
      "type": "slc_pathway",
      "key1": "SLC19A2",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1800-1831": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Neuroendocrine Tumor",
      "text": "ZNF197-AS1 upregulates GABARAPL1 by sponging miR-425, inhibiting UM cell proliferation, migration, and invasion.\nFollowing VSIG-3/IGSF11 silencing in A2058 cells, viability, proliferation, and migration rates were decreased, while apoptosis was increased.\nFurthermore, mTOR pathway was activated under higher matrix stiffness and the migration and invasion of GH3 cells be repressed by mTOR inhibitor.\nCENPA silencing induced changes in R-loop distribution, upregulated Hippo signaling activity, and inhibited tumor cell proliferation and migration.\nTGP inhibited cell viability and migration and induced mitochondrial dysfunction and apoptosis by promoting the degradation of α5-nAChR in melanoma cells.\nFunctionally, BiRDS was observed to inhibit the proliferation, migration, and invasion of UM cells while promoting apoptosis through the miR-30a-5p/E2F7 axis.\nIn vitro, VIAN-c4551 suppressed the B16-F10 cell-induced and VEGF mediated increase in endothelial cell monolayer permeability and the transendothelial migration of B16-F10 cells.\nUSP41 knockdown inhibited cell proliferation, migration, and invasion while promoting cell apoptosis and inhibiting phosphorylated PI3K, AKT, and mTOR in the PI3K/AKT signaling pathway.\nCrucially, PTK6 knockdown suppressed tumor progression through increased apoptosis, reduced cell viability, impaired migration, and decreased tumor volume, mediated by Hippo pathway activation.\nIndeed, in the presence of hAFSC-EVs, a reduction of the G2/M phase was observed on melanoma cell lines, an activation of the apoptotic pathway occurred and the migration and invasion ability reduced.\nThe findings demonstrated that silencing PURPL significantly repressed melanoma cell viability, colony formation, migration, and invasiveness, indicating its potential role in promoting radioresistance.\nOur findings indicate that, in vitro, SUCMSCs reduce melanin content and tyrosinase"
    },
    "222-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A1",
      "key2": "oxidative phosphorylation",
      "text": "Furthermore, Slc25a1 inhibition under HFD conditions activated the SIRT1/PGC1α pathway, promoting mitochondrial proliferation and enhancing oxidative phosphorylation for energy production.\nDuring metabolic stress, SLC25A1 increased oxidative phosphorylation (OXPHOS) to protect protects CRC cells from energy stress-induced cell apoptosis.\nWe show here that lung CSCs rely upon oxidative phosphorylation for energy production and survival through the activity of the mitochondrial citrate transporter, SLC25A1.\nBy restraining glycolysis, CIC inhibition increases NAD content to ensure mitochondrial biogenesis for oxidative phosphorylation.\nFunctional pathway analysis revealed TIC-specific activation of oxidative phosphorylation, PI3K-Akt signaling, and ribosome-related processes.\nMoreover, in different patient-derived tumors, resistance to cisplatin or to epidermal growth factor receptor (EGFR) inhibitor treatment is acquired through SLC25A1-mediated implementation of mitochondrial activity and induction of a stemness phenotype.\nAmong the 640 vulnerability genes identified, many were involved in mitochondrial metabolism, and metabolic flux analysis confirmed enhanced oxidative phosphorylation use in Dnmt3a versus Dnmt3a (WT) HSPCs.\nWe demonstrate that SLC25A1 plays a key role in maintaining the mitochondrial pool of citrate and redox balance in CSCs, whereas its inhibition leads to reactive oxygen species build-up thereby inhibiting the self-renewal capability of CSCs.\nMechanistic analysis via the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway indicated that DMC-GF's anti-GSC activity is associated with disruption of mitochondrial oxidative phosphorylation.\nCollectively, SLC25A1 plays a pivotal role in the promotion of CRC growth and survival by reprogramming energy metabolism.\nFurther research indicates that PTL caused the production of ROS and the reduction of oxidative phosphorylation (OXPHOS) and mitochondrial membrane potential (MMP) levels of LCSCs.\nAbstract: The developing mammalian heart undergoes an important metabol"
    },
    "1802-1850": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "liver cancer",
      "text": ""
    },
    "39-1801": {
      "type": "slc_pathway",
      "key1": "SLC5A2",
      "key2": "apoptosis",
      "text": "After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (P < 0.05).\nMoreover, the increased protein expression levels of autophagy and apoptosis in HG/PA induced HUVECs were also decreased by the treatment of Dapagliflozin (P < 0.05).\nAfter the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (P < 0.05).\nDapagliflozin can improve the dysfunction of high glucose/high fat-induced human umbilical vein endothelial cells by downregulate autophagy through inhibiting SGLT-2.\nFurthermore, the human islet grafts showed no effects of DAPA treatment on hormone content, endocrine cell proliferation or apoptosis, or amyloid deposition.\nThere are numerous ways of treating T2DM with empagliflozin, including by regulating apoptosis, cell aging, as well as the , , , , , , and pathways.\nThe top 10 pathways were endocrine resistance, the signaling pathway, the signaling pathway, apoptosis, cell senescence, the Ras signaling pathway, the signaling pathway, the signaling pathway, the signaling pathway, and the p53 signaling pathway."
    },
    "1801-1850": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "liver cancer",
      "text": ""
    },
    "425-1802": {
      "type": "slc_pathway",
      "key1": "SLC48A1",
      "key2": "oxidative phosphorylation",
      "text": "We found that the levels of the rate-limiting heme synthesis enzyme ALAS1 and uptake protein SLC48A1, along with OXPHOS complex subunits, progressively increased as lung tumorigenesis advanced.\nTo further verify the importance of heme in promoting tumorigenicity, we generated NSCLC cell lines with increased heme synthesis or uptake by overexpressing either the rate-limiting heme synthesis enzyme ALAS1 or uptake protein SLC48A1, respectively.\nThese data show that elevated heme flux and function underlie enhanced OXPHOS and tumorigenicity of NSCLC cells.\nNotably, tumors formed by cells with increased heme synthesis or uptake also displayed elevated OCRs and ATP levels.\nHeme is a central molecule for oxidative metabolism and ATP generation via mitochondrial oxidative phosphorylation (OXPHOS).\nThese findings show that elevated heme availability due to increased heme synthesis and uptake causes intensified oxygen consumption and ATP generation, promoting tumorigenic functions and tumor growth in NSCLC.\nThese results show that the advancing of lung tumorigenesis requires progressive increase in cellular heme synthesis and uptake, leading to intensified OXPHOS activity and ATP generation and promoting aggressive tumorigenic functions.\nHere, we showed that levels of heme synthesis and uptake, mitochondrial heme, oxygen-utilizing hemoproteins, oxygen consumption, ATP generation, and key mitochondrial biogenesis regulators were enhanced in NSCLC cells relative to nontumorigenic cells.\nThese cells exhibited enhanced migration and invasion and accelerated tumor growth in mice.\nFurther analyses indicated that HeSP2 effectively diminished OXPHOS in both ADC and SCC, reduced angiogenesis, alleviated tumor hypoxia, and suppressed cell proliferation.\nEngineered heme-sequestering peptides (HSP) reduced heme uptake, intracellular heme levels, and tumorigenic functions of NSCLC cells.\nImportantly, treatment of KLLuc mice with a heme-sequestering protein, HeSP2, that inhibits heme uptake in tumor cells effectively arrested lung tumor progression, and both ADC and SCC tumors were strongly suppressed."
    },
    "1802-2188": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "colon adenocarcinoma (COAD)",
      "text": ""
    },
    "1794-2429": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "diabetes vascular complications",
      "text": ""
    },
    "391-1796": {
      "type": "slc_pathway",
      "key1": "SLC39A14",
      "key2": "ferroptosis",
      "text": "IRG1/itaconate can alleviate the TAA-induced hepatic fibrosis in mice by regulating the expression of SLC39A14, consequently suppressing hepatic stellate cell ferroptosis.\nSubsequently, miR-1275 downregulated the expression of SLC39A14, a crucial iron transporter that is upregulated in aged livers and plays a pivotal role in promoting ferroptosis.\nIn addition, deleting hepatic Slc39a14 expression in Trf-LKO mice significantly reduced hepatic iron accumulation, thereby reducing ferroptosis-mediated liver fibrosis induced by either a high-iron diet or CCl4 injections.\nNotably, this study is the first to reveal the pivotal role of SLC39A14 in the pathogenesis of hepatic fibrosis in murine models and elucidate how IRG1/itaconate mediates downstream ferroptosis-related signaling pathways by targeting SLC39A14, thereby inhibiting ferroptosis-induced hepatic fibrosis.\nMoreover, SLC39A14 knockdown also facilitated erastin-induced ferroptosis, leading to the suppression of mouse transplantation tumor growth.\nExosomes derived from hBMSCs delivered abundant miR-16-5p into hepatocytes, which post-transcriptionally suppressed the expression of SLC39A14 and reduced cell ferroptosis induced by hepatic IRI.\nOur research demonstrates that iron overload occurs during VC, and that inhibition of Slc39a14 and Slc39a8 significantly relieves VC by intercepting iron overload-induced ferroptosis in VSMCs, providing new insights into the VC treatment.\nIn summary, CLEC3B promotes chemosensitivity via interacting with SLC39A8 and SLC39A14 to induce ferroptosis.\nSilencing SLC39A14 inhibits ferroptosis and tumor progression, potentially involving the regulation of the cGMP-PKG signaling pathway.\nTFRC ablation led to condylar cartilage thickness and condyle length alterations and induced the ferroptosis of chondrocyte by upregulating SLC39A14."
    },
    "272-1801": {
      "type": "slc_pathway",
      "key1": "SLC25A51",
      "key2": "apoptosis",
      "text": "We found that lowering SLC25A51 levels led to increased apoptosis and prolonged survival in orthotopic xenograft models.\nSingle-cell analysis further demonstrated h eightened expression of SLC25A19 in the immune microenvironment of HCC, and in vitro experiments indicated that SLC25A19 may regulate the proliferation, migration, invasion, cycle, and apoptosis of liver cancer cells through the Wnt pathway."
    },
    "1802-2440": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Venous thromboembolism (VTE)",
      "text": "Terms of regulation of actin cytoskeleton enriched by downregulated genes and oxidative phosphorylation enriched by upregulated genes were found in 2 types of VTE.\nThe most significant pathways enriched by module genes were ribosome and oxidative phosphorylation.\nActin cytoskeleton and oxidative phosphorylation may be involved in the common mechanisms of recurrent VTE and single VTE.\nThe most prominent KEGG pathways associated with VTE were ribosome, Parkinson's disease, oxidative phosphorylation, Alzheimer's disease, and Huntington's disease according to GSEA findings.\nKEGG pathway analysis revealed that DEGs were enriched in ribosome, COVID-19, viral infection, oxidative phosphorylation, Parkinson's disease, nonalcoholic fatty liver disease, apoptosis, and cancer.\nThe identified 42 DEGs in RVTE were mainly enriched in biological processes of cellular protein metabolism, gene expression and translational elongation as well as in pathways associated with ribosomes, Parkinson's disease and oxidative phosphorylation.\nThe cell response to acute PE was suggested to involve the uncoupling between glycolysis and oxidative phosphorylation.\nCo-genes are present in nucleolus and extracellular exosomes and are involved in oxidative phosphorylation and ribosome/poly(A)-RNA organization."
    },
    "119-1796": {
      "type": "slc_pathway",
      "key1": "SLC12A5",
      "key2": "ferroptosis",
      "text": "High SLC12A5 levels were correlated with a poor prognosis, promoted tumorigenesis, and inhibited ferroptosis in HCC.\nFurthermore, SLC12A5 inhibited ferroptosis in HCC by upregulating the expression of xCT, a cystine transporter.\nMoreover, SLC12A5 knockdown decreased BC cell ferroptosis resistance and glucose metabolism reprogramming.\nTranscriptional activation of SLC12A5 by ETV4 modulated the migration, invasion, ferroptosis resistance and glucose metabolism reprogramming of BC cells.\nFurthermore, ETV4 overexpression counteracted the suppressive effect of SLC12A5 knockdown on the BC cell proliferative, migratory and invasive abilities, as well as on ferroptosis resistance and glucose metabolism reprogramming.\nThese findings suggested that SLC12A5 is a therapeutic target and provide insight into the link between ER stress and ferroptosis in HCC.\nMechanistically, SLC12A5 promoted ER stress to enhance calcium release and upregulated PNCK expression levels.\nHigh SLC12A5 expression was strongly associated with a poor clinical prognosis and promoted HCC growth.\nPNCK activated and induced the phosphorylation of PI3K/AKT/mTOR pathway components.\nConcomitantly, PNCK was significantly activated by calcium ions released from the ER."
    },
    "4-1795": {
      "type": "slc_pathway",
      "key1": "SLC1A4",
      "key2": "proliferation",
      "text": "Furthermore, the functional analysis revealed that silenced SLC1A4 inhibited cell proliferation, migration, cell cycle, and promoted cell apoptosis in HCC.\nAs a result, silencing SLC1A4 inhibited the proliferation, migration, and stemness of hepatic cancer cells, which was successfully reversed by the introduction of exogenous AKT.\nhUSCs remarkably inhibited CTX-induced apoptosis and promoted the proliferation of GCs, respectively.\nAdditionally, FOXA1 knockout inhibited cell proliferation and further increased the dependence of THBEc1 cells on Glu.\nMore importantly, the knockdown of SLC1A4 or simple supplementation of serine suppressed CTX-induced apoptosis of GCs.\nMechanically, silencing SLC1A4 inhibited the phosphorylation activation of AKT by suppressing the ubiquitin modification of AKT at lysine 63 and amino acid influx represented by D-serine, decreasing the protein level of -catenin in the cell nucleus and suppressing the transcriptional activity of c-Myc and EpCAM promoters.\nIn addition, we observed that miR-27b-3p was highly expressed in hUSC-Exo and markedly suppressed CTX-induced GC apoptosis by specifically inhibiting the expression of SLC1A4, a serine transporter, in ovarian GCs, which, in turn, elevated the concentration of the intracellular serine by inhibiting the outflux of cellular serine.\nIn conclusion, SLC1A4 promotes the malignant transformation of HCC through activating signal transduction mediated by AKT.\nMoreover, epithelial-mesenchymal transition (EMT) in vitro and metastasis potential in vivo of hepatic cancer cells was suppressed by the downregulated SLC1A4 level.\nFinally, we demonstrated that CTX-induced apoptosis of ovarian GCs was essential for POF by reducing the intracellular serine concentration via elevating the expression of SLC1A4, whereas hUSCs protected against CTX-induced POF via miR-27b-3p/SLC1A4/se"
    },
    "1797-2379": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "pancreatic tumor growth",
      "text": "Alcohol-induced C/EBP β-driven VIRMA decreases oxidative stress and promotes pancreatic ductal adenocarcinoma growth and metastasis via the m6A/YTHDF2/SLC43A2 pathway.\nThis stabilization enhances glutamine uptake, as well as the production of aspartate and glutamate, which in turn reduces oxidative stress, thereby promoting tumor cell growth.\nTherefore, strategies to pharmacologically manipulate the levels and/or activity of Nrf2 may have the potential to reduce pancreatic tumor growth, and increase sensitivity to therapeutics.\nA major unanswered question concerns the potential ability of DPP-4 inhibition to have beneficial disease-modifying effects, specifically to attenuate loss of pancreatic β-cell mass and function due to oxidative stress induced inflammation.\nThese data suggest that inhibition of ERK and AKT pathways act together to activate FOXO transcription factors which are involved in resveratrol-mediated pancreatic tumor growth suppression.\nIt decreased expression of the antiapoptotic protein survivin by inhibiting Sp1-mediated transcription and induced oxidative stress-mediated endoplasmic reticulum (ER) stress in pancreatic cancer cells.\nThese effects are mediated through multiple mechanisms, such as inducing oxidative stress, promoting cytotoxicity, and inhibiting cancer progression by suppressing cell proliferation, migration, and invasion.\nFinally, downregulation of SLC27A5 altered tumor metabolism and cellular homeostasis, induced oxidative stress, and disrupted intracellular environmental stability, thereby suppressing the growth of gastric adenocarcinoma.\nMoreover, treatment of pancreatic cancer cells with H2O2 to induce oxidative stress resulted in upregulated ROS levels, decreased Ape1 at both the mRNA and protein level, and alterations in WNT/β-catenin pathway components.\nNano-curcumin liposomes downregulated the expression of FDX1 and GPX4, disrupted mitochondrial energy metabolism, and induced oxidative stress, thereby promoting tumor-associated programmed cell death linked to cuproptosis.\nexperiments showed that DET suppressed the proliferation, invasion and met"
    },
    "10-1795": {
      "type": "slc_pathway",
      "key1": "SLC2A2",
      "key2": "proliferation",
      "text": "Compared with CC, pre- and postnatal LP (RR) decreased β-cell fraction, mass, proliferation, aggregate size, and number and increased Hnf1a, Hnf4a, Pdx1, Isl1, Rfx6, and Slc2a2 mRNA levels.\nPostnatal LP offspring (CR) showed decreased β-cell mass but increased β-cell fraction, aggregate number, and Hnf1a, Hnf4a, Rfx6, and Slc2a2 mRNA levels.\nLP only in pregnancy (RC) also decreased β-cell fraction, mass, proliferation, aggregate size, and number and increased Hnf1a, Hnf4a, Pdx1, Rfx6, and Ins mRNA levels.\nEsculentin-2CHa(1-30) peptides markedly reduced high fat diet-induced increase in beta cell proliferation and apoptosis.\nMale Seipin mice showed obvious, but rosiglitazone-sensitive, increases in islet insulin concentration, islet number and beta cell mass and proliferation, with a notable decline in GSIS.\nIn addition, empagliflozin treatment enhanced β-cell proliferation assessed by Ki-67 immunostaining.\nMimicking this decrease in the islets of wild type animals resulted in impaired insulin secretion, reduced β-cell proliferation, and survival.\nAlthough no developmental phenotype was detected during embryogenesis, mutant mice displayed reduced insulin-expressing β-cells at P14 and P21 without any changes in the rate of cell death and proliferation.\nPKSZ-EO upregulated mRNA expression of SLC2A2, SLC2A3, and SLC2A4, leading to increased glucose uptake in SH-SY5Y cells.\nMoreover, compared to the pretreatment levels, Mafa and insulin 1 expression increased in empagliflozin-treated mice, and Slc2a2 increased in combination-treated mice.\nTargeting glutamine pathway selectively suppressed the proliferation of HLE cells.\nAbstract: M2 macrophages play a crucial role in promoting tumor angiogen"
    },
    "1798-2290": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "oral squamous cell carcinoma (OSCC)",
      "text": ""
    },
    "425-1795": {
      "type": "slc_pathway",
      "key1": "SLC48A1",
      "key2": "proliferation",
      "text": "As an essential microelement, the iron ion is involved in cell proliferation, metabolism, and differentiation.\nThe MAPK pathway is responsible for cell proliferation and plays an important role in hyperplastic growth, which has a positive effect on meat tenderness.\nAs an inducer of ferroptosis, erastin inhibited HCC cell proliferation and progression, and it was showed to affect Th17 cell differentiation and IL-17 signaling pathway through bioinformatics analysis, indicating it a potential agent of cancer immunotherapy.\nThis study verified that the iron metabolism-related gene signature (SLC39A8 and SLC48A1) could be used as a prognostic biomarker for patients with COAD.\nWe identified the prognostic value of two iron metabolism-related genes [SLC39A8 (encoding solute carrier family 39 member 8) and SLC48A1 (encoding solute carrier family 48 member 1)] in COAD.\nFour genes (ABCB6, FLVCR1, SLC48A1 and SLC7A11) were identified to construct prognostic and diagnostic models.\nThe diagnostic models successfully distinguished HCC from normal samples and proliferative nodule samples.\nPoorer overall survival (OS) was exhibited in the high-risk group than that in the low-risk group in both the training cohort (P < 0.001, HR = 0.27) and test cohort (P < 0.001, HR = 0.27).\nThe prognostic and diagnostic models based on the four genes indicated superior diagnostic and predictive performance, indicating new possibilities for individualized treatment of HCC patients.\nFunctional analysis showed that the tumor microenvironment and immune cell infiltrate were different between the low risk and high risk subgroups.\nCompared with low-risk groups, high-risk groups had higher TMB; and exhibited higher expression of CD83, B7H3, OX40 and CD134L.\nhigher fractions of macrophages, follicular helper T cells, memory B cells, and neutrophils;\nIron metabolism plays a crucial role in the occurrence and development of colon adenocarcinoma (COAD)."
    },
    "1795-2188": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "colon adenocarcinoma (COAD)",
      "text": ""
    },
    "232-1796": {
      "type": "slc_pathway",
      "key1": "SLC25A11",
      "key2": "ferroptosis",
      "text": "Specifically, knockdown of SLC25A11 in FUNDC2-knockout (KO) cells reduced mitoGSH and augmented erasin-induced ferroptosis.\nThe regulatory effect of SLC25A11, a mitochondrial glutathione transporter, on mitoGSH and NET-induced ferroptosis of SMCs was investigated using in vitro and in vivo experiments.\nDuring AAA formation, NETs regulate the stability of the mitochondrial carrier protein SLC25A11, leading to the depletion of mitoGSH and subsequent activation of NET-induced ferroptosis of SMCs.\nFUNDC2 also affected the stability of both SLC25A11 and glutathione peroxidase 4 (GPX4), key regulators for ferroptosis.\nInhibition of DIC and OGC aggravated ferroptosis and increased mitochondrial ROS, membrane depolarization, and GSH depletion.\nSpecifically, NETs promoted AAA formation by inducing ferroptosis of SMCs.\nThis depletion induced the ferroptosis of SMCs and promoted AAA formation.\nFurthermore, NETs decreased the stability and dimerization of SLC25A11, leading to the depletion of mitoGSH.\nMechanistic studies reveal that FUNDC2 interacts with SLC25A11, the mitochondrial glutathione transporter, to regulate mitoGSH levels.\nMitochondria regulate the progression of ferroptosis, which is characterized by the depletion of mitochondrial glutathione (mitoGSH) levels.\nOur results demonstrate that FUNDC2 modulates ferroptotic stress via regulating mitoGSH and further support a therapeutic strategy of cardioprotection by preventing mitoGSH depletion and ferroptosis.\nPreventing mitoGSH depletion and ferroptosis in SMCs is a potential strategy for treating AAA.\nHere, we elucidated the role of DIC and OGC as well as mitochondrial bioenergetics in ferroptosis in H9c2 cardioblasts.\nSubsequently, SLC25A11 was identified as a potential biomarker for evaluating the clinical prognosis of"
    },
    "97-1798": {
      "type": "slc_pathway",
      "key1": "SLC9A8",
      "key2": "stemness",
      "text": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD."
    },
    "119-1798": {
      "type": "slc_pathway",
      "key1": "SLC12A5",
      "key2": "stemness",
      "text": ""
    },
    "1798-2470": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "bladder urothelial carcinoma",
      "text": ""
    },
    "1801-2379": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "pancreatic tumor growth",
      "text": "OCIAD2-IQGAP1 interaction promotes pancreatic cancer progression by suppressing oxidative stress and mitochondria-mediated apoptosis.\nLuteolin suppresses pancreatic cancer growth by targeting CCNB1-mediated cell cycle regulation, inducing G2/M arrest, and promoting apoptosis.\nDownregulation of the CCK-B Receptor in Pancreatic Stellate Cells Blocks Molecular Proliferative Pathways and Increases Apoptosis to Decrease Pancreatic Cancer Growth In Vitro.\nWe found that the combination of FAK and PI3K inhibitors synergistically suppressed the growth of cervical and pancreatic cancer cell lines through increased apoptosis and decreased mitosis.\nOur findings demonstrate that gracillin effectively inhibits PDAC cell viability, induces mitochondria-mediated apoptosis, and promotes oxidative damage by disrupting intracellular redox homeostasis.\nTogether, our findings establish the CCL5/CCR1 axis as a key mediator of tumor-macrophage crosstalk in DA, supporting immune evasion and chemoresistance via suppression of macrophage-induced apoptosis.\nIn conclusion, RR-171 induces apoptosis and pyroptosis through multiple pathways and inhibits pancreatic cancer growth, suggesting that RR-171 might be a potential agent for the treatment of pancreatic cancer.\nHigh ST18-AS1 expression was correlated with favorable clinical outcomes, and the upregulation of ST18-AS1 expression in PDAC cell lines suppressed cell proliferation and promoted apoptosis both in vivo and in vitro.\ntRF-Pro-CGG acts as a tumor suppressor in pancreatic cancer by inhibiting cell proliferation, migration, invasion, and promoting apoptosis, likely through targeting CSF1 and regulating the PI3K-AKT signaling pathway.\nIsoferulic Acid Inhibits Proliferation and Migration of Pancreatic Cancer Cells, and Promotes the Apoptosis of Pancreatic Cancer Cells in a Mitochondria-Dependent Manner Through Inhibiting NF-κB Signalling Pathway."
    },
    "92-1798": {
      "type": "slc_pathway",
      "key1": "SLC9A3",
      "key2": "stemness",
      "text": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD."
    },
    "142-1794": {
      "type": "slc_pathway",
      "key1": "SLC16A7",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "225-1800": {
      "type": "slc_pathway",
      "key1": "SLC25A4",
      "key2": "migration",
      "text": "overexpressing OS cells exhibited suppressed proliferation, migration, invasion and enhanced apoptosis.\nFurthermore, combining bioinformatics analysis with literature review, TCONS_00032546 and TCONS_00026102 may induce effects by increasing the CCND1-FGF19-FGF3-FGF4 gene cluster and SLC25A4 via complex mechanisms during neural remodeling.\nSilencing of TCONS_00032546 or TCONS_00026102 with lentiviruses in vivo could significantly shorten or prolong the atrial effective refractory period thereby increasing or preventing AF inducibility by promoting or inhibiting the neurogenesis.\nFurther, the detection of REST-downstream genes involved in cytostasis and migration inhibition demonstrated that CCND1 and CCNE1 were reduced;\nThen CCK-8 assay showed significantly decreased cell proliferation, and the inhibition of migration was verified by scratch wound healing assay and transwell assay.\nCDK5R1, BBC3, EGR1, SLC25A4, PDCD7, MAPK11, MAPK12, FADD and DAXX were enhanced, among which BBC3 and DAXX were direct targets of REST, as verified by ChIP (chromatin immunoprecipitation) and Western blotting.\nUsing cell cycle analysis and Annexin V/PI straining assay, G1 phase cell cycle arrest was found to be a reason for the suppression of cell proliferation and migration upon REST silencing, while apoptosis was not affected by REST silencing.\nThese data suggested that REST is a master regulator that maintains GBM cells proliferation and migration, partly through regulating cell cycle by repressing downstream genes, which might represent a potential target for GBM therapy.\nBesides, the expression of CCND1-FGF19-FGF4-FGF3 gene cluster and SLC25A4, the nearby genes of TCONS_00032546 and TCONS_00026102, were negatively correlated with that of lncRNAs.\nBioinformatics analysis showed that the aberrantly expressed genes were associated with neural development, migration and neurodegenerative disorders"
    },
    "1800-2193": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "pancreatic ductal adenocarcinoma (PDAC)",
      "text": ""
    },
    "63-1796": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "ferroptosis",
      "text": "Collectively, these findings indicate that SLC6A14 facilitates ferroptosis in UC by promoting C/EBPβ expression and binding activity to inhibit PAK6 expression, suggesting that targeting SLC6A14-C/EBPβ-PAK6 axis-mediated ferroptosis may be a promising therapeutic alternative for UC.\nRNA sequencing revealed that SLC6A14 inhibited the expression of P21 (RAC1)-activated kinase 6 (PAK6) and that PAK6 knockdown abolished the effects of SLC6A14 on RAS-selective lethal 3 (RSL3)-induced ferroptosis in Caco-2 cells.\nMoreover, a series of in vitro and in vivo experiments showed that SLC6A14 knockdown markedly suppressed ferroptosis.\nIn this study, we aimed to explore the roles of solute carrier (SLC) family 6 member 14 (SLC6A14) in regulating ferroptosis in UC.\nFurthermore, chromatin immunoprecipitation (ChIP) and Western blot analysis demonstrated that SLC6A14 negatively regulated PAK6 expression in a CCAAT enhancer binding protein beta (C/EBPβ)-dependent manner.\nThe expression of SLC6A14 was significantly increased and positively associated with that of prostaglandin-endoperoxide synthase 2 (PTGS2) in tissue samples from patients with UC.\nSubsequently, intracellular high concentration of GSH and extracellular spatio-temporal controlled US irradiation programmatically triggered the release of α-MT, which enabled the synergistically amplified SDT by inducing amino acid starvation, inhibiting mTOR, and mediating ferroptosis.\nFerroptosis is a unique mode of regulated cell death characterized by iron accumulation and lipid peroxidation, and its induction by aberrant STAT3 signaling may contribute to chemotherapy resistance.\nEmerging evidence suggests that ferroptosis is involved in the pathogenesis of ulcerative colitis (UC)."
    },
    "1799-1929": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Nasopharyngeal Carcinoma(NPC)",
      "text": "FBP1 promoted the radiosensitivity in NPC cells by inhibiting glycolysis through the FBXW7/mTOR axis.\nThe upregulation of HK2 elevated aerobic glycolysis and facilitated proliferation by blocking apoptosis.\nThe decrease in AMPK activity was associated with LMP1-mediated glycolysis and resistance to apoptosis induced by irradiation.\nUBR5 silencing represses proliferation and glycolysis in NPC.\nRORA overexpression inhibits cell proliferation and glycolysis by directly upregulating SPLUNC1.\nUBR5 promotes proliferation, glycolysis and M2 polarization by metabolically reprograming NPC cells through suppression of the RORA/SPLUNC1 signaling.\nThe LPLUNC1-PHB1-p53/c-Myc axis decreased glycolysis in NPC cells.\nXIST knockdown inhibited glycolysis and metastasis in hypoxia-induced NPC cells through regulating miR-381-3p/NEK5 axis.\nLPLUNC1 or PHB1 overexpression decreased glycolysis and increased oxidative phosphorylation (OXPHOS)-related protein expression in NPC cells.\nUpregulation of SUMO2 promotes GLUT1 degradation through SUMOylation and ubiquitination of GLUT1, which regulates the AMPK-mTOR pathway by inhibiting glycolysis, ultimately resulting in the proliferation and metastasis of NPC.\nTreatment with all-trans retinoic acid (ATRA) reduced the viability and clonogenicity of NPC cells, decreased glycolysis, and increased OXPHOS-related protein expression by enhancing LPLUNC1 expression in NPC cells.\nLMP1-mediated glycolysis regulates IL-1β, IL-6 and GM-CSF production through the NLRP3 inflammasome, COX-2 and P-p65 signaling pathways to enhance tumor-associated MDSC expansion, which leads to tumor immunosuppression in NPC."
    },
    "291-1802": {
      "type": "slc_pathway",
      "key1": "SLC27A5",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1795-2159": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "age-related macular degeneration (AMD)",
      "text": "OGC silencing aggravated EMT, while overexpression attenuated TGF-β2-induced EMT, cell proliferation, and migration.\nLoss of OGC promoted cell proliferation and migration through Slug-mediated EMT.\nCell proliferation significantly increased in the TAB1 over-expressed group in RPE.\nIn the in-vitro experiments, we found that activated microglia stimulated VEGFA, TGF-β and CSRP2, which enhanced angiogenesis, migration, proliferation, permeability, and altered the phenotype of co-cultured choroidal endothelial cells.\nSubretinal foveal RPE cell proliferation and RPE loss are roughly equally important as a cause of vision loss in AMD and myopic macular atrophy.\nFor instance, it contributes to RPE degeneration in AMD, vascular proliferation in DR, neuroinflammation in glaucoma, and photoreceptor loss in RP.\nSubretinal proliferations in the foveal region were the main reason for central visual acuity loss in 44% of all eyes with late AMD or myopic macular atrophy in 4 population-based studies.\nAmong all 337 eyes with late AMD or myopic macular atrophy, RPE loss was the main cause for vision loss in 190 (56%) eyes and subretinal proliferations in 147 (44%) eyes, with no significant difference ( > 0.05) between the study cohorts.\nRetinal pigment epithelium cell loss was dominant in 136 (94%) out of 145 eyes with geographic atrophy and in 35 (76%) out of 46 eyes with myopic macular atrophy, whereas subretinal proliferations were predominantly present in 127 (87%) out of 146 eyes with neovascular AMD.\nWe induced pathological retinal neovascularization in Atf6 mice using the oxygen-induced retinopathy (OIR) model and found significantly preserved visual function, accompanied by decreased retinal neovascularization, endothelial cell proliferation, and UPR transcriptional program induction."
    },
    "1799-2429": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "diabetes vascular complications",
      "text": "MGO is mainly formed as a byproduct of glycolysis and, under physiological circumstances, detoxified by the glyoxalase system.\nIn this review we summarize the formation of MGO, the detoxification of MGO by the glyoxalase system, and the biochemical pathways through which MGO is linked to the development of diabetes, vascular complications of diabetes, and other age-related diseases.\nThe formation and accumulation of methylglyoxal (MGO), a highly reactive dicarbonyl compound, has been implicated in the pathogenesis of type 2 diabetes, vascular complications of diabetes, and several other age-related chronic inflammatory diseases such as cardiovascular disease, cancer, and disorders of the central nervous system.\nMGO is the major precursor of nonenzymatic glycation of proteins and DNA, subsequently leading to the formation of advanced glycation end products (AGEs).\nMGO and MGO-derived AGEs can impact on organs and tissues affecting their functions and structure."
    },
    "385-1802": {
      "type": "slc_pathway",
      "key1": "SLC39A8",
      "key2": "oxidative phosphorylation",
      "text": "The expression of wild-type hSLC39A8, but not the disease-associated mutants, promoted mitochondrial functions.\nInterestingly, expression of hSLC39A8 mutants of both CDG type II and Leigh syndrome reduced mitochondrial Mn levels and activity of Mn-dependent mitochondrial superoxide dismutase MnSOD, and in turn increased oxidative stress.\nMoreover, loss of function analyses further corroborate hSLC39A8's critical role in mediating Mn uptake and mitochondrial function.\nWhile expression of wild-type hSLC39A8 increased Mn uptake activity, disease-associated mutations abrogated the ability of the transporter to mediate Mn uptake into the cells, thereby providing a causal link to severe Mn deficiency."
    },
    "393-1801": {
      "type": "slc_pathway",
      "key1": "SLC40A1",
      "key2": "apoptosis",
      "text": "Conversely, the cardiomyocyte-specific knockdown of SLC40A1 improved cardiac dysfunction after MI by enhancing mitochondrial function, suppressing oxidative stress, and reducing cardiomyocytes apoptosis.\nAdditionally, it can inhibit DOX-induced apoptosis by activating PI3K-Akt signaling pathway.\nβ-eudesmol inhibited cell proliferation and promoted cell apoptosis and ferroptosis via regulating MAPK pathway in BC.\nFurthermore, CAP inhibited DOX-induced apoptosis by modulating the phosphoinositide 3-kinase (PI3K)- protein kinase B (Akt) signaling pathway.\nAdditionally, we employed RNA-seq to identify the inhibitory effect of CAP on DOX-induced myocardial apoptosis, which was further confirmed through western blotting.\nThe overexpression of SLC40A1 in the cardiomyocytes of adult mice resulted in significant iron deficiency, leading to mitochondrial dysfunction, oxidative stress, and apoptosis, subsequently resulting in the development of fatal HF.\nSpecifically, CAP activated the PI3K-Akt pathway and regulated downstream BCL2 and BAX to mitigate DOX-induced apoptosis.\nβ-eudesmol promoted cell apoptosis, as evidenced by the decline level of Bcl-2 and the raised level of Bax and cleaved caspase-3.\nThe eventual cell death was significantly inhibited by deferoxamine, ferrostatin-1 and Z-VAD-FMK, suggesting a mixed cell death of ferroptosis and apoptosis.\nCopper chelators reduce ferroptosis sensitivity but do not inhibit other types of cell death, such as apoptosis, necroptosis, and alkaliptosis.\nUnlike apoptosis, necrosis and autophagy, ferroptosis is a novel type of regulated cell death, and the mechanism by which selenium nanoparticles induce ferroptosis in cancer cells has rarely been investigated.\nIn vitro silencing of PDGFRA impeded cell proliferation and migration while promoting apoptosis and inhibiting MMP2 and MMP9 expression in HDF."
    },
    "1801-2099": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Multicancer",
      "text": "In vitro and in vivo studies show baicalein inhibits tumor growth, enhances apoptosis, and regulates cell proliferation, supporting its anticancer effects.\nMoreover, flow cytometric analysis displayed that knocking down of PL2L60 mRNA but not PIWIL2 mRNA effectively inhibited cancer cell proliferation and promoted apoptosis of cancer cells.\nTreatment with G4-stabilizing ligands decreased the fraction of the functional telomerase-encoding full-length isoform, whereas CRISPR/Cas9 deletion of VNTR6-1 increased this fraction and apoptosis while reducing cell proliferation.\nThese results suggested that various cancer could be suppressed by promoting autophagy.\nNext, we explored the possible mechanisms through which POU4F3 promoted the apoptosis of LUAD cells.\nThe PL2L60 was downregulated in various types of cancer cells under the hypoxic condition independently of HIF‑1α, resulting in apoptosis of cancer cells.\nOur results demonstrate that VOCs directly perturb key targets (FN1, PECAM1, CDK1 etc.), hijacking PI3K-Akt signaling, ECM-receptor interactions, and cell cycle regulation to promote apoptosis evasion and unchecked proliferation.\nOur experimental and computational strategy provides evidence that both factors regulate the expression of several coding and non-coding RNAs that in turn mediate for their cancer-promoting phenotypes, including but not limited to cell cycle, apoptosis, ferroptosis, and oxidative stress response.\nLUAD cell apoptosis was suppressed by POU4F3 overexpression based on Flow cytometry.\nFurther studies confirmed that dioscin promoted caspase-3 and Bad-related cell apoptosis in these two cell lines.\nHowever, we found that PERK inhibitor but not IRE1 inhibitor can reverse the effect of POU4F3 overexpression on apoptosis.\nIn two cell lines, CRISPR/Cas9 deletion of VNTR6-1 increases the ratio of TERT-full-length (FL) to the alternative TERT-β isoform, promoting apoptosis and reducing cell proliferation."
    },
    "2-1799": {
      "type": "slc_pathway",
      "key1": "SLC1A2",
      "key2": "glycolysis",
      "text": ""
    },
    "1799-1806": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Brain Tumor",
      "text": ""
    },
    "1794-1815": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "leukemia",
      "text": ""
    },
    "371-1799": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "glycolysis",
      "text": "Since many SLC38A5 substrates are activators of mTORC1 as well as TCA cycle intermediates/precursors, we speculate amino acid insufficiency as a possible link between SLC38A5 deletion and inactivation of mTORC1, glycolysis and mitochondrial respiration, and the underlying mechanism for PDAC attenuation.\nExperimental validation demonstrates inhibition of mTORC1, glycolysis and mitochondrial respiration in KO cells, suggesting a serious metabolic crisis associated with SLC38A5 deletion.\nSLC38A5 transcriptionally mediated by ETV4 expedites CRC cell growth, metastasis, glycolysis, L-OHP resistance, which provides a promising therapeutic target for CRC treatment.\nMoreover, SLC38A5 deficiency could hinder CRC cell proliferation, migration, invasion, glycolysis, and improved L-OHP sensitivity in vitro.\nUpon HSC activation, metabolism is reprogrammed with Myc as a key regulator, transcriptionally controlling LDHA, GLS1, and glutamine transporters SLC1A5 and SLC38A5.\nUsing CRISPR/Cas9-mediated knockout of SLC38A5, we show its tumor promoting role in an in vitro cell line model as well as in a subcutaneous xenograft mouse model.\nOverall, we show that SLC38A5 promotes PDAC, thereby identifying a novel, hitherto unknown, therapeutic target for PDAC.\nHere we show that SLC38A5 (SN2/SNAT5), a neutral amino acid transporter is highly upregulated and functional in PDAC cells.\nUsing metabolomics and RNA sequencing, we show significant reduction in many amino acid substrates of SLC38A5 as well as OXPHOS inactivation in response to SLC38A5 deletion.\nParticularly, amino acids are critical for cancer growth and, as intermediates, connect glucose, lipid and nucleotide metabolism.\nPancreatic ductal adenocarcinoma (PDAC) cells have a great demand for nutrients in the form of sugars, amino acids, and lipids."
    },
    "1799-1843": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Prostate Cancer",
      "text": "LIAS promotes cuproptosis and inhibits cancer cell proliferation in PC by activating the p53 signaling pathway to suppress glycolytic activity.\nJuglone promotes antitumor activity against prostate cancer via suppressing glycolysis and oxidative phosphorylation.\nNPAS2 is upregulated in prostate cancer and promotes cell survival by promoting glycolysis and inhibiting oxidative phosphorylation in PCa cells.\nFibroblast growth factor pathway promotes glycolysis by activating LDHA and suppressing LDHB in a STAT1-dependent manner in prostate cancer.\nFV-429 induced glycolysis inhibition and apoptosis in human prostate cancer cells by downregulating the AR-AKT-HK2 signaling network.\nOur findings reveal that COUP-TFII represses MPC1 expression in prostate cancer cells to facilitate a metabolism switch to increase glycolysis and promote cancer progression.\nRSL3 could decrease the ATP and pyruvate content as well as the protein levels of HKII, PFKP, PKM2, which indicated that RSL3 induced glycolysis dysfunction in prostate cancer cells.\nWe further demonstrate that COUP-TFII, which is upregulated in the prostate cancer patient, regulates MPC1 and glycolysis to promote tumor growth and metastasis.\nDocetaxel treatment led to a significant inhibition of cell proliferation in prostate cancer cells through PFKP-mediated glycolysis.\nhsa_circ_0006620 downregulation inhibited prostate cancerby regulation of the miR-502-3p/HK2 axis mediated by aerobic glycolysis.\nOur results demonstrate a novel PKCε function that promotes cell growth in prostate cancer cells by increasing aerobic glycolysis through crosstalk between PKCε and Smad2/3.\nThe LIFR is upregulated by nuclear EGFR, which acts as a transcriptional regulator, directly binds to the LIFR promoter, and drives NE differentiation and glycolysis of prostate cancer.\nmiR-137 repressed glycolysis in prostate cancer through knockdown of NOX4."
    },
    "1794-2393": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "clear cell renal cell carcinoma (CCRCC)",
      "text": ""
    },
    "138-1795": {
      "type": "slc_pathway",
      "key1": "SLC16A3",
      "key2": "proliferation",
      "text": "While transcriptional repression of SLC16A3 by FBI-1 inhibited lactate efflux, repression of ZBTB7A and activation of lactate efflux by NF-κB, increased colon cancer cell growth and proliferation.\nMechanistically, SLC16A3 emerged as a critical regulator promoting STAD cell proliferation, invasion, and migration while modulating the metabolic landscape.\nAnd the key gene SLC16A3 and STRBP can significantly promote the proliferation and invasion ability of HCC cells.\nAnd SLC16A3 inhibitors significantly suppressed the proliferation of HCC, while simultaneously enhancing T-cell cytotoxicity and reducing exhaustion.\nSubsequent in vitro experiments indicated that the inhibition of β-cell proliferation and the decreased expression of Pdx-1, Creb and Slc16a3 were rescued by DNA methyltransferase 3A (DNMT3A) knockdown in β cells.\nSubsequently, the effects of SLC16A3 expression on cell proliferation and invasion were analyzed using hepatocellular carcinoma (HCC) lines, and Western blot (WB) analysis was performed to explore the changes in pathway proteins and ferroptosis proteins.\nSLC16A3 can directly mediate the proliferation of HBV-positive liver cancer cell lines in vitro.\nMoreover, knockdown of SLC16A3 significantly increased the level of lipid peroxidation and reactive oxygen species (ROS), while the expressions of GPX4, DHODH and SLC7A11 were inhibited.\nTCGA data and WB analysis showed that the high expression of SLC16A3 induced hypoxia, and knockdown could reverse hypoxia and inhibit ERK phosphorylation, thus limiting the malignant behavior of HCC cells.\nOverexpressed Solute Carrier Family 16 Member 3 (SLC16A3, also called MCT4) plays a critical role in hypoxic cancer cell growth and proliferation, by expelling glycolysis-derived lactate across the plasma membrane.\nOur results further indicate that MCT4 promotes proliferation and survival by altered cell cycle regulation and cell death mechanisms."
    },
    "1795-2087": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Glioblastoma (GBM)",
      "text": ""
    },
    "91-1800": {
      "type": "slc_pathway",
      "key1": "SLC9A2",
      "key2": "migration",
      "text": "Importantly, SLC9A2 overexpression in SW480 cells led to a notable inhibition of cell proliferation, migration, and invasion.\nMechanistically, we found that SLC9A2 inhibits epithelial-mesenchymal transition (EMT) and metastasis by suppressing the STAT3 signaling pathway.\nThe results demonstrate that in RGM1 cells, migratory velocity is increased by NHE1 activation, while NHE2 activity inhibit this process.\nMoreover, SLC9A2 reduces VEGFA secretion, normalizing tumor vasculature and reshaping the tumor microenvironment (TME), which ultimately enhances anti-tumor immunity.\nOur study suggests that SLC9A2 acts as a tumor suppressor through the MAPK pathway and could be a potential target for CRC diagnosis and therapy.\nThese findings highlight the critical role of SLC9A2 in regulating metastasis, angiogenesis, and TME remodeling in CRC.\nBy modulating the STAT3 pathway and tumor vasculature, SLC9A2 emerges as a potential prognostic biomarker and therapeutic target.\nTargeting SLC9A2 may enhance immune responses and improve treatment outcomes in CRC, offering a promising avenue for future therapeutic strategies.\nLentiviral NHE2 expression increased the steady-state pH and reduced the restitution velocity after low pH preincubation, which was reversible by pharmacological NHE2 inhibition.\nOur analysis revealed a significant downregulation of SLC9A2 in the highly metastatic CRC cell lines.\nComparative analysis of CRC tissue samples showed reduced SLC9A2 expression in tumor tissues compared to adjacent normal tissues, with a negative correlation to TNM staging.\nImportantly, higher SLC9A2 expression was associated with better treatment responses in immunotherapy cohorts.\nBoth mRNA and protein expression levels of SLC9A2 were markedly reduced in CRC tissues and cell lines.\nWestern blotting analysis revealed that the expression levels of phosphorylated ERK (p-ERK) and phosphorylated JNK (p-JNK) proteins were significantly increased, whereas there were no significant changes"
    },
    "1799-2056": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Cervical cancer",
      "text": "CDK6 increases glycolysis and suppresses autophagy by mTORC1-HK2 pathway activation in cervical cancer cells.\nTargeting HK2 inhibition contributed to suppress HPV16 E7-induced tumor glycolysis metabolism phenotype, inhibiting tumor growth, and induced apoptosis, blocking the cancer cell energy sources and ultimately enhanced the sensitivity of HPV(+) cervical cancer cells to irradiation therapy.\nAltered HOXA1 expression enhance or reduce aerobic glycolysis and progression in cervical cancer.\nThe knockdown or overexpression of HK2 and PGK1 abolished the increased or decreased aerobic glycolysis and cervical cancer progression induced by stable ectopic expression or depletion of ERG, respectively.\nThe aerobic glycolysis levels, cell survival and proliferation of cervical cancer cells decreased significantly after inhibition of LDHA under normal culture condition while LDHA deficiency greatly inhibited glucose starvation-induced ferroptosis and promoted cell proliferation and tumor formation under energy stress conditions.\nSIX1 enhances aerobic glycolysis and progression in cervical cancer through ENO1.\nHypoxia-induced CNPY2 promoted glycolysis in cervical cancer cells by activating the AKT pathway.\nDysregulation of UCA1 and inhibition of glycolysis affected radioresistance of cervical cancer cells.\nPSME3 induces radioresistance and enhances aerobic glycolysis in cervical cancer by regulating PARP1.\nAPLN promoted the proliferation, migration, and glycolysis of cervical cancer cells via the PI3K/AKT/mTOR pathway.\nSOX2 promotes the glycolysis process to accelerate cervical cancer progression by regulating the expression of HK2.\nFBXO45 enhances cell viability and glycolysis in cervical cancer via DUSP2 ubiquitination-mediated ERK1/2 activation.\nAldolase A promotes cervical cancer cell radioresistance by regulating the glycolysis and DNA damage after irradiation.\n2-Deoxy-D-glucose simultaneously targets glycolysis and Wnt/β-catenin signaling"
    },
    "1798-2228": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "acute myeloid leukemia (AML)",
      "text": ""
    },
    "1796-2282": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Esophageal squamous cell carcinoma (ESCC)",
      "text": "5-ALA induced ferroptosis via glutathione peroxidase 4 (GPX4) and heme oxygenase 1 (HMOX1) and had an antitumor effect in esophageal squamous cell carcinoma (ESCC).\nsiRNA-mediated knockdown of GPX4 and SLC7A11 reduced ESCC sensitivity to ponicidin-induced ferroptosis.\nSilencing of ALDH5A1 can reduce DDP resistance in ESCC through promoting ferroptosis signaling pathways.\nHMGA1 is upregulated in ESCC and works as a key driver for cisplatin (DDP) resistance in ESCC by repressing ferroptosis.\nThis in turn not only inhibits the proliferation and migration of ESCC cells but also upregulates the ferroptosis pathway.\ncircPDE3B promotes ESCC progression by suppressing ferroptosis through recruiting HNRNPK/SLC7A11 and miR-516b-5p/CBS axes.\nFunctional studies revealed that FBXO10 ablation suppressed ESCC cell proliferation, migration, and invasion via ACSL4-dependent ferroptosis activation.\nRNA-seq and enrichment analysis suggested the blocked tumor progression was affected by ferroptosis, together with the NFκB signaling pathway activation in ESCC.\ngliotoxin downregulated SUV39H1 expression in ESCC cells and induced ferroptosis, suggesting a novel natural therapy for ESSC.\nIn an RNA microarray analysis of KYSE30, ferroptosis was one of the most frequently induced pathways, with GPX4 suppressed and HMOX1 overexpressed by 5-ALA treatment.\nUA inhibits the malignant biological behavior of ESCC by modulating ferroptosis through the p53/SLC7A11/GPX4 pathway, and enhances the sensitivity of ESCC cells to IR.\nIn ESCC, down-regulation of PLK1 can inhibit PPP, and reduce the level of NADPH and GSH, thereby promoting ferroptosis and improving their sensitivity to radiotherapy and chemotherapy."
    },
    "1796-2717": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "lung squamous cell carcinoma",
      "text": ""
    },
    "184-1797": {
      "type": "slc_pathway",
      "key1": "SLC22A1",
      "key2": "oxidative stress",
      "text": "Ubiquitous knockdowns of related SLC22s-including transporters homologous to those previously identified by us in mammals such as the \"Fly-Like Putative Transporters\" FLIPT1 (SLC22A15) and FLIPT2 (SLC22A16)-have shown modest protection against oxidative stress.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous system) appear critical for managing oxidative stress.\nOur work not only indicates the importance of SLC22 transporters in the fly renal system but also sets the stage for in vivo studies by examining their role in mammalian oxidative stress and organ crosstalk.\nUsing two tissue-selective knockdown strategies, we were able to demonstrate much greater and longer protection from oxidative stress compared to previous whole fly knockdowns as well as both parent and WT strains (CG6126: < 0.001, CG4630: < 0.01, CG16727: < 0.0001 and CG6006: < 0.01).\nSeveral SLC22 transporters in the human kidney and other tissues are thought to regulate endogenous small antioxidant molecules such as uric acid, ergothioneine, carnitine, and carnitine derivatives.\nSince the antioxidant resveratrol (RSV) has shown measurable protective effects against OTA- and CIT-related oxidative stress toxicity in vitro, we investigated the effects of an OTA + CIT + RSV combination on rOct1/2 localization/expression in the same model."
    },
    "39-1794": {
      "type": "slc_pathway",
      "key1": "SLC5A2",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "25-1802": {
      "type": "slc_pathway",
      "key1": "SLC3A2",
      "key2": "oxidative phosphorylation",
      "text": "We further explore the effects of GLUD1 inhibition in endocrine therapy-resistant ILC cells using the small-molecule inhibitor R162, which reduces ER protein levels, increases reactive oxygen species, and inhibits oxidative phosphorylation.\nThis work identifies structure-specific recognition protein 1 (SSRP1), which upregulates SLC3A2, as a co-transcription factor with JUNB.\nHigh SLC3A2 expression predicts poor outcomes in PTCL, as SLC3A2-mediated arginine uptake promotes the malignant behaviors of tumor cells and induces tumor immune escape, thereby fueling tumor progression.\nMechanistically, high arginine levels induce global metabolic changes, including enhanced oxidative phosphorylation by promoting nascent RNA synthesis.\nAll four proteins are associated with increased tumor size in ILC, but not IDC/NST, with SLC3A2 also specifically linked to shorter overall survival and the presence of comorbidities in ILC.\nMechanistically, YBX3 stabilizes the mRNA of Slc3a2 and Pparg, which facilitates branched-chain amino acid (BCAA) influx and catabolism and fuels brown adipocyte differentiation and thermogenesis.\nQuinacrine disrupts SLC3A2-mediated arginine transport by targeting SSRP1.\nSingle-cell transcriptomic analyses reveal aberrant arginine metabolism in patients with PTCL, characterized by excessive solute carrier family 3 member 2 (SLC3A2) mediated arginine uptake preferentially in tumor cells.\nTranscriptome analysis and mitochondrial stress test indicate that Ybx3 deficiency compromises the mitochondrial oxidative phosphorylation, leading to thermogenic failure.\nSLC3A2 plays a role on both sides of this dichotomy as an adaptor to SLC7A5, a transporter of branched-chain amino acids (BCAA: Leu, Ile, Val), and to SLC7A11, a cystine importer supplying cysteine to the synthesis of the antioxidant glutathione.\nIntriguingly, the evolution of modern birds ("
    },
    "1802-2209": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "1798-2539": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Hepatic ischemia-reperfusion (I/R)",
      "text": ""
    },
    "1801-2105": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "cancer tissues",
      "text": "Hes alone showed dose-dependent cytotoxicity, while the combination markedly increased , reduced , and decreased , , and , indicating enhanced intrinsic apoptosis and complementary immunomodulation.\nBiological evaluations demonstrated that TOP60-1 dose-dependently suppressed tumor growth, metastasis, and angiogenesis in a zebrafish xenograft model, induced tumor cell apoptosis, and significantly inhibited tumor cell migration in vitro.\nFunctional assays showed that NIBAN2 enhanced glioma cell aggressiveness by activating JAK2/STAT3 signaling and promoted tumor growth by preventing apoptosis and accelerating the cell cycle.\nTherefore, the aim of this study was to evaluate the potential of D4 from to inhibit colorectal cancer growth in rat models, with a focus on its effects on cell proliferation, apoptosis, and inflammatory responses.\nWe demonstrate that MCM7 is upregulated at both transcript and protein levels in RCC, contributing to cancer progression by regulating cell proliferation and caspase-3/7 activity.\nThis study found that D4 treatment reduced adenocarcinoma and dysplasia severity in colorectal cancer models through significant reduction in cyclin D1, Bcl-2, NF-κB, and COX-2 expression observed across all groups (<0.01), although changes in dysplasia and cancer subgroups were not statistically significant (>0.05).\nThese results suggest that Hes augments DX's pro-apoptotic and anti-inflammatory effects, potentially allowing lower chemotherapy doses and reduced systemic toxicity in cervical cancer treatment.\nIn conclusion, D4 reduces the expression of cyclin D1, Bcl-2, NF-κB, and COX-2 proteins, offering insights into its potential to modulating proliferation and inflammation in colorectal cancer growth.\nThe effects of D4 on cancer progression were assessed through immunohistochemical analysis of cell proliferation (cyclin D1, Bcl-2), apoptosis (p53, caspase-3), and inflammation (nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2))."
    },
    "1-1795": {
      "type": "slc_pathway",
      "key1": "SLC1A1",
      "key2": "proliferation",
      "text": "Both in vitro and in vivo, ectopic expression of SLC1A1 increased cellular glutamine uptake, enhanced glutathione metabolic flux, and induced glutamine addiction, leading to acceleration of cell proliferation and tumor growth.\nCircRNA ZFR overexpression promoted HCC cell proliferation, migration and invasion while its knockdown inhibited HCC progression.\nOur results demonstrate for the first time that EAAT3 facilitates anionic amino acid transport and activates the mTOR pathway, promoting Cys transport and IPEC-J2 cell proliferation.\nSLC1A1 functioned as an extracellular glutamine transporter, promoted tumor growth through reprogramming glutamine metabolism of NKTCL, while rendered tumor cells sensitive to asparaginase treatment.\nMTT and cell counting assays suggested that IPEC-J2 cell proliferation increased (P<0.05) with EAAT3 overexpression.\nCDX2 overexpression in IPEC-1 cells increased cell proliferation, the percentage of cells in S/G2 phase, and the abundance of transcripts of the cell cycle-related genes Cyclin A2\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets\nCollectively, circRNA ZFR knockdown retarded HCC progression by sponging miR-96a-5p and modulating SLC1A1 expression, suggesting that the circZFR/miR-96a-5p/SLC1A1 axis may serve as potential therapeutic targets for HCC.\nAnionic amino acid and cystine (Cys) transport were increased (P<0.05) by EAAT3 overexpression and decreased (P<0.05) by EAAT3 knockdown rather than other amino acids."
    },
    "299-1802": {
      "type": "slc_pathway",
      "key1": "SLC29A2",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1796-2404": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "triple-negative breast cancer(TNBC)",
      "text": "Silencing USP24 enhances ferroptosis-mediated tumor suppression in TNBC cells.\nPGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis.\nEriocalyxin B induces ferroptosis through SIRT3 inhibition in triple-negative breast cancer.\nmeanwhile, the released ML210 efficiently represses the activity of GPX4 to activate ferroptosis pathway.\nPGM5P3-AS1 regulated MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of TNBC.\nMechanistic studies revealed that 7g induces ferroptosis via inhibition of GPX4 activity, leading to tumor cell death.\nBy contrast, Apo-Lf upregulated SLC7a11 expression, increased GSH generation and inhibited ferroptosis of MDA-MB-231 cells.\nCAPE activates AMPK and Foxo3 signaling to induce growth inhibition and ferroptosis in triple-negative breast cancer.\nPSMD14/E2F1 Axis-Mediated CENPF Promotes the Metastasis of Triple-Negative Breast Cancer Through Inhibiting Ferroptosis.\nMore importantly, PSMD14 could suppress arachidonic acid metabolism-induced ferroptosis in TNBC cells through the E2F1/CENPF axis.\nSIM induced ferroptosis in TNBC cells through reduced glutathione (GSH) levels, increased iron levels, ROS and lipid peroxidation.\nSRPX2 knockdown inhibited TNBC cell viability, invasion, and Stemness of tumor while promoting TNBC cell apoptosis and ferroptosis.\nThe PSMD14/E2F1 axis-mediated CENPF could promote the metastasis of TNBC by inhibiting arachidonic acid metabolism-induced ferroptosis.\nEspecially, Aa and P induced mitochondrial apoptosis of cancer cells, while SA and P inhibited TNBC by ferroptosis and upregulating p53.\nDimethylmalonate induces ferroptosis by inhibiting the"
    },
    "1796-2393": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "clear cell renal cell carcinoma (CCRCC)",
      "text": "Ferroptosis is a novel kind of iron- and reactive oxygen-induced cell death, investigation into ferroptosis-associated long noncoding RNAs (FALs) in clear cell renal cell carcinoma (ccRCC) is scarce.\nJS-K induces ferroptosis in RCC cells by depleting glutathione through the inhibition of the c-Myc-GSTP1 axis.\nFinally, through inhibiting SLC7A11 expression, silencing SLC16A1-AS1 induced ferroptosis via increasing miR-143-3p.\nThus, inducing the GABPA-ACSL4 pathway activates ferroptosis, inhibits proliferation or metastasis, and exerts anticancer activity in ccRCC.\nSubsequent overexpression experiments demonstrated that MITD1 knockdown induced ferroptosis and suppressed tumor growth and migration through the TAZ/SLC7A11 pathway.\nMore importantly, the AR probe can be used to track changes in GSH levels and fluorescence imaging during the treatment of clear cell renal cell carcinoma (ccRCC) with celastrol (CeT) via inducing ferroptosis.\nIn summary, silencing of APEX1 promotes ferroptosis and inhibits the malignant progression of ccRCC, potentially through APP-mediated activation of p53/AKT signaling, providing a novel therapeutic strategy for ccRCC treatment.\nUsing a high throughput screen, we identify novel compounds that decrease HIF-1/2α levels and induce ferroptosis by targeting Iron Sulfur Cluster Assembly 2 (ISCA2), a component of the late mitochondrial Iron Sulfur Cluster (L-ISC) assembly complex.\nFerroptosis, a novel form of regulated cell death characterized by disrupted iron metabolism and the accumulation of lipid peroxides, has exhibited enormous potential in the therapy of cancer particularly clear cell renal cell carcinoma (ccRCC).\nTo further explore its underlying mechanism, we speculate that moscatilin may inhibit the phosphorylation level of the JAK-STAT signaling pathway, thereby blocking the function of the key protein SLC7A11 in the ferroptosis signaling pathway, which promotes the occurrence of ferropt"
    },
    "30-1795": {
      "type": "slc_pathway",
      "key1": "SLC4A4",
      "key2": "proliferation",
      "text": "Knockdown of SLC4A4 via shRNA reduced cell proliferation and increased mortality during external acidosis and spheroid growth.\nSLC4A4 knockdown inhibited cell proliferation, migration and invasion, while facilitated apoptosis, which was also confirmed in vivo.\nSLC4A4 overexpression restrained cell proliferation and metastasis by suppressing Kirsten rat sarcoma viral oncogene (KRAS) expression in renal cancer cells.\nImportantly, we demonstrated that high expression of SLC4A4 was able to increase the proliferation level and cytokine secretion of CD8+ T cells for the purpose of promoting the immune system response to LUAD.\nOverexpression of miR-223 downregulates the expression of SLC4A4 and promotes PC cell growth.\nUpregulation of SLC4A4 promoted apoptosis in the LUAD cell line and significantly inhibited the migration and invasive ability of cancer cells (P<0.01).\nSecondly, we investigated the SLC4A4/RB axis, which acts to drive cell proliferation.\nThe target gene SLC4A4 we had selected using bioinformatics had a strong effect on the proliferation of prostate cells;\nThe role of SLC4A4 in the proliferation and migration of colon cancer cells was verified by CCK8, EdU and wound healing assays.\nIn renal cancer cells, overexpression of miR-223-3p enhanced cell proliferation and metastasis, while inhibition of miR-223-3p reduced the malignant capacity of the cells.\nIn MDA-MB-231 breast cancer cells expressing high levels of SLC4A4 compared to LS174 cells, SLC4A4 knockdown had a strong impact on cell proliferation, migration, and invasion.\nOverexpressing miR-224-5p increased the proliferative, migratory and invasive abilities of CRC cells and inhibit CRC cell apoptosis, while overexpressing SLC4A4 caused the opposite result.\nMoreover, SLC4A4 promoted PCa progression through the AKT-mediated signalling pathway."
    },
    "1795-1828": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Testicular Cancer",
      "text": ""
    },
    "9-1797": {
      "type": "slc_pathway",
      "key1": "SLC2A1",
      "key2": "oxidative stress",
      "text": "Finally, we identified 21 upregulated and 9 downregulated FRDEGs, among which 10 key target genes (P53, TXN, PTEN, SLC2A1, HMOX1, PRKAA1, ATG7, HIF1A, TGFBR1, and IL1B) were recognized with enriched functions, mainly relating to responses to oxidative stress and hypoxia in biological processes of PDR.\nEmbryos cultured with 10 or 50 μM DGAT1 inhibitor had greater mitochondrial activity (P < 0.01), and increased number of cells (P < 0.05), while the cytoplasmic lipid content was reduced (P < 0.01), the latter associated with altered expression profiles of selected genes regulating lipid metabolism or genes related with oxidative stress (transcript abundance increased for SLC2A1 and SLC2A5 and decreased for DGAT1 and GPX1).\nIn cultured astrocytes, PIF promotes BDNF-myelin synthesis promoter and SLC2A1 (glucose transport) while reducing deleterious E2F5, and HSP90ab1 (oxidative stress) genes expression.\nFurthermore, both Slc2a1 overexpression in C8-D1A cells and lactate treatment rescued oAβ-induced mitochondrial oxidative stress and membrane potential alterations in energy-deficient HT22 neurons, thereby enhancing lactate secretion from astrocytes and promoting the lactate shuttle to neuron for energy supply.\nBioinformatics results suggested that SLC2A1, Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1), and HIF-1α (Hypoxia Inducible Factor 1 Alpha)-related oxidative stress signaling pathways play an important role in iron homeostasis and OA.\nOxidative stress gene SLC2A1 (also named GLUT1) is related to cuproptosis gene in age-related hearing loss.\nThe interaction network analysis indicated that 10 hub genes, including MT1H, MT1G, MT1X, MT1M"
    },
    "1797-2269": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Nonsmall cell lung cancer (NSCLC)",
      "text": "N-acetyl-L-cysteine (L-NAC), a ROS scavenger, alleviated oxidative stress and inhibited the apoptosis induced by bortezomib.\nThis increases reactive oxygen species production and decreases antioxidant defense mechanisms, leading to postoperative oxidative stress.\nCeritinib significantly inhibits the growth of LSCC cells (TU686 and AMC-HN8), disrupts oxidative stress homeostasis, and induces mitochondrial-mediated apoptosis.\nbuthionine sulfoximine (BSO), an inhibitor of GSH synthetase, aggravated bortezomib-induced oxidative stress and apoptosis.\nfollowing laryngectomies, laryngeal cancer patients had increases in serum antioxidant enzyme activities and decreases in oxidative stress markers.\ntheir combination synergistically suppressed the malignant behavior of LSCC cells, exacerbated mitochondrial dysfunction, and enhanced oxidative stress in vitro.\nsilibinin induced the apoptosis of Hep-2 cells via oxidative stress and down-regulating survivin expression.\nInflammatory response or oxidative stress could induce upregulation of PTPN2, thus promoting the proliferative ability of laryngocarcinoma.\nCISP-induced increase of apoptosis, Ca fluorescence intensity, TRPM2 expression and current densities through the increase of lipid peroxidation, intracellular and mitochondrial oxidative stress were stimulated by CURC treatment.\nthe combination more potently promoting apoptosis and suppressing tumor cell proliferation\nCeritinib triggered mitochondria mediated apoptosis via ROS-PI3K/AKT axis to inhibit the progression of LSCC.\nH2O2 stimulation upregulated the protein level of PTPN2, dose-dependently increased clonality, and Ki-67 positive cell ratio in M4E cells.\nITGA6 accelerates Keap1 proteasomal degradation via enhancing TRIM25 expression, leading to increased Nrf2 stability and exacerbating its aberrant activation."
    },
    "1795-2001": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Bone cancer",
      "text": "Inhibition of microglia not only alleviated pain behaviors in mice with bone cancer but also mitigated myelin phagocytosis and the proliferation of oligodendrocyte precursor cells.\nAIL inhibited the proliferation of human OS cells and induced apoptosis through the ERS pathway.\n5-FU effectively induces apoptosis and inhibits proliferation in AM cells, likely through disruption of cell cycle progression.\nRBM15-mediated the m6A modification of MAT2A promotes osteosarcoma cell proliferation, metastasis and suppresses ferroptosis.\nDownregulation of CREB1 inhibited osteosarcoma cell proliferation and invasion but induced apoptosis through miRNA-183-5p/PROX1 axis.\nIRF2BPL inhibits proliferation, migration and invasion of osteosarcoma cells by inhibiting FOSL2-mediated PI3K/AKT pathway activation.\nSilencing of BCAR4 inhibited osteosarcoma cell proliferation and migration while promoting cellular apoptosis, primarily mediated by miR-1260a.\nDOT1L suppressed the proliferation of osteosarcoma cell line via modulating SYK/EGFR/P53 and SHP2-induced STING-NLRP3-pyroptosis signaling.\nITGB3-KD had a radiosensitizing effect on osteosarcoma in vitro by inhibiting cell viability, proliferation, migration, and invasion and promoting apoptosis.\nThis study revealed that NEK2 promotes osteosarcoma proliferation, invasion, migration, and chemoresistance while inhibiting apoptosis, likely through AKT/p-AKT signaling.\nQuinacrine induces autophagy via the Dlg5/AKT pathway to inhibit osteosarcoma cell proliferation and suppresses migration and invasion through the Dlg5/Girdin pathway.\nThe results revealed that nanocomposite has a strong ability to inhibit cancer cell proliferation in a dose-dependent manner, and induce apoptosis via ROS- mediated mechanism."
    },
    "1796-1815": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "leukemia",
      "text": "Regorafenib promotes ferroptosis in acute myeloid leukemia by upregulating NOX4.\nConsistently, NOX4 inhibitor significantly rescued the ferroptosis promoting effect of Regorafenib.\nImportantly, combining Regorafenib with ferroptosis inducers showed synergistic effect of blocking tumor growth in vivo.\nThis study explored the role of Regorafenib in promoting ferroptosis in AML cells through modulation of NOX4 expression.\nMechanistically, Regorafenib treatment upregulated the expression of the NOX4 protein, leading to increased lipid peroxidation.\nWe demonstrated that Regorafenib sensitizes AML cells to ferroptosis induction both in vitro and in vivo.\nAfter co-treatment with Nano-Iron and adriamycin, more apoptosis of K562/ADR cells was induced and accompanied with an increase of ROS and MDA levels, as well as a decrease of GSH/GSSG ratio and GPX4 expression.\nMn-Zn Ferrite (Nano-Iron) enhances the therapeutic sensitivity of K562/ADR cells to adriamycin by inducing ferroptosis, demonstrating the therapeutic potential in reversing drug resistance.\nIn vivo experiments have shown that the combination therapy of Nano-Iron and adriamycin prolongs the survival period of mice, significantly inhibits the infiltration of tumor cells in the bone marrow and suppresses the expression of GPX4 in the femur of mice.\nThe present review systematically integrates and compares the molecular features of key cell death modalities in AML, including autophagy, apoptosis, pyroptosis, necroptosis, ferroptosis and cuproptosis.\nThis study highlights the potential of Regorafenib as an agent that modulates NOX4 expression, offering new insights into the treatment of AML.\nA novel iron-based nano-reagent of Mn-Zn Ferrite was constructed to explore its role in regulating the redox homeostasis of CML cells and to clarify its therapeutic potential in reversing drug resistance in CML."
    },
    "322-1796": {
      "type": "slc_pathway",
      "key1": "SLC34A2",
      "key2": "ferroptosis",
      "text": ""
    },
    "226-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A5",
      "key2": "oxidative phosphorylation",
      "text": "Moreover, the knockdown of Slc25a5 resulted in significant reduction of oxidative phosphorylation (OXPHOS) protein expression (ATP5A1, CQCRC2, and MTCO1) and ATP production.\nTranscriptional signature revealed that Favourable- and intermediate-risk patients presented enriched molecular programs related to mature myeloid progenitors, cell cycle progression, and oxidative phosphorylation, indicating that this cells differs in their origin, metabolic state, and cell cycle regulation, in comparison to the adverse-risk.\nIn aerobic eukaryotic cells, the high energy metabolite ATP is generated mainly within the mitochondria following the process of oxidative phosphorylation.\nA total of 79 co-immunoprecipitated proteins were common in two or more tissues, mainly participating in mitochondrial activities such as oxidative phosphorylation (OXPHOS) and ATP production, active transport of ions or molecules, and the metabolism.\nOur proteomic approach confirmed known mitochondrial interactors of SLC25A46 including MICOS complex subunits and also OPA1 and VDACs, while we identified novel interactors including the ADP/ATP translocases SLC25A4 and SLC25A5, subunits of the OXPHOS complexes and FF-ATP synthase, and components of the mitochondria-ER contact sites.\nIn this study, based on a bioinformatics analysis to identify the genes and pathways that display significant differences between tumour tissues of NFPA patients and normal pituitary tissues, we selected lncRNAs related to cAMP and oxidative phosphorylation pathways, namely DNAH17-AS1, LINC00706 and SLC25A5-AS1.\nThe mitochondrial ATP is exported to the cytoplasm using a specialized transport protein, the ADP/ATP carrier, to provide energy to the cell.\nAny deficiency or dysfunction of this membrane protein leads to serious consequences on cell metabolism and can cause various diseases such as muscular dystrophy.\nOur results show that SLC25A46 interacts with a large number of proteins and protein complexes involved in the mitochondria architecture, energy production, and flux and also in inter-organ"
    },
    "1795-2412": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "endometrial carcinoma (EC)",
      "text": ""
    },
    "1796-1828": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Testicular Cancer",
      "text": "Carbenoxolone enhances the inhibitory effect of RSL3 on the proliferation, invasion and migration of cisplatin-resistant testicular cancer cells by promoting RSL3-induced ferroptosis.\nRapamycin enhances the inhibitory effect of RSL3 on proliferation, invasion and migration of I-10 cells by enhancing RSL3-mediated cell ferroptosis.\nMoreover, IATL induced ferroptosis by modulating expression levels of GPX4, xCT, NRF2, and HO-1.\nNext-generation sequencing (NGS) and pathway analysis highlighted the involvement of ferroptosis and HIF-1 signaling in IATL-mediated effects.\nRSL3 treatment significantly decreased GPX4 expression (=0.001) and increased lipid ROS level (=0.001) and Fe level in the cells, and these effects were further enhanced by the combined treatment with carbenoxolone ( < 0.01).\nTreatment of I-10 cells with RSL3 alone significantly decreased cell colony numbers ( < 0.05), wounding-healing rates ( < 0.01), and invasion and migration cell numbers ( < 0.05), increased lipid reactive oxygen species level and MDA content ( < 0.05), and lowered GSH content and expression level of GPX4 protein in the cells ( < 0.01).\nThe combination with carbenoxolone significantly enhanced the inhibitory effect of RSL3 on colony formation, wound healing rate (=0.005), invasion and migration of the cells ( < 0.001)."
    },
    "1798-2137": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "hearts suffered ischemia/reperfusion (I/R)",
      "text": ""
    },
    "191-1794": {
      "type": "slc_pathway",
      "key1": "SLC22A8",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2346": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "treatments with cytostatics such as methotrexate and cisplatin",
      "text": ""
    },
    "1802-2269": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Nonsmall cell lung cancer (NSCLC)",
      "text": "I have carefully reviewed all the provided text, searching for any explicit statements about relationships between \"oxidative phosphorylation\" and \"Nonsmall cell lung cancer (NSCLC)\".\nUnfortunately, the source text provided appears to contain only a single title about \"The effect of unconjugated bilirubin and some bilirubin precursors on cell culture\" which does not mention either oxidative phosphorylation or NSCLC.\nWithout any relevant content in the source material that discusses both entities or their relationship, I cannot extract any verbatim phrases or sentences meeting the requirements."
    },
    "1801-1864": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "prostate cancer",
      "text": "Collectively, these findings demonstrate that Annonacin exerts potent antitumor activity and synergistically enhances DTX efficacy by promoting DNA damage and suppressing FAK signalling, supporting its potential as a promising adjuvant candidate for PCa treatment.\nIn vivo, the combination therapy achieved more than 74% tumour growth inhibition (p < 0.0001), accompanied by increased tumour cell death, reduced Ki-67 expression and elevated γ-H2AX levels.\nThe antitumor effects and underlying mechanisms of Annonacin and/or DTX were investigated in DU145 cells and a xenograft mouse model by assessing proliferation, migration, apoptosis, colony formation, DNA damage and FAK expression and distribution.\nThrough an integrated strategy combining network pharmacology and a series of in vitro assays, the findings demonstrated that Annonacin exerts significant antitumor activity by inducing DNA damage and downregulating FAK expression and localisation."
    },
    "393-1800": {
      "type": "slc_pathway",
      "key1": "SLC40A1",
      "key2": "migration",
      "text": "CA9 suppression by inhibitors (S4 and U104) decreased viability and migration of MM cells, accompanied by overexpression of TFRC, IREB1/2 and FPN1(SLC40A1) and by downregulation of FTH/FTL.\nThe PI3K/AKT signaling pathway mediates TBMS1-induced ferroptosis, which was accompanied by altered expression of NRF2, SLC40A1, and GPX4, ultimately suppressing cell proliferation and collagen synthesis.\nThe natural IGF1R inhibitor PPP induced ferroptosis through blockage of PI3K/AKT/NRF2 signaling pathway and subsequent inhibition of downstream gene expression of SLC7A11 and SLC40A1 in hepatocellular carcinoma.\nmiR-4735-3p facilitates ferroptosis and tumor suppression in ccRCC by targeting SLC40A1.\nFurthermore, PRPF19 regulates the expression of solute carrier family 40 member 1 (SLC40A1) and mono-ADP ribosylhydrolase 2 (MACROD2), knockdown of SLC40A1 or MACROD2 decreases the sensitivity of tongue cancer cells to radiation and cisplatin treatment.\nβ-elemene in combination with cetuximab was shown to induce iron-dependent reactive oxygen species (ROS) accumulation, glutathione (GSH) depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) in KRAS mutant CRC cells.\nstudies indicated that TBMS1 hindered HSFs proliferation, migration, and myofibroblast activation.\nFerroportin Q248H but not low iron stores was associated with lower circulating macrophage migration inhibitory factor as well.\nFerroportin Q248H and low iron stores are both associated with lower circulating tumor necrosis factor-alpha, while only ferroportin Q248H is associated with lower circulating mac"
    },
    "1796-1853": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "ovarian cancer",
      "text": "This study aimed to investigate the mechanisms through which ART induces ferroptosis to inhibit ovarian cancer.\nThis study explores whether metformin induces ferroptosis and inhibits ovarian cancer progression through the RBMS3 pathway.\nHypoxia promotes the growth and metastasis of ovarian cancer cells by suppressing ferroptosis via upregulating SLC2A12.\nC-MYC Inhibited Ferroptosis and Promoted Immune Evasion in Ovarian Cancer Cells through NCOA4 Mediated Ferritin Autophagy.\nHypoxia promoted ovarian cancer progression by upregulating SLC2A12 and then regulating glutathione metabolism to inhibit ferroptosis.\nMetformin inhibited the viability of ovarian cancer A2780 cells, promoted ferroptosis, increased MDA and Fe²⁺ levels, and reduced GSH.\nPARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.\nRopivacaine represses the ovarian cancer cell stemness and facilitates cell ferroptosis through inactivating the PI3K/AKT signaling pathway.\nARHGAP10 overexpression promoted ferroptosis in ovarian cancer cells, resulting in decreased cell viability, and increased lipid reactive oxygen species (ROS) level.\nInhibition of HOXC11 by artesunate induces ferroptosis and suppresses ovarian cancer progression through transcriptional regulation of the PROM2/PI3K/AKT pathway.\nIn vivo experiments showed that C-MYC could promote tumorigenesis and immune evasion in ovarian cancer cells through inhibiting HMGB1 release induced by NCOA4-mediated ferroptosis.\nObacunone exhibits potential therapeutic significance through the modulation of the Akt/p53 signaling pathway, which may induce ferroptosis and inhibit the proliferation of ovarian cancer cells.\nOur findings suggest that metformin promotes ferroptosis and inhibits ovarian cancer progression by upregulating RBMS3, offering a promising direction for clinical application in ov"
    },
    "136-1797": {
      "type": "slc_pathway",
      "key1": "SLC16A1",
      "key2": "oxidative stress",
      "text": "However, feeding OVE upregulated the acute-phase protein SAA3 by 3.5-fold and downregulated a volatile fatty acid transporter (SLC16A1) and a Fe and Cu transporter (SLC11A2).\nGene expression analysis revealed significant tissue-specific alterations including changes in the expression of SDHA in the liver, an upregulated SLC16A1 in cardiac tissue (in-silico and in-vivo), a downregulated SLC5A3 in cardiac tissue (in-vivo), an upregulated SLC25A10 in cardiac tissue (in-vivo) and differential in-silico expression of SLC25A10 across liver and kidney tissues.\nTo address the potential mechanisms, transcripts related to oxidative stress, cell fate, and cell metabolism (Pdk1, Pdk2, Pdk4, Spr, Slc16a1, Slc16a3, Ppargc1a, Cs, Lgr5, Casp3, Tnfr2, Bax, Bcl2, Sod1, Sod2, and Cat) were measured, and untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to profile the metabolic responses of colonocytes following exposure to butyrate and TNFα.\nIt was found for the first time that EMB promoted lactic acid accumulation and further induced redox dyshomeostasis and glycolysis disorder by simultaneously inhibiting SLC16A1/3.\nAfter SMPs treatment, the serum levels of ALT, AST, liver LPO, ROS, and IL-6 were significantly reduced (P < 0.0 5 or P < 0.01), and the contents of T-AOC, GSH-PX, IL-4, and IL-10 in the liver were significantly increased (P < 0.0 5 or P < 0.01).\nCompared with the GP1 group, the serum levels of ALT, AST, liver LPO, ROS, and IL-6 in the GP2 group were significantly increased (P < 0.0 5 or P"
    },
    "1797-1872": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "breast cancer(BC)",
      "text": "Oxidative stress increases susceptibility to breast cancer (BC) risk, and we previously showed that the Mediterranean diet (MD), which is rich in antioxidants, reduces BC risk in Greek-Cypriot women.\nMechanically, we observed that DPP-4i treatment induced aberrant oxidative stress by triggering ROS overproduction, as well as ROS-dependent NRF2 and HO-1 activations in BC cells, while specific inhibition of ROS, NRF2 or HO-1 activations abrogated DPP-4i-driven BC metastasis and metastasis-associated gene expression.\nROS are able to activate many signal transduction pathways, producing an inflammatory environment that leads to the suppression of programmed cell death and the promotion of tumor proliferation, angiogenesis, and metastasis;\nGK-1 decreased catalase activity, reduced glutathione (GSH) content and GSH/oxidized glutathione (GSSG) ratio while increased hydrogen peroxide (HO) production, GSSG, and protein carbonyl content, inducing oxidative stress (OS) in tumoral tissues.\nAbstract: The system x transporter is upregulated in cancer cells in response to oxidative stress (OS).\nHowever, the mechanism by which BC cells deal with the glucose-shortage-induced oxidative stress remains unclear.\nAbstract: Iron may induce oxidative stress via production of reactive oxygen species, facilitating mammary carcinogenesis.\nThis study reveals that Vit-C induces oxidative stress-mediated cell death in both non-aggressive and aggressive BC spheroids.\nFurthermore, ALA, a NRF2 activator significantly promoted BC metastasis and , which can be abrogated by specific HO-1 inhibition.\nThese results indicate that CS-LO-PEG-HER NPs are biocompatible with mice while inhibiting tumor growth through alter the oxidative stress.\nWe propose a novel mechanism through which exosomes derived from oxidative stress-induced MSCs may contribute to tumor progression and angiogenesis.\nTreating breast cancer cells with TQ and BC significantly inhibited the growth and proliferation (IC values 28.3 µM and 34.8 µM) and induce"
    },
    "1796-1938": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Kidney Cancer",
      "text": "ferroptosis appears to be highly susceptible to ferroptosis in RCC\ninducing the GABPA-ACSL4 pathway activates ferroptosis, inhibits proliferation or metastasis, and exerts anticancer activity in ccRCC\nCYP11A1 activation inhibited the migration of cancer cells, promoted ferroptosis, and triggered autophagy signaling\nMITD1 knockdown induced ferroptosis and suppressed tumor growth and migration through the TAZ/SLC7A11 pathway\nsilencing of APEX1 promotes ferroptosis and inhibits the malignant progression of ccRCC\nThrough promoting STAT1 nuclear translocation, BICD2 facilitated IFNγ signaling transduction and enhanced IFNγ-mediated suppression of cystine/glutamate antiporter system X, eventually increasing cell sensitivity to ferroptosis\nwe identify novel compounds that decrease HIF-1/2α levels and induce ferroptosis by targeting Iron Sulfur Cluster Assembly 2 (ISCA2)\nmoscatilin may inhibit the phosphorylation level of the JAK-STAT signaling pathway, thereby blocking the function of the key protein SLC7A11 in the ferroptosis signaling pathway, which promotes the occurrence of ferroptosis\nChrysin induced ferroptosis, as evidenced by increased ROS levels, Fe accumulation, GSH depletion, and lipid peroxidation\nChrysin suppressed the PI3K/Akt signaling pathway, which resulted in the reduced expression of SLC7A11 and GPX4\nWe found potent synergy of the fatty acid amide hydrolase (FAAH) inhibitor URB597 with ferroptosis inducer (1S, 3R)-RSL3 (RSL3) in inhibiting the growth and metastasis of RCC cells both in vitro and in vivo via induction of G1 cell cycle arrest and promotion of the production of lipid peroxides\nLut probably promoted the heme degradation and accumulation of labile iron pool (LIP) by excessively upregulating the HO-1 expression, which led to the Fenton reaction, GSH depletion, and lipid per"
    },
    "1796-2532": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Pulmory arterial hypertension (PAH)",
      "text": "Loss of ALKBH5 downregulated ACSL4 mRNA and protein levels, depressed lipid peroxidation and rendered hypoxic PASMCs resistant to erastin-induced ferroptosis.\nPRDX6 overexpression significantly inhibited ferroptosis in PAECs under PH conditions in vitro and in vivo, as indicated by increased cell viability, decreased MDA, ROS and LIP levels, inhibited mitochondrial damage, upregulated GPX4 and FTH1 expression, and downregulated NOX4 expression.\nMoreover, SLC7A11 inhibited ferroptosis and promoted proliferation by overexpressing SLC7A11 in PASMCs.\nNotably, ACE2 activation induced ferroptosis, whereas reduced ACE2 activity led to resistance to ferroptosis.\nWe aimed to explore whether induction of ferroptosis could suppress abnormal PASMC proliferation and mitigate hypoxia-induced PVR.\nEleutheroside B pretreatment facilitated the translocation of nuclear factor E2-related factor 2 (Nrf2) into the nucleus, contributing to the inhibition of ferroptosis and necroptosis.\nFurthermore, erastin induced ferroptosis by inhibiting SLC7A11 and glutathione peroxidase 4 (GPX4) expressions in vivo and in vitro, suggesting that the continuous proliferation in hypoxic PASMCs could be reversed by erastin.\nThese results suggest that Fer-1 plays a role in inhibiting ferroptosis-mediated PAEC loss during the progression of PH.\nTreating PH with a ferroptosis inhibitor and exploring new treatments based on ferroptosis regulation might be promising therapeutic strategies for PH.\nCollectively, the beneficial effects of eleutheroside B against HAPE were associated with the inhibition of ferroptosis and necroptosis through Nrf2-antioxidant response signaling.\nThese findings suggest that enhanced ACE2 activity may inhibit abnormal PASMC proliferation and reverse hypoxia-induced PVR, as demonstrated by both in vivo and in vitro experiments.\nWe are the first to suggest that pulmonary ar"
    },
    "1794-1853": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "ovarian cancer",
      "text": ""
    },
    "1796-1900": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "lymphoma",
      "text": ""
    },
    "1801-2209": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "222-1801": {
      "type": "slc_pathway",
      "key1": "SLC25A1",
      "key2": "apoptosis",
      "text": "Overexpression of SLC25A1 attenuated both the decreased proliferation and enhanced apoptosis caused by DMC-GF (p < 0.01).\nThe targeted silencing of SLC25A1 or inhibition of its protein led to a significant decrease in proliferative, invasive and migratory capabilities of ESCC cells, accompanied by increased apoptosis.\nDuring metabolic stress, SLC25A1 increased oxidative phosphorylation (OXPHOS) to protect protects CRC cells from energy stress-induced cell apoptosis.\nKnockdown or pharmacological inhibition of SLC25A1 significantly suppressed AML cell proliferation by inducing apoptosis, without affecting cell cycle progression or differentiation.\nKnockdown of SLC25A1 significantly inhibited the growth of CRC cells by suppressing the progression of the G1/S cell cycle and inducing cell apoptosis both in vitro and in vivo, whereas SLC25A1 overexpression suppressed the malignant phenotype.\nWe further demonstrated that the inhibition of could inhibit the proliferation and increase the apoptosis of AML cells.\nWithin LUAD cells, SLC25A1 was observed to not only boost proliferation but also hinder apoptosis and further augment fatty acid synthesis.\nThis shift promotes NADPH generation through increased cytosolic conversion of malate to pyruvate, protecting cells from glucose deprivation-induced apoptosis.\nMechanistically, we demonstrated that SLC25A1 inhibition disrupted citrate homeostasis, leading to mitochondrial dysfunction and reduced fatty acid metabolism.\nThe present results indicate that knockdown or blockade of SLC25A1 can significantly impede the malignant biological behavior of ESCC.\nCollectively, SLC25A1 plays a pivotal role in the promotion of CRC growth and survival by reprogramming energy metabolism."
    },
    "1794-1917": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Gastric cancer (GC)",
      "text": ""
    },
    "313-1795": {
      "type": "slc_pathway",
      "key1": "SLC31A1",
      "key2": "proliferation",
      "text": "MiR-522-3p inhibited proliferation and activation by regulating SLC31A1 expression in T cells.\nTreatment with si-METTL3 or oe-SLC31A1 suggested increased cell viability, proliferation, migration and invasion, and reduced cell damage and apoptosis rate, while cells treated with oe-METTL3 or si-SLC31A1 had reversed results.\nLentivirus knockdown of SLC31A1 blocked the lactate-induced proliferation and invasion of trophoblasts by inhibiting cell cuproptosis.\nElevated SLC31A1 expression increases intracellular copper, inducing cuproptosis and inhibiting ESCC cell proliferation and tumor growth.\nAdditionally, restored miR-375 expression resulted in suppressed cell proliferation, migration and invasion, and increased apoptosis by targeting SLC31A1.\nMechanically, we identified that Grhl2 mediated SLC31A1 expression through transcription and participated in SLC31A1-inhibited proliferation, invasion, and cuproptosis of trophoblasts.\nConversely, promoting SLC31A1 significantly facilitated the proliferation and invasion of wild-type breast cancer cells.\nIn vitro study shows that SLC31A1 can promote cell proliferation, and migration, and depress the cell apoptosis of glioma cells.\nSLC31A1 knockdown significantly reduces cell proliferation and mobility.\nThe in vitro KD experiment shows the SLC31A1 knockdown depressed the glioma cell proliferation and migration and promoted the apoptosis rate.\nFibroblast-specific SLC31A1 deficiency enhances mitochondrial copper depletion, augments glycolysis, promotes fibroblast proliferation and triggers CF.\nFurther functional analysis of SLC31A1 showed that its elevation was associated with increased glioma cell malignancy, promoting proliferation and migration.\nAdditionally, treatment with the mitotic inhibitor MP-HJ-1b markedly suppressed SLC31A1 expression, consequently inhibiting glioma cell proliferation and migration.\nThe proliferation, migration, and invasiveness of Her2 + enriche"
    },
    "371-1798": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "stemness",
      "text": "In conclusion, CDH17 plays a crucial role in maintaining colorectal cancer cell stemness and chemoresistance via LGR5/Wnt/MYC signaling and SLC38A5 expression.\nLoss of CDH17 resulted in a marked down-regulation of the intestinal cancer stem cell (CSC) marker LGR5, leading to the inhibition of Wnt/β-catenin signaling, suppression of pluripotency genes such as MYC, and a subsequent reduction in stemness properties.\nCDH17 silencing also down-regulated various transporters associated with drug-resistance, including the glutamine-transporter SLC38A5.\nNotably, SLC38A5 silencing was necessary for CDH17-driven effects on drug resistance and survival.\nPharmacological inhibition of SLC38A5 with amiloride, significantly increased cell sensitivity to 5-FU and irinotecan, and improved mouse survival in metastasis models."
    },
    "1796-2668": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Vaginal Cancer",
      "text": ""
    },
    "1801-2539": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Hepatic ischemia-reperfusion (I/R)",
      "text": "Remimazolam (RMZL) remarkably improved cell viability and decreased apoptosis in H/R-induced hepatocyte injury.\nImportantly, activated AXL ameliorated liver injury by inhibiting IRE1 and PERK pathway to reduce ER stress-associated apoptosis.\nMoreover, Pec treatment inhibited oxidative stress, inflammation and apoptosis and could activate the PI3K/AKT/Nrf2 pathway during I/R and H/R.\nIn conclusion, our results indicated that IL-22 inhibited I/R-induced oxidative stress injury, Ca overload, and mitochondrial apoptosis via STAT3 activation.\nAdditionally, hepatocyte-specific MEF2D deficiency significantly alleviated I/R-induced liver injury and inhibited the hepatic inflammatory response and apoptosis.\nPretreatment with Gas6 increased p-AXL expression, reduced ER stress-associated cell apoptosis, alleviated liver damage, and restored ER and mitochondria ultrastructure during hepatic I/R in mice.\nNF-κB signaling pathway and the expression of promoting apoptosis factors such as Bax and Caspase3 were inhibited, while antiapoptotic protein Bcl-2 was promoted in the SRT1720 group compared with the I/R group.\nCompared with HIRI + NC mice, HIRI + miR-25b-3p mice had significantly increased miR-25b-3p expression, decreased ALT/AST levels and apoptosis-related protein expression (P < 0.05), and alleviated liver necrosis.\nIn summary, our results show that Pec inhibits oxidative stress, inflammatory responses, and apoptosis, thereby attenuating I/R-induced liver injury and H/R-induced cell damage via activation of the PI3K/AKT/Nrf2 pathway.\nIn vitro experiments further showed that corynoline pretreatment increased cellular viability, decreased LDH activity, reduced cellular apoptosis, and inhibited oxidative stress and inflammatory injury in H/R-induced BRL-3A cells.\nFurthermore, Eto also showed the ability to inhib"
    },
    "1798-2583": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "ischemic proliferative retinopathies",
      "text": ""
    },
    "3-1801": {
      "type": "slc_pathway",
      "key1": "SLC1A3",
      "key2": "apoptosis",
      "text": "In vivo and in vitro experiments showed that silencing FN1 inhibits the activation of the YAP1/Hippo pathway by enhancing YAP1 phosphorylation, down-regulates SLC1A3-mediated aspartate uptake and utilization by tumor cells, inhibits BC cell proliferation, invasion and migration, and promotes apoptosis.\nInactivation of Trp53 and Rb1, whose pathways are commonly altered in HGSC, leads to elimination of targeted Slc1a3+ cells by apoptosis, thereby preventing their malignant transformation.\nIn combination with ASNase, SLC1A3 inhibition caused cell cycle arrest or apoptosis, and myriads of metabolic vulnerabilities in tricarboxylic acid (TCA) cycle, urea cycle, nucleotides biosynthesis, energy production, redox homeostasis, and lipid biosynthesis.\nThe results indicated that suppression of miR-342-3p improves expression of Glu transporter and promotes dopaminergic neuron proliferation while suppressing apoptosis through the Wnt signaling pathway by targeting PAK1 in mice with PD.\nKnockdown of Rhotekin 2 expression suppresses proliferation and induces apoptosis in colon cancer cells.\nexperiments demonstrated that knockdown of restrained the proliferation activity of ovarian cancer cells, enhanced cell apoptosis, and inhibited cell migration.\nTreatment with FA resulted in a significant decrease in both glial activation and the rate of apoptosis in GCL in comparison with diabetic mice treated with vehicle.\nLastly, in vivo experiments indicated that SLC1A3 expression promoted tumor development and metastasis while negating the suppressive effects of ASNase by fueling aspartate, glutamate, and glutamine metabolisms despite of asparagine shortage.\nAfter 8 weeks of intraocular pressure (IOP) elevation, staining with terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) revealed an increase in the ganglion cell layer, and the number of TUNEL-positive cells was reduced by brimonidine treatment (P<0.05)."
    },
    "39-1799": {
      "type": "slc_pathway",
      "key1": "SLC5A2",
      "key2": "glycolysis",
      "text": "Although these inhibitors can influence tumor glycolysis, the underlying mechanism requires further exploration.\nRTV treatment but not IDV treatment induced AMP-activated protein kinase (AMPKα) phosphorylation that paralleled the decrease in glycolytic activity and cell growth.\nIn addition to activation of glycolysis, we observed activation of the pentose phosphate pathway (PPP) and an increase in the total amount of amino acids in miR-210-transfected cells.\nGlucose transport across glioblastoma membranes plays a crucial role in maintaining the enhanced glycolysis typical of high-grade gliomas and glioblastoma.\nOn the basis of these findings, we propose that miR-210 may induce a shift of energy metabolism from OxPhos to glycolysis by acting on the mitochondrial inner membrane.\nFurthermore, metabolome analysis revealed activation of anaerobic glycolysis in miR-210-transfected cells, and consistent with this the secretion of lactate, the final metabolite of anaerobic glycolysis, was significantly increased.\nWe tested the ability of two inhibitors of the glucose transporters GLUT/SLC2A superfamily, indinavir (IDV) and ritonavir (RTV), and of one inhibitor of the Na/glucose antiporter type 2 (SGLT2/SLC5A2) superfamily, phlorizin (PHZ), in decreasing glucose consumption and cell proliferation of human and murine glioblastoma cells.\nWe found in vitro that RTV, active on at least three different GLUT/SLC2A transporters, was more effective than IDV, a specific inhibitor of GLUT4/SLC2A4, both in decreasing glucose consumption and lactate production and in inhibiting growth of U87MG and Hu197 human glioblastoma cell lines and primary cultures of human glioblastoma.\nSGLT1 and SGLT2 are expressed in various tumors where they supply the tumor cells with glucose for euglycemic glycolysis.\nLactate concentration was higher in the kidney cortex of transgenic mice relative to wild-type mice, although the difference was not significant (p = 0.070)."
    },
    "1800-2379": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "pancreatic tumor growth",
      "text": "THBS1 knockdown suppressed cell proliferation, migration, and invasion while enhanced cell apoptosis through the JAK2/STAT3 signaling pathway.\nThe upregulation of TRIM46 rescued ONECUT3 knockdown-induced suppression of cell proliferation, migration and invasion abilities, and tumor growth in PC.\nAfter transfection, pancreatic cancer cells exhibit a sustained increase in expression of miR-200, which inhibits cell viability, invasion, and migration.\nMir-200c inhibits pancreatic cancer cell proliferation and migration through dual mechanisms: activation of PTPN6 transcription and repression of CDH17 expression.\nCell functional experiments verified that miR-130b suppressed cell proliferation, migration, promoted apoptosis, and inhibited the PI3K/Akt pathway by targeting MET in PC cells.\nWe found that IgG18 and IgG56 antibodies antagonized CXCL8-induced CXCR2 signaling, suppressed CXCL8-mediated cell proliferation and migration, and induced apoptosis in pancreatic cancer cells.\nThis study confirms that CuB inhibits pancreatic cancer by suppressing the PI3K/Akt/mTOR pathway and activating PINK1/Parkin to induce mitophagy, thereby inhibiting cell migration, invasion, and proliferation.\ntRF-Pro-CGG acts as a tumor suppressor in pancreatic cancer by inhibiting cell proliferation, migration, invasion, and promoting apoptosis, likely through targeting CSF1 and regulating the PI3K-AKT signaling pathway.\nMechanistically, miR-145-5p overexpression increased the sensitivity of PC drug-resistant cells to gemcitabine through the inhibition of CDCA3, thereby inhibiting the proliferation and migration of PC drug-resistant cells.\non the contrary, in HIF-3α overexpressed PANC-1 cells, notably increased migration distance, and elevated number of invaded cells and colonies were observed, along with decreased autophagosome, upregulated p62, and downregulated Beclin1, LC3II/I, ATG7, and TP53INP"
    },
    "199-1798": {
      "type": "slc_pathway",
      "key1": "SLC22A16",
      "key2": "stemness",
      "text": "The genetic inactivation of PSMB10 resulted in increased senescence and cytotoxic T lymphocyte (CTL) killing, as well as increased intracellular drug concentrations and drug-induced cellular senescence in different types of human AML cells, which also impeded human and murine leukemia initiation and stemness maintenance in vivo with a 19-fold decrease in the frequency of human LSCs and a 7.6-fold decrease of drug-resistant mouse LSCs, while normal hematopoietic cells remained unaffected.\nMechanistically, the downregulation of PSMB10 boosted SLC22A16-mediated drug endocytosis and further induced chemotherapy drug-mediated senescence through the RPL6/RPS6-MDM2-P21 pathway in AML cells.\nHowever, whether and how drug-resistant LSCs retain stemness via senescence and immune regulation remains unknown."
    },
    "1798-2001": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Bone cancer",
      "text": "Pharmacological inhibition of glycolysis counteracted the upregulation of ATF3 expression and increased stemness in OSCs by PDK1 overexpression.\nIn this study, we observed that RH significantly inhibited osteosarcoma cell proliferation, migration, invasion and stemness in vitro while promoting death and curtailing tumourigenesis in vivo.\nImmunohistochemical analysis revealed that CDN upregulated LC3 expression and decreased CD133 and β-catenin expression, aligned with the findings of the in vitro experiments.\nThese findings indicate that NOTCH2 is a critical regulator of OS cell behavior, and that targeting NOTCH2 - especially in combination with Importazole - may offer a promising therapeutic strategy to promote differentiation and suppress tumor progression in OS.\nThis shows that CDN-induced autophagy inhibited the growth of osteosarcoma stem cells.\nGenetic inhibition of PDK1 via RNA interference reduced OSC stemness, glycolysis, and heterotopic tumor formation.\nAdditionally, our findings reveal that CD155 promotes osteosarcoma stemness by modulating the Wnt/β-catenin signaling pathway.\nWhen combined with NOTCH2 knockdown, Importazole exerted a synergistic effect, further inhibiting tumor progression and promoting differentiation.\nTreatment with Importazole alone inhibited OS cell proliferation and invasion, reduced stem-like features, and enhanced osteogenic differentiation.\nThe weakening of CSCs' ability to maintain their stemness in OS is achieved by blocking the Wnt/β-catenin (WBC) signaling pathway via the action of CDN.\nTaken together, the results showed AZD1080 as a specific inhibitor of CSC stemness, without cytotoxicity, and indicated it was a promising therapeutic agent that targeted GSK‑3β signaling in osteosarcoma.\nUsing MG-63 and Saos-2 OS cell lines, we found that NOTCH2 silencing suppressed cell proliferation, invasion, and stem-like properties, while promoting osteogenic differentiation under inductive conditions.\nOur findings reveal that troxerutin effectively inhibits CD155, attenuates the SRC/A"
    },
    "1797-2353": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "inflammatory bowel disease",
      "text": "Excessive oxidative stress and NLRP3 inflammasome activation are considered the main drivers of inflammatory bowel disease (IBD), and inhibition of inflammasomes ameliorates clinical symptoms and morphological manifestations of IBD.\nInflammatory bowel disease (IBD) etiology is intricately linked to oxidative stress and inflammasome activation.\nOxidative stress leads to intestinal barrier damage, which induces immune responses to occur and further promotes oxidative stress exacerbating inflammatory bowel disease (IBD).\nOne of the key pathological contributors to the development and progression of inflammatory bowel disease (IBD) is oxidative stress, which results in reactive oxygen species (ROS)-induced mucosal damage.\nInflammatory bowel disease (IBD) is associated with oxidative stress and redox signaling disruption.\nOxidative stress (OS) is an important pathophysiological mechanism in inflammatory bowel disease (IBD).\nMechanically, morroniside suppressed NLRP3 and NF-κB pathways, and alleviated LPS-induced inflammatory and oxidative stress in IBD.\nUlcerative colitis (UC) is a chronic inflammatory bowel disease characterized by oxidative stress, immune dysregulation, and compromised intestinal barrier integrity.\nExcessive oxidative stress, dysregulated immune homeostasis, and disruption of the intestinal epithelial barrier are crucial features of inflammatory bowel disease (IBD).\nOxidative stress is believed to play an important role in the pathogenesis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC).\nOxidative stress caused by the overproduction of reactive oxygen species (ROS) plays an important role in inflammatory bowel disease (IBD).\nUlcerative colitis (UC) is an inflammatory bowel disease (IBD), accompanied by intense inflammation, oxidative stress, and intestinal microbiota dysbiosis.\nInflammatory bowel disease (IBD), including ulcerative colitis (UC), is a global health concern characterized by chronic inflammation and oxidative stress.\nStudies have shown that saffron may protect against inflammatory bowel disease (IBD) through several mechanisms by inhibiting pro-inflammatory cytokines (TNF-α, IL-1"
    },
    "265-1797": {
      "type": "slc_pathway",
      "key1": "SLC25A44",
      "key2": "oxidative stress",
      "text": ""
    },
    "63-1801": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "apoptosis",
      "text": "Reducing SLC6A14 increased cell proliferation and suppressed apoptosis.\nWhile SLC6A14 genetic deficiency does not have a major impact on cell proliferation, combined depletion of AMPK and SLC6A14 leads to an increase in apoptosis upon methionine starvation, suggesting that combined targeting of SLC6A14 and AMPK can be exploited as a therapeutic approach to starve tumor cells.\nIn PDAC cell line, knockdown inhibited cells proliferation, migration and promoted cells apoptosis.\nAdministration of α-MT to mice showed evidence of IDO1 inhibition and rectification of metabolic dysfunctions with concurrent suppression of mTOR signaling and apoptosis.\nThese studies show that blockade of amino acid entry amplifies the anticancer effect of lapatinib via interference with mTOR signaling, promotion of apoptosis, and suppression of cell proliferation and metastasis.\nReducing SLC6A14 decreased pyroptosis-associated proteins (ASC, IL-1β, IL-18, NLRP3).\nNLRP3 overexpression counteracted the effects of sh-SLC6A14 on LPS-induced FHC and NCM460 cell pyroptosis.\nFurther knockdown SLC6A14 with siRNA or treatment with α-MT in CRC cell lines reduced cell proliferation and migration in vitro and inhibited xenograft tumor growth in vivo.\nSLC6A14 promotes UC pyroptosis by regulating NLRP3, suggesting the therapeutic potential of modulating the SLC6A14/NLRP3 axis.\nMechanistically, SLC6A14 was demonstrated to regulate the expression and phosphorylation of Akt-mTOR, which mediates the promoting tumor growth function of SLC6A14.\nSLC6A14 was upregulated in CRC and could promote tumor progression by activating the Akt-mTOR signaling pathway, which may serve as an effective molecular target for the treatment of CRC.\nThese disturbances are chiefly characterized by alterations in amino acid metabolism, energy production pathways, membrane biochemical features, and nicotinamide metabolism, all of which"
    },
    "1801-2557": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "malignt cancers",
      "text": ""
    },
    "1799-1893": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Thyroid Cancer",
      "text": "Canagliflozin inhibited glucose uptake, glycolysis and AKT/mTOR signaling activation, and increased AMPK activation in thyroid cancer cell.\nOverall, Cdc42 can promote cell proliferation and migration through the PTEN/AKT pathway and promote tumor-related M2 macrophage polarization and inhibit T cell activity by enhancing aerobic glycolysis, animal experiments confirmed that tumor volume increased after Cdc42 overexpressed in TBP-3743 murine thyroid cancer cells.\nIn thyroid cancer cells, the overexpression of BRAF V600E inhibited OXPHOS gene expression and mitochondrial respiration but enhanced aerobic glycolysis.\nFurthermore, RON interference inhibited glycolysis, promoted ferroptosis, elevated cell sensitivity to chemotherapy and affected mitochondrial function in thyroid cancer cells.\nPolyphyllin II simultaneously inhibits glycolysis and OXPHOS, thereby suppressing the invasion, migration, and proliferation of thyroid cancer cells, while also promoting apoptosis.\nThese results indicate that in thyroid cancer, the BRAF V600E mutation alters the HIF1α-MYC-PGC-1β axis, causing mitochondrial respiration to be inhibited and aerobic glycolysis to be enhanced.\nWe hypothesize that lenvatinib-resistant differentiated thyroid cancer cells will have an increased dependency on glycolysis and that a novel C-terminal heat shock protein 90 inhibitor (KU757) can effectively treat lenvatinib-resistant cells by targeting glycolysis.\nThe present study observed that at lower concentration, butein, a major bioactive chalcone, significantly inhibits NPA (papillary thyroid cancer cell line) cell migration and reduces extracellular acidification rate (ECAR) an indicator of enhanced glycolysis, required for cell migration.\nCollectively, AKR1C3 silencing inhibited autophagy-dependent glycolysis in thyroid cancer by inactivating ERK signaling.\nFurthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E mutant thyroid cancer specimens, thereby promoting glycolysis."
    },
    "146-1799": {
      "type": "slc_pathway",
      "key1": "SLC16A11",
      "key2": "glycolysis",
      "text": "Consistent with this, a type 2 diabetes risk haplotype in SLC16A11 that reduces pyruvate transport (thus limiting lactate production) increases D5D/D6D activity in vitro and in humans, demonstrating a chronic effect of desaturase-mediated NAD recycling.\nHere, we show that D5D/D6D provide a mechanism for glycolytic NAD recycling that permits ongoing glycolysis and cell viability when the cytosolic NAD/NADH ratio is reduced, analogous to lactate fermentation.\nAlthough lesser in magnitude than lactate production, this desaturase-mediated NAD recycling is acutely adaptive when aerobic respiration is impaired in vivo.\nThese findings highlight key biologic roles for D5D/D6D activity independent of their HUFA end products and expand the current paradigm of glycolytic NAD regeneration.\nThe reactions catalyzed by the delta-5 and delta-6 desaturases (D5D/D6D), key enzymes responsible for highly unsaturated fatty acid (HUFA) synthesis, regenerate NAD from NADH.\nNotably, inhibition of either HUFA synthesis or lactate fermentation increases the other, underscoring their interdependence."
    },
    "243-1798": {
      "type": "slc_pathway",
      "key1": "SLC25A22",
      "key2": "stemness",
      "text": "Organoids from ApcKrasSLC25A22 mice had reduced expression of LGR5 and other markers of stemness compared with organoids derived from ApcKras mice.\nIn CRC cells that express activated KRAS, SLC25A22 promotes accumulation of succinate, resulting in increased DNA methylation, activation of WNT signaling to β-catenin, increased expression of LGR5, proliferation, stem cell features, and resistance to 5-fluorouacil.\nLevel of SLC25A22 correlated with levels of LGR5, nuclear β-catenin, and a stem cell-associated gene expression pattern in human colorectal tumors with mutations in KRAS and reduced survival times of patients.\nKnockdown of SLC25A22 in human colorectal tumor organoids reduced clonogenicity.\nApcKrasSLC25A22 mice developed fewer colon tumors than ApcKras mice (P < .01).\nKnockdown of lysine demethylases, or succinate supplementation, restored expression of LGR5 to SLC25A22-knockout CRC cells.\nExpression of the protocadherin genes reduced WNT signaling to β-catenin and expression of the stem cell marker LGR5.\nThis results in inhibition of demethylases and epigenetic alterations in cells that increase proliferation and stem cell features.\nMutant KRAS promotes glutaminolysis, a process that uses steps from the tricarboxylic cycle to convert glutamine to α-ketoglutarate and other molecules via glutaminase and SLC25A22.\nKnockout of SLC25A22 in CRC cells that express mutant KRAS increased their sensitivity to 5-fluorouacil."
    },
    "1798-1811": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Osteosarcoma(OS)",
      "text": "On the other hand, EGCG could partially inactivate Notch3/DLL3 signaling cascade targeting SOX2OT variant 7 to reduce the stemness then abated drug-resistance of osteosarcoma cells.\nNotably, knockdown reduced the ability of overexpression to promote the stemness of OS cells.\nIn addition, the loss of SKP2 also promoted an apoptotic microenvironment and reduced the stemness of DKO tumors.\nThe stemness of CSCs in OS such as self-renewal and differentiation potentials was both impaired with a significant decrease of Oct-4 and Nanog activation.\nNotably, antagonizing miR-135b potently inhibits OS lung metastasis, cancer cell stemness, CSC-induced tumor formation, and recurrence in xenograft animal models.\nTreating OS cells with the histone lysine demethylase inhibitor 5-carboxy-8-hydroxyquinoline (IOX-1) dose-dependently increased histone H3 methylation and inhibited cellular migratory and invasive capabilities, suppressed matrix metalloproteinase expression, reversed epithelial-to-mesenchymal transition by increasing levels of epithelial markers E-cadherin and ZO-1 and decreasing the expression of mesenchymal markers N-cadherin, vimentin, and TWIST, and also reduced stemness properties.\nMore importantly, it was the short form of DCLK1 that was upregulated in osteospheres, which was suppressed in response to pimozide.\nImmunohistochemical analysis revealed that CDN upregulated LC3 expression and decreased CD133 and β-catenin expression, aligned with the findings of the in vitro experiments.\nThese findings suggest that miR-135b mediates the constitutive activation of Wnt/β-catenin and Notch signaling, and that the inhibition of miR-135b is a novel strategy to inhibit tumor metastasis and prevent CSC-induced recurrence in OS.\nKnockdown of FER1L4 in OS cells decreased the apoptosis rate, but increased the OS cell proliferation, upregulated the expression levels of CD133"
    },
    "1794-2209": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "425-1797": {
      "type": "slc_pathway",
      "key1": "SLC48A1",
      "key2": "oxidative stress",
      "text": "Abstract: Heme is critical for a variety of cellular processes, but excess intracellular heme may result in oxidative stress and membrane injury.\nUsing the dietary isothiocyanate sulforaphane (SFN) to activate NRF2, chromatin immunoprecipitation sequencing (ChIP-seq) identified several hundred novel NRF2-mediated targets beyond its role in oxidative stress.\nUnder oxidative stress, NRF2 heterodimerizes with small Maf proteins and binds cis-acting enhancer sequences found near oxidative stress response genes.\nActivated NRF2 bound the antioxidant response element (ARE) in promoters of several known and novel target genes involved in iron homeostasis and heme metabolism, including known targets FTL and FTH1, as well as novel binding in the globin locus control region.\nFive novel NRF2 target genes were chosen for followup: AMBP, ABCB6, FECH, HRG-1 (SLC48A1), and TBXAS1.\nSLC48A1 (heme responsive gene-1, HRG-1), the sole member of the SLC48 family, is associated with the endosome and appears to transport heme from the endosome into the cytosol.\nAbstract: Nuclear factor- (erythroid-derived 2) like 2 (NFE2L2, NRF2) is a key transcriptional activator of the antioxidant response pathway and is closely related to erythroid transcription factor NFE2."
    },
    "1797-2188": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "colon adenocarcinoma (COAD)",
      "text": "This disruption induced oxidative stress, ultimately resulting in cell death and reduced cell viability.\nSpecifically, the suppression of cGAS through siRNA-mediated knockdown or doxycycline-inducible knockout reversed this metabolic switch, resulting in increased OXPHOS activity, elevated production of OXPHOS byproduct reactive oxygen species (ROS), and consequently caused oxidative stress.\nHowever, it is unknown whether ferroptosis-related genes (FRGs) are associated with colon adenocarcinoma (COAD) metastasis, immune cell infiltration, and oxidative stress in COAD.\nAdditionally, as a CDK4 inhibitor, HER developed triple anti-tumor effects including induced G0/G1 phase arrest, suppressed glycolysis, and disrupted the anti-oxidative capacity of CC cells.\nFRGs may improve tumor cell survival by activating the TGFB pathway, which can stimulate ROS production, accelerates ECM breakdown, and promote tumor progression and invasion.\nSignificantly higher oxidative stress was found among high-risk patients.\nThese findings offer new insights into the role of oxidative stress in colon cancer.\nBioinformatics analyses revealed that TRPV4 is closely associated with ferroptosis-related genes, participating in key biological processes such as responses to external stimuli, oxidative stress, and cell adhesion.\nThis study provides a novel perspective on the role of mitochondrial oxidative stress in COAD, proposing innovative prognostic evaluation methods and potential therapeutic targets, thus offering new directions for the clinical treatment of COAD.\nThe results first time revealed that CDK4 modulated glycolytic and anti-oxidative capacity of CC cells via bound to its endogenous substrates, PKM2 and NRF2.\nFurther analyses revealed that the disparity in prognostic outcomes between risk groups could be attributed to the reactive oxygen species pathway and the p53 signaling pathway.\nAccording to the single sample gene set enrichment analysis (ssGSEA) results, FRGs are involved in variety of pathological pathways including PI3K-AKT-mTOR pathway, reactive oxygen species (ROS) pathway, response to hypoxia pathway, and other inflammation related pathways."
    },
    "1794-2188": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "colon adenocarcinoma (COAD)",
      "text": ""
    },
    "30-1801": {
      "type": "slc_pathway",
      "key1": "SLC4A4",
      "key2": "apoptosis",
      "text": "Upregulation of SLC4A4 promoted apoptosis in the LUAD cell line and significantly inhibited the migration and invasive ability of cancer cells (P<0.01).\nSLC4A4 knockdown inhibited cell proliferation, migration and invasion, while facilitated apoptosis, which was also confirmed in vivo.\nOverexpressing miR-224-5p increased the proliferative, migratory and invasive abilities of CRC cells and inhibit CRC cell apoptosis, while overexpressing SLC4A4 caused the opposite result.\nOverall, 14% of the top candidate biomarkers also had evidence for involvement in psychological stress response, and 19% for involvement in programmed cell death/cellular suicide (apoptosis).\nMoreover, SLC4A4 promoted PCa progression through the AKT-mediated signalling pathway.\nSLC4A4 knockdown suppressed PCa development in vitro and in vivo.\nmiR-224-5p in CAFs-derived EVs facilitated the proliferation, migration, invasion and anti-apoptosis of CRC cells.\nRescue assay also demonstrated that overexpressing miR-224-5p reversed the inhibitory effect of overexpressed SLC4A4 on cancer cell growth.\nImportantly, we demonstrated that high expression of SLC4A4 was able to increase the proliferation level and cytokine secretion of CD8+ T cells for the purpose of promoting the immune system response to LUAD.\nIt has been demonstrated that lipopolysaccharide (LPS)-induced vascular occlusion is associated with the apoptosis, activating calpain and increased [Ca(2+)]i that are related to NHE1 activity in endothelia cells.\nIt may be that in the face of adversity (stress), death mechanisms are turned on at a cellular (apoptosis) and organismal level.\nSLC4A4 acts as a tumor promotor in PCa by regulating key components of the AKT pathway and may therefore act as a potential therapeutic target for PCa treatment.\nThe results of this study indicated that SLC4A4 overexpression was closely associated with the progression of PCa.\nAltered expression and activity of solute carrier"
    },
    "75-1799": {
      "type": "slc_pathway",
      "key1": "SLC7A5",
      "key2": "glycolysis",
      "text": "E2F2 deficiency upregulates the expression of SLC7A5 to mediate amino acids flux, resulting in enhanced glycolysis, impaired mitochondrial function, and increased macrophages proinflammatory response in a Leu-mTORC1-dependent manner.\nWe demonstrated that the elevated SLC7A5 expression activated the amino acid pathway and promoted cell proliferation, tumor growth, and therapeutic resistance by inducing the switch from PKM1 to PKM2 expression, thereby mediating the crosstalk between amino acid metabolism and glycolysis.\nKnockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in GC by suppressing glycolysis.\nIn addition, the miR-152/SLC7A5 axis mediated the expression of PTBP1, which maintains the balance between PKM1 and PKM2, linking amino acid signaling with the glycolysis pathway.\nFurthermore, knockdown of SLC7A5 downregulated the expression of HK2, LDHA, Glut1, and PDK1 both in vivo and in vitro, leading to increased extracellular glucose levels and decreased lactate levels.\nDeletion of SLC7A5 in T cells compromises mTORC1, glycolysis and mitochondrial oxidation.\nWe provide evidence that SLC7A5-mediated leucine influx contributes to pro-inflammatory cytokine production mTOR complex 1 (mTORC1)-induced glycolytic reprograming in activated human monocytes/macrophages.\nInhibition of SLC7A5-mediated leucine influx was linked to downregulation of glycolytic metabolism as evidenced by the decreased extracellular acidification rate, suggesting a regulatory role for this molecule in glycolytic reprograming.\nOn the contrary, L-Leu removal reduced mTORC1 and completely blocked glycolysis but preserved mitochondrial function, favoring the generation of central memory responses and expression of stemness marker TCF1.\nMechanistically, E2F2 can inhibit the SLC7A5 transcription directly.\nIn this study, we found that MAIT cells significantly"
    },
    "1799-2119": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": "We report here that circPETH, a circular RNA (circRNA) transported via extracellular vesicles (EVs) from tumor-associated macrophages (TAMs) to hepatocellular carcinoma (HCC) cells, facilitates glycolysis and metastasis in recipient HCC cells.\nHepatocellular carcinoma (HCC) is a malignant hepatic neoplasm characterized by rapid cellular proliferation facilitated by aerobic glycolysis.\nThe functional assay revealed that silencing PYCR2 inhibited cell viability, glycolysis, and AKT activation.\nAdditionally, overexpression of EFNA3 reversed the inhibition of cell viability and glycolysis induced by NSUN5 silence.\nKAT2A overexpression promoted the viability and glycolysis of SNU-182 and Huh7 cell lines, which were partly blocked following PGAM1 inhibition.\nYAP1 knockdown inhibited GLUT1-mediated aerobic glycolysis, whereas YAP1 overexpression promoted GLUT1-mediated aerobic glycolysis in HCC cells.\nPathway inhibition analysis indicated that CENPL activated the MEK1/2-ERK1/2 signaling pathway to promote proliferation and glycolysis in HCC cells.\nUCHL5 downregulates its degree of ubiquitination by binding to β-catenin, which activates the Wnt/β-catenin pathway and accelerates HCC cell glycolysis.\nIn conclusion, GJB2 promotes HCC progression by activating glycolysis through cytoplasmic translocation and generating a suppressive tumor microenvironment.\nKnocking down CDC45 inhibited HCC cell proliferation, migration, invasion, EMT, stemness, and glycolysis, and promoted apoptosis, which was verified through experiments.\nMechanistically, PFKFB4 suppresses phosphorylated AMP-activated protein kinase (p-AMPK) through enhanced aerobic glycolysis, which in turn stimulates the level of SREBP1.\nThe repressive effects of NFYC knockdown on EMT and glycolysis in HCC"
    },
    "1802-2532": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Pulmory arterial hypertension (PAH)",
      "text": "AAV1-induced CHCHD4 elevation conspicuously alleviates vascular remodeling and pulmonary artery resistance, and orchestrates mitochondrial oxidative phosphorylation in PASMCs.\nBy promoting the switch from oxidative phosphorylation to glycolysis, cellular metabolic reprogramming plays an important role in PH development.\nMitochondrial oxidative phosphorylation is inappropriately enhanced and, as a result of impaired electron transport and mitochondrial ROS increase, caspase-3 is activated and DNA damage is induced.\nConsistent with this, we previously showed that platelets from Group 1 PH patients demonstrate increased glycolysis and enhanced maximal capacity for oxidative phosphorylation, which is due to increased fatty acid oxidation (FAO).\nSuppression of glucose oxidation and secondary upregulation of glycolysis are responsible for various features of PH, including the proliferation and apoptosis resistance of pulmonary artery endothelial and smooth muscle cells.\nEndothelial dysfunction along with metabolic changes towards increased glycolysis are important in PAH pathophysiology.\nIn PH there is a metabolic change from oxidative phosphorylation to mainly glycolysis for energy production.\nCollectively, our data demonstrated that CHCHD4 elevation orchestrates mitochondrial oxidative phosphorylation and antagonizes aberrant PASMC cell growth and migration, thereby disturbing hypoxic PAH, which could serve as a promising therapeutic target for PAH treatment.\nMechanistically, through lung tissues bulk RNA-sequencing (RNA-seq), we further identified CHCHD4 modulated mitochondrial dynamics by directly interacting with SAM50, a barrel protein on mitochondrial outer membrane surface.\nOxidative phosphorylation associated proteins had an increased expression in PAH-EC compared to CTEPH-EC and HPAEC.\nThis increased platelet reserve capacity correlated with mean pulmonary artery pressure, pulmonary vascular resistance, and right ventricular stroke work index in PH patients and was abolished by the inhibition of fatty acid oxidation (FAO).\nWe report that smooth muscle cells isolated from the pulmonary vessels of rats with PH (PH-PASMC), induced by a"
    },
    "1797-2393": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "clear cell renal cell carcinoma (CCRCC)",
      "text": "cabozantinib + Honokiol combination can significantly inhibit c-Met-induced and Nrf2-mediated anti-oxidant pathway in renal cancer cells to promote increased oxidative stress and tumor cell death.\nThis research clarified a novel mechanism by which HIF2α stabilises sirtuin 3 (SIRT3) through direct transcriptional activation of NUDT1, thereby inhibiting oxidative stress to promote the development of ccRCC.\nConsumption with HW suppressed Fe-NTA-induced oxidative stress through decreasing formation of lipid peroxidation and peroxynitrite and activities of NADPH oxidase and xanthine oxidase, increasing activity of catalase, and restoring mitochondrial function in kidneys.\nHowever, renal cancer cells are known to hijack these stress mechanisms and exploit them to their advantage in order to promote their survival through rewiring of their metabolism, activation of oxidative stress responses, autophagy, inhibition of apoptosis and senescence.\nThese data suggest that oxidative stress during dialysis enhances antioxidant activity, with an inhibiting effect on carcinogenesis.\nMechanistically, HIF2α transcription activates the expression of NUDT1, thereby inhibiting oxidative stress and promoting the progression of ccRCC.\nOur results indicate that increased prolidase seems to be related to increased oxidative stress along with decreased antioxidant levels in renal cancer.\nThe miR-4735-3p mimic increased, while the miR-4735-3p inhibitor decreased oxidative stress, lipid peroxidation, iron overload, and ferroptosis of human ccRCC cell lines.\nThese results suggest that overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in RCC.\nMoreover, overexpressing ZC3H13 hindered KIRC cell proliferation, promoted apoptosis, oxidative stress, and disrupted mitochondrial function in vitro, as well as blocked tumor growth in vivo.\nIn experiments, RAC not only obviously damaged tumor cells and decreased the release of inflammatory cytokines and oxidative stress factors but also enhanced the apoptosis of the tumor cell in R"
    },
    "405-1800": {
      "type": "slc_pathway",
      "key1": "SLC43A3",
      "key2": "migration",
      "text": "Furthermore, the orphan protein SLC43A3, a core member of the 7-SLC classification system, was identified as a key facilitator of tumour cell proliferation and migration, suggesting its potential as a novel target for cancer therapy."
    },
    "1800-2196": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "glioma",
      "text": ""
    },
    "222-1794": {
      "type": "slc_pathway",
      "key1": "SLC25A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "403-1794": {
      "type": "slc_pathway",
      "key1": "SLC43A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1796-1897": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Heart Tumor",
      "text": "Herein, we reveal that Doxorubicin (DOX)-treated breast cancer cells secrete sEVs (D-BCC-sEVs) that exacerbate DOX-induced ferroptosis of human iPSC-derived cardiomyocytes (hiCMs).\nClinically, plasma sEVs isolated from patients experiencing DOXIC enhance DOX-induced ferroptosis in hiCM, which is rescued by miR-338-3p inhibitor.\nIncubation of hiCMs with D-BCC-sEVs or overexpression of miR-338-3p alone intensifies DOX-induced ferroptosis.\nD-BCCs-enriched miR-338-3p is packaged in sEVs and transferred into hiCMs in a RBMX-dependent manner, miR-338-3p further targets anti-ferroptotic genes CP, SLC7A11, and GPX4 to facilitate their degradation.\nTherapeutically, dual-functional decoying sEVs encapsulated with miR-338-3p inhibitor mitigate DOXIC in an orthotopic breast cancer mouse model.\nOur findings uncovered for the first time that DOX-treated BCCs exacerbated DOXIC through releasing pro-ferroptotic miR-338-3p-enriched sEVs.\nmiRNA expression profiling and experimental validations reveal that miR-338-3p is upregulated in D-BCC-sEVs and mediate its detrimental effects.\nTherefore, targeting sEVs-mediated tumor/cardiomyocyte pathological communication may offer a novel approach for the management of DOXIC.\nSmall extracellular vesicles (sEVs) critically orchestrate inter-tissue and inter-organ communications and may play essential roles in heart-tumor interaction.\nHowever, whether cancer-secreted sEVs affect the progression of doxorubicin-induced cardiotoxicity (DOXIC) via orchestrating the tumor cell-cardiomyocyte crosstalk has not yet been explored.\nN-methyladenosine (mA) is revealed to mediate the upregulation of"
    },
    "243-1796": {
      "type": "slc_pathway",
      "key1": "SLC25A22",
      "key2": "ferroptosis",
      "text": "The animal study further confirms that SLC25A22 inhibits ferroptosis-mediated tumor suppression.\nThe downregulation of SLC25A22 expression was associated with increased sensitivity to ferroptosis, but not to apoptosis.\nThe RSL3-induced ferroptosis of LUAD led to upregulation of SLC25A22 and SIRT3, and SIRT3 protected RSL3-induced LUAD from ferroptosis in vitro and in vivo.\nTherefore, our results demonstrated that SIRT3 protected LUAD cells from RSL3-induced ferroptosis, and this effect is at least partially due to its deacetylation of SLC25A22, revealing that the SIRT3-SLC25A22 axis has an important role in regulating the ferroptosis of LUAD cells.\nSLC25A22 is a novel metabolic repressor of ferroptosis by producing GSH and MUFAs.\nSolute carrier family 25 member A22 (SLC25A22) is a glutamate transporter in the inner mitochondrial membrane that is known to suppress ferroptosis in pancreatic ductal adenocarcinoma (PDAC).\nHere, we identify solute carrier family 25 member 22 (SLC25A22), a mitochondrial glutamate transporter, as a driver of ferroptosis resistance in pancreatic ductal adenocarcinoma (PDAC) cells.\nMechanistically, on the one hand, SLC25A22-dependent NAPDH synthesis blocks ferroptotic cell death in PDAC cells through mediating the production of glutathione (GSH), the most important hydrophilic antioxidant.\nOn the other hand, SLC25A22 promotes the expression of stearoyl-CoA desaturase in PDAC cells in an AMP-activated protein kinase-dependent manner, resulting in the production of antiferroptotic monounsaturated fatty acids (MUFAs).\nThese findings establish a previously unrecognized metabolic defense pathway to limit ferroptotic cell death."
    },
    "1801-2613": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Esophageal Cancer",
      "text": "By targeting SHP2-mediated AKT and ERK signaling pathways, and suppressed cell proliferation and induced apoptosis in esophageal cancer cells.\nIn summary, downregulation of ZCCHC4 leads to increased sensitivity of ESCC cells to cisplatin, inhibits proliferation, and promotes apoptosis in esophageal cancer cells, potentially via the ROS/c-myc axis.\nFurther research shows that Atractylenolide I inhibited the Wnt/β-catenin signaling pathway, decreased the expression of CCND1, MYC, and FN1 genes, and thus increased the apoptosis of esophageal cancer cells and blocked the cell cycle in G/G phase, hence exerting the role of inhibiting esophageal cancer cells in vivo and .\nPBX3 then transcriptionally repressed TET2 expression to promote esophageal cancer cell proliferation, and suppress apoptosis and autophagy.\nConversely, overexpression of ZCCHC4 promotes proliferation, inhibits apoptosis, and increases resistance to cisplatin in esophageal cancer cells.\nAS1411-HSA-LDP-AE exhibited a strong cell-killing activity in esophageal cancer cells, inhibited cell migration and invasion, and induced cell apoptosis.\nLoss-of-function analysis demonstrated that TRIM31 depletion inhibited esophageal cancer cell proliferation while suppressing tumor growth and promoting apoptosis in vivo.\nPHAX or PBX3 knockdown not only inhibited esophageal cancer cell proliferation, and promoted apoptosis and autophagy in vitro, but it also repressed tumor growth and lung metastasis in mice.\nKnockdown of ZCCHC4 induces DNA damage, leading to an elevation of reactive oxygen species (ROS), which in turn triggers S-phase arrest, enhances apoptosis, augments sensitivity to cisplatin treatment, and inhibits proliferation in esophageal cancer cells.\nThe results indicated that the combined treatment emerged a synergistic effect, which could effectively inhibit the proliferation, migration, and invasion of esophageal cancer cells, induce more obvious cell"
    },
    "1794-1839": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "bladder cancer",
      "text": ""
    },
    "1795-2429": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "diabetes vascular complications",
      "text": "Consequently, tyrosol exerts cytoprotective function against hyperglycemia-induced oxidative stress in skeletal muscle cells, increases their proliferation vigorously, and simultaneously suppresses apoptosis.\nThis leads to enhanced proliferation and migration capabilities of vascular endothelial and smooth muscle cells, two types of cells that are responsible in forming blood vessels, through cell-cell communication.\nFunctionally, results indicated that IGF2BP1 knockdown recovered the proliferation of HUVECs inhibited by HG-administration.\nIn diabetes mellitus pathophysiology, high glucose (HG)-induced vascular endothelial dysfunction is associated with diabetes vascular complications.\nOxidative stress and chronic non-infectious inflammation caused vascular endothelial dysfunction (VED) is a critical and initiating factor in Type 2 diabetes induced vascular complications, while macrophage polarization plays a regulatory role in VED.\nAPS promoted the migration and angiogenesis of endothelial cells in co-cultured of HUVECs and macrophages under high glucose.\nFurthermore, endothelial cells proliferation and apoptosis were ameliorated after APS treatment.\nTherefore, these findings provided compelling evidence demonstrating that mA reader IGF2BP1 contributes to the proliferation and apoptosis of vascular endothelial cells in hyperglycaemia, serving as a target for development of diabetic angiopathy therapeutics.\nOur results demonstrated that APS ameliorated vascular endothelial dysfunction in diabetes by stimulating macrophage polarization to M2 via enhancing the Nrf2/HO-1 pathway.\nAs one of the most severe manifestations of diabetes, vascular complications are the main causes of diabetes-related morbidity and mortality.\nFinally, similar results were observed in vivo, APS alleviated thoracic aorta complications of diabetic rats accompanied by a remarkable reduction in inflammation and an increased in the number of anti-inflammatory macrophage polarization.\nThe present study showed that tyrosol, a phenylethanoid compound, suppresses accumulation of intracellular reactive oxygen species (ROS) caused by hyperglycemia, most plausibly by promoting heme oxygenase-1 (HO-1)"
    },
    "1794-2613": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Esophageal Cancer",
      "text": ""
    },
    "269-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A48",
      "key2": "oxidative phosphorylation",
      "text": "SLC25A48 was upregulated in glioblastoma when compared to the milder form.\nThese genes are associated with essential pathways for the tumor, such as glucose metabolization, gluconeogenesis, calcium and vitamin D metabolism, tumor progression and activation of the invasion cascade.\nThe deregulation of mitochondrial metabolism has not yet been fully elucidated.\nGenes involved in mitochondrial metabolism can influence the proliferative cascade and be associated with tumor invasion."
    },
    "1802-2708": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "glioblastoma",
      "text": ""
    },
    "1802-2228": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "acute myeloid leukemia (AML)",
      "text": "As acute myeloid leukemia (AML) cells and stem cells have an increased reliance on oxidative phosphorylation, we sought to evaluate polymerase γ inhibitors in AML.\nHere, we demonstrate that the inhibition of autophagy induces an accumulation of lipid droplets (LD) due to a decrease in fatty acid β-oxidation, that leads to a reduction of oxidative phosphorylation (OxPHOS) in acute myeloid leukemia (AML), but not in normal cells.\nAcute myeloid leukemia (AML) cells have an atypical metabolic phenotype characterized by increased mitochondrial mass, as well as a greater reliance on oxidative phosphorylation and fatty acid oxidation (FAO) for survival.\nThe palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML.\nTargeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation.\nInhibition of the Nrf2-ALDH2/PolG2 pathway reduced AML metabolic fitness and oxidative phosphorylation levels, highlighting the key role of this pathway in promoting cell survival.\nAcute myeloid leukemia (AML) cells are highly dependent on oxidative phosphorylation and the mitochondrial dynamics regulated by fusion-related genes MFN1, MFN2, and OPA1 and fission-related genes DNM1L and MFF.\nIn conclusions, we identified a downregulated expression of oxidative phosphorylation (OXPHOS) at relapse in AML with inv(16), and explored the in vitro effects of metformin as a potential drug to enhance chemosensitivity in this setting.\nTargeting JMJD1C-mediated metabolism via pharmacologic inhibition of glycolysis and oxidative phosphorylation led to ATP depletion, induced necrosis/apoptosis and decreased tumor growth in vivo in leukemias co-expressing JMJD1C and HOXA9.\nA recent study shows that loss of Erbin increases the release of acyl-"
    },
    "1796-2025": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Anal Cancer",
      "text": ""
    },
    "100-1798": {
      "type": "slc_pathway",
      "key1": "SLC9B2",
      "key2": "stemness",
      "text": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD."
    },
    "405-1802": {
      "type": "slc_pathway",
      "key1": "SLC43A3",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1802-2196": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "glioma",
      "text": ""
    },
    "380-1802": {
      "type": "slc_pathway",
      "key1": "SLC39A3",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1796-2539": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Hepatic ischemia-reperfusion (I/R)",
      "text": ""
    },
    "1799-1924": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Head and Neck Cancer",
      "text": "Enhanced glycolysis and nicotinamide metabolism in HPV-positive head and neck cancer.\nHPV-positive HNSCC uniquely enhances metabolic pathways advantageous for rapid cell proliferation, including glycolysis and nicotinamide metabolism.\nNSD1 wild-type HNSCC is more sensitive to mitochondrial respiration inhibitors, whereas NSD1 mutant HNSCC shows increased sensitivity to glycolysis inhibitors.\nNSD1 wild-type HNSCC exhibiting higher mitochondrial respiration and NSD1 mutant HNSCC showing weaker mitochondrial respiration but enhanced glycolysis.\nPDIA3P1 competes with miR-152-3p to prevent degradation of glucose transporter 1 (GLUT1) mRNA, and disrupts the binding between membrane-associated RING-CH 8 (MARCH8) and hexokinase 2 (HK2) to reduce ubiquitination degradation of HK2, thereby promoting glycolysis.\nTALDO1 deacetylation inhibited its nuclear translocation and interaction with BRCA1, thereby reducing the inhibition of c-Myc transcriptional activation, promoting the expression of HK2/LDHA/PDK1, and further enhancing glycolysis independent of TALDO1 enzyme activity.\nMETTL1 facilitated cell development, glycolysis and radioresistance via promoting PFKFB3.\nNCAPD2 enhanced the proliferation and metastasis of EC cells by promoting glycolysis through Wnt5A-mediated activation of the Notch pathway.\nMETTL1 induced m7G modification to stabilize PFKFB3 mRNA that further enhanced radiation resistance in EC via stimulating glycolysis.\nDownregulation of LBX2-AS1 decreased cell proliferation, glycolysis, cell cycle progression, and radioresistance, along with a reduction in cyclin D1, HIF-1, and PKM2 levels.\nPDIA3P1 is highly expressed in ESCC, produces more lactate by regulating glycolysis, and the increased lactate upregulates lactylation"
    },
    "12-1798": {
      "type": "slc_pathway",
      "key1": "SLC2A4",
      "key2": "stemness",
      "text": "Three metabolism-associated clusters with significantly different characteristics in disease-free survival (DFS), clinical stage, stemness index, tumor microenvironment including stromal and immune cells, DNA mutation ( and ), copy number variation, and microsatellite instability were identified in PCa."
    },
    "1798-2708": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "glioblastoma",
      "text": ""
    },
    "372-1798": {
      "type": "slc_pathway",
      "key1": "SLC38A7",
      "key2": "stemness",
      "text": ""
    },
    "58-1799": {
      "type": "slc_pathway",
      "key1": "SLC6A8",
      "key2": "glycolysis",
      "text": "Importantly, we discovered that inhibiting Slc6a8 can counter these detrimental effects, offering a new strategy for treating AML by targeting metabolic pathways.\nThe upregulation of creatine synthetases Gatm and Gamt, as well as the creatine transporter Slc6a8, resulted in a marked accumulation of creatine within tumor foci.\nThis process further enhances oxidative phosphorylation and glycolysis of leukemia cells, thereby boosting ATP production to foster proliferation and infiltration.\nIn the absence of adequate creatine, IECs transition toward a stressed, glycolysis-predominant form of metabolism;\nCorrespondingly, RNA-sequencing datasets showed altered gene expression of key metabolic enzymes involved in NAD, creatine, glucose and glutamine metabolism (e.g NAMPT, SLC6A8, HK2) in Mtb-infected M2 macrophages.\nWe studied the functions of the creatine transporter solute carrier family 6 member 8 (SLC6A8, also called CRT) in intestinal epithelial cells (IECs) and mice, and we measured levels in mucosal biopsies from patients with IBD.\nIn analyses of IECs with CRT knockdown or overexpression, we found that CRT regulates intracellular creatine, barrier formation, and wound healing.\nIn an analysis of IEC cell lines and colonoids derived from CRT-knockout mice, we found that CRT regulates energy balance in IECs and thereby epithelial integrity and barrier function.\nStimulation of macrophages with Mtb lysate or lipopolysaccharide (LPS) induced a relative increase in glycolysis versus oxidative phosphorylation."
    },
    "28-1800": {
      "type": "slc_pathway",
      "key1": "SLC4A2",
      "key2": "migration",
      "text": "siRNA-mediated SLC4A2 knockdown significantly suppressed BPS-induced cell migration and reversed EMT phenotypes.\nThis study first demonstrates that BPS promotes CRC cell migration by activating the EMT signaling pathway via SLC4A2 upregulation.\nBPS exposure within the concentration range of 10⁻¹ ⁰ to 10⁻⁶ M did not significantly inhibit HCT8 cell viability but markedly enhanced migration and invasion capabilities, accompanied by EMT progression.\nWe further demonstrate a previously unrecognized consequence of SLC4A2 loss of function in the osteoclast: dysregulation of calpain-dependent podosome disassembly, leading to abnormal actin belt formation, cell spreading, and migration.\nNotably, BPS exposure specifically induced SLC4A2 upregulation, while siRNA-mediated SLC4A2 knockdown significantly suppressed BPS-induced cell migration and reversed EMT phenotypes.\nSLC4A2, being a key player in BPS-induced tumorigenesis, could function as a promising biomarker and therapeutic target for CRC.\nRescue of SLC4A2-deficient osteoclasts with functionally defined mutants of SLC4A2 indicates regulation of actin cytoskeletal reorganization by anion-exchange activity and intracellular pH, independent of SLC4A2's long N-terminal cytoplasmic domain.\nThe impact of BPS on HCT8 cell proliferation, migratory ability, and EMT progression were systematically evaluated through Western blot, CCK-8 proliferation assays, scratch wound healing experiments, and Transwell assays for migration and invasion."
    },
    "380-1794": {
      "type": "slc_pathway",
      "key1": "SLC39A3",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1796-2412": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "endometrial carcinoma (EC)",
      "text": "Fancd2 increases drug resistance in EC cells by inhibiting the cellular ferroptosis pathway.\nTBX2 suppressed Cisplatin-induced ferroptosis through up-regulating FSP1 expression level in EC cells.\nInterestingly, silence FSP1 could reverse TBX2-mediated ferroptosis inhibition and tumor-promoting effect.\nAs a result, AF inhibited the viability and proliferation of KLE cells but promoted apoptosis and ferroptosis.\nSOX4 inhibits ferroptosis and promotes proliferation of endometrial cancer cells via the p53/SLC7A11 signaling.\nLncRNA FAM83H-AS1 inhibits ferroptosis of endometrial cancer by promoting DNMT1-mediated CDO1 promoter hypermethylation.\nKnockdown of FOXM1 downregulated ferroptosis-resistant gene expression and increased MDA and ROS levels in DDP-resistant EC cells.\nGPX4 suppresses ferroptosis to promote malignant progression of endometrial carcinoma via transcriptional activation by ELK1.\nThese findings collectively suggested that SOX4 inhibited ferroptosis and promoted proliferation of EC cells via the p53/SLC7A11 signaling.\nHNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2.\nNaBu indirectly downregulates the expression of SLC7A11 by promoting the expression of RBM3, thereby promoting ferroptosis in endometrial cancer cells.\nIn conclusion, HNRNPA2B1-mediated mA modification of FOXM1 facilitates drug resistance and inhibits ferroptosis in EC cells by upregulating LCN2 expression.\nMechanistically, loss of ADCK3 primarily suppresses MPA-mediated ferroptosis by abrogating arachidonate 15-lipoxygenase (ALOX15) transcriptional activation.\nFanconi anemia complementation group D2 promotes sensitivity of endometrial cancer cells to chemotherapeutic agents by inhibiting the ferroptosis"
    },
    "123-1798": {
      "type": "slc_pathway",
      "key1": "SLC12A9",
      "key2": "stemness",
      "text": ""
    },
    "1798-2468": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "uveal melanoma (UVM)",
      "text": "The expression of TLRs was negatively correlated with mRNA expression-based stemness scores (RNAss) in nearly almost type of tumors except kidney renal clear cell carcinoma (KIRC) and also negatively correlated with DNA methylation-based stemness scores (DNAss) in many types of tumors except adrenocortical carcinoma (ACC), cholangiocarcinoma (CHOL), KIRC, acute myeloid leukemia (LAML), low-grade glioma (LGG), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), thymoma (THYM), and uveal melanoma (UVM).\nWe discovered mDNAsi-associated signatures improved the prediction capacity of individualized UVM prognosis and indicated prospective targets for stemness-regulated immunotherapy.\nBesides, we established and verified a prognostic stemness-associated gene signature which can classify UVM patients into subgroups with distinct clinical outcomes, tumor mutation, immune microenvironment, and molecular pathways.\nThis study offers a comprehensive examination of UVM stemness characteristics.\nBesides, UVM patients classified into subgroups based on the stemness-associated signature.\nThe prognostic value of stemness indices among four subtypes of UVM (subtype A-D) was investigated.\nAccording to the one-class logistic regression (OCLR) approach, we first estimated two stemness indices (mDNAsi and mRNAsi) in a cohort of UVM (n = 80).\nMoreover, univariate Cox regression and Lasso-penalized algorithms were conducted to identify a stemness-associated signature and verify in several independent cohorts.\nAnalysis of the interaction between stemness and tumor microenvironment may shed light on combinational treatment that targets both stem cell and the tumor microenvironment.\nStratification analysis indicated that the prognostic value of mDNAsi was only limited in subtype D of UVM.\nWe observed that mDNAsi was significantly linked with overall survival (OS) time of UVM, but no association was discovered between mRNAsi and OS.\nTumor stem cells have emerged as a crucial focus of investigation and a therapeutic target in the context"
    },
    "372-1801": {
      "type": "slc_pathway",
      "key1": "SLC38A7",
      "key2": "apoptosis",
      "text": ""
    },
    "1796-2758": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "papillary thyroid carcinoma",
      "text": ""
    },
    "380-1800": {
      "type": "slc_pathway",
      "key1": "SLC39A3",
      "key2": "migration",
      "text": ""
    },
    "1795-2154": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "preeclampsia (PE)",
      "text": "Decreased proliferation and invasion of trophoblast were proven to be involved in the pathogenesis of preeclampsia (PE).\nElevated PGT promotes proliferation and inhibits cell apoptosis in preeclampsia by Erk signaling pathway.\nUpregulation of lncRNA XIST in HTR-8/SVneo cells inhibited the cell proliferation and invasion, and induced apoptosis.\nHRK inhibited cell proliferation and migration in human trophoblasts and promoted their apoptosis via p53 upregulation.\nIn HTR8/SVneo cells, HDAC2 downregulation suppressed cell proliferation, migration, and invasion and increased pyroptosis.\nCirc_0008440 Inhibits Proliferation and Promotes Apoptosis of Trophoblast Cells through the miR-194-5p/PFKFB2 Axis.\nSIRT5 suppresses the trophoblast cell proliferation, invasion, and migration to promote preeclampsia via desuccinylating HOXB3.\nSilencing RBM15 enhanced trophoblast proliferation and migration while suppressing apoptosis and oxidative stress by upregulating HTR1D.\nTherefore, circ_0090100 activated AHNAK to suppress trophoblast cell proliferation and invasion, and promote cell apoptosis, via miR-139-5p.\nUpregulation of hsa_circ_0015382 repressed trophoblast proliferation, migration, invasion and lowered trophoblast-induced HUVEC tube formation.\nAdditionally, circRNA_0088196 inhibited HTR-8/SVneo cell proliferation and promoted cell apoptosis via the miR-337-3p/HSPA5 axis, thereby facilitating PE.\nIncreased expression of miR-101-3p in placenta contributes to the development of PE by suppressing WDR5-mediated proliferation and invasion of trophoblast.\nIn vitro studies revealed that forced expression of PGT in HTR8/Sveno cell inhibited its apoptosis, but promoted its proliferation by activating Erk signaling."
    },
    "381-1801": {
      "type": "slc_pathway",
      "key1": "SLC39A4",
      "key2": "apoptosis",
      "text": "RNAi knockdown of Zip4 in mouse Hepa cells significantly increased apoptosis and modestly slowed progression from G(0)/G(1) to S phase when cells were released from hydroxyurea block into zinc-deficient medium.\nZIP4 may play a role in the acquisition of zinc by hepatocellular carcinomas, and potentially many different cancerous cell-types, leading to repressed apoptosis, enhanced growth rate and enhanced invasive behavior.\nUKLF promoted cell proliferation, migration and invasion, and inhibited cell apoptosis.\nCell migration assays revealed that RNAi knockdown of Zip4 in Hepa cells depressed in vitro migration whereas forced over-expression in Hepa cells and MCF-7 cells enhanced in vitro migration.\nIn addition, CP induced apoptosis modestly and modulated antimicrobial gene expression.\nHowever, in the Znhigh group, we found a prevention of villus atrophy and decreased caspase-3-mediated apoptosis of jejunal epithelium.\nMoreover, UKLF modulated the expression of solute carrier family 39 member 4 (SLC39A4) at the transcriptional level.\nTaken together, these findings elucidated the regulatory mechanism of UKLF and uncovered the importance of the PCBP2/UKLF/SLC39A4 pathway.\nCP had antiproliferative effects and reduced the expression of proliferative and stemness genes in jejunal organoids, effects that were largely independent of Zn chelation.\nCP addition upregulated the expression of the Zn absorptive transporter Slc39a4 and of methallothionein Mt1 in a Zn-sensitive manner, while downregulating the expression of the Zn exporter Slc30a2 and of methallothionein 2 (Mt2).\nThe promotion effect of UKLF on tumor growth was further confirmed in vivo."
    },
    "1796-2365": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Neuroblastoma (NBM)",
      "text": "DHODH blockade induces ferroptosis in neuroblastoma.\nIn summary, our study highlights DHODH blockade as a novel approach to induce ferroptosis through lipid metabolism reprogramming, underscoring DHODH as a viable therapeutic target for neuroblastoma treatment.\nIn conclusion, our research has successfully indicated that ATO could induce ferroptosis and initiate lipid peroxidation by regulating the transcriptional repression of GPX4, and ATO holds promise as a potential anti-tumor agent in NB, specifically for patients with RA-resistant HR-NB.\nFurthermore, Ferroptosis inhibitor ferrostatin-1 partially blocked ATO-induced cell death.\nConsistently, TFRC overexpression in NB cells also induces selective sensitivity to GPX4 inhibition and ferroptosis.\nIn vitro, ATO significantly inhibited the proliferation and migration ability of NB cells SK-N-AS and SH-SY5Y, and induced ferroptosis.\nFurthermore, NANT dramatically inhibits the growth of high-risk NB in both tumor spheroid and xenograft models by promoting noncanonical ferroptosis evidenced by enhanced intratumoral Fe(II) and heme oxygenase-1.\nHere, this research findings revealed that m A-modification was decreased in PD models, meanwhile, the FTO level upregulated in the PD models.\nIn conclusion, NB cells harboring MYCN amplification are prone to undergo ferroptosis conferred by TFRC upregulation, suggesting that GPX4-targeting ferroptosis inducers or TFRC agonists can be potential strategies in treating MYCN-amplified NB.\nHere, we report that MYCN-amplified NB cells are sensitive to GPX4-targeting ferroptosis inducers.\nHere, we first identified ATO as a novel GPX4 inhibitor, which could trigger the ferroptosis in NB cells.\nThis gold nanocluster, namely, NANT, shows excellent NB targeting efficiency and dramatically promotes ferroptosis.\nThis study investigated the anti-cancer function of ferroptosis inducer Erastin or RSL3 in neuroblastoma N2A cells."
    },
    "90-1794": {
      "type": "slc_pathway",
      "key1": "SLC9A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "188-1798": {
      "type": "slc_pathway",
      "key1": "SLC22A5",
      "key2": "stemness",
      "text": ""
    },
    "1798-1845": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Endometrial Cancer (EC)",
      "text": "SIRT2 promotes cell stemness and activates the MEK/ERK signaling pathway while represses chemosensitivity in EC.\nPC accumulation suppressed EC cell proliferation and stemness by inhibiting the activation of the mammalian target of rapamycin (mTOR)-c-Myc signaling.\nSox2 promoted the malignant behavior and the stemness of ECCs and ECSCs, and overexpression Sox2 inhibited the anticancer effects of up-regulated miR-136.\nIncreased PIK3CA alterations and downregulation of SCGB2A1, the inhibitor of PI3K kinase, in hDNAmad+ tumors, might promote tumor growth/proliferation and stemness.\nInhibiting the Hippo pathway results in aberrant activation of its downstream core component YAP/TAZ, which can enhance cancer cells' metabolism and maintain their stemness.\nWe also identified the mechanism related to this potential tumor-predisposing phenotype: loss of Dicer1 induced abnormal expression of the let-7 family, which comprises well-known tumor suppressors, thus regulating stemness in endometrial carcinoma cells.\nThe stemness maintenance ability of endometrial cancer stem cell can be reduced through deSUMOylation of HIF-1α protein by silencing Ubc9 gene expression, and their sensitivity to chemotherapy be enhanced, which provides a new reference for future gene therapy of endometrial carcinoma.\nCell stemness analysis showed that overexpression of circFAT1 and miR-21 increased cell stemness, and miR-21 inhibition decreased cell stemness.\nStemness index analysis revealed that decreased WFS1 expression was associated with increased tumor grade and enhanced tumor stemness, suggesting increased malignancy of EC.\nOur results demonstrate that silencing of LPCAT1 inhibits the growth of endometrial cancer, while overexpression of LPCAT1 results in enhanced stemness and metastasis in endometrial cancer cell lines.\nOverexpression of SENP1 can induce protein deSUMOylation modification, inhibit the stemness maintenance potential of endometrial cancer side population cells, and enhance their chemotherapy sensitivity, which"
    },
    "27-1794": {
      "type": "slc_pathway",
      "key1": "SLC4A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "233-1802": {
      "type": "slc_pathway",
      "key1": "SLC25A12",
      "key2": "oxidative phosphorylation",
      "text": "In response to physiological glutamate signals, cytosolic Ca(2+) activates respiration by stimulation of the NADH malate-aspartate shuttle through Ca(2+)-binding to the mitochondrial aspartate/glutamate carrier (Aralar/AGC1/Slc25a12), and by stimulation of adenine nucleotide uptake through Ca(2+) binding to the mitochondrial ATP-Mg/Pi carrier (SCaMC-3/Slc25a23).\nAGC1 is an important component of the malate/aspartate shuttle, a crucial system supporting oxidative phosphorylation and adenosine triphosphate production.\nAGC1 is an important component of the malate/aspartate shuttle, a crucial system supporting oxidative phosphorylation and adenosine triphosphate (ATP) production.\nAralar/slc25a12/AGC1 is the neuronal isoform of the aspartate-glutamate mitochondrial carrier, a component of the malate-aspartate shuttle (MAS) which plays an important role in redox balance, which is essential to maintain glycolytic pyruvate supply to neuronal mitochondria.\nThe concomitant down-regulation of all participating proteins (SLC25A11, SLC25A12, GOT2 and MDH2) of malate-aspartate shuttle might be responsible for the metabolic in-coordination between the cytosol and mitochondria resulting in the failure of energy metabolism.\nBioinformatics data mining and immunochemical validation of pivotal perturbed proteins revealed a global failure of the cellular energy metabolism in the infarcted tissues as seen by the parallel down-regulation of proteins related to glycolysis, pyruvate dehydrogenase complex, TCA cycle and oxidative phosphorylation.\nOxidative phosphorylation is required in order to respond to the metabolic challenge caused by glutamate.\nWe found that the ATP synthase inhibitor oligomycin caused a smaller inhibition of mitochondrial movement in Aralar-KO than control neurons, whereas the glycolysis inhibitor iodoacetate had similar effects in neurons from both genotypes."
    },
    "1800-1920": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Cervical Cancer",
      "text": "Inhibition of STIM1-mediated SOCE can decrease proliferation and migration, and promoted the apoptosis of cervical cancer cells.\nScutellaria Barbata inhibits epithelial-mesenchymal transformation through PI3K/AKT and MDM2 thus inhibiting the proliferation, migration and promoting apoptosis of Cervical Cancer cells.\nthis study demonstrated that LB inhibited the proliferation of cervical cancer cells, induced its apoptosis, and reduced its invasion and migration via targeting the PI3K/AKT signaling pathway.\nZiyu I inhibits cervical cancer progression through a multitarget regulatory network involving MAPK signaling pathway-mediated inhibition of cell proliferation and migration, apoptosis activation, and cell cycle arrest.\nthe active ingredient of Sculellaria Barbata can regulate the PI3K/AKT signaling pathway and down-regulate the expression of MDM2 gene to inhibit the epithelial-mesenchymal transition, which can inhibit cervical cancer cell proliferation, migration, and promote their apoptosis.\npiperine inhibited cervical cancer cell proliferation, migration, and invasion, and promoted apoptosis.\nElevating DLG2 levels significantly suppressed cervical cancer cell proliferation, migration, and invasion, while promoting apoptosis.\nSIRT7 enhanced the proliferation, migration, and invasion of HeLa and SiHa cells, inhibited apoptosis, and promoted cervical cancer growth.\nα-Hederin significantly inhibited SiHa and HeLa cell growth, promoted apoptosis, and inhibited migration and invasion of cervical cancer cells.\nthe overexpression of CRABP2 reverted the HPV16 E6/E7 knockdown-induced inhibition of cell proliferation, migration, and invasion in cervical cancer cells.\nZiyu I significantly inhibited the proliferation and migration of cervical cancer cells and promoted apoptosis and cell cycle arrest.\nSFN overexpression was observed to enhance invasion and migration of cervical cancer cells, induce cytoskeletal remodeling, facilitate cell proliferation, and suppress apoptosis.\nDemethylation of HPV16 CpGs significantly suppresse"
    },
    "1802-2146": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "liver hepatocellular carcinoma (LIHC)",
      "text": "SALL4-induced expression of oxidative phosphorylation (OXPHOS) genes may serve as a therapeutically targetable vulnerability in HCC through OXPHOS inhibition.\nPOLRMT increased oxidative phosphorylation levels and mitochondrial ATP production through transcriptional upregulation of respiratory chain complexes, which counteracted lenvatinib-induced cellular ATP decrease and the AMPK-caspase 3 signaling pathway.\nMechanistically, energy stress-induced mitochondrial elongation facilitated cristae formation and assembly of respiratory complexes to enhance oxidative phosphorylation, which in turn exhibited a feedback inhibitory effect on glycolysis through NAD-dependent SIRT1 activation.\nHere we show in a rat model of hepatocarcinogenesis that early preneoplastic foci and nodules that progress towards hepatocellular carcinoma (HCC) are characterized both by inhibition of oxidative phosphorylation (OXPHOS) and by enhanced glucose utilization to fuel the pentose phosphate pathway (PPP).\nIn HCC cells, Dau dose-dependently inhibited glucose glycolysis and increased oxidative phosphorylation.\nDCA reduced lactate production and increased ROS and ATP, indicating activation of oxidative phosphorylation (OXPHOS).\nCancer cells show enhanced glycolysis and inhibition of oxidative phosphorylation, even in the presence of sufficient oxygen (aerobic glycolysis).\nNANOG represses mitochondrial oxidative phosphorylation (OXPHOS) genes, as well as ROS generation, and activates fatty acid oxidation (FAO) to support TIC self-renewal and drug resistance.\nUsing gene set enrichment analysis, we found that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division.\nIn the present study, it was found dicoumarol (DIC) reduced the phosphorylation of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1, which converted the metabolism of human hepatocellular carcinoma (HCC) cells to oxidative phosphorylation, leading to an increase in mitochondrial reactive oxygen"
    },
    "1798-1917": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Gastric cancer (GC)",
      "text": "Gastric cancer (GC) is among the deadliest malignancies globally, characterized by hypoxia-driven pathways that promote cancer progression, including stemness mechanisms facilitating invasion and metastasis.\nncRNAs can participate in the regulation of gastric cancer (GC) radiotherapy response, and its mechanism may be related to its effect on DNA damage repair, gastric cancer cell stemness, cell apoptosis, activation of epidermal growth factor receptor signaling pathway, etc.\nN2-EXO enhanced the proliferation and metastasis of gastric cancer (GC) cells by promoting their stemness.\nPGD2 suppressed viability, invasion, and stemness and increased the apoptosis of GCSCs.\nCOL12A1 specifically enhanced GC cell progression and stemness via suppressing ferroptosis.\nDownregulating L-PTGDS and PTGDR2 promoted viability, invasion, and stemness and reduced the apoptosis of GCSCs.\nPGD2 suppressed the stemness of GCSCs and induced GCSCs autophagy, whereas the downregulation of PTGDR2 had the opposite effect.\nIts overexpression increased resistance to doxorubicin and cisplatin (↑IC50), inhibited apoptosis, and enhanced stemness via upregulation of SOX-2 and OCT-4.\nPGC inhibited the proliferation, viability, epithelial-mesenchymal transition, migration, invasion, and stemness of GC cells and promoted GC cell differentiation.\nHJSS inhibits cancer stemness by suppressing the activation of SCD-mediated aberrant Wnt/β-catenin, positioning it as a promising candidate for delaying gastric malignant progression.\nGastric cancer (GC) is a highly heterogeneous and complex malignancy, often characterized by tumor stemness and immune evasion mechanisms, which contribute to a poor response to neoadjuvant chemotherapy (NAC) and treatment resistance.\nConsiderable evidence suggests that tumor cells with stemness features contribute to initiation, progression, recurrence of gastric cancer (GC) and resistance to therapy, but involvement of underlying regulators and mechanisms remain largely unclear."
    },
    "1798-2282": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Esophageal squamous cell carcinoma (ESCC)",
      "text": "Cell signaling pathways play central roles in cellular stemness state, and aberrant activation of these cascades is attributed to the severity of esophageal squamous cell carcinoma (ESCC).\nOverexpression of SAMD9 promotes tumor stemness, angiogenesis, and EMT, while downregulation of SAMD9 reduced these phenotypes.\nIn ESCC EC109 cells, PCAT6 knockdown inhibited the ability of CP, CI, CM, and stemness, and inhibited the activation of JAK/STAT signaling pathway.\nOur findings suggest that SOCS6 can promote the radiosensitivity of HPV ESCC and ESCC cells and reduce their stemness via ubiquitylation and degradation of c-Kit.\nmiR339 inhibited ESCC cell stemness and enhanced radiation-induced DNA damage by targeting USP8, suggesting that it acts as a potential CSC regulator and radiosensitizer.\nTaken together, our findings indicated that LBP could enhance the radiosensitivity of ESCC cells by increasing radiation-induced apoptosis, attenuating cancer stemness and inhibiting PI3K/AKT pathway.\nWe aimed in this study to elucidate contribution of Notch signaling pathway in stemness state of esophageal squamous cell carcinoma (ESCC) through their relevance with stem cell markers SOX2 and SALL4.\nMechanistically, M2-TAMs highly secreted TGF-β1 which activated the TGFβR1-smad2/3 pathway to promote and maintain the stemness characteristic of ESCC cells, which could inhibit the sensitivity to cisplatin.\nWe used RNA sequencing to comprehensively demonstrate that the inhibition of Src activity effectively blocked several critical tumor-promoting pathways, such as JAK/STAT, mTOR, stemness-related, and metabolism-related pathways.\nTreatment with a miR-455-3p antagomir dramatically chemosensitized ESCC cells and reduced the subpopulations of CD90 and CD271 T-ICs via deactivation of multiple stemness-associated pathways, including Wnt/β-caten"
    },
    "1794-2264": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "laryngeal carcinoma",
      "text": ""
    },
    "45-1797": {
      "type": "slc_pathway",
      "key1": "SLC5A8",
      "key2": "oxidative stress",
      "text": "Oxidative stress was induced in ARPE-19 cells and primary RPE cells isolated from wild type and Slc5a8(-/-) mouse retinas using H(2)O(2), and the effects of OTC on cell death and intracellular glutathione concentration were examined.\nTo evaluate the role of SLC5A8 in the transport of 2-oxothiazolidine-4-carboxylate (OTC) and to determine whether OTC augments glutathione production in RPE cells, thereby providing protection against oxidative stress.\nRats fed with ethanol-containing Lieber-DeCarli liquid diet showed decreased expression of TJ proteins, and increased intestinal barrier injury resulting in pro-inflammatory response and oxidative stress in the colon.\nTransport via SLC5A8 is obligatory for this process.\nOTC increased glutathione levels and protected ARPE-19 and primary RPE cells isolated from wild type mouse retinas from H(2)O(2)-induced cell death.\nThese effects were abolished in primary RPE isolated from Slc5a8(-/-) mouse retinas.\nOTC augments glutathione production in RPE cells, thereby protecting them from oxidative damage.\nthe concentration necessary for half-maximal inhibition was 17 ± 1 μM.\nThe transport of OTC via SLC5A8 was saturable, with a K(t) of 104 ± 3 μM.\nOTC is a transportable substrate for SLC5A8.\nOxidative stress is a common pathological factor in degenerative retinal diseases;\nGiven the important role played by butyrate in the intestine, this mechanism may contribute to the procarcinogenic and proinflammatory effect of oxidative stress at this level.\nThe effect of tBOOH upon uptake of [(14)C]butyrate ([(14)C]BT) (10μM) can be summarized as follows: (a) it caused a reduction in the intracellular accumulation of [(14)C]BT over time, (b) it strongly reduced total [(14)C]BT uptake but did not affect Na(+)-independent uptake of [(14)C]BT"
    },
    "291-1795": {
      "type": "slc_pathway",
      "key1": "SLC27A5",
      "key2": "proliferation",
      "text": "experiments revealed that SLC27A5 inhibited cell proliferation and migration of HCC cells and could upregulate FDX1, the key regulator of cuproptosis.\nHere, we investigated the hypoxia-induced downregulation of SLC27A5 and its impact on HCC proliferation via the repression of hepatocyte nuclear factor 4 alpha (HNF4A).\nHypoxia reduces SLC27A5 to promote hepatocellular carcinoma proliferation by repressing HNF4A.\nFinally, downregulation of SLC27A5 altered tumor metabolism and cellular homeostasis, induced oxidative stress, and disrupted intracellular environmental stability, thereby suppressing the growth of gastric adenocarcinoma.\nCellular experiments demonstrated that nano-curcumin liposomes significantly inhibited proliferation and invasive capacity of gastric adenocarcinoma cells while promoting cellular oxidative stress.\nThis study revealed that nano-curcumin liposomes inhibited growth and survival of gastric adenocarcinoma cells by interfering with the expression of FDX1, GPX4, SERPINE1 and SLC27A5, which were closely linked to copper-induced oxidative stress.\nThis study investigated how nano-curcumin liposomes mediated the inhibition of gastric adenocarcinoma cell proliferation and survival via cuproptosis.\nThe findings recapitulated that UBAP2 promoted HCC progression and radioresistance via SLC27A5 stability mediated by the ubiquitin-proteasome pathway.\nUtilizing in vitro and in vivo hepatocellular carcinoma models, we have demonstrated that hypoxic conditions significantly reduce SLC27A5 transcription, which is mediated by the suppression of HNF4A.\nSolute carrier family 27 member 5 (SLC27A5/FATP5), a pivotal enzyme in hepatic fatty acid transport and bile acid metabolism, is frequently downregulated in hepatocellular carcinoma, resulting in poor prognosis.\nThis reduction leads to the activation of the AKT pathway and an increase in cyclin-dependent kinase 2 (CDK2) and Cyclin"
    },
    "238-1801": {
      "type": "slc_pathway",
      "key1": "SLC25A17",
      "key2": "apoptosis",
      "text": "Furthermore, the pro-apoptotic effect of SLC25A17 knockdown was reversed when treated with autophagy inhibitor 3-MA in TNBC cells, suggesting that SLC25A17 knockdown-induced autophagic cell death.\nOn the other hand, SLC25A17 knockdown promoted autophagy through triggering ROS accumulation, which was counteracted by N-acetyl-l-cysteine (NAC).\nMoreover, it prompted apoptosis and autophagy.\nFunctional assays demonstrated that SLC25A17 knockdown suppressed proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion.\nIn a nude mice xenograft study, SLC25A17 knockdown markedly decreased breast tumor growth and metastasis.\nMechanistically, SLC25A17 performed its function through regulation JAK2/STAT3 signaling in TNBC.\nSLC25A17 up-regulation may be a critical factor driving TNBC progression by modulating ROS production and autophagy.\nConsequently, targeting SLC25A17 could be an effective therapeutic strategy against TNBC.\nSLC25A17 was highly expressed in breast cancer tissues, which was found to be associated with unfavorable prognosis.\nAdditionally, SLC25A17 overexpression exacerbates lipid accumulation in A549 cells by activating the janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway, while AG490, a JAK2 inhibitor, eliminates this effect.\nUpregulated PEX3 promotes abnormal lipid metabolism in LUAD cells by interacting with solute carrier family 25 member 17 (SLC25A17) to upregulate its protein levels."
    },
    "1797-2099": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Multicancer",
      "text": "The NRF2-KEAP1 pathway plays an important role in the cellular response to oxidative stress but may also contribute to metabolic changes and drug resistance in cancer.\nThe nuclear factor erythroid 2-related factor 2-Kelch-like ECH-associated protein 1 (NRF2-KEAP1) pathway plays an important role in the cellular response to oxidative stress but may also contribute to metabolic changes and drug resistance in cancer.\nIn the present study, it was further identified by using western blot assay that the PL2L60 proteins could be degraded in cancer cells through a mechanism of selective autophagy in response to oxidative stress.\nOur experimental and computational strategy provides evidence that both factors regulate the expression of several coding and non-coding RNAs that in turn mediate for their cancer-promoting phenotypes, including but not limited to cell cycle, apoptosis, ferroptosis, and oxidative stress response.\nThese results suggested that various cancer could be suppressed by promoting autophagy.\nThe present study revealed a key role of autophagic degradation of PL2L60 in hypoxia‑induced cancer cell death, which could be used as a novel therapeutic target of cancer.\nUsing this gene signature, we uncovered novel selective drug resistance and cancer prognosis associated with NRF2 activation.\nWe validated these findings and also found NRF2 activation led to radioresistance in cancer cell lines.\nAn NRF2 activity score based on expression of these core target genes correlates with resistance to drugs such as PX-12 and necrosulfonamide but not to paclitaxel or bardoxolone methyl.\nFinally, our NRF2 score is prognostic for cancer survival and validated in additional independent cohorts for lung adenocarcinoma and also novel cancer types not associated with NRF2-KEAP1 mutations such as clear cell renal carcinoma, hepatocellular carcinoma, and acute myeloid leukemia."
    },
    "381-1797": {
      "type": "slc_pathway",
      "key1": "SLC39A4",
      "key2": "oxidative stress",
      "text": "ZIP4 upregulation aggravates nucleus pulposus cell degradation by promoting inflammation and oxidative stress by mediating the HDAC4-FoxO3a axis.\nZIP4 upregulation aggravates the extracellular matrix (ECM) degradation of NP cells by mediating inflammation and oxidative stress through the HDAC4-FoxO3a axis.\nZIP4 upregulation bolstered inflammation and oxidative stress in NP cells undergoing IL-1β treatment and exacerbated their extracellular matrix degradation, whereas ZIP4 knockdown produced the opposite outcome.\nMechanistically, ZIP4 upregulated HDAC4 and enhanced NF-κB phosphorylation while repressing Sirt1 and FoxO3a phosphorylation levels.\nHDAC4 knockdown or Sirt1 promotion attenuated the effects mediated by ZIP4 overexpression in NP cells.\nThe ZIP4 profile increased in the NP tissues of IDD patients and IL-1β- or HO-treated NP cells.\nWe found that CBD upregulates the expression of the mRNAs for metallothionein 2 (Mt2), N-myc-downstream regulated gene 1 and matrix metalloproteinase 23 as well as of the zinc transporters ZnT1/Slc30a1 and Zip4/Slc39a4 but downregulates the expression of the mRNA for the zinc transporter Zip10/Slc39a10 as well as for the zinc finger protein 472.\nGene expression signature showed dysregulation in mediators associated with autophagy, ubiquitination, ER stress, oxidative stress, carbohydrate metabolism, solute transport, and T cell regulation in the colonic mucosa from patients with UC, suggesting that these genes could be involved in the pathogenesis of UC.\nThe gene expressions of FOXO4, ALDOB, SOD2, TOD2, SLC26A3, and SLC39A4 were associated with the clinical course and histological activity and are of relevance since these provide the utility of new prognostic markers in IBD."
    },
    "1797-2282": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Esophageal squamous cell carcinoma (ESCC)",
      "text": "VDR may inhibit p53 signaling pathway activation and induce ESCC proliferation, invasion, and metastasis by activating oxidative stress.\nIn this study, we demonstrated that GTSE1 induces CIN in ESCC cells, and increases intracellular ROS production, which leads to cellular oxidative stress, contributes to the activation of the JNK signaling pathway, and thereby inhibits apoptosis leading to ESCC tumorigenesis.\nTranscriptome sequencing analysis revealed that the promoted cell proliferation in TYMS-overexpression ESCC cells were mediated through activating genes expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and Nrf2 dependent antioxidant enzymes to relieve oxidative stress, which was confirmed by increased glutathione (GSH), glutathione peroxidase (GPX) activities, and reduced reactive oxygen species.\nIn cell culture experiments, TDCPP induced cytotoxicity, oxidative stress, and inhibited colony formation.\nThe experiments demonstrated that knockdown of 6PGD induces oxidative stress and suppresses ESCC cell proliferation.\nSilenced circ-ATIC suppressed the proliferation, migration, invasion, promoted the apoptosis and oxidative stress of ESCC cells.\nOxidative stress and the immune microenvironment both contribute to the pathogenesis of esophageal squamous cell carcinoma (ESCC).\nIn ESCC xenograft tumours, pharmacological autophagy inhibition with chloroquine derivatives depletes cells with high CD44 expression while promoting oxidative stress.\nMoreover, CCT4 silence raised oxidative stress and inhibited glycolysis of ESCC cells, which significantly inhibited cell proliferation and migration, promoted apoptosis and caused cell cycle arrest in ESCC cells.\nEnvironmental factors such as cigarette smoking and alcohol consumption are critical risk factors for the development and progression of esophageal squamous cell carcinoma (ESCC), suggesting that oxidative stress contributes to the pathogenesis of ESCC."
    },
    "3-1795": {
      "type": "slc_pathway",
      "key1": "SLC1A3",
      "key2": "proliferation",
      "text": "In vivo and in vitro experiments showed that silencing FN1 inhibits the activation of the YAP1/Hippo pathway by enhancing YAP1 phosphorylation, down-regulates SLC1A3-mediated aspartate uptake and utilization by tumor cells, inhibits BC cell proliferation, invasion and migration, and promotes apoptosis.\nThe PI3K/AKT inhibitor LY294002 prevented SLC1A3-induced glucose metabolism and cell proliferation.\nHere, we demonstrate that ASNase stimulates aspartate and glutamate consumptions, and their refilling through SLC1A3 promotes cancer cell proliferation.\nLastly, in vivo experiments indicated that SLC1A3 expression promoted tumor development and metastasis while negating the suppressive effects of ASNase by fueling aspartate, glutamate, and glutamine metabolisms despite of asparagine shortage.\nWe show that the glutamate-aspartate transporter EAAT1 (SLC1A3), which is normally expressed in the central nervous system, is crucial for glutamine conversion to aspartate and nucleotides and that T-ALL cell proliferation depends on EAAT1 function.\nSLC1A3 Promotes Gastric Cancer Progression via the PI3K/AKT Signalling Pathway.\nSLC1A3 overexpression activated the PI3K/AKT pathway and up-regulated GLUT1, HK II and LDHA expression.\nOur findings indicate that SLC1A3 promotes gastric cancer progression via the PI3K/AKT signalling pathway.\nCell lines least sensitive to ETC inhibition maintain aspartate levels by importing it through an aspartate/glutamate transporter, SLC1A3.\nImportantly, inhibition of the IGF1R-MTOR pathway decreases cell proliferation and reactivity of mutant SOD1 astrocytes, and attenuates their toxicity to motor neurons.\nInhibition of GID8 attenuated CRC proliferation and metastasis both in vitro and in vivo.\nIn vitro and in vivo assays showed that SLC1A3 affected glucose metabolism and promote"
    },
    "119-1797": {
      "type": "slc_pathway",
      "key1": "SLC12A5",
      "key2": "oxidative stress",
      "text": "Physical trauma, psychosocial stress, and oxidative stress increase the neuronal transcription ratio of genes encoding the sodium-potassium chloride cotransporter () and the potassium chloride cotransporter (), which leads to neuronal depolarization and excitability."
    },
    "1797-2470": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "bladder urothelial carcinoma",
      "text": "Our results suggest that with advancing stage of bladder UC, the levels of oxidative stress increase, while levels of antioxidant molecules decrease.\nInorganic arsenic (iAs), a known human carcinogen, induces oxidative DNA damage and epigenetic silencing of tumor suppressor genes related to tumor progression.\nThe data showed that sodium arsenite and DMA exposure significantly increased the tissue arsenic contents, ROS, TBARS levels, catalase, SOD activities and significantly decreased GSH level which might be responsible for an increased 8-OHdG level.\nThe observed redox imbalance in UC of bladder in correlation with the grade and stage, as a consequence of decreased levels of antioxidant vitamins, enzymes, and AOA, along with increased MDA levels in circulation, may be important factors in tumor development and growth.\nAt the molecular level, reduced level of oxidative stress was observed in female UUC patients.\nManipulation of oxidative stress may afford an opportunity to enhance the antitumor effects of BCG.\nManipulating the cellular oxidative stress induced by bacillus Calmette-Guérin represents a potential target to increase the efficacy of the bacillus.\nTaken together, the present study demonstrated that TCC cells exposed to hypoxic conditions rendered mitochondria less sensitive to oxidative stress induced by cisplatin treatment, leading to enhanced drug resistance.\nTo overcome these barriers, the establishment of strategies combining PDTs with HSP inhibitors may be promising and the identification of HSPs involved with oxidative stress from bladder tumors in animal models represents a key step in this direction.\nResults suggest that mortalin is preferentially expressed in the MB49 cancer model and plays a key role in tumoral survival, especially under oxidative stress, making this HSP a potential target for an alternative treatment combining PDT with HSP inhibitors.\nWe further revealed that LRPPRC promoted UCB tumorigenesis by regulating the intracellular ROS homeostasis.\nEarly signs of urinary bladder carcinogenesis were observed in arsenic and DMA exposed rats which were linked to metal accumulation, oxidative/ nitrosative stress, 8-OHdG, MMP-9 and survivin which were reduced by MiADMSA possibly via its"
    },
    "1795-1920": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Cervical Cancer",
      "text": "Inhibition of STIM1-mediated SOCE can decrease proliferation and migration, and promoted the apoptosis of cervical cancer cells.\nSS exerted its anti-cervical cancer effects by inhibiting cell proliferation, promoting apoptosis, and inhibiting the PI3K/AKT signaling pathway.\nwhereas has-miR-449a, as an upstream regulatory miRNA of NOTCH1, could inhibit cervical cancer cell proliferation and enhance radiosensitivity by inhibiting NOTCH1 expression.\nZiyu I inhibits cervical cancer progression through a multitarget regulatory network involving MAPK signaling pathway-mediated inhibition of cell proliferation and migration, apoptosis activation, and cell cycle arrest.\nIn vitro experiments revealed that Fu/CA NPs significantly inhibited the proliferation of cervical cancer HeLa cells (by 65.73 ± 4.06 %) and induced apoptosis through the accumulation of reactive oxygen species and mitochondrial damage.\nAfter combining with EGFR, TNF-α and VEGFA, the active ingredient of Sculellaria Barbata can regulate the PI3K/AKT signaling pathway and down-regulate the expression of MDM2 gene to inhibit the epithelial-mesenchymal transition, which can inhibit cervical cancer cell proliferation, migration, and promote their apoptosis.\nPIN1 can increase the proliferation and invasion of cervical cancer cells by significantly inhibiting ferroptosis.\nElevating DLG2 levels significantly suppressed cervical cancer cell proliferation, migration, and invasion, while promoting apoptosis.\nSIRT7 enhanced the proliferation, migration, and invasion of HeLa and SiHa cells, inhibited apoptosis, and promoted cervical cancer growth.\nSurprisingly, PGE inhibited CaSki cell proliferation, while it increased the proliferation of SiHa, HeLa, and C-33 A cervical cancer cells.\nChrysin selectively inhibited cell proliferation and induced apoptosis in every cervical cancer cell line assessed while exerting minimal effects on HaCaT cells.\nCellular experiments revealed that Ziyu I significantly inhibited the proliferation and migration of cervical cancer"
    },
    "1795-2539": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Hepatic ischemia-reperfusion (I/R)",
      "text": ""
    },
    "32-1802": {
      "type": "slc_pathway",
      "key1": "SLC4A7",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "25-1800": {
      "type": "slc_pathway",
      "key1": "SLC3A2",
      "key2": "migration",
      "text": "Overexpression of hsa-miR-605-3p regulated SLC3A2 to promote ICC cell ferroptosis and inhibit proliferation and migration.\nTaken together, knockdown of hsa_circ_0050900 inhibited SLC3A2 expression via sponging hsa-miR-605-3p to promote ICC cell ferroptosis, and finally suppressed proliferation and migration.\nUpregulation of SLC3A2 significantly decreased cell viability in response to cisplatin, increased cisplatin-induced apoptosis, and decreased migration and invasion in the presence of cisplatin.\nOur results suggest that circBTBD7-420aa may inhibit the abnormal proliferation and migration of human coronary artery smooth muscle cells by promoting SLC3A2 degradation through the ubiquitin-proteasome pathway.\nIn vitro experiments showed that knocking down of SLC3A2 was associated with reduced migration, invasion, and proliferation, but increased apoptosis of OSCC cells.\nKnockout of SLC3A2 suppressed the migration and invasion of BGC-823 cells and , whereas overexpression of SLC3A2 in NCI-N87 cells promoted the migration and invasion and .\nUpregulated SLC3A2 influenced the tumor microenvironment by altering immune cell infiltration, particularly of macrophages, and tumor migration and invasion.\nKnockdown of SLC3A2 suppressed melanoma cell proliferation and migration in vitro.\nThe proliferation, invasion, and migration of BLCA cells were reduced after interfering with SLC3A2.\nIn vitro experiments showed that reduced SLC3A2 expression decreased cell proliferation, migration, and invasion.\nKnockdown HOXA13 inhibited PCa cell proliferation, migration, and invasion, partially rescued by SLC7A11/SLC3A2 overexpression.\nInhibition of MIF or SLC3A2 expression prevented cell proliferation, migration, epithelial-mesenchymal transition (EMT) and invasion.\nInhibition of miR-142-3p or overexpression of SLC3A2 reversed ferroptosis and inhibited the prolif"
    },
    "1796-1893": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Thyroid Cancer",
      "text": "ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis.\nCirc_0067934 upregulated the expression of the ferroptosis-negative regulator SLC7A11 by sponging and inhibiting miR-545-3p in thyroid cancer cells.\nCircular RNA circKIF4A facilitates the malignant progression and suppresses ferroptosis by sponging miR-1231 and upregulating GPX4 in papillary thyroid cancer.\nTIAM1 knockdown repressed thyroid cancer cell proliferation and promoted ferroptosis through regulating Nrf2/HO-1 axis.\nferroptosis inducers could suppress the growth of thyroid cancer cells.\nknockdown of GPX4 suppressed proliferation and induced ferroptosis in thyroid cancer cells.\nthe diaryl ether derivative, 16 inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells.\nIncreased expression of GPX4 promotes the tumorigenesis of thyroid cancer by inhibiting ferroptosis and predicts poor clinical outcomes.\nRON interference inhibited glycolysis, promoted ferroptosis, elevated cell sensitivity to chemotherapy and affected mitochondrial function in thyroid cancer cells.\nUSP7 inhibition by P5091 enhances PLX4032 efficacy by promoting tumor suppression and ferroptosis in BRAF-mutant thyroid cancer, offering a promising strategy to overcome resistance.\nGGCT knockdown inhibited GSH synthesis and promoted malondialdehyde (MDA) and reactive oxygen species (ROS) accumulation, thereby promoting ferroptosis in papillary thyroid cancer cells.\nferroptosis inducer sulfasalazine dramatically reduced tumor growth of mice with feeding arachidonic acid.\nCurcumin Induces Ferroptosis in Follicular Thyroid Cancer by Upregulating HO-1 Expression.\nUSP10 might attenuate the ferroptosis to promote thyroid cancer malignancy by facilitating GPX4 via elevating SIRT6.\nneferine exerted an antitumor effect and ferropt"
    },
    "1802-2133": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "autism spectrum disorders",
      "text": "Previous reports indicate an association between autism spectrum disorders (ASD) and disorders of mitochondrial oxidative phosphorylation.\nSurprisingly, an Axin2 stabilizer, XAV939, effectively blocked Axin2/ENO1 interaction, switched glycolysis/oxidative phosphorylation balance, promoted synaptic maturation, and rescued social function.\nThe prolonged opening of this pore affects the redox state of the mitochondria, impairs oxidative phosphorylation, and activates apoptosis, ultimately leading to cell death.\nNeuroinflammation triggered by microglia activation is hallmark of autism spectrum disorder (ASD), and this process includes crucial metabolic reprogramming from oxidative phosphorylation to glycolysis, which may cause neuron loss and functional impairment.\nA significant difference in energy metabolism and proteome phenotype was also observed in ASD organoids at this time point, specifically, prevalence of glycolysis over oxidative phosphorylation, decreased ATP production and mitochondrial respiratory chain activity, differently expressed cell adhesion proteins, cell cycle (spindle formation), cytoskeleton, and several transcription factors.\nDysregulation of energetic metabolism might promote cell deregulation and progression of ASD.\nGenetic and epigenetic regulation of brain development may also be disrupted by mt dysfunction, including mt-induced oxidative stress.\nPossible pathogenetic mechanisms linking mt dysfunction and ASD include mt activation of the immune system, abnormal mt Ca(2+) handling, and mt-induced oxidative stress.\nUpregulation of WNT/β-catenin pathway induces aerobic glycolysis, named Warburg effect, through activation of glucose transporter (Glut), pyruvate kinase M2 (PKM2), pyruvate dehydrogenase kinase 1(PDK1), monocarboxylate lactate transporter 1 (MCT-1), lactate dehydrogenase kinase-A (LDH-A) and inactivation of pyruvate dehydrogenase complex (PDH).\nSuppressing glycolysis in ASD mice partially rescued synaptic and social phenotype.\nOverexpressing β-catenin in the ACC of wild-type mice"
    },
    "85-1802": {
      "type": "slc_pathway",
      "key1": "SLC8A1",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1802-2097": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "penile cancer",
      "text": ""
    },
    "131-1795": {
      "type": "slc_pathway",
      "key1": "SLC15A1",
      "key2": "proliferation",
      "text": "Functional analyses indicated that some DEGs were involved in the transcriptional regulation of nutrient transportation (SLC15A1, SLC5A1, and SLC3A1), cell differentiation (LGR5, HOXA5 and KLF4), cell proliferation (PLK2 and TGFB3), transcriptional regulation (JUN, FOS and ATF3), and signaling transduction (WNT10B and BMP1), suggesting that these genes were related to intestinal epithelial cell maturation and cell renewal.\nUnlike single decitabine treatment, the combined decitabine/PBA treatment caused > 95% inhibition of cell proliferation, prevented cell cycle progression especially in the S and G2-phase and induced programmed cell death.\nOverall, is a novel potential biomarker involved in CRC progression and promotes the proliferation and migration of tumor cells by positively regulating the function of Hsp70.\nThe number of Ki67 positive cells per crypt was decreased (linear, P < 0.05) with the dietary niacin on day 7 but increased (linear, P < 0.05) with dietary niacin contents on day 14.\nFurthermore, we found that knockdown of inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it.\nIn addition, extended spermine administration also markedly promoted cell proliferation, depressed apoptosis and modulated amino acid transport (p&lt;\nWe focused on the inhibition of cell proliferation, the recovery of tumor suppressors and programmed cell death, and established clinical relevance by evaluating drug responsive genes among 270 COAD patients.\nRegardless of supplementation time, spermine intake significantly enhanced the expressions of amino acid transporter-related genes (SLC1A1, SLC1A5, SLC7A1, SLC7A7, and SLC15A1) in both thymus and spleen, as well as SLC7A9 in the spleen of piglets (p&lt;0.05).\nSpermine supplementation may regulate cell cycle during the G1/S phase, suppress apoptosis and modulate amino acid transport."
    },
    "1794-2137": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "hearts suffered ischemia/reperfusion (I/R)",
      "text": ""
    },
    "1796-1862": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Myelodysplastic Syndrome",
      "text": "Loss of FTH1 Induces Ferritinophagy-Mediated Ferroptosis in Anaemia of Myelodysplastic Syndromes.\nFerroptosis has anti-tumor effect in acute myeloid leukemia and myelodysplastic syndrome.\nWe observed that erastin treatment led to glutathione depletion, reduced GPX4 activity, and increased ROS, culminating in cell death by ferroptosis.\nFerroptosis plays a central role in benzene-induced hematotoxicity, mediated by oxidative stress, disruption of iron metabolism, and suppression of GPX4.\nGPX4 knockout and erastin treatment mimicked benzene-induced effects, causing decreased cell viability, impaired colony formation, and lipid peroxidation accumulation.\nFerroptosis inhibitors show potential as therapeutic agents for mitigating benzene-induced hematological damage, offering novel therapeutic strategies for disorders induced by environmental toxins.\nThe expression profiling revealed significant enrichment of genes involved in ferroptosis, which is a form of regulated cell death induced by iron accumulation and lipid peroxidation.\nXLSA clones exhibited significantly higher levels of intracellular lipid peroxides and enhanced expression of BACH1, a regulator of iron metabolism and potential accelerator of ferroptosis.\nNotably, treatment with erastin, a ferroptosis inducer, caused a higher proportion of cell death in XLSA clones.\nWe discover that the ferroptosis level of bone marrow NEs in MDS patients was increased, which is related to anemia and iron overload.\nOur experiments confirm erastin's ability to induce ferroptosis in MDS and highlight its potential synergistic use with azacitidine for treatment.\nCollectively, defective heme biosynthesis in XLSA clones could confer enhanced BACH1 expression, leading to increased susceptibility to ferroptosis.\nThese events increase lipid peroxidation and ferroptosis susceptibility in hematopoietic cells as evidenced by enhanced BODIPY-C11 oxidation and erastin sensitivity.\nAdministration of ferroptosis inhibitors reversed these effects, restoring cellular function, reducing reactive oxygen species (ROS), and preventing oxidative"
    },
    "291-1798": {
      "type": "slc_pathway",
      "key1": "SLC27A5",
      "key2": "stemness",
      "text": "-US upregulation by SLC27A5 suppressed the stemness of HCC.\nIn conclusion, SLC27A5/PABPC1 inhibits HCC stemness via APA-regulated expression of METTL14, providing potential avenues for the development of novel therapeutic strategies.\nMechanistically, SLC27A5 facilitates the usage of the proximal polyadenylation site of by downregulating the expression of the APA-associated factor PABPC1, resulting in the shortening of the -3'UTR and the conversion of -UL to -US.\nDeficiency of SLC27A5 promotes the progression of hepatocellular carcinoma (HCC) and is strongly associated with a poor prognosis."
    },
    "1796-1823": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Melanoma",
      "text": ""
    },
    "1797-2159": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "age-related macular degeneration (AMD)",
      "text": ""
    },
    "354-1803": {
      "type": "slc_pathway",
      "key1": "SLC35G5",
      "key2": "radioresistance",
      "text": ""
    },
    "1803-2756": {
      "type": "pathway_disease",
      "key1": "radioresistance",
      "key2": "oral squamous cell carcinoma",
      "text": ""
    },
    "1796-2133": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "autism spectrum disorders",
      "text": "Mechanistic studies showed that both VPA and ferroptosis inducers promoted the expression of DDIT4 in neurons, thereby inhibiting the activation of the PI3K/Akt pathway.\nFerroptosis inhibitors reversed the anti-survival effect of DDIT4, indicating that DDIT4 enhances ferroptosis through the PI3K/Akt pathway, thereby inhibiting neuronal viability.\nafter downregulation of DDIT4 expression, the accumulation of ROS, MDA and Fe was significantly reduced, while the expression levels of GPX4, p-PI3K and p-Akt were upregulated, indicating that DDIT4 knockdown reduces ferroptosis in autistic mice.\nIn addition, DDIT4 downregulation, PI3K/Akt pathway activation, and ferroptosis inhibitors all improved social behavior deficits, repetitive stereotyped and compulsive behaviors, anxiety and exploratory behaviors in autistic mice, but PI3K/Akt pathway inhibitors significantly blocked the rescue of abnormal behaviors by DDIT4 downregulation in autistic mice.\nWe highlight the role of ferroptosis in the hippocampus neurogenesis and confirm that puerarin treatment inhibited iron overload, lipid peroxidation accumulation, and mitochondrial dysfunction, as well as enhanced the expression of ferroptosis inhibitory proteins, including Nrf2, GPX4, Slc7a11, and FTH1 in the hippocampus of VPA mouse model of autism.\nDDIT4 increased the accumulation of ROS, MDA and Fe, inhibited neuronal viability and downregulated GPX4 expression by inactivating the PI3K/Akt pathway.\nFurther in vivo experiments found that autistic mice had high levels of ROS, MDA and Fe, increased DDIT4 expression, and downregulated expression levels of GPX4, p-PI3K and p-Akt;\nThe unbeneficial DHA/ARA ratio induced ferroptosis via lipid peroxidation.\nIn addition, we confirmed that inhibition of xCT/Slc7a11-mediated ferroptosis occurring in the hippocampus"
    },
    "2-1802": {
      "type": "slc_pathway",
      "key1": "SLC1A2",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1799-2290": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "oral squamous cell carcinoma (OSCC)",
      "text": "NFIC and DEPTOR were significantly downregulated in OSCC cells and tissues, accompanied by enhanced mTOR signaling.\nOverexpression of either NFIC or DEPTOR significantly inhibited OSCC cell proliferation, glycolytic activity, and enhanced CD8 T cell killing capacity.\nNFIC mediates DEPTOR transcription to repress mTOR signaling, thereby hindering OSCC progression by suppressing cell proliferation, glycolytic activity, and CD8 T cell-related immune escape.\nNFIC activated DEPTOR by binding to its promoter.\nCombined DEPTOR knockdown rescued the malignant progression of OSCC inhibited by NFIC overexpression.\nSimilarly, they inhibited tumor growth in vivo, blocked TME acidification, and weakened tumor immune escape."
    },
    "385-1795": {
      "type": "slc_pathway",
      "key1": "SLC39A8",
      "key2": "proliferation",
      "text": "As an miR-205_R-1 sponge, circAMN1 regulated the expression of SLC39A8 to control erastin-induced ferroptosis and regulated the proliferation, invasion, and migration of trophoblast cells.\nIn vitro experimental results indicated that the overexpression of SLC39A8 inhibited the proliferation and invasion of colorectal cancer cells.\nFurthermore, we found that overexpression of SLC39A8 or treatment with low concentration of zinc chloride could effectively inhibit the proliferation, migration and invasion of ccRCC cells.\nZnT8 haploinsufficiency disrupts expression of a distinct array of important β-cell markers, decreases cellular proliferation via mitogen-activated protein (MAP) kinase cascades and downregulates insulin gene expression.\nMoreover, the inhibition effect of SLC39A8 overexpression could be enhanced by low concentration zinc supplement.\nP4HA1 facilitates the advancement of colorectal cancer, while its suppression diminishes the proliferation and migration of colorectal cancer cells.\nOur previous work showed that maternal selenium deficiency suppressed proliferation, induced autophagy dysfunction, and apoptosis in the placenta of mice.\nWe identify 30 independent genome-wide significant variants after Bonferroni correction for the number of measures studied (126 variants at nominal genome-wide significance) implicating genes involved in myelination (SEMA3A), neurite elongation and guidance (NUAK1, STRN, DPYSL2, EPHA3, SEMA3A, HGF, SHTN1), neural cell proliferation and differentiation (GMNC, CELF4, HGF), neuronal migration (CCDC88C), cytoskeletal organization (CTTNBP2, MAPT, DAAM1, MYO16, PLEC), and brain metal transport (SLC39A8).\nThese results suggested that maternal selenium deficiency may impair progesterone biosynthesis, reduce nutrient transporters expression, and promote immune response by increasing the oxidative stress of the placentae.\nWith the progression of tumor, the expression of SLC39A8 decreased progressively."
    },
    "119-1799": {
      "type": "slc_pathway",
      "key1": "SLC12A5",
      "key2": "glycolysis",
      "text": "SLC12A5 knockdown decreased BC cell ferroptosis resistance and glucose metabolism reprogramming.\nMoreover, ETV4 overexpression counteracted the suppressive effect of SLC12A5 knockdown on the BC cell proliferative, migratory and invasive abilities, as well as on ferroptosis resistance and glucose metabolism reprogramming.\nTranscriptional activation of SLC12A5 by ETV4 modulated the migration, invasion, ferroptosis resistance and glucose metabolism reprogramming of BC cells.\nThe transcription factor ETV4 was demonstrated to bind to the SLC12A5 promoter and upregulate its transcription."
    },
    "1797-2228": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "acute myeloid leukemia (AML)",
      "text": ""
    },
    "1801-2287": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "septic myocardial injury",
      "text": "Cardiomyocyte apoptosis plays a positive regulatory role in septic myocardial injury and dysfunction.\nMyocardial apoptosis plays a key role in septic myocardial injury.\nUSP13 overexpression increased Nrf2 levels and reduced apoptosis.\nInhibition of MMP9 alleviates LPS-induced myocardial matrix disruption and apoptosis.\nPD pretreatment suppressed LPS-induced H9c2 cell apoptosis by promotion of SIRT6-mediated autophagy.\nFurthermore, inhibition of NF-кB signaling by DHMEQ abolished LPS-induced myocardial inflammation and apoptosis.\nDownregulation of SIRT6 or inhibition of autophagy reversed the protective effect of PD on LPS-induced apoptosis.\nATX inhibited LPS-induced mitochondrial apoptosis of H9C2 cells by PTP1B/JNK pathway and PTP1B was the target of ATX.\nMatrine regulates PI3K/AKT pathway activity to inhibit apoptosis and ferroptosis and thereby alleviates sepsis-induced myocardial injury.\nLuteolin administration improved cardiac function, attenuated the inflammatory response, alleviated mitochondrial injury, decreased oxidative stress, inhibited cardiac apoptosis and enhanced autophagy.\nexosomes derived from patients with sepsis may inhibit glycolysis and promote the apoptosis of human myocardial cells through exosomal hsa‑miR‑1262 via its target SLC2A1.\nATX inhibited the LPS-induced apoptosis, loss of mitochondrial membrane potential and upregulation of mitochondrial apoptosis-associated proteins in H9C2 cells via JNK signaling.\nPSO prominently improved cardiac function, attenuated inflammation, inhibited oxidative stress, improved mitochondrial function, regulated ERS, suppressed apoptosis, and particularly increased NR1H3 and p-AMPK levels.\nthe increase in inflammatory cytokines in LPS-induced model was also blocked by inhibition of GSK-3β, which curbe"
    },
    "1798-2269": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Nonsmall cell lung cancer (NSCLC)",
      "text": "Silencing NAT10 inhibited cell viability, proliferation, invasion, migration, and stemness, while promoting apoptosis in NSCLC cells.\nFOXA1 expression was increased in NSCLC tissues and cells, and its knockdown repressed NSCLC cell viability, proliferation, migration, invasion, stemness, and induced apoptosis in vitro.\nIn vivo animal models further demonstrated that knockdown of TEDC2 could inhibit tumor cell stemness and enhance the therapeutic efficacy of DDP.\nBHB treatment reduced viability, stemness, and migratory and invasive abilities of NSCLC cells.\nActivation of the non-homologous end joining (NHEJ) DNA repair pathway by DDP facilitated the stemness of NSCLC.\nIGFL2-AS1 promoted lung cancer proliferation, metastasis, drug resistance, and stemness by upregulating HSPA1A expression both in vitro and in vivo.\nMechanistically, 2B7 inhibited key signaling pathways, including PI3K/AKT/GSK3β/β-catenin and JAK2/STAT3, leading to a reduction in EMT-associated stemness and therapy resistance.\nFunctional assays demonstrated that the knockdown of TEDC2 inhibited the proliferation, migration, and maintenance of stemness in tumor cells, primarily through the inhibition of the Hedgehog (Hh) signaling pathway.\nThese factors regulate epithelial‑mesenchymal transition and angiogenesis, interact with epidermal growth factor receptor/KRAS pathways to influence tumor invasion and promote chemotherapy resistance by sustaining tumor stemness.\nAC exerted significant anti-proliferative effects on A549 and NCI-H1975 cells, inhibited cancer cell migration and invasion, reduced the stemness of NSCLC cells, and markedly downregulated the expression of LCSC markers in vitro.\nThis study revealed that NSCLC cells acquire stemness traits through NF-κB activation, with p-DNA-PKcs-induced phosphorylation of p65 being a prerequisite for p65 acetylation and sustained NF-κB activation in drug-"
    },
    "396-1795": {
      "type": "slc_pathway",
      "key1": "SLC41A2",
      "key2": "proliferation",
      "text": "By inhibiting the ubiquitin-proteasome degradation of GSK3β, SLC41A2 can significantly upregulate the expression of GSK3β, which ultimately suppresses the proliferation and migration of colon cancer cells.\nFurthermore, elevated expression of SLC41A2 notably decreased the proliferation, migration and invasion of colon cancer cells, along with increased apoptosis.\nBy transfecting plasmids or siRNA to overexpress or knock down SLC41A2 in colon cancer cells, the effects of SLC41A2 on colon cancer cell proliferation, migration, and apoptosis were detected through EdU, MTT, wound-healing, Transwell, and JC-1 experiments.\nThe overexpression of SLC41A2 and rescue experiments confirmed that SLC41A2 enhances the protein stability of GSK3β by inhibiting its ubiquitin-proteasome degradation and causes the upregulation of GSK3β, thereby suppressing the progression of colon cancer.\nRecent studies have shown that the vertebrate magnesium transporters Solute carrier family 41, members 1 and 2 (SLC41A1, SLC41A2) and Magnesium transporter subtype 1 (MagT1) can endow vertebrate B-cells lacking the ion-channel kinase Transient receptor potential cation channel, subfamily M, member 7 (TRPM7) with a capacity to grow and proliferate.\nOverall, our findings show that consistent with its proposed function, Mg(2+) uptake mediated by MgtE is able to restore cell growth and proliferation of TRPM7-deficient cells and supports the concept of functional homology between MgtE and its vertebrate homologs.\nHere, we report that overexpression of MgtE is able to rescue the growth of TRPM7-KO DT40 B-cells."
    },
    "1799-2450": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Head and Neck tumors",
      "text": "Treatment with sinomenine upregulated miR-140-5p and suppressed anaerobic glycolysis of OSCC cells.\nFurthermore, A-to-I editing of miR-1304-3p can inhibit glycolysis and inactivate the Wnt5a/ROR2 signaling pathway in ESCC.\nSuppression of CBP/EP300-mediated PFKL transcription inhibited cell viability and glycolysis and promoted mito-ROS in LSCC.\nDown-regulation of tumor glycolysis facilitates tumor infiltration of cytotoxic T cells via suppression of glycolysis-dependent interleukin-8 signaling.\nIn terms of mechanism, TRIM33 binds to p53 to inhibit its stability and promote the expression of downstream glycolysis target genes GLUT1, HK2, PKM2, and LDHA.\nThe glycolysis related proteins GLUT1, HK2, PFKP, PKM2, LDHA and Wnt/β-catenin pathway proteins WNT5A, cyclin D1, β-catenin were inhibited, GSK-3β is increased in si-PLOD1 group.\nTPL was shown to have a strong CDDP‑sensitizing effect and and its mechanism may involve inhibiting anaerobic glycolysis and causing mitochondrial energy metabolism impairment to induce apoptosis.\nAll OSCC fragments exhibited an increase in glycolysis-related proteins and a decrease in mitochondrial activity compared to the TAE region (p < 0.05), probably due to the downregulation of pyruvate dehydrogenase and antioxidant proteins.\nRegarding energy metabolism, Chaga mushroom extract inhibited glycolysis and mitochondrial membrane potential in HSC-4 cells, thereby triggering autophagy-mediated apoptotic cell death through activation of the p38 MAPK and NF-κB signaling pathways.\nCollectively, our findings demonstrated that rhodiolin inhibited the proliferation and induced the apoptosis of PTC cells by blocking glycolysis through the glycolytic enzyme GPI, thereby inhibiting phosphorylation of the PI3"
    },
    "129-1795": {
      "type": "slc_pathway",
      "key1": "SLC13A5",
      "key2": "proliferation",
      "text": "Accumulating evidence suggests that SLC13A5 is involved in hepatic lipogenesis, cell proliferation, epilepsy, and bone development in mammals.\nIn HepG2 cells with the highest NaCT expression, extracellular citrate treatment upon hypoxia induced HIF1α degradation, which led to reduced glycolysis and cellular proliferation.\nThe perturbation of SLC13A5 expression and/or activity is associated with non-alcoholic fatty liver disease, obesity, insulin resistance, cell proliferation, and early infantile epileptic encephalopathy.\nReducing expression in human hepatocarcinoma cells has recently been shown to inhibit cell proliferation.\nReduced expression in the fly intestine affects intestinal stem cell proliferation, and has recently been shown to also inhibit germ cell proliferation in males with delayed sperm maturation and decreased spermatocyte numbers.\nTogether, our findings demonstrate that knockdown of SLC13A5 promotes hepatic ketogenesis and enhances cellular stress response in HepG2 cells, suggesting a potential role of this transporter in metabolic disorders and liver cancer.\nFurther ingenuity pathway analysis predicted 40 canonical pathways and 28 upstream regulators (p < .01), of which most were associated with metabolism, cell proliferation, and stress response.\nThese results highlight a new connection between energy metabolism and cell proliferation.\nAdditional experiments showed that SLC13A5-KD sensitizes HepG2 cells to cellular stress caused by a number of chemotherapeutic agents.\nExtracellular citrate treatment induced the failure of metabolic adaptation to hypoxia and tumor growth inhibition, which can be a potential therapeutic strategy in HCCs."
    },
    "1795-1900": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "lymphoma",
      "text": ""
    },
    "119-1802": {
      "type": "slc_pathway",
      "key1": "SLC12A5",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1798-1815": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "leukemia",
      "text": ""
    },
    "1801-2404": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "triple-negative breast cancer(TNBC)",
      "text": "We found that EM2 induced apoptosis of MDA-MB-231 cells by inhibiting AKT and HR pathways.\nB8 effectively reduced cell viability, induced apoptosis, and caused G2/M cell cycle arrest in TNBC cells.\nCollectively, pirfenidone arrests the cell cycle and promotes apoptosis of TNBC cells by suppressing Hedgehog/GLI1 signaling.\nLoaded with gambogenic acid (GNA), OPDMA-PCL-GNA induces apoptosis in MDA-MB-231 cells by inhibiting the PI3K/AKT/mTOR pathway.\nSRPX2 knockdown inhibited TNBC cell viability, invasion, and Stemness of tumor while promoting TNBC cell apoptosis and ferroptosis.\nFlow cytometry confirmed increased apoptosis, evidenced by upregulation of pro-apoptotic genes and suppression of anti-apoptotic genes.\nIn vivo, GDP-uPA/GTI significantly downregulated R2 expression and activated caspase 8 and caspase 3, indicating caspase-dependent apoptosis.\nEukaryotic Elongation Factor 2 Kinase (eEF2K) is overexpressed in TNBC, promoting cell survival by inhibiting apoptosis through phosphorylation of eEF2.\nIn vitro, KEAF inhibited MDA-MB-231 cell proliferation and migration, modulated the cell cycle, and induced apoptosis by downregulating PI3K/Akt signaling.\nIn conclusion, PD effectively inhibited the proliferation and induced apoptosis in TNBC cells through the activation of ROS and endoplasmic reticulum stress.\nIn vivo, DMA (25 mg/kg) suppressed MDA-MB-231 xenograft tumor growth by approximately 78% ( < 0.01) and induced apoptosis through regulating AKT/Hh/Gli1 axis.\nFurthermore, in primary tumors formed by TIE1-expressing cells, we observed TIE1 cleavage, reduced apoptosis, and activation of the AK"
    },
    "91-1798": {
      "type": "slc_pathway",
      "key1": "SLC9A2",
      "key2": "stemness",
      "text": "Besides, mRNA expressions of NHE family were extremely associated with clinicopathological features, tumor immune microenvironment and stemness score, DNA methylation, and patient prognosis in COAD."
    },
    "380-1801": {
      "type": "slc_pathway",
      "key1": "SLC39A3",
      "key2": "apoptosis",
      "text": "Zip3-null mice also had altered mammary tissue architecture, increased number of apoptotic cells, and reduced mammary gland weight implicating subtle changes in Zip3-mediated intracellular Zn pools in apoptosis regulation."
    },
    "367-1794": {
      "type": "slc_pathway",
      "key1": "SLC38A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1798-2087": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Glioblastoma (GBM)",
      "text": ""
    },
    "1798-1823": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Melanoma",
      "text": ""
    },
    "79-1796": {
      "type": "slc_pathway",
      "key1": "SLC7A9",
      "key2": "ferroptosis",
      "text": "SLC7A9 promotes gastric cancer progression by acting as a suppressor of ferroptosis, independent of SLC7A11, which is negatively regulated by p53.\nSLC7A9 suppression increases chemosensitivity by inducing ferroptosis via the inhibition of cystine transport in gastric cancer.\nErastin was more effective at inducing ferroptosis in PDO and PDX models upon SLC7A9 knockdown.\nSLC7A9 knockdown reduced cystine transport into cells, hampered intracellular cystine and GSH metabolic flow, decreased GSH synthesis, and increased lipid ROS levels in gastric cancer cells.\nDifferentially expressed genes and metabolites between the SLC7A9 overexpression and control groups were associated with ferroptosis and GSH metabolism.\nCystine/cysteine transport is related to ferroptosis.\nChemotherapy was more effective in PDX and immunocompetent mice models upon SLC7A9 knockdown.\nSLC7A9 knockdown suppressed the proliferation and increased the chemotherapy sensitivity of the cells.\nElevated SLC7A9 expression levels in gastric cancer cells were attributed to p53 loss.\nSLC7A9 is responsible for the exchange of dibasic amino acids and cystine (influx) for neutral amino acids (efflux)."
    },
    "396-1801": {
      "type": "slc_pathway",
      "key1": "SLC41A2",
      "key2": "apoptosis",
      "text": "Furthermore, elevated expression of SLC41A2 notably decreased the proliferation, migration and invasion of colon cancer cells, along with increased apoptosis.\nBy inhibiting the ubiquitin-proteasome degradation of GSK3β, SLC41A2 can significantly upregulate the expression of GSK3β, which ultimately suppresses the proliferation and migration of colon cancer cells.\nBy transfecting plasmids or siRNA to overexpress or knock down SLC41A2 in colon cancer cells, the effects of SLC41A2 on colon cancer cell proliferation, migration, and apoptosis were detected through EdU, MTT, wound-healing, Transwell, and JC-1 experiments.\nThe overexpression of SLC41A2 and rescue experiments confirmed that SLC41A2 enhances the protein stability of GSK3β by inhibiting its ubiquitin-proteasome degradation and causes the upregulation of GSK3β, thereby suppressing the progression of colon cancer.\nOverexpression of TMPRSS3 increased cell viability, whereas suppression of TMPRSS3 increased the percentage of apoptotic cells and decreased cell viability, compared to the control group.\nTMPRSS3 is an important molecule in the regulation of cell viability and cell apoptosis of HEI-OC1 cells.\nMagnesium may influence blood pressure by modulating vascular tone and structure through its effects on myriad biochemical reactions that control vascular contraction/dilation, growth/apoptosis, differentiation and inflammation."
    },
    "369-1799": {
      "type": "slc_pathway",
      "key1": "SLC38A3",
      "key2": "glycolysis",
      "text": "The expression levels of SLC38A3, SLC2A1, and ASRGL1 are higher in tumor samples by RT-qPCR, with IHC confirming increased SLC38A3 expression.\nFinally, SLC38A3 may function as oncogenes in EC, as revealed by the results of in vitro experiments.\nSubsequently, six prognostic genes were derived, including ASRGL1, SLC38A3, SLC2A1, ALDH1B1, GAD1, and GLYATL1.\nIn this study, we developed six novel prognostic genes in EC based on glycolysis, and corresponding prognostic models were developed.\nMetabolic syndrome associated with glucose metabolism plays a pivotal role in tumorigenesis, potentially elevating the risk of endometrial cancer (EC).\nNotably, we identified SLC38A3 as the key gene, which offers valuable insights for further research into EC."
    },
    "1796-1931": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Nasopharyngeal Cancer (NPC)",
      "text": "EMC2 suppresses ferroptosis and promotes tumor progression, and the EMC2-TFRC axis is a novel ferroptosis regulatory pathway.\nThese findings indicated that isoquercitrin might enhance oxidative stress and ferroptosis in NPC via AMPK/NF-κB p65 inhibition.\nEMC2 knockdown promoted ferroptosis, inhibiting cell viability, migration, and invasion, and enhancing the efficacy of cisplatin in NPC cells.\nHOXA9 restrained ferroptosis via promoting UBR5 expression, and UBR5 suppressed ferroptosis through promotion of SIRT6 ubiquitination and degradation.\nOur findings suggest that the AGT-HIF-1α-HILPDA pathway promotes radioresistance in NPC by enhancing lipid droplet accumulation, thereby suppressing ferroptosis.\nRescued experiments indicated that FGFR2 overexpression inhibited DDP-induced ferroptosis, and CAFs protected against DDP-induced ferroptosis via FGF5/FGFR2 axis in NPC cells.\nErastin (a ferroptosis inducer) and ACSL4 increased lipid peroxidation, decreased cell viability, colony formation, cell proliferation, migration and invasion, and inhibited EMT.\nMechanistically, NAT10 promotes proteins of solute carrier family 7 member 11 (SLC7A11) expression through ac4C acetylation, inhibiting sorafenib-induced ferroptosis in NPC cells.\nTaken together, our data suggest that BBR induced ferroptosis of NPC cells via suppressing the system Xc/GSH/GPX4 axis, provides new insights into the mechanism of BBR anti-NPC metastasis.\nCrucially, ferroptosis inhibitors (Fer-1/Lip-1), but not apoptosis, necroptosis, or autophagy inhibitors, rescued solasodine-induced cell death, confirming ferroptosis as the dominant mechanism.\nIn conclusion, luteolin reduces the binding of SOX4 to the GDF15 promoter by suppressing SOX4 expression, thereby down-regulating G"
    },
    "1798-2766": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Glioblastoma multiforme",
      "text": ""
    },
    "1800-2532": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Pulmory arterial hypertension (PAH)",
      "text": "CGRP reduces PDGF-BB-induced proliferation, and migration, and downregulates smooth muscle cell phenotypic proteins.\nEPC-Exos suppress cell viability, proliferation, and migration and promote apoptosis in PASMCs under hypoxic conditions.\nBoth restoring mTORC1 activity and AKT reactivation abolished silencing TRIM24-mediated inhibition of proliferation and migration of PASMCs.\nConversely, atherogenic and hypoxic stimuli downregulate miR-34a levels and promote VSMCs proliferation and migration during atherosclerosis and PAH.\nmiR-361-3p upregulation mitigated hypoxia-induced hPASMC proliferation, invasion, and migration by inhibiting KLF5 expression.\nCordycepin may activate the P53-P21 pathway to inhibit abnormal proliferation and migration of PASMC and promote apoptosis, offering a potential approach for PAH treatment.\nSilencing of PLOD2 inhibits PI3K/AKT signaling to limit PASMC glycolysis which allows PASMC proliferation and migration in CIH-induced pulmonary arterial hypertension (PAH).\nThe viability, migration of hypoxia-induced PASMCs, the expression of VEGF, FGF-2, and HIF-α were significantly repressed by transfection of si-LINC00963 or miR-328-3p mimics.\nJag2 was upregulated under hypoxic conditions, promoting PASMC proliferation and migration and inhibiting apoptosis through NADPH oxidase 2 (NOX2)/reactive oxygen species (ROS) signaling.\nSYN overexpression promoted phenotypic switch, proliferation, and migration of hPASMCs, whereas these effects were notably alleviated by the protein kinase B (AKT) inhibitor MK-2206.\nmiR-361-3p downregulation reversed the inhibitory effects of circ_0068481 silencing on hypoxia-induced hPASMC proliferation, invasion, and migration."
    },
    "367-1800": {
      "type": "slc_pathway",
      "key1": "SLC38A1",
      "key2": "migration",
      "text": "C5a increased SLC38A1, and SLC38A1 knockdown or overexpression inhibited or promoted RPE cell viability and migration.\nBy contrast, HIF-1 overexpression induced miR-373-3p downregulation and SLC38A1 upregulation, reducing cell growth and migration, which could be reversed by a miR-373-3p inhibitor.\nImportantly, the miR-373-3p inhibitor and mimic reproduced phenomena similar to those induced by HIF-1 downregulation and overexpression, respectively (including altered SLC38A1 expression, mTOR activation, cell growth, and migration).\nHypoxia enhanced the levels of miR-373-3p and hypoxia-inducible factor (HIF)-1, while knockdown not only boosted the migration and proliferation of HTR8 cells but also suppressed the hypoxia-induced upregulation of miR-373-3p and SLC38A1.\nC5a promotes RPE cell viability and migration, and SLC38A1-mediated improved glutamine metabolism is the downstream signal pathway of the C5a complement pathway.\nThe C5a complement system may target the SLC38A1 to promote RPE cell migration.\nWe found that the knockdown of SLC38A1 notably suppressed the growth and migration of HCC cells.\nInhibition of SLC38A1 reduced tumour growth and suppressed proliferation and migration of SW480 cells.\nSLC38A1 knockdown suppressed HCC cell proliferation, migration, invasion, and EMT and inhibited ferroptosis in vitro.\nInhibiting Slc38a1 using shRNA technology could decrease the growth and migration of representative pancreatic cancer cells.\nTCF12 targeted SLC38A1 to promote HCC cell proliferation, migration and invasion and restrained ferroptosis, providing a novel sight for HCC pathogenesis.\nCircRUNX1 promoted CRC cell growth, metastasis and glutamine metabolism and repressed apoptosis by elevating SLC38A1 through sponging miR-485-5p, which might provide a novel target for CRC treatment."
    },
    "1795-2146": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "liver hepatocellular carcinoma (LIHC)",
      "text": ""
    },
    "25-1797": {
      "type": "slc_pathway",
      "key1": "SLC3A2",
      "key2": "oxidative stress",
      "text": "RY-A induced neuroprotective effects by increasing the production of key proteins involved in ferroptosis inhibition, such as SLC7A11, SLC3A2, GSS, and GPX4, while increasing antioxidant enzyme activities and alleviating oxidative stress.\nIn this study, we showed that HCV upregulated both mRNA and protein expression levels of SLC3A2 and this upregulation occurred through NS3/4A-mediated oxidative stress.\nInterestingly, SLC7A11 and SLC3A2 mRNA were also both deregulated in JEV-infected SH-SY5Y cells and encode the two constituent subunits of the plasma membrane xCT amino acid antiporter that relieves oxidative stress by export of glutamate and import of cystine.\nTaken together, our data suggested that acupuncture was effective in treating asthma by attenuation of AHR, mucus secretion and airway inflammation, and the mechanism was associated with regulation of ferroptosis, SLC3A2 and ATP1A3 protein expression as well as oxidative stress.\nAdditionally, iron overload inhibited Xc system (SLC7A11 and SLC3A2), decreasing GSH synthesis, ultimately further induced ferroptosis.\nAfter adjustment for differences in the background characteristics of the two groups, we finally identified seven Cd-responsive genes (CASP9, TNFRSF1B, GPX3, SLC3A2, ITGAL, BCL2A1, and COX7B), all of which constituted a network that controls oxidative stress response by IPA.\nCancer cells overexpress CD98hc-transporters in order to meet their increased nutritional and antioxidant demands, since they provide branched-chain AA (BCAA) and aromatic AA (AAA) availability while protecting cells from oxidative stress.\nFurthermore, system xc (SLC7A11 and SLC3A2) were found to be suppressed and a decreased GSH/GSSG ratio was observed at the same time when treated with FZKA.\nCatalpol treatment inhibited changes to several ferroptosis-related proteins, including p-PI3K"
    },
    "1801-2137": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "hearts suffered ischemia/reperfusion (I/R)",
      "text": "NGF pretreatment may protect the ischemic heart via inhibition of the ER stress-induced apoptosis\nDownregulation of TRIM11 was determined to have significantly reduced I/R-induced proliferation suppression and apoptosis.\nAll in all, the treatment of Sev upregulated miR-219a expression, which blocked the TLR4 pathway by targeting AIM2 and attenuated cardiomyocyte apoptosis in myocardial I/R mouse model.\nIn conclusion, the present study demonstrated that SA inhibits the apoptosis of H9c2 cardiomyocytes following H/R injury via reduced activation of the p38MAPK and JNK signaling pathways.\nOur results demonstrate that activation of CB2 receptor by JWH133 prevent apoptosis during ischemia/reperfusion through inhibition of the intrinsic mitochondria-mediated apoptotic pathway and involvement of the PI3K/Akt signal pathway.\nThe results of this study suggest that DEX postconditioning may increase the phosphorylation of GSK-3 by activating the PI3K/Akt signaling pathway and may inhibit apoptosis and oxidative stress of the myocardium, thus exerting protective effects in diabetic rat hearts suffering from I/R injury.\nAlda-1, a specific activator of ALDH2, significantly decreased ALDH2 O-GlcNAc modification and improved infarct size, apoptosis index and cardiac dysfunction induced by I/R combined with hyperglycemia.\nGRP78, caspase-12 and CHOP were highly expressed in ischemic myocardium, while NGF significantly inhibited the overexpression of these proteins which were involved in ER stress-induced myocardial apoptosis.\nBesides, I/R-activated c-Jun N-terminal kinase (JNK) signaling and cleaved caspase 3 and Bax expression were significantly inhibited by TRIM11 downregulation.\nSA also markedly downregulated B‑cell lymphoma 2 (Bcl‑2) expression and inhibited the expression of Bcl‑2‑"
    },
    "39-1796": {
      "type": "slc_pathway",
      "key1": "SLC5A2",
      "key2": "ferroptosis",
      "text": ""
    },
    "116-1797": {
      "type": "slc_pathway",
      "key1": "SLC12A2",
      "key2": "oxidative stress",
      "text": "These include genes with a potential role in protection against oxidative stress (Dhcr24, Cdo1, Akr1b7, Prdx6), inflammation (Ltb4dh, Wdr1), ion transport (Pdzk1ip1, Slc12a2, Slc25a17) and transcription (Zfp36l3, Pdzk1ip1).\nAbstract: The cation cotransporters Na(+)-K(+)-2Cl(-) cotransporter 1 and 2 (NKCC1 and NKCC2) and Na(+)-Cl cotransporter (NCC) are phosphorylated and activated by the kinases Ste20-related proline alanine-rich kinase (SPAK) and oxidative stress-responsive kinase (OSR1), and their targeted disruption in mice causes phenotypes resembling the human disorders Bartter syndrome and Gitelman syndrome, reflecting reduced NKCC2 and NCC activity, respectively.\nIn the CLP + NAC group, oxidative stress was significantly lower and survival rates were significantly higher than in the CLP group.\nIn SLC12A2-deficient phagocytes, the canonical anti-inflammatory program was replaced by pro-inflammatory and oxidative-stress-associated gene programs.\nThe protective effects of NAC (against kidney and lung injury) are likely attributable to the decrease in oxidative stress, suggesting that NAC can be useful in the treatment of sepsis.\nWe therefore address that enhanced physical force-sensitive cytokine and oxidative stress by the gravitational force mediate activation of the cotransporter involved in possibilities of edema and calcium loading in cardiac tissue.\nAbstract: Physical trauma, psychosocial stress, and oxidative stress increase the neuronal transcription ratio of genes encoding the sodium-potassium chloride cotransporter () and the potassium chloride cotransporter (), which leads to neuronal depolarization and excitability.\nAbstract: We analyzed the mechanisms underlying the ion transport induced by tert-butyl hydroperoxide (t-BOOH), a membrane-permeant oxidant that has been widely used as a model of oxidative stress, in human airway epithelial cells ("
    },
    "188-1794": {
      "type": "slc_pathway",
      "key1": "SLC22A5",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "372-1802": {
      "type": "slc_pathway",
      "key1": "SLC38A7",
      "key2": "oxidative phosphorylation",
      "text": "SLC38A7 silencing suppressed cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in cancer cells.\nOur results suggest that SLC38A7, stabilized by METTL3 and IGF2BP2-mediated mA methylation, enhances cell viability, migration, invasion, oxidative phosphorylation, and mitochondrial function in GC, highlighting its role as a potential therapeutic target for GC."
    },
    "381-1798": {
      "type": "slc_pathway",
      "key1": "SLC39A4",
      "key2": "stemness",
      "text": "Moreover, SLC39A4 knockdown enhanced cancer cell sensitivity to cisplatin-induced death by inhibiting stemness in lung cancer cells.\nSLC39A4 silencing by lentivirus-mediated shRNA blocked human lung cancer cell epithelial-mesenchymal transition and metastasis in vitro and in vivo, respectively.\nCP had antiproliferative effects and reduced the expression of proliferative and stemness genes in jejunal organoids, effects that were largely independent of Zn chelation.\nThe zinc transporter SLC39A4 influences epithelial cell morphology and migration in various cancers.\nSLC39A4 expression is significantly correlated with increased tumour size and regional lymph node spread, as well as shorter overall survival (OS) and disease-free survival (DFS).\nCollectively, these data suggest that SLC39A4 may be a novel therapeutic target and predictive marker of tumour metastasis in non-small cell lung cancer."
    },
    "322-1794": {
      "type": "slc_pathway",
      "key1": "SLC34A2",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1797-2532": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Pulmory arterial hypertension (PAH)",
      "text": "Collectively, fucoxanthin suppressed hypoxia-induced oxidative stress primarily by regulating the HIF-1α-ROS pathway, thereby alleviating pulmonary remodeling in HPH.\nPA exerted noticeable protective and curative effects against MCT-induced PAH and pulmonary vascular remodeling through inhibiting cellular proliferation, oxidative stress, and inflammation.\nCollectively, these results suggest that hypoxia-induced DEC1 inhibits PPARγ, and that this is a predominant mechanism underpinning oxidative stress and inflammatory responses in PASMCs during PAH.\nNetwork pharmacology, transcriptomics, and biological results suggested that CANA could ameliorate PH by suppressing excessive oxidative stress and pulmonary artery smooth muscle cell proliferation partially through the activation of PPARγ.\nIn this study, the inhibition of proteinase-activated receptor (PAR) 1/2 significantly reduced oxidative stress and fibrosis while suppressing the activation of MAPK or Smad pathways and the gene expression of molecules responsible for the pathways in the myocardium, consequently attenuating hypoxia-mediated cardiomyocyte hypertrophy.\nWestern blot experiments showed that methyleugenol regulated the oxidative stress level in rats by activating Nrf2/HO-1 signaling pathway, activate p27Kip1, inhibit CDK4/CCND1/ p-ERK1/2 and inhibited HIF-1α/RASSF1/Ras axis to inhibit cell proliferation, thereby improving the occurrence and development of high altitude pulmonary hypertension in rats.\nThe cardiac systolic function improved and mitochondrial structure of pulmonary artery smooth muscle cells in rats with high altitude pulmonary hypertension was significantly improved after methyleugenol gavage intervention, and malondialdehyde levels in serum of rats were decreased while those of superoxide dismutase and glutathione increased, suggesting that the reduction of oxidative stress may be one of the mechanisms to improve mitochondrial function.\nmusclin treatment suppresses hypoxia-induced glycolysis, oxidative stress, proliferation, and migration."
    },
    "116-1801": {
      "type": "slc_pathway",
      "key1": "SLC12A2",
      "key2": "apoptosis",
      "text": "For instance, SLC12A2 was found to enhance invasion, proliferation, and migration of colorectal cancer cells while inhibiting apoptosis.\nTherefore, blocking NKCC1 function augments TMZ-induced apoptosis in glioma cells.\nInhibition of NKCC1 activity with bumetanide accelerated AVD, early apoptosis, as well as activation of caspase-3 and caspase-8.\nInterfering with SLC12A2 expression or function resulted in a significant increase in apoptotic corpse uptake per phagocyte, whereas the loss of SLC12A4 inhibited corpse uptake.\nACVR1 overexpression can promote the proliferation of sweat gland cells and inhibit apoptosis by promoting the expression of AQP5 and NKCC1.\nPharmacological inhibitor bumetanide (Bume) or NKCC1 RNA interference significantly attenuated TBI-induced intracellular Na(+) increase, inhibited neuronal apoptosis, and improved brain edema and neurological function.\nThis study demonstrates the role of NKCC1 in TBI-induced brain cortex injury, establishing that NKCC1 may play a neurotoxic role in TBI and that the inhibition of NKCC1 may protect neurons from TBI via the regulation of Erk signaling.\nIn addition, silencing of WNK3 reduced neuronal apoptosis, and inflammatory responses in rats that underwent ICH.\nAfter inhibiting p‑SPAK, the expression level of p‑NKCC1, neuronal apoptosis and BBB permeability were significantly reduced in SBI model rats.\nChoroid plexuses with increased AQP1 and NKCC1 after 6 hr of hyponatremia showed caspase 3-dependent apoptosis and disruption of the blood-CSF barrier.\nWe introduce a preclinical mouse model for small-interfering RNA (siRNA)-based gene silencing to provide protection of SG from radiation-induced apoptosis."
    },
    "1801-2087": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Glioblastoma (GBM)",
      "text": "Knockdown of NR4A1 or NR4A2 by RNA interference in glioblastoma (GBM) cells decreased growth and induced apoptosis and comparable effects were observed for DIM-3,5 analogs, which exhibit inverse agonist activity and inhibit NR4A1- and NR4A2-mediated pro-oncogenic activity.\nGlyceraldehyde-3-phosphate dehydrogenase (GAPDH) is significantly upregulated in glioblastoma (GBM) and plays a crucial role in cell apoptosis and drug resistance.\nHyperthermia with radiation and temozolomide significantly reduced cell viability and increased apoptosis.\nIn glioblastoma cells, small interfering RNA‑mediated DR5 knockdown markedly suppressed chaetocin/TRAIL‑induced apoptosis.\nTreatment with 4-phenylbutyrate (4-PBA) suppressed SFN-induced cytotoxicity, further supporting ER stress-mediated apoptosis.\nSFN-Cys promoted 26S proteasome-mediated degradation of α-tubulin and PD-L1, and reduced the binding of α-tubulin to PD-L1 causing apoptosis.\nIonizing radiation and the STAT3 inhibitor WP1066 both induced apoptosis in U87 cells by activating the Bcl-2/BAX/Caspase-3 signaling pathway.\nKnockdown of lncRNA BBOX1-AS1 inhibits U-87 MG cell proliferation and promotes apoptosis by upregulating miR-382-5p and downregulating CBX3 expression.\nIn vitro, [At]At-PDA-FAPI was able to significantly reduce the cell viability, induce DSB formation, arrest cell cycle at G2/M phase and promote cell apoptosis.\nOur findings highlight Rb⁺ as a promising and innovative candidate for GBM therapy, leveraging the PI3K/AKT/mTOR pathway to inhibit tumor growth and promote apoptosis.\nWe found that knockdown of ADAM12 was shown"
    },
    "326-1794": {
      "type": "slc_pathway",
      "key1": "SLC35A2",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1794-2234": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "breast invasive carcinoma (BRCA)",
      "text": ""
    },
    "13-1795": {
      "type": "slc_pathway",
      "key1": "SLC2A5",
      "key2": "proliferation",
      "text": "We discovered that CRISPR/Cas9-mediated inactivation of the SLC2A5 gene inhibited cancer cell proliferation and migration as well as metastases in several animal models.\nCompensating for this, fructose was flexibly utilized by tumor cells as an alternative energy source to maintain proliferation and exert chemotherapy resistance in vitro by upregulating GLUT5, a major fructose transporter encoded by SLC2A5.\nCrucially, overexpression of SLC2A5 rescued the inhibitory effects of KLC3 knockdown on the MAPK pathway and EMT.\nOverexpression of enhances cell proliferation, migration, invasion, and tumorigenic.\nDepletion of undermined cell proliferation and invasion meanwhile increased cell apoptosis.\nIts knockdown suppressed GC cell growth, invasion, and migration in vitro and in vivo, attenuated EMT, and reduced SLC2A5 expression.\nThis indicates that fructose uptake is the limiting factor for fructose-mediated cell proliferation.\nOn the other hand, deletion of the GLUT5-encoding gene SLC2A5 dramatically attenuated cellular malignancy via activating the apoptotic pathway.\nMechanistically, KLC3 interacts with SLC2A5, potentially regulating its membrane localization and stability, and thus activating the MAPK pathway.\nMoreover, administration of 2,5-anhydro-D-mannitol (2,5-AM), a competitive inhibitor of fructose uptake, could markedly suppress ccRCC cell growth.\nIn addition, reducing dietary fructose or pharmacological blockade of fructose utilization significantly reduced CRC growth and sensitized CRC cells to chemotherapy in vivo.\nHigh GLUT5 expression exacerbated the neoplastic phenotypes of ccRCC cells, including cell proliferation and colony formation.\nWe show that GLUT5 is a robust and generalizable driver of fructose-dependent cell proliferation.\nA positive selection approach was used to \"train\" non-fructolytic PC3 cells to utilize fructose for proliferation.\nThe expression of determined fructose uptake and utilization efficacy in"
    },
    "1801-2146": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "liver hepatocellular carcinoma (LIHC)",
      "text": ""
    },
    "1801-1815": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "leukemia",
      "text": ""
    },
    "131-1794": {
      "type": "slc_pathway",
      "key1": "SLC15A1",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1796-1819": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "skin cancer",
      "text": "treatment with CAP induced ferroptosis, resulting in a significant reduction in the viability, migration, and invasive capacities of A431 squamous cell carcinoma, a type of skin cancer.\nBy suppressing the expression of target gene DKK1, miR-130b-3p activated the Nrf2/HO-1 pathway, whereby repressing ferroptosis.\nIn particular, we find that ATAD2 inhibition induces ferroptosis in both contexts by downregulating the ferroptosis suppressor GPX4.\nThen we proved that CAMKK2 negatively regulated ferroptosis through the activation of NRF2 and the suppression of lipid peroxidation.\nWe found that inhibition of DCPS by shRNA or RG3039 induced gene transcript alteration and ferroptosis through reducing the mRNA turnover of GLRX.\nIn conclusion, ELK4 enhances proliferation, invasion, and migration while inhibiting ferroptosis in SKCM cells by upregulating CHMP6 transcription.\nWe also show that Arg2 suppresses ferroptosis by activating the Akt/GPX4 signaling pathway, negatively regulating sorafenib-induced cell death in melanoma cells.\nIn vivo experiments confirmed that vemurafenib treatment enhanced PSMB9 expression, increased iron ion accumulation, and suppressed tumor growth via ferroptosis induction.\nThus, T cell-promoted tumour ferroptosis is an anti-tumour mechanism, and targeting this pathway in combination with checkpoint blockade is a potential therapeutic approach.\nAt the same time, the expression of ATF3 protein increased and the expression of NRF2 protein decreased, suggesting that metformin may induce ferroptosis through the ATF3/NRF2 axis.\nFerroptosis, driven by iron-dependent lipid peroxidation (LPO), enhances immunogenicity through damage-associated molecular pattern (DAMP) release and depletion of immunosuppressive cells.\nInterestingly, overexpression of USP14 antagonized all the ferroptosis cascade events induced by MitoCur-1, therefore, we conclude that MitoCur-1 indu"
    },
    "1795-2264": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "laryngeal carcinoma",
      "text": ""
    },
    "179-1797": {
      "type": "slc_pathway",
      "key1": "SLCO1B1",
      "key2": "oxidative stress",
      "text": "Modification of CYPs, PPAR-α, and SLCO1B1 by palm oil might increase the risk of fatty acid accumulation with associated oxidative stress.\nTreatment with tauroursodeoxycholic acid (TUDCA) increased the expression levels of the bile acid transporters and Nrf2, decreased the expression levels of glucose-regulated protein 78 (GRP78), PKR-like ER kinase (PERK), activating transcription factor 4 (ATF4), and C/EBP-homologous protein (CHOP), and inhibited RFP-induced oxidative stress.\nBoth of the reused oils-induced profiles of all CYP and SLCO1B1, but the new oil upregulated CYP2E1, CYP3A4, and CYP4A11.\nExpression of CYP1A2, CYP2C19, CYP2E1, CYP3A4, CYP4A11, and SLCO1B1 was induced by reused oils.\nThese findings revealed the impacts of reused palm oil on metabolism via CYPs which related to oxidative stress for further study.\nThis study evaluated effects of reused palm oil (from frying pork or potato) on expression of cytochrome P450s (CYPs), the transporter (SLCO1B1), and lipid metabolism regulators;\nBilirubin is an endogenous antioxidant that protects cells against oxidative stress.\nBioactive fatty acid-derived oxylipin molecules play key roles mediating inflammation and oxidative stress.\nBioactive fatty acid-derived oxylipin molecules play key roles in mediating inflammation and oxidative stress, which underlie many chronic diseases.\n2-Ethyl-6-methyl-3-hydroxypyridine succinate (EMHPS, Mexidol) is an original antioxidant and an anti-ischemic drug with the possibility of wide applications in the complex therapy of diseases, accompanied by the development of oxidative stress and ischemia;\nThe anticancer effect of the combined treatment of SN38 and EP is related to changes in the redox-homeostasis of cancer cells, leading to"
    },
    "335-1798": {
      "type": "slc_pathway",
      "key1": "SLC35C2",
      "key2": "stemness",
      "text": "The knockdown and overexpression of SLC35C2 inhibited or promoted stemness in HCC cell.\nInhibition of ACSL4 with PRGL493 can reverse the lipogenesis, stemness and proliferation induced by SLC35C2 overexpression.\nIn conclusion, our study demonstrates the pivotal role of SLC35C2 in stemness and malignant progression in HCC by promoting lipogenesis.\nThe present study identified SLC35C2 as a crucial factor in maintaining the stem-cell characteristics of HCC cells through CRISPR-dCas9 screening.\nBoth in vitro and in vivo studies demonstrated that SLC35C2 promoted the proliferation, migration, invasion and metastasis in HCC cells.\nMechanistically, SLC35C2 stimulated lipogenesis through the up-regulation of SREBP1, ACC, FAS, and SCD-1, thereby increasing lipid accumulation in HCC cells.\nSLC35C2 interacted with ACSL4, which plays a critical role in lipogenesis, and to protect it from degradation.\nThrough RNA-seq and lipidomics analysis, it was found that SLC35C2 regulated lipid reprogramming, particularly triglyceride synthesis.\nFurther investigation demonstrated that SLC35C2 was significantly elevated in HCC tissues and correlated with a poor prognosis in HCC patients.\nThese findings suggest that SLC35C2 is a prognostic marker and promising therapeutic target for HCC treatment.\nIt is an independent prognostic factor for HCC patients.\nCancer stem cells (CSC) are a contributing factor to the recurrence and metastasis of HCC."
    },
    "1801-2450": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Head and Neck tumors",
      "text": "PLSCR1 knockdown inhibited TSCC cell proliferation, migration, and invasion, and upregulated apoptosis.\nIts upregulation promoted proliferation, inhibited apoptosis, and enhanced migration and invasion in HNSCC cells.\nKnockdown of SARS1 in HNSCC cell lines inhibited cell viability, migration, and colony formation while promoting apoptosis.\nTranscriptome sequencing and Western blot analysis revealed that Ceritinib suppresses PI3K/Akt signaling to promote apoptosis.\nCollectively, the cytotoxic effects induced by CFZ involve cell growth inhibition and apoptosis via the PI3K/AKT/mTOR and p21 signaling pathways.\nBoth curcumin and EF24 inhibit the viability, migration, and invasion, and induce apoptosis of OSCC cells and the IC of EF24 was much lower than that of curcumin.\nUnder detachment stress, Nrf2 activation enhances cell viability, inhibits apoptosis, and facilitates multicellular aggregate formation, thereby promoting survival.\nOur study revealed anticancer efficacy of silibinin in suppressing cell viability and proliferation, promoting DNA damage, apoptosis and cell cycle arrest in HNSCC.\nIn summary, GOT1 knockdown inhibited proliferation and promoted apoptosis via ROS overproduction from mitochondrial dysfunction, thereby increasing cisplatin sensitivity.\nIn this study, we demonstrated that Ceritinib significantly inhibits the growth of LSCC cells (TU686 and AMC-HN8), disrupts oxidative stress homeostasis, and induces mitochondrial-mediated apoptosis.\nIn in vitro experiments, both CAFs-CM and CAFs-exo enhanced Cal27 cell proliferation and upregulated RORA-AS1 and IFITM1 expression, while concurrently inhibiting apoptosis, upon exposure to 8 Gy X-rays irradiation.\nIn this study we showed that erianin significantly inhibited cell viability and colony formation of thyroid cancer cells in a genetic mutation -independent manner, and treatment thyroid cancer cells with erianin induced remarkable"
    },
    "1798-2379": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "pancreatic tumor growth",
      "text": "Silencing USP22 can inhibit the Wnt/β-catenin pathway to reduce cell stemness and enhance the sensitivity of PC cells to cisplatin.\nOverall, this study illustrates that Huaier augments the tumor-killing effect of gemcitabine through suppressing the stemness induced by gemcitabine in a FoxM1-dependent way.\nExtracellular administration of TFF1 inhibited gemcitabine-induced EMT, Wnt pathway activation and cancer stemness, eventually increased apoptosis of pancreatic cancer cells in vitro.\nWe revealed that circ_0030167 mainly regulates miR-338-5p, enhances Wif1 expression, and inhibits the Wnt8/β-catenin pathway, thereby inhibiting the stemness of PC cells and tumor progression.\nOur work suggested that Amatuximab inhibits the adhesion of cancer cells to peritoneum and suppresses the stemness and viability of those, that lead to enhance the sensitivity for gemcitabine.\nMechanistically, pyrvinium pamoate induced DNA damage, inhibited stemness markers and the PI3K/AKT cell survival pathway, triggered an S-phase cell cycle arrest and induced apoptotic and autophagic cell death.\nThe ALKBH5-mediated mA modification led to DDIT4-AS1 overexpression in PDAC, and DDIT-AS1 increased cancer stemness and suppressed chemosensitivity to GEM by destabilizing DDIT4 and activating the mTOR pathway.\nIn conclusion, these findings demonstrate that Erianin directly interacts with MEK1/2, thereby inhibiting the activation of MAPK pathway and effectively suppressing both proliferation and stemness in pancreatic cancer cells.\nGinsenoside Rg3 increased the PAAD cell-derived exosomal miR-204 levels, which subsequently inhibited its target genes DVL3 expression in the receptor PAAD cells, and the down-regulated DVL3 broke stemness maintenance, ultimately suppressing VM formation of PAAD.\nDDIT4-AS1 silencing inhibited stemness and enhanced chemosens"
    },
    "1799-2137": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "hearts suffered ischemia/reperfusion (I/R)",
      "text": "Changes in the levels of ATP, high‐energy phosphates, intracellular pH, and glycolysis during low‐flow ischemia in the wild‐type mice hearts were attenuated in the ATPGD 1‐transgenic hearts.\nCardiospecific overexpression of ATPGD 1 increased myocardial histidyl dipeptides levels and protected the heart from I/R injury.\nWe report here that β‐alanine and carnosine feeding enhanced myocardial carnosine levels and protected the heart against I/R injury.\nEither exogenous administration or enhanced endogenous formation of histidyl dipeptides prevents I/R injury by attenuating changes in intracellular pH and preventing the accumulation of lipid peroxidation derived aldehydes.\nThe overexpression of ATPGD 1 prevented the accumulation of acrolein and 4‐hydroxy trans ‐2‐nonenal–protein adducts in ischemic hearts and delayed acrolein or 4‐hydroxy trans ‐2‐nonenal–induced hypercontracture in isolated cardiac myocytes.\nIsolated cardiac myocytes from ATPGD 1‐transgenic hearts were protected against hypoxia reoxygenation injury.\nThe recently identified enzyme ATPGD1 (Carnosine Synthase), which synthesizes histidyl dipeptides such as carnosine, has the potential to counteract multiple effectors of I/R injury by buffering intracellular pH and quenching lipid peroxidation products and may protect against I/R injury.\nMyocardial ischemia reperfusion (I/R) injury is associated with complex pathophysiological changes characterized by pH imbalance, the accumulation of lipid peroxidation products acrolein and 4‐hydroxy trans ‐2‐nonenal, and the depletion of ATP levels."
    },
    "1800-2404": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "triple-negative breast cancer(TNBC)",
      "text": "Both Gli-1 siRNA and GANT61 (an inhibitor of Gli-1) could abrogate the increased TNBC trans-endothelial migration through TNFα-treated ECs.\nIn vitro, LINC02544 silencing via exo/si-LINC02544 reduced CAPRIN1 levels, upregulated miR-497-5p, and inhibited TNBC cell proliferation and migration.\nUSP33 was significantly downregulated in TNBC tissues and cell lines, correlating with enhanced proliferation, migration, and epithelial-mesenchymal transition.\nKp-10 treatment significantly reduced cell viability and migration and induced a dose-dependent upregulation of KISS1 mRNA, suggesting a positive feedback loop.\nFurthermore, preferentially expressed antigen in melanoma (PRAME), an inhibitor of retinoic acid signaling, was reported to promote TNBC cell migration and invasion.\nSpecifically, the combination therapy inhibits FOXC2-driven EMT and induces ferroptosis via the FOXC2-Hippo signaling axis, suppressing tumor proliferation, migration, and invasion.\nMoreover, we report that selective RET inhibition using pralsetinib and selpercatinib significantly reduces cell viability, enhances apoptosis, and attenuates migration of brain-tropic breast cancer cells.\nPE32 can effectively inhibit the proliferation and migration of TNBC cells, and can induce PANoptosis in TNBC cells, increase the level of reactive oxygen species, and activate related inflammatory pathways.\nThrough comprehensive in vitro and in vivo experiments, we proved that copper facilitated cell proliferation, migration, xenograft tumor growth and lung metastasis, which were inhibited by copper chelator tetrathiomolybdate.\nLinarin treatment reduced cell viability (2D IC:120.8 µM *** < 0.001, 3D IC: 1949 µM **** < 0.0001 respectively) and migration (*** < 0.001, **** < 0.0001), increased apoptosis, and upregulated Bax and Caspase3/"
    },
    "1801-2393": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "clear cell renal cell carcinoma (CCRCC)",
      "text": "While the p53 upregulated modulator of apoptosis (PUMA) is traditionally recognized for promoting cell apoptosis and enhancing chemotherapy efficacy in various cancers, its role in clear cell renal cell carcinoma (ccRCC) remains unclear due to ccRCC's chemotherapy resistance.\nDownregulation of Sam68 expression inhibited RCC cell apoptosis induced by sunitinib.\nIn mouse models, monotropein reduced RCC tumor growth, induced apoptosis, and blocked NF-κB pathway.\nApoptosis was induced in BHB-treated cells as caspase-3 and Bax were increased and Bcl-2 was downregulated.\nAdditionally, treatment with the SUV420H2 inhibitor A-196 induced cell apoptosis via upregulation of DHRS2.\nRopivacaine effectively suppressed RCC cell viability, migration and invasion and enhanced cell apoptosis rate.\nThe use of the ERK inhibitor AZD6244 to block the ERK pathway could effectively promote cell apoptosis induced by MTI-31.\nHOXA3 induced RCC cell proliferation, and suppressed autophagy and apoptosis via transcriptionally activating USP15 expression.\nNF-κB pathway dysregulation, a common driver of therapy resistance in cancer, promotes survival by suppressing apoptosis.\nIn addition, HRE inhibited proliferation through promoting apoptosis and P21-induced G/M phase arrest via PI3K/AKT signaling pathway.\nexperiments verified that LINC00460 downregulation contributed to the growth inhibition of KIRC cell lines and promoted apoptosis of cancer cells.\nRg3 dose-dependently decreased the viability, inhibited migration, invasion, colony formation and tube formation, and enhanced apoptosis of RCC cells.\nFurthermore, PLCL1 decreased lipid accumulation through UCP1-mediated lipid browning and facilitated tumor apoptosis by activating p38 phosphorylation.\nFurther mechanistic studies revealed that SELS enhanced cell proliferation and inhibited apoptosis through activating AKT/GSK3β/NF-κB signaling pathway."
    },
    "1797-2613": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Esophageal Cancer",
      "text": "Statistical analysis revealed significant increases in Cu, Fe, and TOS levels and a marked decrease in Se in cancerous tissues.\nOxidative stress process plays a key role in aging and cancer;\nOxidative stress and the immune microenvironment both contribute to the pathogenesis of esophageal squamous cell carcinoma (ESCC).\nStrong correlations have been shown between systemic oxidative stress (SOS) and the occurrence, metastasis, and prognosis of many types of cancers.\nThese findings demonstrate that the combined profiling of trace elements and oxidative stress biomarkers, enhanced with machine learning, can offer powerful tools for early ESCC diagnosis.\nOur findings shed light on the complex interrelationships between oxidative stress and the immune microenvironment in ESCC, which may have implications for personalized therapies and improved patient outcomes.\nThe dysregulation of PD-L1 and aberrant activation of the NRF2 signaling pathway are implicated in resistance to NACT.\nIn conclusion, the expression of PD-L1 is associated with aberrant NRF2 signaling pathway, advanced TNM stage, lymph node metastases, and unfavorable prognosis.\nMoreover, both PD-L1 CPS and the nuclear expression of NRF2 were found to be predictive of shorter overall survival in stage II-IV ESCC.\nThe NQO1 scores of post-NACT surgical specimens were significantly higher in the TRG-5 group than in the TRG 3 + 4 group.\nBy using the Mandard-tumor regression grading (TRG) system to evaluate the pathological response of tumors to neoadjuvant chemotherapy (NACT), we found that the TRG-5 group had higher NRF2 nuclear score, PD-L1 CPS, and TPS in pre-NACT biopsy samples compared with the TRG-3 + 4 group.\nNotably, PD-L1 expression, as assessed by either CPS or TPS, was positively correlated with both NRF2 nuclear score and NQO1 score in stage II-IV ESCC."
    },
    "1799-1931": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Nasopharyngeal Cancer (NPC)",
      "text": "FBP1 promoted the radiosensitivity in NPC cells by inhibiting glycolysis through the FBXW7/mTOR axis.\nThe upregulation of HK2 elevated aerobic glycolysis and facilitated proliferation by blocking apoptosis.\nLMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma.\nThe decrease in AMPK activity was associated with LMP1-mediated glycolysis and resistance to apoptosis induced by irradiation.\nUBR5 silencing represses proliferation and glycolysis in NPC.\nRORA overexpression inhibits cell proliferation and glycolysis by directly upregulating SPLUNC1.\nUBR5 promotes proliferation, glycolysis and M2 polarization by metabolically reprograming NPC cells through suppression of the RORA/SPLUNC1 signaling.\nThe LPLUNC1-PHB1-p53/c-Myc axis decreased glycolysis in NPC cells.\nXIST knockdown inhibited glycolysis and metastasis in hypoxia-induced NPC cells through regulating miR-381-3p/NEK5 axis.\nLPLUNC1 or PHB1 overexpression decreased glycolysis and increased oxidative phosphorylation (OXPHOS)-related protein expression in NPC cells.\nUpregulation of SUMO2 promotes GLUT1 degradation through SUMOylation and ubiquitination of GLUT1, which regulates the AMPK-mTOR pathway by inhibiting glycolysis, ultimately resulting in the proliferation and metastasis of NPC.\nTreatment with all-trans retinoic acid (ATRA) reduced the viability and clonogenicity of NPC cells, decreased glycolysis, and increased OXPHOS-related protein expression by enhancing LPLUNC1 expression in NPC cells.\nLMP1-mediated glycolysis regulates IL-1β, IL-6 and GM-CSF production through the NLRP3 inflammasome, COX-2 and P-p65 signaling pathways to"
    },
    "383-1798": {
      "type": "slc_pathway",
      "key1": "SLC39A6",
      "key2": "stemness",
      "text": "BRY812 has an inhibitory effect on the growth, migration and stemness of CRC cells, and may exert its killing effect by downregulating the AKT pathway."
    },
    "1798-1893": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Thyroid Cancer",
      "text": "Our study suggests that thyroid cancer cells adapted to PLX4032 have limited self-renewal capacity due to impaired STAT3 activation and decreased expression of the stemness-related genes.\nKnockdown of CRSP8 suppressed cell growth, migration, invasion, stemness, and induced apoptosis and differentiation in ATC cells, while its overexpression displayed opposite effects in differentiated thyroid cancer (DTC) cells.\nWe also showed that TGF-β1 was able to induce Snail and vimentin expression in the Marca cell thyroid cancer line, indicating the induction of EMT in these cells, and this induction of EMT and stemness was significantly inhibited by celastro a natural inhibitor of neoplastic cells.\nWe found that ID2 significantly promotes thyroid cancer cell proliferation, migration, EMT, and stemness through the PI3K/Akt pathway.\nHere we report that KDM1A regulates the stemness of thyroid cancer and promotes thyroid cancer progression via the Wnt/β-catenin pathway.\nexpression is induced in thyroid cancer and is associated with stemness and aggressiveness of PTC.\nFunctional experiments demonstrated that the stemness signature gene DPYSL3 promotes the proliferation, migration, and invasion of thyroid cancer cells and is associated with cancer stem cell properties.\nHere, we report that ERβ is overexpressed in papillary thyroid cancer stem cells (PTCSCs), whereas ablation of ERβ decreases stemness-related factors expression, diminishes ALDH cell populations, and suppresses sphere formation ability and tumor growth.\nOur findings support our earlier hypothesis that stemness in thyroid cancer is derived via EMT rather than from resident thyroid stem cells.\nWhen cells were treated with Dickkopf-1 (DKK1), an inhibitor of Wnt/β-catenin pathway, the promoting effects of SEMA3C on cell migration and stemness were offset.\nIn this study, we uncovered the unique function of CRSP8 in suppressing thyroid cancer differentiation and promoting thyroid cancer progression via targeting IKKα signaling.\nOf note, exogenous IGF‑1/IGF‑2 promoted the invasion and stemness"
    },
    "395-1802": {
      "type": "slc_pathway",
      "key1": "SLC41A1",
      "key2": "oxidative phosphorylation",
      "text": "Thus, our data delineate the effect of dietary Mg content and of SLC41A1 functionality on the energy-production in cardiac mitochondria.\nWe have investigated the effects of dietary Mg content and presence/functionality of the Na/Mg exchanger SLC41A1 on enzymatic functions of selected constituents of the Krebs cycle and complexes of the electron transport chain (ETC).\nOur data demonstrate that both, the type of Mg diet and the genotype largely impact on the activities of enzymes of the Krebs cycle and ETC.\nMoreover, a compensatory effect of genotype on the effect of low Mg diet on activities of the tested Krebs cycle enzymes has been identified."
    },
    "1796-1940": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Cholangiocarcinoma",
      "text": "GOLPH3 promotes tumor malignancy via inhibition of ferroptosis by upregulating SLC7A11 in cholangiocarcinoma.\nSHARPIN promotes cell proliferation of cholangiocarcinoma and inhibits ferroptosis via p53/SLC7A11/GPX4 signaling.\nHSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis.\nHypericin mediated photodynamic therapy induces ferroptosis via inhibiting the AKT/mTORC1/GPX4 axis in cholangiocarcinoma.\nJUND/linc00976 promotes cholangiocarcinoma progression and metastasis, inhibits ferroptosis by regulating the miR-3202/GPX4 axis.\nPhotodynamic therapy inhibits cancer progression and induces ferroptosis and apoptosis by targeting P53/GPX4/SLC7A11 signaling pathways in cholangiocarcinoma.\nThis study reveals that 2',4'-DHC induces ferroptosis through modulation of the ERO1A/GPX4 signaling axis, thereby suppressing the progression of cholangiocarcinoma.\nPDT promotes apoptosis and ferroptosis of cholangiocarcinoma cells by activating the P53/SLC7A11/GPX4 signaling pathway and inhibits the growth of cholangiocarcinoma.\nOur findings suggest that Erastin or Lenvatinib can enhance the induction of ferroptosis in cholangiocarcinoma cells by photodynamic therapy by increasing intracellular ROS and inhibiting intracellular antioxidant pathways.\nA novel protein encoded by circFOXP1 enhances ferroptosis and inhibits tumor recurrence in intrahepatic cholangiocarcinoma.\nFUNDC1 drives cholangiocarcinoma progression via RAC1 interaction and ferroptosis suppression.\n2',4'-dihydroxychalcone induces ferroptosis through ERO1A/GPX4 regulatory axis in cholangiocarcinoma."
    },
    "1795-2763": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Invasive Lobular Carcinoma",
      "text": ""
    },
    "1795-2269": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "Nonsmall cell lung cancer (NSCLC)",
      "text": ""
    },
    "39-1795": {
      "type": "slc_pathway",
      "key1": "SLC5A2",
      "key2": "proliferation",
      "text": "After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (P < 0.05).\nFurthermore, our data reveal that the knockdown of SGLT2 using siRNA inhibits cell proliferation and impedes cell cycle progression.\nSodium-glucose co-transporter-2 [SGLT2, also known as solute carrier family 5 member 2 (SLC5A2)] is an oncogene that promotes tumorigenesis.\nAfter the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (P < 0.05).\nCollectively, data suggest that miR‑296‑5p not only inhibits NSCLC by downregulating SGLT2 expression, but also acts as a novel regulator of aberrant lung cancer cells to limit lung cancer progression.\nWe tested the ability of two inhibitors of the glucose transporters GLUT/SLC2A superfamily, indinavir (IDV) and ritonavir (RTV), and of one inhibitor of the Na/glucose antiporter type 2 (SGLT2/SLC5A2) superfamily, phlorizin (PHZ), in decreasing glucose consumption and cell proliferation of human and murine glioblastoma cells.\nRTV treatment but not IDV treatment induced AMP-activated protein kinase (AMPKα) phosphorylation that paralleled the decrease in glycolytic activity and cell growth.\nWe found in vitro that RTV, active on at least three different GLUT/SLC2A transporters, was more effective than IDV, a specific inhibitor of GLUT4/SLC2A4, both in decreasing glucose consumption and lactate production and in inhibiting growth of U87MG and Hu197 human glioblastoma cell lines and primary cultures of human glioblastoma."
    },
    "292-1796": {
      "type": "slc_pathway",
      "key1": "SLC27A6",
      "key2": "ferroptosis",
      "text": ""
    },
    "120-1800": {
      "type": "slc_pathway",
      "key1": "SLC12A6",
      "key2": "migration",
      "text": "In neurons, the regulation of intracellular Cl(-) concentration ([Cl(-) ](i) ) is mediated by NKCC1 and KCC2 transporters: NKCC1 increases while KCC2 decreases [Cl(-) ](i) .\nOnce in the cortex, upregulation of the potassium-chloride cotransporter KCC2 is both necessary and sufficient to reduce interneuron motility through its ability to reduce membrane potential upon GABA(A) receptor activation, which decreases the frequency of spontaneous intracellular calcium transients initiated by L-type voltage-sensitive calcium channel (VSCC) activation.\nWe found that, during migration into the cortex, ambient GABA and glutamate initially stimulate the motility of interneurons through both GABA(A) and AMPA/NMDA receptor activation.\nFurthermore, BPA evoked increase in tangential interneuron migration and increased chloride in migrating neurons.\nIn addition, insulin-like growth factor 1 (IGF-1)-induced cell migration and invasiveness were significantly increased by overexpression of KCC2.\nWe constructed two SLC12A5 overexpression cell lines to verify the function of SLC12A5 that suppressed tumour cell proliferation and migration in vitro.\nKCC2-induced cell migration and invasion were not dependent on KCC2 transport function since overexpression of an activity-deficient mutant KCC2 still increased IGF-1-induced cell migration and invasion.\nBoth pharmacological and genetic manipulations revealed that NKCC1 maintains high [Cl-]i and regulates the resting membrane potential of migratory neuroblasts whilst its functional expression is strongly reduced at the time cells reach the GCL.\nMoreover, overexpression of KCC2 significantly diminished the number of focal adhesions, while knockdown of KCC2 increased their number.\nOverexpression of KCC2 had no significant effect on cell proliferation but dramatically suppressed cell spreading and stress fibre organization, while knockdown of KCC2 showed opposite effects.\nTime-lapse video imaging of organotypic cultures treated with either drug, shows a significant increase in the average speed, step size, an"
    },
    "1799-2087": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Glioblastoma (GBM)",
      "text": "transcription factor homeobox A3 (HOXA3), which is aberrantly highly expressed in glioblastoma (GBM) patients and predicts poor prognosis, transcriptionally activates aerobic glycolysis, leading to a significant acceleration in cell proliferation and tumor growth.\nwe identify hexosaminidase B (HEXB) as a key regulator for glycolysis in glioblastoma (GBM).\nmiR-21-5p directly binds to the mRNA of PDHA1 and downregulates its transcription, thereby promoting GBM glycolysis.\niPA reduced the expression of pyruvate kinase M2 (PKM2), which plays a key role in the regulation of aerobic glycolysis, promoting tumor cell proliferation.\nMBNL1, circNTRK2, and NTRK2-243aa were markedly downregulated and inhibited glycolysis in GBM, whereas PAX5 was upregulated and promoted glycolysis.\nThe metabolomic profiles of the PAM-treated U251SP cells were changed significantly with inhibition of the glycolysis pathway and with enhancement of the pentose phosphate pathway.\nDensely-plated glioma cells increase oxygen consumption, aerobic glycolysis, and the pentose phosphate pathway to synthesize cholesterol, resulting in a decrease in reactive oxygen species, TCA cycle intermediates, and ATP.\nextracellular CypB can bind to the CD147 receptor, activate p-AKT, upregulate HIF-1α and DRP1 in order to promote glycolysis while inhibiting mitochondrial function to adapt to the Gln-deprived microenvironment.\nmiR-143 is significantly down-regulated in glioma tissues and glioblastoma stem-like cells (GSLCs), while miR-143 over-expression inhibits glycolysis by directly targeting hexokinase 2, and promotes differentiation of GSLCs.\nhypomethylation of the CpG island in the promoter region of U3 led to the upregulation of U3 expression in IDH1 GBM cells, and the knockdown of U3 suppressed aerobic glycol"
    },
    "1802-2539": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Hepatic ischemia-reperfusion (I/R)",
      "text": ""
    },
    "368-1798": {
      "type": "slc_pathway",
      "key1": "SLC38A2",
      "key2": "stemness",
      "text": "SNAT2/SLC38A2 Confers the Stemness of Gastric Cancer Cells via Regulating Glutamine Level.\nPWAR6 promotes immune evasion by inhibiting NRF2 degradation through competitive binding with Keap1, thereby upregulating SLC38A2 expression, which enhances glutamine uptake in CRC cells and depletes glutamine availability for NK cells.\nNotably, SNAT2-mediated promoting effects on GC cell stemness were rescued by Gln deprivation.\nSNAT2 can promote the stemness of GC cells in a Gln-dependent manner.\nSNAT2 overexpression significantly increased the Gln consumption in GC cells and increased the expression of stemness markers, sphere-formation ability and ALDH activity.\nThe Gln transporter SNAT2 was highly expressed in GC spheres compared to that in the parental GC cells.\nIn vivo and in vitro assays confirmed PWAR6's roles in CRC cell stemness, migration, and glutamine uptake.\nWhat's more, high expression of SNAT2 was associated with a poor GC patient survival through different online datasets."
    },
    "1795-2105": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "cancer tissues",
      "text": "These findings reveal a novel mechanism of KGF action: an initial disruption of TEC-mediated signaling that transiently impairs early thymocyte differentiation, followed by enhanced proliferation and long-term thymic recovery.\nThis early block is characterized by an increased expansion of uncommitted thymocytes and is driven by KGF-induced alterations in both cortical and medullary thymic epithelial cells (TECs).\nIn numerous studies, the involvement of decorin is not restricted to matrix structural proteins, and it also affects a diverse variety of biological functions like cell growth, adhesion, migration, proliferation and differentiation.\nKGF suppresses Wnt/β-catenin signaling by downregulating distinct Wnt ligands in cTECs and mTECs, leading to reduced expression of FOXN1, a master regulator of TEC differentiation.\nDecorin activation enhanced ITGB1 expression (+46.7% vs. NC, p < 0.01).\nsi-ITGB1 suppressed the expression of p-S473-Akt and p-Ser2448-mTOR in NOR-10 cells with Dcn overexpression.\nThe comprehensive results show that decorin plays a sarcoprotective role by activating the ITGB1/Akt/mTOR pathway and may serve as a potential therapeutic reagent in age-associated sarcopenia.\nIn terms of the underlying mechanisms, the Akt/mTOR signalling pathway was downregulated in Dcn-D-gal mice compared with aged Dcn-D-gal mice.\nsi-Dcn promoted the expression of α-SMA (+37.2%) and fibronectin (+53.1%), which are related to muscle fibrosis in D-gal-induced NOR-10 cells."
    },
    "326-1795": {
      "type": "slc_pathway",
      "key1": "SLC35A2",
      "key2": "proliferation",
      "text": "Knockdown of SLC35A2 could reduce BRCA cell proliferation, motility, and cause G2/M arrest and cell apoptosis via ERK signaling.\nFunctional experiments demonstrated that SLC35A2 silencing inhibited the proliferation, migration, and invasion of BC cells, affecting their metastatic potential through modulation of the Wnt/β-catenin/EMT signaling pathway.\nDifferent BC cell lines were used in experiments, and the roles of SLC35A2 in cell proliferation, invasion, and migration was assessed through gene silencing and functional assays.\nOur research substantiates that SLC35A2 exerts a notable influence on mitochondrial autophagy in osteosarcoma, thereby exerting cascading effects on the proliferation, migration, invasion, and apoptosis of osteosarcoma cells.\nHere, we report that SLC35A2 promotes BRCA progression by activating extracellular signal regulated kinase (ERK).\nFurthermore, our CRC cell models revealed the tumor-promoting role of SLC35A2 and discovered that the upregulation of SLC35A2 is associated with chemoresistance against irinotecan.\nIn conclusion, AC074117.1/hsa-let-7b-5p axis-mediated high expression of SLC35A2 acts as a tumor promoter in BRCA via ERK signaling, which provides a potential target for BRCA treatment.\nHere we showed that glucose has the ability to induce lactose synthesis in dairy cow mammary epithelial cells, as well as increase cell viability and proliferation.\nIn vitro, 12 mM glucose enhanced lactose content, along with the expression of genes involved in glucose transportation and the lactose biosynthesis pathway, including GLUT1, SLC35A2, SLC35B1, HK2, β4GalT-I, and AKT1.\nIn addition, we found that AKT1 knockdown inhibited cell growth and lactose synthesis as well as expression of GLUT1, SLC35A2, SLC35B1, HK2, and β4GalT-I."
    },
    "1795-2234": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "breast invasive carcinoma (BRCA)",
      "text": ""
    },
    "1796-2627": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Oral squamous cell carcinoma",
      "text": ""
    },
    "1802-2137": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "hearts suffered ischemia/reperfusion (I/R)",
      "text": "Furthermore, recently identified mechanisms of mitochondrial regeneration can increase the capacity for oxidative phosphorylation, decrease oxidative stress and might help to beneficially impact myocardial remodeling, as well as invigorate the heart against subsequent ischemic insults.\nPharmacologic cardiac conditioning increases the intrinsic resistance against ischemia and reperfusion (I/R) injury."
    },
    "1794-1828": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Testicular Cancer",
      "text": ""
    },
    "13-1802": {
      "type": "slc_pathway",
      "key1": "SLC2A5",
      "key2": "oxidative phosphorylation",
      "text": "In gene expression analyses, oxidative phosphorylation, glycolysis, and protein secretion were upregulated in patients with TP53 and/or RB1 alterations.\nIn the brain, microglia predominantly express the fructose transporter SLC2A5 (GLUT5), and enzymes involved in fructolysis and endogenous fructose production, with their expression being upregulated in aging and disease.\nWhile homeostatic microglia are driven by oxidative phosphorylation (OXPHOS) and glycolysis, in aging and AD, microglia shift further towards glycolysis.\nOther pathways, including the TCA cycle, oxidative phosphorylation, and Parkinson's and Huntington's disease, were highly enriched by hypoxia in male fish, suggesting that mitochondrial function was dysregulated.\nMulti-omics suggested that SLC2A5, CD209, LGMN, and NEDD8 served as sex-specific markers in these fish under chronic hypoxia."
    },
    "313-1799": {
      "type": "slc_pathway",
      "key1": "SLC31A1",
      "key2": "glycolysis",
      "text": "In summary, ARNTL2 facilitates the progression of BLCA via activating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner.\nUp-regulation of SLC31A1, ENO1, and enhancement of SLC31A1-mediated ENO1 activity were critical for ARNTL2-triggered glycolysis and malignant growth in BLCA cells.\nDepletion of SLC31A1 and inhibition of glycolysis completely blunted the growth ability of BLCA cells.\nInhibiting SLC31A1 and glycolysis may be an aspirational approach for the treatment of BLCA patients with overexpression of ARNTL2.\nFibroblast-specific SLC31A1 deficiency enhances mitochondrial copper depletion, augments glycolysis, promotes fibroblast proliferation and triggers CF.\nOverexpression of ARNTL2 facilitates the proliferation and tumorigenesis of BLCA cells through suppression of apoptosis and enhancement of glycolysis.\nFurthermore, FX decreases whole‑cell ATP levels, which indicates that promotion of glycolysis does not compensate for FX‑induced ATP depletion in mitochondria.\nThese changes were associated with mitochondrial copper depletion, enhanced glycolysis, and CF.\nFX switches mitochondrial respiration to aerobic glycolysis in PC cells.\nTargeted deletion of CTR1 in neuroblastoma cells produced copper deficiency that was associated with a metabolic shift favoring glycolysis over oxidative phosphorylation.\nARNTL2 was positively correlated with SLC31A1 and ENO1 in BLCA patients.\nLower copper concentrations are accompanied by SLC31A1 down-regulation and mitochondrial copper depletion in CF."
    },
    "1799-2365": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Neuroblastoma (NBM)",
      "text": ""
    },
    "90-1802": {
      "type": "slc_pathway",
      "key1": "SLC9A1",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1797-2154": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "preeclampsia (PE)",
      "text": "Preeclampsia (PE) pathogenesis is strongly related to diminished nitric oxide (NO) bioavailability and enhanced oxidative stress.\nPreeclampsia (PE) is a pregnancy-specific disorder characterized by placental dysfunction, immune activation, and oxidative stress.\nHydroxychloroquine treatment activated the PI3K/AKT/mTOR pathway and inhibited excessive autophagy to ameliorate oxidative stress injury, and these effects were attenuated after application of the PI3K inhibitor LY294002.\nKLF15 overexpression promoted the proliferation and metastasis, and suppressed oxidative stress and cell apoptosis of H/R-induced HTR8/SVneo cells through mediating the PI3K/Akt pathway, which may provide a promising target for the treatment of preeclampsia.\nactivation of the microdomain-confined signaling pathway with an agonist for the eNOS-coupled β3-AR eliminates inhibitory glutathionylation of the Na-K pump's β1 subunit, uncoupling of eNOS, and activation of NADPH oxidase that are sources of H/R-induced oxidative stress.\nIn vitro experiments showed that hypoxia promoted SIRT3 expression, while oxidative stress inhibited SIRT3 expression in HTR-8/SVneo cells.\nReduced CD34 levels were found to exacerbate endothelial oxidative stress and induce inflammation-related endothelial pyroptosis in the placenta.\nKLF15 overexpression increased H/R-induced HTR8/SVneo cell proliferation, invasion and migration, and inhibited oxidative stress and cell apoptosis.\nPreeclampsia (PE) is a severe hypertensive pregnancy disorder characterized by endothelial dysfunction, placental ischemia and oxidative stress;\nOxidative stress induced by tumor necrosis factor α increased soluble fms-like tyrosine kinase receptor 1 (sFlt-1) trophoblast release, a marker of preeclampsia, and reduced trophoblast integration into endothelial cellular networks.\nin an LPS-induced rat model of inflammation-driven PE, NR administration (200 mg"
    },
    "21-1800": {
      "type": "slc_pathway",
      "key1": "SLC2A13",
      "key2": "migration",
      "text": ""
    },
    "63-1800": {
      "type": "slc_pathway",
      "key1": "SLC6A14",
      "key2": "migration",
      "text": "Upregulated SLC6A14 expression promoted glutamine catabolism and enhanced BC cell proliferation, migration, and invasion.\nFunctionally, we confirmed that SLC6A14 was highly expressed in PC and its knockdown suppressed the proliferation, migration, invasion and EMT signal via regulating Wnt/β-catenin signaling pathway.\nFurther knockdown SLC6A14 with siRNA or treatment with α-MT in CRC cell lines reduced cell proliferation and migration in vitro and inhibited xenograft tumor growth in vivo.\nMost importantly, pharmacological blockade and gene silence of SLC6A14 both restricted epithelial-mesenchymal transition- (EMT-) driven GC metastasis, in which attenuated activation of the PI3K/AKT/mTORC1 pathway caused by amino acid starvation was involved.\nIn particular, most significant change with a dampening trend in the migration potentiality of GC cells emerged after SLC6A14 gene was silenced.\nSLC6A14 expression was positively correlated with the migrated capability of different GC cell lines, and SLC6A14 was also constitutively expressed in GC patients with venous or lymphatic invasion, lymph node, or distant metastasis and poor prognosis, thus prompting SLC6A14 as a nonnegligible presence in supporting GC migration and invasion.\nSLC6A14 may promote PC progression via modulating Wnt/β-catenin signaling.\nUpregulates SLC6A14 transcription and glutamine catabolism, thereby promoting BC growth and metastasis.\nConsistently, SLC6A14 depletion drastically depressed GC metastasis and.\nIn summary, it is conceivable that targeting SLC6A14 has a tremendous promising for the treatment of metastatic GC.\nHypoxia-induced PYCR1 enhances glycolysis, leading to increased lactate production and elevated H3K18la levels, which upregulates SLC6A14 transcription and glutamine catabolism, thereby promoting BC growth and metastasis."
    },
    "1800-2557": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "malignt cancers",
      "text": ""
    },
    "232-1795": {
      "type": "slc_pathway",
      "key1": "SLC25A11",
      "key2": "proliferation",
      "text": "Loss of OGC promoted cell proliferation and migration through Slug-mediated EMT.\nOGC silencing aggravated EMT, while overexpression attenuated TGF-β2-induced EMT, cell proliferation, and migration.\nOGC knockdown significantly enhanced RPE EMT, as evidenced by upregulated expression of α-SMA, fibronectin, collagen type I, and Slug, while E-cadherin was downregulated.\nOGC depletion stimulated EMT via pSmad2/3 upregulation, dependent on the PI3K/AKT signaling pathway activation.\nIn vivo studies further demonstrate that subretinal fibrosis was significantly augmented in OGC mice via TGF-β2-dependent PI3K signaling.\nOGC overexpression improved mitochondrial bioenergetics, whereas its inhibition reduced mitochondrial respiration, which was further aggravated by co-treatment with TGF-β2.\nPT cells from NPX rats that were first preincubated with GSH were protected from cytotoxicity due to the mitochondrial inhibitor antimycin A by overexpression of either of the two mitochondrial GSH transporters.\nOur previous studies showed that overexpression of two mitochondrial anion transporters, the dicarboxylate (DIC, Slc25a10) and oxoglutarate (OGC, Slc25a11) carriers, in NRK-52E cells resulted in increased mitochondrial uptake of glutathione (GSH) and protection from chemically induced apoptosis.\nCompensatory renal hypertrophy following reduction in renal mass leads to a hypermetabolic state and increases in basal mitochondrial oxidative stress and susceptibility to several nephrotoxicants.\nEpithelial-to-mesenchymal transition (EMT) in RPE cells is a key early step in subretinal fibrosis.\nThis study explores the role of oxoglutarate carrier (OGC; Slc25a11) on EMT and investigates the molecular mechanisms, focusing on its role in mitochondrial metabolism and GSH transport."
    },
    "290-1802": {
      "type": "slc_pathway",
      "key1": "SLC27A4",
      "key2": "oxidative phosphorylation",
      "text": "In mice, deficiency in one or both RabGAPs leads to reduced insulin- and contraction-stimulated glucose uptake and to elevated fatty acid (FA) uptake and oxidation in both glycolytic and oxidative muscle fibers without altering mitochondrial copy number and the abundance of proteins for oxidative phosphorylation."
    },
    "121-1795": {
      "type": "slc_pathway",
      "key1": "SLC12A7",
      "key2": "proliferation",
      "text": "HMG20A bound to the metastasis-specific enhancers of ADRM1 and SLC12A7, thereby promoting ADRM1 and SLC12A7 expression.\nSeventeen metastasis-specific enhancer-controlled upregulated DNA repair-related genes, with the top two upregulated genes being ADRM1 26 S proteasome ubiquitin receptor (ADRM1) and solute carrier family 12 member 7 (SLC12A7) were screened.\nKnockdown of HMG20A enhanced cisplatin sensitivity of cells, and inhibited OSCC cells from repairing DNA damage caused by cisplatin, as well as proliferation and invasion of OSCC cells.\nDNA repair was positively associated with the OSCC metastatic phenotype."
    },
    "396-1800": {
      "type": "slc_pathway",
      "key1": "SLC41A2",
      "key2": "migration",
      "text": "By inhibiting the ubiquitin-proteasome degradation of GSK3β, SLC41A2 can significantly upregulate the expression of GSK3β, which ultimately suppresses the proliferation and migration of colon cancer cells.\nFurthermore, elevated expression of SLC41A2 notably decreased the proliferation, migration and invasion of colon cancer cells, along with increased apoptosis.\nBy transfecting plasmids or siRNA to overexpress or knock down SLC41A2 in colon cancer cells, the effects of SLC41A2 on colon cancer cell proliferation, migration, and apoptosis were detected through EdU, MTT, wound-healing, Transwell, and JC-1 experiments.\nThe overexpression of SLC41A2 and rescue experiments confirmed that SLC41A2 enhances the protein stability of GSK3β by inhibiting its ubiquitin-proteasome degradation and causes the upregulation of GSK3β, thereby suppressing the progression of colon cancer."
    },
    "1794-1821": {
      "type": "pathway_disease",
      "key1": "chemotherapy resistance",
      "key2": "Germ Cell Tumor",
      "text": ""
    },
    "53-1801": {
      "type": "slc_pathway",
      "key1": "SLC6A3",
      "key2": "apoptosis",
      "text": "In conclusion, our findings suggest that scoulerine may induce apoptosis in RCC by targeting SLC6A3 and inhibiting the activation of the MAPK signaling pathway, thereby positioning it as a promising natural compound for potential future RCC treatment.\nUnexpectedly, RSB protected PC12 cells from oxidative stress induced by H2O2 via inhibiting autophagy and apoptosis.\nIn addition, scoulerine inhibited the viability of 769-P and 786-O cell lines in a time-dependent and dose-dependent manner, and promoted the level of apoptosis associated with B-cell lymphoma-2 associated X protein (Bax).\nThe results showed that EUMF significantly rescued the dyskinesia of zebrafish and inhibited Aβ deposition, Ache activity, and occurrence of cell apoptosis in the head of zebrafish induced by AlCl.\nMoreover, the administration of scoulerine resulted in a significant suppression of the mitogen activated protein kinase (MAPK) signaling pathway.\nMechanistically, quercetin activated the Nrf2/STAT3 signaling pathway, promoting nuclear translocation of Nrf2 and transcriptional upregulation of the dopamine transporter gene SLC6A3.\nThe results of our study indicate a significant affinity between scoulerine and SLC6A3, with competitive inhibition of this interaction leading to a reduction in the inhibitory impact of scoulerine on RCC cell viability.\nFurthermore, DA at a high concentration induced apoptosis in PCOS-derived GCs.\nDA, in the concentration range found in follicular fluid, did not induce apoptosis of cultured GCs.\nAn increase in apoptosis-related genes expression (casp8, casp9 and casp3) was observed in the MPs exposed group.\nQuercetin significantly reduced cerebral edema, improved neurological function, and inhibited neuronal apoptosis following MCAO.\nMatrine treatment in this model resulted in significant improvements in neurological function, reductions in brain damage, and marked decreases in oxidative stress and apoptosis.\nThe GDGSHJ formulation reduced Lactate Dehydrogenase (L"
    },
    "1798-2050": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Wilms Tumor",
      "text": ""
    },
    "1795-2404": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "triple-negative breast cancer(TNBC)",
      "text": "CAPN-1 promoted cancer cell survival and negatively regulated CAPN-2 at both the protein and mRNA levels, whereas CAPN-2 suppressed proliferation.\nIn vitro, LINC02544 silencing via exo/si-LINC02544 reduced CAPRIN1 levels, upregulated miR-497-5p, and inhibited TNBC cell proliferation and migration.\nUSP33 was significantly downregulated in TNBC tissues and cell lines, correlating with enhanced proliferation, migration, and epithelial-mesenchymal transition.\nBy inhibiting FAK activation and upregulating PIK3IP1, Ifebemtinib and paclitaxel blocked the PI3K/Akt pathway, effectively suppressing TNBC proliferation and metastasis.\nIn vitro, FGF4 activated IL6/STAT3 signaling, inducing macrophage polarization to an M2 phenotype with elevated IL-10/TGF-βsecretion and suppression of T cell proliferation.\nSpecifically, the combination therapy inhibits FOXC2-driven EMT and induces ferroptosis via the FOXC2-Hippo signaling axis, suppressing tumor proliferation, migration, and invasion.\nThese limit metastasis, induce apoptosis, inhibit proliferation, and reverse chemoresistance by altering vital pathways like PI3K/AKT/ mTOR, MAPK/ERK, NF-κB, JAK/STAT, and Wnt/β-catenin.\nTAS-115 significantly reduced cell proliferation and viability, enhanced apoptosis, and suppressed c-mesenchymal-epithelial transition/hepatocyte growth factor and PI3K/Akt/mTOR signaling.\nThe PLGA nanoparticles loaded with MP-1 targeted the PD-L1 effectively and modulated the Molecular Pathways related with EMT which inhibit tumor cell proliferation and enhance their apoptosis.\nPE32 can effectively inhibit the proliferation and migration of TNBC cells, and can induce PANoptosis in TN"
    },
    "1796-2154": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "preeclampsia (PE)",
      "text": "BTN3A2 interacted with MFGE8 to alleviate PE by promoting ferroptosis and inhibiting angiogenesis.\nBTN3A2 was increased in PE placentae and inhibited the viability of hypoxic HUVECs by inducing ferroptosis.\nKnockdown of METTL3 increased cell viability and suppressed ferroptosis in hypoxia-stimulated trophoblasts.\nRosiglitazone intervention reverses hypoxia-induced trophoblast ferroptosis and decreases lipid synthesis by regulating Nfr2 and SREBP1.\nCell viability, invasion, and migration were notably decreased, but ferroptosis was markedly enhanced in hypoxia-treated HTR-8/SVneo cells.\nUSP7-mediated NRF2 deubiquitination stabilizes NRF2 and activates the xCT/GPX4 pathway, suppressing trophoblast ferroptosis in the setting of PE.\nPue ameliorated PE-like symptoms in mice by repressing trophoblast ferroptosis via inhibition of CREB signalling and affecting the Homx1 promoter.\ndown-regulation of WTAP promotes PE progression through m6A-dependent ferroptosis regulation.\nMetformin treatment obviously attenuated PM2.5-induced inhibition of proliferation, migration, invasion, and angiogenesis of the cells, and effectively reversed PM2.5-induced ferroptosis in the trophoblasts as shown by significantly increased intracellular GSH level and SOD activity, reduced MDA and Fe levels, and upregulated GPX4 and SLC7A11 protein expression\nUSP46 interacts with CIRBP to reduce its ubiquitination and stabilize its expression, thereby promoting ferroptosis.\nNOC2L knockdown exacerbated the hypoxia-induced increase in ferroptosis and inhibited cell migratory and invasive capabilities.\nInhibition of MLL1 improved PE symptoms in mice, repressed ferroptosis in placental tissues, and inhibited Erastin-induced ferroptosis in vitro."
    },
    "1796-2269": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "Nonsmall cell lung cancer (NSCLC)",
      "text": "SLC3A2 deficiency facilitated ferroptosis through upregulating the expression of mTOR and P70S6K, whereas inhibited p-mTOR and p-P70S6K expression in laryngeal carcinoma cells.\nRBM15 promoted KDM5B expression, and KDM5B upregulation inhibited ferroptosis and promoted DDP resistance in LC by downregulating FER1L4 and upregulating GPX4, as well as by upregulating KCNQ1OT1 and inhibiting ACSL4.\nDUOX1 could inhibit the expression levels of ferroptosis-related genes GPX4 and F1H1 in LSCC cells DUOX1 inhibited the expression levels of ROS and ferroptosis-related genes GPX4 and F1H1 and increased intracellular iron content in LSCC cells, but ZC3H13 reversed this phenomenon by inhibiting DUOX1 gene through m6A methylation modification.\nIn ferroptosis-induced laryngeal cancer cells, the cell viability, migration rate, invasion ability, and the expression of glutathione peroxidase 4, glutathione, and superoxide dismutase were further decreased and the expression of cyclooxygenase 2, Acyl-CoA synthetase long-chain family member 4, iron ions, and malondialdehyde were further increased after silencing KPNA2.\nKDM5B/KCNQ1OT1 overexpression or FER1L4 knockdown promoted DDP resistance in LC by inhibiting ferroptosis.\nFurthermore, knockdown of SLC3A2 expression induced the efficacy of ferroptosis and suppressed ferroptosis related proteins expression.\nZC3H13 reduced DUOX1-mediated ferroptosis in LSCC cells through m6A-dependent modification.\nDown-regulation of KPNA2 can promote ferroptosis in laryngeal cancer by stimulating the FoxO signaling pathway.\nMechanistic studies reveal that dauricine, when combined with osimertinib, efficiently induces ferroptosis in resistant lung cancer cells."
    },
    "1801-2532": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Pulmory arterial hypertension (PAH)",
      "text": "Nevertheless, it is unclear whether the hypoxia-induced inhibition on PASMC apoptosis is mediated by BVR.\nTherefore, we hypothesized that 5-HT may be the promoter of decreased apoptosis in PAH through the 5-HT2A receptor.\nIn conclusion, EPC-Exos suppress cell viability, proliferation, and migration and promote apoptosis in PASMCs under hypoxic conditions.\nOur results indicate that IPR2 may inhibit the progression of PAH by promoting apoptosis and inhibiting SOCE via the STIM-Orai pathway in PASMCs.\nSAA ameliorates the pulmonary arterial remodeling in MCT-induced PAH rats most likely via activating the BMPRII-Smad pathway and inhibiting apoptosis.\nThe present study is aimed to assess whether PPARγ is involved in 5-HT induced PASMC proliferation and apoptosis inhibition and the possible mechanism.\nAt present, we found that hypoxia can up-regulate the expression of mitophagy protein PINK1/Parkin, induce the proliferation of PASMCs, and inhibit apoptosis.\nThese results demonstrate that miR-29b suppressed cellular proliferation and promoted apoptosis of PASMCs, possibly through the inhibition of Mcl-1 and CCND2.\nMoreover, inhibiting the Hippo/LATS1/Yap pathway with XMU-MP-1 blocked apoptosis in pulmonary vascular cells induced by ACE2 activation during the prevention of PAH.\nMSC-mediated apelin gene therapy effectively reduced pulmonary artery pressure, mitigated pulmonary vascular remodeling, and modulated apoptosis in MCT-induced PAH rats.\nCordycepin may activate the P53-P21 pathway to inhibit abnormal proliferation and migration of PASMC and promote apoptosis, offering a potential approach for PAH treatment.\nFGF21 may attenuate the hypoxia‑induced apoptosis and dysfunction of HPAECs through alleviating ERS, via the PERK/CHOP signaling pathway and inhib"
    },
    "1800-2209": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "acute lymphoblastic leukemia (ALL)",
      "text": ""
    },
    "1802-1900": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "lymphoma",
      "text": ""
    },
    "1800-1839": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "bladder cancer",
      "text": "COL6A1 downregulation inhibited bladder cancer cell proliferation, invasion, and migration and induced cell apoptosis.\nInterestingly, downregulation of SVIL by SVIL-specifc small hairpin RNAs significantly reduced the promoting effect of CRH on bladder cancer cell migration.\nHigh expression of miR-204-5p promotes proliferation, migration and invasion and reduces apoptosis of bladder cancer cells by negatively regulating RAB22A expression.\nBoth CAPE-induced GDF15 expression and the supernatant from bladder cancer cells with overexpressing GDF15 impeded the HBdSF and HBdSMC migration, suggesting that CAPE-upregulated GDF15 blocked the cell migration.\nIncreased CELF2 expression suppressed the proliferation and migration of bladder cancer cells.\nSRT1720 treatment also suppressed bladder cancer cells migration, invasion and induced apoptosis.\nRo-31-8220 treatment suppressed bladder cancer cell migration and invasion and also induced cell apoptosis in a dose-dependent manner.\nIn bladder cancer cells, miR-204-5p overexpression significantly promoted cell proliferation, migration and invasion and reduced cell apoptosis.\nMoreover, PLACS NPs simultaneously activated the expression of four target genes, inhibiting proliferation and migration, and promoting apoptosis in bladder cancer cells.\nRB1 mutations and the 4-aminobiphenyl interference could significantly decrease the RB1 expression level and thus promote the proliferation, invasion, and migration ability of bladder cancer cells.\nOverexpression of CK17 promoted the proliferation, migration and invasion abilities of bladder cancer cells 5637, and silencing of CK17 inhibited the proliferation, migration and invasion abilities of bladder cancer cells T24.\nSubsequently, CCK8, clone formation assay and Transwell result showed Curdione enhances GEM inhibition of bladder cancer cell activity, clonal formation and migration, these combine therapeutic schedule also could inhibited growth of in vivo xenograft tumors.\nFunctional experiments revealed that hypoxia-induced bladder cancer cell migration through up-regulating VASN."
    },
    "226-1801": {
      "type": "slc_pathway",
      "key1": "SLC25A5",
      "key2": "apoptosis",
      "text": "Moreover, SLC25A5-AS1 could inhibit GC cell proliferation, induce G1/G1 cell cycle arrest and cell apoptosis in vitro, as well as GC growth in vivo.\nAts-1 targeted translocation to the mitochondria where it up-regulated the expression of NDUFB5, NDUFB3, NDUFS7, COX6C, and SLC25A5, thereby enhancing energy production and inhibiting HEK293T cells apoptosis while enhancing HEK293T cells proliferation, and ultimately facilitating Anaplasma phagocytophilum replication in HEK293T cells.\nExperimental validation demonstrated that SLC25A5 enhanced the proliferative, migratory, invasive, and osteolytic properties of drug-resistant osteosarcoma cells while reducing apoptosis, intensifying cisplatin resistance.\nDual-luciferase reporter assay confirmed the direct interaction between SLC25A5-AS1 and miR-19a-3p, rescue experiment showed that co-transfection miR-19a-3p mimics and pcDNA-SLC25A5-AS1 could partially restore the ability of GC cell proliferation and the inhibition of cell apoptosis.\nSLC25A5 attenuated cell proliferation, upregulated the expression of programmed cell death-related signatures, and exerted its biological function by inhibiting the MAPK signaling pathway.\nPhyllanthin inhibited the malignant phenotype of cisplatin-resistant osteosarcoma cells and enhanced their sensitivity to cisplatin by suppressing SLC25A5 expression.\nTaken together, this study indicated that SLC25A5-AS1 was down-regulated in GC and functioned as a suppressor in the progression of GC.\nAfter intracellular expression of Ats-1, adenosine triphosphate levels and the proliferation of HEK293T cells were both up-regulated, while HEK293T cells apoptosis was inhibited.\nThis study demonstrated that Anaplasma phagocytophilum Ats-1 induces anti-apopt"
    },
    "11-1799": {
      "type": "slc_pathway",
      "key1": "SLC2A3",
      "key2": "glycolysis",
      "text": "Additionally, METTL14 restrains aerobic glycolysis in p53-WT CRC, by repressing SLC2A3 and PGAM1 expression via selectively promoting m A-YTHDF2-dependent pri-miR-6769b/pri-miR-499a processing.\nDNMT1-driven methylation of RORA promotes ESCC progression largely through affecting SLC2A3 transcription and glycolysis.\nWe then investigated the consequences of SLC2A3 upregulation or inhibition on aerobic glycolysis, also explored the underlying mechanism.\nSLC2A3 activates the TGF-β signaling pathway through lactic acid generated from glycolysis, thus regulating the biological behavior of OSCC.\nFurthermore, rescue experiments revealed that RORA-mediated suppressive effects on ESCC cell migration and invasion were largely based on its negative regulation of SLC2A3 and glycolysis.\nSLC2A3 is frequently upregulated in various tumors, playing a pivotal role in aerobic glycolysis and thereby furnishing vital energy for tumor sustenance and malignant advancement, particularly in adverse conditions.\nHere we found that the transcription factor Bcl-6 directly repressed genes encoding molecules involved in the glycolysis pathway, including Slc2a1, Slc2a3, Pkm and Hk2, in type 1 helper T cells (TH1 cells) exposed to low concentrations of interleukin 2 (IL-2).\nWe hypothesize that during regeneration, cells use leptin, slc2a3, proinsulin, g6pd, hif1α expression, receptor tyrosine kinase (RTK) signaling, and the production of reactive oxygen species (ROS) to promote glucose entry into glycolysis and the pentose phosphate pathway (PPP), thus stimulating macromolecular biosynthesis.\nHere, we show that SLC2A3 acts as a tumor promoter and accelerates aerobic glycolysis in GC cells.\nWe also found that oral squamous cell carcinoma cells had increased proliferation, migration, invasion, EMT phenotype, and glycolysis due to SLC"
    },
    "381-1802": {
      "type": "slc_pathway",
      "key1": "SLC39A4",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1800-1811": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Osteosarcoma(OS)",
      "text": "Silencing ISG15 restored pathway activation and reversed the inhibitory effect of EGR3 on OS cell migration.\nKIAA1429 depletion inhibited viability, migration, and invasion and promoted apoptosis of MG-63 and U2OS cells through suppression of the Nrf2/NQO1 signaling.\nAdditionally, PLEKHF1 overexpression inhibited OS cell viability, colony formation, migration, invasion, and epithelial-mesenchymal transition (EMT), while promoting apoptosis.\nIn vitro, VDC597 inhibited cellular viability, migration, and invasion, vascular endothelial growth factor production, and phosphorylation of signaling proteins, while promoting cell death.\nFunctional assays confirmed TNK2's role in cell proliferation, viability, and migration, and showed that TNK2 knockdown mitigated cycloheximide-induced proliferation inhibition, linking TNK2 to paraptosis regulation.\nThe results showed that TIMM23-induced M2 polarization upregulated TIMM23-PARGP1 expression in OS cells, thereby enhancing their proliferation, migration, and invasion while inhibiting apoptosis and reducing the effectiveness of chemotherapeutic agents.\nAIL exhibited a dose-and time-dependent inhibitory effect on U-2OS cell growth, significantly reducing cell proliferation and migration rates while promoting apoptosis.\nUsing PP2A inhibitor Endothall can abolish the dephosphorylation effect of HCAR1 on STAT1/2, inhibit cancer cell proliferation, migration, and cell cycle, and promote apoptosis.\nFunctional experiments demonstrated that silencing hsa_circ_0000253 or COL5A2 suppressed OS cell proliferation and migration, whereas inhibition of miR-7 enhanced these processes.\nKnocking down GPX8 expression inhibited the promoting effects of KLF16 overexpression on OS cell proliferation, invasion, and migration, whereas overexpressing GPX8 reversed the inhibitory effects of KLF16 knockdown on OS cell proliferation, invasion, and migration.\nAIL inhibited the proliferation of human OS cells and induced apopt"
    },
    "1796-2119": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "hepatocellular carcinoma (HCC)",
      "text": "This study indicated that SEH1L siliencing could induce ferroptosis and suppresses hepatocellular carcinoma (HCC) progression via ATF3/HMOX1/GPX4 axis.\nIn addition, the oxygen produced by the complexes improved the hypoxic microenvironment of hepatocellular carcinoma (HCC), synergistically downregulated HIF-1α expression in mitochondria, promoted mitochondrial-derived ferroptosis and enhanced the PDT effect of the MTTPY unit.\nMDH2 deficiency inhibits the growth of hepatocellular carcinoma (HCC) cells and enhances their sensitivity to ferroptosis induced by RAS-selective lethal 3 (RSL3), a compound known to cause ferroptosis.\nIn summary, our findings indicate that ACSM5 induces ferroptosis in hepatocellular carcinoma (HCC) by upregulating POR.\nThis study aimed to elucidate the mechanism by which ST induces ferroptosis in hepatocellular carcinoma (HCC), the combination effect with lenvatinib, and the impact on lenvatinib-resistant cells.\nIn advanced hepatocellular carcinoma (HCC), RNA helicase DDX5 regulates the Wnt/β-catenin-ferroptosis axis, influencing the efficacy of the multi-tyrosine kinase inhibitor (mTKI) sorafenib.\nHere, RBPs screening and integrating analyses identify major vault protein (MVP) as an oncogenic RBP in the occurrence of hepatocellular carcinoma (HCC) and sorafenib resistance via suppressing ferroptosis.\nTo isolate exosome-like nanovesicles from Salvia chinensis Benth (SCENs), and expire the mechanisms SCENs induce ferroptosis in hepatocellular carcinoma (HCC) in vivo and in vitro, thereby offering a novel therapeutic option for HCC.\nAs a common malignancy, hepatocellular carcinoma (HCC) proliferation and metastasis could be promoted by ferroptosis and cuproptosis."
    },
    "291-1794": {
      "type": "slc_pathway",
      "key1": "SLC27A5",
      "key2": "chemotherapy resistance",
      "text": ""
    },
    "1798-1853": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "ovarian cancer",
      "text": "Myeloid-derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p-STAT3 signalling pathway.\nThese results suggest that an estrogen-mediated E2F6 ceRNA network epigenetically and competitively inhibits microRNA-193a activity, promoting ovarian cancer stemness and tumorigenesis.\nOur findings suggested that GEN can inhibit the increased M2 polarization of macrophages and stemness of ovarian cancer cells by co-culture of macrophages with OCSLCs through disrupting IL-8/STAT3 signaling axis.\nE2F6 promotes ovarian cancer stemness, whereas E2F6 or EZH2 depletion derepressed miR-193a, which opposes cancer stemness, by alleviating DNA methylation and repressive chromatin.\nRNA sequencing results confirm that SMFs increased the oxidative stress level and reduced the stemness of ovarian cancer cells.\nInhibiting CPT1A's LSTase activity with Glyburide reduces OCSCs' stemness and enhances cisplatin's anti-tumor effects against ovarian cancer in vitro and in vivo.\nHOOK1 contributes to maintaining the tumorigenic and stemness properties of ovarian cancer cells by preserving protein homeostasis and could be considered an alternative therapeutic target, especially in combination with inducers of endoplasmic reticulum or proteotoxic stress such as proteasome inhibitors.\nHMGB3 promotes ovarian cancer malignant phenotypes and stemness through the MAPK/ERK signaling pathway.\nKLF5 enhances stemness and contributes to PARPi resistance in ovarian cancer through Vimentin regulation.\nThe downregulation of ALG3 decreased the proliferation, stemness and peritoneal metastasis of ovarian cancer cells.\nTargeting Gli may reduce the stemness of ovarian cancer cell, which may be achieved via indirect targeting of NANOG.\nCA-MSC activate ovarian cancer cell STAT3 signaling via IL6 and LIF and increase tumor cell stemness.\nHigh serum LDL uptake mediated by LDLR enhances EMT and stemness of"
    },
    "243-1797": {
      "type": "slc_pathway",
      "key1": "SLC25A22",
      "key2": "oxidative stress",
      "text": "SLC25A22 induces intracellular synthesis of aspartate, activation of mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signaling and reduces oxidative stress.\nAn increased ratio of oxidized nicotinamide adenine dinucleotide phosphate to reduced nicotinamide adenine dinucleotide phosphate induced oxidative stress and glutathione oxidation, which suppressed cell proliferation.\nKnockdown of SLC25A22 reduced aspartate biosynthesis, leading to apoptosis, decreased cell proliferation in KRAS mutant CRC cells.\nDecreased levels of oxaloacetate in cells with knockdown of SLC25A22 reduced regeneration of oxidized nicotinamide adenine dinucleotide and reduced nicotinamide adenine dinucleotide phosphate.\nKnockdown of SLC25A22 in KRAS mutant CRC cells reduced their proliferation, migration, and invasion in vitro, and tumor formation and metastasis in mice, compared with cells without SLC25A22 knockdown.\nIncubation of KRAS mutant CRC cells with knockdown of SLC25A22 with aspartate increased proliferation and reduced apoptosis, which required GOT1, indicating that oxaloacetate is required for cell survival.\nReduced oxidized nicotinamide adenine dinucleotide inhibited glycolysis and decreased levels of adenosine triphosphate, which inactivated mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signaling via activation of AMP-activated protein kinase."
    },
    "1797-1811": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "Osteosarcoma(OS)",
      "text": "Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo.\nFurthermore, we elucidate that the inhibition of STAT3 is mainly induced by ROS-mediated oxidative stress.\nOur findings revealed a wavelength- and time-dependent decrease in cell viability, accompanied by increased apoptosis and oxidative stress.\nWe also found that allicin promotes oxidative stress and autophagy to inhibit osteosarcoma growth by inhibiting the Wnt/-catenin pathway and .\nOverall, our findings demonstrate that GLA could exhibit potent anticancer effects through effectively blocking the STAT3 signaling pathway, which was induced by ROS-mediated oxidative stress in OS in vitro and in vivo.\nSilencing the ATG7 gene promoted the proliferation and migration in osteosarcoma cells, suppressing the oxidative stress and ferroptosis process.\nOur results also reveal the novel finding that knockdown of ATG5 protein reduces both basal oxidative stress and drug-induced oxidative stress.\nSignificantly, autophagy inhibition not only reduced CPT-induced oxidative stress but also reduced basal oxidative stress.\nAll data showed that allicin promotes oxidative stress and autophagy of osteosarcoma via the MALATI-miR-376a-Wnt/-catenin pathway.\nThis effect is achieved by growth inhibition and apoptosis induction, which is mediated by oxidative stress and damage, and mitochondrial dysfunction.\nThese actions may be mediated by oxidative stress induced by selenium compounds, leading to the activation of p53, proapoptotic proteins and caspases.\nOverall, we propose that LAMTOR5-AS1 globally regulates chemotherapy-induced cellular oxidative stress by controlling the expression and activity of NRF2.\nThe results suggest that oxidative stress induced by low-dose DOX promotes the invasiveness of osteosarcoma cell line U2OS in vitro, through MMP-9 induction.\nIn conclusion, this work demonstrates that lncRNA-XIST promotes the oxidative stress-induced OS cell invasion, migration, and EMT through the miR-"
    },
    "1802-1806": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Brain Tumor",
      "text": "Using single-cell transcriptomics, we find that Drosophila brain tumors contain a rapidly dividing stem cell population defined by upregulation of oxidative phosphorylation (OxPhos).\nHere, we show that heterozygous Kmt2d loss in murine cerebellar regions promotes MB genesis driven by heterozygous loss of the MB-suppressor gene Ptch via the upregulation of tumor-promoting programs (e.g., oxidative phosphorylation [OXPHOS]).\nThe accumulation of mitochondrial mass and the optimization of mitochondrial quality accounted for the increased oxidative phosphorylation, and interruption of the mitochondrial fusion process downregulated the efficiency of oxidative phosphorylation and sensitized GBM cells to TMZ, which was also confirmed in the in vivo experiment.\nTherapeutically, targeting oxidative phosphorylation with gamitrinib in patient-derived organoids of LC-BrMs induced apoptosis and inhibited cell proliferation.\nMetabolomic analysis suggested that oxidative phosphorylation was reduced within individual mitochondria, and that there was no reciprocal increase in glycolytic activity.\nLoss of TSPO resulted in a greater number of fragmented mitochondria, increased glucose uptake and lactic acid conversion, decreased oxidative phosphorylation, and increased glycolysis.\nAt the functional level, V-ATPase inhibition in GSC induces ROS production, mitochondrial damage, while hindering mitochondrial oxidative phosphorylation and reducing protein synthesis.\nThese APC-high states (mean difference = -0.43, adjusted < 0.001) also showed a shift in metabolic activity, with decreased oxidative phosphorylation and increased lipid and steroid metabolism.\nFinally, comparative analysis of MBMs from patients with MBMs only showed that these tumors were characterized by decreased oxidative phosphorylation (OXPHOS) and increased immune infiltration signature versus MBMs from patients with concurrent ECMs.\nWe demonstrated that incubation of TMZ-resistant GBM cells with SH-4-54 led to mitochondrial STAT3 (mitoSTAT3) activation and respiratory dysfunction reflected by disrupted (or suppressed) activities of oxi"
    },
    "39-1800": {
      "type": "slc_pathway",
      "key1": "SLC5A2",
      "key2": "migration",
      "text": "After the overexpression of SGLT-2 in HUVECs, the proliferation, migration and tubule formation ability of HUVECs were inhibited, and autophagy and apoptosis were increased, which were reversed by 3-MA (P < 0.05).\nAfter the addition of Sodium-glucose co-transporters 2 inhibitor, Dapagliflozin, the proliferation of HUVECs, the tubule formation, autophagy, apoptosis and migration ability of cells inhibited by HG/PA were significantly improved (P < 0.05).\nDapagliflozin can improve the dysfunction of high glucose/high fat-induced human umbilical vein endothelial cells by downregulate autophagy through inhibiting SGLT-2."
    },
    "1798-1938": {
      "type": "pathway_disease",
      "key1": "stemness",
      "key2": "Kidney Cancer",
      "text": "up to 30% of stem cell promoting stemness regulatory genes are positively correlated with angiogenesis genes CD31/PECAM1 and KDR, and 64 genes are also strongly positively correlated with CD31/PECAM1 and KDR genes.\nTranscriptional inhibition of OCT4 and Nanog via inhibiting GLI1 was important for penfluridol-induced stemness and proliferation inhibition.\nThymoquinone suppresses the proliferation of renal cell carcinoma cells via reactive oxygen species-induced apoptosis and reduces cell stemness.\nHGFK1 could also decrease sorafenib-induced autophagy and stemness via blockading NF-κB signaling pathway in RCC both in vitro and in vivo.\nThis study establishes REN as a pivotal driver of tumor stemness and immune evasion in WT, playing a dual role in promoting tumor aggressiveness and suppressing NK-mediated immune surveillance.\nFor human-derived CSCs, TDS inhibits stemness by reducing endogenic miR-19b and its transportation via CSCs-derived exosomes, which increases PTEN expression and consequently suppresses CSCs-mediated metastasis.\nDRD2 antagonists such as penfluridol induce UPR signaling and suppress the GLI1/OCT4/Nanog axis in ccRCC cells to reduce their growth through inducing autophagy-mediated apoptosis and stemness inhibition.\nPLEKHO1 depletion significantly inhibited cell proliferation, invasion, migration, stemness, and induced cell apoptosis in ccRCC cells.\nSalinomycin suppresses cancer cell stemness and attenuates TGF-β-induced epithelial-mesenchymal transition of renal cell carcinoma cells.\nHigh-CSPI tumors exhibited enhanced tumor stemness phenotypes, metabolic reprogramming (ROS/oxidative phosphorylation), and suppressed immune activity.\nLINC00887, by recruiting SPI1, activated CD70 transcription, thereby propelling malignant progression and cell stemness and suppressing T cell chemotaxis in ccRCC."
    },
    "226-1796": {
      "type": "slc_pathway",
      "key1": "SLC25A5",
      "key2": "ferroptosis",
      "text": "The six pivotal CDRDDEGs in AS patients, healthy controls, were identified as CLIC4, BIRC2, MATK, PKN2, SLC25A5, and EDEM1.\nOur focus extended specifically to ferroptosis-related DEGs (FRDEGs), cuproptosis-related DEGs (CRDEGs), anoikis-related DEGs (ARDEGs), autophagy-related DEGs (AURDEGs), and pyroptosis-related DEGs (PRDEGs).\nAmong AS patients, 82 FRDEGs, 29 CRDEGs, 54 AURDEGs, 21 ARDEGs, and 74 PRDEGs were identified.\nRelative to healthy controls, a myriad of differentially expressed genes (DEGs) linked to cell death surfaced in AS patients.\nEmploying machine learning techniques, LASSO, RF, and SVM-RFE were employed to discern key DEGs related to cell death (CDRDDEGs).\nLeveraging machine learning (ML) methodologies, we formulated disease prediction models employing cell death-related DEGs (CDRDEGs) and identified biomarkers intertwined with cell death in AS."
    },
    "90-1801": {
      "type": "slc_pathway",
      "key1": "SLC9A1",
      "key2": "apoptosis",
      "text": "Most importantly, NHE1 inhibition prevented prosurvival extracellular signal-regulated kinase activation and accelerated TMZ-induced apoptosis.\nThese results demonstrate that CT could ameliorate DOX-induced cardiotoxicity by inhibiting the NHE1-mediated oxidative stress, apoptosis in rats.\nInhibition of RSK1 or siRNA-mediated silencing of RSK1 attenuates H/R-induced apoptosis, demonstrating the role of RSK1 in cardiomyocyte apoptosis.\nLJE inhibited doxorubicin-induced apoptosis and upregulated Na/H exchanger isoform 1 (NHE1) expression in NRK-52E cells, which were blocked by the NHE1 inhibitor cariporide.\nOverall, our findings demonstrate that H/R-mediated decrease in PKARIα protein levels leads to activation of RSK1, which via phosphorylation of NHE1 induces cardiomyocyte apoptosis.\nUsing adult rat ventricular myocytes and mouse-derived cardiac HL-1 cardiomyocytes, we demonstrate that hypoxia/reoxygenation (H/R)-induced apoptosis is accompanied by a decrease in the type I PKA regulatory subunit (PKARIα) and activation of RSK1.\nWe found that the knockdown of NHE1 in ESCC cells inhibited apoptosis and promoted cell proliferation, migration, and invasion and showed increases in Snail, β-catenin, and activation of PI3K-AKT signaling, which was consistent with the results obtained from microarrays.\nInhibitors of NHE-1 are able to decrease intracellular pH and induce apoptosis.\nKnockout, knockdown, or chemical inhibition of SLC9A1 blocked necroptosis induced by osmotic stresses.\nCombining TMZ therapy with NHE1 inhibition suppresses GC migration and invasion, and also augments TMZ-induced apoptosis.\nMoreover, cariporide decreased MDR1 expression and activated cleaved caspase-3 and casp"
    },
    "117-1800": {
      "type": "slc_pathway",
      "key1": "SLC12A3",
      "key2": "migration",
      "text": "Regardless of salinity tolerance, all lamprey downregulated FW ion-uptake mechanisms [gill transcripts of Na(+):Cl(-) cotransporter (NCC/slc12a3) and epithelial Na(+) channel (ENaC/scnn1) and kidney Na(+)/K(+)-ATPase (NKA) protein and activity but not transcript].\nAQP1 overexpression inhibited invasion, migration, EMT, and cytoskeletal rearrangement of WT cells, indicating that AQP1 plays a role in the pathogenesis of WT.\nAQP1 overexpression significantly reduced the migratory and invasive capacity of Wit-49 cells, as evidenced by reducing the scratch healing rate and the number of perforated control cells by Wit-49 cells.\nAQP1 overexpression also reduced the expression of biomarkers of epithelial-mesenchymal transformation, decreased levels of vimentin and N-cadherin and increased expression of E-cadherin, resulting in decreased formation of conspicuous lamellipodial protrusions, characteristic of diminished WT cell invasion and migration.\nFinally, top five key genes were identified using CytoHubba, including Renin (REN), nephrosis 2 (NPHS2), Solute Carrier Family 12 Member 3 (SLC12A3), Solute Carrier Family 12 Member 1 (SLC12A1) and AQP1."
    },
    "1800-2050": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Wilms Tumor",
      "text": "piNU13 may regulate the expression of NOP56 indirectly to inhibit the proliferation, migration and invasion and promote apoptosis of Wilms tumor cells .\nAmong the panel, clone 288.1 induced significant cell death in primary Wilms tumor cells and inhibited cell proliferation and migration.\nmiR-155-5p participates in the progression of Wilms tumor by inhibiting the proliferation and migration and promoting apoptosis of the tumor cells, and may serve as a novel biomarker for diagnosis, therapy and prognostic evaluation of Wilms tumor.\nFunctionally, over-expression of EMCN and CCNA1 knockdown inhibited cell viability, proliferation, migration, and invasion of Wilms tumor cells.\nWe find that A1CF is a positive regulator of Axin2, a Wnt/β-catenin pathway inhibitor, and A1CF-Axin2 signal axis regulates Wilms tumor-derived cells' apoptosis and migration through Axin2.\nInterestingly, we also found that the knockdown of ARRB2 decreased several cancer pathways mediated by the expression of Wilms tumor 1 associated protein (WTAP), which led to the inhibition of cell proliferation and migration.\nFurthermore, miR‑92a‑3p mimics suppressed Wilms tumor cell proliferation, migration and invasion by in vitro assays.\nSuppression of circ0093740 remarkably inhibited the proliferation and migration ability in Wilms tumor, validated by several experiments.\nKnockdown of NOTCH1 expression reversed the promotive effect of miR‑92a‑3p inhibitor on the cell proliferation, migration and invasion in Wilms tumor.\nKnockdown of RPL10 inhibited cell viability, migration, and invasion, and increased cell apoptosis.\nCell apoptosis was increased while cell viability, migration, and invasion were repressed by circSLC7A6 silencing.\nOn the contrary, upregulation of RPL10 increased cell viability, migration, invasion, and decreased cell apoptosis.\nSilencing TCF3 expression in G401 kidney tumor cells significantly inhibited cell viability an"
    },
    "1796-2146": {
      "type": "pathway_disease",
      "key1": "ferroptosis",
      "key2": "liver hepatocellular carcinoma (LIHC)",
      "text": "CD155 promoted liver cancer by suppressing p53-mediated ferroptosis via CD96.\nFM induces ferroptosis by inhibiting the p53/xCT/GPX4 signaling pathway.\nNAT10 promotes HCC progression by inhibiting ferroptosis through ac4C acetylation of SLC7A11 mRNA.\nThe blockade of the Notch signaling pathway substantially diminished NELL2's capacity to induce ferroptosis.\nNELL2 modulates the Notch signaling pathway to inhibit EMT and promote ferroptosis.\nCelastrol (Cel) has the ability to inhibit the progression of HCC by regulating multiple signaling pathways and induce ferroptosis.\nCD155 might facilitate hepatocellular carcinoma advancement through blocking the p53-mediated ferroptosis via interacting with CD96.\nKnockdown of EOGT inhibited HCC cell proliferation and enhanced sensitivity to ferroptosis by downregulating SLC7A11, a process mediated by HEY1.\nGINS4 silencing suppressed proliferation and cycle while promoted ferroptosis in HCC cells by regulating PI3K/AKT signaling via binding to POLE2.\nGSTA1 enhances the accumulation of lipid peroxides and suppresses ferroptosis by exerting its peroxidase function to regulate the SR.\nHCG18 can inhibit ferroptosis by regulating the expression of RRM2, thereby promoting HCC proliferation.\nDTX2 attenuates Lenvatinib-induced ferroptosis by inhibiting DHA biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in HCC.\nKnockdown of FOXM1 induced ferroptosis and inhibited cell malignant phenotypes by downregulating IGF2BP3.\nESR1 suppressed LCN2 transcription, which in turn activated autophagy-mediated ferroptosis, mitigating sorafenib tolerance in HCC and enhancing the therapeutic index.\nFOXM1-induced IGF2BP3 upregulation promotes HCC cell malignant behaviors and macrophages M2 polarization by rep"
    },
    "1799-2766": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "Glioblastoma multiforme",
      "text": ""
    },
    "298-1795": {
      "type": "slc_pathway",
      "key1": "SLC29A1",
      "key2": "proliferation",
      "text": "Importantly, knocking down Slc29a1 in PC12 cells inhibited proliferation and induced differentiation into neuron-like cells.\nIn conclusion, this study showed that miR-33-3p regulated Slc29a1, which in turn controlled the proliferation and differentiation of PC12 cells.\nMechanistically, miR-33-3p repressed the expression of Slc29a1 in PC12 cells.\nWe found that miR-33-3p significantly suppressed PC12 cell proliferation, but had no effect on apoptosis.\nFurthermore, miR-33-3p promoted the differentiation of PC12 cells into Tuj1-positive and choline acetyltransferase-positive neuron-like cells.\nThus, we hypothesize that the miR-33-3p/Slc29a1 axis could be a promising therapeutic target for recovering neurons and the cholinergic nervous system.\nInducible re-expression of KDM6A in KDM6A-null cell lines suppressed proliferation and sensitized cells again to AraC treatment.\nRNA expression analysis and functional studies revealed that resistance to AraC was conferred by downregulation of the nucleoside membrane transporter ENT1 (SLC29A1) by reduced H3K27 acetylation at the ENT1 locus.\nFollowing HAT inhibitor treatment, classical cell lines exhibited a loss of epithelial marker gene expression, decreased chemotherapy response gene score and increased cell migration, indicating a tumor‑promoting phenotype.\nEpigenetic reprogramming of classical and basal‑like tumor cells did not have a major impact on gemcitabine response, although the gemcitabine transporter gene (solute carrier family 29 member 1) was epigenetically regulated."
    },
    "1800-2228": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "acute myeloid leukemia (AML)",
      "text": ""
    },
    "180-1799": {
      "type": "slc_pathway",
      "key1": "SLCO1B3",
      "key2": "glycolysis",
      "text": "The key biochemical feature of malignant tumor is the conversion of energy metabolism from oxidative phosphorylation to glycolysis, which provides sufficient capacity and raw materials for tumor cell rapid growth."
    },
    "92-1802": {
      "type": "slc_pathway",
      "key1": "SLC9A3",
      "key2": "oxidative phosphorylation",
      "text": ""
    },
    "1802-2087": {
      "type": "pathway_disease",
      "key1": "oxidative phosphorylation",
      "key2": "Glioblastoma (GBM)",
      "text": "Mitochondrial-localized calcineurin dephosphorylates PDHA1 at Ser232, Ser293 and Ser300, and thus enhances PDC enzymatic activity, remodels cellular glycolysis and oxidative phosphorylation, and suppresses cancer cell proliferation.\nOur findings indicate that calcineurin is a critical regulator of mitochondrial metabolism and suggest that CNIs may promote tumorigenesis through inhibition of the calcineurin-PDC pathway.\nAccumulating evidence suggests that CNIs may promote the malignant transformation of cancer cells in addition to its role in immunosuppression, but the underlying mechanisms remain poorly understood.\nThe metabolic background of PGC formation was confirmed by the attenuation of GBM recovery from DOX-induced stress following the chemical inhibition of GSK-3β, OXPHOS, and the pentose phosphate pathway.\nOxidative phosphorylation is a highly active cellular pathway in GBM, and NFYB is a tumor-associated transcription factor.\nOxidative phosphorylation pathway activity is elevated in both the Glioma and C5 subgroup, and NFYB is a key transcription factor for the C5 subgroup, suggesting its possible involvement in GBM proliferation and recurrence, and its close association with mitochondrial function.\nIn this review, we aim to explore how dysregulated metabolic enzymes from the TCA cycle and oxidative phosphorylation, along with their metabolites, modulate both catabolic and anabolic metabolic pathways, as well as pro-oncogenic signaling pathways, transcriptional changes, and epigenetic modifications in GBM cells, contributing to the formation, survival, growth, and invasion of glioma cells.\nWe identify three molecular subtypes among PDGCs: mesenchymal (MES), proneural (PN), and oxidative phosphorylation (OXPHOS).\nDevelopment of PGCs was accompanied by the mobilization of their metabolic proteome, transient induction of oxidative phosphorylation (OXPHOS), and differential intracellular accumulation of NADH, NADPH, and ATP.\nIn this study, we demonstrate that an alternating magnetic"
    },
    "1801-1813": {
      "type": "pathway_disease",
      "key1": "apoptosis",
      "key2": "Sarcoma",
      "text": "PA induced apoptosis in osteosarcoma cells through a decrease in mitochondrial membrane potential.\nHEA significantly decreased osteosarcoma cell viability and induced apoptosis in a dose- and time-dependent manner.\nGO-Y030 dose-dependently reduced viability and induced sub-G1 arrest and apoptosis in human osteosarcoma U2OS and 143B cells.\nDownregulation of CREB1 inhibited osteosarcoma cell proliferation and invasion but induced apoptosis through miRNA-183-5p/PROX1 axis.\nAdditionally, downregulation of ZNF560 resulted in decreased cell viability, fewer colonies, and induced apoptosis of osteosarcoma cells.\nSilencing of BCAR4 inhibited osteosarcoma cell proliferation and migration while promoting cellular apoptosis, primarily mediated by miR-1260a.\nITGB3-KD had a radiosensitizing effect on osteosarcoma in vitro by inhibiting cell viability, proliferation, migration, and invasion and promoting apoptosis.\nThis study revealed that NEK2 promotes osteosarcoma proliferation, invasion, migration, and chemoresistance while inhibiting apoptosis, likely through AKT/p-AKT signaling.\nThese findings indicated that PA exerts anti-osteosarcoma effects by inhibiting osteosarcoma cell proliferation, inducing apoptosis, promoting autophagy and inhibiting PI3K/Akt pathway, suggesting PA as a potential agent against osteosarcoma.\nIn vitro, the Zn-0.8Li scaffold significantly inhibits osteosarcoma progression by suppressing tumor cell proliferation, promoting apoptosis, alleviating migration, and simultaneously promotes osteogenic differentiation through the enhanced expression of osteogenic markers.\nInhibition of the PERK pathway could exacerbate ER stress and promote apoptosis in osteosarcoma cells, while also altering the polarization state of TAMs from the immunosuppressive M2 phenotype to the anti-tumorigenic M1 phenotype, thereby disrupting tumor immunosuppression."
    },
    "185-1797": {
      "type": "slc_pathway",
      "key1": "SLC22A2",
      "key2": "oxidative stress",
      "text": "The results of this study suggest that CA attenuates CP-induced kidney injury through suppression of oxidative stress, inflammation, apoptosis and autophagy, with the improvement in kidney regeneration.\nRenal oxidative stress, evidenced by increased 4-hydroxynonenal (4-HNE) expression, was significantly reduced with CA.\nIt also activates apoptotic pathways and inflicts cellular damage via oxidative stress and inflammation.\nNotably, glutamine reduced the cisplatin-induced expression of organic cation transporter 2 (OCT2) and cisplatin accumulation.\nDOX significantly reduced the expression of OCT2, lipid peroxidation marker (MDA), and inflammatory cytokines, including TNF-α, IL-6, IL-1, IL-2, and IL-1β, and increased the activity of antioxidant enzymes.\nDOX exerts a nephroprotective impact against CP-mediated nephrotoxicity via the inhibition of OCT2, suppression of inflammation, oxidative stress, and apoptotic markers, and modulation of PI3K/Akt signaling cascade.\nThe expression of multidrug resistance-associated proteins (Mrp1 and Mrp2) increased and organic cation transporter 2 (Oct2) decreased by CP, protecting the kidneys from nephrotoxicity by reducing the burden of tubular cells.\nCisplatin increased cell death, caspase-3 cleavage, activation of MAPKs and p53, oxidative stress, and mRNA expression of TNF-α and TNFR1 in HK-2 cells.\nThis study suggests the promising nephroprotective impact of Clon as an OCT2 inhibitor against CP nephrotoxicity and its proficient role in attenuating oxidative stress, inflammatory status and apoptotic status.\nConsistent with the Remote Sensing and Signaling Theory, this indicates an important in vivo role in the oxidative stress response for multiple SLC22 transporters within the fly renal system, perhaps through interaction with SLC22 counterparts in non-renal tissues.\nExpression in the Malpighian tubule and likely other tissues as well (e.g., gut, fat body, nervous"
    },
    "1797-2360": {
      "type": "pathway_disease",
      "key1": "oxidative stress",
      "key2": "acute and chronic renal failure",
      "text": ""
    },
    "371-1795": {
      "type": "slc_pathway",
      "key1": "SLC38A5",
      "key2": "proliferation",
      "text": "Upregulation of SLC38A5 promotes proliferation, migration, and invasion of osteosarcoma cells, while the PI3K inhibitor BKM120 can counteract these effects.\nSLC38A5 promotes osteosarcoma cell proliferation, migration, and invasion via the glutamine-mediated PI3K/AKT/mTOR signaling pathway and inhibits ferroptosis.\nα cell expression of the AA transporter Slc38a5 was markedly increased in mice with interrupted glucagon signaling and played a role in α cell proliferation.\nWe found that arginine activation of mTOR signaling and induction of the glutamine transporter SLC38A5 was dependent on SLC7A2, showing that both's role in α cell proliferation is dependent on arginine transport and SLC7A2.\nFurthermore, the deletion of SLC38A5 decreased the proliferation and migration of gemcitabine-resistant PDAC cells.\nSLC38A5 inhibition could attenuate the pro-tumoral abilities of CAFs in terms of proliferation, migration, and invasion.\nmost notably, mice deficient in Slc38a5 exhibit markedly decreased α cell hyperplasia to glucagon pathway blockade-induced hyperaminoacidemia.\nMechanistically, SLC38A5 mediates the activation of the PI3K/AKT/mTOR signaling pathway by transporting glutamine, which subsequently enhances the SREBP1/SCD-1 signaling pathway, thereby suppressing ferroptosis in osteosarcoma cells.\nOur findings suggest that SLC38A5 enhances BC cell viability by glutamine metabolism, inhibits the chemical sensitivity of cisplatin in BC cells, and promotes tumor growth, emphasizing the clinical relevance of SLC38A5 in BC management as a novel potential therapeutic target.\nWe confirm and extend these findings by demonstrating that glucagon pathway blockade selectively increases expression of the sodium-coupled neutral amino acid transporter Slc38a5 in a subset of highly proliferative α cells and that Slc38a5 controls the pancreatic response to glucagon pathway blockade;\nMoreover, SLC38A5 deficiency could hinder CRC"
    },
    "1795-2583": {
      "type": "pathway_disease",
      "key1": "proliferation",
      "key2": "ischemic proliferative retinopathies",
      "text": "Apatinib inhibited VEGF-mediated activation of VEGFR2 signaling and substantially reduced VEGF-induced proliferation, migration, and cord formation in HRMECs.\nTogether, our data suggest that Müller cells release TGF-β2, inhibiting the proliferation of retinal endothelial cells via activation of Smad2/Smad3 and attenuation of ERK signaling.\ndown-regulation or inactivation of ADAM10 significantly inhibited the proliferation, sprouting, migration, and tube formation of human retinal microvascular endothelial cell.\nH promotes the proliferation of HUVECs under hypoxia by negatively regulating the Dll4/Notch pathway and reducing ROS levels through Nrf2 pathway aligning with our findings in vivo.\nhydrogen-mediated retinal revascularization and neovascularization suppression.\ninhibition of dysregulated cell proliferation in proliferative retinopathies.\nCurcumolide suppressed VEGF-induced HRMECs proliferation, migration and tube formation in a dose-dependent manner.\nBFGF-neutralizing antibodies suppressed the enhanced endothelial cell proliferation to a similar extent as anti-VEGF antibodies.\nExogenous TSP-1 reduced the VEGF-induced proliferation and migration of BRECs and decreased the phosphorylation level of ERK1/2 in BRECs.\nADORA2A knockdown decreases hypoxia-induced glycolytic enzyme expression, glycolytic flux, and endothelial cell proliferation, sprouting and tubule formation.\nH plays a protective role in vascular regeneration by promoting Nrf2 activation and suppressing the Dll4-induced Notch signaling pathway in vivo.\noral administration of apatinib significantly reduced laser-induced CNV in mice.\nOur study demonstrates that apatinib inhibits pathologic ocular neovascularization in mice with OIR or laser-induced CNV.\nNeutralizing TGF-β or TGF-β type-II receptor or blocking the activation of Smads partially abrogated the effect of"
    },
    "1799-2739": {
      "type": "pathway_disease",
      "key1": "glycolysis",
      "key2": "oral squamous cell carcinoma",
      "text": ""
    },
    "1800-2450": {
      "type": "pathway_disease",
      "key1": "migration",
      "key2": "Head and Neck tumors",
      "text": "PLSCR1 knockdown inhibited TSCC cell proliferation, migration, and invasion, and upregulated apoptosis.\nIts upregulation promoted proliferation, inhibited apoptosis, and enhanced migration and invasion in HNSCC cells.\nEnhanced SPRY4 inhibited tumor cell proliferation and migration while simultaneously reducing tumor cell sensitivity to pro-apoptotic factors in the tumor microenvironment, primarily by suppressing the p38 MAPK signaling pathway.\nPharmacological inhibition of AKT abolished TTC7B-induced phosphorylation of AKT and JKAMP expression, suppressing migration and invasion, whereas IGF-1-mediated AKT activation restored JKAMP expression and rescued TTC7B-knockdown phenotypes.\nExperimental validation demonstrated curcumin's dose-dependent inhibition of viability, invasion, and migration in FaDu and CAL 27 cells, while promoting apoptosis and downregulating EGFR/STAT3 expression at both mRNA and protein levels-effects that were synergistically enhanced when combined with AG490 inhibitor.\nMETTL14 overexpression inhibited TC cell proliferation, migration, and invasion, and promoted cell apoptosis.\nFunctional validation experiments revealed that knockdown of circ_0003997 inhibited cell proliferation, migration, invasion, and EMT, while its overexpression promoted PTC progression.\nResults indicated that baicalin dose-dependently repressed the proliferation and migration of OSCC cells, and strengthened the antitumor immune activity of activated PBMCs to OSCC cells.\nWe also found that SHMT1 could inhibit the proliferation, migration, and invasion of laryngeal squamous cell carcinoma cells while promoting cell apoptosis by constructing SHMT1-overexpressing cell lines.\nSPP1-CD44 upregulates stemness and migration abilities of tumor cells in HNSCC.\nFinally, experiments showed that the viability, migration, and invasion of OSCC cells were markedly suppressed after knockdown of.\nNormal cells maintain their homeostasis through Anoikis, and tumor cells enhance their own invasion and migration by resisting Anoikis."
    }
  }
}